(lp0
(dp1
S'line'
p2
VJacobsen syndrome (JBS) is a contiguous gene deletion syndrome involving terminal chromosome 11q.
p3
sS'genes'
p4
(lp5
sS'diseases'
p6
(lp7
(dp8
S'index'
p9
I0
sS'cui'
p10
VC0795841
p11
sS'lengthInChars'
p12
I17
sS'name'
p13
VJacobsen syndrome
p14
sS'lengthInWords'
p15
I2
sa(dp16
g9
I40
sg10
VC1442161
p17
sg12
I13
sg13
Vgene deletion
p18
sg15
I2
sa(dp19
g9
I9
sg10
VC0039082
p20
sg12
I8
sg13
Vsyndrome
p21
sg15
I1
sa(dp22
g9
I19
sg10
VC0795841
p23
sg12
I3
sg13
VJBS
p24
sg15
I1
sasa(dp25
g2
VWe investigated a boy with features of JBS using classic cytogenetic methods, FISH and high-resolution array CGH.
p26
sg4
(lp27
sg6
(lp28
(dp29
g9
I109
sg10
VC1855900
p30
sg12
I3
sg13
VCGH
p31
sg15
I1
sa(dp32
g9
I39
sg10
VC0795841
p33
sg12
I3
sg13
VJBS
p34
sg15
I1
sasa(dp35
g2
VThe patient had a hemizygous deletion in the FLI1 gene region without apparent thrombocytopenia, and he developed diabetes mellitus type I, which has not previously been described in the spectrum of disorders associated with JBS.
p36
sg4
(lp37
(dp38
g9
I45
sS'uniprot'
p39
S''
p40
sg12
I9
sg13
VFLI1 gene
p41
sg15
I2
sasg6
(lp42
(dp43
g9
I225
sg10
VC0795841
p44
sg12
I3
sg13
VJBS
p45
sg15
I1
sa(dp46
g9
I114
sg10
VC0011854
p47
sg12
I24
sg13
Vdiabetes mellitus type I
p48
sg15
I4
sasa(dp49
g2
VThe relationship of some of the genes within the context of the phenotype caused by a partial deletion of 11q has provided insights concerning the developmental anomalies presented in this patient with atypical features of JBS.
p50
sg4
(lp51
sg6
(lp52
(dp53
g9
I223
sg10
VC0795841
p54
sg12
I3
sg13
VJBS
p55
sg15
I1
sasa(dp56
g2
VAll local patients were clustered "high-risk" for future CV events based on the Framingham score (mean 21.8%, 95% CI 20.0-23.6), JBS-2 (16.3%, 14.7-17.9) and ASSIGN (25.2%, 22.7-27.7).
p57
sg4
(lp58
(dp59
g9
I129
sg39
g40
sg12
I5
sg13
VJBS-2
p60
sg15
I1
sasg6
(lp61
(dp62
g9
I129
sg10
VC0795841
p63
sg12
I3
sg13
VJBS
p64
sg15
I1
sasa(dp65
g2
VLoss-of-function mutations in the UBR1 gene cause Johanson-Blizzard syndrome, which involves pancreatic exocrine insufficiency.
p66
sg4
(lp67
(dp68
g9
I34
sg39
g40
sg12
I9
sg13
VUBR1 gene
p69
sg15
I2
sasg6
(lp70
(dp71
g9
I50
sg10
VC0175692
p72
sg12
I26
sg13
VJohanson-Blizzard syndrome
p73
sg15
I2
sasa(dp74
g2
VNo previous studies have examined an association of UBR1 variants with pancreatitis, in part due to the large size of the gene.
p75
sg4
(lp76
(dp77
g9
I52
sg39
g40
sg12
I13
sg13
VUBR1 variants
p78
sg15
I2
sasg6
(lp79
(dp80
g9
I71
sg10
VC0030305
p81
sg12
I12
sg13
Vpancreatitis
p82
sg15
I1
sasa(dp83
g2
VThis study aimed to clarify whether UBR1 variants are associated with chronic pancreatitis (CP) by the application of targeted next generation sequencing.
p84
sg4
(lp85
(dp86
g9
I36
sg39
g40
sg12
I13
sg13
VUBR1 variants
p87
sg15
I2
sasg6
(lp88
(dp89
g9
I70
sg10
VC0149521
p90
sg12
I20
sg13
Vchronic pancreatitis
p91
sg15
I2
sa(dp92
g9
I92
sg10
VC0149521
p93
sg12
I2
sg13
VCP
p94
sg15
I1
sasa(dp95
g2
VJacobsen syndrome (JBS) is a contiguous gene deletion syndrome involving 11q terminal deletion.
p96
sg4
(lp97
sg6
(lp98
(dp99
g9
I0
sg10
VC0795841
p100
sg12
I17
sg13
VJacobsen syndrome
p101
sg15
I2
sa(dp102
g9
I40
sg10
VC1442161
p103
sg12
I13
sg13
Vgene deletion
p104
sg15
I2
sa(dp105
g9
I9
sg10
VC0039082
p106
sg12
I8
sg13
Vsyndrome
p107
sg15
I1
sa(dp108
g9
I19
sg10
VC0795841
p109
sg12
I3
sg13
VJBS
p110
sg15
I1
sasa(dp111
g2
VInterstitial deletions at distal 11q are rare and their contributions to the clinical phenotype of JBS are unknown.
p112
sg4
(lp113
sg6
(lp114
(dp115
g9
I99
sg10
VC0795841
p116
sg12
I3
sg13
VJBS
p117
sg15
I1
sasa(dp118
g2
VOur finds support the notion that more than one critical region at 11q23.3-qter are responsible for the variable clinical presentation of JBS, thus JBS is a true contiguous gene deletion syndrome where multiple loci contributed to the clinical characteristics of JBS.
p119
sg4
(lp120
(dp121
g9
I138
sg39
g40
sg12
I3
sg13
VJBS
p122
sg15
I1
sasg6
(lp123
(dp124
g9
I138
sg10
VC0795841
p125
sg12
I3
sg13
VJBS
p126
sg15
I1
sa(dp127
g9
I138
sg10
VC0795841
p128
sg12
I3
sg13
VJBS
p129
sg15
I1
sa(dp130
g9
I138
sg10
VC0795841
p131
sg12
I3
sg13
VJBS
p132
sg15
I1
sa(dp133
g9
I187
sg10
VC0039082
p134
sg12
I8
sg13
Vsyndrome
p135
sg15
I1
sa(dp136
g9
I173
sg10
VC1442161
p137
sg12
I13
sg13
Vgene deletion
p138
sg15
I2
sasa(dp139
g2
VJacobsen syndrome (JBS) is an uncommon contiguous gene syndrome.
p140
sg4
(lp141
sg6
(lp142
(dp143
g9
I0
sg10
VC0795841
p144
sg12
I17
sg13
VJacobsen syndrome
p145
sg15
I2
sa(dp146
g9
I9
sg10
VC0039082
p147
sg12
I8
sg13
Vsyndrome
p148
sg15
I1
sa(dp149
g9
I19
sg10
VC0795841
p150
sg12
I3
sg13
VJBS
p151
sg15
I1
sasa(dp152
g2
VThe typical clinical features in JBS include intellectual disability, growth retardation, craniofacial dysmorphism as well as craniosynostosis, congenital heart disease, and platelet abnormalities.
p153
sg4
(lp154
sg6
(lp155
(dp156
g9
I126
sg10
VC0010278
p157
sg12
I16
sg13
Vcraniosynostosis
p158
sg15
I1
sa(dp159
g9
I144
sg10
VC0152021
p160
sg12
I24
sg13
Vcongenital heart disease
p161
sg15
I3
sa(dp162
g9
I45
sg10
VC0025362
p163
sg12
I23
sg13
Vintellectual disability
p164
sg15
I2
sa(dp165
g9
I33
sg10
VC0795841
p166
sg12
I3
sg13
VJBS
p167
sg15
I1
sa(dp168
g9
I70
sg10
VC0151686
p169
sg12
I18
sg13
Vgrowth retardation
p170
sg15
I2
sa(dp171
g9
I103
sg10
VC1737329
p172
sg12
I11
sg13
Vdysmorphism
p173
sg15
I1
sasa(dp174
g2
VWe report a novel deletion in JBS that increases the knowledge of the variability in the mutation sites in this region and expands the spectrum of molecular and clinical defects in this syndrome.
p175
sg4
(lp176
sg6
(lp177
(dp178
g9
I186
sg10
VC0039082
p179
sg12
I8
sg13
Vsyndrome
p180
sg15
I1
sa(dp181
g9
I30
sg10
VC0795841
p182
sg12
I3
sg13
VJBS
p183
sg15
I1
sasa(dp184
g2
VJohanson-Blizzard syndrome (JBS) is considered as an infrequent, but clinically easily recognizable autosomal recessive entity by the pathognomonic combination of congenital exocrine pancreatic insufficiency and hypoplastic alae nasi, in addition to other distinctive findings such as scalp defects, hypothyroidism, and rectourogenital malformations.
p185
sg4
(lp186
sg6
(lp187
(dp188
g9
I336
sg10
VC0000768
p189
sg12
I13
sg13
Vmalformations
p190
sg15
I1
sa(dp191
g9
I0
sg10
VC0175692
p192
sg12
I26
sg13
VJohanson-Blizzard syndrome
p193
sg15
I2
sa(dp194
g9
I300
sg10
VC0020676
p195
sg12
I14
sg13
Vhypothyroidism
p196
sg15
I1
sa(dp197
g9
I28
sg10
VC0175692
p198
sg12
I3
sg13
VJBS
p199
sg15
I1
sa(dp200
g9
I174
sg10
VC0267963
p201
sg12
I33
sg13
Vexocrine pancreatic insufficiency
p202
sg15
I3
sasa(dp203
g2
VThere are few reports of patients with JBS in association with facial clefting, referring all to types 2 to 6 of Tessier's classification that can be characterized properly as oblique facial clefts (OFCs).
p204
sg4
(lp205
sg6
(lp206
(dp207
g9
I199
sg10
VC1838348
p208
sg12
I4
sg13
VOFCs
p209
sg15
I1
sa(dp210
g9
I176
sg10
VC1838348
p211
sg12
I21
sg13
Voblique facial clefts
p212
sg15
I3
sa(dp213
g9
I39
sg10
VC0795841
p214
sg12
I3
sg13
VJBS
p215
sg15
I1
sasa(dp216
g2
VWe describe the clinical aspects in four patients with JBS and extensive OFCs.
p217
sg4
(lp218
sg6
(lp219
(dp220
g9
I55
sg10
VC0795841
p221
sg12
I3
sg13
VJBS
p222
sg15
I1
sasa(dp223
g2
VIn all of them, the diagnosis of JBS was confirmed by the demonstration of homozygous or compound-heterozygous mutations in the UBR1 gene.
p224
sg4
(lp225
(dp226
g9
I128
sg39
g40
sg12
I9
sg13
VUBR1 gene
p227
sg15
I2
sasg6
(lp228
(dp229
g9
I33
sg10
VC0795841
p230
sg12
I3
sg13
VJBS
p231
sg15
I1
sasa(dp232
g2
VAdditionally, we review three previously reported cases of JBS with OFCs.
p233
sg4
(lp234
sg6
(lp235
(dp236
g9
I59
sg10
VC0795841
p237
sg12
I3
sg13
VJBS
p238
sg15
I1
sasa(dp239
g2
VTaking into account a number of approximately 100 individuals affected by JBS that have been published in the literature we estimate that the frequency of OFCs in JBS is between 5% and 10%.
p240
sg4
(lp241
sg6
(lp242
(dp243
g9
I74
sg10
VC0795841
p244
sg12
I3
sg13
VJBS
p245
sg15
I1
sa(dp246
g9
I74
sg10
VC0795841
p247
sg12
I3
sg13
VJBS
p248
sg15
I1
sasa(dp249
g2
VThis report emphasizes that extensive OFCs may be the severe end of the spectrum of facial malformations occurring in JBS.
p250
sg4
(lp251
sg6
(lp252
(dp253
g9
I84
sg10
VC0266617
p254
sg12
I20
sg13
Vfacial malformations
p255
sg15
I2
sa(dp256
g9
I118
sg10
VC0795841
p257
sg12
I3
sg13
VJBS
p258
sg15
I1
sasa(dp259
g2
VJacobsen syndrome (JBS) is a rare congenital disorder caused by a terminal deletion of the long arm of chromosome 11.
p260
sg4
(lp261
sg6
(lp262
(dp263
g9
I0
sg10
VC0795841
p264
sg12
I17
sg13
VJacobsen syndrome
p265
sg15
I2
sa(dp266
g9
I34
sg10
VC0242354
p267
sg12
I19
sg13
Vcongenital disorder
p268
sg15
I2
sa(dp269
g9
I19
sg10
VC0795841
p270
sg12
I3
sg13
VJBS
p271
sg15
I1
sasa(dp272
g2
VPX-RICS is located in the chromosomal region commonly deleted in JBS patients with autistic-like behaviour.
p273
sg4
(lp274
(dp275
g9
I0
sg39
g40
sg12
I7
sg13
VPX-RICS
p276
sg15
I1
sasg6
(lp277
(dp278
g9
I65
sg10
VC0795841
p279
sg12
I3
sg13
VJBS
p280
sg15
I1
sa(dp281
g9
I83
sg10
VC0004352
p282
sg12
I8
sg13
Vautistic
p283
sg15
I1
sasa(dp284
g2
VOur findings demonstrate a critical role of PX-RICS in cognition and suggest a causal link between PX-RICS deletion and ASD-like behaviour in JBS patients.
p285
sg4
(lp286
(dp287
g9
I44
sg39
g40
sg12
I7
sg13
VPX-RICS
p288
sg15
I1
sasg6
(lp289
(dp290
g9
I142
sg10
VC0795841
p291
sg12
I3
sg13
VJBS
p292
sg15
I1
sa(dp293
g9
I120
sg10
VC1510586
p294
sg12
I3
sg13
VASD
p295
sg15
I1
sasa(dp296
g2
VJohanson-Blizzard Syndrome (JBS) (MIM #243800) is a rare autosomal recessive genetic disorder characterized by exocrine pancreatic insufficiency, abnormal facial appearance and varying degrees of mental retardation.
p297
sg4
(lp298
sg6
(lp299
(dp300
g9
I0
sg10
VC0175692
p301
sg12
I26
sg13
VJohanson-Blizzard Syndrome
p302
sg15
I2
sa(dp303
g9
I77
sg10
VC0019247
p304
sg12
I16
sg13
Vgenetic disorder
p305
sg15
I2
sa(dp306
g9
I28
sg10
VC0175692
p307
sg12
I3
sg13
VJBS
p308
sg15
I1
sa(dp309
g9
I196
sg10
VC0025362
p310
sg12
I18
sg13
Vmental retardation
p311
sg15
I2
sa(dp312
g9
I111
sg10
VC0267963
p313
sg12
I33
sg13
Vexocrine pancreatic insufficiency
p314
sg15
I3
sasa(dp315
g2
VHere, we report a 3 year-old mentally normal JBS girl.
p316
sg4
(lp317
sg6
(lp318
(dp319
g9
I45
sg10
VC0795841
p320
sg12
I3
sg13
VJBS
p321
sg15
I1
sasa(dp322
g2
VWith these findings, JBS diagnosis was established clinically.
p323
sg4
(lp324
sg6
(lp325
(dp326
g9
I21
sg10
VC0795841
p327
sg12
I3
sg13
VJBS
p328
sg15
I1
sasa(dp329
g2
VJoubert syndrome (JBS) is a rare neurodevelopmental disorder belonging to the group of ciliary diseases.
p330
sg4
(lp331
sg6
(lp332
(dp333
g9
I18
sg10
VC0795841
p334
sg12
I3
sg13
VJBS
p335
sg15
I1
sa(dp336
g9
I0
sg10
VC0431399
p337
sg12
I16
sg13
VJoubert syndrome
p338
sg15
I2
sa(dp339
g9
I33
sg10
VC1535926
p340
sg12
I27
sg13
Vneurodevelopmental disorder
p341
sg15
I2
sasa(dp342
g2
VJBS is genetically heterogeneous, with &gt;20 causative genes identified to date.
p343
sg4
(lp344
sg6
(lp345
(dp346
g9
I0
sg10
VC0795841
p347
sg12
I3
sg13
VJBS
p348
sg15
I1
sasa(dp349
g2
VA molecular diagnosis of JBS is essential for prediction of disease progression and genetic counseling.
p350
sg4
(lp351
sg6
(lp352
(dp353
g9
I25
sg10
VC0795841
p354
sg12
I3
sg13
VJBS
p355
sg15
I1
sa(dp356
g9
I60
sg10
VC0242656
p357
sg12
I19
sg13
Vdisease progression
p358
sg15
I2
sasa(dp359
g2
VWe developed a targeted next-generation sequencing (NGS) approach for parallel sequencing of 22 known JBS genes plus 599 additional ciliary genes.
p360
sg4
(lp361
sg6
(lp362
(dp363
g9
I102
sg10
VC0795841
p364
sg12
I3
sg13
VJBS
p365
sg15
I1
sasa(dp366
g2
VThis method was used to genotype a cohort of 51 well-phenotyped Northern European JBS cases (in some of the cases, Sanger sequencing of individual JBS genes had been performed previously).
p367
sg4
(lp368
sg6
(lp369
(dp370
g9
I82
sg10
VC0795841
p371
sg12
I3
sg13
VJBS
p372
sg15
I1
sa(dp373
g9
I82
sg10
VC0795841
p374
sg12
I3
sg13
VJBS
p375
sg15
I1
sasa(dp376
g2
VAltogether, 21 of the 51 cases (41%) harbored biallelic pathogenic mutations in known JBS genes, including 14 mutations not previously described.
p377
sg4
(lp378
sg6
(lp379
(dp380
g9
I86
sg10
VC0795841
p381
sg12
I3
sg13
VJBS
p382
sg15
I1
sasa(dp383
g2
VOur study represents a population-based cohort of JBS patients not enriched for consanguinity, providing insight into the relative importance of the different JBS genes in a Northern European population.
p384
sg4
(lp385
(dp386
g9
I159
sg39
g40
sg12
I9
sg13
VJBS genes
p387
sg15
I2
sasg6
(lp388
(dp389
g9
I50
sg10
VC0795841
p390
sg12
I3
sg13
VJBS
p391
sg15
I1
sa(dp392
g9
I50
sg10
VC0795841
p393
sg12
I3
sg13
VJBS
p394
sg15
I1
sasa(dp395
g2
VFurthermore, we report a case with heterozygous mutations in CC2D2A and B9D1, a gene associated with the more severe Meckel-Gruber syndrome that was recently published as a potential new JBS gene, and discuss the significance of this finding.
p396
sg4
(lp397
(dp398
g9
I187
sg39
g40
sg12
I8
sg13
VJBS gene
p399
sg15
I2
sa(dp400
g9
I72
sg39
g40
sg12
I4
sg13
VB9D1
p401
sg15
I1
sa(dp402
g9
I61
sg39
g40
sg12
I6
sg13
VCC2D2A
p403
sg15
I1
sasg6
(lp404
(dp405
g9
I187
sg10
VC0795841
p406
sg12
I3
sg13
VJBS
p407
sg15
I1
sa(dp408
g9
I117
sg10
VC0265215
p409
sg12
I22
sg13
VMeckel-Gruber syndrome
p410
sg15
I2
sasa(dp411
g2
VZIC2 and OVOL1 may function in nasopharyngeal carcinoma through targeting significantly up-regulated genes (such as PTGS2, FN1, CXCL9 and CXCL10) in the Transcription factor-differentially expressed gene regulatory network (e.g., ZIC2-&gt;PTGS2 and OVOL1-&gt;CXCL10).
p412
sg4
(lp413
(dp414
g9
I116
sg39
VP35354
p415
sg12
I5
sg13
VPTGS2
p416
sg15
I1
sa(dp417
g9
I128
sg39
g40
sg12
I5
sg13
VCXCL9
p418
sg15
I1
sa(dp419
g9
I116
sg39
VP35354
p420
sg12
I5
sg13
VPTGS2
p421
sg15
I1
sa(dp422
g9
I0
sg39
g40
sg12
I4
sg13
VZIC2
p423
sg15
I1
sa(dp424
g9
I9
sg39
g40
sg12
I5
sg13
VOVOL1
p425
sg15
I1
sa(dp426
g9
I0
sg39
g40
sg12
I4
sg13
VZIC2
p427
sg15
I1
sa(dp428
g9
I-1
sg39
g40
sg12
I13
sg13
VOVOL1->CXCL10
p429
sg15
I1
sa(dp430
g9
I138
sg39
VP02778
p431
sg12
I6
sg13
VCXCL10
p432
sg15
I1
sasg6
(lp433
(dp434
g9
I31
sg10
VC2931822
p435
sg12
I24
sg13
Vnasopharyngeal carcinoma
p436
sg15
I2
sasa(dp437
g2
VPTGS2, FN1, CXCL9, CXCL10, ZIC2 and OVOL1 might play roles in nasopharyngeal carcinoma.
p438
sg4
(lp439
(dp440
g9
I12
sg39
g40
sg12
I5
sg13
VCXCL9
p441
sg15
I1
sa(dp442
g9
I36
sg39
g40
sg12
I5
sg13
VOVOL1
p443
sg15
I1
sa(dp444
g9
I27
sg39
g40
sg12
I4
sg13
VZIC2
p445
sg15
I1
sa(dp446
g9
I19
sg39
VP02778
p447
sg12
I6
sg13
VCXCL10
p448
sg15
I1
sa(dp449
g9
I0
sg39
VP35354
p450
sg12
I5
sg13
VPTGS2
p451
sg15
I1
sasg6
(lp452
(dp453
g9
I48
sg10
VC0699820
p454
sg12
I10
sg13
Vplay roles
p455
sg15
I2
sa(dp456
g9
I62
sg10
VC2931822
p457
sg12
I24
sg13
Vnasopharyngeal carcinoma
p458
sg15
I2
sasa(dp459
g2
VLiterature data indicate that hyperprolactinemia (HPRL) is one of the important factors in the pathogenesis and course of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjogren's syndrome.
p460
sg4
(lp461
(dp462
g9
I50
sg39
VP01236
p463
sg12
I4
sg13
VHPRL
p464
sg15
I1
sa(dp465
g9
I30
sg39
VP01236
p466
sg12
I18
sg13
Vhyperprolactinemia
p467
sg15
I1
sasg6
(lp468
(dp469
g9
I225
sg10
VC1527336
p470
sg12
I18
sg13
VSjogren's syndrome
p471
sg15
I2
sa(dp472
g9
I180
sg10
VC0003873
p473
sg12
I20
sg13
Vrheumatoid arthritis
p474
sg15
I2
sa(dp475
g9
I202
sg10
VC0036421
p476
sg12
I18
sg13
Vsystemic sclerosis
p477
sg15
I2
sa(dp478
g9
I30
sg10
VC0020514
p479
sg12
I18
sg13
Vhyperprolactinemia
p480
sg15
I1
sa(dp481
g9
I122
sg10
VC0004364
p482
sg12
I19
sg13
Vautoimmune diseases
p483
sg15
I2
sa(dp484
g9
I50
sg10
VC0020514
p485
sg12
I4
sg13
VHPRL
p486
sg15
I1
sa(dp487
g9
I95
sg10
VC0699748
p488
sg12
I12
sg13
Vpathogenesis
p489
sg15
I1
sa(dp490
g9
I150
sg10
VC0024141
p491
sg12
I28
sg13
Vsystemic lupus erythematosus
p492
sg15
I3
sasa(dp493
g2
VFurthermore in the last 2 decades multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT), multiple sclerosis (MS), psoriasis, hepatitis C patients, Behcet's disease, peripartum cardiomyopathy (PPCM) and active celiac disease were discussed to be associated with HPRL.
p494
sg4
(lp495
(dp496
g9
I380
sg39
VP01236
p497
sg12
I4
sg13
VHPRL
p498
sg15
I1
sasg6
(lp499
(dp500
g9
I148
sg10
VC0003873
p501
sg12
I2
sg13
VRA
p502
sg15
I1
sa(dp503
g9
I120
sg10
VC0024141
p504
sg12
I3
sg13
VSLE
p505
sg15
I1
sa(dp506
g9
I173
sg10
VC1527336
p507
sg12
I2
sg13
VSS
p508
sg15
I1
sa(dp509
g9
I244
sg10
VC0019196
p510
sg12
I11
sg13
Vhepatitis C
p511
sg15
I2
sa(dp512
g9
I90
sg10
VC0024141
p513
sg12
I28
sg13
Vsystemic lupus erythematosus
p514
sg15
I3
sa(dp515
g9
I233
sg10
VC0033860
p516
sg12
I9
sg13
Vpsoriasis
p517
sg15
I1
sa(dp518
g9
I208
sg10
VC0026769
p519
sg12
I18
sg13
Vmultiple sclerosis
p520
sg15
I2
sa(dp521
g9
I153
sg10
VC1527336
p522
sg12
I18
sg13
VSjogren's syndrome
p523
sg15
I2
sa(dp524
g9
I284
sg10
VC0877208
p525
sg12
I25
sg13
Vperipartum cardiomyopathy
p526
sg15
I2
sa(dp527
g9
I203
sg10
VC0920350
p528
sg12
I2
sg13
VHT
p529
sg15
I1
sa(dp530
g9
I65
sg10
VC0004364
p531
sg12
I19
sg13
Vautoimmune diseases
p532
sg15
I2
sa(dp533
g9
I266
sg10
VC0004943
p534
sg12
I16
sg13
VBehcet's disease
p535
sg15
I2
sa(dp536
g9
I228
sg10
VC0026769
p537
sg12
I2
sg13
VMS
p538
sg15
I1
sa(dp539
g9
I126
sg10
VC0003873
p540
sg12
I20
sg13
Vrheumatoid arthritis
p541
sg15
I2
sa(dp542
g9
I328
sg10
VC0007570
p543
sg12
I14
sg13
Vceliac disease
p544
sg15
I2
sa(dp545
g9
I311
sg10
VC0877208
p546
sg12
I4
sg13
VPPCM
p547
sg15
I1
sa(dp548
g9
I178
sg10
VC0920350
p549
sg12
I23
sg13
VHashimoto's thyroiditis
p550
sg15
I2
sasa(dp551
g2
VHyperprolactinemia (HPRL) is observed in multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE) rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT) and multiple sclerosis (MS).
p552
sg4
(lp553
(dp554
g9
I20
sg39
VP01236
p555
sg12
I4
sg13
VHPRL
p556
sg15
I1
sa(dp557
g9
I0
sg39
VP01236
p558
sg12
I18
sg13
VHyperprolactinemia
p559
sg15
I1
sasg6
(lp560
(dp561
g9
I97
sg10
VC0024141
p562
sg12
I28
sg13
Vsystemic lupus erythematosus
p563
sg15
I3
sa(dp564
g9
I154
sg10
VC0003873
p565
sg12
I2
sg13
VRA
p566
sg15
I1
sa(dp567
g9
I127
sg10
VC0024141
p568
sg12
I3
sg13
VSLE
p569
sg15
I1
sa(dp570
g9
I159
sg10
VC1527336
p571
sg12
I18
sg13
VSjogren's syndrome
p572
sg15
I2
sa(dp573
g9
I179
sg10
VC1527336
p574
sg12
I2
sg13
VSS
p575
sg15
I1
sa(dp576
g9
I217
sg10
VC0026769
p577
sg12
I18
sg13
Vmultiple sclerosis
p578
sg15
I2
sa(dp579
g9
I132
sg10
VC0003873
p580
sg12
I20
sg13
Vrheumatoid arthritis
p581
sg15
I2
sa(dp582
g9
I20
sg10
VC0020514
p583
sg12
I4
sg13
VHPRL
p584
sg15
I1
sa(dp585
g9
I72
sg10
VC0004364
p586
sg12
I19
sg13
Vautoimmune diseases
p587
sg15
I2
sa(dp588
g9
I237
sg10
VC0026769
p589
sg12
I2
sg13
VMS
p590
sg15
I1
sa(dp591
g9
I0
sg10
VC0020514
p592
sg12
I18
sg13
VHyperprolactinemia
p593
sg15
I1
sa(dp594
g9
I184
sg10
VC0920350
p595
sg12
I23
sg13
VHashimoto's thyroiditis
p596
sg15
I2
sa(dp597
g9
I209
sg10
VC0920350
p598
sg12
I2
sg13
VHT
p599
sg15
I1
sasa(dp600
g2
VWe describe the role of PRL in the pathogenesis of rheumatic diseases, particularly connective tissue diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjoegren's syndrome, systemic sclerosis, polymyalgia rheumatica, and seronegative arthritis.
p601
sg4
(lp602
(dp603
g9
I24
sg39
VP01236
p604
sg12
I3
sg13
VPRL
p605
sg15
I1
sasg6
(lp606
(dp607
g9
I214
sg10
VC0036421
p608
sg12
I18
sg13
Vsystemic sclerosis
p609
sg15
I2
sa(dp610
g9
I158
sg10
VC0003873
p611
sg12
I20
sg13
Vrheumatoid arthritis
p612
sg15
I2
sa(dp613
g9
I35
sg10
VC0699748
p614
sg12
I12
sg13
Vpathogenesis
p615
sg15
I1
sa(dp616
g9
I193
sg10
VC1527336
p617
sg12
I19
sg13
VSjoegren's syndrome
p618
sg15
I2
sa(dp619
g9
I122
sg10
VC0024141
p620
sg12
I28
sg13
Vsystemic lupus erythematosus
p621
sg15
I3
sa(dp622
g9
I152
sg10
VC0024141
p623
sg12
I3
sg13
VSLE
p624
sg15
I1
sa(dp625
g9
I262
sg10
VC0409679
p626
sg12
I22
sg13
Vseronegative arthritis
p627
sg15
I2
sa(dp628
g9
I180
sg10
VC0003873
p629
sg12
I2
sg13
VRA
p630
sg15
I1
sa(dp631
g9
I84
sg10
VC0009782
p632
sg12
I26
sg13
Vconnective tissue diseases
p633
sg15
I3
sa(dp634
g9
I234
sg10
VC0032533
p635
sg12
I22
sg13
Vpolymyalgia rheumatica
p636
sg15
I2
sa(dp637
g9
I51
sg10
VC0035435
p638
sg12
I18
sg13
Vrheumatic diseases
p639
sg15
I2
sasa(dp640
g2
VMoreover, we show that the reduction of eosinophilia and the recruitment of inflammatory monocytes to the lungs required early triggering of TLR9, IFN-Gamma and CCR2 by immunotherapy components.
p641
sg4
(lp642
(dp643
g9
I147
sg39
VP01579
p644
sg12
I9
sg13
VIFN-Gamma
p645
sg15
I1
sa(dp646
g9
I161
sg39
VP41597
p647
sg12
I4
sg13
VCCR2
p648
sg15
I1
sa(dp649
g9
I141
sg39
g40
sg12
I4
sg13
VTLR9
p650
sg15
I1
sasg6
(lp651
(dp652
g9
I61
sg10
VC0271510
p653
sg12
I11
sg13
Vrecruitment
p654
sg15
I1
sa(dp655
g9
I40
sg10
VC0014457
p656
sg12
I12
sg13
Veosinophilia
p657
sg15
I1
sasa(dp658
g2
VSubjects treated with TLR9 agonists were at a higher risk of anemia (risk ratio [RR] 1.04, 95% confidence interval [CI]: 1.02-1.06), neutropenia (RR 1.16, 95% CI: 1.11-1.21), leukopenia (RR 1.16, 95% CI: 1.11-1.22), lymphopenia (RR 1.17, 95% CI: 1.10-1.25), thrombocytopenia (RR 1.20, 95% CI: 1.14-1.27), flu-like symptoms (RR 10.59, 95% CI: 3.66-30.66), diarrhea (RR 1.40, 95% CI: 1.18-1.67) and headache (RR 1.61, 95% CI: 1.26-2.06).
p659
sg4
(lp660
(dp661
g9
I305
sg39
g40
sg12
I3
sg13
Vflu
p662
sg15
I1
sa(dp663
g9
I22
sg39
g40
sg12
I4
sg13
VTLR9
p664
sg15
I1
sasg6
(lp665
(dp666
g9
I61
sg10
VC0002871
p667
sg12
I6
sg13
Vanemia
p668
sg15
I1
sa(dp669
g9
I305
sg10
VC0392171
p670
sg12
I17
sg13
Vflu-like symptoms
p671
sg15
I2
sa(dp672
g9
I355
sg10
VC0011991
p673
sg12
I8
sg13
Vdiarrhea
p674
sg15
I1
sa(dp675
g9
I397
sg10
VC0018681
p676
sg12
I8
sg13
Vheadache
p677
sg15
I1
sa(dp678
g9
I216
sg10
VC0024312
p679
sg12
I11
sg13
Vlymphopenia
p680
sg15
I1
sa(dp681
g9
I175
sg10
VC0023530
p682
sg12
I10
sg13
Vleukopenia
p683
sg15
I1
sasa(dp684
g2
VBoth the TLR7 and TLR9 agonists dose dependently reduced airway eosinophilia, while the TLR3 agonist only reduced airway eosinophilia at a dose of 1.0 mg/kg.
p685
sg4
(lp686
(dp687
g9
I18
sg39
g40
sg12
I4
sg13
VTLR9
p688
sg15
I1
sa(dp689
g9
I9
sg39
g40
sg12
I4
sg13
VTLR7
p690
sg15
I1
sa(dp691
g9
I88
sg39
g40
sg12
I4
sg13
VTLR3
p692
sg15
I1
sasg6
(lp693
(dp694
g9
I64
sg10
VC0014457
p695
sg12
I12
sg13
Veosinophilia
p696
sg15
I1
sa(dp697
g9
I64
sg10
VC0014457
p698
sg12
I12
sg13
Veosinophilia
p699
sg15
I1
sasa(dp700
g2
V&lt;p&gt;Lichen planopilaris (LPP) is a variant of lichen planus that affects the scalp causing scarring hair loss.
p701
sg4
(lp702
sg6
(lp703
(dp704
g9
I51
sg10
VC0023646
p705
sg12
I13
sg13
Vlichen planus
p706
sg15
I2
sa(dp707
g9
I96
sg10
VC0008767
p708
sg12
I8
sg13
Vscarring
p709
sg15
I1
sa(dp710
g9
I9
sg10
VC0023645
p711
sg12
I19
sg13
VLichen planopilaris
p712
sg15
I2
sasa(dp713
g2
VThis family of diseases contains 2 subgroups, largely based on clinical features: keratosis pilaris atrophicans (KPA; including keratosis pilaris atrophicans faciei/ulerythema ophryogenes, atrophoderma vermiculata, and keratosis follicularis spinulosa decalvans); and the lichen planopilaris (LPP) subgroup (including LPP, frontal fibrosing alopecia, Graham-Little-Piccardi-Lassueur Syndrome and fibrosing alopecia in a pattern distribution).
p714
sg4
(lp715
sg6
(lp716
(dp717
g9
I113
sg10
VC0263428
p718
sg12
I3
sg13
VKPA
p719
sg15
I1
sa(dp720
g9
I82
sg10
VC0263428
p721
sg12
I29
sg13
Vkeratosis pilaris atrophicans
p722
sg15
I3
sa(dp723
g9
I323
sg10
VC1274700
p724
sg12
I26
sg13
Vfrontal fibrosing alopecia
p725
sg15
I3
sa(dp726
g9
I189
sg10
VC0151514
p727
sg12
I12
sg13
Vatrophoderma
p728
sg15
I1
sa(dp729
g9
I383
sg10
VC0039082
p730
sg12
I8
sg13
VSyndrome
p731
sg15
I1
sa(dp732
g9
I293
sg10
VC0023645
p733
sg12
I3
sg13
VLPP
p734
sg15
I1
sa(dp735
g9
I219
sg10
VC0343057
p736
sg12
I42
sg13
Vkeratosis follicularis spinulosa decalvans
p737
sg15
I4
sa(dp738
g9
I165
sg10
VC0263428
p739
sg12
I22
sg13
Vulerythema ophryogenes
p740
sg15
I2
sa(dp741
g9
I82
sg10
VC0263428
p742
sg12
I29
sg13
Vkeratosis pilaris atrophicans
p743
sg15
I3
sa(dp744
g9
I293
sg10
VC0023645
p745
sg12
I3
sg13
VLPP
p746
sg15
I1
sa(dp747
g9
I272
sg10
VC0023645
p748
sg12
I19
sg13
Vlichen planopilaris
p749
sg15
I2
sasa(dp750
g2
VAn interface dermatitis with lichenoid inflammation is characteristic of the LPP group of disorders, but the literature provides scant information about the histopathology of the KPA group.
p751
sg4
(lp752
sg6
(lp753
(dp754
g9
I39
sg10
VC0021368
p755
sg12
I12
sg13
Vinflammation
p756
sg15
I1
sa(dp757
g9
I3
sg10
VC0262981
p758
sg12
I20
sg13
Vinterface dermatitis
p759
sg15
I2
sasa(dp760
g2
VRecently, there have been25 cases reported in the literature of lichen planuspigmentosus (LPPi) that preceded the developmentof frontal fibrosing alopecia (FFA), which is a variantof lichen planopilaris (LPP).
p761
sg4
(lp762
sg6
(lp763
(dp764
g9
I64
sg10
VC0023643
p765
sg12
I6
sg13
Vlichen
p766
sg15
I1
sa(dp767
g9
I90
sg10
VC0023645
p768
sg12
I3
sg13
VLPP
p769
sg15
I1
sa(dp770
g9
I128
sg10
VC1274700
p771
sg12
I26
sg13
Vfrontal fibrosing alopecia
p772
sg15
I3
sa(dp773
g9
I183
sg10
VC0023645
p774
sg12
I19
sg13
Vlichen planopilaris
p775
sg15
I2
sa(dp776
g9
I156
sg10
VC1274700
p777
sg12
I3
sg13
VFFA
p778
sg15
I1
sasa(dp779
g2
VLower levels of acylCer and LPP accompany skin diseases, such as atopic dermatitis, lamellar ichthyosis, and psoriasis.
p780
sg4
(lp781
sg6
(lp782
(dp783
g9
I109
sg10
VC0033860
p784
sg12
I9
sg13
Vpsoriasis
p785
sg15
I1
sa(dp786
g9
I84
sg10
VC0020758
p787
sg12
I19
sg13
Vlamellar ichthyosis
p788
sg15
I2
sa(dp789
g9
I42
sg10
VC0037274
p790
sg12
I13
sg13
Vskin diseases
p791
sg15
I2
sa(dp792
g9
I65
sg10
VC0011615
p793
sg12
I17
sg13
Vatopic dermatitis
p794
sg15
I2
sasa(dp795
g2
VA number of associations such as hepatitis C virus infection, frontal fibrosing alopecia, acrokeratosis of Bazex and nephrotic syndrome have been reported with LPP.
p796
sg4
(lp797
sg6
(lp798
(dp799
g9
I62
sg10
VC1274700
p800
sg12
I26
sg13
Vfrontal fibrosing alopecia
p801
sg15
I3
sa(dp802
g9
I117
sg10
VC0027726
p803
sg12
I18
sg13
Vnephrotic syndrome
p804
sg15
I2
sa(dp805
g9
I90
sg10
VC0001202
p806
sg12
I13
sg13
Vacrokeratosis
p807
sg15
I1
sa(dp808
g9
I33
sg10
VC0019196
p809
sg12
I11
sg13
Vhepatitis C
p810
sg15
I2
sa(dp811
g9
I45
sg10
VC0042769
p812
sg12
I15
sg13
Vvirus infection
p813
sg15
I2
sasa(dp814
g2
VLichen planopilaris (LPP) is a follicular variant of lichen planus.
p815
sg4
(lp816
sg6
(lp817
(dp818
g9
I21
sg10
VC0023645
p819
sg12
I3
sg13
VLPP
p820
sg15
I1
sa(dp821
g9
I0
sg10
VC0023645
p822
sg12
I19
sg13
VLichen planopilaris
p823
sg15
I2
sa(dp824
g9
I53
sg10
VC0023646
p825
sg12
I13
sg13
Vlichen planus
p826
sg15
I2
sasa(dp827
g2
VHowever, genes like HSP90, PAK2, CD247 and others included in the first 1% of the prioritized list need to be further explored in preeclampsia pathogenesis through experimental approaches.
p828
sg4
(lp829
(dp830
g9
I20
sg39
VP07900
p831
sg12
I5
sg13
VHSP90
p832
sg15
I1
sa(dp833
g9
I33
sg39
VP20963
p834
sg12
I5
sg13
VCD247
p835
sg15
I1
sa(dp836
g9
I27
sg39
g40
sg12
I4
sg13
VPAK2
p837
sg15
I1
sasg6
(lp838
(dp839
g9
I143
sg10
VC0699748
p840
sg12
I12
sg13
Vpathogenesis
p841
sg15
I1
sa(dp842
g9
I130
sg10
VC0032914
p843
sg12
I12
sg13
Vpreeclampsia
p844
sg15
I1
sasa(dp845
g2
VWe report a case of acute pancreatitis with diabetic ketoacidosis associated with increased serum myoglobin concentration, acute renal failure, and disseminated intravascular coagulation.
p846
sg4
(lp847
(dp848
g9
I92
sg39
VP02144
p849
sg12
I15
sg13
Vserum myoglobin
p850
sg15
I2
sasg6
(lp851
(dp852
g9
I148
sg10
VC0012739
p853
sg12
I38
sg13
Vdisseminated intravascular coagulation
p854
sg15
I3
sa(dp855
g9
I44
sg10
VC0011880
p856
sg12
I21
sg13
Vdiabetic ketoacidosis
p857
sg15
I2
sa(dp858
g9
I20
sg10
VC0001339
p859
sg12
I18
sg13
Vacute pancreatitis
p860
sg15
I2
sa(dp861
g9
I123
sg10
VC0022660
p862
sg12
I19
sg13
Vacute renal failure
p863
sg15
I3
sasa(dp864
g2
VWe examined the relationship among acute pancreatitis, diabetic ketoacidosis, and hypermyoglobinemia in the literature.
p865
sg4
(lp866
sg6
(lp867
(dp868
g9
I35
sg10
VC0001339
p869
sg12
I18
sg13
Vacute pancreatitis
p870
sg15
I2
sa(dp871
g9
I55
sg10
VC0011880
p872
sg12
I21
sg13
Vdiabetic ketoacidosis
p873
sg15
I2
sasa(dp874
g2
VThe frequency of nontraumatic rhabdomyolysis in diabetic ketoacidosis was investigated by serial measurements of the serum levels of myoglobin and the serum activity of creatine kinase isoenzyme MM in 12 consecutively admitted ketoacidotic patients.
p875
sg4
(lp876
(dp877
g9
I133
sg39
VP02144
p878
sg12
I9
sg13
Vmyoglobin
p879
sg15
I1
sa(dp880
g9
I169
sg39
VP12532
p881
sg12
I15
sg13
Vcreatine kinase
p882
sg15
I2
sasg6
(lp883
(dp884
g9
I30
sg10
VC0035410
p885
sg12
I14
sg13
Vrhabdomyolysis
p886
sg15
I1
sa(dp887
g9
I48
sg10
VC0011880
p888
sg12
I21
sg13
Vdiabetic ketoacidosis
p889
sg15
I2
sasa(dp890
g2
VIn conclusion, our findings suggest that nontraumatic rhabdomyolysis with hypermyoglobinaemia and elevated serum activity of creatine kinase isoenzyme MM may be a hitherto unrecognized common feature of diabetic ketoacidosis.
p891
sg4
(lp892
(dp893
g9
I125
sg39
VP12532
p894
sg12
I28
sg13
Vcreatine kinase isoenzyme MM
p895
sg15
I4
sasg6
(lp896
(dp897
g9
I54
sg10
VC0035410
p898
sg12
I14
sg13
Vrhabdomyolysis
p899
sg15
I1
sa(dp900
g9
I203
sg10
VC0011880
p901
sg12
I21
sg13
Vdiabetic ketoacidosis
p902
sg15
I2
sasa(dp903
g2
VBioinformatics and luciferase reporter assays demonstrated that miR-495 targets the 3'-untranslated region of high-mobility group nucleosome-binding domain 5 (HMGN5), a potential oncogene in various types of cancers.
p904
sg4
(lp905
(dp906
g9
I110
sg39
VP00390
p907
sg12
I47
sg13
Vhigh-mobility group nucleosome-binding domain 5
p908
sg15
I5
sa(dp909
g9
I159
sg39
VP82970
p910
sg12
I5
sg13
VHMGN5
p911
sg15
I1
sasg6
(lp912
(dp913
g9
I208
sg10
VC0006826
p914
sg12
I7
sg13
Vcancers
p915
sg15
I1
sasa(dp916
g2
VHigh-mobility group nucleosome-binding domain 5 (HMGN5), a well-known oncogene in gliomas, was identified as a functional target of miR-409-3p using bioinformatics, dual-luciferase reporter assay, real-time quantitative polymerase chain reaction, and Western blot analysis.
p917
sg4
(lp918
(dp919
g9
I132
sg39
g40
sg12
I10
sg13
VmiR-409-3p
p920
sg15
I1
sa(dp921
g9
I49
sg39
VP82970
p922
sg12
I5
sg13
VHMGN5
p923
sg15
I1
sa(dp924
g9
I0
sg39
VP00390
p925
sg12
I47
sg13
VHigh-mobility group nucleosome-binding domain 5
p926
sg15
I5
sasg6
(lp927
(dp928
g9
I82
sg10
VC0017638
p929
sg12
I7
sg13
Vgliomas
p930
sg15
I1
sasa(dp931
g2
VRestoration of HMGN5 expression significantly reversed the inhibitory effects of miR-409-3p overexpression on glioma cell invasion and proliferation.
p932
sg4
(lp933
(dp934
g9
I81
sg39
g40
sg12
I10
sg13
VmiR-409-3p
p935
sg15
I1
sa(dp936
g9
I15
sg39
VP82970
p937
sg12
I5
sg13
VHMGN5
p938
sg15
I1
sasg6
(lp939
(dp940
g9
I135
sg10
VC0334094
p941
sg12
I13
sg13
Vproliferation
p942
sg15
I1
sa(dp943
g9
I110
sg10
VC0017638
p944
sg12
I6
sg13
Vglioma
p945
sg15
I1
sa(dp946
g9
I117
sg10
VC2699153
p947
sg12
I13
sg13
Vcell invasion
p948
sg15
I2
sasa(dp949
g2
VTaken together, our results suggest that miR-409-3p inhibits glioma cell invasion and proliferation by targeting HMGN5, representing a potential therapeutic target for glioma.
p950
sg4
(lp951
(dp952
g9
I41
sg39
g40
sg12
I10
sg13
VmiR-409-3p
p953
sg15
I1
sa(dp954
g9
I113
sg39
VP82970
p955
sg12
I5
sg13
VHMGN5
p956
sg15
I1
sasg6
(lp957
(dp958
g9
I86
sg10
VC0334094
p959
sg12
I13
sg13
Vproliferation
p960
sg15
I1
sa(dp961
g9
I61
sg10
VC0017638
p962
sg12
I6
sg13
Vglioma
p963
sg15
I1
sa(dp964
g9
I68
sg10
VC2699153
p965
sg12
I13
sg13
Vcell invasion
p966
sg15
I2
sa(dp967
g9
I61
sg10
VC0017638
p968
sg12
I6
sg13
Vglioma
p969
sg15
I1
sasa(dp970
g2
VIt was first discovered in mouse, and recent studies found that the expressions of HMGN5 in many human cancers were also highly regulated, such as prostate, bladder, breast, and lung and clear cell renal cell carcinoma.
p971
sg4
(lp972
(dp973
g9
I83
sg39
VP82970
p974
sg12
I5
sg13
VHMGN5
p975
sg15
I1
sasg6
(lp976
(dp977
g9
I103
sg10
VC0006826
p978
sg12
I7
sg13
Vcancers
p979
sg15
I1
sa(dp980
g9
I187
sg10
VC0279702
p981
sg12
I31
sg13
Vclear cell renal cell carcinoma
p982
sg15
I5
sasa(dp983
g2
VImportantly, deficiency of HMGN5 has been shown to be linked to cancer cell growth, cell cycle regulation, migration, invasion, and clinical outcomes, and it represents a promising therapeutic target for many malignant tumors.
p984
sg4
(lp985
(dp986
g9
I27
sg39
VP82970
p987
sg12
I5
sg13
VHMGN5
p988
sg15
I1
sasg6
(lp989
(dp990
g9
I64
sg10
VC1516170
p991
sg12
I18
sg13
Vcancer cell growth
p992
sg15
I3
sa(dp993
g9
I209
sg10
VC0006826
p994
sg12
I16
sg13
Vmalignant tumors
p995
sg15
I2
sa(dp996
g9
I118
sg10
VC2699153
p997
sg12
I8
sg13
Vinvasion
p998
sg15
I1
sasa(dp999
g2
VIn the present review, we provide an overview of the current knowledge concerning the role of HMGN5 in cancer development and progression.
p1000
sg4
(lp1001
(dp1002
g9
I94
sg39
VP82970
p1003
sg12
I5
sg13
VHMGN5
p1004
sg15
I1
sasg6
(lp1005
(dp1006
g9
I103
sg10
VC0006826
p1007
sg12
I6
sg13
Vcancer
p1008
sg15
I1
sasa(dp1009
g2
VNucleosome-binding protein 1 (NSBP1) has been suggested as an oncogene in various types of human cancers.
p1010
sg4
(lp1011
(dp1012
g9
I0
sg39
VP14222
p1013
sg12
I28
sg13
VNucleosome-binding protein 1
p1014
sg15
I3
sa(dp1015
g9
I30
sg39
VP82970
p1016
sg12
I5
sg13
VNSBP1
p1017
sg15
I1
sasg6
(lp1018
(dp1019
g9
I97
sg10
VC0006826
p1020
sg12
I7
sg13
Vcancers
p1021
sg15
I1
sasa(dp1022
g2
VWe found that NSBP1 was highly expressed in non-small cell lung cancer (NSCLC) cells, and knockdown of NSBP1 by NSBP1 small interfering RNA (siRNA) significantly suppressed NSCLC cell proliferation and invasion.
p1023
sg4
(lp1024
(dp1025
g9
I112
sg39
VP82970
p1026
sg12
I27
sg13
VNSBP1 small interfering RNA
p1027
sg15
I4
sa(dp1028
g9
I14
sg39
VP82970
p1029
sg12
I5
sg13
VNSBP1
p1030
sg15
I1
sa(dp1031
g9
I14
sg39
VP82970
p1032
sg12
I5
sg13
VNSBP1
p1033
sg15
I1
sasg6
(lp1034
(dp1035
g9
I72
sg10
VC0007131
p1036
sg12
I5
sg13
VNSCLC
p1037
sg15
I1
sa(dp1038
g9
I44
sg10
VC0007131
p1039
sg12
I26
sg13
Vnon-small cell lung cancer
p1040
sg15
I4
sa(dp1041
g9
I184
sg10
VC0334094
p1042
sg12
I13
sg13
Vproliferation
p1043
sg15
I1
sa(dp1044
g9
I72
sg10
VC0007131
p1045
sg12
I5
sg13
VNSCLC
p1046
sg15
I1
sa(dp1047
g9
I202
sg10
VC2699153
p1048
sg12
I8
sg13
Vinvasion
p1049
sg15
I1
sasa(dp1050
g2
VOverexpression of miR-326 significantly inhibited NSCLC cell proliferation and invasion, which mimicked the effect of NSBP1 siRNA.
p1051
sg4
(lp1052
(dp1053
g9
I118
sg39
VP82970
p1054
sg12
I11
sg13
VNSBP1 siRNA
p1055
sg15
I2
sa(dp1056
g9
I18
sg39
g40
sg12
I7
sg13
VmiR-326
p1057
sg15
I1
sasg6
(lp1058
(dp1059
g9
I50
sg10
VC0007131
p1060
sg12
I5
sg13
VNSCLC
p1061
sg15
I1
sa(dp1062
g9
I79
sg10
VC2699153
p1063
sg12
I8
sg13
Vinvasion
p1064
sg15
I1
sa(dp1065
g9
I61
sg10
VC0334094
p1066
sg12
I13
sg13
Vproliferation
p1067
sg15
I1
sasa(dp1068
g2
VFurthermore, suppression of NSBP1 by NSBP1 siRNA or miR-326 overexpression remarkably repressed the expression of cyclin B1 and matrix metalloproteinase 9 (MMP9), which are associated with cancer cell proliferation and invasion.
p1069
sg4
(lp1070
(dp1071
g9
I114
sg39
VP14635
p1072
sg12
I9
sg13
Vcyclin B1
p1073
sg15
I2
sa(dp1074
g9
I37
sg39
VP82970
p1075
sg12
I11
sg13
VNSBP1 siRNA
p1076
sg15
I2
sa(dp1077
g9
I28
sg39
VP82970
p1078
sg12
I5
sg13
VNSBP1
p1079
sg15
I1
sa(dp1080
g9
I156
sg39
VP14780
p1081
sg12
I4
sg13
VMMP9
p1082
sg15
I1
sa(dp1083
g9
I52
sg39
g40
sg12
I7
sg13
VmiR-326
p1084
sg15
I1
sa(dp1085
g9
I128
sg39
VP14780
p1086
sg12
I26
sg13
Vmatrix metalloproteinase 9
p1087
sg15
I3
sasg6
(lp1088
(dp1089
g9
I201
sg10
VC0334094
p1090
sg12
I13
sg13
Vproliferation
p1091
sg15
I1
sa(dp1092
g9
I219
sg10
VC2699153
p1093
sg12
I8
sg13
Vinvasion
p1094
sg15
I1
sa(dp1095
g9
I13
sg10
VC0221103
p1096
sg12
I11
sg13
Vsuppression
p1097
sg15
I1
sa(dp1098
g9
I189
sg10
VC0006826
p1099
sg12
I6
sg13
Vcancer
p1100
sg15
I1
sasa(dp1101
g2
VIn addition, an inverse correlation between miR-326 and NSBP1 expression levels was found in NSCLC clinical specimens.
p1102
sg4
(lp1103
(dp1104
g9
I56
sg39
VP82970
p1105
sg12
I5
sg13
VNSBP1
p1106
sg15
I1
sasg6
(lp1107
(dp1108
g9
I93
sg10
VC0007131
p1109
sg12
I5
sg13
VNSCLC
p1110
sg15
I1
sasa(dp1111
g2
VOur study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells.
p1112
sg4
(lp1113
(dp1114
g9
I60
sg39
VP82970
p1115
sg12
I5
sg13
VNSBP1
p1116
sg15
I1
sa(dp1117
g9
I70
sg39
g40
sg12
I7
sg13
VmiR-326
p1118
sg15
I1
sasg6
(lp1119
(dp1120
g9
I133
sg10
VC2699153
p1121
sg12
I8
sg13
Vinvasion
p1122
sg15
I1
sa(dp1123
g9
I115
sg10
VC0334094
p1124
sg12
I13
sg13
Vproliferation
p1125
sg15
I1
sa(dp1126
g9
I145
sg10
VC0007131
p1127
sg12
I5
sg13
VNSCLC
p1128
sg15
I1
sasa(dp1129
g2
VThus, miR-326-NSBP1 is a promising candidate target for developing novel anticancer therapeutics for NSCLC.
p1130
sg4
(lp1131
(dp1132
g9
I6
sg39
g40
sg12
I13
sg13
VmiR-326-NSBP1
p1133
sg15
I1
sasg6
(lp1134
(dp1135
g9
I101
sg10
VC0007131
p1136
sg12
I5
sg13
VNSCLC
p1137
sg15
I1
sasa(dp1138
g2
VCorrelation analysis also showed that HMGN5 expression levels were significantly inversely correlated with the miR-340 expression in prostate cancer tissues.
p1139
sg4
(lp1140
(dp1141
g9
I38
sg39
VP82970
p1142
sg12
I5
sg13
VHMGN5
p1143
sg15
I1
sa(dp1144
g9
I111
sg39
g40
sg12
I7
sg13
VmiR-340
p1145
sg15
I1
sasg6
(lp1146
(dp1147
g9
I133
sg10
VC0600139
p1148
sg12
I15
sg13
Vprostate cancer
p1149
sg15
I2
sasa(dp1150
g2
VIn addition, overexpression of HMGN5 significantly reversed the inhibitory effect of miR-340 on prostate cancer cell proliferation and invasion.
p1151
sg4
(lp1152
(dp1153
g9
I31
sg39
VP82970
p1154
sg12
I5
sg13
VHMGN5
p1155
sg15
I1
sa(dp1156
g9
I85
sg39
g40
sg12
I7
sg13
VmiR-340
p1157
sg15
I1
sasg6
(lp1158
(dp1159
g9
I135
sg10
VC2699153
p1160
sg12
I8
sg13
Vinvasion
p1161
sg15
I1
sa(dp1162
g9
I117
sg10
VC0334094
p1163
sg12
I13
sg13
Vproliferation
p1164
sg15
I1
sa(dp1165
g9
I96
sg10
VC0600139
p1166
sg12
I15
sg13
Vprostate cancer
p1167
sg15
I2
sasa(dp1168
g2
VMoreover, the decreased miR-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5.
p1169
sg4
(lp1170
(dp1171
g9
I146
sg39
VP82970
p1172
sg12
I5
sg13
VHMGN5
p1173
sg15
I1
sasg6
(lp1174
(dp1175
g9
I81
sg10
VC1739135
p1176
sg12
I30
sg13
Vprogression of prostate cancer
p1177
sg15
I4
sasa(dp1178
g2
VThus, miR340 and its target gene HMGN5 can serve as potentially useful therapeutic candidates for prostate cancer treatment.
p1179
sg4
(lp1180
(dp1181
g9
I33
sg39
VP82970
p1182
sg12
I5
sg13
VHMGN5
p1183
sg15
I1
sasg6
(lp1184
(dp1185
g9
I98
sg10
VC0600139
p1186
sg12
I15
sg13
Vprostate cancer
p1187
sg15
I2
sasa(dp1188
g2
VThe high-mobility group nucleosome-binding protein-5 (HMGN5) is frequently overexpressed in various malignant cancers.
p1189
sg4
(lp1190
(dp1191
g9
I54
sg39
VP82970
p1192
sg12
I5
sg13
VHMGN5
p1193
sg15
I1
sa(dp1194
g9
I4
sg39
VP00390
p1195
sg12
I48
sg13
Vhigh-mobility group nucleosome-binding protein-5
p1196
sg15
I4
sasg6
(lp1197
(dp1198
g9
I110
sg10
VC0006826
p1199
sg12
I7
sg13
Vcancers
p1200
sg15
I1
sasa(dp1201
g2
VHowever, the potential correlation between HMGN5 and prognosis in patients with meningiomas remains unknown.
p1202
sg4
(lp1203
(dp1204
g9
I43
sg39
VP82970
p1205
sg12
I5
sg13
VHMGN5
p1206
sg15
I1
sasg6
(lp1207
(dp1208
g9
I80
sg10
VC0025286
p1209
sg12
I11
sg13
Vmeningiomas
p1210
sg15
I1
sasa(dp1211
g2
VIn the present study, we explored the expression of HMGN5 in meningiomas with immunohistochemistry and correlated the results to the patient outcome.
p1212
sg4
(lp1213
(dp1214
g9
I52
sg39
VP82970
p1215
sg12
I5
sg13
VHMGN5
p1216
sg15
I1
sasg6
(lp1217
(dp1218
g9
I61
sg10
VC0025286
p1219
sg12
I11
sg13
Vmeningiomas
p1220
sg15
I1
sasa(dp1221
g2
VWe demonstrate that there is a positive association between HMGN5 expression and meningioma histological grade.
p1222
sg4
(lp1223
(dp1224
g9
I60
sg39
VP82970
p1225
sg12
I5
sg13
VHMGN5
p1226
sg15
I1
sasg6
(lp1227
(dp1228
g9
I81
sg10
VC0025286
p1229
sg12
I10
sg13
Vmeningioma
p1230
sg15
I1
sasa(dp1231
g2
VStatistical analysis reveals that lower HMGN5 expression predict lower meningioma recurrence.
p1232
sg4
(lp1233
(dp1234
g9
I40
sg39
VP82970
p1235
sg12
I5
sg13
VHMGN5
p1236
sg15
I1
sasg6
(lp1237
(dp1238
g9
I82
sg10
VC1458156
p1239
sg12
I10
sg13
Vrecurrence
p1240
sg15
I1
sa(dp1241
g9
I71
sg10
VC0025286
p1242
sg12
I10
sg13
Vmeningioma
p1243
sg15
I1
sasa(dp1244
g2
VOur results further revealed that HMGN5 inhibition decreased P-glycoprotein (MDR-1) expression without affecting multidrug resistance associated proteins 1 (MRP-1) expression to increase chemosensitivity to temozolomide (TMZ) of meningioma cells.
p1245
sg4
(lp1246
(dp1247
g9
I113
sg39
g40
sg12
I42
sg13
Vmultidrug resistance associated proteins 1
p1248
sg15
I5
sa(dp1249
g9
I61
sg39
VP08183
p1250
sg12
I14
sg13
VP-glycoprotein
p1251
sg15
I1
sa(dp1252
g9
I34
sg39
VP82970
p1253
sg12
I5
sg13
VHMGN5
p1254
sg15
I1
sa(dp1255
g9
I77
sg39
g40
sg12
I5
sg13
VMDR-1
p1256
sg15
I1
sa(dp1257
g9
I157
sg39
VP08183
p1258
sg12
I5
sg13
VMRP-1
p1259
sg15
I1
sasg6
(lp1260
(dp1261
g9
I229
sg10
VC0025286
p1262
sg12
I10
sg13
Vmeningioma
p1263
sg15
I1
sasa(dp1264
g2
VCollectively, this study indicates that HMGN5 is a novel target for developing effective therapeutic strategies for malignant meningiomas.
p1265
sg4
(lp1266
(dp1267
g9
I40
sg39
VP82970
p1268
sg12
I5
sg13
VHMGN5
p1269
sg15
I1
sasg6
(lp1270
(dp1271
g9
I116
sg10
VC0259785
p1272
sg12
I21
sg13
Vmalignant meningiomas
p1273
sg15
I2
sasa(dp1274
g2
VLuciferase reporter assay showed that miR-186 targets NSBP1 3'-untranslated region (UTR) directly and suppresses NSBP1 (HMGN5) expression in human bladder cancer cells.
p1275
sg4
(lp1276
(dp1277
g9
I54
sg39
VP82970
p1278
sg12
I7
sg13
VNSBP1 3
p1279
sg15
I2
sa(dp1280
g9
I54
sg39
VP82970
p1281
sg12
I5
sg13
VNSBP1
p1282
sg15
I1
sa(dp1283
g9
I38
sg39
g40
sg12
I15
sg13
VmiR-186 targets
p1284
sg15
I2
sa(dp1285
g9
I120
sg39
VP82970
p1286
sg12
I5
sg13
VHMGN5
p1287
sg15
I1
sasg6
(lp1288
(dp1289
g9
I147
sg10
VC0699885
p1290
sg12
I14
sg13
Vbladder cancer
p1291
sg15
I2
sasa(dp1292
g2
VOur data first time identified miR-186 as the upstream regulator of NSBP1 and also suggest miR-186-suppressed NSBP1 as a novel therapeutic approach for bladder cancer.
p1293
sg4
(lp1294
(dp1295
g9
I91
sg39
g40
sg12
I24
sg13
VmiR-186-suppressed NSBP1
p1296
sg15
I2
sa(dp1297
g9
I68
sg39
VP82970
p1298
sg12
I5
sg13
VNSBP1
p1299
sg15
I1
sa(dp1300
g9
I31
sg39
g40
sg12
I7
sg13
VmiR-186
p1301
sg15
I1
sasg6
(lp1302
(dp1303
g9
I152
sg10
VC0699885
p1304
sg12
I14
sg13
Vbladder cancer
p1305
sg15
I2
sasa(dp1306
g2
VIn this study, we show that TK1 is upregulated and localizes on the plasma membrane of Burkitt's lymphoma, acute promyelocytic leukemia, T cell leukemia, and acute lymphoblastic leukemia (ALL).
p1307
sg4
(lp1308
(dp1309
g9
I28
sg39
VP04183
p1310
sg12
I3
sg13
VTK1
p1311
sg15
I1
sasg6
(lp1312
(dp1313
g9
I107
sg10
VC0023487
p1314
sg12
I28
sg13
Vacute promyelocytic leukemia
p1315
sg15
I3
sa(dp1316
g9
I87
sg10
VC0006413
p1317
sg12
I18
sg13
VBurkitt's lymphoma
p1318
sg15
I2
sa(dp1319
g9
I188
sg10
VC1961102
p1320
sg12
I3
sg13
VALL
p1321
sg15
I1
sa(dp1322
g9
I158
sg10
VC1961102
p1323
sg12
I28
sg13
Vacute lymphoblastic leukemia
p1324
sg15
I3
sa(dp1325
g9
I137
sg10
VC0023492
p1326
sg12
I15
sg13
VT cell leukemia
p1327
sg15
I3
sasa(dp1328
g2
VTK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma.
p1329
sg4
(lp1330
(dp1331
g9
I0
sg39
VP04183
p1332
sg12
I3
sg13
VTK1
p1333
sg15
I1
sasg6
(lp1334
(dp1335
g9
I57
sg10
VC0280100
p1336
sg12
I12
sg13
Vsolid tumors
p1337
sg15
I2
sa(dp1338
g9
I170
sg10
VC0024305
p1339
sg12
I20
sg13
Vnon-Hodgkin lymphoma
p1340
sg15
I2
sa(dp1341
g9
I74
sg10
VC0023434
p1342
sg12
I28
sg13
Vchronic lymphocytic leukemia
p1343
sg15
I3
sasa(dp1344
g2
VIn this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL).
p1345
sg4
(lp1346
(dp1347
g9
I46
sg39
VP04183
p1348
sg12
I3
sg13
VTK1
p1349
sg15
I1
sasg6
(lp1350
(dp1351
g9
I135
sg10
VC0024301
p1352
sg12
I19
sg13
Vfollicular lymphoma
p1353
sg15
I2
sa(dp1354
g9
I156
sg10
VC0024301
p1355
sg12
I2
sg13
VFL
p1356
sg15
I1
sasa(dp1357
g2
VThe TK1 level at the time of treatment initiation was shown to correlate with the clinical stage, Follicular Lymphoma International Prognostic Index (FLIPI) score, Beta(2)-microglobulin level, lactate dehydrogenase level and B symptoms.
p1358
sg4
(lp1359
(dp1360
g9
I164
sg39
VP61769
p1361
sg12
I21
sg13
VBeta(2)-microglobulin
p1362
sg15
I1
sa(dp1363
g9
I4
sg39
VP04183
p1364
sg12
I3
sg13
VTK1
p1365
sg15
I1
sa(dp1366
g9
I193
sg39
VP49366
p1367
sg12
I21
sg13
Vlactate dehydrogenase
p1368
sg15
I2
sasg6
(lp1369
(dp1370
g9
I98
sg10
VC0024301
p1371
sg12
I19
sg13
VFollicular Lymphoma
p1372
sg15
I2
sasa(dp1373
g2
VWe show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome).
p1374
sg4
(lp1375
(dp1376
g9
I134
sg39
VP28907
p1377
sg12
I4
sg13
VCD38
p1378
sg15
I1
sa(dp1379
g9
I96
sg39
g40
sg12
I36
sg13
Vimmunoglobulin variable region genes
p1380
sg15
I4
sa(dp1381
g9
I24
sg39
VP04183
p1382
sg12
I3
sg13
VTK1
p1383
sg15
I1
sa(dp1384
g9
I143
sg39
VP43403
p1385
sg12
I6
sg13
VZAP-70
p1386
sg15
I1
sasg6
(lp1387
(dp1388
g9
I219
sg10
VC0349631
p1389
sg12
I16
sg13
VRichter syndrome
p1390
sg15
I2
sa(dp1391
g9
I202
sg10
VC0079731
p1392
sg12
I15
sg13
VB-cell lymphoma
p1393
sg15
I2
sasa(dp1394
g2
VIn the present study, we revealed that the Hippo transducer, the transcriptional coactivator with PDZ-binding motif (TAZ), acts as a downstream mediator of PODXL in colon cancer.
p1395
sg4
(lp1396
(dp1397
g9
I156
sg39
g40
sg12
I5
sg13
VPODXL
p1398
sg15
I1
sa(dp1399
g9
I65
sg39
g40
sg12
I50
sg13
Vtranscriptional coactivator with PDZ-binding motif
p1400
sg15
I5
sa(dp1401
g9
I117
sg39
g40
sg12
I3
sg13
VTAZ
p1402
sg15
I1
sasg6
(lp1403
(dp1404
g9
I165
sg10
VC0699790
p1405
sg12
I12
sg13
Vcolon cancer
p1406
sg15
I2
sasa(dp1407
g2
VMoreover, PODXL plays a critical role in cancer stemness, invasiveness, and sensitivity to chemotherapies in colon cancer HCT15 cells.
p1408
sg4
(lp1409
(dp1410
g9
I10
sg39
g40
sg12
I5
sg13
VPODXL
p1411
sg15
I1
sasg6
(lp1412
(dp1413
g9
I41
sg10
VC0006826
p1414
sg12
I6
sg13
Vcancer
p1415
sg15
I1
sa(dp1416
g9
I109
sg10
VC0699790
p1417
sg12
I12
sg13
Vcolon cancer
p1418
sg15
I2
sasa(dp1419
g2
VNotably, expression of PODXL showed a positive correlation with stem-like and epithelial-mesenchymal transition (EMT) core signatures, and was associated with poor survival outcomes in patients with colon cancer.
p1420
sg4
(lp1421
(dp1422
g9
I23
sg39
g40
sg12
I5
sg13
VPODXL
p1423
sg15
I1
sasg6
(lp1424
(dp1425
g9
I199
sg10
VC0699790
p1426
sg12
I12
sg13
Vcolon cancer
p1427
sg15
I2
sa(dp1428
g9
I101
sg10
VC0599156
p1429
sg12
I10
sg13
Vtransition
p1430
sg15
I1
sasa(dp1431
g2
VThese findings provide novel insights into the molecular mechanism of PODXL-mediated tumorigenesis in colon cancer.
p1432
sg4
(lp1433
(dp1434
g9
I70
sg39
g40
sg12
I5
sg13
VPODXL
p1435
sg15
I1
sasg6
(lp1436
(dp1437
g9
I102
sg10
VC0699790
p1438
sg12
I12
sg13
Vcolon cancer
p1439
sg15
I2
sa(dp1440
g9
I85
sg10
VC0007621
p1441
sg12
I13
sg13
Vtumorigenesis
p1442
sg15
I1
sasa(dp1443
g2
VPodocalyxin (PODXL), which belongs to the CD34 family and regulates cell morphology, has been linked to EMT in lung cancer, and PODXL overexpression is associated with poor prognosis in several different classes of cancers.
p1444
sg4
(lp1445
(dp1446
g9
I104
sg39
g40
sg12
I3
sg13
VEMT
p1447
sg15
I1
sa(dp1448
g9
I13
sg39
g40
sg12
I5
sg13
VPODXL
p1449
sg15
I1
sa(dp1450
g9
I42
sg39
VP28906
p1451
sg12
I11
sg13
VCD34 family
p1452
sg15
I2
sa(dp1453
g9
I13
sg39
g40
sg12
I5
sg13
VPODXL
p1454
sg15
I1
sa(dp1455
g9
I0
sg39
g40
sg12
I11
sg13
VPodocalyxin
p1456
sg15
I1
sasg6
(lp1457
(dp1458
g9
I215
sg10
VC0006826
p1459
sg12
I7
sg13
Vcancers
p1460
sg15
I1
sa(dp1461
g9
I111
sg10
VC0684249
p1462
sg12
I11
sg13
Vlung cancer
p1463
sg15
I2
sasa(dp1464
g2
VThe aim of this study was to clarify the role of PODXL overexpression in EMT in lung cancer, and to determine the prognostic value of PODXL overexpression in tumors from lung cancer patients.
p1465
sg4
(lp1466
(dp1467
g9
I49
sg39
g40
sg12
I5
sg13
VPODXL
p1468
sg15
I1
sa(dp1469
g9
I73
sg39
g40
sg12
I3
sg13
VEMT
p1470
sg15
I1
sa(dp1471
g9
I49
sg39
g40
sg12
I5
sg13
VPODXL
p1472
sg15
I1
sasg6
(lp1473
(dp1474
g9
I158
sg10
VC0027651
p1475
sg12
I6
sg13
Vtumors
p1476
sg15
I1
sa(dp1477
g9
I80
sg10
VC0684249
p1478
sg12
I11
sg13
Vlung cancer
p1479
sg15
I2
sa(dp1480
g9
I80
sg10
VC0684249
p1481
sg12
I11
sg13
Vlung cancer
p1482
sg15
I2
sasa(dp1483
g2
VThe morphology, EMT marker expression, and migration and invasion abilities of engineered A549 PODXL-knockdown (KD) or PODXL-overexpression (OE) lung adenocarcinoma cells were examined.
p1484
sg4
(lp1485
sg6
(lp1486
(dp1487
g9
I145
sg10
VC0152013
p1488
sg12
I19
sg13
Vlung adenocarcinoma
p1489
sg15
I2
sa(dp1490
g9
I57
sg10
VC2699153
p1491
sg12
I8
sg13
Vinvasion
p1492
sg15
I1
sasa(dp1493
g2
VPODXL expression levels were assessed by immunohistochemistry in 114 human clinical lung adenocarcinoma specimens and correlated with clinical outcomes.
p1494
sg4
(lp1495
(dp1496
g9
I0
sg39
g40
sg12
I5
sg13
VPODXL
p1497
sg15
I1
sasg6
(lp1498
(dp1499
g9
I84
sg10
VC0152013
p1500
sg12
I19
sg13
Vlung adenocarcinoma
p1501
sg15
I2
sasa(dp1502
g2
VA highly selective inhibitor of phosphatidylinositol 3-kinase-Akt signaling attenuated EMT of PODXL-OE cells, while a transforming growth factor inhibitor did not, suggesting that PODXL induces EMT of lung adenocarcinoma cells via the phosphatidylinositol 3-kinase pathway.
p1503
sg4
(lp1504
(dp1505
g9
I87
sg39
g40
sg12
I3
sg13
VEMT
p1506
sg15
I1
sa(dp1507
g9
I118
sg39
g40
sg12
I26
sg13
Vtransforming growth factor
p1508
sg15
I3
sa(dp1509
g9
I94
sg39
g40
sg12
I5
sg13
VPODXL
p1510
sg15
I1
sa(dp1511
g9
I32
sg39
VP42336
p1512
sg12
I29
sg13
Vphosphatidylinositol 3-kinase
p1513
sg15
I2
sa(dp1514
g9
I32
sg39
VP42336
p1515
sg12
I29
sg13
Vphosphatidylinositol 3-kinase
p1516
sg15
I2
sa(dp1517
g9
I94
sg39
g40
sg12
I8
sg13
VPODXL-OE
p1518
sg15
I1
sa(dp1519
g9
I62
sg39
g40
sg12
I3
sg13
VAkt
p1520
sg15
I1
sasg6
(lp1521
(dp1522
g9
I201
sg10
VC0152013
p1523
sg12
I19
sg13
Vlung adenocarcinoma
p1524
sg15
I2
sasa(dp1525
g2
VIn lung adenocarcinoma clinical specimens, PODXL expression was detected in minimally invasive and invasive adenocarcinoma, but not in non-invasive adenocarcinoma.
p1526
sg4
(lp1527
(dp1528
g9
I43
sg39
g40
sg12
I5
sg13
VPODXL
p1529
sg15
I1
sasg6
(lp1530
(dp1531
g9
I3
sg10
VC0152013
p1532
sg12
I19
sg13
Vlung adenocarcinoma
p1533
sg15
I2
sa(dp1534
g9
I8
sg10
VC0001418
p1535
sg12
I14
sg13
Vadenocarcinoma
p1536
sg15
I1
sa(dp1537
g9
I8
sg10
VC0001418
p1538
sg12
I14
sg13
Vadenocarcinoma
p1539
sg15
I1
sasa(dp1540
g2
VPODXL overexpression induces EMT in lung adenocarcinoma and contributes to tumor progression.
p1541
sg4
(lp1542
(dp1543
g9
I29
sg39
g40
sg12
I3
sg13
VEMT
p1544
sg15
I1
sa(dp1545
g9
I0
sg39
g40
sg12
I5
sg13
VPODXL
p1546
sg15
I1
sasg6
(lp1547
(dp1548
g9
I75
sg10
VC0178874
p1549
sg12
I17
sg13
Vtumor progression
p1550
sg15
I2
sa(dp1551
g9
I36
sg10
VC0152013
p1552
sg12
I19
sg13
Vlung adenocarcinoma
p1553
sg15
I2
sasa(dp1554
g2
VThe aim of this study was to investigate the impact of PODXL expression on survival in esophageal and gastric adenocarcinoma.
p1555
sg4
(lp1556
(dp1557
g9
I55
sg39
g40
sg12
I5
sg13
VPODXL
p1558
sg15
I1
sasg6
(lp1559
(dp1560
g9
I102
sg10
VC0278701
p1561
sg12
I22
sg13
Vgastric adenocarcinoma
p1562
sg15
I2
sasa(dp1563
g2
VIn gastric adenocarcinoma, patients with PODXL negative tumors had a superior TTR and a trend towards an improved OS.
p1564
sg4
(lp1565
sg6
(lp1566
(dp1567
g9
I56
sg10
VC0027651
p1568
sg12
I6
sg13
Vtumors
p1569
sg15
I1
sa(dp1570
g9
I3
sg10
VC0278701
p1571
sg12
I22
sg13
Vgastric adenocarcinoma
p1572
sg15
I2
sasa(dp1573
g2
VIn esophageal and gastric adenocarcinoma combined, the prognostic significance of PODXL expression on TTR was confirmed in unadjusted Cox regression analysis (HR = 5.36, 95 % CI 1.68-17.06, p = 0.005) and remained significant in the adjusted model (HR = 3.39, 95 % CI 1.01-11.35, p = 0.048).
p1574
sg4
(lp1575
(dp1576
g9
I82
sg39
g40
sg12
I5
sg13
VPODXL
p1577
sg15
I1
sa(dp1578
g9
I102
sg39
VP02766
p1579
sg12
I3
sg13
VTTR
p1580
sg15
I1
sasg6
(lp1581
(dp1582
g9
I18
sg10
VC0278701
p1583
sg12
I22
sg13
Vgastric adenocarcinoma
p1584
sg15
I2
sasa(dp1585
g2
VIn esophageal and gastric adenocarcinoma, PODXL expression is an independent prognostic biomarker for reduced time to recurrence and poor overall survival.
p1586
sg4
(lp1587
(dp1588
g9
I42
sg39
g40
sg12
I5
sg13
VPODXL
p1589
sg15
I1
sasg6
(lp1590
(dp1591
g9
I118
sg10
VC1458156
p1592
sg12
I10
sg13
Vrecurrence
p1593
sg15
I1
sa(dp1594
g9
I18
sg10
VC0278701
p1595
sg12
I22
sg13
Vgastric adenocarcinoma
p1596
sg15
I2
sasa(dp1597
g2
VHere, we report that high PODXL expression was an independent predictor of worse overall survival of pancreatic cancer patients, and that PODXL promoted pancreatic cancer cell motility and invasion by physically binding to the cytoskeletal protein gelsolin.
p1598
sg4
(lp1599
(dp1600
g9
I26
sg39
g40
sg12
I5
sg13
VPODXL
p1601
sg15
I1
sa(dp1602
g9
I26
sg39
g40
sg12
I5
sg13
VPODXL
p1603
sg15
I1
sasg6
(lp1604
(dp1605
g9
I101
sg10
VC0235974
p1606
sg12
I17
sg13
Vpancreatic cancer
p1607
sg15
I2
sa(dp1608
g9
I101
sg10
VC0235974
p1609
sg12
I17
sg13
Vpancreatic cancer
p1610
sg15
I2
sa(dp1611
g9
I189
sg10
VC2699153
p1612
sg12
I8
sg13
Vinvasion
p1613
sg15
I1
sasa(dp1614
g2
VFurthermore, transfection of a PODXL-rescue construct into pancreatic cancer cells in which both PODXL and gelsolin were suppressed failed to increase the formation of the protrusions.
p1615
sg4
(lp1616
(dp1617
g9
I31
sg39
g40
sg12
I5
sg13
VPODXL
p1618
sg15
I1
sa(dp1619
g9
I107
sg39
VP06396
p1620
sg12
I8
sg13
Vgelsolin
p1621
sg15
I1
sa(dp1622
g9
I31
sg39
g40
sg12
I22
sg13
VPODXL-rescue construct
p1623
sg15
I2
sasg6
(lp1624
(dp1625
g9
I172
sg10
VC0333056
p1626
sg12
I11
sg13
Vprotrusions
p1627
sg15
I1
sa(dp1628
g9
I59
sg10
VC0235974
p1629
sg12
I17
sg13
Vpancreatic cancer
p1630
sg15
I2
sasa(dp1631
g2
VPodocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demonstrated to be an independent factor of poor prognosis in colorectal cancer (CRC).
p1632
sg4
(lp1633
(dp1634
g9
I20
sg39
g40
sg12
I5
sg13
VPODXL
p1635
sg15
I1
sa(dp1636
g9
I0
sg39
g40
sg12
I18
sg13
VPodocalyxin-like 1
p1637
sg15
I2
sasg6
(lp1638
(dp1639
g9
I164
sg10
VC1527249
p1640
sg12
I3
sg13
VCRC
p1641
sg15
I1
sa(dp1642
g9
I145
sg10
VC1527249
p1643
sg12
I17
sg13
Vcolorectal cancer
p1644
sg15
I2
sasa(dp1645
g2
VIn addition, we identified a possible target of miR-5100, podocalyxin-like 1 (PODXL), and demonstrated miR-5100 directly binds to the 3' untranslated region of PODXL and post-transcriptionally regulates its expression in pancreatic cancer cells.
p1646
sg4
(lp1647
(dp1648
g9
I78
sg39
g40
sg12
I5
sg13
VPODXL
p1649
sg15
I1
sa(dp1650
g9
I78
sg39
g40
sg12
I5
sg13
VPODXL
p1651
sg15
I1
sa(dp1652
g9
I58
sg39
g40
sg12
I18
sg13
Vpodocalyxin-like 1
p1653
sg15
I2
sa(dp1654
g9
I48
sg39
g40
sg12
I8
sg13
VmiR-5100
p1655
sg15
I1
sasg6
(lp1656
(dp1657
g9
I221
sg10
VC0235974
p1658
sg12
I17
sg13
Vpancreatic cancer
p1659
sg15
I2
sasa(dp1660
g2
VWe also clarified the close relationship between expression of PODXL in human pancreatic cancer specimens and liver metastasis (P=0.0003), and determined that post-operative survival was longer in the low-PODXL expression group than in the high-PODXL expression group (P&lt;0.05).
p1661
sg4
(lp1662
(dp1663
g9
I63
sg39
g40
sg12
I5
sg13
VPODXL
p1664
sg15
I1
sa(dp1665
g9
I63
sg39
g40
sg12
I5
sg13
VPODXL
p1666
sg15
I1
sasg6
(lp1667
(dp1668
g9
I110
sg10
VC0494165
p1669
sg12
I16
sg13
Vliver metastasis
p1670
sg15
I2
sa(dp1671
g9
I78
sg10
VC0235974
p1672
sg12
I17
sg13
Vpancreatic cancer
p1673
sg15
I2
sasa(dp1674
g2
VThese results indicate that miR-5100 and PODXL have considerable therapeutic potential for anti-metastatic therapy and could be potential indicators for cancer metastases in patients with pancreatic cancer.
p1675
sg4
(lp1676
(dp1677
g9
I28
sg39
g40
sg12
I8
sg13
VmiR-5100
p1678
sg15
I1
sa(dp1679
g9
I41
sg39
g40
sg12
I5
sg13
VPODXL
p1680
sg15
I1
sasg6
(lp1681
(dp1682
g9
I188
sg10
VC0235974
p1683
sg12
I17
sg13
Vpancreatic cancer
p1684
sg15
I2
sa(dp1685
g9
I160
sg10
VC0027627
p1686
sg12
I10
sg13
Vmetastases
p1687
sg15
I1
sa(dp1688
g9
I153
sg10
VC0006826
p1689
sg12
I6
sg13
Vcancer
p1690
sg15
I1
sasa(dp1691
g2
VPreviously we demonstrated that miR-199b was significantly downregulated in acute myeloid leukemia (AML) and targets podocalyxin and discoidin domain receptor 1.
p1692
sg4
(lp1693
(dp1694
g9
I117
sg39
g40
sg12
I11
sg13
Vpodocalyxin
p1695
sg15
I1
sa(dp1696
g9
I133
sg39
g40
sg12
I27
sg13
Vdiscoidin domain receptor 1
p1697
sg15
I4
sa(dp1698
g9
I32
sg39
g40
sg12
I8
sg13
VmiR-199b
p1699
sg15
I1
sasg6
(lp1700
(dp1701
g9
I76
sg10
VC0023467
p1702
sg12
I22
sg13
Vacute myeloid leukemia
p1703
sg15
I3
sa(dp1704
g9
I100
sg10
VC0023467
p1705
sg12
I3
sg13
VAML
p1706
sg15
I1
sasa(dp1707
g2
VTherefore, we set out to determine if podocalyxin plays a functional role in breast tumor progression.
p1708
sg4
(lp1709
sg6
(lp1710
(dp1711
g9
I84
sg10
VC0178874
p1712
sg12
I17
sg13
Vtumor progression
p1713
sg15
I2
sasa(dp1714
g2
VForced overexpression of podocalyxin caused cohesive clusters of epithelial MCF-7 breast tumor cells to bud off from the primary tumor and collectively invade the stroma of the mouse mammary gland in vivo.
p1715
sg4
(lp1716
sg6
(lp1717
(dp1718
g9
I121
sg10
VC0677930
p1719
sg12
I13
sg13
Vprimary tumor
p1720
sg15
I2
sa(dp1721
g9
I82
sg10
VC1458155
p1722
sg12
I12
sg13
Vbreast tumor
p1723
sg15
I2
sasa(dp1724
g2
VThe DEGs MAPT, DSTN, SPTBN1, ARHGEF2 and SKA1 are suggested to be candidate biomarkers for childhood obesity.
p1725
sg4
(lp1726
(dp1727
g9
I4
sg39
g40
sg12
I9
sg13
VDEGs MAPT
p1728
sg15
I2
sa(dp1729
g9
I15
sg39
VP60981
p1730
sg12
I4
sg13
VDSTN
p1731
sg15
I1
sa(dp1732
g9
I29
sg39
g40
sg12
I7
sg13
VARHGEF2
p1733
sg15
I1
sa(dp1734
g9
I21
sg39
g40
sg12
I6
sg13
VSPTBN1
p1735
sg15
I1
sa(dp1736
g9
I41
sg39
g40
sg12
I4
sg13
VSKA1
p1737
sg15
I1
sasg6
(lp1738
(dp1739
g9
I91
sg10
VC2362324
p1740
sg12
I17
sg13
Vchildhood obesity
p1741
sg15
I2
sasa(dp1742
g2
VAll received support and advice by community Diabetes Specialist Nurses (DSNs) and Dieticians covering Central and Eastern Cheshire, UK.
p1743
sg4
(lp1744
sg6
(lp1745
(dp1746
g9
I45
sg10
VC0011849
p1747
sg12
I8
sg13
VDiabetes
p1748
sg15
I1
sasa(dp1749
g2
VIn 2009, the PCT confirmed 3 years funding for a Paediatric Diabetes specialist nurse (PDSN) for schools.
p1750
sg4
(lp1751
sg6
(lp1752
(dp1753
g9
I60
sg10
VC0011849
p1754
sg12
I8
sg13
VDiabetes
p1755
sg15
I1
sa(dp1756
g9
I13
sg10
VC0162566
p1757
sg12
I3
sg13
VPCT
p1758
sg15
I1
sasa(dp1759
g2
VThe aim of this study was to explore the interaction between diabetes specialist nurses (DSNs) and patients with type 2 diabetes (T2D) during group sessions about self-management.
p1760
sg4
(lp1761
sg6
(lp1762
(dp1763
g9
I130
sg10
VC0011860
p1764
sg12
I3
sg13
VT2D
p1765
sg15
I1
sa(dp1766
g9
I113
sg10
VC0011860
p1767
sg12
I15
sg13
Vtype 2 diabetes
p1768
sg15
I3
sa(dp1769
g9
I61
sg10
VC0011849
p1770
sg12
I8
sg13
Vdiabetes
p1771
sg15
I1
sasa(dp1772
g2
VIn 8 Italian municipalities, 2,512 men and women without both diabetes and CI-DSN at baseline are examined.
p1773
sg4
(lp1774
sg6
(lp1775
(dp1776
g9
I78
sg10
VC0011195
p1777
sg12
I3
sg13
VDSN
p1778
sg15
I1
sa(dp1779
g9
I62
sg10
VC0011849
p1780
sg12
I8
sg13
Vdiabetes
p1781
sg15
I1
sasa(dp1782
g2
VThe majority (72%) of PHCCs had diabetes-responsible general practitioners (GPs) and almost all (97%) had diabetes specialist nurses (DSNs) with some degree of postgraduate education in diabetes.
p1783
sg4
(lp1784
sg6
(lp1785
(dp1786
g9
I32
sg10
VC0011849
p1787
sg12
I8
sg13
Vdiabetes
p1788
sg15
I1
sa(dp1789
g9
I32
sg10
VC0011849
p1790
sg12
I8
sg13
Vdiabetes
p1791
sg15
I1
sa(dp1792
g9
I53
sg10
VC0272302
p1793
sg12
I21
sg13
Vgeneral practitioners
p1794
sg15
I2
sa(dp1795
g9
I32
sg10
VC0011849
p1796
sg12
I8
sg13
Vdiabetes
p1797
sg15
I1
sa(dp1798
g9
I76
sg10
VC0272302
p1799
sg12
I3
sg13
VGPs
p1800
sg15
I1
sasa(dp1801
g2
VThe PHCCs reported that they used regional/local diabetes guidelines (93%), were engaged in call-recall diabetic reviews by GP(s) (66%) and DSN(s) (89%), checked that patients had participated in the reviews by GP(s) (69%) and DSN(s) (78%), arranged group education programmes (23%) and reported data to a National Diabetes Register (82%).
p1802
sg4
(lp1803
sg6
(lp1804
(dp1805
g9
I315
sg10
VC0011849
p1806
sg12
I8
sg13
VDiabetes
p1807
sg15
I1
sa(dp1808
g9
I140
sg10
VC0011195
p1809
sg12
I3
sg13
VDSN
p1810
sg15
I1
sa(dp1811
g9
I140
sg10
VC0011195
p1812
sg12
I3
sg13
VDSN
p1813
sg15
I1
sa(dp1814
g9
I49
sg10
VC0011849
p1815
sg12
I8
sg13
Vdiabetes
p1816
sg15
I1
sasa(dp1817
g2
VThe presence of diabetes-responsible GP(s) and DSN(s) who use guidelines may contribute to good and equal quality of care.
p1818
sg4
(lp1819
sg6
(lp1820
(dp1821
g9
I47
sg10
VC0011195
p1822
sg12
I3
sg13
VDSN
p1823
sg15
I1
sa(dp1824
g9
I16
sg10
VC0011849
p1825
sg12
I8
sg13
Vdiabetes
p1826
sg15
I1
sasa(dp1827
g2
VTo review the working practices of UK diabetes specialist nurses (DSNs), specific clinical roles, and to examine changes since 2000.
p1828
sg4
(lp1829
sg6
(lp1830
(dp1831
g9
I38
sg10
VC0011849
p1832
sg12
I8
sg13
Vdiabetes
p1833
sg15
I1
sasa(dp1834
g2
VPostal questionnaires were sent to lead DSNs from all identifiable UK diabetes centres (n = 361).
p1835
sg4
(lp1836
sg6
(lp1837
(dp1838
g9
I70
sg10
VC0011849
p1839
sg12
I8
sg13
Vdiabetes
p1840
sg15
I1
sasa(dp1841
g2
VQuantitative and qualitative data were collected on the specific clinical roles, employment, and continual professional development of hospital and community DSNs, Nurse Consultants and Diabetes Healthcare Assistants.
p1842
sg4
(lp1843
sg6
(lp1844
(dp1845
g9
I186
sg10
VC0011849
p1846
sg12
I8
sg13
VDiabetes
p1847
sg15
I1
sasa(dp1848
g2
V22% of DSNs have a formal role in diabetes research compared with 48% in 2000.
p1849
sg4
(lp1850
sg6
(lp1851
(dp1852
g9
I34
sg10
VC0011849
p1853
sg12
I8
sg13
Vdiabetes
p1854
sg15
I1
sasa(dp1855
g2
VPatients were recruited from 40 general practices and randomised (40:40:20 ratio) to receive routine care alone or, in addition, motivational telephone support from a peer supporter or a diabetes specialist nurse (9 peers and 12 DSNs) for a period of up to 6 months.
p1856
sg4
(lp1857
sg6
(lp1858
(dp1859
g9
I187
sg10
VC0011849
p1860
sg12
I8
sg13
Vdiabetes
p1861
sg15
I1
sasa(dp1862
g2
VWe exposed the human NSCLC cell lines Calu-1, CL3, H1299, CH27, H23, and H1355 to B[a]P and assessed cell cycle progression using flow cytometry.
p1863
sg4
(lp1864
sg6
(lp1865
(dp1866
g9
I21
sg10
VC0007131
p1867
sg12
I5
sg13
VNSCLC
p1868
sg15
I1
sasa(dp1869
g2
VMoreover, DOX-loaded micelles could slowly and efficiency decrease cell viability of non-small-cell lung carcinoma CL3 cells.
p1870
sg4
(lp1871
sg6
(lp1872
(dp1873
g9
I85
sg10
VC0007131
p1874
sg12
I29
sg13
Vnon-small-cell lung carcinoma
p1875
sg15
I3
sasa(dp1876
g2
VComet assay was used to evaluate the DNA damage induced by a relatively low dose of COF (100 g/ml) in human lung adenocarcinoma CL-3 cells.
p1877
sg4
(lp1878
sg6
(lp1879
(dp1880
g9
I108
sg10
VC0152013
p1881
sg12
I19
sg13
Vlung adenocarcinoma
p1882
sg15
I2
sa(dp1883
g9
I37
sg10
VC0012860
p1884
sg12
I10
sg13
VDNA damage
p1885
sg15
I2
sasa(dp1886
g2
VPb(II) increased the phosphorylated ERK1/2 and phosphorylated AKT but not the phosphorylated ERK5, phosphorylated p38 and JNK activity in human non-small cell lung adenocarcinoma CL3 cells.
p1887
sg4
(lp1888
(dp1889
g9
I36
sg39
VP27361
p1890
sg12
I6
sg13
VERK1/2
p1891
sg15
I1
sa(dp1892
g9
I93
sg39
VP53778
p1893
sg12
I4
sg13
VERK5
p1894
sg15
I1
sa(dp1895
g9
I114
sg39
VP46108
p1896
sg12
I3
sg13
Vp38
p1897
sg15
I1
sa(dp1898
g9
I122
sg39
VP53779
p1899
sg12
I3
sg13
VJNK
p1900
sg15
I1
sa(dp1901
g9
I62
sg39
g40
sg12
I3
sg13
VAKT
p1902
sg15
I1
sasg6
(lp1903
(dp1904
g9
I159
sg10
VC0152013
p1905
sg12
I19
sg13
Vlung adenocarcinoma
p1906
sg15
I2
sasa(dp1907
g2
VThe results from reverse-transcription polymerase chain reaction showed that the hOGG1 mRNA expression was induced by hydrogen peroxide (H2O2) and COF in human lung adenocarcinoma CL-3 cells.
p1908
sg4
(lp1909
sg6
(lp1910
(dp1911
g9
I160
sg10
VC0152013
p1912
sg12
I19
sg13
Vlung adenocarcinoma
p1913
sg15
I2
sasa(dp1914
g2
VTo reveal the relationship between the high mortality rate of lung cancer in Chinese women and exposure to cooking oil fumes (COF), DNA adduct formation, induced by COF collected from frying fish under domestic conditions, was assessed in human lung adenocarcinoma CL-3 cell lines using the (32)P-postlabeling assay.
p1915
sg4
(lp1916
sg6
(lp1917
(dp1918
g9
I245
sg10
VC0152013
p1919
sg12
I19
sg13
Vlung adenocarcinoma
p1920
sg15
I2
sa(dp1921
g9
I62
sg10
VC0684249
p1922
sg12
I11
sg13
Vlung cancer
p1923
sg15
I2
sa(dp1924
g9
I132
sg10
VC1511660
p1925
sg12
I20
sg13
VDNA adduct formation
p1926
sg15
I3
sasa(dp1927
g2
VIn this study we have explored the involvement of oxidative stress in Cr(VI)-induced JNK, p38 and ERK signaling pathways and their effects on Cr(VI) cytotoxicity in human non-small cell lung carcinoma CL3 cells.
p1928
sg4
(lp1929
(dp1930
g9
I90
sg39
VP46108
p1931
sg12
I3
sg13
Vp38
p1932
sg15
I1
sa(dp1933
g9
I98
sg39
VP29323
p1934
sg12
I3
sg13
VERK
p1935
sg15
I1
sa(dp1936
g9
I85
sg39
VP53779
p1937
sg12
I3
sg13
VJNK
p1938
sg15
I1
sasg6
(lp1939
(dp1940
g9
I171
sg10
VC0007131
p1941
sg12
I29
sg13
Vnon-small cell lung carcinoma
p1942
sg15
I4
sa(dp1943
g9
I149
sg10
VC0596402
p1944
sg12
I12
sg13
Vcytotoxicity
p1945
sg15
I1
sa(dp1946
g9
I50
sg10
VC0242606
p1947
sg12
I16
sg13
Voxidative stress
p1948
sg15
I2
sasa(dp1949
g2
VThe expression pattern of mucin genes was studied in 7 lung adenocarcinoma cell lines (CL1, CL2, CL3, NCL2, PC9, PC13, PC14) and 12 lung adenocarcinoma tissues.
p1950
sg4
(lp1951
(dp1952
g9
I102
sg39
g40
sg12
I4
sg13
VNCL2
p1953
sg15
I1
sa(dp1954
g9
I92
sg39
g40
sg12
I3
sg13
VCL2
p1955
sg15
I1
sa(dp1956
g9
I108
sg39
g40
sg12
I3
sg13
VPC9
p1957
sg15
I1
sa(dp1958
g9
I26
sg39
g40
sg12
I11
sg13
Vmucin genes
p1959
sg15
I2
sa(dp1960
g9
I87
sg39
g40
sg12
I3
sg13
VCL1
p1961
sg15
I1
sasg6
(lp1962
(dp1963
g9
I55
sg10
VC0152013
p1964
sg12
I19
sg13
Vlung adenocarcinoma
p1965
sg15
I2
sa(dp1966
g9
I55
sg10
VC0152013
p1967
sg12
I19
sg13
Vlung adenocarcinoma
p1968
sg15
I2
sasa(dp1969
g2
VOsteogenesis imperfecta model, oim(-/-) , mice have a defect in the collagen, which leads to brittle bone; PHOSPHO1 mutants, Phospho1(-/-) , have ductile bone resulting from altered mineralization.
p1970
sg4
(lp1971
(dp1972
g9
I107
sg39
g40
sg12
I16
sg13
VPHOSPHO1 mutants
p1973
sg15
I2
sasg6
(lp1974
(dp1975
g9
I0
sg10
VC0029434
p1976
sg12
I23
sg13
VOsteogenesis imperfecta
p1977
sg15
I2
sasa(dp1978
g2
VBecause two mammalian isoforms of iPLA2 (iPLA2beta and iPLA2gamma) have been cloned and characterized, the aim of this study was to identify the specific isoform(s) in macrophages that regulates the expression of iNOS in response to virus infection.
p1979
sg4
(lp1980
(dp1981
g9
I34
sg39
g40
sg12
I5
sg13
ViPLA2
p1982
sg15
I1
sa(dp1983
g9
I55
sg39
g40
sg12
I10
sg13
ViPLA2gamma
p1984
sg15
I1
sa(dp1985
g9
I41
sg39
g40
sg12
I9
sg13
ViPLA2beta
p1986
sg15
I1
sasg6
(lp1987
(dp1988
g9
I233
sg10
VC0042769
p1989
sg12
I15
sg13
Vvirus infection
p1990
sg15
I2
sasa(dp1991
g2
VcAMP response element-binding protein (CREB) is one downstream target of iPLA2 that is required for the transcriptional activation of iNOS in response to virus infection, and consistent with the effects of BEL enantiomers on iNOS expression, (S)-BEL more effectively inhibits EMCV-induced CREB phosphorylation than (R)-BEL in macrophages.
p1992
sg4
(lp1993
(dp1994
g9
I73
sg39
g40
sg12
I5
sg13
ViPLA2
p1995
sg15
I1
sa(dp1996
g9
I0
sg39
g40
sg12
I37
sg13
VcAMP response element-binding protein
p1997
sg15
I4
sa(dp1998
g9
I39
sg39
VP16220
p1999
sg12
I4
sg13
VCREB
p2000
sg15
I1
sa(dp2001
g9
I39
sg39
VP16220
p2002
sg12
I4
sg13
VCREB
p2003
sg15
I1
sa(dp2004
g9
I134
sg39
g40
sg12
I4
sg13
ViNOS
p2005
sg15
I1
sasg6
(lp2006
(dp2007
g9
I154
sg10
VC0042769
p2008
sg12
I15
sg13
Vvirus infection
p2009
sg15
I2
sasa(dp2010
g2
VUsing macrophages isolated from iPLA2beta-null mice, virus infection fails to stimulate iNOS mRNA accumulation and protein expression, thus providing genetic evidence that iPLA2beta is required for EMCV-induced iNOS expression.
p2011
sg4
(lp2012
(dp2013
g9
I88
sg39
g40
sg12
I9
sg13
ViNOS mRNA
p2014
sg15
I2
sa(dp2015
g9
I88
sg39
g40
sg12
I4
sg13
ViNOS
p2016
sg15
I1
sa(dp2017
g9
I32
sg39
g40
sg12
I9
sg13
ViPLA2beta
p2018
sg15
I1
sa(dp2019
g9
I32
sg39
g40
sg12
I9
sg13
ViPLA2beta
p2020
sg15
I1
sasg6
(lp2021
(dp2022
g9
I53
sg10
VC0042769
p2023
sg12
I15
sg13
Vvirus infection
p2024
sg15
I2
sasa(dp2025
g2
VSpecific attention will be placed on the ability of virus infection to activate multiple signaling cascades (such as PKR, MAPK, iPLA2, NF-kappaB) and how these pathways are integrated in the regulation of individual target gene expression.
p2026
sg4
(lp2027
(dp2028
g9
I135
sg39
VP19838
p2029
sg12
I9
sg13
VNF-kappaB
p2030
sg15
I1
sa(dp2031
g9
I117
sg39
g40
sg12
I3
sg13
VPKR
p2032
sg15
I1
sa(dp2033
g9
I122
sg39
VP53779
p2034
sg12
I4
sg13
VMAPK
p2035
sg15
I1
sa(dp2036
g9
I128
sg39
g40
sg12
I5
sg13
ViPLA2
p2037
sg15
I1
sasg6
(lp2038
(dp2039
g9
I52
sg10
VC0042769
p2040
sg12
I15
sg13
Vvirus infection
p2041
sg15
I2
sasa(dp2042
g2
VIn comparison with PRCC1, PRCC2 cases showed upregulated expression of Alfa5-integrin (ITGA5) whereas the expression of Alfa6- (ITGA6) and Beta8-integrins (ITGB8) was downregulated.
p2043
sg4
(lp2044
(dp2045
g9
I87
sg39
VP08648
p2046
sg12
I5
sg13
VITGA5
p2047
sg15
I1
sa(dp2048
g9
I156
sg39
VP26012
p2049
sg12
I5
sg13
VITGB8
p2050
sg15
I1
sasg6
(lp2051
sa(dp2052
g2
VHFD-fed mice lacking Cnot7 and Tob express elevated levels of Ucp1 mRNA in iWAT and are resistant to diet-induced obesity.
p2053
sg4
(lp2054
(dp2055
g9
I31
sg39
VP50616
p2056
sg12
I3
sg13
VTob
p2057
sg15
I1
sa(dp2058
g9
I21
sg39
g40
sg12
I5
sg13
VCnot7
p2059
sg15
I1
sa(dp2060
g9
I62
sg39
VP25874
p2061
sg12
I9
sg13
VUcp1 mRNA
p2062
sg15
I2
sasg6
(lp2063
(dp2064
g9
I114
sg10
VC0028754
p2065
sg12
I7
sg13
Vobesity
p2066
sg15
I1
sasa(dp2067
g2
VThus, the Cnot7-Tob-BRF1 axis inhibits Ucp1 expression and contributes to obesity.
p2068
sg4
(lp2069
(dp2070
g9
I39
sg39
VP25874
p2071
sg12
I4
sg13
VUcp1
p2072
sg15
I1
sa(dp2073
g9
I20
sg39
g40
sg12
I4
sg13
VBRF1
p2074
sg15
I1
sa(dp2075
g9
I16
sg39
VP50616
p2076
sg12
I3
sg13
VTob
p2077
sg15
I1
sa(dp2078
g9
I10
sg39
g40
sg12
I5
sg13
VCnot7
p2079
sg15
I1
sasg6
(lp2080
(dp2081
g9
I74
sg10
VC0028754
p2082
sg12
I7
sg13
Vobesity
p2083
sg15
I1
sasa(dp2084
g2
VSince abnormal and unbalanced JAK/STAT activation is associated with immune disorders and cancer, hCAF1 could play a major role in innate immunity and oncogenesis, contributing to tumour escape.
p2085
sg4
(lp2086
(dp2087
g9
I34
sg39
g40
sg12
I4
sg13
VSTAT
p2088
sg15
I1
sa(dp2089
g9
I98
sg39
g40
sg12
I5
sg13
VhCAF1
p2090
sg15
I1
sasg6
(lp2091
(dp2092
g9
I180
sg10
VC0027651
p2093
sg12
I6
sg13
Vtumour
p2094
sg15
I1
sa(dp2095
g9
I69
sg10
VC0021053
p2096
sg12
I16
sg13
Vimmune disorders
p2097
sg15
I2
sa(dp2098
g9
I151
sg10
VC0007621
p2099
sg12
I11
sg13
Voncogenesis
p2100
sg15
I1
sa(dp2101
g9
I90
sg10
VC0006826
p2102
sg12
I6
sg13
Vcancer
p2103
sg15
I1
sasa(dp2104
g2
VOur previous study (Nakamura et al., 2004) showed that deletion of the Cnot7 gene in mice caused almost no abnormal phenotypes except for male infertility, due to oligo-astheno-teratozoospermia.
p2105
sg4
(lp2106
(dp2107
g9
I71
sg39
g40
sg12
I10
sg13
VCnot7 gene
p2108
sg15
I2
sasg6
(lp2109
(dp2110
g9
I138
sg10
VC0021364
p2111
sg12
I16
sg13
Vmale infertility
p2112
sg15
I2
sasa(dp2113
g2
VMutations in the gene encoding the neural cell adhesion molecule L1CAM cause several neurological disorders collectively referred to as L1 syndrome.
p2114
sg4
(lp2115
(dp2116
g9
I35
sg39
g40
sg12
I35
sg13
Vneural cell adhesion molecule L1CAM
p2117
sg15
I5
sasg6
(lp2118
(dp2119
g9
I85
sg10
VC0027765
p2120
sg12
I22
sg13
Vneurological disorders
p2121
sg15
I2
sa(dp2122
g9
I139
sg10
VC0039082
p2123
sg12
I8
sg13
Vsyndrome
p2124
sg15
I1
sa(dp2125
g9
I47
sg10
VC0001511
p2126
sg12
I8
sg13
Vadhesion
p2127
sg15
I1
sasa(dp2128
g2
VA 59-year-old woman receiving methotrexate and tacrolimus for rheumatoid arthritis (RA) was referred to our hospital following bilateral ground-glass opacity observed in her chest X-ray and elevated serum KL-6.
p2129
sg4
(lp2130
(dp2131
g9
I199
sg39
g40
sg12
I10
sg13
Vserum KL-6
p2132
sg15
I2
sasg6
(lp2133
(dp2134
g9
I84
sg10
VC0003873
p2135
sg12
I2
sg13
VRA
p2136
sg15
I1
sa(dp2137
g9
I150
sg10
VC1265876
p2138
sg12
I7
sg13
Vopacity
p2139
sg15
I1
sa(dp2140
g9
I62
sg10
VC0003873
p2141
sg12
I20
sg13
Vrheumatoid arthritis
p2142
sg15
I2
sasa(dp2143
g2
VDuring treatment of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) with prednisolone, chest image findings improved in association with decreased KL-6 levels.
p2144
sg4
(lp2145
sg6
(lp2146
(dp2147
g9
I57
sg10
VC0206062
p2148
sg12
I25
sg13
Vinterstitial lung disease
p2149
sg15
I3
sa(dp2150
g9
I20
sg10
VC0003873
p2151
sg12
I20
sg13
Vrheumatoid arthritis
p2152
sg15
I2
sa(dp2153
g9
I42
sg10
VC0003873
p2154
sg12
I2
sg13
VRA
p2155
sg15
I1
sa(dp2156
g9
I84
sg10
VC0206062
p2157
sg12
I3
sg13
VILD
p2158
sg15
I1
sasa(dp2159
g2
VThe results showed that treatment with the MUC1-MBP/BCG anti-tumor vaccine did not cause any organ toxicity, except for arthritis or local nodules induced by BCG in several rats.
p2160
sg4
(lp2161
(dp2162
g9
I48
sg39
VP13727
p2163
sg12
I3
sg13
VMBP
p2164
sg15
I1
sasg6
(lp2165
(dp2166
g9
I120
sg10
VC0003864
p2167
sg12
I9
sg13
Varthritis
p2168
sg15
I1
sa(dp2169
g9
I139
sg10
VC0028259
p2170
sg12
I7
sg13
Vnodules
p2171
sg15
I1
sa(dp2172
g9
I61
sg10
VC0027651
p2173
sg12
I5
sg13
Vtumor
p2174
sg15
I1
sasa(dp2175
g2
VTo investigate leptin, adiponectin, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) levels and their relationship with each other and metabolic parameters in women with polycystic ovary syndrome (PCOS).
p2176
sg4
(lp2177
(dp2178
g9
I23
sg39
g40
sg12
I11
sg13
Vadiponectin
p2179
sg15
I1
sa(dp2180
g9
I97
sg39
VP19320
p2181
sg12
I33
sg13
Vvascular cell adhesion molecule-1
p2182
sg15
I4
sa(dp2183
g9
I79
sg39
VP05362
p2184
sg12
I7
sg13
VsICAM-1
p2185
sg15
I1
sa(dp2186
g9
I36
sg39
VP05362
p2187
sg12
I41
sg13
Vsoluble intercellular adhesion molecule-1
p2188
sg15
I4
sa(dp2189
g9
I15
sg39
VP41159
p2190
sg12
I6
sg13
Vleptin
p2191
sg15
I1
sasg6
(lp2192
(dp2193
g9
I253
sg10
VC0032460
p2194
sg12
I4
sg13
VPCOS
p2195
sg15
I1
sa(dp2196
g9
I58
sg10
VC0001511
p2197
sg12
I8
sg13
Vadhesion
p2198
sg15
I1
sa(dp2199
g9
I58
sg10
VC0001511
p2200
sg12
I8
sg13
Vadhesion
p2201
sg15
I1
sa(dp2202
g9
I226
sg10
VC0032460
p2203
sg12
I25
sg13
Vpolycystic ovary syndrome
p2204
sg15
I3
sasa(dp2205
g2
VNon-insulin resistant PCOS had significantly higher adiponectin and sVCAM-1 levels.
p2206
sg4
(lp2207
(dp2208
g9
I4
sg39
VP01308
p2209
sg12
I7
sg13
Vinsulin
p2210
sg15
I1
sa(dp2211
g9
I52
sg39
g40
sg12
I11
sg13
Vadiponectin
p2212
sg15
I1
sasg6
(lp2213
(dp2214
g9
I22
sg10
VC0032460
p2215
sg12
I4
sg13
VPCOS
p2216
sg15
I1
sasa(dp2217
g2
VIncreases in IL-6 and TNF-Alfa and adhesion molecules (E-selectin, ICAM-1 and VCAM-1) were also observed, particularly in the PCOS IR group, providing evidence that inflammation and oxidative stress are related in PCOS patients.
p2218
sg4
(lp2219
(dp2220
g9
I22
sg39
VP01375
p2221
sg12
I31
sg13
VTNF-Alfa and adhesion molecules
p2222
sg15
I4
sa(dp2223
g9
I78
sg39
VP19320
p2224
sg12
I6
sg13
VVCAM-1
p2225
sg15
I1
sa(dp2226
g9
I67
sg39
VP05362
p2227
sg12
I6
sg13
VICAM-1
p2228
sg15
I1
sa(dp2229
g9
I13
sg39
VP05231
p2230
sg12
I4
sg13
VIL-6
p2231
sg15
I1
sa(dp2232
g9
I55
sg39
VP16581
p2233
sg12
I10
sg13
VE-selectin
p2234
sg15
I1
sasg6
(lp2235
(dp2236
g9
I182
sg10
VC0242606
p2237
sg12
I16
sg13
Voxidative stress
p2238
sg15
I2
sa(dp2239
g9
I126
sg10
VC0032460
p2240
sg12
I4
sg13
VPCOS
p2241
sg15
I1
sa(dp2242
g9
I165
sg10
VC0021368
p2243
sg12
I12
sg13
Vinflammation
p2244
sg15
I1
sa(dp2245
g9
I35
sg10
VC0001511
p2246
sg12
I8
sg13
Vadhesion
p2247
sg15
I1
sa(dp2248
g9
I126
sg10
VC0032460
p2249
sg12
I4
sg13
VPCOS
p2250
sg15
I1
sasa(dp2251
g2
VInflammation in PCOS induces leukocyte-endothelium interactions and a simultaneous increase in IL-6, TNF-Alfa, E-selectin, ICAM-1 and VCAM-1.
p2252
sg4
(lp2253
(dp2254
g9
I123
sg39
VP05362
p2255
sg12
I6
sg13
VICAM-1
p2256
sg15
I1
sa(dp2257
g9
I95
sg39
VP05231
p2258
sg12
I4
sg13
VIL-6
p2259
sg15
I1
sa(dp2260
g9
I101
sg39
VP01375
p2261
sg12
I8
sg13
VTNF-Alfa
p2262
sg15
I1
sa(dp2263
g9
I111
sg39
VP16581
p2264
sg12
I10
sg13
VE-selectin
p2265
sg15
I1
sa(dp2266
g9
I134
sg39
VP19320
p2267
sg12
I6
sg13
VVCAM-1
p2268
sg15
I1
sasg6
(lp2269
(dp2270
g9
I0
sg10
VC0021368
p2271
sg12
I12
sg13
VInflammation
p2272
sg15
I1
sa(dp2273
g9
I16
sg10
VC0032460
p2274
sg12
I4
sg13
VPCOS
p2275
sg15
I1
sasa(dp2276
g2
VIn conclusion, we disclosed a novel mechanism that JQ1 inhibits cell proliferation, induces cell senescence and apoptosis of chondrosarcoma cells through the regulation of the YAP/p21/c-Myc/Bcl-xL signaling axis.
p2277
sg4
(lp2278
(dp2279
g9
I190
sg39
g40
sg12
I6
sg13
VBcl-xL
p2280
sg15
I1
sa(dp2281
g9
I176
sg39
VP46937
p2282
sg12
I3
sg13
VYAP
p2283
sg15
I1
sa(dp2284
g9
I180
sg39
VP42857
p2285
sg12
I3
sg13
Vp21
p2286
sg15
I1
sa(dp2287
g9
I184
sg39
VP12524
p2288
sg12
I5
sg13
Vc-Myc
p2289
sg15
I1
sasg6
(lp2290
(dp2291
g9
I125
sg10
VC0008479
p2292
sg12
I14
sg13
Vchondrosarcoma
p2293
sg15
I1
sa(dp2294
g9
I69
sg10
VC0334094
p2295
sg12
I13
sg13
Vproliferation
p2296
sg15
I1
sasa(dp2297
g2
VBH-3 mimetics ABT-737 and ABT-263 are synthetic small-molecule inhibitors of anti-apoptotic proteins B-cell lymphoma-2 (Bcl2) and Bcl-xL, which play a critical role in survival of chondrosarcoma cells.
p2298
sg4
(lp2299
(dp2300
g9
I120
sg39
VP10415
p2301
sg12
I4
sg13
VBcl2
p2302
sg15
I1
sa(dp2303
g9
I77
sg39
g40
sg12
I41
sg13
Vanti-apoptotic proteins B-cell lymphoma-2
p2304
sg15
I4
sa(dp2305
g9
I130
sg39
g40
sg12
I6
sg13
VBcl-xL
p2306
sg15
I1
sasg6
(lp2307
(dp2308
g9
I180
sg10
VC0008479
p2309
sg12
I14
sg13
Vchondrosarcoma
p2310
sg15
I1
sa(dp2311
g9
I101
sg10
VC0079731
p2312
sg12
I15
sg13
VB-cell lymphoma
p2313
sg15
I2
sasa(dp2314
g2
VHere we show that the IHh signal pathway was activated in chondrosarcoma, and knocking down the expression of Gli1 attenuated the disturbed IHh signal pathway, which not only suppressed cell proliferation and promoted G2/M cell cycle arrest but also enhanced cell apoptosis by downregulating Bcl-2 and Bcl-xl expression.
p2315
sg4
(lp2316
(dp2317
g9
I292
sg39
VP10415
p2318
sg12
I5
sg13
VBcl-2
p2319
sg15
I1
sa(dp2320
g9
I22
sg39
g40
sg12
I3
sg13
VIHh
p2321
sg15
I1
sa(dp2322
g9
I110
sg39
VP08151
p2323
sg12
I4
sg13
VGli1
p2324
sg15
I1
sa(dp2325
g9
I302
sg39
g40
sg12
I6
sg13
VBcl-xl
p2326
sg15
I1
sasg6
(lp2327
(dp2328
g9
I191
sg10
VC0334094
p2329
sg12
I13
sg13
Vproliferation
p2330
sg15
I1
sa(dp2331
g9
I22
sg10
VC0342384
p2332
sg12
I3
sg13
VIHh
p2333
sg15
I1
sa(dp2334
g9
I58
sg10
VC0008479
p2335
sg12
I14
sg13
Vchondrosarcoma
p2336
sg15
I1
sa(dp2337
g9
I22
sg10
VC0342384
p2338
sg12
I3
sg13
VIHh
p2339
sg15
I1
sasa(dp2340
g2
VAs in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and/or Bcl-xl) were highly expressed in all subtypes.
p2341
sg4
(lp2342
(dp2343
g9
I73
sg39
g40
sg12
I6
sg13
VBcl-xl
p2344
sg15
I1
sa(dp2345
g9
I59
sg39
VP10415
p2346
sg12
I5
sg13
VBcl-2
p2347
sg15
I1
sasg6
(lp2348
(dp2349
g9
I6
sg10
VC1335473
p2350
sg12
I27
sg13
Vconventional chondrosarcoma
p2351
sg15
I2
sasa(dp2352
g2
VBPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.
p2353
sg4
(lp2354
(dp2355
g9
I64
sg39
VP10415
p2356
sg12
I5
sg13
VBcl-2
p2357
sg15
I1
sa(dp2358
g9
I71
sg39
VP55957
p2359
sg12
I3
sg13
VBid
p2360
sg15
I1
sa(dp2361
g9
I79
sg39
g40
sg12
I6
sg13
VBcl-XL
p2362
sg15
I1
sa(dp2363
g9
I41
sg39
g40
sg12
I3
sg13
VBak
p2364
sg15
I1
sa(dp2365
g9
I33
sg39
g40
sg12
I3
sg13
VBad
p2366
sg15
I1
sasg6
(lp2367
(dp2368
g9
I121
sg10
VC0008479
p2369
sg12
I14
sg13
Vchondrosarcoma
p2370
sg15
I1
sasa(dp2371
g2
VEGCG induced upregulation of Bax and Bak, downregulation of Bcl-2 and Bcl-XL, and dysfunction of mitochondria in chondrosarcoma.
p2372
sg4
(lp2373
(dp2374
g9
I70
sg39
g40
sg12
I6
sg13
VBcl-XL
p2375
sg15
I1
sa(dp2376
g9
I37
sg39
g40
sg12
I3
sg13
VBak
p2377
sg15
I1
sa(dp2378
g9
I60
sg39
VP10415
p2379
sg12
I5
sg13
VBcl-2
p2380
sg15
I1
sasg6
(lp2381
(dp2382
g9
I113
sg10
VC0008479
p2383
sg12
I14
sg13
Vchondrosarcoma
p2384
sg15
I1
sasa(dp2385
g2
VFPTB induced up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.
p2386
sg4
(lp2387
(dp2388
g9
I72
sg39
g40
sg12
I6
sg13
VBcl-XL
p2389
sg15
I1
sa(dp2390
g9
I62
sg39
VP10415
p2391
sg12
I5
sg13
VBcl-2
p2392
sg15
I1
sa(dp2393
g9
I38
sg39
g40
sg12
I3
sg13
VBak
p2394
sg15
I1
sa(dp2395
g9
I0
sg39
VP49356
p2396
sg12
I4
sg13
VFPTB
p2397
sg15
I1
sasg6
(lp2398
(dp2399
g9
I114
sg10
VC0008479
p2400
sg12
I14
sg13
Vchondrosarcoma
p2401
sg15
I1
sasa(dp2402
g2
VThis study aims to investigate the expression patterns of HIF-1Alfa in chondrosarcoma, and its association with clinicopathologic features, Bcl-xL expression, apoptosis index (AI), and overall survival of patients with chondrosarcoma.
p2403
sg4
(lp2404
(dp2405
g9
I140
sg39
g40
sg12
I6
sg13
VBcl-xL
p2406
sg15
I1
sasg6
(lp2407
(dp2408
g9
I71
sg10
VC0008479
p2409
sg12
I14
sg13
Vchondrosarcoma
p2410
sg15
I1
sa(dp2411
g9
I71
sg10
VC0008479
p2412
sg12
I14
sg13
Vchondrosarcoma
p2413
sg15
I1
sasa(dp2414
g2
VIn eight patients with chondrosarcoma, increased expression of HIF-1Alfa and Bcl-xL was detected in chondrosarcoma tissues compared with the paired adjacent normal tissues.
p2415
sg4
(lp2416
(dp2417
g9
I77
sg39
g40
sg12
I6
sg13
VBcl-xL
p2418
sg15
I1
sasg6
(lp2419
(dp2420
g9
I23
sg10
VC0008479
p2421
sg12
I14
sg13
Vchondrosarcoma
p2422
sg15
I1
sa(dp2423
g9
I23
sg10
VC0008479
p2424
sg12
I14
sg13
Vchondrosarcoma
p2425
sg15
I1
sasa(dp2426
g2
VThese findings suggest that increased HIF-1Alfa levels mediated up-regulation of Bcl-xL play a prominent role in evasion of apoptosis and tumor progression, and can be predictive for the prognosis in human chondrosarcoma.
p2427
sg4
(lp2428
(dp2429
g9
I81
sg39
g40
sg12
I6
sg13
VBcl-xL
p2430
sg15
I1
sasg6
(lp2431
(dp2432
g9
I138
sg10
VC0178874
p2433
sg12
I17
sg13
Vtumor progression
p2434
sg15
I2
sa(dp2435
g9
I206
sg10
VC0008479
p2436
sg12
I14
sg13
Vchondrosarcoma
p2437
sg15
I1
sasa(dp2438
g2
VThree-dimensional speckle tracking echocardiography (3D-STE) was used to evaluate the improvement of continuous subcutaneous insulin infusion on the left ventricular (LV) systolic function of patients with type 2 diabetes mellitu (T2DM).
p2439
sg4
(lp2440
(dp2441
g9
I125
sg39
VP01308
p2442
sg12
I7
sg13
Vinsulin
p2443
sg15
I1
sasg6
(lp2444
(dp2445
g9
I206
sg10
VC0011860
p2446
sg12
I15
sg13
Vtype 2 diabetes
p2447
sg15
I3
sasa(dp2448
g2
VTo elucidate association of renal dysfunction (RD) with unfavorable outcomes of in-hospital and long-term (1 year) treatment stages of patients with ST-elevation (STE) myocardial infarction (MI) and concomitant diabetes mellitus (DM).
p2449
sg4
(lp2450
sg6
(lp2451
(dp2452
g9
I230
sg10
VC0011849
p2453
sg12
I2
sg13
VDM
p2454
sg15
I1
sa(dp2455
g9
I211
sg10
VC0011849
p2456
sg12
I17
sg13
Vdiabetes mellitus
p2457
sg15
I2
sa(dp2458
g9
I168
sg10
VC0027051
p2459
sg12
I21
sg13
Vmyocardial infarction
p2460
sg15
I2
sa(dp2461
g9
I191
sg10
VC0027051
p2462
sg12
I2
sg13
VMI
p2463
sg15
I1
sasa(dp2464
g2
VMultivariate regression analysis showed that GPLS and diabetes mellitus were independent predictors for complex NSTE-ACS.
p2465
sg4
(lp2466
(dp2467
g9
I112
sg39
g40
sg12
I8
sg13
VNSTE-ACS
p2468
sg15
I1
sasg6
(lp2469
(dp2470
g9
I54
sg10
VC0011849
p2471
sg12
I17
sg13
Vdiabetes mellitus
p2472
sg15
I2
sasa(dp2473
g2
VNo differences were observed between the two groups in baseline characteristics; except AS-STEMI group had more patients with diabetes and EA-STEMI group had more patients with family history of coronary artery disease.
p2474
sg4
(lp2475
sg6
(lp2476
(dp2477
g9
I195
sg10
VC1956346
p2478
sg12
I23
sg13
Vcoronary artery disease
p2479
sg15
I3
sa(dp2480
g9
I91
sg10
VC1536220
p2481
sg12
I5
sg13
VSTEMI
p2482
sg15
I1
sa(dp2483
g9
I126
sg10
VC0011849
p2484
sg12
I8
sg13
Vdiabetes
p2485
sg15
I1
sa(dp2486
g9
I91
sg10
VC1536220
p2487
sg12
I5
sg13
VSTEMI
p2488
sg15
I1
sasa(dp2489
g2
VTo elucidate association of renal dysfunction (RD) with unfavorable outcomes of in-hospital and long-term (1 year) treatment stages of patients with ST-elevation (STE) myocardial infarction (M) and concomitant diabetes mellitus (DM).
p2490
sg4
(lp2491
sg6
(lp2492
(dp2493
g9
I229
sg10
VC0011849
p2494
sg12
I2
sg13
VDM
p2495
sg15
I1
sa(dp2496
g9
I210
sg10
VC0011849
p2497
sg12
I17
sg13
Vdiabetes mellitus
p2498
sg15
I2
sa(dp2499
g9
I168
sg10
VC0027051
p2500
sg12
I21
sg13
Vmyocardial infarction
p2501
sg15
I2
sasa(dp2502
g2
VIncidence of complicated diabetes (P &lt; 0.05), pre-PCI Killip &gt;= II (55.9% (19/34) vs. 26.8% (15/56), P &lt; 0.05) and multivessel disease (70.6% (24/34) vs. 35.7% (20/56), P &lt; 0.05) were significantly higher in group D than in group C. TIMI 3 and the opening time of IRA was similar between group A and group B and between group C and group D. The incidence of in-hospital MACE was significantly higher in group B than in group A (14.4% (13/90) vs. 3.0% (4/135), P &lt; 0.05) which was similar between group C and group D. Early (1 hour) but not late (24 hours) ST resolution post PCI is related to a favorable clinical outcome in STEMI patients.
p2503
sg4
(lp2504
sg6
(lp2505
(dp2506
g9
I640
sg10
VC1536220
p2507
sg12
I5
sg13
VSTEMI
p2508
sg15
I1
sa(dp2509
g9
I312
sg10
VC0348801
p2510
sg12
I7
sg13
Vgroup B
p2511
sg15
I2
sa(dp2512
g9
I25
sg10
VC0011849
p2513
sg12
I8
sg13
Vdiabetes
p2514
sg15
I1
sa(dp2515
g9
I312
sg10
VC0348801
p2516
sg12
I7
sg13
Vgroup B
p2517
sg15
I2
sasa(dp2518
g2
VImmunohistochemistry (IHC) and Western blotting were performed to evaluate SOX4 expression between OLP and OLP-OSCC tissues and among oral cancer cell lines and normal human oral keratinocytes (NHOKs).
p2519
sg4
(lp2520
(dp2521
g9
I75
sg39
g40
sg12
I4
sg13
VSOX4
p2522
sg15
I1
sasg6
(lp2523
(dp2524
g9
I134
sg10
VC0153381
p2525
sg12
I11
sg13
Voral cancer
p2526
sg15
I2
sasa(dp2527
g2
VLC-MS/MS analysis showed that 88 proteins including SOX4 were only identified in OLP-OSCC FFPE tissues when compared to OLP FFPE tissues.
p2528
sg4
(lp2529
(dp2530
g9
I52
sg39
g40
sg12
I4
sg13
VSOX4
p2531
sg15
I1
sasg6
(lp2532
sa(dp2533
g2
VIHC confirmed that SOX4 expression was significantly higher in OLP-OSCC than OLP and Western blot analysis indicated that SOX4 was over-expressed in UM1/UM2 cells when compared to NHOKs.
p2534
sg4
(lp2535
(dp2536
g9
I19
sg39
g40
sg12
I4
sg13
VSOX4
p2537
sg15
I1
sa(dp2538
g9
I19
sg39
g40
sg12
I4
sg13
VSOX4
p2539
sg15
I1
sasg6
(lp2540
sa(dp2541
g2
VOur study indicated that SOX4 is significantly upregulated in OLP-OSCC versus OLP tissues.
p2542
sg4
(lp2543
(dp2544
g9
I25
sg39
g40
sg12
I4
sg13
VSOX4
p2545
sg15
I1
sasg6
(lp2546
sa(dp2547
g2
VThese findings suggest that SOX4 might be actively involved in the progression of OLP to OSCC.
p2548
sg4
(lp2549
(dp2550
g9
I28
sg39
g40
sg12
I4
sg13
VSOX4
p2551
sg15
I1
sasg6
(lp2552
sa(dp2553
g2
VThis study evaluated whether SOX4 affects oncogenic behavior and chemoradiotherapy response in head and neck squamous cell carcinoma (HNSCC) cells, and documented the relationship between its expression and prognosis in oral squamous cell carcinoma (OSCC).
p2554
sg4
(lp2555
(dp2556
g9
I29
sg39
g40
sg12
I4
sg13
VSOX4
p2557
sg15
I1
sasg6
(lp2558
(dp2559
g9
I95
sg10
VC1168401
p2560
sg12
I37
sg13
Vhead and neck squamous cell carcinoma
p2561
sg15
I6
sa(dp2562
g9
I109
sg10
VC0007137
p2563
sg12
I23
sg13
Vsquamous cell carcinoma
p2564
sg15
I3
sa(dp2565
g9
I134
sg10
VC1168401
p2566
sg12
I5
sg13
VHNSCC
p2567
sg15
I1
sasa(dp2568
g2
VSOX4 expression in OSCC tissues was investigated by immunohistochemistry.
p2569
sg4
(lp2570
(dp2571
g9
I0
sg39
g40
sg12
I4
sg13
VSOX4
p2572
sg15
I1
sasg6
(lp2573
sa(dp2574
g2
VImmunostaining showed SOX4 protein was significantly increased in OSCC tissues compared with adjacent normal mucosa.
p2575
sg4
(lp2576
(dp2577
g9
I22
sg39
g40
sg12
I12
sg13
VSOX4 protein
p2578
sg15
I2
sasg6
(lp2579
sa(dp2580
g2
VSOX4 expression was observed in 51.8 % of 85 OSCC tissues, and was significantly correlated with treatment failure (P = 0.032) and shorter overall survival (P = 0.036) in patients with OSCC.
p2581
sg4
(lp2582
(dp2583
g9
I0
sg39
g40
sg12
I4
sg13
VSOX4
p2584
sg15
I1
sasg6
(lp2585
sa(dp2586
g2
VThis study was the first to investigate correlations between SOX4 expression levels and the clinicopathologic factors of oral squamous cell carcinoma (OSCC).
p2587
sg4
(lp2588
(dp2589
g9
I61
sg39
g40
sg12
I4
sg13
VSOX4
p2590
sg15
I1
sasg6
(lp2591
(dp2592
g9
I126
sg10
VC0007137
p2593
sg12
I23
sg13
Vsquamous cell carcinoma
p2594
sg15
I3
sasa(dp2595
g2
VWe analyzed SOX4 expression levels in 50 patients with OSCC using immunohistochemistry.
p2596
sg4
(lp2597
(dp2598
g9
I12
sg39
g40
sg12
I4
sg13
VSOX4
p2599
sg15
I1
sasg6
(lp2600
sa(dp2601
g2
VThe expression level of SOX4 in primary foci of poorly differentiated OSCC was higher than that of well differentiated OSCC, which indicated that SOX4 expression is associated with the differentiation of OSCC.
p2602
sg4
(lp2603
(dp2604
g9
I24
sg39
g40
sg12
I4
sg13
VSOX4
p2605
sg15
I1
sa(dp2606
g9
I24
sg39
g40
sg12
I4
sg13
VSOX4
p2607
sg15
I1
sasg6
(lp2608
sa(dp2609
g2
VThese results indicate that undifferentiated OSCC cells expressing SOX4 are more likely to metastasize and neoadjuvant therapy including chemoradiation therapy may have some effect in metastatic prevention.
p2610
sg4
(lp2611
(dp2612
g9
I67
sg39
g40
sg12
I4
sg13
VSOX4
p2613
sg15
I1
sasg6
(lp2614
(dp2615
g9
I91
sg10
VC0027627
p2616
sg12
I11
sg13
Vmetastasize
p2617
sg15
I1
sasa(dp2618
g2
VCryptorchidism was significantly associated with development of MGCSCTs, SCTs, and SEMs, but not ICTs (p&lt;0.01).
p2619
sg4
(lp2620
sg6
(lp2621
(dp2622
g9
I0
sg10
VC0010417
p2623
sg12
I14
sg13
VCryptorchidism
p2624
sg15
I1
sa(dp2625
g9
I67
sg10
VC0796149
p2626
sg12
I4
sg13
VSCTs
p2627
sg15
I1
sasa(dp2628
g2
VSince nerve functions are affected by inflammatory response during the course of leprosy, changes in the production of NGF and its receptor (NGF R) may be directly associated with disability and sensory loss.
p2629
sg4
(lp2630
(dp2631
g9
I119
sg39
VP01138
p2632
sg12
I3
sg13
VNGF
p2633
sg15
I1
sa(dp2634
g9
I119
sg39
VP01138
p2635
sg12
I3
sg13
VNGF
p2636
sg15
I1
sasg6
(lp2637
(dp2638
g9
I38
sg10
VC1155266
p2639
sg12
I21
sg13
Vinflammatory response
p2640
sg15
I2
sa(dp2641
g9
I195
sg10
VC0278134
p2642
sg12
I12
sg13
Vsensory loss
p2643
sg15
I2
sa(dp2644
g9
I81
sg10
VC0023343
p2645
sg12
I7
sg13
Vleprosy
p2646
sg15
I1
sasa(dp2647
g2
VSkin biopsies were collected and submitted to immunohistochemistry using specific antibodies to IL-17, NGF and NGF R. Quantitative analysis of NGF, NGFR and IL-17 immunostaining showed a significant difference between the clinical forms, with higher expression of NGF and NGFR in lepromatous leprosy and IL-17 in tuberculoid leprosy.
p2648
sg4
(lp2649
(dp2650
g9
I111
sg39
VP01138
p2651
sg12
I5
sg13
VNGF R
p2652
sg15
I2
sa(dp2653
g9
I103
sg39
VP01138
p2654
sg12
I3
sg13
VNGF
p2655
sg15
I1
sa(dp2656
g9
I103
sg39
VP01138
p2657
sg12
I3
sg13
VNGF
p2658
sg15
I1
sa(dp2659
g9
I103
sg39
VP01138
p2660
sg12
I3
sg13
VNGF
p2661
sg15
I1
sa(dp2662
g9
I148
sg39
VP08138
p2663
sg12
I4
sg13
VNGFR
p2664
sg15
I1
sa(dp2665
g9
I148
sg39
VP08138
p2666
sg12
I4
sg13
VNGFR
p2667
sg15
I1
sasg6
(lp2668
(dp2669
g9
I280
sg10
VC0023348
p2670
sg12
I19
sg13
Vlepromatous leprosy
p2671
sg15
I2
sa(dp2672
g9
I313
sg10
VC0023351
p2673
sg12
I19
sg13
Vtuberculoid leprosy
p2674
sg15
I2
sasa(dp2675
g2
VThe recovered CD271(+) BM-MSCs from post-therapy mice, when injected into healthy mice, caused active tuberculosis infection in the animal's lung.
p2676
sg4
(lp2677
sg6
(lp2678
(dp2679
g9
I102
sg10
VC0041296
p2680
sg12
I22
sg13
Vtuberculosis infection
p2681
sg15
I2
sasa(dp2682
g2
VNext, in human subjects, previously treated for pulmonary tuberculosis, the MTB-containing CD271(+) BM-MSCs exhibited high expression of hypoxia-inducible factor 1Alfa and low expression of CD146, a hypoxia down-regulated cell surface marker of human BM-MSCs.
p2683
sg4
(lp2684
(dp2685
g9
I137
sg39
g40
sg12
I30
sg13
Vhypoxia-inducible factor 1Alfa
p2686
sg15
I3
sa(dp2687
g9
I190
sg39
VP43121
p2688
sg12
I5
sg13
VCD146
p2689
sg15
I1
sasg6
(lp2690
(dp2691
g9
I48
sg10
VC0041327
p2692
sg12
I22
sg13
Vpulmonary tuberculosis
p2693
sg15
I2
sa(dp2694
g9
I137
sg10
VC0242184
p2695
sg12
I7
sg13
Vhypoxia
p2696
sg15
I1
sa(dp2697
g9
I137
sg10
VC0242184
p2698
sg12
I7
sg13
Vhypoxia
p2699
sg15
I1
sasa(dp2700
g2
VThe bone marrow niche of Mycobacterium tuberculosis within CD271(+) BM-MSCs stem cells is the proposed explanation for the localized cortical resorption that is observed in bone stress markers.
p2701
sg4
(lp2702
sg6
(lp2703
(dp2704
g9
I39
sg10
VC0041296
p2705
sg12
I12
sg13
Vtuberculosis
p2706
sg15
I1
sasa(dp2707
g2
VTherefore, the objective of this study was to correlate the immunoexpression patterns of NGF and NGF-R in the different clinical forms of leprosy, and to associate the findings with the in situ expression of TGF-Beta and clinical classification of the disease.
p2708
sg4
(lp2709
(dp2710
g9
I89
sg39
VP01138
p2711
sg12
I3
sg13
VNGF
p2712
sg15
I1
sa(dp2713
g9
I97
sg39
VP01138
p2714
sg12
I5
sg13
VNGF-R
p2715
sg15
I1
sa(dp2716
g9
I208
sg39
VP18075
p2717
sg12
I8
sg13
VTGF-Beta
p2718
sg15
I1
sasg6
(lp2719
(dp2720
g9
I138
sg10
VC0023343
p2721
sg12
I7
sg13
Vleprosy
p2722
sg15
I1
sasa(dp2723
g2
VThere was a significant positive correlation between NGF and NGF-R in the different clinical forms of leprosy.
p2724
sg4
(lp2725
(dp2726
g9
I53
sg39
VP01138
p2727
sg12
I3
sg13
VNGF
p2728
sg15
I1
sa(dp2729
g9
I61
sg39
VP01138
p2730
sg12
I5
sg13
VNGF-R
p2731
sg15
I1
sasg6
(lp2732
(dp2733
g9
I102
sg10
VC0023343
p2734
sg12
I7
sg13
Vleprosy
p2735
sg15
I1
sasa(dp2736
g2
VMoreover, most viable M. tuberculosis was recovered from the bone marrow CD271(+)CD45(-)-enriched cell fraction, and only few viable bacteria could be isolated from the CD271(-)CD45(+) cell fraction.
p2737
sg4
(lp2738
(dp2739
g9
I81
sg39
VP08575
p2740
sg12
I4
sg13
VCD45
p2741
sg15
I1
sa(dp2742
g9
I169
sg39
VP08138
p2743
sg12
I12
sg13
VCD271(-)CD45
p2744
sg15
I1
sasg6
(lp2745
(dp2746
g9
I25
sg10
VC0041296
p2747
sg12
I12
sg13
Vtuberculosis
p2748
sg15
I1
sasa(dp2749
g2
VWe recently developed a systems biological approach to vaccine safety evaluation where identification of specific biomarkers in a rat pre-clinical study evaluated the safety of vaccines for pandemic H5N1 influenza including Irf7, Lgals9, Lgalsbp3, Cxcl11, Timp1, Tap2, Psmb9, Psme1, Tapbp, C2, Csf1, Mx2, Zbp1, Ifrd1, Trafd1, Cxcl9, Beta2m, Npc1, Ngfr and Ifi47.
p2750
sg4
(lp2751
(dp2752
g9
I318
sg39
g40
sg12
I6
sg13
VTrafd1
p2753
sg15
I1
sa(dp2754
g9
I326
sg39
g40
sg12
I5
sg13
VCxcl9
p2755
sg15
I1
sa(dp2756
g9
I311
sg39
g40
sg12
I5
sg13
VIfrd1
p2757
sg15
I1
sa(dp2758
g9
I300
sg39
VP20592
p2759
sg12
I3
sg13
VMx2
p2760
sg15
I1
sa(dp2761
g9
I256
sg39
VP01033
p2762
sg12
I5
sg13
VTimp1
p2763
sg15
I1
sa(dp2764
g9
I248
sg39
g40
sg12
I6
sg13
VCxcl11
p2765
sg15
I1
sa(dp2766
g9
I347
sg39
VP08138
p2767
sg12
I4
sg13
VNgfr
p2768
sg15
I1
sa(dp2769
g9
I224
sg39
g40
sg12
I4
sg13
VIrf7
p2770
sg15
I1
sa(dp2771
g9
I341
sg39
g40
sg12
I4
sg13
VNpc1
p2772
sg15
I1
sa(dp2773
g9
I230
sg39
g40
sg12
I6
sg13
VLgals9
p2774
sg15
I1
sa(dp2775
g9
I333
sg39
VP61769
p2776
sg12
I6
sg13
VBeta2m
p2777
sg15
I1
sa(dp2778
g9
I269
sg39
VP28065
p2779
sg12
I5
sg13
VPsmb9
p2780
sg15
I1
sa(dp2781
g9
I294
sg39
VP09919
p2782
sg12
I4
sg13
VCsf1
p2783
sg15
I1
sa(dp2784
g9
I263
sg39
g40
sg12
I4
sg13
VTap2
p2785
sg15
I1
sa(dp2786
g9
I276
sg39
g40
sg12
I5
sg13
VPsme1
p2787
sg15
I1
sa(dp2788
g9
I305
sg39
g40
sg12
I4
sg13
VZbp1
p2789
sg15
I1
sasg6
(lp2790
(dp2791
g9
I341
sg10
VC3179455
p2792
sg12
I4
sg13
VNpc1
p2793
sg15
I1
sa(dp2794
g9
I199
sg10
VC2748361
p2795
sg12
I14
sg13
VH5N1 influenza
p2796
sg15
I2
sasa(dp2797
g2
VMdmX overexpression contributes to the development of cancer by inhibiting tumor suppressor p53.
p2798
sg4
(lp2799
(dp2800
g9
I75
sg39
VP42771
p2801
sg12
I20
sg13
Vtumor suppressor p53
p2802
sg15
I3
sa(dp2803
g9
I0
sg39
g40
sg12
I4
sg13
VMdmX
p2804
sg15
I1
sasg6
(lp2805
(dp2806
g9
I54
sg10
VC0006826
p2807
sg12
I6
sg13
Vcancer
p2808
sg15
I1
sa(dp2809
g9
I75
sg10
VC0027651
p2810
sg12
I5
sg13
Vtumor
p2811
sg15
I1
sasa(dp2812
g2
VA switch in the alternative splicing of MdmX transcript, leading to the inclusion of exon 6, has been identified as the primary mechanism responsible for increased MdmX protein levels in human cancers, including melanoma.
p2813
sg4
(lp2814
(dp2815
g9
I164
sg39
g40
sg12
I12
sg13
VMdmX protein
p2816
sg15
I2
sa(dp2817
g9
I40
sg39
g40
sg12
I15
sg13
VMdmX transcript
p2818
sg15
I2
sasg6
(lp2819
(dp2820
g9
I193
sg10
VC0006826
p2821
sg12
I7
sg13
Vcancers
p2822
sg15
I1
sa(dp2823
g9
I212
sg10
VC0025202
p2824
sg12
I8
sg13
Vmelanoma
p2825
sg15
I1
sasa(dp2826
g2
VRecent studies showed that interfering with cellular splicing machinery can result in MdmX downregulation in cancer cells.
p2827
sg4
(lp2828
(dp2829
g9
I86
sg39
g40
sg12
I4
sg13
VMdmX
p2830
sg15
I1
sasg6
(lp2831
(dp2832
g9
I109
sg10
VC0006826
p2833
sg12
I6
sg13
Vcancer
p2834
sg15
I1
sasa(dp2835
g2
VWe, therefore, hypothesized that enoxacin could, by modulating miRNAs targeting splicing machinery, activate p53 in melanoma cells overexpressing MdmX.
p2836
sg4
(lp2837
(dp2838
g9
I146
sg39
g40
sg12
I4
sg13
VMdmX
p2839
sg15
I1
sa(dp2840
g9
I109
sg39
VP42771
p2841
sg12
I3
sg13
Vp53
p2842
sg15
I1
sasg6
(lp2843
(dp2844
g9
I116
sg10
VC0025202
p2845
sg12
I8
sg13
Vmelanoma
p2846
sg15
I1
sasa(dp2847
g2
VNot only in melanoma, but also in MCF7 breast carcinoma and A2780 ovarian carcinoma cells overexpressing MdmX.
p2848
sg4
(lp2849
(dp2850
g9
I105
sg39
g40
sg12
I4
sg13
VMdmX
p2851
sg15
I1
sasg6
(lp2852
(dp2853
g9
I39
sg10
VC0678222
p2854
sg12
I16
sg13
Vbreast carcinoma
p2855
sg15
I2
sa(dp2856
g9
I12
sg10
VC0025202
p2857
sg12
I8
sg13
Vmelanoma
p2858
sg15
I1
sa(dp2859
g9
I66
sg10
VC0029925
p2860
sg12
I17
sg13
Vovarian carcinoma
p2861
sg15
I2
sasa(dp2862
g2
VTogether, our results suggest that some clinically approved fluoroquinolones could potentially be repurposed as activators of p53 tumor suppressor in cancers overexpressing MdmX oncoprotein and that p53 activation might contribute to the previously reported activity of enoxacin towards human cancer cells.
p2863
sg4
(lp2864
(dp2865
g9
I126
sg39
VP42771
p2866
sg12
I20
sg13
Vp53 tumor suppressor
p2867
sg15
I3
sa(dp2868
g9
I126
sg39
VP42771
p2869
sg12
I3
sg13
Vp53
p2870
sg15
I1
sa(dp2871
g9
I173
sg39
g40
sg12
I16
sg13
VMdmX oncoprotein
p2872
sg15
I2
sasg6
(lp2873
(dp2874
g9
I130
sg10
VC0027651
p2875
sg12
I5
sg13
Vtumor
p2876
sg15
I1
sa(dp2877
g9
I150
sg10
VC0006826
p2878
sg12
I6
sg13
Vcancer
p2879
sg15
I1
sa(dp2880
g9
I150
sg10
VC0006826
p2881
sg12
I7
sg13
Vcancers
p2882
sg15
I1
sasa(dp2883
g2
VThese will be discussed as will recent findings of MDMX inhibitors: these are of special importance as it has been shown that cancers that become resistant to MDM2 inhibitors often amplify MDM4.
p2884
sg4
(lp2885
(dp2886
g9
I51
sg39
g40
sg12
I4
sg13
VMDMX
p2887
sg15
I1
sa(dp2888
g9
I189
sg39
g40
sg12
I4
sg13
VMDM4
p2889
sg15
I1
sasg6
(lp2890
(dp2891
g9
I126
sg10
VC0006826
p2892
sg12
I7
sg13
Vcancers
p2893
sg15
I1
sasa(dp2894
g2
VWe speculate that E3 ubiquitin ligases MDM2 and MDM4 can be attractive therapeutic target for p53 and Notch signaling pathways in malignant melanoma by using small molecule inhibitors.
p2895
sg4
(lp2896
(dp2897
g9
I94
sg39
VP42771
p2898
sg12
I3
sg13
Vp53
p2899
sg15
I1
sa(dp2900
g9
I18
sg39
VP62979
p2901
sg12
I12
sg13
VE3 ubiquitin
p2902
sg15
I2
sa(dp2903
g9
I48
sg39
g40
sg12
I4
sg13
VMDM4
p2904
sg15
I1
sasg6
(lp2905
(dp2906
g9
I130
sg10
VC0025202
p2907
sg12
I18
sg13
Vmalignant melanoma
p2908
sg15
I2
sasa(dp2909
g2
VOur recent studies conducted in South America have shown that mycotoxin contamination of red chili peppers (RCPs) may be associated with an increased risk of gallbladder cancer (GBC).
p2910
sg4
(lp2911
sg6
(lp2912
(dp2913
g9
I178
sg10
VC0153452
p2914
sg12
I3
sg13
VGBC
p2915
sg15
I1
sa(dp2916
g9
I158
sg10
VC0153452
p2917
sg12
I18
sg13
Vgallbladder cancer
p2918
sg15
I2
sasa(dp2919
g2
VThree proteins were uniquely altered in vaginal carcinoma (DDX48, erbB3-binding protein and biliverdin reductase) and five in cervical carcinoma (peroxiredoxin 2, annexin A2, sarcomeric tropomyosin kappa, human ribonuclease inhibitor and prolyl-4-hydrolase beta).
p2920
sg4
(lp2921
(dp2922
g9
I92
sg39
VP53004
p2923
sg12
I20
sg13
Vbiliverdin reductase
p2924
sg15
I2
sa(dp2925
g9
I59
sg39
VP38919
p2926
sg12
I5
sg13
VDDX48
p2927
sg15
I1
sa(dp2928
g9
I66
sg39
VP21860
p2929
sg12
I21
sg13
VerbB3-binding protein
p2930
sg15
I2
sa(dp2931
g9
I163
sg39
VP07355
p2932
sg12
I40
sg13
Vannexin A2, sarcomeric tropomyosin kappa
p2933
sg15
I5
sa(dp2934
g9
I146
sg39
VP32119
p2935
sg12
I15
sg13
Vperoxiredoxin 2
p2936
sg15
I2
sa(dp2937
g9
I205
sg39
VP13489
p2938
sg12
I28
sg13
Vhuman ribonuclease inhibitor
p2939
sg15
I3
sasg6
(lp2940
(dp2941
g9
I126
sg10
VC0302592
p2942
sg12
I18
sg13
Vcervical carcinoma
p2943
sg15
I2
sa(dp2944
g9
I40
sg10
VC0262659
p2945
sg12
I17
sg13
Vvaginal carcinoma
p2946
sg15
I2
sasa(dp2947
g2
VMitochondrial (mt) DNA-associated NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) syndrome is due to mutation in the MT-ATP6 gene.
p2948
sg4
(lp2949
(dp2950
g9
I34
sg39
VP47972
p2951
sg12
I4
sg13
VNARP
p2952
sg15
I1
sa(dp2953
g9
I137
sg39
VP36543
p2954
sg12
I12
sg13
VMT-ATP6 gene
p2955
sg15
I2
sasg6
(lp2956
(dp2957
g9
I80
sg10
VC0035334
p2958
sg12
I20
sg13
Vretinitis pigmentosa
p2959
sg15
I2
sa(dp2960
g9
I51
sg10
VC0030552
p2961
sg12
I15
sg13
Vmuscle weakness
p2962
sg15
I2
sa(dp2963
g9
I68
sg10
VC0004134
p2964
sg12
I6
sg13
Vataxia
p2965
sg15
I1
sa(dp2966
g9
I102
sg10
VC0039082
p2967
sg12
I8
sg13
Vsyndrome
p2968
sg15
I1
sasa(dp2969
g2
VPathogenic mutations in MT-ATP6 are associated with the Leigh syndrome, the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP), as well as with non-classical phenotypes, while MT-ATP8 is less frequently mutated in patients with mitochondrial disease.
p2970
sg4
(lp2971
(dp2972
g9
I189
sg39
VP03928
p2973
sg12
I7
sg13
VMT-ATP8
p2974
sg15
I1
sa(dp2975
g9
I24
sg39
VP36543
p2976
sg12
I7
sg13
VMT-ATP6
p2977
sg15
I1
sasg6
(lp2978
(dp2979
g9
I241
sg10
VC0751651
p2980
sg12
I21
sg13
Vmitochondrial disease
p2981
sg15
I2
sa(dp2982
g9
I88
sg10
VC1328349
p2983
sg12
I44
sg13
Vneuropathy, ataxia, and retinitis pigmentosa
p2984
sg15
I5
sa(dp2985
g9
I56
sg10
VC0023264
p2986
sg12
I14
sg13
VLeigh syndrome
p2987
sg15
I2
sa(dp2988
g9
I62
sg10
VC0039082
p2989
sg12
I8
sg13
Vsyndrome
p2990
sg15
I1
sasa(dp2991
g2
VAnalysis of these populations demonstrated an altered metabolic signature in cells harbouring decreased levels of mutant m.8993T&gt;G mtDNA, associated with neuropathy, ataxia, and retinitis pigmentosa (NARP).
p2992
sg4
(lp2993
sg6
(lp2994
(dp2995
g9
I157
sg10
VC1328349
p2996
sg12
I44
sg13
Vneuropathy, ataxia, and retinitis pigmentosa
p2997
sg15
I5
sa(dp2998
g9
I114
sg10
VC0596988
p2999
sg12
I6
sg13
Vmutant
p3000
sg15
I1
sasa(dp3001
g2
VNeurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) is caused by m.8993T&gt;G/C mutations in the mitochondrial adenosine triphosphate synthase subunit 6 gene (MT-ATP6).
p3002
sg4
(lp3003
(dp3004
g9
I113
sg39
VP56381
p3005
sg12
I60
sg13
Vmitochondrial adenosine triphosphate synthase subunit 6 gene
p3006
sg15
I7
sa(dp3007
g9
I175
sg39
VP36543
p3008
sg12
I7
sg13
VMT-ATP6
p3009
sg15
I1
sasg6
(lp3010
(dp3011
g9
I28
sg10
VC0004134
p3012
sg12
I6
sg13
Vataxia
p3013
sg15
I1
sa(dp3014
g9
I40
sg10
VC0035334
p3015
sg12
I20
sg13
Vretinitis pigmentosa
p3016
sg15
I2
sa(dp3017
g9
I11
sg10
VC0030552
p3018
sg12
I15
sg13
Vmuscle weakness
p3019
sg15
I2
sasa(dp3020
g2
VIn addition, we successfully reduced human mutated mtDNA levels responsible for Leber's hereditary optic neuropathy (LHOND), and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), in mammalian oocytes using mitochondria-targeted TALEN (mito-TALENs).
p3021
sg4
(lp3022
sg6
(lp3023
(dp3024
g9
I140
sg10
VC0030552
p3025
sg12
I15
sg13
Vmuscle weakness
p3026
sg15
I2
sa(dp3027
g9
I80
sg10
VC0917796
p3028
sg12
I35
sg13
VLeber's hereditary optic neuropathy
p3029
sg15
I4
sa(dp3030
g9
I169
sg10
VC0035334
p3031
sg12
I20
sg13
Vretinitis pigmentosa
p3032
sg15
I2
sa(dp3033
g9
I157
sg10
VC0004134
p3034
sg12
I6
sg13
Vataxia
p3035
sg15
I1
sasa(dp3036
g2
VBased on our previous findings that ROS level was higher in human osteosarcoma cybrids--Neuropathy, Ataxia and Retinitis Pigmentosa (NARP) and was reduced by selenite treatment, this study was designed to elucidate the effects of selenite administration on oxidative and nitrosative damage to lipids, proteins and DNA.
p3037
sg4
(lp3038
sg6
(lp3039
(dp3040
g9
I100
sg10
VC0004134
p3041
sg12
I6
sg13
VAtaxia
p3042
sg15
I1
sa(dp3043
g9
I66
sg10
VC0029463
p3044
sg12
I12
sg13
Vosteosarcoma
p3045
sg15
I1
sa(dp3046
g9
I88
sg10
VC0442874
p3047
sg12
I10
sg13
VNeuropathy
p3048
sg15
I1
sa(dp3049
g9
I111
sg10
VC0035334
p3050
sg12
I20
sg13
VRetinitis Pigmentosa
p3051
sg15
I2
sasa(dp3052
g2
VWe report a patient having classical clinical feature of neurologic muscle weakness, ataxia, and retinitis pigmentosa (NARP) and a novel mutation, m.8729 G&gt;A in mitochondria DNA.
p3053
sg4
(lp3054
sg6
(lp3055
(dp3056
g9
I97
sg10
VC0035334
p3057
sg12
I20
sg13
Vretinitis pigmentosa
p3058
sg15
I2
sa(dp3059
g9
I68
sg10
VC0030552
p3060
sg12
I15
sg13
Vmuscle weakness
p3061
sg15
I2
sa(dp3062
g9
I131
sg10
VC2985438
p3063
sg12
I14
sg13
Vnovel mutation
p3064
sg15
I2
sa(dp3065
g9
I85
sg10
VC0004134
p3066
sg12
I6
sg13
Vataxia
p3067
sg15
I1
sasa(dp3068
g2
VHis mother, who had previously been diagnosed with cerebral palsy, was concurrently diagnosed with neuropathy, ataxia, and retinitis pigmentosa (NARP) due to heteroplasmy of the same mutation.
p3069
sg4
(lp3070
sg6
(lp3071
(dp3072
g9
I99
sg10
VC1328349
p3073
sg12
I44
sg13
Vneuropathy, ataxia, and retinitis pigmentosa
p3074
sg15
I5
sa(dp3075
g9
I51
sg10
VC0007789
p3076
sg12
I14
sg13
Vcerebral palsy
p3077
sg15
I2
sasa(dp3078
g2
VIn this issue, Gammage and colleagues successfully apply this improved technology on patients' cells with two types of genetic alterations responsible for neuropathy ataxia and retinitis pigmentosa (NARP) syndrome and Kearns Sayre syndrome and progressive external ophthalmoplegia (PEO).
p3079
sg4
(lp3080
sg6
(lp3081
(dp3082
g9
I166
sg10
VC0004134
p3083
sg12
I6
sg13
Vataxia
p3084
sg15
I1
sa(dp3085
g9
I155
sg10
VC0442874
p3086
sg12
I10
sg13
Vneuropathy
p3087
sg15
I1
sa(dp3088
g9
I244
sg10
VC0162674
p3089
sg12
I36
sg13
Vprogressive external ophthalmoplegia
p3090
sg15
I3
sa(dp3091
g9
I218
sg10
VC0022541
p3092
sg12
I21
sg13
VKearns Sayre syndrome
p3093
sg15
I3
sa(dp3094
g9
I205
sg10
VC0039082
p3095
sg12
I8
sg13
Vsyndrome
p3096
sg15
I1
sa(dp3097
g9
I177
sg10
VC0035334
p3098
sg12
I20
sg13
Vretinitis pigmentosa
p3099
sg15
I2
sa(dp3100
g9
I282
sg10
VC0162674
p3101
sg12
I3
sg13
VPEO
p3102
sg15
I1
sasa(dp3103
g2
VThere are several diseases that have a mitochondrial origin such as chronic progressive external ophthalmoplegia (CPEO) and the Kearns- Sayre syndrome (KSS), myoclonic epilepsy with ragged-red fibers (MERRF), mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS), Leber's hereditary optic neuropathy (LHON), the syndrome of neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP), and Leigh's syndrome.
p3104
sg4
(lp3105
sg6
(lp3106
(dp3107
g9
I158
sg10
VC0162672
p3108
sg12
I41
sg13
Vmyoclonic epilepsy with ragged-red fibers
p3109
sg15
I5
sa(dp3110
g9
I201
sg10
VC0162672
p3111
sg12
I5
sg13
VMERRF
p3112
sg15
I1
sa(dp3113
g9
I128
sg10
VC0022541
p3114
sg12
I22
sg13
VKearns- Sayre syndrome
p3115
sg15
I3
sa(dp3116
g9
I291
sg10
VC0917796
p3117
sg12
I35
sg13
VLeber's hereditary optic neuropathy
p3118
sg15
I4
sa(dp3119
g9
I114
sg10
VC0162674
p3120
sg12
I4
sg13
VCPEO
p3121
sg15
I1
sa(dp3122
g9
I142
sg10
VC0039082
p3123
sg12
I8
sg13
Vsyndrome
p3124
sg15
I1
sa(dp3125
g9
I142
sg10
VC0039082
p3126
sg12
I8
sg13
Vsyndrome
p3127
sg15
I1
sa(dp3128
g9
I242
sg10
VC0001125
p3129
sg12
I15
sg13
Vlactic acidosis
p3130
sg15
I2
sa(dp3131
g9
I209
sg10
VC0162666
p3132
sg12
I31
sg13
Vmitochondrial encephalomyopathy
p3133
sg15
I2
sa(dp3134
g9
I152
sg10
VC0022541
p3135
sg12
I3
sg13
VKSS
p3136
sg15
I1
sa(dp3137
g9
I283
sg10
VC0162671
p3138
sg12
I5
sg13
VMELAS
p3139
sg15
I1
sa(dp3140
g9
I328
sg10
VC0917796
p3141
sg12
I4
sg13
VLHON
p3142
sg15
I1
sa(dp3143
g9
I351
sg10
VC0342772
p3144
sg12
I59
sg13
Vneurogenic muscle weakness, ataxia and retinitis pigmentosa
p3145
sg15
I7
sa(dp3146
g9
I68
sg10
VC0162674
p3147
sg12
I44
sg13
Vchronic progressive external ophthalmoplegia
p3148
sg15
I4
sasa(dp3149
g2
VNeuroblastoma cells treated with free myb-as or nontargeted CCL-myb-as showed the same level of c-myb protein expression as control cells.
p3150
sg4
(lp3151
(dp3152
g9
I96
sg39
VP10243
p3153
sg12
I13
sg13
Vc-myb protein
p3154
sg15
I2
sa(dp3155
g9
I38
sg39
VP10243
p3156
sg12
I3
sg13
Vmyb
p3157
sg15
I1
sa(dp3158
g9
I38
sg39
VP10243
p3159
sg12
I3
sg13
Vmyb
p3160
sg15
I1
sa(dp3161
g9
I60
sg39
VP43320
p3162
sg12
I3
sg13
VCCL
p3163
sg15
I1
sasg6
(lp3164
(dp3165
g9
I0
sg10
VC0027819
p3166
sg12
I13
sg13
VNeuroblastoma
p3167
sg15
I1
sa(dp3168
g9
I60
sg10
VC1852438
p3169
sg12
I3
sg13
VCCL
p3170
sg15
I1
sasa(dp3171
g2
VImmune cell activation, involving the time-dependent activation of macrophages and NK cells, contributes to the antitumor activity of targeted liposome-CpG-myb-as against neuroblastoma and could improve the effectiveness of antitumor targeted liposomes.
p3172
sg4
(lp3173
sg6
(lp3174
(dp3175
g9
I171
sg10
VC0027819
p3176
sg12
I13
sg13
Vneuroblastoma
p3177
sg15
I1
sasa(dp3178
g2
VWhile YY1 is known to exert both positive and negative regulatory influences on nuclear-encoded mitochondrial proteins, as well as on neurodegeneration-related genes, in all cell lines we studied (including neuroblastoma) the effect of YY1 on GDAP1 expression is activatory.
p3179
sg4
(lp3180
(dp3181
g9
I6
sg39
VP25490
p3182
sg12
I3
sg13
VYY1
p3183
sg15
I1
sa(dp3184
g9
I6
sg39
VP25490
p3185
sg12
I3
sg13
VYY1
p3186
sg15
I1
sa(dp3187
g9
I243
sg39
g40
sg12
I5
sg13
VGDAP1
p3188
sg15
I1
sa(dp3189
g9
I80
sg39
VP02649
p3190
sg12
I38
sg13
Vnuclear-encoded mitochondrial proteins
p3191
sg15
I3
sasg6
(lp3192
(dp3193
g9
I207
sg10
VC0027819
p3194
sg12
I13
sg13
Vneuroblastoma
p3195
sg15
I1
sa(dp3196
g9
I134
sg10
VC0027746
p3197
sg12
I17
sg13
Vneurodegeneration
p3198
sg15
I1
sasa(dp3199
g2
VUsing the DBH-expressing human neuroblastoma SK-N-BE(2)C and DBH-negative HeLa cell lines as model systems, we report here that this CRE/YY1/AP1 area interacts with multiple nuclear proteins, including CRE-binding protein (CREB) and transcription factor YY1 in a cell-specific manner.
p3200
sg4
(lp3201
(dp3202
g9
I202
sg39
g40
sg12
I19
sg13
VCRE-binding protein
p3203
sg15
I2
sa(dp3204
g9
I233
sg39
VP25490
p3205
sg12
I24
sg13
Vtranscription factor YY1
p3206
sg15
I3
sa(dp3207
g9
I10
sg39
VP09172
p3208
sg12
I3
sg13
VDBH
p3209
sg15
I1
sa(dp3210
g9
I223
sg39
VP16220
p3211
sg12
I4
sg13
VCREB
p3212
sg15
I1
sa(dp3213
g9
I137
sg39
VP25490
p3214
sg12
I3
sg13
VYY1
p3215
sg15
I1
sa(dp3216
g9
I141
sg39
VP27695
p3217
sg12
I3
sg13
VAP1
p3218
sg15
I1
sasg6
(lp3219
(dp3220
g9
I31
sg10
VC0027819
p3221
sg12
I13
sg13
Vneuroblastoma
p3222
sg15
I1
sasa(dp3223
g2
VHowever, little is known about the expression of CD44v6 in Gastric Carcinoma (GC).
p3224
sg4
(lp3225
sg6
(lp3226
(dp3227
g9
I59
sg10
VC0699791
p3228
sg12
I17
sg13
VGastric Carcinoma
p3229
sg15
I2
sa(dp3230
g9
I78
sg10
VC0699791
p3231
sg12
I2
sg13
VGC
p3232
sg15
I1
sasa(dp3233
g2
VMultiple carcinomas including breast, ovarian, colon, lung and stomach cancer, overexpress the hyaluronic acid (HA) receptor, CD44.
p3234
sg4
(lp3235
sg6
(lp3236
(dp3237
g9
I63
sg10
VC0024623
p3238
sg12
I14
sg13
Vstomach cancer
p3239
sg15
I2
sa(dp3240
g9
I9
sg10
VC0007097
p3241
sg12
I10
sg13
Vcarcinomas
p3242
sg15
I1
sasa(dp3243
g2
VHere, we show that the transcription of a long non-coding RNA (lncRNA), Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA (GAPLINC), is directly activated by HIF-1Alfa in gastric cancer (GC).
p3244
sg4
(lp3245
sg6
(lp3246
(dp3247
g9
I228
sg10
VC0024623
p3248
sg12
I2
sg13
VGC
p3249
sg15
I1
sa(dp3250
g9
I72
sg10
VC0278701
p3251
sg12
I22
sg13
VGastric Adenocarcinoma
p3252
sg15
I2
sa(dp3253
g9
I212
sg10
VC0024623
p3254
sg12
I14
sg13
Vgastric cancer
p3255
sg15
I2
sasa(dp3256
g2
VThe expressions of 10 putative cell surface markers of CSCs, as well as aldehyde dehydrogenase (ALDH) activity, were studied, and the tumorigenic properties of cells were evaluated by in vitro tumorsphere assays and in vivo xenografts by limiting dilution assays.Results: We found that a subpopulation of gastric carcinoma cells expressing EPCAM, CD133, CD166, CD44, and a high ALDH activity presented the properties to generate new heterogeneous tumorspheres in vitro and tumors in vivo CD44 and CD166 were coexpressed, representing 6.1% to 37.5% of the cells; ALDH activity was detected in 1.6% to 15.4% of the cells; and the ALDH+ cells represented a core within the CD44+/CD166+ subpopulation that contained the highest frequency of tumorigenic CSCs in vivo The ALDH+ cells possessed drug efflux properties and were more resistant to standard chemotherapy than the ALDH- cells, a process that was partially reversed by verapamil treatment.Conclusions: CD44 and ALDH are the most specific biomarkers to detect and isolate tumorigenic and chemoresistant gastric CSCs in noncardia gastric carcinomas independently of the histologic classification of the tumor.
p3257
sg4
(lp3258
(dp3259
g9
I96
sg39
VP00352
p3260
sg12
I4
sg13
VALDH
p3261
sg15
I1
sa(dp3262
g9
I676
sg39
g40
sg12
I6
sg13
VCD166+
p3263
sg15
I1
sa(dp3264
g9
I354
sg39
g40
sg12
I5
sg13
VCD166
p3265
sg15
I1
sa(dp3266
g9
I340
sg39
VP16422
p3267
sg12
I5
sg13
VEPCAM
p3268
sg15
I1
sa(dp3269
g9
I96
sg39
VP49366
p3270
sg12
I4
sg13
VALDH
p3271
sg15
I1
sa(dp3272
g9
I96
sg39
VP00352
p3273
sg12
I4
sg13
VALDH
p3274
sg15
I1
sa(dp3275
g9
I96
sg39
VP00352
p3276
sg12
I4
sg13
VALDH
p3277
sg15
I1
sa(dp3278
g9
I354
sg39
g40
sg12
I5
sg13
VCD166
p3279
sg15
I1
sa(dp3280
g9
I96
sg39
VP00352
p3281
sg12
I4
sg13
VALDH
p3282
sg15
I1
sa(dp3283
g9
I347
sg39
g40
sg12
I5
sg13
VCD133
p3284
sg15
I1
sa(dp3285
g9
I72
sg39
VP49366
p3286
sg12
I22
sg13
Valdehyde dehydrogenase
p3287
sg15
I2
sasg6
(lp3288
(dp3289
g9
I193
sg10
VC0027651
p3290
sg12
I6
sg13
Vtumors
p3291
sg15
I1
sa(dp3292
g9
I778
sg10
VC0850310
p3293
sg12
I9
sg13
Vpossessed
p3294
sg15
I1
sa(dp3295
g9
I305
sg10
VC0699791
p3296
sg12
I17
sg13
Vgastric carcinoma
p3297
sg15
I2
sa(dp3298
g9
I134
sg10
VC0027651
p3299
sg12
I5
sg13
Vtumor
p3300
sg15
I1
sa(dp3301
g9
I1090
sg10
VC0007097
p3302
sg12
I10
sg13
Vcarcinomas
p3303
sg15
I1
sasa(dp3304
g2
VClinically, low CD10 expression was consistent with a specific set of ovarian cancer patient samples.
p3305
sg4
(lp3306
(dp3307
g9
I16
sg39
VP08473
p3308
sg12
I4
sg13
VCD10
p3309
sg15
I1
sasg6
(lp3310
(dp3311
g9
I70
sg10
VC1140680
p3312
sg12
I14
sg13
Vovarian cancer
p3313
sg15
I2
sasa(dp3314
g2
VFurthermore, our data indicate that primary stage targeting of CD10-/ALDH- CSCs in specific ovarian cancer patients in future may facilitate targeting of recurrent disease, before it ever develops.
p3315
sg4
(lp3316
(dp3317
g9
I63
sg39
VP08473
p3318
sg12
I16
sg13
VCD10-/ALDH- CSCs
p3319
sg15
I2
sasg6
(lp3320
(dp3321
g9
I92
sg10
VC1140680
p3322
sg12
I14
sg13
Vovarian cancer
p3323
sg15
I2
sa(dp3324
g9
I154
sg10
VC0277556
p3325
sg12
I17
sg13
Vrecurrent disease
p3326
sg15
I2
sasa(dp3327
g2
VAll cases were negative for CD10 and WT-1 ruling out endometrial stromal tumor and were negative for HMB-45 and melan-A ruling out perivascular epithelioid cell tumor (both endometrial stromal tumor and perivascular epithelioid cell tumor have prominent vessels but have different histomorphology).
p3328
sg4
(lp3329
(dp3330
g9
I112
sg39
g40
sg12
I7
sg13
Vmelan-A
p3331
sg15
I1
sa(dp3332
g9
I28
sg39
VP08473
p3333
sg12
I4
sg13
VCD10
p3334
sg15
I1
sa(dp3335
g9
I101
sg39
g40
sg12
I6
sg13
VHMB-45
p3336
sg15
I1
sasg6
(lp3337
(dp3338
g9
I53
sg10
VC0334695
p3339
sg12
I25
sg13
Vendometrial stromal tumor
p3340
sg15
I3
sa(dp3341
g9
I73
sg10
VC0027651
p3342
sg12
I5
sg13
Vtumor
p3343
sg15
I1
sa(dp3344
g9
I73
sg10
VC0027651
p3345
sg12
I5
sg13
Vtumor
p3346
sg15
I1
sa(dp3347
g9
I53
sg10
VC0334695
p3348
sg12
I25
sg13
Vendometrial stromal tumor
p3349
sg15
I3
sasa(dp3350
g2
VImmunohistochemistry indicated a phenotypic transition from a uterine leiomyosarcoma to a vaginal epithelioid lesion; marker expression changed from the uterine tumor actin+/desmin+/caldesmon+/CD10- phenotype, through the tumor emboli, to an actin-/desmin-/caldesmon-/CD10+ phenotype in the vaginal lesion.
p3351
sg4
(lp3352
(dp3353
g9
I182
sg39
g40
sg12
I10
sg13
Vcaldesmon+
p3354
sg15
I1
sa(dp3355
g9
I257
sg39
g40
sg12
I26
sg13
Vcaldesmon-/CD10+ phenotype
p3356
sg15
I2
sa(dp3357
g9
I174
sg39
VP98155
p3358
sg12
I7
sg13
Vdesmin+
p3359
sg15
I1
sa(dp3360
g9
I242
sg39
VP98155
p3361
sg12
I13
sg13
Vactin-/desmin
p3362
sg15
I1
sa(dp3363
g9
I193
sg39
VP08473
p3364
sg12
I4
sg13
VCD10
p3365
sg15
I1
sasg6
(lp3366
(dp3367
g9
I161
sg10
VC0027651
p3368
sg12
I5
sg13
Vtumor
p3369
sg15
I1
sa(dp3370
g9
I44
sg10
VC0599156
p3371
sg12
I10
sg13
Vtransition
p3372
sg15
I1
sa(dp3373
g9
I291
sg10
VC0566943
p3374
sg12
I14
sg13
Vvaginal lesion
p3375
sg15
I2
sa(dp3376
g9
I62
sg10
VC0280631
p3377
sg12
I22
sg13
Vuterine leiomyosarcoma
p3378
sg15
I2
sa(dp3379
g9
I153
sg10
VC0042138
p3380
sg12
I13
sg13
Vuterine tumor
p3381
sg15
I2
sasa(dp3382
g2
VImmunohistochemistry for IFITM1 and CD10 was performed in 20 cases of smooth muscle neoplasms (10 cases leiomyoma, 10 cases leiomyosarcoma), 14 cases of endometrial stromal sarcoma (ESS) (12 cases of low grade and 2 cases of high grade) and 12 cases of carcinosarcoma.
p3383
sg4
(lp3384
(dp3385
g9
I25
sg39
VP13164
p3386
sg12
I6
sg13
VIFITM1
p3387
sg15
I1
sa(dp3388
g9
I36
sg39
VP08473
p3389
sg12
I4
sg13
VCD10
p3390
sg15
I1
sasg6
(lp3391
(dp3392
g9
I124
sg10
VC0023269
p3393
sg12
I14
sg13
Vleiomyosarcoma
p3394
sg15
I1
sa(dp3395
g9
I182
sg10
VC0206630
p3396
sg12
I3
sg13
VESS
p3397
sg15
I1
sa(dp3398
g9
I253
sg10
VC0007140
p3399
sg12
I14
sg13
Vcarcinosarcoma
p3400
sg15
I1
sa(dp3401
g9
I77
sg10
VC0282606
p3402
sg12
I16
sg13
Vmuscle neoplasms
p3403
sg15
I2
sa(dp3404
g9
I104
sg10
VC0023267
p3405
sg12
I9
sg13
Vleiomyoma
p3406
sg15
I1
sa(dp3407
g9
I153
sg10
VC0206630
p3408
sg12
I27
sg13
Vendometrial stromal sarcoma
p3409
sg15
I3
sasa(dp3410
g2
VWhile both IFITM1 (83%) and CD10 (91%) had high sensitivity in differentiating low-grade ESSs from smooth muscle neoplasms, IFITM1 (70%) had higher specificity compared with CD10 (45%).
p3411
sg4
(lp3412
(dp3413
g9
I28
sg39
VP08473
p3414
sg12
I4
sg13
VCD10
p3415
sg15
I1
sa(dp3416
g9
I28
sg39
VP08473
p3417
sg12
I4
sg13
VCD10
p3418
sg15
I1
sa(dp3419
g9
I11
sg39
VP13164
p3420
sg12
I6
sg13
VIFITM1
p3421
sg15
I1
sa(dp3422
g9
I11
sg39
VP13164
p3423
sg12
I6
sg13
VIFITM1
p3424
sg15
I1
sasg6
(lp3425
(dp3426
g9
I106
sg10
VC0282606
p3427
sg12
I16
sg13
Vmuscle neoplasms
p3428
sg15
I2
sasa(dp3429
g2
VIn this study IFITM1 appears to be a more specific marker of endometrial stromal differentiation compared with CD10 in differentiating low-grade ESSs from smooth muscle neoplasms.
p3430
sg4
(lp3431
(dp3432
g9
I111
sg39
VP08473
p3433
sg12
I4
sg13
VCD10
p3434
sg15
I1
sasg6
(lp3435
(dp3436
g9
I162
sg10
VC0282606
p3437
sg12
I16
sg13
Vmuscle neoplasms
p3438
sg15
I2
sasa(dp3439
g2
VTo further evaluate the nature of the HLA association with alopecia areata (AA), we investigated the HLA-DRB1 locus in 161 AA patients and 165 matched controls from Belgium and Germany.
p3440
sg4
(lp3441
(dp3442
g9
I38
sg39
VP30486
p3443
sg12
I3
sg13
VHLA
p3444
sg15
I1
sa(dp3445
g9
I101
sg39
VP20039
p3446
sg12
I14
sg13
VHLA-DRB1 locus
p3447
sg15
I2
sasg6
(lp3448
(dp3449
g9
I76
sg10
VC0002171
p3450
sg12
I2
sg13
VAA
p3451
sg15
I1
sa(dp3452
g9
I76
sg10
VC0002171
p3453
sg12
I2
sg13
VAA
p3454
sg15
I1
sa(dp3455
g9
I59
sg10
VC0002171
p3456
sg12
I15
sg13
Valopecia areata
p3457
sg15
I2
sasa(dp3458
g2
VIn the present study, we found that miR-19a expression was significantly upregulated in metastatic clear cell renal carcinoma than that in adjacent and primary carcinoma tissues using qPCR and in situ hybridization experiments.
p3459
sg4
(lp3460
(dp3461
g9
I36
sg39
g40
sg12
I7
sg13
VmiR-19a
p3462
sg15
I1
sasg6
(lp3463
(dp3464
g9
I152
sg10
VC1335475
p3465
sg12
I17
sg13
Vprimary carcinoma
p3466
sg15
I2
sa(dp3467
g9
I99
sg10
VC0279702
p3468
sg12
I26
sg13
Vclear cell renal carcinoma
p3469
sg15
I4
sasa(dp3470
g2
VThus, we provide evidence demonstrating that downregulation of miR-19a may be therapeutically beneficial for metastatic renal carcinoma.
p3471
sg4
(lp3472
(dp3473
g9
I63
sg39
g40
sg12
I7
sg13
VmiR-19a
p3474
sg15
I1
sasg6
(lp3475
(dp3476
g9
I109
sg10
VC0919989
p3477
sg12
I26
sg13
Vmetastatic renal carcinoma
p3478
sg15
I3
sasa(dp3479
g2
VTaqman probe stem-loop real-time PCR was used to accurately measure the levels of miR-19a in bladder cancer cell lines, 100 pairs of bladder cancer tissues and the adjacent non-neoplastic tissues and also the plasma collected from bladder cancer patients and normal controls.
p3480
sg4
(lp3481
(dp3482
g9
I82
sg39
g40
sg12
I7
sg13
VmiR-19a
p3483
sg15
I1
sasg6
(lp3484
(dp3485
g9
I93
sg10
VC0699885
p3486
sg12
I14
sg13
Vbladder cancer
p3487
sg15
I2
sa(dp3488
g9
I93
sg10
VC0699885
p3489
sg12
I14
sg13
Vbladder cancer
p3490
sg15
I2
sa(dp3491
g9
I93
sg10
VC0699885
p3492
sg12
I14
sg13
Vbladder cancer
p3493
sg15
I2
sasa(dp3494
g2
VmiR-19a mimics and inhibitors were transfected into bladder cancer cells to investigate its role on regulating cell proliferation which was measured by CCK-8 and colony formation assay.
p3495
sg4
(lp3496
(dp3497
g9
I0
sg39
g40
sg12
I7
sg13
VmiR-19a
p3498
sg15
I1
sasg6
(lp3499
(dp3500
g9
I52
sg10
VC0699885
p3501
sg12
I14
sg13
Vbladder cancer
p3502
sg15
I2
sa(dp3503
g9
I116
sg10
VC0334094
p3504
sg12
I13
sg13
Vproliferation
p3505
sg15
I1
sasa(dp3506
g2
VmiR-19a was significantly up-regulated in bladder cancer tissues and high-level of miR-19a was correlative with more aggressive phenotypes of bladder cancer.
p3507
sg4
(lp3508
(dp3509
g9
I0
sg39
g40
sg12
I7
sg13
VmiR-19a
p3510
sg15
I1
sa(dp3511
g9
I0
sg39
g40
sg12
I7
sg13
VmiR-19a
p3512
sg15
I1
sasg6
(lp3513
(dp3514
g9
I42
sg10
VC0699885
p3515
sg12
I14
sg13
Vbladder cancer
p3516
sg15
I2
sa(dp3517
g9
I117
sg10
VC0001807
p3518
sg12
I10
sg13
Vaggressive
p3519
sg15
I1
sa(dp3520
g9
I42
sg10
VC0699885
p3521
sg12
I14
sg13
Vbladder cancer
p3522
sg15
I2
sasa(dp3523
g2
VMeanwhile, gain or loss of function of miR-19a demonstrated that miR-19a can promote cell growth of bladder cancer cells and the further mechanism studies indicated that its oncogenic role was dependent on targeting PTEN.
p3524
sg4
(lp3525
(dp3526
g9
I39
sg39
g40
sg12
I7
sg13
VmiR-19a
p3527
sg15
I1
sa(dp3528
g9
I216
sg39
VP60484
p3529
sg12
I4
sg13
VPTEN
p3530
sg15
I1
sa(dp3531
g9
I39
sg39
g40
sg12
I7
sg13
VmiR-19a
p3532
sg15
I1
sasg6
(lp3533
(dp3534
g9
I100
sg10
VC0699885
p3535
sg12
I14
sg13
Vbladder cancer
p3536
sg15
I2
sasa(dp3537
g2
VFurthermore, investigation of miR-19a expression in the plasma of bladder cancer patients showed that miR-19a was also increased in plasma of bladder cancer patients which strongly supported miR-19a could be developed as potential diagnostic marker of bladder cancer.
p3538
sg4
(lp3539
(dp3540
g9
I30
sg39
g40
sg12
I7
sg13
VmiR-19a
p3541
sg15
I1
sa(dp3542
g9
I30
sg39
g40
sg12
I7
sg13
VmiR-19a
p3543
sg15
I1
sa(dp3544
g9
I30
sg39
g40
sg12
I7
sg13
VmiR-19a
p3545
sg15
I1
sasg6
(lp3546
(dp3547
g9
I66
sg10
VC0699885
p3548
sg12
I14
sg13
Vbladder cancer
p3549
sg15
I2
sa(dp3550
g9
I66
sg10
VC0699885
p3551
sg12
I14
sg13
Vbladder cancer
p3552
sg15
I2
sa(dp3553
g9
I66
sg10
VC0699885
p3554
sg12
I14
sg13
Vbladder cancer
p3555
sg15
I2
sasa(dp3556
g2
VOur data indicated that miR-19a might act as an oncogenic microRNA in bladder cancer and was significantly up-regulated in bladder cancer carcinogenesis.
p3557
sg4
(lp3558
(dp3559
g9
I24
sg39
g40
sg12
I7
sg13
VmiR-19a
p3560
sg15
I1
sasg6
(lp3561
(dp3562
g9
I70
sg10
VC0699885
p3563
sg12
I14
sg13
Vbladder cancer
p3564
sg15
I2
sa(dp3565
g9
I138
sg10
VC0596263
p3566
sg12
I14
sg13
Vcarcinogenesis
p3567
sg15
I1
sa(dp3568
g9
I70
sg10
VC0699885
p3569
sg12
I14
sg13
Vbladder cancer
p3570
sg15
I2
sasa(dp3571
g2
VThe oncogenic role of miR19a in bladder cancer was dependent on targeting PTEN.
p3572
sg4
(lp3573
(dp3574
g9
I74
sg39
VP60484
p3575
sg12
I4
sg13
VPTEN
p3576
sg15
I1
sasg6
(lp3577
(dp3578
g9
I32
sg10
VC0699885
p3579
sg12
I14
sg13
Vbladder cancer
p3580
sg15
I2
sasa(dp3581
g2
VThe synergy effect between miRNA-19a and arsenic trioxide that advocates targeting the mir-19a may represent a potential approach to enhance the efficacy and safety of ATO to treat bladder cancer by a decrease in dose.
p3582
sg4
(lp3583
(dp3584
g9
I87
sg39
g40
sg12
I7
sg13
Vmir-19a
p3585
sg15
I1
sasg6
(lp3586
(dp3587
g9
I181
sg10
VC0699885
p3588
sg12
I14
sg13
Vbladder cancer
p3589
sg15
I2
sasa(dp3590
g2
VThere was significant decreases in serum albumin and haptoglobin and increases in alpha-1 globulin, ceruloplasmin and alpha-1 globulin, there were no significant differences between schistosomiasis patients and the controls in terms of changes in any laboratory test as a result of the treatment, thus suggesting that patients with active schistosomiasis do not incur a higher risk of hepatic dysfunction while using oral contraception.
p3591
sg4
(lp3592
(dp3593
g9
I100
sg39
VP00450
p3594
sg12
I13
sg13
Vceruloplasmin
p3595
sg15
I1
sa(dp3596
g9
I82
sg39
VP25100
p3597
sg12
I16
sg13
Valpha-1 globulin
p3598
sg15
I2
sa(dp3599
g9
I82
sg39
VP25100
p3600
sg12
I16
sg13
Valpha-1 globulin
p3601
sg15
I2
sa(dp3602
g9
I35
sg39
g40
sg12
I13
sg13
Vserum albumin
p3603
sg15
I2
sa(dp3604
g9
I53
sg39
VP00738
p3605
sg12
I11
sg13
Vhaptoglobin
p3606
sg15
I1
sasg6
(lp3607
(dp3608
g9
I182
sg10
VC0036323
p3609
sg12
I15
sg13
Vschistosomiasis
p3610
sg15
I1
sa(dp3611
g9
I182
sg10
VC0036323
p3612
sg12
I15
sg13
Vschistosomiasis
p3613
sg15
I1
sa(dp3614
g9
I385
sg10
VC0086565
p3615
sg12
I19
sg13
Vhepatic dysfunction
p3616
sg15
I2
sasa(dp3617
g2
VAqueous flare values and the vitreous levels of VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2 were compared between previously untreated patients with BRVO and patients with macular hole (MH).
p3618
sg4
(lp3619
(dp3620
g9
I60
sg39
VP41597
p3621
sg12
I5
sg13
VMCP-1
p3622
sg15
I1
sa(dp3623
g9
I54
sg39
VP05231
p3624
sg12
I4
sg13
VIL-6
p3625
sg15
I1
sasg6
(lp3626
(dp3627
g9
I169
sg10
VC0024441
p3628
sg12
I12
sg13
Vmacular hole
p3629
sg15
I2
sa(dp3630
g9
I183
sg10
VC0024441
p3631
sg12
I2
sg13
VMH
p3632
sg15
I1
sa(dp3633
g9
I8
sg10
VC1517205
p3634
sg12
I5
sg13
Vflare
p3635
sg15
I1
sasa(dp3636
g2
VWe investigated the relations between the aqueous flare value and vitreous levels of vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule-1 (sICAM-1), and interleukin-6 (IL-6) in patients with CRVO and macular edema or patients with idiopathic macular hole (MH).
p3637
sg4
(lp3638
(dp3639
g9
I200
sg39
VP05231
p3640
sg12
I4
sg13
VIL-6
p3641
sg15
I1
sa(dp3642
g9
I185
sg39
VP05231
p3643
sg12
I13
sg13
Vinterleukin-6
p3644
sg15
I1
sa(dp3645
g9
I85
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p3646
sg15
I4
sa(dp3647
g9
I136
sg39
VP05362
p3648
sg12
I33
sg13
Vintercellular adhesion molecule-1
p3649
sg15
I3
sa(dp3650
g9
I121
sg39
g40
sg12
I4
sg13
VVEGF
p3651
sg15
I1
sasg6
(lp3652
(dp3653
g9
I274
sg10
VC0024441
p3654
sg12
I12
sg13
Vmacular hole
p3655
sg15
I2
sa(dp3656
g9
I232
sg10
VC0271051
p3657
sg12
I13
sg13
Vmacular edema
p3658
sg15
I2
sa(dp3659
g9
I150
sg10
VC0001511
p3660
sg12
I8
sg13
Vadhesion
p3661
sg15
I1
sa(dp3662
g9
I288
sg10
VC0024441
p3663
sg12
I2
sg13
VMH
p3664
sg15
I1
sa(dp3665
g9
I50
sg10
VC1517205
p3666
sg12
I5
sg13
Vflare
p3667
sg15
I1
sasa(dp3668
g2
VVitreous fluid levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and pentraxin 3 (PTX3) were significantly higher in CRVO patients than in macular hole patients.
p3669
sg4
(lp3670
(dp3671
g9
I61
sg39
g40
sg12
I4
sg13
VVEGF
p3672
sg15
I1
sa(dp3673
g9
I223
sg39
VP26022
p3674
sg12
I11
sg13
Vpentraxin 3
p3675
sg15
I2
sa(dp3676
g9
I112
sg39
VP05362
p3677
sg12
I33
sg13
Vintercellular adhesion molecule 1
p3678
sg15
I4
sa(dp3679
g9
I76
sg39
g40
sg12
I15
sg13
VVEGF receptor 2
p3680
sg15
I3
sa(dp3681
g9
I236
sg39
VP26022
p3682
sg12
I4
sg13
VPTX3
p3683
sg15
I1
sa(dp3684
g9
I211
sg39
VP41597
p3685
sg12
I5
sg13
VMCP-1
p3686
sg15
I1
sa(dp3687
g9
I172
sg39
VP05231
p3688
sg12
I4
sg13
VIL-6
p3689
sg15
I1
sa(dp3690
g9
I25
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p3691
sg15
I4
sa(dp3692
g9
I157
sg39
VP05231
p3693
sg12
I13
sg13
Vinterleukin 6
p3694
sg15
I2
sa(dp3695
g9
I179
sg39
VP14222
p3696
sg12
I30
sg13
Vmonocyte chemotactic protein 1
p3697
sg15
I4
sasg6
(lp3698
(dp3699
g9
I126
sg10
VC0001511
p3700
sg12
I8
sg13
Vadhesion
p3701
sg15
I1
sa(dp3702
g9
I293
sg10
VC0024441
p3703
sg12
I12
sg13
Vmacular hole
p3704
sg15
I2
sasa(dp3705
g2
VIn 39 patients with BRVO and macular edema and 21 individuals with idiopathic macular hole (MH) serving as controls, vitreous fluid samples were obtained during vitreoretinal surgery, and the levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), pentraxin 3 (PTX3), and pigment epithelium-derived factor (PEDF) were measured by enzyme-linked immunosorbent assay.
p3706
sg4
(lp3707
(dp3708
g9
I202
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p3709
sg15
I4
sa(dp3710
g9
I238
sg39
g40
sg12
I4
sg13
VVEGF
p3711
sg15
I1
sa(dp3712
g9
I349
sg39
VP05231
p3713
sg12
I4
sg13
VIL-6
p3714
sg15
I1
sa(dp3715
g9
I334
sg39
VP05231
p3716
sg12
I13
sg13
Vinterleukin 6
p3717
sg15
I2
sa(dp3718
g9
I388
sg39
VP41597
p3719
sg12
I5
sg13
VMCP-1
p3720
sg15
I1
sa(dp3721
g9
I409
sg39
VP26022
p3722
sg12
I4
sg13
VPTX3
p3723
sg15
I1
sa(dp3724
g9
I396
sg39
VP26022
p3725
sg12
I11
sg13
Vpentraxin 3
p3726
sg15
I2
sa(dp3727
g9
I289
sg39
VP05362
p3728
sg12
I33
sg13
Vintercellular adhesion molecule 1
p3729
sg15
I4
sa(dp3730
g9
I356
sg39
VP14222
p3731
sg12
I30
sg13
Vmonocyte chemotactic protein 1
p3732
sg15
I4
sa(dp3733
g9
I253
sg39
g40
sg12
I15
sg13
VVEGF receptor 2
p3734
sg15
I3
sasg6
(lp3735
(dp3736
g9
I92
sg10
VC0024441
p3737
sg12
I2
sg13
VMH
p3738
sg15
I1
sa(dp3739
g9
I78
sg10
VC0024441
p3740
sg12
I12
sg13
Vmacular hole
p3741
sg15
I2
sa(dp3742
g9
I29
sg10
VC0271051
p3743
sg12
I13
sg13
Vmacular edema
p3744
sg15
I2
sa(dp3745
g9
I303
sg10
VC0001511
p3746
sg12
I8
sg13
Vadhesion
p3747
sg15
I1
sasa(dp3748
g2
VTo investigate relationships among vitreous fluid levels of soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), vascular endothelial growth factor (VEGF), and soluble intercellular adhesion molecule 1 (sICAM-1) in patients with branch retinal vein occlusion (BRVO) and macular edema or patients with idiopathic macular hole.
p3749
sg4
(lp3750
(dp3751
g9
I116
sg39
g40
sg12
I4
sg13
VVEGF
p3752
sg15
I1
sa(dp3753
g9
I68
sg39
VP35968
p3754
sg12
I45
sg13
Vvascular endothelial growth factor receptor-2
p3755
sg15
I5
sa(dp3756
g9
I181
sg39
VP05362
p3757
sg12
I33
sg13
Vintercellular adhesion molecule 1
p3758
sg15
I4
sa(dp3759
g9
I68
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p3760
sg15
I4
sasg6
(lp3761
(dp3762
g9
I283
sg10
VC0271051
p3763
sg12
I13
sg13
Vmacular edema
p3764
sg15
I2
sa(dp3765
g9
I325
sg10
VC0024441
p3766
sg12
I12
sg13
Vmacular hole
p3767
sg15
I2
sa(dp3768
g9
I242
sg10
VC0339505
p3769
sg12
I29
sg13
Vbranch retinal vein occlusion
p3770
sg15
I4
sa(dp3771
g9
I195
sg10
VC0001511
p3772
sg12
I8
sg13
Vadhesion
p3773
sg15
I1
sa(dp3774
g9
I273
sg10
VC0339505
p3775
sg12
I4
sg13
VBRVO
p3776
sg15
I1
sasa(dp3777
g2
VBRVO patients had a significantly higher vitreous fluid level of sVEGFR-2 (median, 1670 pg/mL; interquartile range [IQL], 1205 to 2225 pg/mL) than macular hole patients (median, 1265 pg/mL; IQR, 731 to 1800 pg/mL; P = .017), as was the case for VEGF (median, 237 pg/mL; IQR, 42.2 to 1305 pg/mL; vs median, 15.6 pg/mL; IQR, 15.6 to 15.6 pg/mL; P &lt; .001) and sICAM-1 (median, 10.1 ng/mL; IQR, 6.3 to 22.5 ng/mL; vs median, 4.1 ng/mL; IQR, 3.3 to 6.0 ng/mL; P &lt; .001).
p3778
sg4
(lp3779
sg6
(lp3780
(dp3781
g9
I147
sg10
VC0024441
p3782
sg12
I12
sg13
Vmacular hole
p3783
sg15
I2
sasa(dp3784
g2
VVitreous levels of sICAM-1 were significantly increased in vitreous specimens from both PVR (median +/- SD; 12.0 +/- 76.3 ng/ml; P &lt; 0.01) and PDR (8.4 +/- 24.0 ng/ml; P &lt; 0.01) when compared to vitreous from eyes with macular holes (0.
p3785
sg4
(lp3786
sg6
(lp3787
(dp3788
g9
I88
sg10
VC1860404
p3789
sg12
I3
sg13
VPVR
p3790
sg15
I1
sa(dp3791
g9
I146
sg10
VC1845050
p3792
sg12
I3
sg13
VPDR
p3793
sg15
I1
sa(dp3794
g9
I225
sg10
VC0024441
p3795
sg12
I13
sg13
Vmacular holes
p3796
sg15
I2
sasa(dp3797
g2
VLevels of sICAM-1 in this group were compared with those in vitreous from 31 eyes with RRD without clinical risk factors for PVR, 32 eyes with established PVR and 10 eyes with macular holes.
p3798
sg4
(lp3799
(dp3800
g9
I125
sg39
VP15151
p3801
sg12
I3
sg13
VPVR
p3802
sg15
I1
sasg6
(lp3803
(dp3804
g9
I125
sg10
VC1860404
p3805
sg12
I3
sg13
VPVR
p3806
sg15
I1
sa(dp3807
g9
I125
sg10
VC1860404
p3808
sg12
I3
sg13
VPVR
p3809
sg15
I1
sa(dp3810
g9
I176
sg10
VC0024441
p3811
sg12
I13
sg13
Vmacular holes
p3812
sg15
I2
sasa(dp3813
g2
VVitreous sICAM-1 levels in eyes with RRD at high risk of developing PVR were significantly lower than in eyes with established PVR (p=0.037), but higher than in eyes with macular holes (p &lt;0.0001).
p3814
sg4
(lp3815
(dp3816
g9
I68
sg39
VP15151
p3817
sg12
I3
sg13
VPVR
p3818
sg15
I1
sasg6
(lp3819
(dp3820
g9
I68
sg10
VC1860404
p3821
sg12
I3
sg13
VPVR
p3822
sg15
I1
sa(dp3823
g9
I171
sg10
VC0024441
p3824
sg12
I13
sg13
Vmacular holes
p3825
sg15
I2
sa(dp3826
g9
I68
sg10
VC1860404
p3827
sg12
I3
sg13
VPVR
p3828
sg15
I1
sasa(dp3829
g2
VRare pathogenic alleles with high penetrance and associated haplotypes at 10 loci (CFTR, FAH, HBB, HEXA, LDLR, LPL, PAH, PABP2, PDDR, and SACS) are expressed in probands with cystic fibrosis, tyrosinemia, beta-thalassemia, Tay-Sachs, familial hypercholesterolemia, hyperchylomicronemia, PKU, oculopharyngeal muscular dystrophy, pseudo vitamin D deficiency rickets, and spastic ataxia of Charlevoix-Saguenay, respectively) reveal the interpopulation and intrapopulation genetic diversity of Quebec.
p3830
sg4
(lp3831
(dp3832
g9
I89
sg39
VP16930
p3833
sg12
I3
sg13
VFAH
p3834
sg15
I1
sa(dp3835
g9
I94
sg39
VP02042
p3836
sg12
I3
sg13
VHBB
p3837
sg15
I1
sa(dp3838
g9
I83
sg39
VP13569
p3839
sg12
I4
sg13
VCFTR
p3840
sg15
I1
sa(dp3841
g9
I128
sg39
g40
sg12
I4
sg13
VPDDR
p3842
sg15
I1
sa(dp3843
g9
I116
sg39
VP00439
p3844
sg12
I3
sg13
VPAH
p3845
sg15
I1
sa(dp3846
g9
I99
sg39
VP06865
p3847
sg12
I4
sg13
VHEXA
p3848
sg15
I1
sa(dp3849
g9
I105
sg39
VP01130
p3850
sg12
I4
sg13
VLDLR
p3851
sg15
I1
sa(dp3852
g9
I121
sg39
g40
sg12
I5
sg13
VPABP2
p3853
sg15
I1
sa(dp3854
g9
I111
sg39
VP06858
p3855
sg12
I3
sg13
VLPL
p3856
sg15
I1
sasg6
(lp3857
(dp3858
g9
I175
sg10
VC0010674
p3859
sg12
I15
sg13
Vcystic fibrosis
p3860
sg15
I2
sa(dp3861
g9
I192
sg10
VC0268483
p3862
sg12
I11
sg13
Vtyrosinemia
p3863
sg15
I1
sa(dp3864
g9
I292
sg10
VC0270952
p3865
sg12
I34
sg13
Voculopharyngeal muscular dystrophy
p3866
sg15
I3
sa(dp3867
g9
I116
sg10
VC0152171
p3868
sg12
I3
sg13
VPAH
p3869
sg15
I1
sa(dp3870
g9
I138
sg10
VC1849140
p3871
sg12
I4
sg13
VSACS
p3872
sg15
I1
sa(dp3873
g9
I356
sg10
VC0035579
p3874
sg12
I7
sg13
Vrickets
p3875
sg15
I1
sa(dp3876
g9
I369
sg10
VC1849140
p3877
sg12
I37
sg13
Vspastic ataxia of Charlevoix-Saguenay
p3878
sg15
I4
sa(dp3879
g9
I205
sg10
VC0005283
p3880
sg12
I16
sg13
Vbeta-thalassemia
p3881
sg15
I1
sa(dp3882
g9
I265
sg10
VC0023817
p3883
sg12
I20
sg13
Vhyperchylomicronemia
p3884
sg15
I1
sa(dp3885
g9
I234
sg10
VC0020445
p3886
sg12
I29
sg13
Vfamilial hypercholesterolemia
p3887
sg15
I2
sa(dp3888
g9
I335
sg10
VC0042870
p3889
sg12
I20
sg13
Vvitamin D deficiency
p3890
sg15
I3
sa(dp3891
g9
I287
sg10
VC0031485
p3892
sg12
I3
sg13
VPKU
p3893
sg15
I1
sasa(dp3894
g2
VBiochemical, neuropathological, and genetic evidence suggests an important role for TCERG1 in Huntington's disease (HD) pathogenesis.
p3895
sg4
(lp3896
(dp3897
g9
I84
sg39
g40
sg12
I6
sg13
VTCERG1
p3898
sg15
I1
sasg6
(lp3899
(dp3900
g9
I94
sg10
VC0020179
p3901
sg12
I20
sg13
VHuntington's disease
p3902
sg15
I2
sa(dp3903
g9
I120
sg10
VC0699748
p3904
sg12
I12
sg13
Vpathogenesis
p3905
sg15
I1
sa(dp3906
g9
I116
sg10
VC0020179
p3907
sg12
I2
sg13
VHD
p3908
sg15
I1
sasa(dp3909
g2
VFurther investigations on the underlying mechanisms showed that the depletion of dG9a repressed starvation-induced autophagy by controlling the expression level of Atg8a, a critical gene for the progression of autophagy, in a different manner to that in cancer cells.
p3910
sg4
(lp3911
sg6
(lp3912
(dp3913
g9
I254
sg10
VC0006826
p3914
sg12
I6
sg13
Vcancer
p3915
sg15
I1
sasa(dp3916
g2
VBioinformatic analysis of human tumours revealed that several core autophagy genes, including GABARAP, correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a potential tumour-suppressive effect of the pathway in Ras-driven human cancers.
p3917
sg4
(lp3918
(dp3919
g9
I128
sg39
VP01116
p3920
sg12
I4
sg13
VKRAS
p3921
sg15
I1
sa(dp3922
g9
I94
sg39
g40
sg12
I7
sg13
VGABARAP
p3923
sg15
I1
sa(dp3924
g9
I257
sg39
VP01116
p3925
sg12
I3
sg13
VRas
p3926
sg15
I1
sasg6
(lp3927
(dp3928
g9
I32
sg10
VC0027651
p3929
sg12
I7
sg13
Vtumours
p3930
sg15
I1
sa(dp3931
g9
I32
sg10
VC0027651
p3932
sg12
I6
sg13
Vtumour
p3933
sg15
I1
sa(dp3934
g9
I171
sg10
VC0235974
p3935
sg12
I17
sg13
Vpancreatic cancer
p3936
sg15
I2
sa(dp3937
g9
I274
sg10
VC0006826
p3938
sg12
I7
sg13
Vcancers
p3939
sg15
I1
sasa(dp3940
g2
VUsing a yeast two-hybrid screening approach, based on a thyroid cancer patients library, we showed that CDH6 directly interacts with GABARAP, BNIP3 and BNIP3L, and that through these interactions CDH6 restrains autophagy and promotes re-organization of mitochondrial network through a DRP1-mediated mechanism.
p3941
sg4
(lp3942
(dp3943
g9
I152
sg39
g40
sg12
I6
sg13
VBNIP3L
p3944
sg15
I1
sa(dp3945
g9
I104
sg39
VP55285
p3946
sg12
I4
sg13
VCDH6
p3947
sg15
I1
sa(dp3948
g9
I285
sg39
VP46939
p3949
sg12
I4
sg13
VDRP1
p3950
sg15
I1
sa(dp3951
g9
I104
sg39
VP55285
p3952
sg12
I4
sg13
VCDH6
p3953
sg15
I1
sa(dp3954
g9
I133
sg39
g40
sg12
I7
sg13
VGABARAP
p3955
sg15
I1
sa(dp3956
g9
I142
sg39
g40
sg12
I5
sg13
VBNIP3
p3957
sg15
I1
sasg6
(lp3958
(dp3959
g9
I56
sg10
VC0007115
p3960
sg12
I14
sg13
Vthyroid cancer
p3961
sg15
I2
sasa(dp3962
g2
VWe previously reported that GABARAPL1 expression was frequently downregulated in cancer cells while a high GABARAPL1 expression is a good prognosis marker for patients with lymph node-positive breast cancer.
p3963
sg4
(lp3964
(dp3965
g9
I28
sg39
g40
sg12
I9
sg13
VGABARAPL1
p3966
sg15
I1
sa(dp3967
g9
I28
sg39
g40
sg12
I9
sg13
VGABARAPL1
p3968
sg15
I1
sasg6
(lp3969
(dp3970
g9
I179
sg10
VC3160887
p3971
sg12
I27
sg13
Vnode-positive breast cancer
p3972
sg15
I3
sa(dp3973
g9
I81
sg10
VC0006826
p3974
sg12
I6
sg13
Vcancer
p3975
sg15
I1
sasa(dp3976
g2
VIn this study, we asked using qRT-PCR, western blotting and epigenetic quantification whether the expression of the GABARAP family was regulated in breast cancer by epigenetic modifications.
p3977
sg4
(lp3978
(dp3979
g9
I116
sg39
g40
sg12
I14
sg13
VGABARAP family
p3980
sg15
I2
sasg6
(lp3981
(dp3982
g9
I148
sg10
VC0678222
p3983
sg12
I13
sg13
Vbreast cancer
p3984
sg15
I2
sasa(dp3985
g2
VOur data demonstrated that a specific decrease of GABARAPL1 expression in breast cancers was associated with both DNA methylation and histone deacetylation and that CREB-1 recruitment on GABARAPL1 promoter was required for GABARAPL1 expression.
p3986
sg4
(lp3987
(dp3988
g9
I50
sg39
g40
sg12
I9
sg13
VGABARAPL1
p3989
sg15
I1
sa(dp3990
g9
I165
sg39
VP16220
p3991
sg12
I6
sg13
VCREB-1
p3992
sg15
I1
sa(dp3993
g9
I134
sg39
VP62805
p3994
sg12
I7
sg13
Vhistone
p3995
sg15
I1
sa(dp3996
g9
I187
sg39
g40
sg12
I18
sg13
VGABARAPL1 promoter
p3997
sg15
I2
sa(dp3998
g9
I50
sg39
g40
sg12
I9
sg13
VGABARAPL1
p3999
sg15
I1
sasg6
(lp4000
(dp4001
g9
I172
sg10
VC0271510
p4002
sg12
I11
sg13
Vrecruitment
p4003
sg15
I1
sa(dp4004
g9
I74
sg10
VC0006142
p4005
sg12
I14
sg13
Vbreast cancers
p4006
sg15
I2
sasa(dp4007
g2
VHere we demonstrate that runx1 deletion in mice induces the persistence of MYH10 in platelets, and a similar persistence was observed in platelets of patients with constitutional (familial platelet disorder/acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.
p4008
sg4
(lp4009
(dp4010
g9
I25
sg39
VP01719
p4011
sg12
I14
sg13
Vrunx1 deletion
p4012
sg15
I2
sa(dp4013
g9
I75
sg39
VP35580
p4014
sg12
I5
sg13
VMYH10
p4015
sg15
I1
sasg6
(lp4016
(dp4017
g9
I244
sg10
VC0023480
p4018
sg12
I31
sg13
Vchronic myelomonocytic leukemia
p4019
sg15
I3
sa(dp4020
g9
I189
sg10
VC0005818
p4021
sg12
I17
sg13
Vplatelet disorder
p4022
sg15
I2
sa(dp4023
g9
I207
sg10
VC0023467
p4024
sg12
I22
sg13
Vacute myeloid leukemia
p4025
sg15
I3
sasa(dp4026
g2
VMYH10 was also detected in platelets of patients with the Paris-Trousseau syndrome, a thrombocytopenia related to the deletion of the transcription factor FLI1 that forms a complex with RUNX1 to regulate megakaryopoiesis, whereas MYH10 persistence was not observed in other inherited forms of thrombocytopenia.
p4027
sg4
(lp4028
(dp4029
g9
I155
sg39
g40
sg12
I4
sg13
VFLI1
p4030
sg15
I1
sa(dp4031
g9
I0
sg39
VP35580
p4032
sg12
I5
sg13
VMYH10
p4033
sg15
I1
sa(dp4034
g9
I0
sg39
VP35580
p4035
sg12
I5
sg13
VMYH10
p4036
sg15
I1
sasg6
(lp4037
(dp4038
g9
I58
sg10
VC0795841
p4039
sg12
I24
sg13
VParis-Trousseau syndrome
p4040
sg15
I2
sasa(dp4041
g2
VWe propose MYH10 detection as a new and simple tool to identify inherited platelet disorders and myeloid neoplasms with abnormalities in RUNX1 and its associated proteins.
p4042
sg4
(lp4043
(dp4044
g9
I11
sg39
VP35580
p4045
sg12
I5
sg13
VMYH10
p4046
sg15
I1
sasg6
(lp4047
(dp4048
g9
I74
sg10
VC0005818
p4049
sg12
I18
sg13
Vplatelet disorders
p4050
sg15
I2
sa(dp4051
g9
I105
sg10
VC0027651
p4052
sg12
I9
sg13
Vneoplasms
p4053
sg15
I1
sasa(dp4054
g2
VThe existence of gynecomastia, age, detection of heterogeneous nodules on ultrasound, and preoperative alpha-fetoprotein and beta HCG are relevant data in relation to histological type of tumor.
p4055
sg4
(lp4056
(dp4057
g9
I103
sg39
VP02771
p4058
sg12
I30
sg13
Valpha-fetoprotein and beta HCG
p4059
sg15
I4
sasg6
(lp4060
(dp4061
g9
I130
sg10
VC1855900
p4062
sg12
I3
sg13
VHCG
p4063
sg15
I1
sa(dp4064
g9
I63
sg10
VC0028259
p4065
sg12
I7
sg13
Vnodules
p4066
sg15
I1
sa(dp4067
g9
I17
sg10
VC0018418
p4068
sg12
I12
sg13
Vgynecomastia
p4069
sg15
I1
sa(dp4070
g9
I188
sg10
VC0027651
p4071
sg12
I5
sg13
Vtumor
p4072
sg15
I1
sasa(dp4073
g2
VList of Abbreviations: AO: Acridine orange, AIDS: Acquired immunodeficiency syndrome, ACT: Artemisinin-based combination therapy, CM:Cerebral malaria, BCP:Benzothiocarboxypurine, DDT:Dichloro-diphenyl-trichloroethane, DNA:DeoxyriboNucleic Acid, ELAM-1: Endothelial leukocyte adhesion molecule, G6PD: Glucose-6-Phosphate Dehydrogenase, HIV: Human immuno deficiency virus, HRP 2: Histidine Rich Protein 2, ICAM -1: Inter cellular adhesion molecule1, ICER: Incremental cost effectiveness ratio, IL-1: Interleukin -1, IFN-g: Interferon-gamma, IgG: Immunoglobulin G, MP: Malaria parasite, NADP: Oxidised Nicotinamide Adenine Dinucleotide Phosphate, NADPH: Reduced Nicotinamide Adenine Dinucleotide Phosphate, PCV: Packed Cell Volume (haematocrit), P. falciparum: Plasmodium falciparum, PLDH: Plasmodium lactate dehydrogenase, PCR: Polymerase Chain Reaction, PPV: Positive predictive value, QBC: Quantitative Buffy Coat examination, TNF: Tumour necrosis factor, NPV: Negative predictive value, RDT: Rapid diagnostic test, SP: Sulphadoxine -Pyrimethamine, SMA: Severe malarial anaemia, UM: Uncomplicated malaria, USA:United States of America, VCAM-1: Vascular cell adhesion molecule, WBC: White Blood Cell, WHO: World Health Organization.
p4074
sg4
(lp4075
(dp4076
g9
I1144
sg39
g40
sg12
I31
sg13
VVascular cell adhesion molecule
p4077
sg15
I4
sa(dp4078
g9
I521
sg39
VP01579
p4079
sg12
I16
sg13
VInterferon-gamma
p4080
sg15
I1
sa(dp4081
g9
I413
sg39
VP01185
p4082
sg12
I33
sg13
VInter cellular adhesion molecule1
p4083
sg15
I4
sa(dp4084
g9
I927
sg39
VP01375
p4085
sg12
I3
sg13
VTNF
p4086
sg15
I1
sa(dp4087
g9
I514
sg39
VP01579
p4088
sg12
I5
sg13
VIFN-g
p4089
sg15
I1
sa(dp4090
g9
I300
sg39
VP49366
p4091
sg12
I33
sg13
VGlucose-6-Phosphate Dehydrogenase
p4092
sg15
I2
sa(dp4093
g9
I294
sg39
VP11441
p4094
sg12
I4
sg13
VG6PD
p4095
sg15
I1
sa(dp4096
g9
I498
sg39
VP60568
p4097
sg12
I14
sg13
VInterleukin -1
p4098
sg15
I2
sa(dp4099
g9
I245
sg39
VP16581
p4100
sg12
I6
sg13
VELAM-1
p4101
sg15
I1
sa(dp4102
g9
I539
sg39
g40
sg12
I21
sg13
VIgG: Immunoglobulin G
p4103
sg15
I3
sa(dp4104
g9
I492
sg39
VP01584
p4105
sg12
I4
sg13
VIL-1
p4106
sg15
I1
sa(dp4107
g9
I1136
sg39
VP19320
p4108
sg12
I6
sg13
VVCAM-1
p4109
sg15
I1
sa(dp4110
g9
I932
sg39
VP01375
p4111
sg12
I22
sg13
VTumour necrosis factor
p4112
sg15
I3
sa(dp4113
g9
I340
sg39
g40
sg12
I62
sg13
VHuman immuno deficiency virus, HRP 2: Histidine Rich Protein 2
p4114
sg15
I10
sa(dp4115
g9
I253
sg39
g40
sg12
I39
sg13
VEndothelial leukocyte adhesion molecule
p4116
sg15
I4
sa(dp4117
g9
I787
sg39
VP49366
p4118
sg12
I32
sg13
VPlasmodium lactate dehydrogenase
p4119
sg15
I3
sasg6
(lp4120
(dp4121
g9
I133
sg10
VC0024534
p4122
sg12
I16
sg13
VCerebral malaria
p4123
sg15
I2
sa(dp4124
g9
I275
sg10
VC0001511
p4125
sg12
I8
sg13
Vadhesion
p4126
sg15
I1
sa(dp4127
g9
I988
sg10
VC0206743
p4128
sg12
I3
sg13
VRDT
p4129
sg15
I1
sa(dp4130
g9
I275
sg10
VC0001511
p4131
sg12
I8
sg13
Vadhesion
p4132
sg15
I1
sa(dp4133
g9
I1049
sg10
VC0026847
p4134
sg12
I3
sg13
VSMA
p4135
sg15
I1
sa(dp4136
g9
I275
sg10
VC0001511
p4137
sg12
I8
sg13
Vadhesion
p4138
sg15
I1
sa(dp4139
g9
I50
sg10
VC0001175
p4140
sg12
I34
sg13
VAcquired immunodeficiency syndrome
p4141
sg15
I3
sa(dp4142
g9
I142
sg10
VC0024530
p4143
sg12
I7
sg13
Vmalaria
p4144
sg15
I1
sa(dp4145
g9
I335
sg10
VC0019693
p4146
sg12
I3
sg13
VHIV
p4147
sg15
I1
sa(dp4148
g9
I566
sg10
VC0024530
p4149
sg12
I7
sg13
VMalaria
p4150
sg15
I1
sa(dp4151
g9
I1070
sg10
VC0002871
p4152
sg12
I7
sg13
Vanaemia
p4153
sg15
I1
sa(dp4154
g9
I932
sg10
VC0333516
p4155
sg12
I15
sg13
VTumour necrosis
p4156
sg15
I2
sasa(dp4157
g2
VHS intake increased natriuresis, diuresis, and urinary DA while it decreased cortical NOS I expression (P &lt; 0.05 vs. NS), Nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) activity in MD (P &lt; 0.001 vs. NS) and cortical nitrates+nitrites (NOx) production (NS 2.04 +/- 0.22 vs. HS 1.28 +/- 0.10 nmol mg protein-1, P &lt; 0.01).
p4158
sg4
(lp4159
(dp4160
g9
I125
sg39
VP28331
p4161
sg12
I54
sg13
VNicotinamide adenine dinucleotide phosphate diaphorase
p4162
sg15
I5
sa(dp4163
g9
I181
sg39
VP30043
p4164
sg12
I7
sg13
VNADPH-d
p4165
sg15
I1
sasg6
(lp4166
sa(dp4167
g2
VDecreased G6PD activity and, as a result, decreased NADPH level have been associated with diabetic kidney disease, altered nitric oxide production, aldosterone-mediated endothelial dysfunction, and dialysis-associated anemia.
p4168
sg4
(lp4169
(dp4170
g9
I10
sg39
VP11441
p4171
sg12
I4
sg13
VG6PD
p4172
sg15
I1
sasg6
(lp4173
(dp4174
g9
I169
sg10
VC0856169
p4175
sg12
I23
sg13
Vendothelial dysfunction
p4176
sg15
I2
sa(dp4177
g9
I90
sg10
VC0011881
p4178
sg12
I23
sg13
Vdiabetic kidney disease
p4179
sg15
I3
sa(dp4180
g9
I218
sg10
VC0002871
p4181
sg12
I6
sg13
Vanemia
p4182
sg15
I1
sasa(dp4183
g2
VGlucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells in human subjects, causing hemolytic anemia linked to impaired nicotinamide adenine dinucleotide phosphate (NADPH) production and imbalanced redox homeostasis in erythrocytes.
p4184
sg4
(lp4185
(dp4186
g9
I0
sg39
VP49366
p4187
sg12
I33
sg13
VGlucose-6-phosphate dehydrogenase
p4188
sg15
I2
sa(dp4189
g9
I35
sg39
VP11441
p4190
sg12
I4
sg13
VG6PD
p4191
sg15
I1
sasg6
(lp4192
(dp4193
g9
I163
sg10
VC0684336
p4194
sg12
I8
sg13
Vimpaired
p4195
sg15
I1
sa(dp4196
g9
I136
sg10
VC0002878
p4197
sg12
I16
sg13
Vhemolytic anemia
p4198
sg15
I2
sasa(dp4199
g2
VInterestingly, D2 recovery was accompanied by improvements in photosynthetic parameters (Asat and Fv/Fm) and the NADPH/NADP(+) ratio.
p4200
sg4
(lp4201
sg6
(lp4202
(dp4203
g9
I89
sg10
VC1845028
p4204
sg12
I4
sg13
VAsat
p4205
sg15
I1
sasa(dp4206
g2
VHFD significantly enhanced the Asm activity, ceramide production, colocalization of Nlrp3 (Nod-like receptor protein 3) with ASC (apoptosis-associated speck-like protein) or Caspase-1, NADPH-dependent superoxide (O2(*-)) production in glomeruli of Asm(+/+) mice than in control diet-fed mice.
p4207
sg4
(lp4208
(dp4209
g9
I31
sg39
VP17405
p4210
sg12
I3
sg13
VAsm
p4211
sg15
I1
sa(dp4212
g9
I91
sg39
VP54259
p4213
sg12
I27
sg13
VNod-like receptor protein 3
p4214
sg15
I4
sa(dp4215
g9
I185
sg39
VP30043
p4216
sg12
I26
sg13
VNADPH-dependent superoxide
p4217
sg15
I2
sa(dp4218
g9
I174
sg39
VP29466
p4219
sg12
I9
sg13
VCaspase-1
p4220
sg15
I1
sa(dp4221
g9
I84
sg39
VP54259
p4222
sg12
I5
sg13
VNlrp3
p4223
sg15
I1
sasg6
(lp4224
(dp4225
g9
I91
sg10
VC0751781
p4226
sg12
I3
sg13
VNod
p4227
sg15
I1
sasa(dp4228
g2
VWe have studied the effects of growth factors and cytokines on the tumorigenicity and invasion capacity of tumor cells by using regressor and progressor tumor cell lines (ER-1 and ERpP, respectively) derived from an SHR rat mammary adenocarcinoma.
p4229
sg4
(lp4230
sg6
(lp4231
(dp4232
g9
I224
sg10
VC0858252
p4233
sg12
I22
sg13
Vmammary adenocarcinoma
p4234
sg15
I2
sa(dp4235
g9
I86
sg10
VC2699153
p4236
sg12
I8
sg13
Vinvasion
p4237
sg15
I1
sa(dp4238
g9
I67
sg10
VC1519697
p4239
sg12
I14
sg13
Vtumorigenicity
p4240
sg15
I1
sa(dp4241
g9
I67
sg10
VC0027651
p4242
sg12
I5
sg13
Vtumor
p4243
sg15
I1
sa(dp4244
g9
I67
sg10
VC0027651
p4245
sg12
I5
sg13
Vtumor
p4246
sg15
I1
sasa(dp4247
g2
VWe have studied the effect of growth factors and cytokine on tumorigenesis and invasive capacity of tumor cells by examining a regressor tumor cell line (ER-1) derived from SHR rat mammary adenocarcinoma.
p4248
sg4
(lp4249
sg6
(lp4250
(dp4251
g9
I61
sg10
VC0027651
p4252
sg12
I5
sg13
Vtumor
p4253
sg15
I1
sa(dp4254
g9
I181
sg10
VC0858252
p4255
sg12
I22
sg13
Vmammary adenocarcinoma
p4256
sg15
I2
sa(dp4257
g9
I61
sg10
VC0007621
p4258
sg12
I13
sg13
Vtumorigenesis
p4259
sg15
I1
sa(dp4260
g9
I61
sg10
VC0027651
p4261
sg12
I5
sg13
Vtumor
p4262
sg15
I1
sasa(dp4263
g2
VLevel of several proteins including haptoglobin, transthyretin, osteopontin, vitronectin, complement factor H and different classes of immunoglobulins are found to be considerably increased in CSF of higher grades of gliomas.
p4264
sg4
(lp4265
(dp4266
g9
I36
sg39
VP00738
p4267
sg12
I11
sg13
Vhaptoglobin
p4268
sg15
I1
sa(dp4269
g9
I49
sg39
VP02766
p4270
sg12
I13
sg13
Vtransthyretin
p4271
sg15
I1
sa(dp4272
g9
I64
sg39
VP10451
p4273
sg12
I11
sg13
Vosteopontin
p4274
sg15
I1
sa(dp4275
g9
I77
sg39
VP04004
p4276
sg12
I11
sg13
Vvitronectin
p4277
sg15
I1
sa(dp4278
g9
I135
sg39
g40
sg12
I15
sg13
Vimmunoglobulins
p4279
sg15
I1
sa(dp4280
g9
I90
sg39
g40
sg12
I19
sg13
Vcomplement factor H
p4281
sg15
I3
sasg6
(lp4282
(dp4283
g9
I217
sg10
VC0017638
p4284
sg12
I7
sg13
Vgliomas
p4285
sg15
I1
sasa(dp4286
g2
VVitronectin is an extracellular matrix protein, the synthesis of which by glioma cells correlates with tumor grade.
p4287
sg4
(lp4288
(dp4289
g9
I18
sg39
VP55082
p4290
sg12
I28
sg13
Vextracellular matrix protein
p4291
sg15
I3
sa(dp4292
g9
I0
sg39
VP04004
p4293
sg12
I11
sg13
VVitronectin
p4294
sg15
I1
sasg6
(lp4295
(dp4296
g9
I103
sg10
VC0027651
p4297
sg12
I5
sg13
Vtumor
p4298
sg15
I1
sa(dp4299
g9
I74
sg10
VC0017638
p4300
sg12
I6
sg13
Vglioma
p4301
sg15
I1
sasa(dp4302
g2
VThe current study was designed to investigate the relationship between serum vitronectin levels and clinicopathological characteristics, diagnosis and prognosis in glioma patients.
p4303
sg4
(lp4304
(dp4305
g9
I71
sg39
VP04004
p4306
sg12
I17
sg13
Vserum vitronectin
p4307
sg15
I2
sasg6
(lp4308
(dp4309
g9
I164
sg10
VC0017638
p4310
sg12
I6
sg13
Vglioma
p4311
sg15
I1
sasa(dp4312
g2
VSerum vitronectin levels were significantly elevated in glioma patients as compared with other groups.
p4313
sg4
(lp4314
(dp4315
g9
I0
sg39
VP04004
p4316
sg12
I17
sg13
VSerum vitronectin
p4317
sg15
I2
sasg6
(lp4318
(dp4319
g9
I56
sg10
VC0017638
p4320
sg12
I6
sg13
Vglioma
p4321
sg15
I1
sasa(dp4322
g2
VSerum vitronectin levels could significantly distinguish glioma patients from other groups and discriminate high-grade glioma from low-grade glioma.
p4323
sg4
(lp4324
(dp4325
g9
I0
sg39
VP04004
p4326
sg12
I17
sg13
VSerum vitronectin
p4327
sg15
I2
sasg6
(lp4328
(dp4329
g9
I57
sg10
VC0017638
p4330
sg12
I6
sg13
Vglioma
p4331
sg15
I1
sa(dp4332
g9
I57
sg10
VC0017638
p4333
sg12
I6
sg13
Vglioma
p4334
sg15
I1
sa(dp4335
g9
I131
sg10
VC1997217
p4336
sg12
I16
sg13
Vlow-grade glioma
p4337
sg15
I2
sasa(dp4338
g2
VSerum vitronectin may be a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
p4339
sg4
(lp4340
(dp4341
g9
I6
sg39
VP04004
p4342
sg12
I11
sg13
Vvitronectin
p4343
sg15
I1
sasg6
(lp4344
(dp4345
g9
I135
sg10
VC0017638
p4346
sg12
I6
sg13
Vglioma
p4347
sg15
I1
sasa(dp4348
g2
VBioinformatics analysis emphasized key roles of integrin Beta3, hypoxia and vitronectin and their strong correlations with EGFRvIII expression in malignant glioma patient samples in vivo.
p4349
sg4
(lp4350
(dp4351
g9
I64
sg39
VP04004
p4352
sg12
I23
sg13
Vhypoxia and vitronectin
p4353
sg15
I3
sasg6
(lp4354
(dp4355
g9
I64
sg10
VC0242184
p4356
sg12
I7
sg13
Vhypoxia
p4357
sg15
I1
sa(dp4358
g9
I146
sg10
VC0555198
p4359
sg12
I16
sg13
Vmalignant glioma
p4360
sg15
I2
sasa(dp4361
g2
VIn conclusion, we demonstrate that EGFRvIII/integrin Beta3 complexes promote GBM progression and metastasis in the environment of hypoxia and vitronectin-enrichment, and cilengitide may serve as a promising therapeutics for EGFRvIII-positive GBMs.
p4362
sg4
(lp4363
sg6
(lp4364
(dp4365
g9
I77
sg10
VC0017636
p4366
sg12
I3
sg13
VGBM
p4367
sg15
I1
sa(dp4368
g9
I130
sg10
VC0242184
p4369
sg12
I7
sg13
Vhypoxia
p4370
sg15
I1
sa(dp4371
g9
I97
sg10
VC0027627
p4372
sg12
I10
sg13
Vmetastasis
p4373
sg15
I1
sasa(dp4374
g2
VGlioma cells derived from the brain of the (12) V-Ha-Ras transgenic mice were used to study the effect of PI-3 kinase inhibitor SF1126 on activation of AKT and ERK signaling, proliferation, vitronectin mediated migration and changes in the distribution of cortical actin on vitronectin in the glioma cells in vitro.
p4375
sg4
(lp4376
(dp4377
g9
I106
sg39
g40
sg12
I11
sg13
VPI-3 kinase
p4378
sg15
I2
sa(dp4379
g9
I190
sg39
VP04004
p4380
sg12
I11
sg13
Vvitronectin
p4381
sg15
I1
sa(dp4382
g9
I190
sg39
VP04004
p4383
sg12
I11
sg13
Vvitronectin
p4384
sg15
I1
sa(dp4385
g9
I152
sg39
g40
sg12
I3
sg13
VAKT
p4386
sg15
I1
sa(dp4387
g9
I160
sg39
VP29323
p4388
sg12
I3
sg13
VERK
p4389
sg15
I1
sa(dp4390
g9
I53
sg39
VP01116
p4391
sg12
I3
sg13
VRas
p4392
sg15
I1
sasg6
(lp4393
(dp4394
g9
I293
sg10
VC0017638
p4395
sg12
I6
sg13
Vglioma
p4396
sg15
I1
sa(dp4397
g9
I175
sg10
VC0334094
p4398
sg12
I13
sg13
Vproliferation
p4399
sg15
I1
sa(dp4400
g9
I0
sg10
VC0017638
p4401
sg12
I6
sg13
VGlioma
p4402
sg15
I1
sasa(dp4403
g2
VMost notably, treatment of SF1126 blocked integrin-dependent migration in transwell and scratch assays and caused a significant change in the organization and distribution of cortical actin on vitronectin in the glioma cells.
p4404
sg4
(lp4405
(dp4406
g9
I193
sg39
VP04004
p4407
sg12
I11
sg13
Vvitronectin
p4408
sg15
I1
sasg6
(lp4409
(dp4410
g9
I212
sg10
VC0017638
p4411
sg12
I6
sg13
Vglioma
p4412
sg15
I1
sasa(dp4413
g2
VThe hit compound 5.3d inhibited invasion and migration of both GBM stem cells (Gli7 and Gli4) and GBM cancer cell lines (C6, SNB75) on fibronectin, vitronectin, and laminin.
p4414
sg4
(lp4415
(dp4416
g9
I148
sg39
VP04004
p4417
sg12
I11
sg13
Vvitronectin
p4418
sg15
I1
sa(dp4419
g9
I165
sg39
g40
sg12
I7
sg13
Vlaminin
p4420
sg15
I1
sa(dp4421
g9
I88
sg39
VP10075
p4422
sg12
I4
sg13
VGli4
p4423
sg15
I1
sasg6
(lp4424
(dp4425
g9
I63
sg10
VC0017636
p4426
sg12
I3
sg13
VGBM
p4427
sg15
I1
sa(dp4428
g9
I32
sg10
VC2699153
p4429
sg12
I8
sg13
Vinvasion
p4430
sg15
I1
sa(dp4431
g9
I102
sg10
VC0006826
p4432
sg12
I6
sg13
Vcancer
p4433
sg15
I1
sa(dp4434
g9
I63
sg10
VC0017636
p4435
sg12
I3
sg13
VGBM
p4436
sg15
I1
sasa(dp4437
g2
VIn this study, efficient downregulation of cathepsin B and uPAR by siRNA treatments significantly reduced glioma cell adhesion to laminin as compared to vitronectin, fibronectin, or collagen I in U251 and 4910 glioma cell lines.
p4438
sg4
(lp4439
(dp4440
g9
I130
sg39
g40
sg12
I7
sg13
Vlaminin
p4441
sg15
I1
sa(dp4442
g9
I43
sg39
VP07858
p4443
sg12
I11
sg13
Vcathepsin B
p4444
sg15
I2
sa(dp4445
g9
I153
sg39
VP04004
p4446
sg12
I11
sg13
Vvitronectin
p4447
sg15
I1
sasg6
(lp4448
(dp4449
g9
I106
sg10
VC0017638
p4450
sg12
I6
sg13
Vglioma
p4451
sg15
I1
sa(dp4452
g9
I106
sg10
VC0017638
p4453
sg12
I6
sg13
Vglioma
p4454
sg15
I1
sa(dp4455
g9
I118
sg10
VC0001511
p4456
sg12
I8
sg13
Vadhesion
p4457
sg15
I1
sasa(dp4458
g2
VNecl-5, a cell surface receptor for vitronectin, is expressed in GBM but not normal brain.
p4459
sg4
(lp4460
(dp4461
g9
I36
sg39
VP04004
p4462
sg12
I11
sg13
Vvitronectin
p4463
sg15
I1
sa(dp4464
g9
I0
sg39
VP15151
p4465
sg12
I6
sg13
VNecl-5
p4466
sg15
I1
sasg6
(lp4467
(dp4468
g9
I65
sg10
VC0017636
p4469
sg12
I3
sg13
VGBM
p4470
sg15
I1
sasa(dp4471
g2
VThese included sudden appearance of tender, erythematous nodular eruptions mimicking ENL, severe constitutional symptoms like high grade fever, malaise, vomiting, epistaxis, joint pain and tenosynovitis simulating Type 2 Lepra Reaction.
p4472
sg4
(lp4473
sg6
(lp4474
(dp4475
g9
I65
sg10
VC0302295
p4476
sg12
I9
sg13
Veruptions
p4477
sg15
I1
sa(dp4478
g9
I174
sg10
VC0003862
p4479
sg12
I10
sg13
Vjoint pain
p4480
sg15
I2
sa(dp4481
g9
I144
sg10
VC0231218
p4482
sg12
I7
sg13
Vmalaise
p4483
sg15
I1
sa(dp4484
g9
I189
sg10
VC0039520
p4485
sg12
I13
sg13
Vtenosynovitis
p4486
sg15
I1
sa(dp4487
g9
I214
sg10
VC0343466
p4488
sg12
I21
sg13
VType 2 Lepra Reaction
p4489
sg15
I4
sa(dp4490
g9
I153
sg10
VC0042963
p4491
sg12
I8
sg13
Vvomiting
p4492
sg15
I1
sa(dp4493
g9
I163
sg10
VC0014591
p4494
sg12
I9
sg13
Vepistaxis
p4495
sg15
I1
sasa(dp4496
g2
VOGR1 and TRPC4 are prominently expressed in healthy cerebellar tissue throughout postnatal development and in primary cerebellar medulloblastoma tissues.
p4497
sg4
(lp4498
(dp4499
g9
I9
sg39
g40
sg12
I5
sg13
VTRPC4
p4500
sg15
I1
sa(dp4501
g9
I0
sg39
g40
sg12
I4
sg13
VOGR1
p4502
sg15
I1
sasg6
(lp4503
(dp4504
g9
I118
sg10
VC1862179
p4505
sg12
I26
sg13
Vcerebellar medulloblastoma
p4506
sg15
I2
sasa(dp4507
g2
VOur results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.
p4508
sg4
(lp4509
(dp4510
g9
I25
sg39
g40
sg12
I4
sg13
VOGR1
p4511
sg15
I1
sa(dp4512
g9
I53
sg39
g40
sg12
I5
sg13
VTRPC4
p4513
sg15
I1
sasg6
(lp4514
(dp4515
g9
I166
sg10
VC0025149
p4516
sg12
I15
sg13
Vmedulloblastoma
p4517
sg15
I1
sa(dp4518
g9
I120
sg10
VC0027627
p4519
sg12
I10
sg13
Vmetastasis
p4520
sg15
I1
sa(dp4521
g9
I107
sg10
VC2699153
p4522
sg12
I8
sg13
Vinvasion
p4523
sg15
I1
sasa(dp4524
g2
VHere, we report that OGR1 and G2A are expressed in human medulloblastoma tissue and its corresponding neuronal cell line.
p4525
sg4
(lp4526
(dp4527
g9
I30
sg39
g40
sg12
I3
sg13
VG2A
p4528
sg15
I1
sa(dp4529
g9
I21
sg39
g40
sg12
I4
sg13
VOGR1
p4530
sg15
I1
sasg6
(lp4531
(dp4532
g9
I57
sg10
VC0025149
p4533
sg12
I15
sg13
Vmedulloblastoma
p4534
sg15
I1
sasa(dp4535
g2
VTwo daughters of an affected mother demonstrated symptoms of stage III ADNIV, with posterior uveitis, cystoid macular edema, intraocular fibrosis, retinal neovascularization, retinal degeneration, and cataract.
p4536
sg4
(lp4537
sg6
(lp4538
(dp4539
g9
I175
sg10
VC0035304
p4540
sg12
I20
sg13
Vretinal degeneration
p4541
sg15
I2
sa(dp4542
g9
I137
sg10
VC0016059
p4543
sg12
I8
sg13
Vfibrosis
p4544
sg15
I1
sa(dp4545
g9
I201
sg10
VC0086543
p4546
sg12
I8
sg13
Vcataract
p4547
sg15
I1
sa(dp4548
g9
I102
sg10
VC0024440
p4549
sg12
I21
sg13
Vcystoid macular edema
p4550
sg15
I3
sa(dp4551
g9
I83
sg10
VC0042167
p4552
sg12
I17
sg13
Vposterior uveitis
p4553
sg15
I2
sa(dp4554
g9
I155
sg10
VC0035320
p4555
sg12
I27
sg13
Vneovascularization, retinal
p4556
sg15
I2
sasa(dp4557
g2
VVisual acuity and features of ADNIV, including inflammatory cells, neovascularization, fibrosis, and cystoid macular edema, were reviewed.
p4558
sg4
(lp4559
sg6
(lp4560
(dp4561
g9
I67
sg10
VC0027686
p4562
sg12
I18
sg13
Vneovascularization
p4563
sg15
I1
sa(dp4564
g9
I101
sg10
VC0024440
p4565
sg12
I21
sg13
Vcystoid macular edema
p4566
sg15
I3
sa(dp4567
g9
I87
sg10
VC0016059
p4568
sg12
I8
sg13
Vfibrosis
p4569
sg15
I1
sasa(dp4570
g2
VAutosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is an inherited eye disease characterized by retinal and iris neovascularization, abnormal retinal pigmentation, anterior chamber and vitreous inflammation, cystoid macular edema, vitreous hemorrhage, and traction retinal detachment.
p4571
sg4
(lp4572
sg6
(lp4573
(dp4574
g9
I127
sg10
VC0154916
p4575
sg12
I23
sg13
Viris neovascularization
p4576
sg15
I2
sa(dp4577
g9
I227
sg10
VC0024440
p4578
sg12
I21
sg13
Vcystoid macular edema
p4579
sg15
I3
sa(dp4580
g9
I250
sg10
VC0042909
p4581
sg12
I19
sg13
Vvitreous hemorrhage
p4582
sg15
I2
sa(dp4583
g9
I275
sg10
VC0154828
p4584
sg12
I27
sg13
Vtraction retinal detachment
p4585
sg15
I3
sa(dp4586
g9
I86
sg10
VC0015397
p4587
sg12
I11
sg13
Veye disease
p4588
sg15
I2
sa(dp4589
g9
I213
sg10
VC0021368
p4590
sg12
I12
sg13
Vinflammation
p4591
sg15
I1
sasa(dp4592
g2
VCommon metabolic problems in northeastern Thailand include renal stone disease, distal renal tubular acidosis, hypokalemic periodic paralysis, sudden unexplained nocturnal death and malnutrition-related diabetes mellitus.
p4593
sg4
(lp4594
sg6
(lp4595
(dp4596
g9
I111
sg10
VC0238358
p4597
sg12
I30
sg13
Vhypokalemic periodic paralysis
p4598
sg15
I3
sa(dp4599
g9
I203
sg10
VC0011849
p4600
sg12
I17
sg13
Vdiabetes mellitus
p4601
sg15
I2
sa(dp4602
g9
I80
sg10
VC1704380
p4603
sg12
I29
sg13
Vdistal renal tubular acidosis
p4604
sg15
I4
sa(dp4605
g9
I59
sg10
VC0022650
p4606
sg12
I11
sg13
Vrenal stone
p4607
sg15
I2
sa(dp4608
g9
I182
sg10
VC0162429
p4609
sg12
I12
sg13
Vmalnutrition
p4610
sg15
I1
sasa(dp4611
g2
VHigh prevalence of CD in presence of anemia and short stature in seropositive FDR in index study indicates need of targeted screening of this subgroup for the presence of CD.CD is unlikely in the absence of HLADQ2/DQ8.
p4612
sg4
(lp4613
sg6
(lp4614
(dp4615
g9
I48
sg10
VC0013336
p4616
sg12
I13
sg13
Vshort stature
p4617
sg15
I2
sa(dp4618
g9
I37
sg10
VC0002871
p4619
sg12
I6
sg13
Vanemia
p4620
sg15
I1
sasa(dp4621
g2
VThe concurrence of the intracranial multiple primary tumors (MPTs) consisting of acoustic neuroma (AN) and pituitary adenoma is very rare.
p4622
sg4
(lp4623
sg6
(lp4624
(dp4625
g9
I99
sg10
VC0027859
p4626
sg12
I2
sg13
VAN
p4627
sg15
I1
sa(dp4628
g9
I81
sg10
VC0027859
p4629
sg12
I16
sg13
Vacoustic neuroma
p4630
sg15
I2
sa(dp4631
g9
I45
sg10
VC0677930
p4632
sg12
I14
sg13
Vprimary tumors
p4633
sg15
I2
sa(dp4634
g9
I107
sg10
VC0032000
p4635
sg12
I17
sg13
Vpituitary adenoma
p4636
sg15
I2
sasa(dp4637
g2
VThirty five cases of MPTs were subdivided into three subtypes, i.e., 1) main duct type, 2) branch duct type and 3) peripheral type (mucinous cystadenoma/cystadenocarcinoma).
p4638
sg4
(lp4639
(dp4640
g9
I21
sg39
g40
sg12
I4
sg13
VMPTs
p4641
sg15
I1
sasg6
(lp4642
(dp4643
g9
I153
sg10
VC0010631
p4644
sg12
I18
sg13
Vcystadenocarcinoma
p4645
sg15
I1
sa(dp4646
g9
I132
sg10
VC0010635
p4647
sg12
I20
sg13
Vmucinous cystadenoma
p4648
sg15
I2
sasa(dp4649
g2
VTogether, these data suggest that IL11 could trigger an ER stress response in the placenta, which may contribute to obstetric complications such as preeclampsia.
p4650
sg4
(lp4651
(dp4652
g9
I34
sg39
VP20809
p4653
sg12
I4
sg13
VIL11
p4654
sg15
I1
sasg6
(lp4655
(dp4656
g9
I148
sg10
VC0032914
p4657
sg12
I12
sg13
Vpreeclampsia
p4658
sg15
I1
sasa(dp4659
g2
VThe relationship between IL-11 and CLS has rarely been reported, especially in patients with colorectal cancer.
p4660
sg4
(lp4661
(dp4662
g9
I25
sg39
VP20809
p4663
sg12
I5
sg13
VIL-11
p4664
sg15
I1
sa(dp4665
g9
I35
sg39
VP51812
p4666
sg12
I3
sg13
VCLS
p4667
sg15
I1
sasg6
(lp4668
(dp4669
g9
I35
sg10
VC0265252
p4670
sg12
I3
sg13
VCLS
p4671
sg15
I1
sa(dp4672
g9
I93
sg10
VC1527249
p4673
sg12
I17
sg13
Vcolorectal cancer
p4674
sg15
I2
sasa(dp4675
g2
VAlthough rare, CLS could be a severe side effect after the administration of IL-11.
p4676
sg4
(lp4677
(dp4678
g9
I77
sg39
VP20809
p4679
sg12
I5
sg13
VIL-11
p4680
sg15
I1
sasg6
(lp4681
(dp4682
g9
I15
sg10
VC0265252
p4683
sg12
I3
sg13
VCLS
p4684
sg15
I1
sa(dp4685
g9
I37
sg10
VC0879626
p4686
sg12
I11
sg13
Vside effect
p4687
sg15
I2
sasa(dp4688
g2
VWe describe four cases of the patients with ST-elevation myocardial infarction (STEMI) that were treated with interleukin-11 (IL-11), a cardioprotective cytokine.
p4689
sg4
(lp4690
(dp4691
g9
I110
sg39
VP20809
p4692
sg12
I14
sg13
Vinterleukin-11
p4693
sg15
I1
sa(dp4694
g9
I126
sg39
VP20809
p4695
sg12
I5
sg13
VIL-11
p4696
sg15
I1
sasg6
(lp4697
(dp4698
g9
I80
sg10
VC1536220
p4699
sg12
I5
sg13
VSTEMI
p4700
sg15
I1
sa(dp4701
g9
I44
sg10
VC1536220
p4702
sg12
I34
sg13
VST-elevation myocardial infarction
p4703
sg15
I3
sasa(dp4704
g2
VThe protective role of IL-11, an IL-6 family cytokine, has been implicated in ischemia/reperfusion injury (IRI) in the heart and kidney, but its role has not been elucidated in liver IRI.
p4705
sg4
(lp4706
(dp4707
g9
I33
sg39
VP05231
p4708
sg12
I20
sg13
VIL-6 family cytokine
p4709
sg15
I3
sa(dp4710
g9
I23
sg39
VP20809
p4711
sg12
I5
sg13
VIL-11
p4712
sg15
I1
sasg6
(lp4713
(dp4714
g9
I78
sg10
VC0022116
p4715
sg12
I8
sg13
Vischemia
p4716
sg15
I1
sasa(dp4717
g2
VNext, IL-11 was injected intraperitoneally (ip) 1 hour before ischemia.
p4718
sg4
(lp4719
(dp4720
g9
I6
sg39
VP20809
p4721
sg12
I5
sg13
VIL-11
p4722
sg15
I1
sasg6
(lp4723
(dp4724
g9
I62
sg10
VC0022116
p4725
sg12
I8
sg13
Vischemia
p4726
sg15
I1
sasa(dp4727
g2
VPertussis toxin gene (ptxA-Pr), insertion sequence genes (IS481 and IS1001), adenylate cyclase genes and structural porin and flagellin genes were chosen as targets for PCR, in different studies.
p4728
sg4
(lp4729
(dp4730
g9
I77
sg39
g40
sg12
I17
sg13
Vadenylate cyclase
p4731
sg15
I2
sa(dp4732
g9
I0
sg39
g40
sg12
I20
sg13
VPertussis toxin gene
p4733
sg15
I3
sasg6
(lp4734
(dp4735
g9
I0
sg10
VC0043167
p4736
sg12
I9
sg13
VPertussis
p4737
sg15
I1
sasa(dp4738
g2
VPCR assays targeting insertion sequence IS481 (IS), pertussis toxin ptxA promoter region (PT), and outer membrane porin (PO), or recA (RA) were evaluated in respiratory specimens collected from 4,442 patients with suspected pertussis.
p4739
sg4
(lp4740
(dp4741
g9
I52
sg39
VP0CE72
p4742
sg12
I67
sg13
Vpertussis toxin ptxA promoter region (PT), and outer membrane porin
p4743
sg15
I10
sa(dp4744
g9
I135
sg39
g40
sg12
I2
sg13
VRA
p4745
sg15
I1
sa(dp4746
g9
I129
sg39
g40
sg12
I4
sg13
VrecA
p4747
sg15
I1
sasg6
(lp4748
(dp4749
g9
I52
sg10
VC0043167
p4750
sg12
I9
sg13
Vpertussis
p4751
sg15
I1
sa(dp4752
g9
I52
sg10
VC0043167
p4753
sg12
I9
sg13
Vpertussis
p4754
sg15
I1
sasa(dp4755
g2
VIn this study, we evaluated the role of miR-135b in colorectal cancer (CRC) and its regulatory role for metastasis suppressor-1 (MTSS1) and its mechanisms.
p4756
sg4
(lp4757
(dp4758
g9
I40
sg39
g40
sg12
I35
sg13
VmiR-135b in colorectal cancer (CRC)
p4759
sg15
I5
sa(dp4760
g9
I129
sg39
g40
sg12
I5
sg13
VMTSS1
p4761
sg15
I1
sa(dp4762
g9
I104
sg39
g40
sg12
I23
sg13
Vmetastasis suppressor-1
p4763
sg15
I2
sasg6
(lp4764
(dp4765
g9
I52
sg10
VC1527249
p4766
sg12
I17
sg13
Vcolorectal cancer
p4767
sg15
I2
sa(dp4768
g9
I71
sg10
VC1527249
p4769
sg12
I3
sg13
VCRC
p4770
sg15
I1
sa(dp4771
g9
I104
sg10
VC0027627
p4772
sg12
I10
sg13
Vmetastasis
p4773
sg15
I1
sasa(dp4774
g2
VThe levels of miR-135b and MTSS1 gene expression in 35 CRC and corresponding cancer-adjacent tissues, 27 colorectal adenoma, and 16 normal tissue samples were quantified using qRT-PCR and western blot analysis.
p4775
sg4
(lp4776
(dp4777
g9
I14
sg39
g40
sg12
I8
sg13
VmiR-135b
p4778
sg15
I1
sa(dp4779
g9
I27
sg39
g40
sg12
I31
sg13
VMTSS1 gene expression in 35 CRC
p4780
sg15
I6
sasg6
(lp4781
(dp4782
g9
I55
sg10
VC1527249
p4783
sg12
I3
sg13
VCRC
p4784
sg15
I1
sa(dp4785
g9
I105
sg10
VC1302401
p4786
sg12
I18
sg13
Vcolorectal adenoma
p4787
sg15
I2
sa(dp4788
g9
I77
sg10
VC0006826
p4789
sg12
I6
sg13
Vcancer
p4790
sg15
I1
sasa(dp4791
g2
VJahid and colleagues have shown that miR-23a promotes the transition from indolent to invasive colorectal cancer through inhibition of the MTSS1 tumor suppressor.
p4792
sg4
(lp4793
(dp4794
g9
I139
sg39
g40
sg12
I22
sg13
VMTSS1 tumor suppressor
p4795
sg15
I3
sa(dp4796
g9
I37
sg39
g40
sg12
I7
sg13
VmiR-23a
p4797
sg15
I1
sasg6
(lp4798
(dp4799
g9
I145
sg10
VC0027651
p4800
sg12
I5
sg13
Vtumor
p4801
sg15
I1
sa(dp4802
g9
I95
sg10
VC1527249
p4803
sg12
I17
sg13
Vcolorectal cancer
p4804
sg15
I2
sa(dp4805
g9
I58
sg10
VC0599156
p4806
sg12
I10
sg13
Vtransition
p4807
sg15
I1
sasa(dp4808
g2
VTo investigate the expression of miR-23a and metastasis suppressor 1 (MTSS1) and their clinical significance in colon carcinoma.
p4809
sg4
(lp4810
(dp4811
g9
I33
sg39
g40
sg12
I35
sg13
VmiR-23a and metastasis suppressor 1
p4812
sg15
I5
sa(dp4813
g9
I70
sg39
g40
sg12
I5
sg13
VMTSS1
p4814
sg15
I1
sasg6
(lp4815
(dp4816
g9
I45
sg10
VC0027627
p4817
sg12
I10
sg13
Vmetastasis
p4818
sg15
I1
sa(dp4819
g9
I112
sg10
VC0699790
p4820
sg12
I15
sg13
Vcolon carcinoma
p4821
sg15
I2
sasa(dp4822
g2
VThe expression rates of miR-23a and MTSS1 were 87.0% (80/92) and 17.4% (16/92) in colon carcinoma cases, respectively (P &lt; 0.01).
p4823
sg4
(lp4824
(dp4825
g9
I24
sg39
g40
sg12
I17
sg13
VmiR-23a and MTSS1
p4826
sg15
I3
sasg6
(lp4827
(dp4828
g9
I82
sg10
VC0699790
p4829
sg12
I15
sg13
Vcolon carcinoma
p4830
sg15
I2
sasa(dp4831
g2
VBoth the low expression of MTSS1 and high expression of miR-23a may serve as important biological markers for the malignant phenotypes of colon cancer, such as invasion and metastasis.
p4832
sg4
(lp4833
(dp4834
g9
I56
sg39
g40
sg12
I7
sg13
VmiR-23a
p4835
sg15
I1
sa(dp4836
g9
I27
sg39
g40
sg12
I5
sg13
VMTSS1
p4837
sg15
I1
sasg6
(lp4838
(dp4839
g9
I160
sg10
VC2699153
p4840
sg12
I8
sg13
Vinvasion
p4841
sg15
I1
sa(dp4842
g9
I138
sg10
VC0699790
p4843
sg12
I12
sg13
Vcolon cancer
p4844
sg15
I2
sa(dp4845
g9
I173
sg10
VC0027627
p4846
sg12
I10
sg13
Vmetastasis
p4847
sg15
I1
sasa(dp4848
g2
VThe aims of this study were to investigate metastasis suppressor 1 (MTSS1) expression in benign and malignant colorectal tissues and to explore its significance in the prognosis of colorectal cancer (CRC) patients.
p4849
sg4
(lp4850
sg6
(lp4851
(dp4852
g9
I200
sg10
VC1527249
p4853
sg12
I3
sg13
VCRC
p4854
sg15
I1
sa(dp4855
g9
I43
sg10
VC0027627
p4856
sg12
I10
sg13
Vmetastasis
p4857
sg15
I1
sa(dp4858
g9
I181
sg10
VC1527249
p4859
sg12
I17
sg13
Vcolorectal cancer
p4860
sg15
I2
sasa(dp4861
g2
VMTSS1 expression was detected by immunohistochemistry in CRC, colorectal adenomatous polyp (precancerous lesion) and normal colorectal tissues.
p4862
sg4
(lp4863
(dp4864
g9
I0
sg39
g40
sg12
I5
sg13
VMTSS1
p4865
sg15
I1
sasg6
(lp4866
(dp4867
g9
I57
sg10
VC1527249
p4868
sg12
I3
sg13
VCRC
p4869
sg15
I1
sa(dp4870
g9
I62
sg10
VC3272805
p4871
sg12
I28
sg13
Vcolorectal adenomatous polyp
p4872
sg15
I3
sasa(dp4873
g2
VThese genes (CACNA1C, COL2A1, CPNE8, C3F, C12ORF4, DDX11, GDF11, HOXC8, KCNA1, MDS028, TMEM106C, NR4A1, PHB2, PRICKLE1, Q6ZUQ4, SCN8A, TUBA8 and USP18) are located on porcine chromosome 5 (SSC5) and represent positional and functional candidates for arthrogryposis multiplex congenita (AMC), which maps to SSC5.
p4874
sg4
(lp4875
(dp4876
g9
I128
sg39
g40
sg12
I5
sg13
VSCN8A
p4877
sg15
I1
sa(dp4878
g9
I58
sg39
g40
sg12
I5
sg13
VGDF11
p4879
sg15
I1
sa(dp4880
g9
I87
sg39
g40
sg12
I8
sg13
VTMEM106C
p4881
sg15
I1
sa(dp4882
g9
I51
sg39
g40
sg12
I5
sg13
VDDX11
p4883
sg15
I1
sa(dp4884
g9
I110
sg39
g40
sg12
I8
sg13
VPRICKLE1
p4885
sg15
I1
sa(dp4886
g9
I37
sg39
g40
sg12
I3
sg13
VC3F
p4887
sg15
I1
sa(dp4888
g9
I104
sg39
g40
sg12
I4
sg13
VPHB2
p4889
sg15
I1
sa(dp4890
g9
I97
sg39
VP22736
p4891
sg12
I5
sg13
VNR4A1
p4892
sg15
I1
sa(dp4893
g9
I65
sg39
VP31273
p4894
sg12
I5
sg13
VHOXC8
p4895
sg15
I1
sa(dp4896
g9
I42
sg39
g40
sg12
I7
sg13
VC12ORF4
p4897
sg15
I1
sa(dp4898
g9
I30
sg39
g40
sg12
I5
sg13
VCPNE8
p4899
sg15
I1
sa(dp4900
g9
I79
sg39
g40
sg12
I6
sg13
VMDS028
p4901
sg15
I1
sa(dp4902
g9
I72
sg39
g40
sg12
I5
sg13
VKCNA1
p4903
sg15
I1
sa(dp4904
g9
I135
sg39
g40
sg12
I5
sg13
VTUBA8
p4905
sg15
I1
sa(dp4906
g9
I145
sg39
g40
sg12
I5
sg13
VUSP18
p4907
sg15
I1
sasg6
(lp4908
(dp4909
g9
I250
sg10
VC2931264
p4910
sg12
I34
sg13
Varthrogryposis multiplex congenita
p4911
sg15
I3
sa(dp4912
g9
I286
sg10
VC2931264
p4913
sg12
I3
sg13
VAMC
p4914
sg15
I1
sasa(dp4915
g2
VIn this study, we tested whether this tolerance is intact in systemic lupus erythematosus-prone (New Zealand Black x SWR)F1 mice (SNF1).
p4916
sg4
(lp4917
sg6
(lp4918
(dp4919
g9
I38
sg10
VC0020963
p4920
sg12
I9
sg13
Vtolerance
p4921
sg15
I1
sa(dp4922
g9
I61
sg10
VC0024141
p4923
sg12
I28
sg13
Vsystemic lupus erythematosus
p4924
sg15
I3
sasa(dp4925
g2
VThe F1 cross between SWR and NZB mice, SNF1, develops severe immune complex glomerulonephritis, in a similar manner to humans with systemic lupus erythematosus (SLE).
p4926
sg4
(lp4927
sg6
(lp4928
(dp4929
g9
I131
sg10
VC0024141
p4930
sg12
I28
sg13
Vsystemic lupus erythematosus
p4931
sg15
I3
sa(dp4932
g9
I61
sg10
VC0744421
p4933
sg12
I33
sg13
Vimmune complex glomerulonephritis
p4934
sg15
I3
sa(dp4935
g9
I161
sg10
VC0024141
p4936
sg12
I3
sg13
VSLE
p4937
sg15
I1
sasa(dp4938
g2
VExposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.
p4939
sg4
(lp4940
(dp4941
g9
I79
sg39
VP22083
p4942
sg12
I4
sg13
VCD15
p4943
sg15
I1
sa(dp4944
g9
I194
sg39
VP04198
p4945
sg12
I12
sg13
VNMYC protein
p4946
sg15
I2
sa(dp4947
g9
I17
sg39
VP18075
p4948
sg12
I29
sg13
Vmorphogenetic protein (BMP)-4
p4949
sg15
I3
sa(dp4950
g9
I85
sg39
VP61073
p4951
sg12
I5
sg13
VCD184
p4952
sg15
I1
sasg6
(lp4953
(dp4954
g9
I92
sg10
VC0027819
p4955
sg12
I13
sg13
Vneuroblastoma
p4956
sg15
I1
sasa(dp4957
g2
VIn cell-based assays, it is demonstrated that PST3.1a alters the Beta1,6-GlcNAc N-glycans of GBM-initiating cells (GIC) by inhibiting MGAT5 enzymatic activity, resulting in the inhibition of TGFBetaR and FAK signaling associated with doublecortin (DCX) upregulation and increase oligodendrocyte lineage transcription factor 2 (OLIG2) expression.
p4958
sg4
(lp4959
(dp4960
g9
I279
sg39
g40
sg12
I46
sg13
Voligodendrocyte lineage transcription factor 2
p4961
sg15
I5
sa(dp4962
g9
I234
sg39
g40
sg12
I12
sg13
Vdoublecortin
p4963
sg15
I1
sa(dp4964
g9
I327
sg39
g40
sg12
I5
sg13
VOLIG2
p4965
sg15
I1
sa(dp4966
g9
I204
sg39
g40
sg12
I3
sg13
VFAK
p4967
sg15
I1
sa(dp4968
g9
I248
sg39
g40
sg12
I3
sg13
VDCX
p4969
sg15
I1
sa(dp4970
g9
I134
sg39
g40
sg12
I5
sg13
VMGAT5
p4971
sg15
I1
sasg6
(lp4972
(dp4973
g9
I93
sg10
VC0017636
p4974
sg12
I3
sg13
VGBM
p4975
sg15
I1
sasa(dp4976
g2
VTo assess the expression of Toll-like receptor 3 (TLR-3) and TLR-7 in muscle tissue from patients with polymyositis (PM) and dermatomyositis (DM) and to investigate the function and regulation of TLR-3 in cultured muscle cells.
p4977
sg4
(lp4978
(dp4979
g9
I28
sg39
g40
sg12
I20
sg13
VToll-like receptor 3
p4980
sg15
I3
sa(dp4981
g9
I50
sg39
g40
sg12
I5
sg13
VTLR-3
p4982
sg15
I1
sa(dp4983
g9
I61
sg39
g40
sg12
I5
sg13
VTLR-7
p4984
sg15
I1
sa(dp4985
g9
I50
sg39
g40
sg12
I5
sg13
VTLR-3
p4986
sg15
I1
sasg6
(lp4987
(dp4988
g9
I117
sg10
VC0085655
p4989
sg12
I2
sg13
VPM
p4990
sg15
I1
sa(dp4991
g9
I142
sg10
VC0221056
p4992
sg12
I2
sg13
VDM
p4993
sg15
I1
sa(dp4994
g9
I125
sg10
VC0221056
p4995
sg12
I15
sg13
Vdermatomyositis
p4996
sg15
I1
sa(dp4997
g9
I103
sg10
VC0085655
p4998
sg12
I12
sg13
Vpolymyositis
p4999
sg15
I1
sasa(dp5000
g2
VWe analyzed the coding sequences and exon-intron boundaries of GLIALCAM, encoding an IgG-like cell adhesion protein, in 81 individuals with Autism Spectrum Disorders, either with or without comorbid epilepsy, paroxysmal EEG and/or macrocephaly, and the PTEN gene in the subsample with macrocephaly.
p5001
sg4
(lp5002
(dp5003
g9
I253
sg39
VP60484
p5004
sg12
I9
sg13
VPTEN gene
p5005
sg15
I2
sa(dp5006
g9
I63
sg39
g40
sg12
I8
sg13
VGLIALCAM
p5007
sg15
I1
sa(dp5008
g9
I85
sg39
VP01185
p5009
sg12
I30
sg13
VIgG-like cell adhesion protein
p5010
sg15
I4
sasg6
(lp5011
(dp5012
g9
I231
sg10
VC0221355
p5013
sg12
I12
sg13
Vmacrocephaly
p5014
sg15
I1
sa(dp5015
g9
I199
sg10
VC0014544
p5016
sg12
I8
sg13
Vepilepsy
p5017
sg15
I1
sa(dp5018
g9
I231
sg10
VC0221355
p5019
sg12
I12
sg13
Vmacrocephaly
p5020
sg15
I1
sa(dp5021
g9
I99
sg10
VC0001511
p5022
sg12
I8
sg13
Vadhesion
p5023
sg15
I1
sa(dp5024
g9
I140
sg10
VC1510586
p5025
sg12
I25
sg13
VAutism Spectrum Disorders
p5026
sg15
I3
sasa(dp5027
g2
VWhilst we detected in GLIALCAM several single nucleotide variants without clear pathogenic effects, we found a novel PTEN heterozygous frameshift mutation in one case with "extreme" macrocephaly, autism, intellectual disability and seizures.
p5028
sg4
(lp5029
(dp5030
g9
I117
sg39
VP60484
p5031
sg12
I4
sg13
VPTEN
p5032
sg15
I1
sasg6
(lp5033
(dp5034
g9
I232
sg10
VC0036572
p5035
sg12
I8
sg13
Vseizures
p5036
sg15
I1
sa(dp5037
g9
I182
sg10
VC0221355
p5038
sg12
I12
sg13
Vmacrocephaly
p5039
sg15
I1
sa(dp5040
g9
I135
sg10
VC0079380
p5041
sg12
I19
sg13
Vframeshift mutation
p5042
sg15
I2
sa(dp5043
g9
I196
sg10
VC0004352
p5044
sg12
I6
sg13
Vautism
p5045
sg15
I1
sa(dp5046
g9
I204
sg10
VC0025362
p5047
sg12
I23
sg13
Vintellectual disability
p5048
sg15
I2
sasa(dp5049
g2
VIn other families with dominant HEPACAM mutations, patients had macrocephaly and mental retardation with or without autism.
p5050
sg4
(lp5051
sg6
(lp5052
(dp5053
g9
I64
sg10
VC0221355
p5054
sg12
I12
sg13
Vmacrocephaly
p5055
sg15
I1
sa(dp5056
g9
I81
sg10
VC0025362
p5057
sg12
I18
sg13
Vmental retardation
p5058
sg15
I2
sa(dp5059
g9
I116
sg10
VC0004352
p5060
sg12
I6
sg13
Vautism
p5061
sg15
I1
sasa(dp5062
g2
VDominant HEPACAM mutations can cause either macrocephaly and mental retardation with or without autism or benign familial macrocephaly.
p5063
sg4
(lp5064
sg6
(lp5065
(dp5066
g9
I106
sg10
VC0220690
p5067
sg12
I28
sg13
Vbenign familial macrocephaly
p5068
sg15
I3
sa(dp5069
g9
I96
sg10
VC0004352
p5070
sg12
I6
sg13
Vautism
p5071
sg15
I1
sa(dp5072
g9
I61
sg10
VC0025362
p5073
sg12
I18
sg13
Vmental retardation
p5074
sg15
I2
sa(dp5075
g9
I44
sg10
VC0221355
p5076
sg12
I12
sg13
Vmacrocephaly
p5077
sg15
I1
sasa(dp5078
g2
VB AaHHoe NccneAoBaHNe BownN 59 AeTeN c ANcoyHKmyNeN wyHTNpyhweN cNcTeMbl B Bo3pacTe oT 1 roAa Ao 14 neT, npoxoANBwNx ne4eHNe B OeAepanbHoM myeHTpe HeNpoxNpyprNN (HoBocNbNpcK) c 2014 no 2016 r. KpNTepNN BKnh4eHNR B NccneAoBaHNe: 1) Bo3pacT Ha MoMeHT obcneAoBaHNR cTapwe 1 roAa; 2) NMnnaHTamyNR wyHTNpyhweN cNcTeMbl B nepBble 12 Mec XN3HN.
p5079
sg4
(lp5080
sg6
(lp5081
sa(dp5082
g2
VThus, myocyte autonomous inhibition of PKCalpha protects the adult heart from decompensation and dilated cardiomyopathy after infarction injury in association with a primary enhancement in contractility.
p5083
sg4
(lp5084
(dp5085
g9
I39
sg39
VP17252
p5086
sg12
I8
sg13
VPKCalpha
p5087
sg15
I1
sasg6
(lp5088
(dp5089
g9
I97
sg10
VC0007193
p5090
sg12
I22
sg13
Vdilated cardiomyopathy
p5091
sg15
I2
sa(dp5092
g9
I126
sg10
VC0021308
p5093
sg12
I10
sg13
Vinfarction
p5094
sg15
I1
sasa(dp5095
g2
VHypercontractility caused by Prkca deletion protects against heart failure induced by pressure overload, and against dilated cardiomyopathy induced by deleting the gene encoding muscle LIM protein (Csrp3).
p5096
sg4
(lp5097
(dp5098
g9
I198
sg39
VP50461
p5099
sg12
I5
sg13
VCsrp3
p5100
sg15
I1
sa(dp5101
g9
I164
sg39
VP50461
p5102
sg12
I32
sg13
Vgene encoding muscle LIM protein
p5103
sg15
I5
sasg6
(lp5104
(dp5105
g9
I61
sg10
VC0018802
p5106
sg12
I13
sg13
Vheart failure
p5107
sg15
I2
sa(dp5108
g9
I117
sg10
VC0007193
p5109
sg12
I22
sg13
Vdilated cardiomyopathy
p5110
sg15
I2
sasa(dp5111
g2
VDeletion of Prkca also rescues cardiomyopathy associated with overexpression of PP-1.
p5112
sg4
(lp5113
(dp5114
g9
I80
sg39
g40
sg12
I4
sg13
VPP-1
p5115
sg15
I1
sasg6
(lp5116
(dp5117
g9
I31
sg10
VC0878544
p5118
sg12
I14
sg13
Vcardiomyopathy
p5119
sg15
I1
sasa(dp5120
g2
VPD-L1 staining was detected in 80% of anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma and follicular dendritic cell sarcoma, 75% of nodular lymphocyte predominant Hodgkin lymphoma, 53% of primary mediastinal large B-cell lymphoma, 39% of extranodal NK/T cell lymphoma, 26% of peripheral T-cell lymphoma, 10% of diffuse large B-cell lymphoma and very rare examples of mantle, marginal zone and small lymphocytic lymphomas.
p5121
sg4
(lp5122
sg6
(lp5123
(dp5124
g9
I109
sg10
VC1260325
p5125
sg12
I33
sg13
Vfollicular dendritic cell sarcoma
p5126
sg15
I4
sa(dp5127
g9
I330
sg10
VC0079744
p5128
sg12
I29
sg13
Vdiffuse large B-cell lymphoma
p5129
sg15
I4
sa(dp5130
g9
I271
sg10
VC0079772
p5131
sg12
I15
sg13
VT cell lymphoma
p5132
sg15
I3
sa(dp5133
g9
I295
sg10
VC0079774
p5134
sg12
I26
sg13
Vperipheral T-cell lymphoma
p5135
sg15
I3
sa(dp5136
g9
I207
sg10
VC0855152
p5137
sg12
I41
sg13
Vprimary mediastinal large B-cell lymphoma
p5138
sg15
I5
sa(dp5139
g9
I412
sg10
VC0023434
p5140
sg12
I27
sg13
Vsmall lymphocytic lymphomas
p5141
sg15
I3
sa(dp5142
g9
I151
sg10
VC1334968
p5143
sg12
I47
sg13
Vnodular lymphocyte predominant Hodgkin lymphoma
p5144
sg15
I5
sa(dp5145
g9
I70
sg10
VC0020981
p5146
sg12
I34
sg13
Vangioimmunoblastic T-cell lymphoma
p5147
sg15
I3
sa(dp5148
g9
I38
sg10
VC0206180
p5149
sg12
I30
sg13
Vanaplastic large cell lymphoma
p5150
sg15
I4
sasa(dp5151
g2
VPD-L1 also showed stronger expression in ALK+ ALCL compared with ALK- ALCL, suggesting an additional role of C/EBPBeta in ALK+ ALCL in generating an immunosuppressive environment.
p5152
sg4
(lp5153
(dp5154
g9
I41
sg39
g40
sg12
I9
sg13
VALK+ ALCL
p5155
sg15
I2
sa(dp5156
g9
I65
sg39
g40
sg12
I9
sg13
VALK- ALCL
p5157
sg15
I2
sasg6
(lp5158
(dp5159
g9
I46
sg10
VC0206180
p5160
sg12
I4
sg13
VALCL
p5161
sg15
I1
sa(dp5162
g9
I46
sg10
VC0206180
p5163
sg12
I4
sg13
VALCL
p5164
sg15
I1
sa(dp5165
g9
I46
sg10
VC0206180
p5166
sg12
I4
sg13
VALCL
p5167
sg15
I1
sasa(dp5168
g2
VIn conclusion, surface antigen expression profiling demonstrates that C/EBPBeta plays a critical role in the activation state of ALK+ ALCL cells and reveals CD147 and PD-L1 as important downstream targets.
p5169
sg4
(lp5170
(dp5171
g9
I157
sg39
VP35613
p5172
sg12
I5
sg13
VCD147
p5173
sg15
I1
sasg6
(lp5174
(dp5175
g9
I134
sg10
VC0206180
p5176
sg12
I4
sg13
VALCL
p5177
sg15
I1
sasa(dp5178
g2
VAlso, the neoplastic cells of classical Hodgkin lymphoma, anaplastic large cell lymphoma, schwannoma, thymoma, and squamous cell carcinoma of various sites frequently expressed PD-L1.
p5179
sg4
(lp5180
sg6
(lp5181
(dp5182
g9
I58
sg10
VC0206180
p5183
sg12
I30
sg13
Vanaplastic large cell lymphoma
p5184
sg15
I4
sa(dp5185
g9
I102
sg10
VC0040100
p5186
sg12
I7
sg13
Vthymoma
p5187
sg15
I1
sa(dp5188
g9
I30
sg10
VC1333064
p5189
sg12
I26
sg13
Vclassical Hodgkin lymphoma
p5190
sg15
I3
sa(dp5191
g9
I115
sg10
VC0007137
p5192
sg12
I23
sg13
Vsquamous cell carcinoma
p5193
sg15
I3
sa(dp5194
g9
I90
sg10
VC0027809
p5195
sg12
I10
sg13
Vschwannoma
p5196
sg15
I1
sasa(dp5197
g2
VThese unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine IL-10 and cell-surface protein PD-L1/CD274.
p5198
sg4
(lp5199
(dp5200
g9
I59
sg39
g40
sg12
I3
sg13
VALK
p5201
sg15
I1
sa(dp5202
g9
I360
sg39
g40
sg12
I5
sg13
VCD274
p5203
sg15
I1
sa(dp5204
g9
I55
sg39
g40
sg12
I3
sg13
VNPM
p5205
sg15
I1
sa(dp5206
g9
I235
sg39
VP28908
p5207
sg12
I4
sg13
VCD30
p5208
sg15
I1
sa(dp5209
g9
I199
sg39
VP40763
p5210
sg12
I5
sg13
VSTAT3
p5211
sg15
I1
sasg6
(lp5212
(dp5213
g9
I119
sg10
VC0334094
p5214
sg12
I13
sg13
Vproliferation
p5215
sg15
I1
sa(dp5216
g9
I257
sg10
VC0206180
p5217
sg12
I30
sg13
Vanaplastic large-cell lymphoma
p5218
sg15
I3
sasa(dp5219
g2
VPD-L1 was expressed uniformly by anaplastic large cell lymphoma (ALCL) cell lines, but rarely in B-cell NHL, confined to a subset of diffuse large B-cell lymphomas (DLBCL) with activated B-cell features (3 of 28 cell lines and 24% of primary DLBCL).
p5220
sg4
(lp5221
sg6
(lp5222
(dp5223
g9
I147
sg10
VC0079731
p5224
sg12
I16
sg13
VB-cell lymphomas
p5225
sg15
I2
sa(dp5226
g9
I104
sg10
VC0024305
p5227
sg12
I3
sg13
VNHL
p5228
sg15
I1
sa(dp5229
g9
I65
sg10
VC0206180
p5230
sg12
I4
sg13
VALCL
p5231
sg15
I1
sa(dp5232
g9
I33
sg10
VC0206180
p5233
sg12
I30
sg13
Vanaplastic large cell lymphoma
p5234
sg15
I4
sasa(dp5235
g2
VAnti-PD-L1 blocking antibody boosted proliferation and IFN-Gamma secretion by allogeneic T cells responding to ALCL and DLBCL cells.
p5236
sg4
(lp5237
(dp5238
g9
I55
sg39
VP01579
p5239
sg12
I9
sg13
VIFN-Gamma
p5240
sg15
I1
sasg6
(lp5241
(dp5242
g9
I111
sg10
VC0206180
p5243
sg12
I4
sg13
VALCL
p5244
sg15
I1
sa(dp5245
g9
I11
sg10
VC0233660
p5246
sg12
I8
sg13
Vblocking
p5247
sg15
I1
sa(dp5248
g9
I37
sg10
VC0334094
p5249
sg12
I13
sg13
Vproliferation
p5250
sg15
I1
sasa(dp5251
g2
VIn autologous cultures of primary ALCL and DLBCL, PD-L1 blockade enhanced secretion of inflammatory cytokines IFN-Gamma, granulocyte macrophage colony-stimulating factor, interleukin (IL)-1, IL-6, IL-8, IL-13, TNF-Alfa, and macrophage inflammatory protein-1Alfa.
p5252
sg4
(lp5253
(dp5254
g9
I100
sg39
VP01579
p5255
sg12
I19
sg13
Vcytokines IFN-Gamma
p5256
sg15
I2
sa(dp5257
g9
I203
sg39
VP35225
p5258
sg12
I5
sg13
VIL-13
p5259
sg15
I1
sa(dp5260
g9
I210
sg39
VP01375
p5261
sg12
I8
sg13
VTNF-Alfa
p5262
sg15
I1
sa(dp5263
g9
I121
sg39
VP04141
p5264
sg12
I48
sg13
Vgranulocyte macrophage colony-stimulating factor
p5265
sg15
I4
sa(dp5266
g9
I171
sg39
VP60568
p5267
sg12
I18
sg13
Vinterleukin (IL)-1
p5268
sg15
I2
sa(dp5269
g9
I191
sg39
VP05231
p5270
sg12
I4
sg13
VIL-6
p5271
sg15
I1
sasg6
(lp5272
(dp5273
g9
I34
sg10
VC0206180
p5274
sg12
I4
sg13
VALCL
p5275
sg15
I1
sasa(dp5276
g2
VWe examined B7-H1 expression in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) and found that it was constitutively expressed in both clinical samples and cell lines.
p5277
sg4
(lp5278
(dp5279
g9
I12
sg39
g40
sg12
I5
sg13
VB7-H1
p5280
sg15
I1
sasg6
(lp5281
(dp5282
g9
I92
sg10
VC0019829
p5283
sg12
I2
sg13
VHL
p5284
sg15
I1
sa(dp5285
g9
I74
sg10
VC0019829
p5286
sg12
I16
sg13
VHodgkin lymphoma
p5287
sg15
I2
sa(dp5288
g9
I32
sg10
VC0206180
p5289
sg12
I30
sg13
Vanaplastic large cell lymphoma
p5290
sg15
I4
sa(dp5291
g9
I64
sg10
VC0206180
p5292
sg12
I4
sg13
VALCL
p5293
sg15
I1
sasa(dp5294
g2
VIn anaplastic lymphoma kinase-positive (ALK(+)) ALCL cells, B7-H1 expression was suppressed by the blocking of extracellular signal-regulated kinase (ERK) signaling and upregulated by the augmentation of ERK activity by phorbol 13-myristate 12-acetate stimulation, suggesting that B7-H1 expression is regulated by ERK signaling pathway in ALCL.
p5295
sg4
(lp5296
(dp5297
g9
I150
sg39
VP29323
p5298
sg12
I3
sg13
VERK
p5299
sg15
I1
sa(dp5300
g9
I60
sg39
g40
sg12
I5
sg13
VB7-H1
p5301
sg15
I1
sa(dp5302
g9
I111
sg39
VP53779
p5303
sg12
I37
sg13
Vextracellular signal-regulated kinase
p5304
sg15
I3
sa(dp5305
g9
I150
sg39
VP29323
p5306
sg12
I3
sg13
VERK
p5307
sg15
I1
sa(dp5308
g9
I150
sg39
VP29323
p5309
sg12
I3
sg13
VERK
p5310
sg15
I1
sa(dp5311
g9
I60
sg39
g40
sg12
I5
sg13
VB7-H1
p5312
sg15
I1
sasg6
(lp5313
(dp5314
g9
I48
sg10
VC0206180
p5315
sg12
I4
sg13
VALCL
p5316
sg15
I1
sa(dp5317
g9
I99
sg10
VC0233660
p5318
sg12
I8
sg13
Vblocking
p5319
sg15
I1
sa(dp5320
g9
I48
sg10
VC0206180
p5321
sg12
I4
sg13
VALCL
p5322
sg15
I1
sa(dp5323
g9
I3
sg10
VC1321546
p5324
sg12
I19
sg13
Vanaplastic lymphoma
p5325
sg15
I2
sasa(dp5326
g2
VERK is one of the downstream mediators of nucleophosmin (NPM)/ALK signaling in ALK(+)ALCL, and pharmacological inhibition of ALK was shown to dephosphorylate ERK and down-regulate B7-H1.
p5327
sg4
(lp5328
(dp5329
g9
I62
sg39
g40
sg12
I3
sg13
VALK
p5330
sg15
I1
sa(dp5331
g9
I62
sg39
g40
sg12
I3
sg13
VALK
p5332
sg15
I1
sa(dp5333
g9
I0
sg39
VP29323
p5334
sg12
I3
sg13
VERK
p5335
sg15
I1
sa(dp5336
g9
I180
sg39
g40
sg12
I5
sg13
VB7-H1
p5337
sg15
I1
sa(dp5338
g9
I0
sg39
VP29323
p5339
sg12
I3
sg13
VERK
p5340
sg15
I1
sasg6
(lp5341
(dp5342
g9
I85
sg10
VC0206180
p5343
sg12
I4
sg13
VALCL
p5344
sg15
I1
sasa(dp5345
g2
VThe involvement of NPM/ALK in B7-H1 expression was also demonstrated by introducing the construct into human non-ALCL lymphoid cell lines, which resulted in B7-H1 expression.
p5346
sg4
(lp5347
(dp5348
g9
I30
sg39
g40
sg12
I5
sg13
VB7-H1
p5349
sg15
I1
sa(dp5350
g9
I30
sg39
g40
sg12
I5
sg13
VB7-H1
p5351
sg15
I1
sa(dp5352
g9
I19
sg39
g40
sg12
I3
sg13
VNPM
p5353
sg15
I1
sa(dp5354
g9
I23
sg39
g40
sg12
I3
sg13
VALK
p5355
sg15
I1
sasg6
(lp5356
(dp5357
g9
I113
sg10
VC0206180
p5358
sg12
I4
sg13
VALCL
p5359
sg15
I1
sasa(dp5360
g2
VThese results suggest that B7-H1 expression is controlled by common ERK signaling pathways in ALCL and HL cells.
p5361
sg4
(lp5362
(dp5363
g9
I68
sg39
VP29323
p5364
sg12
I3
sg13
VERK
p5365
sg15
I1
sa(dp5366
g9
I27
sg39
g40
sg12
I5
sg13
VB7-H1
p5367
sg15
I1
sasg6
(lp5368
(dp5369
g9
I94
sg10
VC0206180
p5370
sg12
I4
sg13
VALCL
p5371
sg15
I1
sasa(dp5372
g2
VThe applicability of clinical genetics in nephrology is due to the fact that many kidney diseases are characterized by genetic mutations (e.g., von-Hippel Lindau syndrome, MYH9 related disorders, Fabry's syndrome, Liddle's and Bartter's Syndrome, and others).
p5373
sg4
(lp5374
(dp5375
g9
I172
sg39
VP35579
p5376
sg12
I4
sg13
VMYH9
p5377
sg15
I1
sasg6
(lp5378
(dp5379
g9
I204
sg10
VC0221043
p5380
sg12
I16
sg13
Vsyndrome, Liddle
p5381
sg15
I2
sa(dp5382
g9
I227
sg10
VC0004775
p5383
sg12
I18
sg13
VBartter's Syndrome
p5384
sg15
I2
sa(dp5385
g9
I82
sg10
VC0022658
p5386
sg12
I15
sg13
Vkidney diseases
p5387
sg15
I2
sa(dp5388
g9
I148
sg10
VC0019562
p5389
sg12
I22
sg13
VHippel Lindau syndrome
p5390
sg15
I3
sasa(dp5391
g2
VIn this study, we tested the hypothesis that a common single nucleotide polymorphism rs16996677 in the MYH9 gene may contribute to the etiology of DN in type 2 diabetes (T2D) in a Taiwanese population with T2D.
p5392
sg4
(lp5393
(dp5394
g9
I103
sg39
VP35579
p5395
sg12
I9
sg13
VMYH9 gene
p5396
sg15
I2
sasg6
(lp5397
(dp5398
g9
I170
sg10
VC0011860
p5399
sg12
I3
sg13
VT2D
p5400
sg15
I1
sa(dp5401
g9
I170
sg10
VC0011860
p5402
sg12
I3
sg13
VT2D
p5403
sg15
I1
sa(dp5404
g9
I153
sg10
VC0011860
p5405
sg12
I15
sg13
Vtype 2 diabetes
p5406
sg15
I3
sasa(dp5407
g2
VIt has been demonstrated that Wnt signaling through the secretion of Wnt inhibitors, such as DKK1, sFRP-2, and sFRP-3, plays a key role in the decreased osteoblast activity associated with multiple myeloma (MM) bone disease.
p5408
sg4
(lp5409
(dp5410
g9
I111
sg39
g40
sg12
I6
sg13
VsFRP-3
p5411
sg15
I1
sa(dp5412
g9
I99
sg39
g40
sg12
I6
sg13
VsFRP-2
p5413
sg15
I1
sa(dp5414
g9
I93
sg39
g40
sg12
I4
sg13
VDKK1
p5415
sg15
I1
sasg6
(lp5416
(dp5417
g9
I211
sg10
VC0005940
p5418
sg12
I12
sg13
Vbone disease
p5419
sg15
I2
sa(dp5420
g9
I189
sg10
VC0026764
p5421
sg12
I16
sg13
Vmultiple myeloma
p5422
sg15
I2
sasa(dp5423
g2
VThe authors studied the methylation status of CDKN2A, CDKN2B, XAF1, CDH13, JUNB and a panel of soluble Wnt inhibitors including WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in 31 bone marrow and 21 peripheral blood samples of patients with essential thrombocythaemia.
p5424
sg4
(lp5425
(dp5426
g9
I54
sg39
VP42772
p5427
sg12
I6
sg13
VCDKN2B
p5428
sg15
I1
sa(dp5429
g9
I62
sg39
g40
sg12
I4
sg13
VXAF1
p5430
sg15
I1
sa(dp5431
g9
I128
sg39
g40
sg12
I4
sg13
VWIF1
p5432
sg15
I1
sa(dp5433
g9
I134
sg39
g40
sg12
I4
sg13
VDKK3
p5434
sg15
I1
sa(dp5435
g9
I159
sg39
g40
sg12
I5
sg13
VSFRP4
p5436
sg15
I1
sa(dp5437
g9
I169
sg39
g40
sg12
I5
sg13
VSFRP5
p5438
sg15
I1
sa(dp5439
g9
I145
sg39
g40
sg12
I5
sg13
VSFRP1
p5440
sg15
I1
sa(dp5441
g9
I140
sg39
VP25054
p5442
sg12
I3
sg13
VAPC
p5443
sg15
I1
sa(dp5444
g9
I68
sg39
VP55290
p5445
sg12
I5
sg13
VCDH13
p5446
sg15
I1
sa(dp5447
g9
I46
sg39
VP42771
p5448
sg12
I6
sg13
VCDKN2A
p5449
sg15
I1
sa(dp5450
g9
I152
sg39
g40
sg12
I5
sg13
VSFRP2
p5451
sg15
I1
sa(dp5452
g9
I75
sg39
VP17275
p5453
sg12
I4
sg13
VJUNB
p5454
sg15
I1
sasg6
(lp5455
(dp5456
g9
I270
sg10
VC0040028
p5457
sg12
I26
sg13
Vessential thrombocythaemia
p5458
sg15
I2
sa(dp5459
g9
I140
sg10
VC0033036
p5460
sg12
I3
sg13
VAPC
p5461
sg15
I1
sasa(dp5462
g2
VWe studied the activity of Wnt signaling and the methylation status of WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in myeloma cell lines and primary myeloma samples.
p5463
sg4
(lp5464
(dp5465
g9
I71
sg39
g40
sg12
I4
sg13
VWIF1
p5466
sg15
I1
sa(dp5467
g9
I88
sg39
g40
sg12
I5
sg13
VSFRP1
p5468
sg15
I1
sa(dp5469
g9
I102
sg39
g40
sg12
I5
sg13
VSFRP4
p5470
sg15
I1
sa(dp5471
g9
I77
sg39
g40
sg12
I4
sg13
VDKK3
p5472
sg15
I1
sa(dp5473
g9
I112
sg39
g40
sg12
I5
sg13
VSFRP5
p5474
sg15
I1
sa(dp5475
g9
I95
sg39
g40
sg12
I5
sg13
VSFRP2
p5476
sg15
I1
sa(dp5477
g9
I83
sg39
VP25054
p5478
sg12
I3
sg13
VAPC
p5479
sg15
I1
sasg6
(lp5480
(dp5481
g9
I149
sg10
VC0026764
p5482
sg12
I7
sg13
Vmyeloma
p5483
sg15
I1
sa(dp5484
g9
I149
sg10
VC0026764
p5485
sg12
I7
sg13
Vmyeloma
p5486
sg15
I1
sa(dp5487
g9
I83
sg10
VC0033036
p5488
sg12
I3
sg13
VAPC
p5489
sg15
I1
sasa(dp5490
g2
VOn the other hand, myeloma cells suppress osteoblast function by the secretion of osteoblast inhibiting factors, e.g., the Wnt inhibitors DKK-1 and sFRP-2.
p5491
sg4
(lp5492
(dp5493
g9
I138
sg39
g40
sg12
I5
sg13
VDKK-1
p5494
sg15
I1
sa(dp5495
g9
I148
sg39
g40
sg12
I6
sg13
VsFRP-2
p5496
sg15
I1
sasg6
(lp5497
(dp5498
g9
I19
sg10
VC0026764
p5499
sg12
I7
sg13
Vmyeloma
p5500
sg15
I1
sasa(dp5501
g2
VHedgehog signaling is frequently activated in esophageal cancer, gastric cancer and pancreatic cancer due to transcriptional upregulation of Hedgehog ligands and epigenetic silencing of HHIP1/HHIP gene, encoding the Hedgehog inhibitor.
p5502
sg4
(lp5503
(dp5504
g9
I192
sg39
g40
sg12
I9
sg13
VHHIP gene
p5505
sg15
I2
sasg6
(lp5506
(dp5507
g9
I65
sg10
VC0024623
p5508
sg12
I14
sg13
Vgastric cancer
p5509
sg15
I2
sa(dp5510
g9
I84
sg10
VC0235974
p5511
sg12
I17
sg13
Vpancreatic cancer
p5512
sg15
I2
sa(dp5513
g9
I46
sg10
VC0014859
p5514
sg12
I17
sg13
Vesophageal cancer
p5515
sg15
I2
sasa(dp5516
g2
VSel-1-like (SEL1L) is a putative tumor suppressor gene that is significantly downregulated in human pancreatic ductal adenocarcinoma (PDA).
p5517
sg4
(lp5518
(dp5519
g9
I0
sg39
g40
sg12
I10
sg13
VSel-1-like
p5520
sg15
I1
sa(dp5521
g9
I12
sg39
g40
sg12
I5
sg13
VSEL1L
p5522
sg15
I1
sasg6
(lp5523
(dp5524
g9
I134
sg10
VC0013274
p5525
sg12
I3
sg13
VPDA
p5526
sg15
I1
sa(dp5527
g9
I33
sg10
VC0027651
p5528
sg12
I5
sg13
Vtumor
p5529
sg15
I1
sa(dp5530
g9
I100
sg10
VC1335302
p5531
sg12
I32
sg13
Vpancreatic ductal adenocarcinoma
p5532
sg15
I3
sasa(dp5533
g2
VSEL1L is a putative tumor suppressor gene that is frequently down-regulated in pancreatic ductal adenocarcinoma (PDA).
p5534
sg4
(lp5535
(dp5536
g9
I0
sg39
g40
sg12
I5
sg13
VSEL1L
p5537
sg15
I1
sasg6
(lp5538
(dp5539
g9
I20
sg10
VC0027651
p5540
sg12
I5
sg13
Vtumor
p5541
sg15
I1
sa(dp5542
g9
I79
sg10
VC1335302
p5543
sg12
I32
sg13
Vpancreatic ductal adenocarcinoma
p5544
sg15
I3
sa(dp5545
g9
I113
sg10
VC0013274
p5546
sg12
I3
sg13
VPDA
p5547
sg15
I1
sasa(dp5548
g2
VUsing a functional genomic approach, we identified a seven-gene panel (TNC, TFPI, TGFBI, SEL-1L, L1CAM, WWTR1, and CDC42BPA) that was differentially expressed across three different expression platforms, including pancreatic tumor/normal samples.
p5549
sg4
(lp5550
(dp5551
g9
I76
sg39
VP10646
p5552
sg12
I4
sg13
VTFPI
p5553
sg15
I1
sa(dp5554
g9
I97
sg39
VP32004
p5555
sg12
I5
sg13
VL1CAM
p5556
sg15
I1
sa(dp5557
g9
I71
sg39
VP63316
p5558
sg12
I3
sg13
VTNC
p5559
sg15
I1
sa(dp5560
g9
I89
sg39
g40
sg12
I6
sg13
VSEL-1L
p5561
sg15
I1
sa(dp5562
g9
I104
sg39
g40
sg12
I5
sg13
VWWTR1
p5563
sg15
I1
sasg6
(lp5564
(dp5565
g9
I214
sg10
VC0030297
p5566
sg12
I16
sg13
Vpancreatic tumor
p5567
sg15
I2
sasa(dp5568
g2
VPreviously, it was reported that SEL1L is able to decrease the aggressive behavior of human pancreatic tumor cells both in vitro and in vivo.
p5569
sg4
(lp5570
(dp5571
g9
I33
sg39
g40
sg12
I5
sg13
VSEL1L
p5572
sg15
I1
sasg6
(lp5573
(dp5574
g9
I63
sg10
VC0001807
p5575
sg12
I19
sg13
Vaggressive behavior
p5576
sg15
I2
sa(dp5577
g9
I92
sg10
VC0030297
p5578
sg12
I16
sg13
Vpancreatic tumor
p5579
sg15
I2
sasa(dp5580
g2
VTo gain insights into the involvement of SEL1L in tumor invasion, we performed gene expression analysis on the pancreatic cancer cell line Suit-2 subjected to two complementary strategies: upregulation and downregulation of SEL1L expression by stable transfection of the entire cDNA under an inducible promoter and by RNA-mediated interference.
p5581
sg4
(lp5582
(dp5583
g9
I41
sg39
g40
sg12
I5
sg13
VSEL1L
p5584
sg15
I1
sa(dp5585
g9
I41
sg39
g40
sg12
I5
sg13
VSEL1L
p5586
sg15
I1
sasg6
(lp5587
(dp5588
g9
I50
sg10
VC0027651
p5589
sg12
I5
sg13
Vtumor
p5590
sg15
I1
sa(dp5591
g9
I56
sg10
VC2699153
p5592
sg12
I8
sg13
Vinvasion
p5593
sg15
I1
sa(dp5594
g9
I111
sg10
VC0235974
p5595
sg12
I17
sg13
Vpancreatic cancer
p5596
sg15
I2
sasa(dp5597
g2
VThe gene SEL1L is involved both in human breast and pancreatic cancer progression.
p5598
sg4
(lp5599
(dp5600
g9
I4
sg39
g40
sg12
I10
sg13
Vgene SEL1L
p5601
sg15
I2
sasg6
(lp5602
(dp5603
g9
I63
sg10
VC0178874
p5604
sg12
I18
sg13
Vcancer progression
p5605
sg15
I2
sasa(dp5606
g2
VRecent data suggest that SEL1L may play an important role in pancreatic carcinoma, similar to breast cancer, where the expression of SEL1L has been associated with a reduction in both proliferative activity in vitro and clinical tumor aggressiveness.
p5607
sg4
(lp5608
(dp5609
g9
I25
sg39
g40
sg12
I5
sg13
VSEL1L
p5610
sg15
I1
sa(dp5611
g9
I25
sg39
g40
sg12
I5
sg13
VSEL1L
p5612
sg15
I1
sasg6
(lp5613
(dp5614
g9
I94
sg10
VC0678222
p5615
sg12
I13
sg13
Vbreast cancer
p5616
sg15
I2
sa(dp5617
g9
I229
sg10
VC0027651
p5618
sg12
I5
sg13
Vtumor
p5619
sg15
I1
sa(dp5620
g9
I61
sg10
VC0235974
p5621
sg12
I20
sg13
Vpancreatic carcinoma
p5622
sg15
I2
sa(dp5623
g9
I235
sg10
VC0001807
p5624
sg12
I14
sg13
Vaggressiveness
p5625
sg15
I1
sa(dp5626
g9
I184
sg10
VC0334094
p5627
sg12
I13
sg13
Vproliferative
p5628
sg15
I1
sasa(dp5629
g2
VTo investigate this possibility, we examined the expression of Sel1L in a series of primary pancreatic carcinomas by immunohistochemistry and characterized the effects of Sel1L overexpression both in vitro and in vivo.
p5630
sg4
(lp5631
(dp5632
g9
I63
sg39
g40
sg12
I5
sg13
VSel1L
p5633
sg15
I1
sa(dp5634
g9
I63
sg39
g40
sg12
I5
sg13
VSel1L
p5635
sg15
I1
sasg6
(lp5636
(dp5637
g9
I103
sg10
VC0007097
p5638
sg12
I10
sg13
Vcarcinomas
p5639
sg15
I1
sasa(dp5640
g2
VIn 74 pancreatic cancers analysed, 36% lacked Sel1L expression, although there was no significant correlation between the expression of Sel1L and any clinicopathologic parameter, including survival.
p5641
sg4
(lp5642
(dp5643
g9
I46
sg39
g40
sg12
I5
sg13
VSel1L
p5644
sg15
I1
sa(dp5645
g9
I46
sg39
g40
sg12
I5
sg13
VSel1L
p5646
sg15
I1
sasg6
(lp5647
(dp5648
g9
I6
sg10
VC0346647
p5649
sg12
I18
sg13
Vpancreatic cancers
p5650
sg15
I2
sasa(dp5651
g2
VOverexpression of SEL1L in stably transfected pancreatic cancer cells caused both a decrease in clonogenicity and anchorage-independent growth as well as a significant increase in the levels of activin A and SMAD4.
p5652
sg4
(lp5653
(dp5654
g9
I208
sg39
g40
sg12
I5
sg13
VSMAD4
p5655
sg15
I1
sa(dp5656
g9
I194
sg39
VP08476
p5657
sg12
I9
sg13
Vactivin A
p5658
sg15
I2
sa(dp5659
g9
I18
sg39
g40
sg12
I5
sg13
VSEL1L
p5660
sg15
I1
sasg6
(lp5661
(dp5662
g9
I46
sg10
VC0235974
p5663
sg12
I17
sg13
Vpancreatic cancer
p5664
sg15
I2
sasa(dp5665
g2
VThus, it can be hypothesized that Sel1L plays an important function in the growth and aggressiveness of pancreatic carcinoma.
p5666
sg4
(lp5667
(dp5668
g9
I34
sg39
g40
sg12
I5
sg13
VSel1L
p5669
sg15
I1
sasg6
(lp5670
(dp5671
g9
I86
sg10
VC0001807
p5672
sg12
I14
sg13
Vaggressiveness
p5673
sg15
I1
sa(dp5674
g9
I104
sg10
VC0235974
p5675
sg12
I20
sg13
Vpancreatic carcinoma
p5676
sg15
I2
sasa(dp5677
g2
VLevels of angiogenic markers bFGF, angiogenin and VEGF in EBC significantly discriminated between 17 individuals with newly detected NSCLC versus stable and exacerbated chronic obstructive pulmonary disease (COPD) patients as well as healthy volunteers.
p5678
sg4
(lp5679
(dp5680
g9
I29
sg39
VP53370
p5681
sg12
I4
sg13
VbFGF
p5682
sg15
I1
sa(dp5683
g9
I35
sg39
VP03950
p5684
sg12
I19
sg13
Vangiogenin and VEGF
p5685
sg15
I3
sasg6
(lp5686
(dp5687
g9
I169
sg10
VC0024117
p5688
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p5689
sg15
I4
sa(dp5690
g9
I208
sg10
VC0024117
p5691
sg12
I4
sg13
VCOPD
p5692
sg15
I1
sa(dp5693
g9
I133
sg10
VC0007131
p5694
sg12
I5
sg13
VNSCLC
p5695
sg15
I1
sasa(dp5696
g2
VHereditary amyloidosis of the Finnish type (HAF, or familial amyloid polyneuropathy type IV) is an autosomal dominant disease that has been described most commonly in the Finnish population but has also been found in some other countries.
p5697
sg4
(lp5698
sg6
(lp5699
(dp5700
g9
I0
sg10
VC0206246
p5701
sg12
I22
sg13
VHereditary amyloidosis
p5702
sg15
I2
sa(dp5703
g9
I52
sg10
VC0206245
p5704
sg12
I31
sg13
Vfamilial amyloid polyneuropathy
p5705
sg15
I3
sasa(dp5706
g2
VPlasma fibrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI and FXII activity levels and C4BP concentrations were determined in 73 patients with non-metastatic colorectal cancer (48 colon and 25 rectum) and in 67 matched control subjects.
p5707
sg4
(lp5708
(dp5709
g9
I34
sg39
VP00451
p5710
sg12
I5
sg13
VFVIII
p5711
sg15
I1
sa(dp5712
g9
I7
sg39
VP22087
p5713
sg12
I10
sg13
Vfibrinogen
p5714
sg15
I1
sa(dp5715
g9
I58
sg39
VP00748
p5716
sg12
I4
sg13
VFXII
p5717
sg15
I1
sa(dp5718
g9
I50
sg39
g40
sg12
I3
sg13
VFXI
p5719
sg15
I1
sa(dp5720
g9
I41
sg39
VP00740
p5721
sg12
I3
sg13
VFIX
p5722
sg15
I1
sa(dp5723
g9
I83
sg39
VP04003
p5724
sg12
I4
sg13
VC4BP
p5725
sg15
I1
sasg6
(lp5726
(dp5727
g9
I143
sg10
VC0948380
p5728
sg12
I28
sg13
Vmetastatic colorectal cancer
p5729
sg15
I3
sasa(dp5730
g2
VMean plasma concentrations of fibrinogen (functional and antigen), FVIII, FIX, FV and C4BP were significantly higher in colorectal cancer patients than in control subjects, while FVII and FXII levels were significantly decreased.
p5731
sg4
(lp5732
(dp5733
g9
I86
sg39
VP04003
p5734
sg12
I4
sg13
VC4BP
p5735
sg15
I1
sa(dp5736
g9
I74
sg39
VP00740
p5737
sg12
I3
sg13
VFIX
p5738
sg15
I1
sa(dp5739
g9
I67
sg39
VP00451
p5740
sg12
I5
sg13
VFVIII
p5741
sg15
I1
sa(dp5742
g9
I188
sg39
VP00748
p5743
sg12
I4
sg13
VFXII
p5744
sg15
I1
sa(dp5745
g9
I30
sg39
VP22087
p5746
sg12
I10
sg13
Vfibrinogen
p5747
sg15
I1
sasg6
(lp5748
(dp5749
g9
I120
sg10
VC1527249
p5750
sg12
I17
sg13
Vcolorectal cancer
p5751
sg15
I2
sasa(dp5752
g2
VIn colorectal cancer patients high plasma fibrinogen, FVIII and FIX levels might represent further risk factors for venous thrombotic complications in the immediate post-surgery period, while decreased FVII and FXII concentrations may be an index of intravascular coagulation activation, still in a subclinical phase.
p5753
sg4
(lp5754
(dp5755
g9
I42
sg39
VP00451
p5756
sg12
I25
sg13
Vfibrinogen, FVIII and FIX
p5757
sg15
I4
sa(dp5758
g9
I211
sg39
VP00748
p5759
sg12
I4
sg13
VFXII
p5760
sg15
I1
sasg6
(lp5761
(dp5762
g9
I3
sg10
VC1527249
p5763
sg12
I17
sg13
Vcolorectal cancer
p5764
sg15
I2
sasa(dp5765
g2
VComplications of PPROM include prematurity, chorioamnionitis, neonatal sepsis, limb position defects, respiratory distress syndrome, pulmonary hypoplasia chronic lung disease, periventricular leukomalacia and intraventricular haemorrhage.A number of different sealing techniques have been employed which aim to restore a physical barrier against infection and encourage the re-accumulation of amniotic fluid.
p5766
sg4
(lp5767
sg6
(lp5768
(dp5769
g9
I62
sg10
VC0456103
p5770
sg12
I15
sg13
Vneonatal sepsis
p5771
sg15
I2
sa(dp5772
g9
I102
sg10
VC0035220
p5773
sg12
I29
sg13
Vrespiratory distress syndrome
p5774
sg15
I3
sa(dp5775
g9
I133
sg10
VC0265783
p5776
sg12
I20
sg13
Vpulmonary hypoplasia
p5777
sg15
I2
sa(dp5778
g9
I209
sg10
VC0240059
p5779
sg12
I28
sg13
Vintraventricular haemorrhage
p5780
sg15
I2
sa(dp5781
g9
I44
sg10
VC0008495
p5782
sg12
I16
sg13
Vchorioamnionitis
p5783
sg15
I1
sa(dp5784
g9
I17
sg10
VC0729264
p5785
sg12
I5
sg13
VPPROM
p5786
sg15
I1
sa(dp5787
g9
I154
sg10
VC0746102
p5788
sg12
I20
sg13
Vchronic lung disease
p5789
sg15
I3
sa(dp5790
g9
I346
sg10
VC0009450
p5791
sg12
I9
sg13
Vinfection
p5792
sg15
I1
sa(dp5793
g9
I176
sg10
VC0023529
p5794
sg12
I28
sg13
Vperiventricular leukomalacia
p5795
sg15
I2
sasa(dp5796
g2
VNL infants were unexposed to PPROM or maternal hypertension, had highest requirement for surfactant, did not develop IVH and periventricular leukomalacia (PVL) and none of them were Caucasian.
p5797
sg4
(lp5798
sg6
(lp5799
(dp5800
g9
I29
sg10
VC0729264
p5801
sg12
I5
sg13
VPPROM
p5802
sg15
I1
sa(dp5803
g9
I125
sg10
VC0023529
p5804
sg12
I28
sg13
Vperiventricular leukomalacia
p5805
sg15
I2
sa(dp5806
g9
I155
sg10
VC0023529
p5807
sg12
I3
sg13
VPVL
p5808
sg15
I1
sa(dp5809
g9
I38
sg10
VC0565599
p5810
sg12
I21
sg13
Vmaternal hypertension
p5811
sg15
I2
sasa(dp5812
g2
VMolecular analysis indicated that the livers of BDNF mutants fed HFD contained elevated levels of peroxisome proliferator-activated receptor alpha (Pparalpha or Ppara as listed in the MGI Database) and fibroblast growth factor 21 (Fgf21) transcripts compared with WTs.
p5813
sg4
(lp5814
(dp5815
g9
I48
sg39
g40
sg12
I12
sg13
VBDNF mutants
p5816
sg15
I2
sa(dp5817
g9
I98
sg39
g40
sg12
I48
sg13
Vperoxisome proliferator-activated receptor alpha
p5818
sg15
I4
sa(dp5819
g9
I148
sg39
g40
sg12
I9
sg13
VPparalpha
p5820
sg15
I1
sasg6
(lp5821
(dp5822
g9
I264
sg10
VC1839736
p5823
sg12
I3
sg13
VWTs
p5824
sg15
I1
sasa(dp5825
g2
VWe measured the cerebrospinal fluid (CSF) and plasma concentrations of interleukin (IL)-1Alfa, IL-1Beta, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-Alfa, TNF-Beta, interferon (IFN)-Gamma, the IL-1 receptor antagonist, and soluble IL-4 receptor (sIL-4r) by ELISA in 12 patients each with acute, monosymptomatic, idiopathic optic neuritis (ON), ON as part of MS, other attack forms of MS, and in neurological control subjects.
p5826
sg4
(lp5827
(dp5828
g9
I105
sg39
VP60568
p5829
sg12
I4
sg13
VIL-2
p5830
sg15
I1
sa(dp5831
g9
I95
sg39
VP01584
p5832
sg12
I8
sg13
VIL-1Beta
p5833
sg15
I1
sa(dp5834
g9
I117
sg39
VP05231
p5835
sg12
I4
sg13
VIL-6
p5836
sg15
I1
sa(dp5837
g9
I164
sg39
VP01375
p5838
sg12
I8
sg13
VTNF-Beta
p5839
sg15
I1
sa(dp5840
g9
I153
sg39
VP01375
p5841
sg12
I3
sg13
VTNF
p5842
sg15
I1
sa(dp5843
g9
I111
sg39
VP05112
p5844
sg12
I4
sg13
VIL-4
p5845
sg15
I1
sa(dp5846
g9
I174
sg39
VP01563
p5847
sg12
I10
sg13
Vinterferon
p5848
sg15
I1
sa(dp5849
g9
I255
sg39
VP40967
p5850
sg12
I6
sg13
VsIL-4r
p5851
sg15
I1
sa(dp5852
g9
I232
sg39
VP40967
p5853
sg12
I21
sg13
Vsoluble IL-4 receptor
p5854
sg15
I3
sa(dp5855
g9
I71
sg39
VP60568
p5856
sg12
I22
sg13
Vinterleukin (IL)-1Alfa
p5857
sg15
I2
sa(dp5858
g9
I130
sg39
VP01375
p5859
sg12
I21
sg13
Vtumor necrosis factor
p5860
sg15
I3
sa(dp5861
g9
I186
sg39
VP01562
p5862
sg12
I3
sg13
VIFN
p5863
sg15
I1
sa(dp5864
g9
I202
sg39
g40
sg12
I13
sg13
VIL-1 receptor
p5865
sg15
I2
sasg6
(lp5866
(dp5867
g9
I348
sg10
VC0029134
p5868
sg12
I2
sg13
VON
p5869
sg15
I1
sa(dp5870
g9
I255
sg10
VC0333873
p5871
sg12
I3
sg13
VsIL
p5872
sg15
I1
sa(dp5873
g9
I348
sg10
VC0029134
p5874
sg12
I2
sg13
VON
p5875
sg15
I1
sa(dp5876
g9
I332
sg10
VC0029134
p5877
sg12
I14
sg13
Voptic neuritis
p5878
sg15
I2
sa(dp5879
g9
I130
sg10
VC0333516
p5880
sg12
I14
sg13
Vtumor necrosis
p5881
sg15
I2
sasa(dp5882
g2
VWe have reported previously that ocular infection of different strains of mice with recombinant herpes simplex virus 1 (HSV-1) constitutively expressing interleukin-2 (IL-2) provokes central nervous system (CNS) demyelination and optic neuropathy, as determined by changes in visual evoked cortical potentials and pathological changes in the optic nerve and CNS, whereas recombinant viruses expressing IL-4, gamma interferon, IL-12p35, IL-12p40, or IL-12p70 do not induce this neuropathy.
p5883
sg4
(lp5884
(dp5885
g9
I168
sg39
VP60568
p5886
sg12
I4
sg13
VIL-2
p5887
sg15
I1
sa(dp5888
g9
I153
sg39
VP60568
p5889
sg12
I13
sg13
Vinterleukin-2
p5890
sg15
I1
sa(dp5891
g9
I408
sg39
VP01579
p5892
sg12
I16
sg13
Vgamma interferon
p5893
sg15
I2
sa(dp5894
g9
I402
sg39
VP05112
p5895
sg12
I4
sg13
VIL-4
p5896
sg15
I1
sasg6
(lp5897
(dp5898
g9
I33
sg10
VC0015403
p5899
sg12
I16
sg13
Vocular infection
p5900
sg15
I2
sa(dp5901
g9
I230
sg10
VC0029132
p5902
sg12
I16
sg13
Voptic neuropathy
p5903
sg15
I2
sa(dp5904
g9
I236
sg10
VC0442874
p5905
sg12
I10
sg13
Vneuropathy
p5906
sg15
I1
sa(dp5907
g9
I96
sg10
VC0019348
p5908
sg12
I14
sg13
Vherpes simplex
p5909
sg15
I2
sa(dp5910
g9
I191
sg10
VC0027769
p5911
sg12
I7
sg13
Vnervous
p5912
sg15
I1
sa(dp5913
g9
I212
sg10
VC0011304
p5914
sg12
I13
sg13
Vdemyelination
p5915
sg15
I1
sasa(dp5916
g2
VThe objective of this study was to detect interleukin-17 (IL-17), interferon-gamma (IFN-gamma), interleukin-4 (IL-4) and forkhead/winged helix transcription factor p3 (Foxp3) protein and gene expression of the optic nerve and to further explore the role of T helper cell subsets such as Th1, Th2, Th17 and Treg in the pathogenesis of optic neuritis in experimental autoimmune encephalomyelitis (EAE).
p5917
sg4
(lp5918
(dp5919
g9
I42
sg39
VP60568
p5920
sg12
I14
sg13
Vinterleukin-17
p5921
sg15
I1
sa(dp5922
g9
I121
sg39
g40
sg12
I45
sg13
Vforkhead/winged helix transcription factor p3
p5923
sg15
I5
sa(dp5924
g9
I58
sg39
VP60568
p5925
sg12
I5
sg13
VIL-17
p5926
sg15
I1
sa(dp5927
g9
I168
sg39
g40
sg12
I5
sg13
VFoxp3
p5928
sg15
I1
sa(dp5929
g9
I84
sg39
VP01579
p5930
sg12
I9
sg13
VIFN-gamma
p5931
sg15
I1
sa(dp5932
g9
I96
sg39
VP05112
p5933
sg12
I13
sg13
Vinterleukin-4
p5934
sg15
I1
sa(dp5935
g9
I66
sg39
VP01579
p5936
sg12
I16
sg13
Vinterferon-gamma
p5937
sg15
I1
sa(dp5938
g9
I111
sg39
VP05112
p5939
sg12
I4
sg13
VIL-4
p5940
sg15
I1
sasg6
(lp5941
(dp5942
g9
I334
sg10
VC0029134
p5943
sg12
I14
sg13
Voptic neuritis
p5944
sg15
I2
sa(dp5945
g9
I395
sg10
VC0014070
p5946
sg12
I3
sg13
VEAE
p5947
sg15
I1
sa(dp5948
g9
I318
sg10
VC0699748
p5949
sg12
I12
sg13
Vpathogenesis
p5950
sg15
I1
sa(dp5951
g9
I365
sg10
VC0443146
p5952
sg12
I10
sg13
Vautoimmune
p5953
sg15
I1
sa(dp5954
g9
I376
sg10
VC0014070
p5955
sg12
I17
sg13
Vencephalomyelitis
p5956
sg15
I1
sasa(dp5957
g2
VIn MS and optic neuritis, IL-4 mRNA expressing cells predominated, followed by TGF-beta- and IFN-gamma-positive cells.
p5958
sg4
(lp5959
(dp5960
g9
I26
sg39
VP05112
p5961
sg12
I9
sg13
VIL-4 mRNA
p5962
sg15
I2
sa(dp5963
g9
I93
sg39
VP01579
p5964
sg12
I9
sg13
VIFN-gamma
p5965
sg15
I1
sa(dp5966
g9
I79
sg39
VP18075
p5967
sg12
I8
sg13
VTGF-beta
p5968
sg15
I1
sasg6
(lp5969
(dp5970
g9
I10
sg10
VC0029134
p5971
sg12
I14
sg13
Voptic neuritis
p5972
sg15
I2
sasa(dp5973
g2
VGKN1, GKN2, and the trefoil factors TFF1 and TFF3 were examined in tissue microarrays from 155 distal gastric adenocarcinomas.
p5974
sg4
(lp5975
(dp5976
g9
I36
sg39
VP04155
p5977
sg12
I4
sg13
VTFF1
p5978
sg15
I1
sa(dp5979
g9
I6
sg39
g40
sg12
I4
sg13
VGKN2
p5980
sg15
I1
sa(dp5981
g9
I20
sg39
VP19883
p5982
sg12
I15
sg13
Vtrefoil factors
p5983
sg15
I2
sa(dp5984
g9
I45
sg39
g40
sg12
I4
sg13
VTFF3
p5985
sg15
I1
sa(dp5986
g9
I0
sg39
g40
sg12
I4
sg13
VGKN1
p5987
sg15
I1
sasg6
(lp5988
(dp5989
g9
I110
sg10
VC0001418
p5990
sg12
I15
sg13
Vadenocarcinomas
p5991
sg15
I1
sasa(dp5992
g2
VLoss of GKN1 and GKN2 expression occurs frequently in gastric adenocarcinomas, especially in the diffuse subtype.
p5993
sg4
(lp5994
(dp5995
g9
I17
sg39
g40
sg12
I4
sg13
VGKN2
p5996
sg15
I1
sa(dp5997
g9
I8
sg39
g40
sg12
I4
sg13
VGKN1
p5998
sg15
I1
sasg6
(lp5999
(dp6000
g9
I62
sg10
VC0001418
p6001
sg12
I15
sg13
Vadenocarcinomas
p6002
sg15
I1
sasa(dp6003
g2
VSince RIs significantly correlate with renal function, they have been proposed to be independent risk factors for CKD progression, besides proteinuria, low GFR and arterial hypertension.
p6004
sg4
(lp6005
sg6
(lp6006
(dp6007
g9
I164
sg10
VC0020538
p6008
sg12
I21
sg13
Varterial hypertension
p6009
sg15
I2
sasa(dp6010
g2
VHigh uterine artery Doppler resistance indexes (RIs) are predictive of placental complications of pregnancy, such as preeclampsia, fetal growth restriction, and stillbirth.
p6011
sg4
(lp6012
sg6
(lp6013
(dp6014
g9
I117
sg10
VC0032914
p6015
sg12
I12
sg13
Vpreeclampsia
p6016
sg15
I1
sa(dp6017
g9
I131
sg10
VC0015934
p6018
sg12
I24
sg13
Vfetal growth restriction
p6019
sg15
I3
sa(dp6020
g9
I161
sg10
VC0595939
p6021
sg12
I10
sg13
Vstillbirth
p6022
sg15
I1
sa(dp6023
g9
I81
sg10
VC0032962
p6024
sg12
I26
sg13
Vcomplications of pregnancy
p6025
sg15
I3
sasa(dp6026
g2
VPatients with hypertension or diabetes mellitus showed higher RIs (p &lt; 0.05) than those without the ailments.
p6027
sg4
(lp6028
sg6
(lp6029
(dp6030
g9
I30
sg10
VC0011849
p6031
sg12
I17
sg13
Vdiabetes mellitus
p6032
sg15
I2
sa(dp6033
g9
I14
sg10
VC0020538
p6034
sg12
I12
sg13
Vhypertension
p6035
sg15
I1
sasa(dp6036
g2
VMyelodysplastic syndrome (MDS) and myeloproliferative disorders are rare in children; they are divided into low-grade MDS (refractory cytopenia of childhood [RCC]), advanced MDS (refractory anemia with excess blasts in transformation), and juvenile myelomonocytic leukemia (JMML), each with different characteristics and management strategies.
p6037
sg4
(lp6038
sg6
(lp6039
(dp6040
g9
I274
sg10
VC0349639
p6041
sg12
I4
sg13
VJMML
p6042
sg15
I1
sa(dp6043
g9
I35
sg10
VC0027022
p6044
sg12
I28
sg13
Vmyeloproliferative disorders
p6045
sg15
I2
sa(dp6046
g9
I123
sg10
VC2826323
p6047
sg12
I33
sg13
Vrefractory cytopenia of childhood
p6048
sg15
I4
sa(dp6049
g9
I26
sg10
VC0265219
p6050
sg12
I3
sg13
VMDS
p6051
sg15
I1
sa(dp6052
g9
I240
sg10
VC0349639
p6053
sg12
I32
sg13
Vjuvenile myelomonocytic leukemia
p6054
sg15
I3
sa(dp6055
g9
I158
sg10
VC0007134
p6056
sg12
I3
sg13
VRCC
p6057
sg15
I1
sa(dp6058
g9
I179
sg10
VC0280028
p6059
sg12
I54
sg13
Vrefractory anemia with excess blasts in transformation
p6060
sg15
I7
sa(dp6061
g9
I0
sg10
VC3463824
p6062
sg12
I24
sg13
VMyelodysplastic syndrome
p6063
sg15
I2
sa(dp6064
g9
I26
sg10
VC0265219
p6065
sg12
I3
sg13
VMDS
p6066
sg15
I1
sa(dp6067
g9
I26
sg10
VC0265219
p6068
sg12
I3
sg13
VMDS
p6069
sg15
I1
sasa(dp6070
g2
VThus, genetic ablation or pharmacologic inhibition of Shp2 suppresses the leukemogenic effect of Pten loss, yet simultaneously induces severe anemia in mice with Pten deficiency in blood cells.
p6071
sg4
(lp6072
(dp6073
g9
I97
sg39
VP60484
p6074
sg12
I4
sg13
VPten
p6075
sg15
I1
sa(dp6076
g9
I97
sg39
VP60484
p6077
sg12
I9
sg13
VPten loss
p6078
sg15
I2
sa(dp6079
g9
I54
sg39
g40
sg12
I4
sg13
VShp2
p6080
sg15
I1
sasg6
(lp6081
(dp6082
g9
I97
sg10
VC3272693
p6083
sg12
I9
sg13
VPten loss
p6084
sg15
I2
sa(dp6085
g9
I135
sg10
VC0238644
p6086
sg12
I13
sg13
Vsevere anemia
p6087
sg15
I2
sasa(dp6088
g2
VSurprisingly, the Shp2 and Pten double-knockout mice suffered lethal anemia, a phenotype that reveals previously unappreciated cooperative roles of Pten and Shp2 in erythropoiesis.
p6089
sg4
(lp6090
(dp6091
g9
I27
sg39
VP60484
p6092
sg12
I4
sg13
VPten
p6093
sg15
I1
sa(dp6094
g9
I18
sg39
g40
sg12
I4
sg13
VShp2
p6095
sg15
I1
sa(dp6096
g9
I148
sg39
VP60484
p6097
sg12
I13
sg13
VPten and Shp2
p6098
sg15
I3
sasg6
(lp6099
(dp6100
g9
I53
sg10
VC0683278
p6101
sg12
I8
sg13
Vsuffered
p6102
sg15
I1
sa(dp6103
g9
I69
sg10
VC0002871
p6104
sg12
I6
sg13
Vanemia
p6105
sg15
I1
sasa(dp6106
g2
VConsistently, treatment of Pten-deficient mice with a specific Shp2 inhibitor suppressed myeloproliferative neoplasm while causing anemia.
p6107
sg4
(lp6108
(dp6109
g9
I63
sg39
g40
sg12
I4
sg13
VShp2
p6110
sg15
I1
sasg6
(lp6111
(dp6112
g9
I89
sg10
VC1292778
p6113
sg12
I27
sg13
Vmyeloproliferative neoplasm
p6114
sg15
I2
sa(dp6115
g9
I131
sg10
VC0002871
p6116
sg12
I6
sg13
Vanemia
p6117
sg15
I1
sasa(dp6118
g2
VInfants with non-metabolic disorders (n = 34); 10 (three neuroblastoma [NBL], three brain tumor, two acute meylogenous leukemia [AML], one rhabdomyosarcoma, and one retinoblastoma) received auto HSCT, and 24 (eight hemophagocytic lymphohistiocytosis [HLH], four juvenile meylomonocytic leukemia [JMML], four Wiscott-Aldrych Syndrome [WAS], three acute lymphoblastic leukemia [ALL], two AML, one severe aplastic anemia [SAA], one chronic granulomatous disease [CGD], and one amegakaryocytic thrombocytopenia) received allo HSCT.
p6119
sg4
(lp6120
sg6
(lp6121
(dp6122
g9
I395
sg10
VC1883018
p6123
sg12
I22
sg13
Vsevere aplastic anemia
p6124
sg15
I3
sa(dp6125
g9
I474
sg10
VC0398639
p6126
sg12
I32
sg13
Vamegakaryocytic thrombocytopenia
p6127
sg15
I2
sa(dp6128
g9
I215
sg10
VC0024291
p6129
sg12
I34
sg13
Vhemophagocytic lymphohistiocytosis
p6130
sg15
I2
sa(dp6131
g9
I324
sg10
VC0039082
p6132
sg12
I8
sg13
VSyndrome
p6133
sg15
I1
sa(dp6134
g9
I460
sg10
VC0018203
p6135
sg12
I3
sg13
VCGD
p6136
sg15
I1
sa(dp6137
g9
I129
sg10
VC0023467
p6138
sg12
I3
sg13
VAML
p6139
sg15
I1
sa(dp6140
g9
I346
sg10
VC1961102
p6141
sg12
I28
sg13
Vacute lymphoblastic leukemia
p6142
sg15
I3
sa(dp6143
g9
I139
sg10
VC0035412
p6144
sg12
I16
sg13
Vrhabdomyosarcoma
p6145
sg15
I1
sa(dp6146
g9
I17
sg10
VC0025517
p6147
sg12
I19
sg13
Vmetabolic disorders
p6148
sg15
I2
sa(dp6149
g9
I119
sg10
VC0023418
p6150
sg12
I8
sg13
Vleukemia
p6151
sg15
I1
sa(dp6152
g9
I84
sg10
VC0006118
p6153
sg12
I11
sg13
Vbrain tumor
p6154
sg15
I2
sa(dp6155
g9
I119
sg10
VC0023418
p6156
sg12
I8
sg13
Vleukemia
p6157
sg15
I1
sa(dp6158
g9
I165
sg10
VC0035335
p6159
sg12
I14
sg13
Vretinoblastoma
p6160
sg15
I1
sa(dp6161
g9
I429
sg10
VC0018203
p6162
sg12
I29
sg13
Vchronic granulomatous disease
p6163
sg15
I3
sa(dp6164
g9
I129
sg10
VC0023467
p6165
sg12
I3
sg13
VAML
p6166
sg15
I1
sa(dp6167
g9
I296
sg10
VC0349639
p6168
sg12
I4
sg13
VJMML
p6169
sg15
I1
sa(dp6170
g9
I57
sg10
VC0027819
p6171
sg12
I13
sg13
Vneuroblastoma
p6172
sg15
I1
sa(dp6173
g9
I251
sg10
VC0024291
p6174
sg12
I3
sg13
VHLH
p6175
sg15
I1
sasa(dp6176
g2
VThe human choroideremia-like (CHML) gene and a locus for Usher syndrome type 2 (USH2) were recently mapped to the 1q31-qter region employing physical mapping and genetic linkage studies, respectively.
p6177
sg4
(lp6178
(dp6179
g9
I57
sg39
g40
sg12
I21
sg13
VUsher syndrome type 2
p6180
sg15
I4
sa(dp6181
g9
I80
sg39
g40
sg12
I4
sg13
VUSH2
p6182
sg15
I1
sa(dp6183
g9
I30
sg39
VP26374
p6184
sg12
I4
sg13
VCHML
p6185
sg15
I1
sa(dp6186
g9
I10
sg39
VP26374
p6187
sg12
I18
sg13
Vchoroideremia-like
p6188
sg15
I1
sasg6
(lp6189
(dp6190
g9
I57
sg10
VC0339534
p6191
sg12
I21
sg13
VUsher syndrome type 2
p6192
sg15
I4
sa(dp6193
g9
I80
sg10
VC0339534
p6194
sg12
I4
sg13
VUSH2
p6195
sg15
I1
sa(dp6196
g9
I10
sg10
VC0008525
p6197
sg12
I13
sg13
Vchoroideremia
p6198
sg15
I1
sasa(dp6199
g2
VTo investigate a possible role of the CHML gene in the pathogenesis of USH2, we investigated 10 Dutch and 9 Danish USH2 patients for point mutations in the open reading frame of the CHML gene.
p6200
sg4
(lp6201
(dp6202
g9
I71
sg39
g40
sg12
I4
sg13
VUSH2
p6203
sg15
I1
sa(dp6204
g9
I38
sg39
VP26374
p6205
sg12
I9
sg13
VCHML gene
p6206
sg15
I2
sa(dp6207
g9
I38
sg39
VP26374
p6208
sg12
I9
sg13
VCHML gene
p6209
sg15
I2
sasg6
(lp6210
(dp6211
g9
I55
sg10
VC0699748
p6212
sg12
I12
sg13
Vpathogenesis
p6213
sg15
I1
sasa(dp6214
g2
VThese results suggest that CHML is not involved in the pathogenesis of USH2.
p6215
sg4
(lp6216
(dp6217
g9
I27
sg39
VP26374
p6218
sg12
I4
sg13
VCHML
p6219
sg15
I1
sa(dp6220
g9
I71
sg39
g40
sg12
I4
sg13
VUSH2
p6221
sg15
I1
sasg6
(lp6222
(dp6223
g9
I55
sg10
VC0699748
p6224
sg12
I12
sg13
Vpathogenesis
p6225
sg15
I1
sasa(dp6226
g2
VWe hypothesized that the Hrad17 may be expressed in thymoma, especially in invasive thymoma.
p6227
sg4
(lp6228
(dp6229
g9
I25
sg39
g40
sg12
I6
sg13
VHrad17
p6230
sg15
I1
sasg6
(lp6231
(dp6232
g9
I75
sg10
VC0278846
p6233
sg12
I16
sg13
Vinvasive thymoma
p6234
sg15
I2
sa(dp6235
g9
I52
sg10
VC0040100
p6236
sg12
I7
sg13
Vthymoma
p6237
sg15
I1
sasa(dp6238
g2
VWe attempted to determine the influence of Hrad17 expression on clinicopathological features for patients with thymoma who had undergone surgery.
p6239
sg4
(lp6240
(dp6241
g9
I43
sg39
g40
sg12
I6
sg13
VHrad17
p6242
sg15
I1
sasg6
(lp6243
(dp6244
g9
I111
sg10
VC0040100
p6245
sg12
I7
sg13
Vthymoma
p6246
sg15
I1
sasa(dp6247
g2
VExpression of Hrad17 messenger ribonucleic acid (RNA) was evaluated by reverse transcription-polymerase chain reaction using a LightCycler in 38 thymomas and 10 adjacent histologically normal thymus samples from patients for whom follow-up data was available.
p6248
sg4
(lp6249
(dp6250
g9
I14
sg39
g40
sg12
I16
sg13
VHrad17 messenger
p6251
sg15
I2
sasg6
(lp6252
(dp6253
g9
I145
sg10
VC0040100
p6254
sg12
I8
sg13
Vthymomas
p6255
sg15
I1
sasa(dp6256
g2
VNo relationship was seen between Hrad17 gene expression and age, gender, or pathological thymoma subtypes.
p6257
sg4
(lp6258
(dp6259
g9
I33
sg39
g40
sg12
I11
sg13
VHrad17 gene
p6260
sg15
I2
sasg6
(lp6261
(dp6262
g9
I89
sg10
VC0040100
p6263
sg12
I7
sg13
Vthymoma
p6264
sg15
I1
sasa(dp6265
g2
VHrad17 mRNA expression in invasive thymomas (stage II-IV, 10.067 +/- 5.293) was significantly higher than that in stage I thymomas (5.193 +/- 4.485, p = 0.0168).
p6266
sg4
(lp6267
(dp6268
g9
I0
sg39
g40
sg12
I11
sg13
VHrad17 mRNA
p6269
sg15
I2
sasg6
(lp6270
(dp6271
g9
I35
sg10
VC0040100
p6272
sg12
I8
sg13
Vthymomas
p6273
sg15
I1
sa(dp6274
g9
I35
sg10
VC0040100
p6275
sg12
I8
sg13
Vthymomas
p6276
sg15
I1
sasa(dp6277
g2
VImmunohistochemistry showed that Hrad17 protein was highly expressed in invasive thymoma tumor tissue but not within the normal thymus tissue.
p6278
sg4
(lp6279
(dp6280
g9
I33
sg39
g40
sg12
I14
sg13
VHrad17 protein
p6281
sg15
I2
sasg6
(lp6282
(dp6283
g9
I72
sg10
VC0278846
p6284
sg12
I16
sg13
Vinvasive thymoma
p6285
sg15
I2
sa(dp6286
g9
I89
sg10
VC0027651
p6287
sg12
I5
sg13
Vtumor
p6288
sg15
I1
sasa(dp6289
g2
VHrad17 was highly expressed in invasive thymoma.
p6290
sg4
(lp6291
(dp6292
g9
I0
sg39
g40
sg12
I6
sg13
VHrad17
p6293
sg15
I1
sasg6
(lp6294
(dp6295
g9
I31
sg10
VC0278846
p6296
sg12
I16
sg13
Vinvasive thymoma
p6297
sg15
I2
sasa(dp6298
g2
VIn induced apical periodontitis, osteoblastic expression of SIRT6 was significantly suppressed (P = 0.001) which was associated with significantly elevated levels of LDHA (P = 0.003) and 8-OHdG (P = 0.004) and significantly enhanced recruitment of macrophages (P = 0.004).
p6299
sg4
(lp6300
(dp6301
g9
I166
sg39
VP00338
p6302
sg12
I4
sg13
VLDHA
p6303
sg15
I1
sasg6
(lp6304
(dp6305
g9
I233
sg10
VC0271510
p6306
sg12
I11
sg13
Vrecruitment
p6307
sg15
I1
sa(dp6308
g9
I11
sg10
VC0031030
p6309
sg12
I20
sg13
Vapical periodontitis
p6310
sg15
I2
sasa(dp6311
g2
VThe main objective of this work was to evaluate a new therapeutic strategy against a colitis-related colorectal cancer in vivo and in vitro by targeting mTOR-signaling and lactate dehydrogenase A.
p6312
sg4
(lp6313
(dp6314
g9
I85
sg39
VP31749
p6315
sg12
I33
sg13
Vcolitis-related colorectal cancer
p6316
sg15
I3
sa(dp6317
g9
I153
sg39
VP42345
p6318
sg12
I4
sg13
VmTOR
p6319
sg15
I1
sa(dp6320
g9
I172
sg39
VP49366
p6321
sg12
I23
sg13
Vlactate dehydrogenase A
p6322
sg15
I3
sasg6
(lp6323
(dp6324
g9
I85
sg10
VC0009319
p6325
sg12
I7
sg13
Vcolitis
p6326
sg15
I1
sa(dp6327
g9
I101
sg10
VC1527249
p6328
sg12
I17
sg13
Vcolorectal cancer
p6329
sg15
I2
sasa(dp6330
g2
VThere were striking laboratory abnormalities in the groups diagnosed with toxic hepatitis (mean peak values: AST 775 +/- 464 U/L, ALT 400 +/- 447 U/L, ALP 767 +/- 408 U/L, LDH 1,469 +/- 779 U/L).
p6331
sg4
(lp6332
(dp6333
g9
I172
sg39
g40
sg12
I5
sg13
VLDH 1
p6334
sg15
I2
sasg6
(lp6335
(dp6336
g9
I80
sg10
VC0019159
p6337
sg12
I9
sg13
Vhepatitis
p6338
sg15
I1
sasa(dp6339
g2
VTo determine Lactate Dehydrogenase Activity (LDHA) in whole saliva in individuals with periodontal disease and the effect of ultrasonic scaling on this enzyme activity.
p6340
sg4
(lp6341
(dp6342
g9
I45
sg39
VP00338
p6343
sg12
I4
sg13
VLDHA
p6344
sg15
I1
sa(dp6345
g9
I13
sg39
VP00338
p6346
sg12
I30
sg13
VLactate Dehydrogenase Activity
p6347
sg15
I3
sasg6
(lp6348
(dp6349
g9
I87
sg10
VC0031090
p6350
sg12
I19
sg13
Vperiodontal disease
p6351
sg15
I2
sasa(dp6352
g2
VLDH-1 activity was detected to be significantly higher in the sterile cirrhotic ascites when compared with spontaneous bacterial peritonitis, malignant ascites, tuberculous ascites and congestive heart failure-related ascites.
p6353
sg4
(lp6354
(dp6355
g9
I0
sg39
g40
sg12
I5
sg13
VLDH-1
p6356
sg15
I1
sasg6
(lp6357
(dp6358
g9
I107
sg10
VC0275551
p6359
sg12
I33
sg13
Vspontaneous bacterial peritonitis
p6360
sg15
I3
sa(dp6361
g9
I62
sg10
VC0678108
p6362
sg12
I7
sg13
Vsterile
p6363
sg15
I1
sa(dp6364
g9
I185
sg10
VC0018802
p6365
sg12
I24
sg13
Vcongestive heart failure
p6366
sg15
I3
sa(dp6367
g9
I142
sg10
VC0220656
p6368
sg12
I17
sg13
Vmalignant ascites
p6369
sg15
I2
sa(dp6370
g9
I161
sg10
VC0275919
p6371
sg12
I19
sg13
Vtuberculous ascites
p6372
sg15
I2
sasa(dp6373
g2
VHirudin variants (HV1 and HV2) were produced in infected insect cells as secreted proteins by joining their coding sequences to the leader peptide sequence of the vescicular stomatitis virus G protein.
p6374
sg4
(lp6375
(dp6376
g9
I18
sg39
g40
sg12
I3
sg13
VHV1
p6377
sg15
I1
sa(dp6378
g9
I0
sg39
VP26640
p6379
sg12
I16
sg13
VHirudin variants
p6380
sg15
I2
sasg6
(lp6381
(dp6382
g9
I174
sg10
VC0038362
p6383
sg12
I10
sg13
Vstomatitis
p6384
sg15
I1
sasa(dp6385
g2
VMacrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in systemic, autoimmune, and inflammatory diseases, such as obesity, rheumatoid arthritis, and systemic lupus erythematosus.
p6386
sg4
(lp6387
sg6
(lp6388
(dp6389
g9
I144
sg10
VC0028754
p6390
sg12
I7
sg13
Vobesity
p6391
sg15
I1
sa(dp6392
g9
I97
sg10
VC0443146
p6393
sg12
I10
sg13
Vautoimmune
p6394
sg15
I1
sa(dp6395
g9
I179
sg10
VC0024141
p6396
sg12
I28
sg13
Vsystemic lupus erythematosus
p6397
sg15
I3
sa(dp6398
g9
I153
sg10
VC0003873
p6399
sg12
I20
sg13
Vrheumatoid arthritis
p6400
sg15
I2
sasa(dp6401
g2
VTo systematically review evidence regarding the relationship between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis (RA), and the association between MIF gene polymorphisms and RA susceptibility.
p6402
sg4
(lp6403
(dp6404
g9
I192
sg39
VP05109
p6405
sg12
I8
sg13
VMIF gene
p6406
sg15
I2
sasg6
(lp6407
(dp6408
g9
I159
sg10
VC0003873
p6409
sg12
I2
sg13
VRA
p6410
sg15
I1
sa(dp6411
g9
I159
sg10
VC0003873
p6412
sg12
I2
sg13
VRA
p6413
sg15
I1
sa(dp6414
g9
I137
sg10
VC0003873
p6415
sg12
I20
sg13
Vrheumatoid arthritis
p6416
sg15
I2
sasa(dp6417
g2
VTo investigate the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of ankylosing spondylitis (AS).
p6418
sg4
(lp6419
sg6
(lp6420
(dp6421
g9
I95
sg10
VC0038013
p6422
sg12
I22
sg13
Vankylosing spondylitis
p6423
sg15
I2
sa(dp6424
g9
I79
sg10
VC0699748
p6425
sg12
I12
sg13
Vpathogenesis
p6426
sg15
I1
sa(dp6427
g9
I119
sg10
VC0038013
p6428
sg12
I2
sg13
VAS
p6429
sg15
I1
sasa(dp6430
g2
VRheumatoid SAAT secreted more adiponectin and macrophage migration inhibitory factor (MIF) than respective osteoarthritis tissue.
p6431
sg4
(lp6432
(dp6433
g9
I86
sg39
VP05109
p6434
sg12
I3
sg13
VMIF
p6435
sg15
I1
sa(dp6436
g9
I30
sg39
g40
sg12
I54
sg13
Vadiponectin and macrophage migration inhibitory factor
p6437
sg15
I6
sasg6
(lp6438
(dp6439
g9
I107
sg10
VC0029408
p6440
sg12
I14
sg13
Vosteoarthritis
p6441
sg15
I1
sasa(dp6442
g2
VMacrophage migration inhibitory factor (MIF) has emerged as a promising drug target in diseases including sepsis, rheumatoid arthritis, and cancer.
p6443
sg4
(lp6444
sg6
(lp6445
(dp6446
g9
I114
sg10
VC0003873
p6447
sg12
I20
sg13
Vrheumatoid arthritis
p6448
sg15
I2
sa(dp6449
g9
I140
sg10
VC0006826
p6450
sg12
I6
sg13
Vcancer
p6451
sg15
I1
sa(dp6452
g9
I106
sg10
VC0243026
p6453
sg12
I6
sg13
Vsepsis
p6454
sg15
I1
sasa(dp6455
g2
VMacrophage migration inhibitory factor (MIF) and vascular endothelial growth factor (VEGF), as crucial parameters of angiogenesis and inflammation, were evaluated to identify the role of cyclic citrullinated peptide antibodies (anti-CCP) during angiogenesis in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
p6456
sg4
(lp6457
(dp6458
g9
I49
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p6459
sg15
I4
sa(dp6460
g9
I228
sg39
VP07320
p6461
sg12
I8
sg13
Vanti-CCP
p6462
sg15
I1
sa(dp6463
g9
I85
sg39
g40
sg12
I4
sg13
VVEGF
p6464
sg15
I1
sasg6
(lp6465
(dp6466
g9
I261
sg10
VC0003873
p6467
sg12
I20
sg13
Vrheumatoid arthritis
p6468
sg15
I2
sa(dp6469
g9
I134
sg10
VC0021368
p6470
sg12
I12
sg13
Vinflammation
p6471
sg15
I1
sa(dp6472
g9
I283
sg10
VC0003873
p6473
sg12
I2
sg13
VRA
p6474
sg15
I1
sa(dp6475
g9
I312
sg10
VC1519176
p6476
sg12
I3
sg13
VPsA
p6477
sg15
I1
sa(dp6478
g9
I291
sg10
VC0003872
p6479
sg12
I19
sg13
Vpsoriatic arthritis
p6480
sg15
I2
sa(dp6481
g9
I233
sg10
VC1832526
p6482
sg12
I3
sg13
VCCP
p6483
sg15
I1
sasa(dp6484
g2
VThe aim of this study was to search for any difference between the serum levels of OPG, FGF-23, and vitamin D in patients with hypogonadism and the healthy controls.
p6485
sg4
(lp6486
(dp6487
g9
I83
sg39
g40
sg12
I3
sg13
VOPG
p6488
sg15
I1
sa(dp6489
g9
I88
sg39
g40
sg12
I6
sg13
VFGF-23
p6490
sg15
I1
sasg6
(lp6491
(dp6492
g9
I127
sg10
VC0020619
p6493
sg12
I12
sg13
Vhypogonadism
p6494
sg15
I1
sasa(dp6495
g2
VThese include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
p6496
sg4
(lp6497
(dp6498
g9
I120
sg39
g40
sg12
I5
sg13
VFGF10
p6499
sg15
I1
sa(dp6500
g9
I277
sg39
g40
sg12
I5
sg13
VFGF23
p6501
sg15
I1
sa(dp6502
g9
I38
sg39
VP55075
p6503
sg12
I4
sg13
VFGF8
p6504
sg15
I1
sa(dp6505
g9
I212
sg39
g40
sg12
I5
sg13
VFGF14
p6506
sg15
I1
sa(dp6507
g9
I101
sg39
VP31371
p6508
sg12
I4
sg13
VFGF9
p6509
sg15
I1
sa(dp6510
g9
I14
sg39
VP11487
p6511
sg12
I4
sg13
VFGF3
p6512
sg15
I1
sasg6
(lp6513
(dp6514
g9
I254
sg10
VC0030567
p6515
sg12
I17
sg13
VParkinson disease
p6516
sg15
I2
sa(dp6517
g9
I29
sg10
VC0243065
p6518
sg12
I7
sg13
Vaplasia
p6519
sg15
I1
sa(dp6520
g9
I171
sg10
VC0265269
p6521
sg12
I39
sg13
Vlacrimo-auriculo-dento-digital syndrome
p6522
sg15
I2
sa(dp6523
g9
I46
sg10
VC0158646
p6524
sg12
I16
sg13
Vcleft lip/palate
p6525
sg15
I2
sa(dp6526
g9
I309
sg10
VC1704375
p6527
sg12
I24
sg13
Vhypophosphatemic rickets
p6528
sg15
I2
sa(dp6529
g9
I286
sg10
VC0263628
p6530
sg12
I18
sg13
Vtumoral calcinosis
p6531
sg15
I2
sa(dp6532
g9
I109
sg10
VC0007097
p6533
sg12
I9
sg13
Vcarcinoma
p6534
sg15
I1
sa(dp6535
g9
I29
sg10
VC0243065
p6536
sg12
I7
sg13
Vaplasia
p6537
sg15
I1
sa(dp6538
g9
I70
sg10
VC0022735
p6539
sg12
I29
sg13
Vhypogonadotropic hypogonadism
p6540
sg15
I2
sa(dp6541
g9
I221
sg10
VC0087012
p6542
sg12
I22
sg13
Vspinocerebellar ataxia
p6543
sg15
I2
sasa(dp6544
g2
VRecent studies using genetically modified mice, such as FGF23-/- and Klotho-/- mice that exhibit altered mineral homeostasis due to a high vitamin D activity showed features of premature aging that include retarded growth, osteoporosis, atherosclerosis, ectopic calcification, immunological deficiency, skin and general organ atrophy, hypogonadism and short lifespan.
p6545
sg4
(lp6546
(dp6547
g9
I56
sg39
g40
sg12
I5
sg13
VFGF23
p6548
sg15
I1
sasg6
(lp6549
(dp6550
g9
I326
sg10
VC0333641
p6551
sg12
I7
sg13
Vatrophy
p6552
sg15
I1
sa(dp6553
g9
I335
sg10
VC0020619
p6554
sg12
I12
sg13
Vhypogonadism
p6555
sg15
I1
sa(dp6556
g9
I206
sg10
VC0151686
p6557
sg12
I15
sg13
Vretarded growth
p6558
sg15
I2
sa(dp6559
g9
I223
sg10
VC0029456
p6560
sg12
I12
sg13
Vosteoporosis
p6561
sg15
I1
sa(dp6562
g9
I237
sg10
VC0004153
p6563
sg12
I15
sg13
Vatherosclerosis
p6564
sg15
I1
sa(dp6565
g9
I177
sg10
VC0231341
p6566
sg12
I15
sg13
Vpremature aging
p6567
sg15
I2
sasa(dp6568
g2
VMoreover, Fgf23(-/-)/klotho(-/-) mice show soft tissue and vascular calcification, severe muscle wasting, hypogonadism, pulmonary emphysema, distention of intestinal wall, and skin atrophy, all of which are also seen in Fgf23(-/-) and klotho(-/-) mice.
p6569
sg4
(lp6570
sg6
(lp6571
(dp6572
g9
I176
sg10
VC0151514
p6573
sg12
I12
sg13
Vskin atrophy
p6574
sg15
I2
sa(dp6575
g9
I141
sg10
VC0012359
p6576
sg12
I10
sg13
Vdistention
p6577
sg15
I1
sa(dp6578
g9
I120
sg10
VC0034067
p6579
sg12
I19
sg13
Vpulmonary emphysema
p6580
sg15
I2
sa(dp6581
g9
I59
sg10
VC0342649
p6582
sg12
I22
sg13
Vvascular calcification
p6583
sg15
I2
sa(dp6584
g9
I90
sg10
VC0026846
p6585
sg12
I14
sg13
Vmuscle wasting
p6586
sg15
I2
sa(dp6587
g9
I106
sg10
VC0020619
p6588
sg12
I12
sg13
Vhypogonadism
p6589
sg15
I1
sasa(dp6590
g2
VRecent studies using genetically altered mouse models, such as in Fgf-23(-/-) and klotho mutant mice, that exhibit altered mineral ion metabolism due to high vitamin D activities showed features of premature aging that include atherosclerosis, emphysema, osteopenia/osteoporosis, hypogonadism, soft tissue calcifications and generalized atrophy of organs; the pathologic effects of vitamin D in these mouse models are obvious, as diminution or genetic ablation of the vitamin D pathway ameliorated most of the above-mentioned phenotypes, by reversing mineral ion metabolism, and the resultant effect being prolonged survival of the mutant mice.
p6591
sg4
(lp6592
sg6
(lp6593
(dp6594
g9
I89
sg10
VC0596988
p6595
sg12
I6
sg13
Vmutant
p6596
sg15
I1
sa(dp6597
g9
I244
sg10
VC0013990
p6598
sg12
I9
sg13
Vemphysema
p6599
sg15
I1
sa(dp6600
g9
I280
sg10
VC0020619
p6601
sg12
I12
sg13
Vhypogonadism
p6602
sg15
I1
sa(dp6603
g9
I89
sg10
VC0596988
p6604
sg12
I6
sg13
Vmutant
p6605
sg15
I1
sa(dp6606
g9
I255
sg10
VC0262586
p6607
sg12
I23
sg13
Vosteopenia/osteoporosis
p6608
sg15
I1
sa(dp6609
g9
I337
sg10
VC0333641
p6610
sg12
I7
sg13
Vatrophy
p6611
sg15
I1
sa(dp6612
g9
I227
sg10
VC0004153
p6613
sg12
I15
sg13
Vatherosclerosis
p6614
sg15
I1
sa(dp6615
g9
I198
sg10
VC0231341
p6616
sg12
I15
sg13
Vpremature aging
p6617
sg15
I2
sasa(dp6618
g2
VClinical, cytogenetic and molecular features of acute myeloid leukemia with a MLL-SEPT5 fusion gene are reviewed.
p6619
sg4
(lp6620
(dp6621
g9
I82
sg39
g40
sg12
I5
sg13
VSEPT5
p6622
sg15
I1
sa(dp6623
g9
I78
sg39
g40
sg12
I3
sg13
VMLL
p6624
sg15
I1
sasg6
(lp6625
(dp6626
g9
I48
sg10
VC0023467
p6627
sg12
I22
sg13
Vacute myeloid leukemia
p6628
sg15
I3
sasa(dp6629
g2
VThe MLL-LCX fusion protein lacked a CXXC domain of LCX, but retained an alpha-helical coiled-coil region at the COOH terminus, similar to MLL-SEPTING, MLL-CDCREL1, MLL-AF1p/Eps15, and MLL-AF6, which suggests that these fusion proteins are involved in the pathogenesis of 11q23-associated leukemia through similar mechanisms.
p6630
sg4
(lp6631
(dp6632
g9
I4
sg39
g40
sg12
I22
sg13
VMLL-LCX fusion protein
p6633
sg15
I3
sa(dp6634
g9
I173
sg39
VP42566
p6635
sg12
I5
sg13
VEps15
p6636
sg15
I1
sa(dp6637
g9
I155
sg39
g40
sg12
I7
sg13
VCDCREL1
p6638
sg15
I1
sa(dp6639
g9
I4
sg39
g40
sg12
I3
sg13
VMLL
p6640
sg15
I1
sa(dp6641
g9
I4
sg39
g40
sg12
I3
sg13
VMLL
p6642
sg15
I1
sa(dp6643
g9
I188
sg39
VP55196
p6644
sg12
I3
sg13
VAF6
p6645
sg15
I1
sa(dp6646
g9
I138
sg39
g40
sg12
I11
sg13
VMLL-SEPTING
p6647
sg15
I1
sa(dp6648
g9
I168
sg39
VP42566
p6649
sg12
I4
sg13
VAF1p
p6650
sg15
I1
sa(dp6651
g9
I4
sg39
g40
sg12
I3
sg13
VMLL
p6652
sg15
I1
sasg6
(lp6653
(dp6654
g9
I255
sg10
VC0699748
p6655
sg12
I12
sg13
Vpathogenesis
p6656
sg15
I1
sa(dp6657
g9
I288
sg10
VC0023418
p6658
sg12
I8
sg13
Vleukemia
p6659
sg15
I1
sasa(dp6660
g2
VWe also investigated TG101348 activity against feeder cells and observed that STAT5 phosphorylation, granulocyte macrophage colony-stimulating factor, and interleukin 6 levels decreased, indicating reduced cytokine production in HS-5 cells treated with TG101348.
p6661
sg4
(lp6662
(dp6663
g9
I155
sg39
VP05231
p6664
sg12
I13
sg13
Vinterleukin 6
p6665
sg15
I2
sa(dp6666
g9
I101
sg39
VP04141
p6667
sg12
I48
sg13
Vgranulocyte macrophage colony-stimulating factor
p6668
sg15
I4
sa(dp6669
g9
I78
sg39
VP42229
p6670
sg12
I5
sg13
VSTAT5
p6671
sg15
I1
sasg6
(lp6672
sa(dp6673
g2
VIn the present study, we examined the impact of cytoplasmic/mitochondrial localization of p33ING1b in oral squamous cell carcinoma (OSCC) patient samples and explored the therapeutic potential of adenovirally-overexpressed p33ING1b in OSCC cell lines in combination with ionizing radiation (IR) treatment.
p6674
sg4
(lp6675
sg6
(lp6676
(dp6677
g9
I102
sg10
VC0007137
p6678
sg12
I28
sg13
Voral squamous cell carcinoma
p6679
sg15
I4
sa(dp6680
g9
I132
sg10
VC0007137
p6681
sg12
I4
sg13
VOSCC
p6682
sg15
I1
sa(dp6683
g9
I132
sg10
VC0007137
p6684
sg12
I4
sg13
VOSCC
p6685
sg15
I1
sasa(dp6686
g2
VIn contrast with previous reports, we found that p33ING1b protein and mRNA levels are higher in OSCC compared to normal epithelial cells.
p6687
sg4
(lp6688
sg6
(lp6689
sa(dp6690
g2
VIn OSCC patient samples, higher levels of intra-tumoral cytoplasmic p33ING1b correlated with increased apoptotic markers and significantly better patient survival.
p6691
sg4
(lp6692
sg6
(lp6693
sa(dp6694
g2
VIR treatment induced p33ING1b translocation to the mitochondria and adenoviral-p33ING1b synergized with IR to kill OSCC cells.
p6695
sg4
(lp6696
sg6
(lp6697
(dp6698
g9
I30
sg10
VC0040715
p6699
sg12
I13
sg13
Vtranslocation
p6700
sg15
I1
sasa(dp6701
g2
VOur results identify a novel functional relationship between cytoplasmic p33ING1b and patient survival and highlight the potential for the use of p33ING1b as a therapeutic agent in combination with adjuvant radiotherapy in OSCC.
p6702
sg4
(lp6703
sg6
(lp6704
sa(dp6705
g2
VSince loss of heterozygosity at 13q34 has been reported in squamous cell carcinoma of head and neck, we screened for mutations in ING1 by polymerase chain reaction-single strand conformation polymorphism in 71 oral squamous cell carcinomas (OSCC) from India, 15 of which were known to harbor p53 mutations.
p6706
sg4
(lp6707
(dp6708
g9
I292
sg39
VP42771
p6709
sg12
I13
sg13
Vp53 mutations
p6710
sg15
I2
sasg6
(lp6711
(dp6712
g9
I215
sg10
VC0007137
p6713
sg12
I24
sg13
Vsquamous cell carcinomas
p6714
sg15
I3
sa(dp6715
g9
I59
sg10
VC1168401
p6716
sg12
I40
sg13
Vsquamous cell carcinoma of head and neck
p6717
sg15
I7
sasa(dp6718
g2
VThese results suggest that ING1 is not a target for mutational inactivation in OSCC of Indians.
p6719
sg4
(lp6720
sg6
(lp6721
(dp6722
g9
I63
sg10
VC0544461
p6723
sg12
I12
sg13
Vinactivation
p6724
sg15
I1
sasa(dp6725
g2
VThe incidence of human T cell lymphotropic virus type 1 (HLTV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is not well defined in the literature.
p6726
sg4
(lp6727
(dp6728
g9
I117
sg39
g40
sg12
I3
sg13
VHAM
p6729
sg15
I1
sa(dp6730
g9
I121
sg39
VP07996
p6731
sg12
I3
sg13
VTSP
p6732
sg15
I1
sasg6
(lp6733
(dp6734
g9
I76
sg10
VC0037928
p6735
sg12
I10
sg13
Vmyelopathy
p6736
sg15
I1
sa(dp6737
g9
I87
sg10
VC0030481
p6738
sg12
I28
sg13
Vtropical spastic paraparesis
p6739
sg15
I3
sa(dp6740
g9
I117
sg10
VC0030481
p6741
sg12
I3
sg13
VHAM
p6742
sg15
I1
sasa(dp6743
g2
VFollowing adult T cell leukemia/lymphoma and HLTV-1-associated myelopathy/tropical spastic paraparesis, HTLV-1 uveitis (HU) has been established as a distinct clinical entity caused by HTLV-1 based on seroepidemiological, clinical, and virological studies.
p6744
sg4
(lp6745
sg6
(lp6746
(dp6747
g9
I10
sg10
VC0023492
p6748
sg12
I21
sg13
Vadult T cell leukemia
p6749
sg15
I4
sa(dp6750
g9
I74
sg10
VC0030481
p6751
sg12
I28
sg13
Vtropical spastic paraparesis
p6752
sg15
I3
sa(dp6753
g9
I32
sg10
VC0024299
p6754
sg12
I8
sg13
Vlymphoma
p6755
sg15
I1
sa(dp6756
g9
I63
sg10
VC0037928
p6757
sg12
I10
sg13
Vmyelopathy
p6758
sg15
I1
sa(dp6759
g9
I111
sg10
VC0042164
p6760
sg12
I7
sg13
Vuveitis
p6761
sg15
I1
sasa(dp6762
g2
VThis is a study of the early identification of a new case of tropical spastic paraparesis/HLTV-1-associated myelopathy in a Spanish patient not previously reported on.
p6763
sg4
(lp6764
sg6
(lp6765
(dp6766
g9
I108
sg10
VC0037928
p6767
sg12
I10
sg13
Vmyelopathy
p6768
sg15
I1
sa(dp6769
g9
I61
sg10
VC0030481
p6770
sg12
I28
sg13
Vtropical spastic paraparesis
p6771
sg15
I3
sasa(dp6772
g2
VMyxoid liposarcoma (MLS) is a soft tissue sarcoma characterized by a recurrent t(12;16) translocation.
p6773
sg4
(lp6774
sg6
(lp6775
(dp6776
g9
I88
sg10
VC0040715
p6777
sg12
I13
sg13
Vtranslocation
p6778
sg15
I1
sa(dp6779
g9
I0
sg10
VC0206634
p6780
sg12
I18
sg13
VMyxoid liposarcoma
p6781
sg15
I2
sa(dp6782
g9
I20
sg10
VC0796070
p6783
sg12
I3
sg13
VMLS
p6784
sg15
I1
sa(dp6785
g9
I30
sg10
VC1261473
p6786
sg12
I19
sg13
Vsoft tissue sarcoma
p6787
sg15
I3
sasa(dp6788
g2
VAlthough myxoid liposarcomas (MLS) are the most common type of soft-tissue sarcomas in adults, their primary location in the superficial tissues is rare.
p6789
sg4
(lp6790
sg6
(lp6791
(dp6792
g9
I20
sg10
VC1261473
p6793
sg12
I8
sg13
Vsarcomas
p6794
sg15
I1
sa(dp6795
g9
I30
sg10
VC0796070
p6796
sg12
I3
sg13
VMLS
p6797
sg15
I1
sa(dp6798
g9
I9
sg10
VC0206634
p6799
sg12
I19
sg13
Vmyxoid liposarcomas
p6800
sg15
I2
sasa(dp6801
g2
VPRG4 is one of the downstream molecules of the myxoid liposarcoma (MLS)-specific fusion oncoproteins TLS-CHOP and EWS-CHOP.
p6802
sg4
(lp6803
(dp6804
g9
I101
sg39
VP35637
p6805
sg12
I3
sg13
VTLS
p6806
sg15
I1
sa(dp6807
g9
I114
sg39
g40
sg12
I3
sg13
VEWS
p6808
sg15
I1
sa(dp6809
g9
I105
sg39
VP35638
p6810
sg12
I4
sg13
VCHOP
p6811
sg15
I1
sa(dp6812
g9
I0
sg39
g40
sg12
I4
sg13
VPRG4
p6813
sg15
I1
sa(dp6814
g9
I105
sg39
VP35638
p6815
sg12
I4
sg13
VCHOP
p6816
sg15
I1
sasg6
(lp6817
(dp6818
g9
I67
sg10
VC0796070
p6819
sg12
I3
sg13
VMLS
p6820
sg15
I1
sa(dp6821
g9
I47
sg10
VC0206634
p6822
sg12
I18
sg13
Vmyxoid liposarcoma
p6823
sg15
I2
sasa(dp6824
g2
VThe SUV max values of the low-grade thymomas, high-grade thymomas, TCs and MLs were 3.14 +/- 0.73, 4.34 +/- 1.49, 8.59 +/- 3.05, and 10.08 +/- 2.53, respectively, with significant differences between the low- and high-grade thymomas, and between TCs and MLs.
p6825
sg4
(lp6826
sg6
(lp6827
(dp6828
g9
I75
sg10
VC0796070
p6829
sg12
I3
sg13
VMLs
p6830
sg15
I1
sa(dp6831
g9
I36
sg10
VC0040100
p6832
sg12
I8
sg13
Vthymomas
p6833
sg15
I1
sa(dp6834
g9
I75
sg10
VC0796070
p6835
sg12
I3
sg13
VMLs
p6836
sg15
I1
sa(dp6837
g9
I67
sg10
VC0242387
p6838
sg12
I3
sg13
VTCs
p6839
sg15
I1
sa(dp6840
g9
I36
sg10
VC0040100
p6841
sg12
I8
sg13
Vthymomas
p6842
sg15
I1
sa(dp6843
g9
I36
sg10
VC0040100
p6844
sg12
I8
sg13
Vthymomas
p6845
sg15
I1
sa(dp6846
g9
I67
sg10
VC0242387
p6847
sg12
I3
sg13
VTCs
p6848
sg15
I1
sasa(dp6849
g2
VOf 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease).
p6850
sg4
(lp6851
(dp6852
g9
I134
sg39
VP42336
p6853
sg12
I6
sg13
VPIK3CA
p6854
sg15
I1
sa(dp6855
g9
I360
sg39
VP15056
p6856
sg12
I4
sg13
VBRAF
p6857
sg15
I1
sa(dp6858
g9
I445
sg39
VP04626
p6859
sg12
I5
sg13
VERBB2
p6860
sg15
I1
sa(dp6861
g9
I278
sg39
VP16234
p6862
sg12
I6
sg13
VPDGFRA
p6863
sg15
I1
sasg6
(lp6864
(dp6865
g9
I463
sg10
VC0279628
p6866
sg12
I25
sg13
Vesophageal adenocarcinoma
p6867
sg15
I2
sa(dp6868
g9
I199
sg10
VC0345946
p6869
sg12
I32
sg13
Vtracheal squamous cell carcinoma
p6870
sg15
I4
sa(dp6871
g9
I407
sg10
VC0677932
p6872
sg12
I19
sg13
Vprogressive disease
p6873
sg15
I2
sa(dp6874
g9
I388
sg10
VC0206697
p6875
sg12
I17
sg13
Vadnexal carcinoma
p6876
sg15
I2
sa(dp6877
g9
I407
sg10
VC0677932
p6878
sg12
I19
sg13
Vprogressive disease
p6879
sg15
I2
sa(dp6880
g9
I312
sg10
VC0001418
p6881
sg12
I14
sg13
Vadenocarcinoma
p6882
sg15
I1
sa(dp6883
g9
I161
sg10
VC0007140
p6884
sg12
I14
sg13
Vcarcinosarcoma
p6885
sg15
I1
sasa(dp6886
g2
VThe objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma.
p6887
sg4
(lp6888
(dp6889
g9
I91
sg39
VP04626
p6890
sg12
I4
sg13
VHER2
p6891
sg15
I1
sasg6
(lp6892
(dp6893
g9
I106
sg10
VC0007140
p6894
sg12
I14
sg13
Vcarcinosarcoma
p6895
sg15
I1
sasa(dp6896
g2
VThe efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu.
p6897
sg4
(lp6898
(dp6899
g9
I183
sg39
VP04626
p6900
sg12
I3
sg13
Vneu
p6901
sg15
I1
sa(dp6902
g9
I46
sg39
VP04626
p6903
sg12
I4
sg13
VHER2
p6904
sg15
I1
sa(dp6905
g9
I46
sg39
VP04626
p6906
sg12
I4
sg13
VHER2
p6907
sg15
I1
sasg6
(lp6908
(dp6909
g9
I61
sg10
VC0007140
p6910
sg12
I14
sg13
Vcarcinosarcoma
p6911
sg15
I1
sa(dp6912
g9
I61
sg10
VC0007140
p6913
sg12
I14
sg13
Vcarcinosarcoma
p6914
sg15
I1
sasa(dp6915
g2
VThe efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts.
p6916
sg4
(lp6917
sg6
(lp6918
(dp6919
g9
I83
sg10
VC0007140
p6920
sg12
I14
sg13
Vcarcinosarcoma
p6921
sg15
I1
sasa(dp6922
g2
VTwo of seven (28.5%) carcinosarcoma cell lines were HER2/neu amplified.
p6923
sg4
(lp6924
(dp6925
g9
I52
sg39
VP04626
p6926
sg12
I4
sg13
VHER2
p6927
sg15
I1
sa(dp6928
g9
I57
sg39
VP04626
p6929
sg12
I3
sg13
Vneu
p6930
sg15
I1
sasg6
(lp6931
(dp6932
g9
I21
sg10
VC0007140
p6933
sg12
I14
sg13
Vcarcinosarcoma
p6934
sg15
I1
sasa(dp6935
g2
VHER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean+/-SEM IC50:0.014myM+/-0.004vs.0.164myM+/-0.019 p=0.0003).
p6936
sg4
(lp6937
(dp6938
g9
I5
sg39
VP04626
p6939
sg12
I3
sg13
Vneu
p6940
sg15
I1
sa(dp6941
g9
I5
sg39
VP04626
p6942
sg12
I3
sg13
Vneu
p6943
sg15
I1
sa(dp6944
g9
I0
sg39
VP04626
p6945
sg12
I4
sg13
VHER2
p6946
sg15
I1
sa(dp6947
g9
I0
sg39
VP04626
p6948
sg12
I4
sg13
VHER2
p6949
sg15
I1
sasg6
(lp6950
(dp6951
g9
I134
sg10
VC0007140
p6952
sg12
I14
sg13
Vcarcinosarcoma
p6953
sg15
I1
sa(dp6954
g9
I168
sg10
VC0432222
p6955
sg12
I3
sg13
VSEM
p6956
sg15
I1
sasa(dp6957
g2
VNeratinib inhibited tumor growth (p=0.012) and prolonged survival in mice harboring HER2 amplified carcinosarcoma xenografts (p=0.0039).
p6958
sg4
(lp6959
sg6
(lp6960
(dp6961
g9
I20
sg10
VC0598934
p6962
sg12
I12
sg13
Vtumor growth
p6963
sg15
I2
sa(dp6964
g9
I99
sg10
VC0007140
p6965
sg12
I14
sg13
Vcarcinosarcoma
p6966
sg15
I1
sasa(dp6967
g2
VNeratinib inhibits HER2 amplified carcinosarcoma proliferation, signaling, cell cycle progression and tumor growth in vitro.
p6968
sg4
(lp6969
(dp6970
g9
I19
sg39
VP04626
p6971
sg12
I4
sg13
VHER2
p6972
sg15
I1
sasg6
(lp6973
(dp6974
g9
I49
sg10
VC0334094
p6975
sg12
I13
sg13
Vproliferation
p6976
sg15
I1
sa(dp6977
g9
I34
sg10
VC0007140
p6978
sg12
I14
sg13
Vcarcinosarcoma
p6979
sg15
I1
sa(dp6980
g9
I102
sg10
VC0598934
p6981
sg12
I12
sg13
Vtumor growth
p6982
sg15
I2
sasa(dp6983
g2
VNumerous correlative scientific investigations have demonstrated that the HER2 (ERBB2) gene is amplified in 17%-33% of carcinosarcoma, uterine serous carcinoma, and a subset of high-grade endometrioid endometrial tumors.
p6984
sg4
(lp6985
(dp6986
g9
I74
sg39
VP04626
p6987
sg12
I4
sg13
VHER2
p6988
sg15
I1
sa(dp6989
g9
I80
sg39
VP04626
p6990
sg12
I5
sg13
VERBB2
p6991
sg15
I1
sasg6
(lp6992
(dp6993
g9
I143
sg10
VC0206701
p6994
sg12
I16
sg13
Vserous carcinoma
p6995
sg15
I2
sa(dp6996
g9
I213
sg10
VC0027651
p6997
sg12
I6
sg13
Vtumors
p6998
sg15
I1
sa(dp6999
g9
I119
sg10
VC0007140
p7000
sg12
I14
sg13
Vcarcinosarcoma
p7001
sg15
I1
sasa(dp7002
g2
VThe analysis of human datasets and GBM tumors revealed higher expression of p65 in GBM-associated CD68+ macrophages compared to neighboring stroma.
p7003
sg4
(lp7004
(dp7005
g9
I76
sg39
VP21579
p7006
sg12
I3
sg13
Vp65
p7007
sg15
I1
sa(dp7008
g9
I83
sg39
g40
sg12
I20
sg13
VGBM-associated CD68+
p7009
sg15
I2
sasg6
(lp7010
(dp7011
g9
I39
sg10
VC0027651
p7012
sg12
I6
sg13
Vtumors
p7013
sg15
I1
sa(dp7014
g9
I35
sg10
VC0017636
p7015
sg12
I3
sg13
VGBM
p7016
sg15
I1
sa(dp7017
g9
I35
sg10
VC0017636
p7018
sg12
I3
sg13
VGBM
p7019
sg15
I1
sasa(dp7020
g2
VOf paramount importance in the recognition of oligodendroglial and astrocytic tumor cells were the double immunostainings for ATRX/GFAP, ATRX/IDH1R132H, ATRX/Iba-1 and ATRX/CD68.
p7021
sg4
(lp7022
(dp7023
g9
I173
sg39
VP34810
p7024
sg12
I4
sg13
VCD68
p7025
sg15
I1
sasg6
(lp7026
(dp7027
g9
I126
sg10
VC1845055
p7028
sg12
I4
sg13
VATRX
p7029
sg15
I1
sa(dp7030
g9
I126
sg10
VC1845055
p7031
sg12
I4
sg13
VATRX
p7032
sg15
I1
sa(dp7033
g9
I126
sg10
VC1845055
p7034
sg12
I4
sg13
VATRX
p7035
sg15
I1
sa(dp7036
g9
I67
sg10
VC0004114
p7037
sg12
I16
sg13
Vastrocytic tumor
p7038
sg15
I2
sa(dp7039
g9
I126
sg10
VC1845055
p7040
sg12
I4
sg13
VATRX
p7041
sg15
I1
sasa(dp7042
g2
VTherefore, Dan-gua Fang might be an ideal drug for comprehensive intervention for glucose and lipid metabolism disorders in type 2 diabetes mellitus.
p7043
sg4
(lp7044
(dp7045
g9
I11
sg39
VP41271
p7046
sg12
I12
sg13
VDan-gua Fang
p7047
sg15
I2
sasg6
(lp7048
(dp7049
g9
I124
sg10
VC0011860
p7050
sg12
I24
sg13
Vtype 2 diabetes mellitus
p7051
sg15
I4
sa(dp7052
g9
I94
sg10
VC0154251
p7053
sg12
I26
sg13
Vlipid metabolism disorders
p7054
sg15
I3
sasa(dp7055
g2
VAn electrochemical study of the oxidation of 8-hydroxyguanine (8-OH-Gua) at gold nanoparticles attached to single walled carbon nanotube modified edge plane pyrolytic graphite electrode (AuNP-SWCNT/EPPGE) has been carried out to develop a method for the self diagnosis of diabetes.
p7056
sg4
(lp7057
sg6
(lp7058
(dp7059
g9
I272
sg10
VC0011849
p7060
sg12
I8
sg13
Vdiabetes
p7061
sg15
I1
sasa(dp7062
g2
VConsequently, Metformin - the biguanide drug of choice orally administered for diabetes type II - is anticipated to see a spike in production.
p7063
sg4
(lp7064
sg6
(lp7065
(dp7066
g9
I79
sg10
VC0011860
p7067
sg12
I16
sg13
Vdiabetes type II
p7068
sg15
I3
sasa(dp7069
g2
VTo study the toxicity features of high glucose on the endothelial cell cycle and the influence of Dan Gua-Fang, a Chinese herbal compound prescription, on the reproductive cycle of vascular endothelial cells cultivated under a high glucose condition; to reveal the partial mechanisms of Dan Gua-Fang in the prevention and treatment of endothelial injury caused by hyperglycemia in diabetes mellitus (DM); and offer a reference for dealing with the vascular complications of DM patients with long-term high blood glucose.
p7070
sg4
(lp7071
(dp7072
g9
I98
sg39
VP41271
p7073
sg12
I7
sg13
VDan Gua
p7074
sg15
I2
sasg6
(lp7075
(dp7076
g9
I240
sg10
VC0012634
p7077
sg12
I9
sg13
Vcondition
p7078
sg15
I1
sa(dp7079
g9
I381
sg10
VC0011849
p7080
sg12
I17
sg13
Vdiabetes mellitus
p7081
sg15
I2
sa(dp7082
g9
I400
sg10
VC0011849
p7083
sg12
I2
sg13
VDM
p7084
sg15
I1
sa(dp7085
g9
I400
sg10
VC0011849
p7086
sg12
I2
sg13
VDM
p7087
sg15
I1
sa(dp7088
g9
I364
sg10
VC0020456
p7089
sg12
I13
sg13
Vhyperglycemia
p7090
sg15
I1
sasa(dp7091
g2
VTo study the effect of anticolchicine cytotoxicity of Dan Gua-Fang, a Chinesea Chinese), a Chinese herbal compound prescription on endothelial cells of vein (ECV304) cultivated in mediums of different glucose concentrations as well as the proliferation of those cells in the same conditions, in order to reveal the value of Dan Gua-Fang in preventing and treating endothelial damage caused by hyperglycemia in diabetes mellitus.
p7092
sg4
(lp7093
(dp7094
g9
I54
sg39
VP41271
p7095
sg12
I12
sg13
VDan Gua-Fang
p7096
sg15
I2
sasg6
(lp7097
(dp7098
g9
I239
sg10
VC0334094
p7099
sg12
I13
sg13
Vproliferation
p7100
sg15
I1
sa(dp7101
g9
I410
sg10
VC0011849
p7102
sg12
I17
sg13
Vdiabetes mellitus
p7103
sg15
I2
sa(dp7104
g9
I38
sg10
VC0596402
p7105
sg12
I12
sg13
Vcytotoxicity
p7106
sg15
I1
sa(dp7107
g9
I393
sg10
VC0020456
p7108
sg12
I13
sg13
Vhyperglycemia
p7109
sg15
I1
sasa(dp7110
g2
V(1) Dan Gua-Fang at all concentrations reduced the floating cell population of ECV304 cultivated in hyperglycemia mediums.
p7111
sg4
(lp7112
sg6
(lp7113
(dp7114
g9
I100
sg10
VC0020456
p7115
sg12
I13
sg13
Vhyperglycemia
p7116
sg15
I1
sasa(dp7117
g2
V(2) Dan Gua-Fang at all concentrations and hyperglycemia both had a function of promoting "pseudopod-like" structure formation in cultivated ECV304, but the function was not superimposed in mediums containing both hyperglycemia and Dan Gua-Fang.
p7118
sg4
(lp7119
sg6
(lp7120
(dp7121
g9
I43
sg10
VC0020456
p7122
sg12
I13
sg13
Vhyperglycemia
p7123
sg15
I1
sa(dp7124
g9
I43
sg10
VC0020456
p7125
sg12
I13
sg13
Vhyperglycemia
p7126
sg15
I1
sasa(dp7127
g2
V(3) Colchicine reduced and even vanished the "pseudopod-like" structure of the endotheliocyte apparently cultivated in mediums of hyperglycemia or with Dan Gua-Fang.
p7128
sg4
(lp7129
sg6
(lp7130
(dp7131
g9
I130
sg10
VC0020456
p7132
sg12
I13
sg13
Vhyperglycemia
p7133
sg15
I1
sasa(dp7134
g2
VThe "pseudopod-like" structure of the endotheliocyte emerged quickly in Dan Gua-Fang groups after colchicine was removed, but it was not the case in hyperglycemia only without Dan Gua-Fang groups.
p7135
sg4
(lp7136
sg6
(lp7137
(dp7138
g9
I149
sg10
VC0020456
p7139
sg12
I13
sg13
Vhyperglycemia
p7140
sg15
I1
sasa(dp7141
g2
VThe spinodal point concentration of statistical significance of hyperglycemia cytotoxicity is 22.2 mmol/l; 1/300 Dan Gua can reverse the endothelia cytotoxicity in different concentrations of hyperglycemia.
p7142
sg4
(lp7143
sg6
(lp7144
(dp7145
g9
I78
sg10
VC0596402
p7146
sg12
I12
sg13
Vcytotoxicity
p7147
sg15
I1
sa(dp7148
g9
I64
sg10
VC0020456
p7149
sg12
I13
sg13
Vhyperglycemia
p7150
sg15
I1
sa(dp7151
g9
I78
sg10
VC0596402
p7152
sg12
I12
sg13
Vcytotoxicity
p7153
sg15
I1
sa(dp7154
g9
I64
sg10
VC0020456
p7155
sg12
I13
sg13
Vhyperglycemia
p7156
sg15
I1
sasa(dp7157
g2
VPatients with resected stage III colon cancer who were 18 years of age or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1, from four randomised controlled trials (NSABP C-08, XELOXA, X-ACT, and AVANT; 8734 patients in total) were pooled and analysed.
p7158
sg4
(lp7159
sg6
(lp7160
(dp7161
g9
I23
sg10
VC3146254
p7162
sg12
I22
sg13
Vstage III colon cancer
p7163
sg15
I4
sasa(dp7164
g2
VBased on the results of the X-ACT study, capecitabine has become one of the standard postoperative adjuvant chemotherapies for colon cancer.
p7165
sg4
(lp7166
sg6
(lp7167
(dp7168
g9
I127
sg10
VC0699790
p7169
sg12
I12
sg13
Vcolon cancer
p7170
sg15
I2
sasa(dp7171
g2
VIn the adjuvant setting, the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial demonstrated that capecitabine as a single agent led to improvement in relapse-free survival (hazard ratio: 0.86, 95% confidence interval: 0.74-0.99, P = 0.04) and was associated with significantly fewer adverse events than 5-FU plus leucovorin (LV, folinic acid).
p7172
sg4
(lp7173
sg6
(lp7174
(dp7175
g9
I48
sg10
VC0699790
p7176
sg12
I12
sg13
VColon Cancer
p7177
sg15
I2
sa(dp7178
g9
I154
sg10
VC0277556
p7179
sg12
I7
sg13
Vrelapse
p7180
sg15
I1
sasa(dp7181
g2
VOn the basis of the X-ACT trial, capecitabine was approved by the United States Food and Drug Administration, the National Institute for Clinical Excellence, and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer.
p7182
sg4
(lp7183
sg6
(lp7184
(dp7185
g9
I241
sg10
VC3146254
p7186
sg12
I22
sg13
Vstage III colon cancer
p7187
sg15
I4
sasa(dp7188
g2
VThe Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) study confirmed that capecitabine (Xeloda) is at least as effective and is less toxic than a bolus 5-FU and leucovorin regimen for patients with stage III colon cancer.
p7189
sg4
(lp7190
sg6
(lp7191
(dp7192
g9
I23
sg10
VC0699790
p7193
sg12
I12
sg13
VColon Cancer
p7194
sg15
I2
sa(dp7195
g9
I197
sg10
VC3146254
p7196
sg12
I22
sg13
Vstage III colon cancer
p7197
sg15
I4
sasa(dp7198
g2
VIn the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes' C colorectal cancer.
p7199
sg4
(lp7200
sg6
(lp7201
(dp7202
g9
I255
sg10
VC1527249
p7203
sg12
I17
sg13
Vcolorectal cancer
p7204
sg15
I2
sa(dp7205
g9
I40
sg10
VC0699790
p7206
sg12
I12
sg13
VColon cancer
p7207
sg15
I2
sasa(dp7208
g2
VThe X-ACT trial (Xeloda in Adjuvant Colon Cancer Therapy) compared traditional bolus 5-FU/LV (as per the Mayo Clinic regimen) with capecitabine, in the adjuvant treatment of 1987 stage III colon cancer patients.
p7209
sg4
(lp7210
sg6
(lp7211
(dp7212
g9
I179
sg10
VC3146254
p7213
sg12
I22
sg13
Vstage III colon cancer
p7214
sg15
I4
sa(dp7215
g9
I36
sg10
VC0699790
p7216
sg12
I12
sg13
VColon Cancer
p7217
sg15
I2
sasa(dp7218
g2
VOn the basis of the X-ACT trial, capecitabine was approved by the US FDA, the National Institute for Clinical Excellence and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer.
p7219
sg4
(lp7220
sg6
(lp7221
(dp7222
g9
I204
sg10
VC3146254
p7223
sg12
I22
sg13
Vstage III colon cancer
p7224
sg15
I4
sasa(dp7225
g2
VIn order to specifically target GD2 overexpressed on the surface of neuroblastoma stNB-V1 cells, anti-GD2 was conjugated to chitosan modified GNRs (CGNRs).
p7226
sg4
(lp7227
sg6
(lp7228
(dp7229
g9
I68
sg10
VC0027819
p7230
sg12
I13
sg13
Vneuroblastoma
p7231
sg15
I1
sasa(dp7232
g2
VOur results illustrated that anti-GD2-conjugated CGNRs were extensively endocytosed by GD2+ stNB-V1 neuroblastoma cells via antibody-mediated endocytosis.
p7233
sg4
(lp7234
sg6
(lp7235
(dp7236
g9
I100
sg10
VC0027819
p7237
sg12
I13
sg13
Vneuroblastoma
p7238
sg15
I1
sasa(dp7239
g2
VIn order to specifically target disialoganglioside (GD2) overexpressed on the surface of neuroblastoma stNB-V1 cells, GD2 monoclonal antibody (anti-GD2) was conjugated to acidified CNTs.
p7240
sg4
(lp7241
sg6
(lp7242
(dp7243
g9
I89
sg10
VC0027819
p7244
sg12
I13
sg13
Vneuroblastoma
p7245
sg15
I1
sasa(dp7246
g2
VIn addition to the well-known increase in glial fibrillary acidic protein and other proteins in reactive astrocytes, astrocytopathy is evidenced by deposition of abnormal proteins such as Beta-amyloid, hyper-phosphorylated tau, abnormal Alfa-synuclein, mutated huntingtin, phosphorylated TDP-43 and mutated SOD1, and PrPres , in Alzheimer's disease, tauopathies, Lewy body diseases, Huntington's disease, amyotrophic lateral sclerosis and Creutzfeldt-Jakob disease, respectively.
p7247
sg4
(lp7248
(dp7249
g9
I299
sg39
VP00441
p7250
sg12
I12
sg13
Vmutated SOD1
p7251
sg15
I2
sa(dp7252
g9
I273
sg39
g40
sg12
I21
sg13
Vphosphorylated TDP-43
p7253
sg15
I2
sa(dp7254
g9
I237
sg39
VP37840
p7255
sg12
I14
sg13
VAlfa-synuclein
p7256
sg15
I1
sa(dp7257
g9
I253
sg39
VP42858
p7258
sg12
I18
sg13
Vmutated huntingtin
p7259
sg15
I2
sa(dp7260
g9
I42
sg39
VP05230
p7261
sg12
I31
sg13
Vglial fibrillary acidic protein
p7262
sg15
I4
sasg6
(lp7263
(dp7264
g9
I193
sg10
VC0011560
p7265
sg12
I7
sg13
Vamyloid
p7266
sg15
I1
sa(dp7267
g9
I329
sg10
VC1521724
p7268
sg12
I19
sg13
VAlzheimer's disease
p7269
sg15
I2
sa(dp7270
g9
I405
sg10
VC0002736
p7271
sg12
I29
sg13
Vamyotrophic lateral sclerosis
p7272
sg15
I3
sa(dp7273
g9
I350
sg10
VC0949664
p7274
sg12
I11
sg13
Vtauopathies
p7275
sg15
I1
sa(dp7276
g9
I383
sg10
VC0020179
p7277
sg12
I20
sg13
VHuntington's disease
p7278
sg15
I2
sa(dp7279
g9
I439
sg10
VC0022336
p7280
sg12
I25
sg13
VCreutzfeldt-Jakob disease
p7281
sg15
I2
sasa(dp7282
g2
VInterestingly, BAG3-mediated selective macroautophagy is also involved in the clearance of aggregated proteins associated with age-related neurodegenerative disorders, like Alzheimer's disease (tau-protein), Huntington's disease (mutated huntingtin/polyQ proteins), and amyotrophic lateral sclerosis (mutated SOD1).
p7283
sg4
(lp7284
(dp7285
g9
I249
sg39
VP02649
p7286
sg12
I14
sg13
VpolyQ proteins
p7287
sg15
I2
sa(dp7288
g9
I15
sg39
g40
sg12
I4
sg13
VBAG3
p7289
sg15
I1
sa(dp7290
g9
I238
sg39
VP42858
p7291
sg12
I10
sg13
Vhuntingtin
p7292
sg15
I1
sa(dp7293
g9
I309
sg39
VP00441
p7294
sg12
I4
sg13
VSOD1
p7295
sg15
I1
sasg6
(lp7296
(dp7297
g9
I173
sg10
VC1521724
p7298
sg12
I19
sg13
VAlzheimer's disease
p7299
sg15
I2
sa(dp7300
g9
I270
sg10
VC0002736
p7301
sg12
I29
sg13
Vamyotrophic lateral sclerosis
p7302
sg15
I3
sa(dp7303
g9
I208
sg10
VC0020179
p7304
sg12
I20
sg13
VHuntington's disease
p7305
sg15
I2
sa(dp7306
g9
I139
sg10
VC0524851
p7307
sg12
I27
sg13
Vneurodegenerative disorders
p7308
sg15
I2
sasa(dp7309
g2
VThis report is the first successful generation of neural cells using iPSCs from sleep bruxism patients with 5-HT2A polymorphism, which has the potential to elucidate the etiology and underlying mechanism of SB.
p7310
sg4
(lp7311
(dp7312
g9
I110
sg39
g40
sg12
I4
sg13
VHT2A
p7313
sg15
I1
sasg6
(lp7314
(dp7315
g9
I80
sg10
VC0751771
p7316
sg12
I13
sg13
Vsleep bruxism
p7317
sg15
I2
sasa(dp7318
g2
VAt present, variants of the 5-hydroxytryptamine receptor 2A (5-HTR2A) and interleukin-6 (IL-6) genes may be susceptible markers to develop for obstructive sleep apnea-hypopnea syndrome (OSAHS).
p7319
sg4
(lp7320
(dp7321
g9
I89
sg39
VP05231
p7322
sg12
I4
sg13
VIL-6
p7323
sg15
I1
sa(dp7324
g9
I74
sg39
VP05231
p7325
sg12
I13
sg13
Vinterleukin-6
p7326
sg15
I1
sasg6
(lp7327
(dp7328
g9
I186
sg10
VC0520679
p7329
sg12
I5
sg13
VOSAHS
p7330
sg15
I1
sa(dp7331
g9
I143
sg10
VC0520679
p7332
sg12
I41
sg13
Vobstructive sleep apnea-hypopnea syndrome
p7333
sg15
I4
sasa(dp7334
g2
VThe results of our study showed that tumor necrosis factor-Alfa (TNF-Alfa) -308 G/A (OR = 3.70, 95 % CI = 1.39-9.83), gene-linked polymorphic region (LPR) (OR = 0.57, 95 % CI = 0.41-0.79), and variable number tandem repeat (VNTR) of the 5-hydroxytryptamine transporter gene (5-HTT) (OR = 3.44, 95 % CI = 1.49-7.95) polymorphisms were associated with OSAS risk in the Chinese population, while there was no significant association between 5-hydroxytryptamine 2A receptor (5-HTR2A) 102C/T, 5-HTR2A A1438G, angiotensin-converting enzyme (ACE) insertion (I)/deletion (D), or leptin receptor (LEPR)-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.
p7335
sg4
(lp7336
(dp7337
g9
I237
sg39
VP31645
p7338
sg12
I36
sg13
V5-hydroxytryptamine transporter gene
p7339
sg15
I3
sa(dp7340
g9
I488
sg39
VP28223
p7341
sg12
I14
sg13
V5-HTR2A A1438G
p7342
sg15
I2
sa(dp7343
g9
I588
sg39
VP48357
p7344
sg12
I4
sg13
VLEPR
p7345
sg15
I1
sa(dp7346
g9
I535
sg39
VP12821
p7347
sg12
I3
sg13
VACE
p7348
sg15
I1
sa(dp7349
g9
I37
sg39
VP01375
p7350
sg12
I26
sg13
Vtumor necrosis factor-Alfa
p7351
sg15
I3
sa(dp7352
g9
I504
sg39
VP12821
p7353
sg12
I29
sg13
Vangiotensin-converting enzyme
p7354
sg15
I2
sa(dp7355
g9
I65
sg39
VP01375
p7356
sg12
I8
sg13
VTNF-Alfa
p7357
sg15
I1
sa(dp7358
g9
I571
sg39
VP48357
p7359
sg12
I15
sg13
Vleptin receptor
p7360
sg15
I2
sa(dp7361
g9
I438
sg39
VP34969
p7362
sg12
I31
sg13
V5-hydroxytryptamine 2A receptor
p7363
sg15
I3
sa(dp7364
g9
I275
sg39
VP31645
p7365
sg12
I5
sg13
V5-HTT
p7366
sg15
I1
sa(dp7367
g9
I471
sg39
VP28223
p7368
sg12
I7
sg13
V5-HTR2A
p7369
sg15
I1
sasg6
(lp7370
(dp7371
g9
I350
sg10
VC0520679
p7372
sg12
I4
sg13
VOSAS
p7373
sg15
I1
sa(dp7374
g9
I37
sg10
VC0333516
p7375
sg12
I14
sg13
Vtumor necrosis
p7376
sg15
I2
sa(dp7377
g9
I193
sg10
VC1710347
p7378
sg12
I29
sg13
Vvariable number tandem repeat
p7379
sg15
I4
sa(dp7380
g9
I224
sg10
VC1710347
p7381
sg12
I4
sg13
VVNTR
p7382
sg15
I1
sa(dp7383
g9
I350
sg10
VC0520679
p7384
sg12
I4
sg13
VOSAS
p7385
sg15
I1
sasa(dp7386
g2
VOur study demonstrated that TNF-Alfa 308 G/A, 5-HTT LPR, and 5-HTT-VNTR polymorphisms were associated with OSAS risk, whereas little association was observed between 5-HTR2A 102C/T, 5-HTR2A A1438G, ACE I/D, or LEPR-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.
p7387
sg4
(lp7388
(dp7389
g9
I198
sg39
VP12821
p7390
sg12
I7
sg13
VACE I/D
p7391
sg15
I2
sa(dp7392
g9
I28
sg39
VP01375
p7393
sg12
I3
sg13
VTNF
p7394
sg15
I1
sa(dp7395
g9
I182
sg39
VP28223
p7396
sg12
I14
sg13
V5-HTR2A A1438G
p7397
sg15
I2
sa(dp7398
g9
I166
sg39
VP28223
p7399
sg12
I12
sg13
V5-HTR2A 102C
p7400
sg15
I2
sasg6
(lp7401
(dp7402
g9
I107
sg10
VC0520679
p7403
sg12
I4
sg13
VOSAS
p7404
sg15
I1
sa(dp7405
g9
I107
sg10
VC0520679
p7406
sg12
I4
sg13
VOSAS
p7407
sg15
I1
sasa(dp7408
g2
VWe performed a meta-analysis to better evaluate the associations between 5-HT2A, 5-HTT, and LEPR polymorphisms, and OSAS.
p7409
sg4
(lp7410
(dp7411
g9
I75
sg39
g40
sg12
I4
sg13
VHT2A
p7412
sg15
I1
sa(dp7413
g9
I81
sg39
VP31645
p7414
sg12
I5
sg13
V5-HTT
p7415
sg15
I1
sasg6
(lp7416
(dp7417
g9
I116
sg10
VC0520679
p7418
sg12
I4
sg13
VOSAS
p7419
sg15
I1
sasa(dp7420
g2
V5-HT2A, 5-HTT, and LEPR polymorphisms and OSAS were identified in PubMed and EMBASE.
p7421
sg4
(lp7422
(dp7423
g9
I2
sg39
g40
sg12
I4
sg13
VHT2A
p7424
sg15
I1
sa(dp7425
g9
I8
sg39
VP31645
p7426
sg12
I5
sg13
V5-HTT
p7427
sg15
I1
sasg6
(lp7428
(dp7429
g9
I42
sg10
VC0520679
p7430
sg12
I4
sg13
VOSAS
p7431
sg15
I1
sasa(dp7432
g2
VThe -1438 "A" allele of 5-HT2A was identified as a candidate genetic risk factor for OSAS (OR: 2.33, 95%CI 1.49-3.66).
p7433
sg4
(lp7434
(dp7435
g9
I26
sg39
g40
sg12
I4
sg13
VHT2A
p7436
sg15
I1
sasg6
(lp7437
(dp7438
g9
I85
sg10
VC0520679
p7439
sg12
I4
sg13
VOSAS
p7440
sg15
I1
sasa(dp7441
g2
VThere was no significant association between 5-HT2A 102C/T and OSAS risk, using any model.
p7442
sg4
(lp7443
(dp7444
g9
I45
sg39
VP28223
p7445
sg12
I11
sg13
V5-HT2A 102C
p7446
sg15
I2
sasg6
(lp7447
(dp7448
g9
I63
sg10
VC0520679
p7449
sg12
I4
sg13
VOSAS
p7450
sg15
I1
sasa(dp7451
g2
VEight studies were finally included in the meta-analysis of the association between 5-HTR2A gene variants (including 102T/C and 1438G/A), 5-HTT gene polymorphisms (including 5-HTT gene-linked promoter region (5-HTTLRP), and serotonin transporter intron 2 variable number tandem repeat (STin2VNTR) and OSAS risk.
p7452
sg4
(lp7453
(dp7454
g9
I224
sg39
VP31645
p7455
sg12
I21
sg13
Vserotonin transporter
p7456
sg15
I2
sa(dp7457
g9
I138
sg39
VP31645
p7458
sg12
I10
sg13
V5-HTT gene
p7459
sg15
I2
sa(dp7460
g9
I84
sg39
VP28223
p7461
sg12
I12
sg13
V5-HTR2A gene
p7462
sg15
I2
sasg6
(lp7463
(dp7464
g9
I301
sg10
VC0520679
p7465
sg12
I4
sg13
VOSAS
p7466
sg15
I1
sa(dp7467
g9
I255
sg10
VC1710347
p7468
sg12
I29
sg13
Vvariable number tandem repeat
p7469
sg15
I4
sasa(dp7470
g2
VThe G allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR were shown to increase OSAS susceptibility, with ORs of 2.33 (A vs. G, 95% CI 1.48-3.66), 1.24 (L vs. S, 95% CI: 1.04-1.49), and 2.87 (10 vs. 12, 95% CI: 1.38-5.97), respectively.
p7471
sg4
(lp7472
(dp7473
g9
I4
sg39
VP28223
p7474
sg12
I75
sg13
VG allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR
p7475
sg15
I10
sa(dp7476
g9
I103
sg39
VP27986
p7477
sg12
I19
sg13
VOSAS susceptibility
p7478
sg15
I2
sasg6
(lp7479
(dp7480
g9
I103
sg10
VC0520679
p7481
sg12
I4
sg13
VOSAS
p7482
sg15
I1
sasa(dp7483
g2
VOf the 5-HTR2A 1438G/A gene polymorphism, the AA genotype increased the OSAS risk, with an OR of 4.21 (95% CI: 2.83-6.25) in a recessive model in male OSAS patients, but no significant association was found in females.
p7484
sg4
(lp7485
(dp7486
g9
I7
sg39
VP28223
p7487
sg12
I13
sg13
V5-HTR2A 1438G
p7488
sg15
I2
sasg6
(lp7489
(dp7490
g9
I72
sg10
VC0520679
p7491
sg12
I4
sg13
VOSAS
p7492
sg15
I1
sa(dp7493
g9
I72
sg10
VC0520679
p7494
sg12
I4
sg13
VOSAS
p7495
sg15
I1
sasa(dp7496
g2
VOur meta-analysis demonstrated that polymorphisms in the 5-HTR2A 1438G/A and 5-HTT genes contributed to susceptibility to OSAS.
p7497
sg4
(lp7498
(dp7499
g9
I77
sg39
VP31645
p7500
sg12
I11
sg13
V5-HTT genes
p7501
sg15
I2
sa(dp7502
g9
I57
sg39
VP28223
p7503
sg12
I13
sg13
V5-HTR2A 1438G
p7504
sg15
I2
sasg6
(lp7505
(dp7506
g9
I122
sg10
VC0520679
p7507
sg12
I4
sg13
VOSAS
p7508
sg15
I1
sasa(dp7509
g2
VThe serotonin 2A (5-HT2A) receptor has been implicated in obstructive sleep apnea (OSA).
p7510
sg4
(lp7511
(dp7512
g9
I4
sg39
g40
sg12
I12
sg13
Vserotonin 2A
p7513
sg15
I2
sasg6
(lp7514
(dp7515
g9
I83
sg10
VC0520679
p7516
sg12
I3
sg13
VOSA
p7517
sg15
I1
sa(dp7518
g9
I58
sg10
VC0520679
p7519
sg12
I23
sg13
Vobstructive sleep apnea
p7520
sg15
I3
sasa(dp7521
g2
VOur findings suggest that upregulated functional TRPC5 gene may be one cause of EPO-induced hypertension in patients with chronic kidney disease.
p7522
sg4
(lp7523
(dp7524
g9
I49
sg39
g40
sg12
I10
sg13
VTRPC5 gene
p7525
sg15
I2
sa(dp7526
g9
I80
sg39
VP01588
p7527
sg12
I3
sg13
VEPO
p7528
sg15
I1
sasg6
(lp7529
(dp7530
g9
I92
sg10
VC0020538
p7531
sg12
I12
sg13
Vhypertension
p7532
sg15
I1
sa(dp7533
g9
I122
sg10
VC1561643
p7534
sg12
I22
sg13
Vchronic kidney disease
p7535
sg15
I3
sasa(dp7536
g2
VTTR (transthyretin) gene could be a possible candidate for lumbosacral stenosis in Labrador retrievers based on previous human studies that have reported an association between human lumbar spinal stenosis and transthyretin protein amyloidosis.
p7537
sg4
(lp7538
(dp7539
g9
I0
sg39
VP02766
p7540
sg12
I3
sg13
VTTR
p7541
sg15
I1
sa(dp7542
g9
I5
sg39
VP02766
p7543
sg12
I13
sg13
Vtransthyretin
p7544
sg15
I1
sa(dp7545
g9
I5
sg39
VP02766
p7546
sg12
I13
sg13
Vtransthyretin
p7547
sg15
I1
sasg6
(lp7548
(dp7549
g9
I59
sg10
VC1299881
p7550
sg12
I20
sg13
Vlumbosacral stenosis
p7551
sg15
I2
sa(dp7552
g9
I183
sg10
VC0158288
p7553
sg12
I22
sg13
Vlumbar spinal stenosis
p7554
sg15
I3
sa(dp7555
g9
I232
sg10
VC0002726
p7556
sg12
I11
sg13
Vamyloidosis
p7557
sg15
I1
sasa(dp7558
g2
VWild-type ATTR amyloidosis mainly involves the heart, although the reported occurrence of bilateral carpal tunnel syndrome, spinal stenosis and biceps tendon rupture in these patients speaks to more generalized protein deposition.
p7559
sg4
(lp7560
(dp7561
g9
I0
sg39
VP02766
p7562
sg12
I14
sg13
VWild-type ATTR
p7563
sg15
I2
sasg6
(lp7564
(dp7565
g9
I100
sg10
VC0007286
p7566
sg12
I22
sg13
Vcarpal tunnel syndrome
p7567
sg15
I3
sa(dp7568
g9
I124
sg10
VC0037944
p7569
sg12
I15
sg13
Vspinal stenosis
p7570
sg15
I2
sa(dp7571
g9
I211
sg10
VC0333584
p7572
sg12
I18
sg13
Vprotein deposition
p7573
sg15
I2
sa(dp7574
g9
I15
sg10
VC0002726
p7575
sg12
I11
sg13
Vamyloidosis
p7576
sg15
I1
sasa(dp7577
g2
VIn all groups, but the HBD group, the livers were pretreated with FK506 and prostaglandin I2 analogue, and were preserved in University of Wisconsin solution after cardiac arrest.
p7578
sg4
(lp7579
sg6
(lp7580
(dp7581
g9
I23
sg10
VC1840321
p7582
sg12
I3
sg13
VHBD
p7583
sg15
I1
sa(dp7584
g9
I164
sg10
VC0018790
p7585
sg12
I14
sg13
Vcardiac arrest
p7586
sg15
I2
sasa(dp7587
g2
VWe used a new vasodilator, TTC-909 (a prostaglandin I2 analog incorporated in lipid microspheres), which produced marked reduction in the pulmonary arterial pressure and resistance in an infant with primary pulmonary hypertension.
p7588
sg4
(lp7589
sg6
(lp7590
(dp7591
g9
I199
sg10
VC0152171
p7592
sg12
I30
sg13
Vprimary pulmonary hypertension
p7593
sg15
I3
sasa(dp7594
g2
VA prostaglandin I2 (PGI2) was administered before cardiac arrest by St. Thomas solution.
p7595
sg4
(lp7596
sg6
(lp7597
(dp7598
g9
I50
sg10
VC0018790
p7599
sg12
I14
sg13
Vcardiac arrest
p7600
sg15
I2
sasa(dp7601
g2
VRecently, with the introduction of prostacyclin (Prostaglandin I2, epoprostenon) as a potent vasodilator, several reports have shown a positive effect in primary pulmonary hypertension.
p7602
sg4
(lp7603
sg6
(lp7604
(dp7605
g9
I154
sg10
VC0152171
p7606
sg12
I30
sg13
Vprimary pulmonary hypertension
p7607
sg15
I3
sasa(dp7608
g2
VFurthermore, the involvement of functional GREM1 in the epithelial-mesenchymal transition (EMT) process of glioma was investigated by detecting the expression levels of glioma-associated oncogene homologue 3 (GLI3) and EMT-related molecules.
p7609
sg4
(lp7610
(dp7611
g9
I219
sg39
g40
sg12
I21
sg13
VEMT-related molecules
p7612
sg15
I2
sa(dp7613
g9
I43
sg39
g40
sg12
I5
sg13
VGREM1
p7614
sg15
I1
sa(dp7615
g9
I169
sg39
VP08151
p7616
sg12
I38
sg13
Vglioma-associated oncogene homologue 3
p7617
sg15
I4
sa(dp7618
g9
I209
sg39
VP10071
p7619
sg12
I4
sg13
VGLI3
p7620
sg15
I1
sasg6
(lp7621
(dp7622
g9
I91
sg10
VC0599156
p7623
sg12
I3
sg13
VEMT
p7624
sg15
I1
sa(dp7625
g9
I91
sg10
VC0599156
p7626
sg12
I3
sg13
VEMT
p7627
sg15
I1
sa(dp7628
g9
I107
sg10
VC0017638
p7629
sg12
I6
sg13
Vglioma
p7630
sg15
I1
sa(dp7631
g9
I56
sg10
VC0599156
p7632
sg12
I33
sg13
Vepithelial-mesenchymal transition
p7633
sg15
I2
sa(dp7634
g9
I107
sg10
VC0017638
p7635
sg12
I6
sg13
Vglioma
p7636
sg15
I1
sasa(dp7637
g2
VSuppression of GLI1/GLI2 functions by a C-terminus truncated GLI3 repressor mutant (GLI3R), or by GANT61, a pharmacological inhibitor of GLI1/GLI2, reduced hTERT protein expression in human colon cancer, prostate cancer and Glioblastoma multiforme (GBM) cell lines.
p7638
sg4
(lp7639
(dp7640
g9
I20
sg39
VP10070
p7641
sg12
I4
sg13
VGLI2
p7642
sg15
I1
sa(dp7643
g9
I156
sg39
g40
sg12
I13
sg13
VhTERT protein
p7644
sg15
I2
sa(dp7645
g9
I84
sg39
VP10071
p7646
sg12
I5
sg13
VGLI3R
p7647
sg15
I1
sa(dp7648
g9
I15
sg39
VP08151
p7649
sg12
I4
sg13
VGLI1
p7650
sg15
I1
sa(dp7651
g9
I20
sg39
VP10070
p7652
sg12
I4
sg13
VGLI2
p7653
sg15
I1
sa(dp7654
g9
I15
sg39
VP08151
p7655
sg12
I4
sg13
VGLI1
p7656
sg15
I1
sa(dp7657
g9
I61
sg39
VP10071
p7658
sg12
I21
sg13
VGLI3 repressor mutant
p7659
sg15
I3
sasg6
(lp7660
(dp7661
g9
I196
sg10
VC0376358
p7662
sg12
I16
sg13
Vcancer, prostate
p7663
sg15
I2
sa(dp7664
g9
I196
sg10
VC0006826
p7665
sg12
I6
sg13
Vcancer
p7666
sg15
I1
sa(dp7667
g9
I224
sg10
VC1621958
p7668
sg12
I23
sg13
VGlioblastoma multiforme
p7669
sg15
I2
sa(dp7670
g9
I249
sg10
VC1621958
p7671
sg12
I3
sg13
VGBM
p7672
sg15
I1
sa(dp7673
g9
I76
sg10
VC0596988
p7674
sg12
I6
sg13
Vmutant
p7675
sg15
I1
sa(dp7676
g9
I0
sg10
VC0221103
p7677
sg12
I11
sg13
VSuppression
p7678
sg15
I1
sasa(dp7679
g2
VInhibitor of DNA binding protein-1 (ID1) has been shown to maintain the self-renewal capacity of neural stem cells and might be involved in the therapeutic resistance of GBM.
p7680
sg4
(lp7681
(dp7682
g9
I36
sg39
VP29372
p7683
sg12
I3
sg13
VID1
p7684
sg15
I1
sa(dp7685
g9
I0
sg39
VP29372
p7686
sg12
I34
sg13
VInhibitor of DNA binding protein-1
p7687
sg15
I5
sasg6
(lp7688
(dp7689
g9
I170
sg10
VC0017636
p7690
sg12
I3
sg13
VGBM
p7691
sg15
I1
sasa(dp7692
g2
VIn glioblastoma neurosphere cultures that contain cancer stem cells (GBM-CSCs), the bHLH family member inhibitors of DNA binding protein 2 and 4 (Id2 and Id4) were found to be upregulated during the differentiation of GBM-CSCs in response to histone deacetylase inhibitors.
p7693
sg4
(lp7694
(dp7695
g9
I84
sg39
g40
sg12
I11
sg13
VbHLH family
p7696
sg15
I2
sa(dp7697
g9
I154
sg39
VP47928
p7698
sg12
I3
sg13
VId4
p7699
sg15
I1
sa(dp7700
g9
I242
sg39
VP56524
p7701
sg12
I19
sg13
Vhistone deacetylase
p7702
sg15
I2
sa(dp7703
g9
I117
sg39
VP51523
p7704
sg12
I27
sg13
VDNA binding protein 2 and 4
p7705
sg15
I6
sa(dp7706
g9
I146
sg39
g40
sg12
I3
sg13
VId2
p7707
sg15
I1
sasg6
(lp7708
(dp7709
g9
I69
sg10
VC0017636
p7710
sg12
I3
sg13
VGBM
p7711
sg15
I1
sa(dp7712
g9
I50
sg10
VC0006826
p7713
sg12
I6
sg13
Vcancer
p7714
sg15
I1
sa(dp7715
g9
I3
sg10
VC0017636
p7716
sg12
I12
sg13
Vglioblastoma
p7717
sg15
I1
sa(dp7718
g9
I69
sg10
VC0017636
p7719
sg12
I3
sg13
VGBM
p7720
sg15
I1
sasa(dp7721
g2
VThe improvement in mitral regurgitation was greater for the mitral repair group (-2.1 +/- 0.3 vs -1.1 +/- 0.8, P &lt; .0001), and mitral regurgitation remained significantly lower on follow-up at 6 months or more (0.6 +/- 0.4 0.9 +/- 0.2, P = .002).
p7722
sg4
(lp7723
sg6
(lp7724
(dp7725
g9
I19
sg10
VC0026266
p7726
sg12
I20
sg13
Vmitral regurgitation
p7727
sg15
I2
sa(dp7728
g9
I19
sg10
VC0026266
p7729
sg12
I20
sg13
Vmitral regurgitation
p7730
sg15
I2
sasa(dp7731
g2
VThis study was undertaken to examine changes in 1-cysPrx expression in human cataract samples, human lens epithelial (HLE B3) cell line, and rat organ-cultured lenses in response to oxidative insult induced by H2O2 or transforming growth factor-beta1 (TGF-beta1).
p7732
sg4
(lp7733
(dp7734
g9
I252
sg39
VP01137
p7735
sg12
I9
sg13
VTGF-beta1
p7736
sg15
I1
sa(dp7737
g9
I218
sg39
VP01137
p7738
sg12
I32
sg13
Vtransforming growth factor-beta1
p7739
sg15
I3
sasg6
(lp7740
(dp7741
g9
I77
sg10
VC0086543
p7742
sg12
I8
sg13
Vcataract
p7743
sg15
I1
sasa(dp7744
g2
VIn a functional analysis, transient cotransfections in nonerythroid NIH/3T3 cells of SP1, SP3, BKLF, or EKLF and HS2 epsilony promoter-luciferase constructs, with or without coactivators (p300, CREB-binding protein [CBP], or p300/CBP-associated factor [PCAF]) and SCFAs, were performed.
p7745
sg4
(lp7746
(dp7747
g9
I230
sg39
g40
sg12
I28
sg13
VCBP-associated factor [PCAF]
p7748
sg15
I3
sa(dp7749
g9
I85
sg39
VP08047
p7750
sg12
I3
sg13
VSP1
p7751
sg15
I1
sa(dp7752
g9
I113
sg39
VP11277
p7753
sg12
I43
sg13
VHS2 epsilony promoter-luciferase constructs
p7754
sg15
I4
sa(dp7755
g9
I95
sg39
VP57682
p7756
sg12
I4
sg13
VBKLF
p7757
sg15
I1
sa(dp7758
g9
I194
sg39
g40
sg12
I26
sg13
VCREB-binding protein [CBP]
p7759
sg15
I3
sa(dp7760
g9
I90
sg39
g40
sg12
I3
sg13
VSP3
p7761
sg15
I1
sa(dp7762
g9
I188
sg39
g40
sg12
I4
sg13
Vp300
p7763
sg15
I1
sa(dp7764
g9
I188
sg39
g40
sg12
I4
sg13
Vp300
p7765
sg15
I1
sa(dp7766
g9
I104
sg39
g40
sg12
I4
sg13
VEKLF
p7767
sg15
I1
sasg6
(lp7768
sa(dp7769
g2
VUsing our newly created Ngb overexpressing transgenic (Ngb-Tg) mice, we measured brain infarction on day 1 and day 14 after transient focal cerebral ischemia and performed neurobehavioral assessments in sensorimotor deficits on days 1, 3, 7, and 14.
p7770
sg4
(lp7771
(dp7772
g9
I24
sg39
g40
sg12
I3
sg13
VNgb
p7773
sg15
I1
sa(dp7774
g9
I24
sg39
g40
sg12
I3
sg13
VNgb
p7775
sg15
I1
sasg6
(lp7776
(dp7777
g9
I140
sg10
VC0917798
p7778
sg12
I17
sg13
Vcerebral ischemia
p7779
sg15
I2
sa(dp7780
g9
I81
sg10
VC0751955
p7781
sg12
I16
sg13
Vbrain infarction
p7782
sg15
I2
sasa(dp7783
g2
VCompared with wild-type controls, brain infarction volumes 1 day and 14 days after transient focal cerebral ischemia were significantly reduced in Ngb-Tg mice.
p7784
sg4
(lp7785
(dp7786
g9
I147
sg39
g40
sg12
I3
sg13
VNgb
p7787
sg15
I1
sasg6
(lp7788
(dp7789
g9
I34
sg10
VC0751955
p7790
sg12
I16
sg13
Vbrain infarction
p7791
sg15
I2
sa(dp7792
g9
I99
sg10
VC0917798
p7793
sg12
I17
sg13
Vcerebral ischemia
p7794
sg15
I2
sasa(dp7795
g2
VEvidence includes the observations that neuronal hypoxia and cerebral ischemia induce Ngb expression, that enhancing Ngb expression reduces--and knocking down Ngb expression increases--hypoxic neuronal injury in vitro and ischemic cerebral injury in vivo, and that Ngb-overexpressing transgenic mice are resistant to cerebral infarction.
p7796
sg4
(lp7797
(dp7798
g9
I86
sg39
g40
sg12
I3
sg13
VNgb
p7799
sg15
I1
sa(dp7800
g9
I86
sg39
g40
sg12
I3
sg13
VNgb
p7801
sg15
I1
sa(dp7802
g9
I86
sg39
g40
sg12
I3
sg13
VNgb
p7803
sg15
I1
sa(dp7804
g9
I86
sg39
g40
sg12
I3
sg13
VNgb
p7805
sg15
I1
sasg6
(lp7806
(dp7807
g9
I61
sg10
VC0917798
p7808
sg12
I17
sg13
Vcerebral ischemia
p7809
sg15
I2
sa(dp7810
g9
I317
sg10
VC0038454
p7811
sg12
I19
sg13
Vcerebral infarction
p7812
sg15
I2
sa(dp7813
g9
I185
sg10
VC0242184
p7814
sg12
I7
sg13
Vhypoxic
p7815
sg15
I1
sa(dp7816
g9
I49
sg10
VC0242184
p7817
sg12
I7
sg13
Vhypoxia
p7818
sg15
I1
sasa(dp7819
g2
VSono stati presentati i casi di un effetto paradosso di aggressivita sotto la possibile influenza di acepromazina e un protocollo modificato per il trattamento di un avvelenamento da permetrina nei gatti.
p7820
sg4
(lp7821
sg6
(lp7822
(dp7823
g9
I88
sg10
VC0021400
p7824
sg12
I9
sg13
Vinfluenza
p7825
sg15
I1
sasa(dp7826
g2
VADRP and perilipin localized to the phagosomal membrane, which contains M. leprae in skin biopsy specimens of lepromatous leprosy.
p7827
sg4
(lp7828
(dp7829
g9
I9
sg39
g40
sg12
I9
sg13
Vperilipin
p7830
sg15
I1
sa(dp7831
g9
I0
sg39
g40
sg12
I4
sg13
VADRP
p7832
sg15
I1
sasg6
(lp7833
(dp7834
g9
I110
sg10
VC0023348
p7835
sg12
I19
sg13
Vlepromatous leprosy
p7836
sg15
I2
sasa(dp7837
g2
VIn this work, two novel exonic BCKDK mutations, c.520C&gt;G/p.R174G and c.1166T&gt;C/p.L389P, were identified at the homozygous state in two unrelated children with persistently reduced body fluid levels of branched-chain amino acids (BCAAs), developmental delay, microcephaly, and neurobehavioral abnormalities.
p7838
sg4
(lp7839
(dp7840
g9
I31
sg39
g40
sg12
I5
sg13
VBCKDK
p7841
sg15
I1
sasg6
(lp7842
(dp7843
g9
I264
sg10
VC0025958
p7844
sg12
I12
sg13
Vmicrocephaly
p7845
sg15
I1
sa(dp7846
g9
I243
sg10
VC0424605
p7847
sg12
I19
sg13
Vdevelopmental delay
p7848
sg15
I2
sasa(dp7849
g2
VAR-12-stimulated the co-localization of Influenza, EBV and HIV virus proteins with LC3 in autophagosomes and reduced viral protein association with the chaperones HSP90, HSP70, and GRP78.
p7850
sg4
(lp7851
(dp7852
g9
I83
sg39
g40
sg12
I3
sg13
VLC3
p7853
sg15
I1
sa(dp7854
g9
I170
sg39
VP34932
p7855
sg12
I5
sg13
VHSP70
p7856
sg15
I1
sa(dp7857
g9
I181
sg39
VP11021
p7858
sg12
I5
sg13
VGRP78
p7859
sg15
I1
sa(dp7860
g9
I163
sg39
VP07900
p7861
sg12
I5
sg13
VHSP90
p7862
sg15
I1
sasg6
(lp7863
(dp7864
g9
I40
sg10
VC0021400
p7865
sg12
I9
sg13
VInfluenza
p7866
sg15
I1
sa(dp7867
g9
I59
sg10
VC0019693
p7868
sg12
I3
sg13
VHIV
p7869
sg15
I1
sasa(dp7870
g2
VHence, in agreement with heat shock protein 70 (HSP70) acting as Th1 cytokine-like adjuvant, an Escherichia coli-expressed r4M2e.HSP70c fusion protein comprising C-terminus of Mycobacterium tuberculosis HSP70 genetically fused to four tandem repeats of influenza A virus M2e was constructed.
p7871
sg4
(lp7872
(dp7873
g9
I48
sg39
VP34932
p7874
sg12
I5
sg13
VHSP70
p7875
sg15
I1
sa(dp7876
g9
I25
sg39
VP34932
p7877
sg12
I21
sg13
Vheat shock protein 70
p7878
sg15
I4
sa(dp7879
g9
I48
sg39
VP34932
p7880
sg12
I5
sg13
VHSP70
p7881
sg15
I1
sa(dp7882
g9
I253
sg39
g40
sg12
I21
sg13
Vinfluenza A virus M2e
p7883
sg15
I4
sa(dp7884
g9
I129
sg39
VP35637
p7885
sg12
I21
sg13
VHSP70c fusion protein
p7886
sg15
I3
sasg6
(lp7887
(dp7888
g9
I190
sg10
VC0041296
p7889
sg12
I12
sg13
Vtuberculosis
p7890
sg15
I1
sa(dp7891
g9
I253
sg10
VC0021400
p7892
sg12
I9
sg13
Vinfluenza
p7893
sg15
I1
sasa(dp7894
g2
VFurthermore, a virus challenge experiment revealed that mice vaccinated with r4M2e.HSP70c limited the severity of influenza A disease by 100% survival rate, less sever body weight loss and delaying the onset of morbidity in mice for 2days rather than other control groups.
p7895
sg4
(lp7896
sg6
(lp7897
(dp7898
g9
I114
sg10
VC0021400
p7899
sg12
I9
sg13
Vinfluenza
p7900
sg15
I1
sasa(dp7901
g2
VTo prepare an effective vaccine against influenza A viruses, a chimerical DNA plasmid encoding Influenza virus M2 protein and Leishmania major HSP70 was constructed.
p7902
sg4
(lp7903
(dp7904
g9
I126
sg39
VP34932
p7905
sg12
I22
sg13
VLeishmania major HSP70
p7906
sg15
I3
sasg6
(lp7907
(dp7908
g9
I40
sg10
VC0021400
p7909
sg12
I9
sg13
Vinfluenza
p7910
sg15
I1
sa(dp7911
g9
I95
sg10
VC0021400
p7912
sg12
I9
sg13
VInfluenza
p7913
sg15
I1
sasa(dp7914
g2
VOur previous study have shown that a prime-boost administration of recombinant 4xM2e.HSP70c (r4M2e/H70c) fusion protein compared to conventional HA-based influenza vaccines provided full protection against lethal dose of influenza A viruses in mice.
p7915
sg4
(lp7916
sg6
(lp7917
(dp7918
g9
I154
sg10
VC0021400
p7919
sg12
I9
sg13
Vinfluenza
p7920
sg15
I1
sa(dp7921
g9
I154
sg10
VC0021400
p7922
sg12
I9
sg13
Vinfluenza
p7923
sg15
I1
sasa(dp7924
g2
VThe data reported herein show that protection against H9N2 viral challenge was significantly increased in chickens by injection of r4M2e/H70c compared with injection of conventional HA-based influenza vaccine adjuvanted with MF59 or recombinant 4xM2e (r4M2e) without HSP70c.
p7925
sg4
(lp7926
sg6
(lp7927
(dp7928
g9
I191
sg10
VC0021400
p7929
sg12
I9
sg13
Vinfluenza
p7930
sg15
I1
sasa(dp7931
g2
VThis protective immunity might be attributed to enhanced cell-mediated immunity, which is interpreted as increased lymphocytes proliferation, increased levels of Th1-type (IFN-Gamma) and Th2-type (IL-4) cytokines production and increased CD4(+) to CD8(+) ratios, resulting from the injection of four tandem repeats of the ectodomain of the conserved influenza matrix protein M2 (4xM2e) genetically fused to C-terminus of Mycobacterium tuberculosis HSP70 (mHSP70c).
p7932
sg4
(lp7933
(dp7934
g9
I448
sg39
VP34932
p7935
sg12
I5
sg13
VHSP70
p7936
sg15
I1
sa(dp7937
g9
I248
sg39
VP01732
p7938
sg12
I3
sg13
VCD8
p7939
sg15
I1
sa(dp7940
g9
I238
sg39
VP01730
p7941
sg12
I3
sg13
VCD4
p7942
sg15
I1
sa(dp7943
g9
I172
sg39
VP01579
p7944
sg12
I9
sg13
VIFN-Gamma
p7945
sg15
I1
sasg6
(lp7946
(dp7947
g9
I435
sg10
VC0041296
p7948
sg12
I12
sg13
Vtuberculosis
p7949
sg15
I1
sa(dp7950
g9
I350
sg10
VC0021400
p7951
sg12
I9
sg13
Vinfluenza
p7952
sg15
I1
sa(dp7953
g9
I127
sg10
VC0334094
p7954
sg12
I13
sg13
Vproliferation
p7955
sg15
I1
sasa(dp7956
g2
VHeat shock protein 70 (Hsp70) was identified as a cellular interaction partner of the influenza virus ribonucleoprotein (RNP) complex.
p7957
sg4
(lp7958
(dp7959
g9
I0
sg39
VP34932
p7960
sg12
I21
sg13
VHeat shock protein 70
p7961
sg15
I4
sa(dp7962
g9
I23
sg39
VP34932
p7963
sg12
I5
sg13
VHsp70
p7964
sg15
I1
sasg6
(lp7965
(dp7966
g9
I86
sg10
VC0021400
p7967
sg12
I9
sg13
Vinfluenza
p7968
sg15
I1
sasa(dp7969
g2
VHere we demonstrated that Hsp70 was involved in the regulation of influenza A viral transcription and replication.
p7970
sg4
(lp7971
(dp7972
g9
I26
sg39
VP34932
p7973
sg12
I5
sg13
VHsp70
p7974
sg15
I1
sasg6
(lp7975
(dp7976
g9
I66
sg10
VC0021400
p7977
sg12
I9
sg13
Vinfluenza
p7978
sg15
I1
sasa(dp7979
g2
VFurthermore, delivered Hsp70 could inhibit the replication of influenza A virus in mice.
p7980
sg4
(lp7981
(dp7982
g9
I23
sg39
VP34932
p7983
sg12
I5
sg13
VHsp70
p7984
sg15
I1
sasg6
(lp7985
(dp7986
g9
I62
sg10
VC0021400
p7987
sg12
I9
sg13
Vinfluenza
p7988
sg15
I1
sasa(dp7989
g2
VIn this study, antigenic peptides from tetanus toxin and influenza hemagglutinin complexed to human stress-inducible Hsp70 were found to enhance the proliferation and cytokine production of human antigen-specific CD4(+) T cells.
p7990
sg4
(lp7991
(dp7992
g9
I117
sg39
VP34932
p7993
sg12
I5
sg13
VHsp70
p7994
sg15
I1
sa(dp7995
g9
I190
sg39
VP14209
p7996
sg12
I26
sg13
Vhuman antigen-specific CD4
p7997
sg15
I3
sasg6
(lp7998
(dp7999
g9
I57
sg10
VC0021400
p8000
sg12
I9
sg13
Vinfluenza
p8001
sg15
I1
sa(dp8002
g9
I39
sg10
VC0039614
p8003
sg12
I7
sg13
Vtetanus
p8004
sg15
I1
sa(dp8005
g9
I149
sg10
VC0334094
p8006
sg12
I13
sg13
Vproliferation
p8007
sg15
I1
sasa(dp8008
g2
VHerein, to construct a recombinant M2e-based vaccine candidate with the appropriate structural conformation and immunogenicity the corresponding nucleotide sequence from an H9N2 influenza strain was fused to the N-terminus of the truncated Mycobacterium tuberculosis HSP70(359-610), as a potent adjuvant, and following its cloning into the pPICZ alpha A plasmid the fusion gene was expressed in Pichia pastoris KM71H yeast.
p8009
sg4
(lp8010
(dp8011
g9
I267
sg39
VP34932
p8012
sg12
I14
sg13
VHSP70(359-610)
p8013
sg15
I1
sasg6
(lp8014
(dp8015
g9
I178
sg10
VC0021400
p8016
sg12
I9
sg13
Vinfluenza
p8017
sg15
I1
sa(dp8018
g9
I254
sg10
VC0041296
p8019
sg12
I12
sg13
Vtuberculosis
p8020
sg15
I1
sasa(dp8021
g2
VAccording to previous reports, this study was designed to produce a novel influenza A virus recombinant fusion protein consisted of M2e, a potent immunogenic protein from influenza A virus, fused to C-terminal domain of mycobacterium tuberculosis HSP70, HSP70(359-610), as a carrier and adjuvant.
p8022
sg4
(lp8023
(dp8024
g9
I247
sg39
VP34932
p8025
sg12
I5
sg13
VHSP70
p8026
sg15
I1
sa(dp8027
g9
I254
sg39
VP34932
p8028
sg12
I14
sg13
VHSP70(359-610)
p8029
sg15
I1
sasg6
(lp8030
(dp8031
g9
I234
sg10
VC0041296
p8032
sg12
I12
sg13
Vtuberculosis
p8033
sg15
I1
sa(dp8034
g9
I74
sg10
VC0021400
p8035
sg12
I9
sg13
Vinfluenza
p8036
sg15
I1
sa(dp8037
g9
I74
sg10
VC0021400
p8038
sg12
I9
sg13
Vinfluenza
p8039
sg15
I1
sasa(dp8040
g2
VDe novo mutations in ATAD3A (ATPase family AAA-domain containing protein 3A) were recently found to cause a neurological syndrome with developmental delay, hypotonia, spasticity, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
p8041
sg4
(lp8042
(dp8043
g9
I21
sg39
g40
sg12
I6
sg13
VATAD3A
p8044
sg15
I1
sa(dp8045
g9
I29
sg39
VP38606
p8046
sg12
I46
sg13
VATPase family AAA-domain containing protein 3A
p8047
sg15
I6
sasg6
(lp8048
(dp8049
g9
I194
sg10
VC0270921
p8050
sg12
I17
sg13
Vaxonal neuropathy
p8051
sg15
I2
sa(dp8052
g9
I156
sg10
VC0026827
p8053
sg12
I9
sg13
Vhypotonia
p8054
sg15
I1
sa(dp8055
g9
I121
sg10
VC0039082
p8056
sg12
I8
sg13
Vsyndrome
p8057
sg15
I1
sa(dp8058
g9
I179
sg10
VC0029124
p8059
sg12
I13
sg13
Voptic atrophy
p8060
sg15
I2
sa(dp8061
g9
I167
sg10
VC0026838
p8062
sg12
I10
sg13
Vspasticity
p8063
sg15
I1
sa(dp8064
g9
I43
sg10
VC0162871
p8065
sg12
I3
sg13
VAAA
p8066
sg15
I1
sa(dp8067
g9
I217
sg10
VC0007194
p8068
sg12
I27
sg13
Vhypertrophic cardiomyopathy
p8069
sg15
I2
sa(dp8070
g9
I135
sg10
VC0424605
p8071
sg12
I19
sg13
Vdevelopmental delay
p8072
sg15
I2
sasa(dp8073
g2
VWe identified a recurrent de novo ATAD3A c.1582C&gt;T (p.Arg528Trp) variant by whole-exome sequencing (WES) in five unrelated individuals with a core phenotype of global developmental delay, hypotonia, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
p8074
sg4
(lp8075
(dp8076
g9
I34
sg39
g40
sg12
I14
sg13
VATAD3A c.1582C
p8077
sg15
I2
sasg6
(lp8078
(dp8079
g9
I217
sg10
VC0270921
p8080
sg12
I17
sg13
Vaxonal neuropathy
p8081
sg15
I2
sa(dp8082
g9
I240
sg10
VC0007194
p8083
sg12
I27
sg13
Vhypertrophic cardiomyopathy
p8084
sg15
I2
sa(dp8085
g9
I202
sg10
VC0029124
p8086
sg12
I13
sg13
Voptic atrophy
p8087
sg15
I2
sa(dp8088
g9
I163
sg10
VC0557874
p8089
sg12
I26
sg13
Vglobal developmental delay
p8090
sg15
I3
sa(dp8091
g9
I191
sg10
VC0026827
p8092
sg12
I9
sg13
Vhypotonia
p8093
sg15
I1
sasa(dp8094
g2
VImmunoblot and mass spectrometry analyses revealed that the 800-kDa complex contained the OMM translocator protein (18-kDa) and VDAC along with IMM CYP11A1, ATPase family AAA domain-containing protein 3A (ATAD3A), and optic atrophy type 1 proteins, but not ANT.
p8095
sg4
(lp8096
(dp8097
g9
I144
sg39
VP05108
p8098
sg12
I11
sg13
VIMM CYP11A1
p8099
sg15
I2
sa(dp8100
g9
I157
sg39
g40
sg12
I46
sg13
VATPase family AAA domain-containing protein 3A
p8101
sg15
I6
sa(dp8102
g9
I257
sg39
VP12235
p8103
sg12
I3
sg13
VANT
p8104
sg15
I1
sa(dp8105
g9
I90
sg39
VP30536
p8106
sg12
I24
sg13
VOMM translocator protein
p8107
sg15
I3
sa(dp8108
g9
I205
sg39
g40
sg12
I6
sg13
VATAD3A
p8109
sg15
I1
sasg6
(lp8110
(dp8111
g9
I218
sg10
VC0338508
p8112
sg12
I20
sg13
Voptic atrophy type 1
p8113
sg15
I4
sa(dp8114
g9
I171
sg10
VC0162871
p8115
sg12
I3
sg13
VAAA
p8116
sg15
I1
sasa(dp8117
g2
VKnockdown of ATAD3A, but not ANT or optic atrophy type 1, in Leydig cells resulted in a significant decrease in hormone-induced, but not 22R-hydroxycholesterol-supported, steroid production.
p8118
sg4
(lp8119
(dp8120
g9
I29
sg39
VP12235
p8121
sg12
I3
sg13
VANT
p8122
sg15
I1
sa(dp8123
g9
I13
sg39
g40
sg12
I6
sg13
VATAD3A
p8124
sg15
I1
sasg6
(lp8125
(dp8126
g9
I36
sg10
VC0338508
p8127
sg12
I20
sg13
Voptic atrophy type 1
p8128
sg15
I4
sasa(dp8129
g2
VSo, we attempted to evaluate the association between dopamine D2 (DRD2) receptor, serotonergic (5HT2A) receptor and CYP2D6 gene polymorphisms and response to treatment with risperidone in persons with schizophrenia from North India.
p8130
sg4
(lp8131
(dp8132
g9
I53
sg39
VP14416
p8133
sg12
I27
sg13
Vdopamine D2 (DRD2) receptor
p8134
sg15
I4
sa(dp8135
g9
I116
sg39
VP10635
p8136
sg12
I11
sg13
VCYP2D6 gene
p8137
sg15
I2
sa(dp8138
g9
I82
sg39
VP28223
p8139
sg12
I29
sg13
Vserotonergic (5HT2A) receptor
p8140
sg15
I3
sasg6
(lp8141
(dp8142
g9
I201
sg10
VC0036341
p8143
sg12
I13
sg13
Vschizophrenia
p8144
sg15
I1
sasa(dp8145
g2
VWe identified 60 miRNAs that were significantly increased in recurrent serous ovarian carcinoma compared with primary tumor tissue, including miR-630, miR-370, and miR-575.
p8146
sg4
(lp8147
(dp8148
g9
I142
sg39
g40
sg12
I7
sg13
VmiR-630
p8149
sg15
I1
sa(dp8150
g9
I151
sg39
g40
sg12
I7
sg13
VmiR-370
p8151
sg15
I1
sasg6
(lp8152
(dp8153
g9
I110
sg10
VC0677930
p8154
sg12
I13
sg13
Vprimary tumor
p8155
sg15
I2
sa(dp8156
g9
I78
sg10
VC0029925
p8157
sg12
I17
sg13
Vovarian carcinoma
p8158
sg15
I2
sasa(dp8159
g2
VThree other miRNAs, miR-19b, miR-433, and miR-370 were associated with lymph node metastasis, decreased curvature, and poorly differentiated carcinoma.
p8160
sg4
(lp8161
(dp8162
g9
I29
sg39
g40
sg12
I7
sg13
VmiR-433
p8163
sg15
I1
sa(dp8164
g9
I42
sg39
g40
sg12
I7
sg13
VmiR-370
p8165
sg15
I1
sa(dp8166
g9
I20
sg39
g40
sg12
I7
sg13
VmiR-19b
p8167
sg15
I1
sasg6
(lp8168
(dp8169
g9
I71
sg10
VC0686619
p8170
sg12
I21
sg13
Vlymph node metastasis
p8171
sg15
I3
sa(dp8172
g9
I119
sg10
VC0741899
p8173
sg12
I31
sg13
Vpoorly differentiated carcinoma
p8174
sg15
I3
sasa(dp8175
g2
VA preliminary screening study suggested that down-regulation of miR-370 occurs in oral squamous cell carcinoma (OSCC) tissue.
p8176
sg4
(lp8177
(dp8178
g9
I64
sg39
g40
sg12
I7
sg13
VmiR-370
p8179
sg15
I1
sasg6
(lp8180
(dp8181
g9
I87
sg10
VC0007137
p8182
sg12
I23
sg13
Vsquamous cell carcinoma
p8183
sg15
I3
sasa(dp8184
g2
VSquamous cell carcinoma tissues with perineural invasion had lowered miR-370 expression compared with contrasting OSCC.
p8185
sg4
(lp8186
(dp8187
g9
I69
sg39
g40
sg12
I7
sg13
VmiR-370
p8188
sg15
I1
sasg6
(lp8189
(dp8190
g9
I48
sg10
VC2699153
p8191
sg12
I8
sg13
Vinvasion
p8192
sg15
I1
sa(dp8193
g9
I0
sg10
VC0007137
p8194
sg12
I23
sg13
VSquamous cell carcinoma
p8195
sg15
I3
sasa(dp8196
g2
VExpression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues.
p8197
sg4
(lp8198
(dp8199
g9
I36
sg39
g40
sg12
I7
sg13
VmiR-30d
p8200
sg15
I1
sa(dp8201
g9
I57
sg39
g40
sg12
I7
sg13
VmiR-370
p8202
sg15
I1
sa(dp8203
g9
I27
sg39
g40
sg12
I7
sg13
VmiR-30c
p8204
sg15
I1
sa(dp8205
g9
I45
sg39
g40
sg12
I10
sg13
VmiR-30e-3p
p8206
sg15
I1
sasg6
(lp8207
(dp8208
g9
I102
sg10
VC0007097
p8209
sg12
I9
sg13
Vcarcinoma
p8210
sg15
I1
sa(dp8211
g9
I102
sg10
VC0007097
p8212
sg12
I10
sg13
Vcarcinomas
p8213
sg15
I1
sasa(dp8214
g2
VPruritus was assessed by the number of scratching bouts, whilst skin inflammation was evaluated by the extravascular accumulation of intravenously injected 125I-albumin (plasma extravasation) and myeloperoxidase (MPO) activity (neutrophil recruitment).
p8215
sg4
(lp8216
(dp8217
g9
I196
sg39
VP05164
p8218
sg12
I15
sg13
Vmyeloperoxidase
p8219
sg15
I1
sa(dp8220
g9
I161
sg39
VP00441
p8221
sg12
I7
sg13
Valbumin
p8222
sg15
I1
sa(dp8223
g9
I213
sg39
VP05164
p8224
sg12
I3
sg13
VMPO
p8225
sg15
I1
sasg6
(lp8226
(dp8227
g9
I239
sg10
VC0271510
p8228
sg12
I11
sg13
Vrecruitment
p8229
sg15
I1
sa(dp8230
g9
I64
sg10
VC0011603
p8231
sg12
I17
sg13
Vskin inflammation
p8232
sg15
I2
sa(dp8233
g9
I0
sg10
VC0033774
p8234
sg12
I8
sg13
VPruritus
p8235
sg15
I1
sa(dp8236
g9
I177
sg10
VC0015376
p8237
sg12
I13
sg13
Vextravasation
p8238
sg15
I1
sasa(dp8239
g2
VThe neuropeptide PACAP and VPAC1 were previously found to negatively regulate megakaryopoiesis, and inhibition of their physiological pathway was found to have a thrombopoietic effect in conditions where megakaryopoiesis and thrombopoiesis were impaired, such as chemotherapy-induced thrombocytopenia and congenital thrombocytopenia.
p8240
sg4
(lp8241
(dp8242
g9
I27
sg39
VP32241
p8243
sg12
I5
sg13
VVPAC1
p8244
sg15
I1
sa(dp8245
g9
I17
sg39
g40
sg12
I5
sg13
VPACAP
p8246
sg15
I1
sasg6
(lp8247
(dp8248
g9
I305
sg10
VC0272278
p8249
sg12
I27
sg13
Vcongenital thrombocytopenia
p8250
sg15
I2
sa(dp8251
g9
I245
sg10
VC0684336
p8252
sg12
I8
sg13
Vimpaired
p8253
sg15
I1
sasa(dp8254
g2
VThe present study explored the thrombopoietic effect of VPAC1 inhibition in a murine model of syngeneic bone marrow transplantation (BMT) and in passive immune thrombocytopenia.
p8255
sg4
(lp8256
(dp8257
g9
I56
sg39
VP32241
p8258
sg12
I5
sg13
VVPAC1
p8259
sg15
I1
sasg6
(lp8260
(dp8261
g9
I153
sg10
VC0272286
p8262
sg12
I23
sg13
Vimmune thrombocytopenia
p8263
sg15
I2
sasa(dp8264
g2
VRheumatoid arthritis (RA) is an autoimmune disease which may lead to severe disabilities due to structural joint damage and extraarticular manifestations The dendritic cell marker CD83 belongs to the immunoglobulin superfamily and has previously been associated with autoimmune diseases.
p8265
sg4
(lp8266
(dp8267
g9
I180
sg39
g40
sg12
I4
sg13
VCD83
p8268
sg15
I1
sa(dp8269
g9
I200
sg39
g40
sg12
I26
sg13
Vimmunoglobulin superfamily
p8270
sg15
I2
sasg6
(lp8271
(dp8272
g9
I32
sg10
VC0004364
p8273
sg12
I18
sg13
Vautoimmune disease
p8274
sg15
I2
sa(dp8275
g9
I267
sg10
VC0004364
p8276
sg12
I19
sg13
Vautoimmune diseases
p8277
sg15
I2
sa(dp8278
g9
I22
sg10
VC0003873
p8279
sg12
I2
sg13
VRA
p8280
sg15
I1
sa(dp8281
g9
I0
sg10
VC0003873
p8282
sg12
I20
sg13
VRheumatoid arthritis
p8283
sg15
I2
sasa(dp8284
g2
VPatients with PLCH displayed a normal expression of the maturity marker CD83 on BALF myeloid DCs.
p8285
sg4
(lp8286
(dp8287
g9
I72
sg39
g40
sg12
I4
sg13
VCD83
p8288
sg15
I1
sasg6
(lp8289
(dp8290
g9
I93
sg10
VC0268238
p8291
sg12
I3
sg13
VDCs
p8292
sg15
I1
sasa(dp8293
g2
VTo the differentiation-related markers, the BRAF/MAP2K1-mut LCH expressed CD14 but rarely expressed CD83 or CD86 (P &lt; .001).
p8294
sg4
(lp8295
(dp8296
g9
I56
sg39
VP22033
p8297
sg12
I3
sg13
Vmut
p8298
sg15
I1
sa(dp8299
g9
I100
sg39
g40
sg12
I4
sg13
VCD83
p8300
sg15
I1
sa(dp8301
g9
I49
sg39
g40
sg12
I6
sg13
VMAP2K1
p8302
sg15
I1
sa(dp8303
g9
I74
sg39
VP08571
p8304
sg12
I4
sg13
VCD14
p8305
sg15
I1
sa(dp8306
g9
I108
sg39
VP42081
p8307
sg12
I4
sg13
VCD86
p8308
sg15
I1
sa(dp8309
g9
I44
sg39
VP15056
p8310
sg12
I4
sg13
VBRAF
p8311
sg15
I1
sasg6
(lp8312
(dp8313
g9
I60
sg10
VC0019621
p8314
sg12
I3
sg13
VLCH
p8315
sg15
I1
sasa(dp8316
g2
VOn the contrary, BRAF/MAP2K1-wt LCH cells rarely expressed CD14 but expressed CD86, and some also expressed CD83 (P &lt; .001).
p8317
sg4
(lp8318
(dp8319
g9
I108
sg39
g40
sg12
I4
sg13
VCD83
p8320
sg15
I1
sa(dp8321
g9
I59
sg39
VP08571
p8322
sg12
I4
sg13
VCD14
p8323
sg15
I1
sa(dp8324
g9
I17
sg39
VP15056
p8325
sg12
I4
sg13
VBRAF
p8326
sg15
I1
sa(dp8327
g9
I22
sg39
g40
sg12
I6
sg13
VMAP2K1
p8328
sg15
I1
sa(dp8329
g9
I78
sg39
VP42081
p8330
sg12
I4
sg13
VCD86
p8331
sg15
I1
sasg6
(lp8332
(dp8333
g9
I32
sg10
VC0019621
p8334
sg12
I3
sg13
VLCH
p8335
sg15
I1
sasa(dp8336
g2
VThe protein phosphatase 1-like gene (PPM1l) was identified as causal gene for obesity and metabolic abnormalities in mice.
p8337
sg4
(lp8338
(dp8339
g9
I4
sg39
g40
sg12
I31
sg13
Vprotein phosphatase 1-like gene
p8340
sg15
I4
sa(dp8341
g9
I37
sg39
g40
sg12
I5
sg13
VPPM1l
p8342
sg15
I1
sasg6
(lp8343
(dp8344
g9
I78
sg10
VC0028754
p8345
sg12
I7
sg13
Vobesity
p8346
sg15
I1
sasa(dp8347
g2
VThree genes in this network, lipoprotein lipase (Lpl), lactamase beta (Lactb) and protein phosphatase 1-like (Ppm1l), are validated as previously unknown obesity genes, strengthening the association between this network and metabolic disease traits.
p8348
sg4
(lp8349
(dp8350
g9
I110
sg39
g40
sg12
I5
sg13
VPpm1l
p8351
sg15
I1
sa(dp8352
g9
I71
sg39
VP83111
p8353
sg12
I5
sg13
VLactb
p8354
sg15
I1
sa(dp8355
g9
I49
sg39
VP06858
p8356
sg12
I3
sg13
VLpl
p8357
sg15
I1
sa(dp8358
g9
I55
sg39
VP83111
p8359
sg12
I14
sg13
Vlactamase beta
p8360
sg15
I2
sa(dp8361
g9
I29
sg39
VP06858
p8362
sg12
I18
sg13
Vlipoprotein lipase
p8363
sg15
I2
sa(dp8364
g9
I82
sg39
g40
sg12
I26
sg13
Vprotein phosphatase 1-like
p8365
sg15
I3
sasg6
(lp8366
(dp8367
g9
I154
sg10
VC0028754
p8368
sg12
I7
sg13
Vobesity
p8369
sg15
I1
sa(dp8370
g9
I224
sg10
VC0025517
p8371
sg12
I17
sg13
Vmetabolic disease
p8372
sg15
I2
sasa(dp8373
g2
VBased on previous research, we hypothesized that RES regulates FoxO1 transcriptional activity through the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway to achieve an antioxidative effect on osteoporosis and then we confirmed this hypothesis in the present study.
p8374
sg4
(lp8375
(dp8376
g9
I137
sg39
VP42336
p8377
sg12
I4
sg13
VPI3K
p8378
sg15
I1
sa(dp8379
g9
I106
sg39
VP33981
p8380
sg12
I29
sg13
Vphosphatidylinositol-3-kinase
p8381
sg15
I1
sa(dp8382
g9
I143
sg39
g40
sg12
I3
sg13
VAKT
p8383
sg15
I1
sasg6
(lp8384
(dp8385
g9
I203
sg10
VC0029456
p8386
sg12
I12
sg13
Vosteoporosis
p8387
sg15
I1
sasa(dp8388
g2
VFoxO1 is a major action target of RES to confer anti-osteoporosis function, and whose effect stems from its power to improve redox balance.
p8389
sg4
(lp8390
(dp8391
g9
I0
sg39
g40
sg12
I5
sg13
VFoxO1
p8392
sg15
I1
sasg6
(lp8393
(dp8394
g9
I53
sg10
VC0029456
p8395
sg12
I12
sg13
Vosteoporosis
p8396
sg15
I1
sasa(dp8397
g2
VBut whether FoxO1 is involved in the oxidative damage during osteoporosis is largely unknown.
p8398
sg4
(lp8399
(dp8400
g9
I12
sg39
g40
sg12
I5
sg13
VFoxO1
p8401
sg15
I1
sasg6
(lp8402
(dp8403
g9
I61
sg10
VC0029456
p8404
sg12
I12
sg13
Vosteoporosis
p8405
sg15
I1
sasa(dp8406
g2
VIn conclusion, our study revealed that the decline of FoxO1 is an important etiology factor of osteoporosis and unclosed a novel mechanism of FoxO1 regulation by TNF-Alfa.
p8407
sg4
(lp8408
(dp8409
g9
I162
sg39
VP01375
p8410
sg12
I8
sg13
VTNF-Alfa
p8411
sg15
I1
sa(dp8412
g9
I54
sg39
g40
sg12
I5
sg13
VFoxO1
p8413
sg15
I1
sa(dp8414
g9
I54
sg39
g40
sg12
I5
sg13
VFoxO1
p8415
sg15
I1
sasg6
(lp8416
(dp8417
g9
I95
sg10
VC0029456
p8418
sg12
I12
sg13
Vosteoporosis
p8419
sg15
I1
sasa(dp8420
g2
VIn addition, several new PheWAS findings were identified including a cluster of association near the NDFIP1 gene for mental retardation (best SNP rs10057309, p = 4.33 x 10(-7), OR = 1.70, 95%CI = 1.38 - 2.09); association near PLCL1 gene for developmental delays and speech disorder [best SNP rs1595825, p = 1.13 x 10(-8), OR = 0.65(0.57 - 0.76)]; a cluster of associations in the IL5-IL13 region with Eosinophilic Esophagitis (EoE) [best at rs12653750, p = 3.03 x 10(-9), OR = 1.73 95%CI = (1.44 - 2.07)], previously implicated in asthma, allergy, and eosinophilia; and association of variants in GCKR and JAZF1 with allergic rhinitis in our pediatric cohorts [best SNP rs780093, p = 2.18 x 10(-5), OR = 1.39, 95%CI = (1.19 - 1.61)], previously demonstrated in metabolic disease and diabetes in adults.
p8421
sg4
(lp8422
(dp8423
g9
I101
sg39
g40
sg12
I11
sg13
VNDFIP1 gene
p8424
sg15
I2
sa(dp8425
g9
I227
sg39
g40
sg12
I10
sg13
VPLCL1 gene
p8426
sg15
I2
sa(dp8427
g9
I598
sg39
g40
sg12
I4
sg13
VGCKR
p8428
sg15
I1
sa(dp8429
g9
I607
sg39
g40
sg12
I5
sg13
VJAZF1
p8430
sg15
I1
sa(dp8431
g9
I381
sg39
VP05113
p8432
sg12
I15
sg13
VIL5-IL13 region
p8433
sg15
I2
sasg6
(lp8434
(dp8435
g9
I428
sg10
VC0341106
p8436
sg12
I3
sg13
VEoE
p8437
sg15
I1
sa(dp8438
g9
I762
sg10
VC0025517
p8439
sg12
I17
sg13
Vmetabolic disease
p8440
sg15
I2
sa(dp8441
g9
I784
sg10
VC0011849
p8442
sg12
I8
sg13
Vdiabetes
p8443
sg15
I1
sa(dp8444
g9
I553
sg10
VC0014457
p8445
sg12
I12
sg13
Veosinophilia
p8446
sg15
I1
sa(dp8447
g9
I267
sg10
VC0037822
p8448
sg12
I15
sg13
Vspeech disorder
p8449
sg15
I2
sa(dp8450
g9
I540
sg10
VC0020517
p8451
sg12
I7
sg13
Vallergy
p8452
sg15
I1
sa(dp8453
g9
I117
sg10
VC0025362
p8454
sg12
I18
sg13
Vmental retardation
p8455
sg15
I2
sa(dp8456
g9
I618
sg10
VC2607914
p8457
sg12
I17
sg13
Vallergic rhinitis
p8458
sg15
I2
sa(dp8459
g9
I402
sg10
VC0341106
p8460
sg12
I24
sg13
VEosinophilic Esophagitis
p8461
sg15
I2
sa(dp8462
g9
I532
sg10
VC0004096
p8463
sg12
I6
sg13
Vasthma
p8464
sg15
I1
sasa(dp8465
g2
V177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.
p8466
sg4
(lp8467
(dp8468
g9
I1876
sg39
VP49366
p8469
sg12
I49
sg13
Vsuccinate dehydrogenase complex assembly factor 2
p8470
sg15
I6
sa(dp8471
g9
I1927
sg39
VP21912
p8472
sg12
I4
sg13
VSDHB
p8473
sg15
I1
sa(dp8474
g9
I1771
sg39
g40
sg12
I3
sg13
VSDH
p8475
sg15
I1
sa(dp8476
g9
I2023
sg39
VP61278
p8477
sg12
I30
sg13
VSSTRs = somatostatin receptors
p8478
sg15
I4
sa(dp8479
g9
I438
sg39
g40
sg12
I5
sg13
VEGLN2
p8480
sg15
I1
sa(dp8481
g9
I2266
sg39
VP40337
p8482
sg12
I3
sg13
VVHL
p8483
sg15
I1
sa(dp8484
g9
I1802
sg39
VP31040
p8485
sg12
I4
sg13
VSDHA
p8486
sg15
I1
sa(dp8487
g9
I1760
sg39
VP33981
p8488
sg12
I9
sg13
VS6 kinase
p8489
sg15
I2
sa(dp8490
g9
I578
sg39
g40
sg12
I5
sg13
VEPAS1
p8491
sg15
I1
sa(dp8492
g9
I1434
sg39
VP13674
p8493
sg12
I33
sg13
Vprolyl hydroxylase domain protein
p8494
sg15
I4
sa(dp8495
g9
I2303
sg39
VP49366
p8496
sg12
I33
sg13
Valpha-ketoglutarate dehydrogenase
p8497
sg15
I2
sa(dp8498
g9
I464
sg39
g40
sg12
I26
sg13
Vhypoxia inducible factor 2
p8499
sg15
I4
sa(dp8500
g9
I1140
sg39
VP42345
p8501
sg12
I4
sg13
VmTOR
p8502
sg15
I1
sa(dp8503
g9
I1754
sg39
VP62753
p8504
sg12
I3
sg13
VS6K
p8505
sg15
I1
sa(dp8506
g9
I592
sg39
g40
sg12
I32
sg13
Vendothelial PAS domain protein 2
p8507
sg15
I5
sa(dp8508
g9
I492
sg39
g40
sg12
I3
sg13
VelF
p8509
sg15
I1
sa(dp8510
g9
I584
sg39
g40
sg12
I5
sg13
VHIF2A
p8511
sg15
I1
sa(dp8512
g9
I2063
sg39
g40
sg12
I21
sg13
Vsuccinyl-CoA synthase
p8513
sg15
I2
sa(dp8514
g9
I231
sg39
VP31947
p8515
sg12
I20
sg13
VO-methyl transferase
p8516
sg15
I2
sa(dp8517
g9
I958
sg39
g40
sg12
I33
sg13
VIGF-1R = growth factor 1 receptor
p8518
sg15
I6
sa(dp8519
g9
I1777
sg39
VP49366
p8520
sg12
I23
sg13
Vsuccinate dehydrogenase
p8521
sg15
I2
sa(dp8522
g9
I926
sg39
VP48735
p8523
sg12
I30
sg13
VIDH = isocitrate dehydrogenase
p8524
sg15
I4
sa(dp8525
g9
I748
sg39
VP84243
p8526
sg12
I5
sg13
VH3F3A
p8527
sg15
I1
sa(dp8528
g9
I900
sg39
VP01116
p8529
sg12
I3
sg13
VRAS
p8530
sg15
I1
sa(dp8531
g9
I1058
sg39
VP49366
p8532
sg12
I27
sg13
VMDH2 = malate dehydrogenase
p8533
sg15
I4
sa(dp8534
g9
I385
sg39
g40
sg12
I7
sg13
VEGLN1/2
p8535
sg15
I1
sa(dp8536
g9
I253
sg39
VP16870
p8537
sg12
I24
sg13
VCPE = carboxypeptidase E
p8538
sg15
I4
sa(dp8539
g9
I1001
sg39
g40
sg12
I7
sg13
Vkinesin
p8540
sg15
I1
sa(dp8541
g9
I756
sg39
VP62805
p8542
sg12
I25
sg13
Vhistone 3.3 encoding gene
p8543
sg15
I4
sa(dp8544
g9
I625
sg39
g40
sg12
I30
sg13
Vhypoxia-inducible factor 2Alfa
p8545
sg15
I3
sa(dp8546
g9
I1648
sg39
VP35125
p8547
sg12
I20
sg13
Vrat sarcoma oncogene
p8548
sg15
I3
sa(dp8549
g9
I1670
sg39
VP07949
p8550
sg12
I3
sg13
VRET
p8551
sg15
I1
sa(dp8552
g9
I657
sg39
VP29323
p8553
sg12
I3
sg13
VERK
p8554
sg15
I1
sa(dp8555
g9
I1027
sg39
VP61244
p8556
sg12
I29
sg13
VMAX = myc-associated factor X
p8557
sg15
I5
sa(dp8558
g9
I408
sg39
g40
sg12
I28
sg13
Vhypoxia inducible factor 1/2
p8559
sg15
I4
sa(dp8560
g9
I2230
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p8561
sg15
I4
sa(dp8562
g9
I444
sg39
g40
sg12
I4
sg13
VPHD1
p8563
sg15
I1
sasg6
(lp8564
(dp8565
g9
I1771
sg10
VC0018946
p8566
sg12
I3
sg13
VSDH
p8567
sg15
I1
sa(dp8568
g9
I1261
sg10
VC0206754
p8569
sg12
I21
sg13
Vneuroendocrine tumors
p8570
sg15
I2
sa(dp8571
g9
I1477
sg10
VC0031511
p8572
sg12
I16
sg13
VPheochromocytoma
p8573
sg15
I1
sa(dp8574
g9
I1648
sg10
VC1882848
p8575
sg12
I11
sg13
Vrat sarcoma
p8576
sg15
I2
sa(dp8577
g9
I408
sg10
VC0242184
p8578
sg12
I7
sg13
Vhypoxia
p8579
sg15
I1
sa(dp8580
g9
I790
sg10
VC0242184
p8581
sg12
I7
sg13
VHypoxia
p8582
sg15
I1
sa(dp8583
g9
I1213
sg10
VC1850380
p8584
sg12
I3
sg13
VNAd
p8585
sg15
I1
sa(dp8586
g9
I94
sg10
VC1845055
p8587
sg12
I4
sg13
VATRX
p8588
sg15
I1
sa(dp8589
g9
I197
sg10
VC2678439
p8590
sg12
I3
sg13
VCoA
p8591
sg15
I1
sa(dp8592
g9
I1498
sg10
VC0030421
p8593
sg12
I14
sg13
VParagangliomas
p8594
sg15
I1
sa(dp8595
g9
I883
sg10
VC0030421
p8596
sg12
I14
sg13
Vparagangliomas
p8597
sg15
I1
sa(dp8598
g9
I408
sg10
VC0242184
p8599
sg12
I7
sg13
Vhypoxia
p8600
sg15
I1
sa(dp8601
g9
I1284
sg10
VC0027831
p8602
sg12
I3
sg13
VNF1
p8603
sg15
I1
sa(dp8604
g9
I408
sg10
VC0242184
p8605
sg12
I7
sg13
Vhypoxia
p8606
sg15
I1
sa(dp8607
g9
I2266
sg10
VC0019562
p8608
sg12
I3
sg13
VVHL
p8609
sg15
I1
sa(dp8610
g9
I729
sg10
VC1260386
p8611
sg12
I3
sg13
VGSH
p8612
sg15
I1
sa(dp8613
g9
I135
sg10
VC0279702
p8614
sg12
I31
sg13
Vclear cell renal cell carcinoma
p8615
sg15
I5
sa(dp8616
g9
I566
sg10
VC0599156
p8617
sg12
I10
sg13
Vtransition
p8618
sg15
I1
sa(dp8619
g9
I94
sg10
VC1845055
p8620
sg12
I4
sg13
VATRX
p8621
sg15
I1
sa(dp8622
g9
I2144
sg10
VC0040715
p8623
sg12
I13
sg13
Vtranslocation
p8624
sg15
I1
sa(dp8625
g9
I197
sg10
VC2678439
p8626
sg12
I3
sg13
VCoA
p8627
sg15
I1
sa(dp8628
g9
I408
sg10
VC0242184
p8629
sg12
I7
sg13
Vhypoxia
p8630
sg15
I1
sasa(dp8631
g2
VWe report a case of MAX-associated renal cell carcinoma and confirm the role of TMEM127 mutations with renal cell carcinoma predisposition.
p8632
sg4
(lp8633
sg6
(lp8634
(dp8635
g9
I35
sg10
VC0007134
p8636
sg12
I20
sg13
Vrenal cell carcinoma
p8637
sg15
I3
sa(dp8638
g9
I35
sg10
VC0007134
p8639
sg12
I20
sg13
Vrenal cell carcinoma
p8640
sg15
I3
sasa(dp8641
g2
VAlterations of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX), and TMEM127 have been associated with the development of pheochromocytomas (PCs) and paragangliomas (PGLs) and are also associated with the development of renal neoplasms.
p8642
sg4
(lp8643
(dp8644
g9
I40
sg39
VP49366
p8645
sg12
I23
sg13
Vsuccinate dehydrogenase
p8646
sg15
I2
sa(dp8647
g9
I34
sg39
VP40337
p8648
sg12
I3
sg13
VVHL
p8649
sg15
I1
sa(dp8650
g9
I76
sg39
g40
sg12
I7
sg13
VTMEM127
p8651
sg15
I1
sa(dp8652
g9
I15
sg39
VP40337
p8653
sg12
I17
sg13
Vvon Hippel-Lindau
p8654
sg15
I2
sasg6
(lp8655
(dp8656
g9
I129
sg10
VC0031511
p8657
sg12
I17
sg13
Vpheochromocytomas
p8658
sg15
I1
sa(dp8659
g9
I15
sg10
VC0019562
p8660
sg12
I17
sg13
Vvon Hippel-Lindau
p8661
sg15
I2
sa(dp8662
g9
I148
sg10
VC1864389
p8663
sg12
I3
sg13
VPCs
p8664
sg15
I1
sa(dp8665
g9
I157
sg10
VC0030421
p8666
sg12
I14
sg13
Vparagangliomas
p8667
sg15
I1
sa(dp8668
g9
I34
sg10
VC0019562
p8669
sg12
I3
sg13
VVHL
p8670
sg15
I1
sa(dp8671
g9
I227
sg10
VC0022665
p8672
sg12
I15
sg13
Vrenal neoplasms
p8673
sg15
I2
sa(dp8674
g9
I173
sg10
VC0030421
p8675
sg12
I4
sg13
VPGLs
p8676
sg15
I1
sasa(dp8677
g2
VImmunohistochemistry for SDHB and mutation analysis for TMEM127 was performed, in addition to analysis of The Cancer Genome Atlas datasets for SDHX and TMEM127 mutated renal cell carcinomas (RCCs).
p8678
sg4
(lp8679
(dp8680
g9
I25
sg39
VP21912
p8681
sg12
I4
sg13
VSDHB
p8682
sg15
I1
sa(dp8683
g9
I56
sg39
g40
sg12
I7
sg13
VTMEM127
p8684
sg15
I1
sasg6
(lp8685
(dp8686
g9
I110
sg10
VC0006826
p8687
sg12
I6
sg13
VCancer
p8688
sg15
I1
sa(dp8689
g9
I168
sg10
VC0007134
p8690
sg12
I21
sg13
Vrenal cell carcinomas
p8691
sg15
I3
sa(dp8692
g9
I191
sg10
VC0007134
p8693
sg12
I4
sg13
VRCCs
p8694
sg15
I1
sasa(dp8695
g2
VThe expanding etiology for hereditary pheochromocytomas and paragangliomas has recently included SDHA, TMEM127, MAX, and SDHAF2 as susceptibility genes.
p8696
sg4
(lp8697
(dp8698
g9
I103
sg39
g40
sg12
I7
sg13
VTMEM127
p8699
sg15
I1
sa(dp8700
g9
I121
sg39
g40
sg12
I6
sg13
VSDHAF2
p8701
sg15
I1
sa(dp8702
g9
I97
sg39
VP31040
p8703
sg12
I4
sg13
VSDHA
p8704
sg15
I1
sasg6
(lp8705
(dp8706
g9
I38
sg10
VC0031511
p8707
sg12
I17
sg13
Vpheochromocytomas
p8708
sg15
I1
sa(dp8709
g9
I60
sg10
VC0030421
p8710
sg12
I14
sg13
Vparagangliomas
p8711
sg15
I1
sasa(dp8712
g2
VThis study analyzed the prospective, longitudinally followed up European-American-Asian Pheochromocytoma-Paraganglioma Registry for prevalence of SDHA, TMEM127, MAX, and SDHAF2 germline mutation carriers from 1993 to 2016.
p8713
sg4
(lp8714
(dp8715
g9
I146
sg39
VP31040
p8716
sg12
I4
sg13
VSDHA
p8717
sg15
I1
sa(dp8718
g9
I170
sg39
g40
sg12
I6
sg13
VSDHAF2
p8719
sg15
I1
sa(dp8720
g9
I152
sg39
g40
sg12
I7
sg13
VTMEM127
p8721
sg15
I1
sasg6
(lp8722
(dp8723
g9
I177
sg10
VC1705427
p8724
sg12
I17
sg13
Vgermline mutation
p8725
sg15
I2
sa(dp8726
g9
I105
sg10
VC0030421
p8727
sg12
I13
sg13
VParaganglioma
p8728
sg15
I1
sa(dp8729
g9
I88
sg10
VC0031511
p8730
sg12
I16
sg13
VPheochromocytoma
p8731
sg15
I1
sasa(dp8732
g2
VOf 972 unrelated registrants without mutations in the classic pheochromocytoma- and paraganglioma-associated genes (632 female [65.0%] and 340 male [35.0%]; age range, 8-80; mean [SD] age, 41.0 [13.3] years), 58 (6.0%) carried germline mutations of interest, including 29 SDHA, 20 TMEM127, 8 MAX, and 1 SDHAF2.
p8733
sg4
(lp8734
sg6
(lp8735
(dp8736
g9
I62
sg10
VC0031511
p8737
sg12
I16
sg13
Vpheochromocytoma
p8738
sg15
I1
sa(dp8739
g9
I84
sg10
VC0030421
p8740
sg12
I13
sg13
Vparaganglioma
p8741
sg15
I1
sasa(dp8742
g2
VNewly uncovered are 7 of 63 (11%) malignant pheochromocytomas and paragangliomas in SDHA and TMEM127 disease.
p8743
sg4
(lp8744
sg6
(lp8745
(dp8746
g9
I44
sg10
VC0031511
p8747
sg12
I17
sg13
Vpheochromocytomas
p8748
sg15
I1
sa(dp8749
g9
I66
sg10
VC0030421
p8750
sg12
I14
sg13
Vparagangliomas
p8751
sg15
I1
sasa(dp8752
g2
VThe SDHA, TMEM127, MAX, and SDHAF2 genes may contribute to hereditary pheochromocytoma and paraganglioma.
p8753
sg4
(lp8754
(dp8755
g9
I4
sg39
VP31040
p8756
sg12
I4
sg13
VSDHA
p8757
sg15
I1
sa(dp8758
g9
I28
sg39
g40
sg12
I12
sg13
VSDHAF2 genes
p8759
sg15
I2
sa(dp8760
g9
I10
sg39
g40
sg12
I7
sg13
VTMEM127
p8761
sg15
I1
sasg6
(lp8762
(dp8763
g9
I91
sg10
VC0030421
p8764
sg12
I13
sg13
Vparaganglioma
p8765
sg15
I1
sa(dp8766
g9
I70
sg10
VC0031511
p8767
sg12
I16
sg13
Vpheochromocytoma
p8768
sg15
I1
sasa(dp8769
g2
V3-MT = 3-methoxytyramine; EPAS1 = endothelial pas domain protein 1; FH = fumarate hydratase; HIF2A = hypoxia inducible factor type 2A; MEN2 = multiple endocrine neoplasia type 2; NF1 = neurofibromatosis type 1; PNMT = phenylethanolamine N-methyltransferase; PPGL = pheochromocytoma and paraganglioma; RET = rearranged during transfection; SDH = succinate dehydrogenase; SDHAF2 = succinate dehydrogenase complex assembly factor 2; TCA = tricarboxylic acid; TH = tyrosine hydroxylase; TMEM127 = transmembrane protein 127; VHL = von Hippel-Lindau.
p8770
sg4
(lp8771
(dp8772
g9
I370
sg39
g40
sg12
I6
sg13
VSDHAF2
p8773
sg15
I1
sa(dp8774
g9
I93
sg39
g40
sg12
I5
sg13
VHIF2A
p8775
sg15
I1
sa(dp8776
g9
I101
sg39
g40
sg12
I32
sg13
Vhypoxia inducible factor type 2A
p8777
sg15
I5
sa(dp8778
g9
I483
sg39
g40
sg12
I7
sg13
VTMEM127
p8779
sg15
I1
sa(dp8780
g9
I456
sg39
VP07101
p8781
sg12
I25
sg13
VTH = tyrosine hydroxylase
p8782
sg15
I4
sa(dp8783
g9
I339
sg39
g40
sg12
I3
sg13
VSDH
p8784
sg15
I1
sa(dp8785
g9
I345
sg39
VP49366
p8786
sg12
I23
sg13
Vsuccinate dehydrogenase
p8787
sg15
I2
sa(dp8788
g9
I345
sg39
VP49366
p8789
sg12
I23
sg13
Vsuccinate dehydrogenase
p8790
sg15
I2
sasg6
(lp8791
(dp8792
g9
I265
sg10
VC0031511
p8793
sg12
I16
sg13
Vpheochromocytoma
p8794
sg15
I1
sa(dp8795
g9
I286
sg10
VC0030421
p8796
sg12
I13
sg13
Vparaganglioma
p8797
sg15
I1
sa(dp8798
g9
I179
sg10
VC0027831
p8799
sg12
I3
sg13
VNF1
p8800
sg15
I1
sa(dp8801
g9
I520
sg10
VC0019562
p8802
sg12
I3
sg13
VVHL
p8803
sg15
I1
sa(dp8804
g9
I142
sg10
VC0025268
p8805
sg12
I35
sg13
Vmultiple endocrine neoplasia type 2
p8806
sg15
I5
sa(dp8807
g9
I101
sg10
VC0242184
p8808
sg12
I7
sg13
Vhypoxia
p8809
sg15
I1
sa(dp8810
g9
I339
sg10
VC0018946
p8811
sg12
I3
sg13
VSDH
p8812
sg15
I1
sa(dp8813
g9
I185
sg10
VC0027831
p8814
sg12
I24
sg13
Vneurofibromatosis type 1
p8815
sg15
I3
sasa(dp8816
g2
VThis study assessed the effects of leukemia-related protein 16 (LRP16) on the regulation of pancreatic functions in mouse insulinoma (MIN6) cells.
p8817
sg4
(lp8818
(dp8819
g9
I35
sg39
g40
sg12
I27
sg13
Vleukemia-related protein 16
p8820
sg15
I3
sa(dp8821
g9
I64
sg39
g40
sg12
I5
sg13
VLRP16
p8822
sg15
I1
sasg6
(lp8823
(dp8824
g9
I35
sg10
VC0023418
p8825
sg12
I8
sg13
Vleukemia
p8826
sg15
I1
sa(dp8827
g9
I116
sg10
VC1522248
p8828
sg12
I16
sg13
Vmouse insulinoma
p8829
sg15
I2
sasa(dp8830
g2
VOur recent studies have shown that a selective ABHD6 inhibitor WWL70 has anti-inflammatory and neuroprotective effects in animal models of traumatic brain injury and multiple sclerosis.
p8831
sg4
(lp8832
(dp8833
g9
I47
sg39
g40
sg12
I5
sg13
VABHD6
p8834
sg15
I1
sasg6
(lp8835
(dp8836
g9
I166
sg10
VC0026769
p8837
sg12
I18
sg13
Vmultiple sclerosis
p8838
sg15
I2
sasa(dp8839
g2
VIn this study, we investigated the role of targeting ABHD6 in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
p8840
sg4
(lp8841
(dp8842
g9
I53
sg39
g40
sg12
I5
sg13
VABHD6
p8843
sg15
I1
sasg6
(lp8844
(dp8845
g9
I105
sg10
VC0014070
p8846
sg12
I3
sg13
VEAE
p8847
sg15
I1
sa(dp8848
g9
I86
sg10
VC0014070
p8849
sg12
I17
sg13
Vencephalomyelitis
p8850
sg15
I1
sa(dp8851
g9
I150
sg10
VC0026769
p8852
sg12
I2
sg13
VMS
p8853
sg15
I1
sa(dp8854
g9
I130
sg10
VC0026769
p8855
sg12
I18
sg13
Vmultiple sclerosis
p8856
sg15
I2
sa(dp8857
g9
I75
sg10
VC0443146
p8858
sg12
I10
sg13
Vautoimmune
p8859
sg15
I1
sasa(dp8860
g2
VExpression of clusterin correlates with tumor progression and therapeutic response in several human malignancies, including breast cancer.
p8861
sg4
(lp8862
sg6
(lp8863
(dp8864
g9
I100
sg10
VC0006826
p8865
sg12
I12
sg13
Vmalignancies
p8866
sg15
I1
sa(dp8867
g9
I40
sg10
VC0178874
p8868
sg12
I17
sg13
Vtumor progression
p8869
sg15
I2
sa(dp8870
g9
I124
sg10
VC0678222
p8871
sg12
I13
sg13
Vbreast cancer
p8872
sg15
I2
sasa(dp8873
g2
VThe objective of this explorative study was to determine whether clusterin expression in breast cancer correlated with clinical pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy (NAC).
p8874
sg4
(lp8875
sg6
(lp8876
(dp8877
g9
I89
sg10
VC0678222
p8878
sg12
I13
sg13
Vbreast cancer
p8879
sg15
I2
sasa(dp8880
g2
VWe determined the clusterin expression pattern in 72 triple negative breast cancers (TNBC) treated with NAC before surgery.
p8881
sg4
(lp8882
(dp8883
g9
I18
sg39
VP10909
p8884
sg12
I9
sg13
Vclusterin
p8885
sg15
I1
sasg6
(lp8886
(dp8887
g9
I69
sg10
VC0006142
p8888
sg12
I14
sg13
Vbreast cancers
p8889
sg15
I2
sasa(dp8890
g2
VClusterin was present at higher levels in both fractions of patients with early and intermediate stages of breast cancer.
p8891
sg4
(lp8892
(dp8893
g9
I0
sg39
VP10909
p8894
sg12
I9
sg13
VClusterin
p8895
sg15
I1
sasg6
(lp8896
(dp8897
g9
I107
sg10
VC0678222
p8898
sg12
I13
sg13
Vbreast cancer
p8899
sg15
I2
sasa(dp8900
g2
VDiscovery and development of a novel anticancer PEG-SMR-Clu peptide to prevent breast cancer metastasis.
p8901
sg4
(lp8902
(dp8903
g9
I48
sg39
VP09466
p8904
sg12
I19
sg13
VPEG-SMR-Clu peptide
p8905
sg15
I2
sasg6
(lp8906
(dp8907
g9
I93
sg10
VC0027627
p8908
sg12
I10
sg13
Vmetastasis
p8909
sg15
I1
sa(dp8910
g9
I79
sg10
VC0678222
p8911
sg12
I13
sg13
Vbreast cancer
p8912
sg15
I2
sasa(dp8913
g2
VPEG-SMRwt-Clu and PEG-SMRwt peptides inhibited the growth of both of MCF-7 (estrogen responsive, ER+) and MDA-MD-231 (estrogen non-responsive, ER-) human breast cancer cells in a dose and time-dependent manner, without inducing cytotoxic effects.
p8914
sg4
(lp8915
(dp8916
g9
I18
sg39
VP09466
p8917
sg12
I18
sg13
VPEG-SMRwt peptides
p8918
sg15
I2
sa(dp8919
g9
I0
sg39
VP09466
p8920
sg12
I3
sg13
VPEG
p8921
sg15
I1
sa(dp8922
g9
I10
sg39
VP10909
p8923
sg12
I3
sg13
VClu
p8924
sg15
I1
sasg6
(lp8925
(dp8926
g9
I154
sg10
VC0678222
p8927
sg12
I13
sg13
Vbreast cancer
p8928
sg15
I2
sasa(dp8929
g2
VPEG-SMRwt-CLU peptides inhibited the growth of human breast cancer cells and blocked tumor exosome release in vitro.
p8930
sg4
(lp8931
(dp8932
g9
I0
sg39
VP09466
p8933
sg12
I22
sg13
VPEG-SMRwt-CLU peptides
p8934
sg15
I2
sasg6
(lp8935
(dp8936
g9
I53
sg10
VC0678222
p8937
sg12
I13
sg13
Vbreast cancer
p8938
sg15
I2
sa(dp8939
g9
I85
sg10
VC0027651
p8940
sg12
I5
sg13
Vtumor
p8941
sg15
I1
sasa(dp8942
g2
VClinically, breast cancer patients possess sCLU expression only in mature CD68(+) macrophages but not in immature CD33(+) immunosuppressive myeloid cells infiltrating the tumors.
p8943
sg4
(lp8944
(dp8945
g9
I74
sg39
VP34810
p8946
sg12
I4
sg13
VCD68
p8947
sg15
I1
sasg6
(lp8948
(dp8949
g9
I35
sg10
VC0850310
p8950
sg12
I7
sg13
Vpossess
p8951
sg15
I1
sa(dp8952
g9
I154
sg10
VC0332448
p8953
sg12
I12
sg13
Vinfiltrating
p8954
sg15
I1
sa(dp8955
g9
I12
sg10
VC0678222
p8956
sg12
I13
sg13
Vbreast cancer
p8957
sg15
I2
sa(dp8958
g9
I171
sg10
VC0027651
p8959
sg12
I6
sg13
Vtumors
p8960
sg15
I1
sasa(dp8961
g2
VImmunoblotting and MRM-based validation in a separate cohort testified a panel of 21 proteins such as zinc-alpha2-glycoprotein, A2GL, retinol-binding protein 4, annexin A1, SAP3, SRC8, gelsolin, kininogen 1, CO9, clusterin, ceruloplasmin, and Alfa1-antitrypsin could be a panel of candidate markers that could discriminate HE breast cancer from healthy controls.
p8962
sg4
(lp8963
(dp8964
g9
I224
sg39
VP00450
p8965
sg12
I13
sg13
Vceruloplasmin
p8966
sg15
I1
sa(dp8967
g9
I208
sg39
g40
sg12
I3
sg13
VCO9
p8968
sg15
I1
sa(dp8969
g9
I173
sg39
VP17900
p8970
sg12
I4
sg13
VSAP3
p8971
sg15
I1
sa(dp8972
g9
I134
sg39
VP02753
p8973
sg12
I25
sg13
Vretinol-binding protein 4
p8974
sg15
I3
sa(dp8975
g9
I213
sg39
VP10909
p8976
sg12
I9
sg13
Vclusterin
p8977
sg15
I1
sa(dp8978
g9
I243
sg39
g40
sg12
I17
sg13
VAlfa1-antitrypsin
p8979
sg15
I1
sa(dp8980
g9
I185
sg39
VP06396
p8981
sg12
I8
sg13
Vgelsolin
p8982
sg15
I1
sa(dp8983
g9
I195
sg39
VP01042
p8984
sg12
I11
sg13
Vkininogen 1
p8985
sg15
I2
sa(dp8986
g9
I102
sg39
VP36222
p8987
sg12
I24
sg13
Vzinc-alpha2-glycoprotein
p8988
sg15
I1
sa(dp8989
g9
I161
sg39
VP04083
p8990
sg12
I10
sg13
Vannexin A1
p8991
sg15
I2
sasg6
(lp8992
(dp8993
g9
I326
sg10
VC0678222
p8994
sg12
I13
sg13
Vbreast cancer
p8995
sg15
I2
sasa(dp8996
g2
VExportin 4 (XPO4) is a novel identified candidate tumour-suppressor gene involved in the pathogenesis of hepatocellular carcinoma (HCC).
p8997
sg4
(lp8998
(dp8999
g9
I12
sg39
g40
sg12
I4
sg13
VXPO4
p9000
sg15
I1
sa(dp9001
g9
I0
sg39
g40
sg12
I10
sg13
VExportin 4
p9002
sg15
I2
sasg6
(lp9003
(dp9004
g9
I105
sg10
VC2239176
p9005
sg12
I24
sg13
Vhepatocellular carcinoma
p9006
sg15
I2
sa(dp9007
g9
I131
sg10
VC2239176
p9008
sg12
I3
sg13
VHCC
p9009
sg15
I1
sa(dp9010
g9
I89
sg10
VC0699748
p9011
sg12
I12
sg13
Vpathogenesis
p9012
sg15
I1
sa(dp9013
g9
I50
sg10
VC0027651
p9014
sg12
I6
sg13
Vtumour
p9015
sg15
I1
sasa(dp9016
g2
VTo evaluate potential biomarkers in HCC, we employed multiple methods in this study, including qPCR, immunostaining methods and tissue microarrays (TMAs), as well as histological and pathological analysis, to assess TGFBeta, XPO4, elF5A2 and ANGPTL4 in cancerous and paracancerous liver tissues from 280 patients suffering from liver cancer.
p9017
sg4
(lp9018
(dp9019
g9
I225
sg39
g40
sg12
I4
sg13
VXPO4
p9020
sg15
I1
sa(dp9021
g9
I216
sg39
VP01137
p9022
sg12
I7
sg13
VTGFBeta
p9023
sg15
I1
sa(dp9024
g9
I242
sg39
g40
sg12
I7
sg13
VANGPTL4
p9025
sg15
I1
sasg6
(lp9026
(dp9027
g9
I313
sg10
VC0683278
p9028
sg12
I9
sg13
Vsuffering
p9029
sg15
I1
sa(dp9030
g9
I328
sg10
VC0345904
p9031
sg12
I12
sg13
Vliver cancer
p9032
sg15
I2
sa(dp9033
g9
I36
sg10
VC2239176
p9034
sg12
I3
sg13
VHCC
p9035
sg15
I1
sasa(dp9036
g2
VXPO4 in cancerous liver tissue and TGFBeta1 in paracancerous liver tissue were positively correlated with tumor differentiation.
p9037
sg4
(lp9038
(dp9039
g9
I0
sg39
g40
sg12
I4
sg13
VXPO4
p9040
sg15
I1
sasg6
(lp9041
(dp9042
g9
I106
sg10
VC0027651
p9043
sg12
I5
sg13
Vtumor
p9044
sg15
I1
sasa(dp9045
g2
VAdditionally, higher levels of XPO4 in cancerous liver tissue suggested that the patient would have a better prognosis and survival rate.
p9046
sg4
(lp9047
(dp9048
g9
I31
sg39
g40
sg12
I4
sg13
VXPO4
p9049
sg15
I1
sasg6
(lp9050
sa(dp9051
g2
VHowever, higher production of XPO4 in paracancerous liver tissue suggested a worse prognosis.
p9052
sg4
(lp9053
(dp9054
g9
I30
sg39
g40
sg12
I4
sg13
VXPO4
p9055
sg15
I1
sasg6
(lp9056
sa(dp9057
g2
VAll the results above provide new insights into better understanding biological indicators, such as XPO4, TGFBeta1, ANGPTL4 and elF5A2, in the prediction and evaluation of liver cancer, as well as signaling pathways in the control of liver cancer.
p9058
sg4
(lp9059
(dp9060
g9
I106
sg39
VP01137
p9061
sg12
I8
sg13
VTGFBeta1
p9062
sg15
I1
sa(dp9063
g9
I116
sg39
g40
sg12
I7
sg13
VANGPTL4
p9064
sg15
I1
sa(dp9065
g9
I100
sg39
g40
sg12
I4
sg13
VXPO4
p9066
sg15
I1
sasg6
(lp9067
(dp9068
g9
I172
sg10
VC0345904
p9069
sg12
I12
sg13
Vliver cancer
p9070
sg15
I2
sa(dp9071
g9
I172
sg10
VC0345904
p9072
sg12
I12
sg13
Vliver cancer
p9073
sg15
I2
sasa(dp9074
g2
VXPO4 and TGFBeta1 may serve as useful markers to evaluate the size and prognosis of liver cancer.
p9075
sg4
(lp9076
(dp9077
g9
I9
sg39
VP01137
p9078
sg12
I8
sg13
VTGFBeta1
p9079
sg15
I1
sa(dp9080
g9
I0
sg39
g40
sg12
I4
sg13
VXPO4
p9081
sg15
I1
sasg6
(lp9082
(dp9083
g9
I84
sg10
VC0345904
p9084
sg12
I12
sg13
Vliver cancer
p9085
sg15
I2
sasa(dp9086
g2
VExportin 4 (XPO4) is a recently-discovered candidate tumor-suppressor gene identified in a liver cancer mouse model.
p9087
sg4
(lp9088
(dp9089
g9
I12
sg39
g40
sg12
I4
sg13
VXPO4
p9090
sg15
I1
sa(dp9091
g9
I0
sg39
g40
sg12
I10
sg13
VExportin 4
p9092
sg15
I2
sasg6
(lp9093
(dp9094
g9
I91
sg10
VC0345904
p9095
sg12
I12
sg13
Vliver cancer
p9096
sg15
I2
sa(dp9097
g9
I53
sg10
VC0027651
p9098
sg12
I5
sg13
Vtumor
p9099
sg15
I1
sasa(dp9100
g2
VTo investigate the role of XPO4 in hepatocellular carcinoma (HCC) pathogenesis, we determined XPO4 expression and its correlation to prognosis in human primary HCC.
p9101
sg4
(lp9102
(dp9103
g9
I27
sg39
g40
sg12
I4
sg13
VXPO4
p9104
sg15
I1
sa(dp9105
g9
I27
sg39
g40
sg12
I4
sg13
VXPO4
p9106
sg15
I1
sasg6
(lp9107
(dp9108
g9
I66
sg10
VC0699748
p9109
sg12
I12
sg13
Vpathogenesis
p9110
sg15
I1
sa(dp9111
g9
I61
sg10
VC2239176
p9112
sg12
I3
sg13
VHCC
p9113
sg15
I1
sa(dp9114
g9
I61
sg10
VC2239176
p9115
sg12
I3
sg13
VHCC
p9116
sg15
I1
sa(dp9117
g9
I35
sg10
VC2239176
p9118
sg12
I24
sg13
Vhepatocellular carcinoma
p9119
sg15
I2
sasa(dp9120
g2
VOne gene, XPO4, encodes a nuclear export protein whose substrate, EIF5A2, is amplified in human tumors, is required for proliferation of XPO4-deficient tumor cells, and promotes hepatocellular carcinoma in mice.
p9121
sg4
(lp9122
(dp9123
g9
I10
sg39
g40
sg12
I4
sg13
VXPO4
p9124
sg15
I1
sa(dp9125
g9
I10
sg39
g40
sg12
I4
sg13
VXPO4
p9126
sg15
I1
sa(dp9127
g9
I66
sg39
g40
sg12
I6
sg13
VEIF5A2
p9128
sg15
I1
sasg6
(lp9129
(dp9130
g9
I120
sg10
VC0334094
p9131
sg12
I13
sg13
Vproliferation
p9132
sg15
I1
sa(dp9133
g9
I96
sg10
VC0027651
p9134
sg12
I5
sg13
Vtumor
p9135
sg15
I1
sa(dp9136
g9
I96
sg10
VC0027651
p9137
sg12
I6
sg13
Vtumors
p9138
sg15
I1
sa(dp9139
g9
I178
sg10
VC1512411
p9140
sg12
I24
sg13
Vhepatocellular carcinoma
p9141
sg15
I2
sasa(dp9142
g2
VIn a population of 159 patients on renal replacement therapy (RDT) we performed a 1-yr prospective observational study, with common parameters to indicate cardiovascular pathologies (PAS, LVMI), calcium-phosphorous metabolism (Ca, PO 4 , Ca x PO 4 ), dialytic adequacy (Kt/V, URR%), nutritional status (nPCR, Alb, K), and anemia (hemoglobin (Hb)).
p9143
sg4
(lp9144
(dp9145
g9
I330
sg39
g40
sg12
I10
sg13
Vhemoglobin
p9146
sg15
I1
sa(dp9147
g9
I276
sg39
g40
sg12
I3
sg13
VURR
p9148
sg15
I1
sa(dp9149
g9
I309
sg39
g40
sg12
I3
sg13
VAlb
p9150
sg15
I1
sasg6
(lp9151
(dp9152
g9
I322
sg10
VC0002871
p9153
sg12
I6
sg13
Vanemia
p9154
sg15
I1
sa(dp9155
g9
I62
sg10
VC0206743
p9156
sg12
I3
sg13
VRDT
p9157
sg15
I1
sasa(dp9158
g2
VBased on serial mortality rates for the general population of England and Wales, significantly increased mortality was shown for cancers of the pharynx (observed (Obs) 4, expected (Exp) 0.7, standardised mortality ratio (SMR) 559, p&lt;0.05), non-malignant diseases of the respiratory system (Obs 61, Exp 43.0, SMR 142, p&lt;0.05), and non-malignant diseases of the genitourinary system (Obs 10, Exp 4.1, SMR 243, p&lt;0.05).
p9159
sg4
(lp9160
sg6
(lp9161
(dp9162
g9
I350
sg10
VC0080276
p9163
sg12
I36
sg13
Vdiseases of the genitourinary system
p9164
sg15
I5
sa(dp9165
g9
I129
sg10
VC0006826
p9166
sg12
I7
sg13
Vcancers
p9167
sg15
I1
sa(dp9168
g9
I257
sg10
VC0035204
p9169
sg12
I34
sg13
Vdiseases of the respiratory system
p9170
sg15
I5
sasa(dp9171
g2
VNon-significantly increased SMRs were shown for lung cancer (Obs 45, Exp 40.7, SMR 111) and cancer of the prostate (Obs 9, Exp 7.5, SMR 116).
p9172
sg4
(lp9173
(dp9174
g9
I79
sg39
g40
sg12
I7
sg13
VSMR 111
p9175
sg15
I2
sa(dp9176
g9
I116
sg39
VP41159
p9177
sg12
I5
sg13
VObs 9
p9178
sg15
I2
sa(dp9179
g9
I123
sg39
g40
sg12
I5
sg13
VExp 7
p9180
sg15
I2
sasg6
(lp9181
(dp9182
g9
I92
sg10
VC0600139
p9183
sg12
I22
sg13
Vcancer of the prostate
p9184
sg15
I4
sa(dp9185
g9
I48
sg10
VC0684249
p9186
sg12
I11
sg13
Vlung cancer
p9187
sg15
I2
sasa(dp9188
g2
VIn this largest-ever GWAS meta-analysis for nicotine dependence and the largest-ever cross-ancestry GWAS meta-analysis for any smoking phenotype, we reconfirmed the well-known CHRNA5-CHRNA3-CHRNB4 genes and further yielded a novel association in the DNA methyltransferase gene DNMT3B.
p9189
sg4
(lp9190
(dp9191
g9
I250
sg39
g40
sg12
I33
sg13
VDNA methyltransferase gene DNMT3B
p9192
sg15
I4
sa(dp9193
g9
I176
sg39
VP30532
p9194
sg12
I26
sg13
VCHRNA5-CHRNA3-CHRNB4 genes
p9195
sg15
I2
sasg6
(lp9196
(dp9197
g9
I44
sg10
VC0028043
p9198
sg12
I19
sg13
Vnicotine dependence
p9199
sg15
I2
sasa(dp9200
g2
VThe relationship of HTR4 (rs3995090), HTR2A (rs6313), GRIK5 (rs8099939), GRIN2B (rs2268132), and CHRNB4 (rs1948) gene polymorphisms and COPD, as well as the contribution of these polymorphisms to the variations in quantitative characteristics that describe respiratory function, smoking behavior, and nicotine dependence was assessed in an ethnically homogeneous Tatar population.
p9201
sg4
(lp9202
(dp9203
g9
I38
sg39
VP28223
p9204
sg12
I5
sg13
VHTR2A
p9205
sg15
I1
sa(dp9206
g9
I97
sg39
VP30926
p9207
sg12
I6
sg13
VCHRNB4
p9208
sg15
I1
sa(dp9209
g9
I73
sg39
g40
sg12
I6
sg13
VGRIN2B
p9210
sg15
I1
sa(dp9211
g9
I54
sg39
g40
sg12
I5
sg13
VGRIK5
p9212
sg15
I1
sasg6
(lp9213
(dp9214
g9
I136
sg10
VC0024117
p9215
sg12
I4
sg13
VCOPD
p9216
sg15
I1
sa(dp9217
g9
I301
sg10
VC0028043
p9218
sg12
I19
sg13
Vnicotine dependence
p9219
sg15
I2
sasa(dp9220
g2
VGenome-wide association studies (GWASs) have identified associations between the CHRNA5-CHRNA3-CHRNB4 gene cluster and smoking heaviness and nicotine dependence.
p9221
sg4
(lp9222
(dp9223
g9
I81
sg39
VP30532
p9224
sg12
I6
sg13
VCHRNA5
p9225
sg15
I1
sa(dp9226
g9
I95
sg39
VP30926
p9227
sg12
I6
sg13
VCHRNB4
p9228
sg15
I1
sa(dp9229
g9
I88
sg39
VP32297
p9230
sg12
I6
sg13
VCHRNA3
p9231
sg15
I1
sasg6
(lp9232
(dp9233
g9
I141
sg10
VC0028043
p9234
sg12
I19
sg13
Vnicotine dependence
p9235
sg15
I2
sasa(dp9236
g2
VPolymorphisms in the CHRNA5-CHRNA3-CHRNB4 gene cluster (Chr15q25) have been robustly associated with nicotine dependence, including genome-wide studies, as well as with cognitive and neuropsychological measures.
p9237
sg4
(lp9238
(dp9239
g9
I21
sg39
VP30532
p9240
sg12
I33
sg13
VCHRNA5-CHRNA3-CHRNB4 gene cluster
p9241
sg15
I3
sasg6
(lp9242
(dp9243
g9
I101
sg10
VC0028043
p9244
sg12
I19
sg13
Vnicotine dependence
p9245
sg15
I2
sasa(dp9246
g2
VHere, we evaluated the effect of polymorphisms in CHRNA5-CHRNA3-CHRNB4 gene cluster and their interaction with tobacco smoking status on cognition in patients with Attention Deficit/Hyperactivity Disorder (ADHD).
p9247
sg4
(lp9248
(dp9249
g9
I50
sg39
VP30532
p9250
sg12
I33
sg13
VCHRNA5-CHRNA3-CHRNB4 gene cluster
p9251
sg15
I3
sasg6
(lp9252
(dp9253
g9
I164
sg10
VC1263846
p9254
sg12
I40
sg13
VAttention Deficit/Hyperactivity Disorder
p9255
sg15
I3
sa(dp9256
g9
I206
sg10
VC1263846
p9257
sg12
I4
sg13
VADHD
p9258
sg15
I1
sasa(dp9259
g2
VEight SNPs from the CHRNA5-CHRNA3-CHRNB4 gene cluster were evaluated on a clinical sample of 403 adults with ADHD.
p9260
sg4
(lp9261
(dp9262
g9
I34
sg39
VP30926
p9263
sg12
I6
sg13
VCHRNB4
p9264
sg15
I1
sa(dp9265
g9
I20
sg39
VP30532
p9266
sg12
I6
sg13
VCHRNA5
p9267
sg15
I1
sa(dp9268
g9
I27
sg39
VP32297
p9269
sg12
I6
sg13
VCHRNA3
p9270
sg15
I1
sasg6
(lp9271
(dp9272
g9
I109
sg10
VC1263846
p9273
sg12
I4
sg13
VADHD
p9274
sg15
I1
sasa(dp9275
g2
VThe associations between CHRNA5-CHRNA3-CHRNB4 variants and cigarettes per day (CPD), the Fagerstroem Test for Nicotine Dependence (FTND), and craving were analyzed in data from 662 lifetime smokers from an Israeli adult Jewish household sample.
p9276
sg4
(lp9277
(dp9278
g9
I25
sg39
VP30532
p9279
sg12
I29
sg13
VCHRNA5-CHRNA3-CHRNB4 variants
p9280
sg15
I2
sasg6
(lp9281
(dp9282
g9
I110
sg10
VC0028043
p9283
sg12
I19
sg13
VNicotine Dependence
p9284
sg15
I2
sasa(dp9285
g2
VWe found a significant increase in levels of adhesion molecules (VCAM-1) and selectins (E-selectin) in parallel with increased severity of diabetic retinopathy, with a significant difference of inflammatory markers between stages of retinopathy.
p9286
sg4
(lp9287
(dp9288
g9
I88
sg39
VP16581
p9289
sg12
I10
sg13
VE-selectin
p9290
sg15
I1
sa(dp9291
g9
I65
sg39
VP19320
p9292
sg12
I6
sg13
VVCAM-1
p9293
sg15
I1
sasg6
(lp9294
(dp9295
g9
I148
sg10
VC0035309
p9296
sg12
I11
sg13
Vretinopathy
p9297
sg15
I1
sa(dp9298
g9
I139
sg10
VC0011884
p9299
sg12
I20
sg13
Vdiabetic retinopathy
p9300
sg15
I2
sa(dp9301
g9
I45
sg10
VC0001511
p9302
sg12
I8
sg13
Vadhesion
p9303
sg15
I1
sasa(dp9304
g2
VOur aim was to investigate the role of soluble E-selectin in the formation of diabetic retinopathy.
p9305
sg4
(lp9306
(dp9307
g9
I47
sg39
VP16581
p9308
sg12
I10
sg13
VE-selectin
p9309
sg15
I1
sasg6
(lp9310
(dp9311
g9
I78
sg10
VC0011884
p9312
sg12
I20
sg13
Vdiabetic retinopathy
p9313
sg15
I2
sasa(dp9314
g2
VAn elevated E-selectin level can play a role in the development of diabetic retinopathy, but it does not seem to alter disease severity.
p9315
sg4
(lp9316
(dp9317
g9
I12
sg39
VP16581
p9318
sg12
I10
sg13
VE-selectin
p9319
sg15
I1
sasg6
(lp9320
(dp9321
g9
I67
sg10
VC0011884
p9322
sg12
I20
sg13
Vdiabetic retinopathy
p9323
sg15
I2
sasa(dp9324
g2
VHowever, glycemic control and the reduction of cardiovascular risk factors may also alter the level of E-selectin that might play a role in the prevention of diabetic retinopathy.
p9325
sg4
(lp9326
(dp9327
g9
I103
sg39
VP16581
p9328
sg12
I10
sg13
VE-selectin
p9329
sg15
I1
sasg6
(lp9330
(dp9331
g9
I158
sg10
VC0011884
p9332
sg12
I20
sg13
Vdiabetic retinopathy
p9333
sg15
I2
sasa(dp9334
g2
VTo evaluate efficacy of the treatment, the progression of the disease (number of laser treatments, number of bevacizumab treatments, and incidence of retinal detachment) was evaluated by serial ophthalmologic examinations, and plasma soluble E-selectin levels were measured weekly.
p9335
sg4
(lp9336
(dp9337
g9
I227
sg39
VP16581
p9338
sg12
I25
sg13
Vplasma soluble E-selectin
p9339
sg15
I3
sasg6
(lp9340
(dp9341
g9
I150
sg10
VC0035305
p9342
sg12
I18
sg13
Vretinal detachment
p9343
sg15
I2
sasa(dp9344
g2
VAfter adjusting for age, glycemic control, and other potential confounders, baseline plasma levels of E-selectin were associated significantly with progression of DR, E-selectin and tumor necrosis factor-Alfa (TNF-Alfa) levels with incidence of proliferative DR (PDR), and soluble intercellular adhesion molecule-1 (sICAM-1) and TNF-Alfa levels with incidence of macular edema (ME).
p9345
sg4
(lp9346
(dp9347
g9
I210
sg39
VP01375
p9348
sg12
I8
sg13
VTNF-Alfa
p9349
sg15
I1
sa(dp9350
g9
I210
sg39
VP01375
p9351
sg12
I8
sg13
VTNF-Alfa
p9352
sg15
I1
sa(dp9353
g9
I102
sg39
VP16581
p9354
sg12
I10
sg13
VE-selectin
p9355
sg15
I1
sa(dp9356
g9
I102
sg39
VP16581
p9357
sg12
I10
sg13
VE-selectin
p9358
sg15
I1
sa(dp9359
g9
I281
sg39
VP05362
p9360
sg12
I33
sg13
Vintercellular adhesion molecule-1
p9361
sg15
I3
sa(dp9362
g9
I182
sg39
VP01375
p9363
sg12
I26
sg13
Vtumor necrosis factor-Alfa
p9364
sg15
I3
sasg6
(lp9365
(dp9366
g9
I263
sg10
VC1845050
p9367
sg12
I3
sg13
VPDR
p9368
sg15
I1
sa(dp9369
g9
I363
sg10
VC0271051
p9370
sg12
I13
sg13
Vmacular edema
p9371
sg15
I2
sa(dp9372
g9
I182
sg10
VC0333516
p9373
sg12
I14
sg13
Vtumor necrosis
p9374
sg15
I2
sa(dp9375
g9
I295
sg10
VC0001511
p9376
sg12
I8
sg13
Vadhesion
p9377
sg15
I1
sa(dp9378
g9
I378
sg10
VC0271051
p9379
sg12
I2
sg13
VME
p9380
sg15
I1
sa(dp9381
g9
I245
sg10
VC1845050
p9382
sg12
I16
sg13
Vproliferative DR
p9383
sg15
I2
sasa(dp9384
g2
VThe 6-HT was administrated by perfusion and ejection in "brain slices" of hippocampus, inducing epileptic activity after its administration; the toxin was not able to block the epileptogenic crisis observed in the chronic model of the epilepsy, suggesting that 6-HT did not block the overactive GluRs responsible for this epileptic activity.
p9385
sg4
(lp9386
sg6
(lp9387
(dp9388
g9
I96
sg10
VC0014544
p9389
sg12
I9
sg13
Vepileptic
p9390
sg15
I1
sa(dp9391
g9
I96
sg10
VC0014544
p9392
sg12
I9
sg13
Vepileptic
p9393
sg15
I1
sa(dp9394
g9
I235
sg10
VC0014544
p9395
sg12
I8
sg13
Vepilepsy
p9396
sg15
I1
sasa(dp9397
g2
VIn patients with systemic sclerosis (SSc), the relationship between innate immune activation, represented by increased expression of interferon (IFN)-regulated genes, and vascular injury/activation, manifest by increased endothelin-1 (ET-1), endothelin converting enzyme-1 (ECE1) and intercellular adhesion molecule-1, is uncertain.
p9398
sg4
(lp9399
(dp9400
g9
I274
sg39
g40
sg12
I4
sg13
VECE1
p9401
sg15
I1
sa(dp9402
g9
I145
sg39
VP01562
p9403
sg12
I3
sg13
VIFN
p9404
sg15
I1
sa(dp9405
g9
I235
sg39
VP05305
p9406
sg12
I4
sg13
VET-1
p9407
sg15
I1
sa(dp9408
g9
I221
sg39
VP20800
p9409
sg12
I12
sg13
Vendothelin-1
p9410
sg15
I1
sa(dp9411
g9
I242
sg39
g40
sg12
I30
sg13
Vendothelin converting enzyme-1
p9412
sg15
I3
sa(dp9413
g9
I284
sg39
VP05362
p9414
sg12
I33
sg13
Vintercellular adhesion molecule-1
p9415
sg15
I3
sa(dp9416
g9
I133
sg39
VP01563
p9417
sg12
I10
sg13
Vinterferon
p9418
sg15
I1
sasg6
(lp9419
(dp9420
g9
I298
sg10
VC0001511
p9421
sg12
I8
sg13
Vadhesion
p9422
sg15
I1
sa(dp9423
g9
I17
sg10
VC0036421
p9424
sg12
I18
sg13
Vsystemic sclerosis
p9425
sg15
I2
sa(dp9426
g9
I37
sg10
VC0036421
p9427
sg12
I3
sg13
VSSc
p9428
sg15
I1
sasa(dp9429
g2
VRecent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer.
p9430
sg4
(lp9431
(dp9432
g9
I43
sg39
g40
sg12
I5
sg13
VSR-BI
p9433
sg15
I1
sasg6
(lp9434
(dp9435
g9
I75
sg10
VC0001807
p9436
sg12
I14
sg13
Vaggressiveness
p9437
sg15
I1
sa(dp9438
g9
I122
sg10
VC0600139
p9439
sg12
I15
sg13
Vprostate cancer
p9440
sg15
I2
sasa(dp9441
g2
VFurthermore, we performed immunohistochemistry analysis on human primary prostate cancer tissue sections derived from patients to investigate the correlation of SR-BI with clinicopathological parameters and the mTOR target pS6.
p9442
sg4
(lp9443
(dp9444
g9
I211
sg39
VP42345
p9445
sg12
I4
sg13
VmTOR
p9446
sg15
I1
sa(dp9447
g9
I161
sg39
g40
sg12
I5
sg13
VSR-BI
p9448
sg15
I1
sasg6
(lp9449
(dp9450
g9
I73
sg10
VC0600139
p9451
sg12
I15
sg13
Vprostate cancer
p9452
sg15
I2
sasa(dp9453
g2
VIn contrast to LDLR, we identified SR-BI mRNA and protein expression to be induced in high Gleason grade primary prostate cancers.
p9454
sg4
(lp9455
(dp9456
g9
I15
sg39
VP01130
p9457
sg12
I4
sg13
VLDLR
p9458
sg15
I1
sa(dp9459
g9
I35
sg39
g40
sg12
I10
sg13
VSR-BI mRNA
p9460
sg15
I2
sasg6
(lp9461
(dp9462
g9
I113
sg10
VC0376358
p9463
sg12
I16
sg13
Vprostate cancers
p9464
sg15
I2
sasa(dp9465
g2
VWe identified SR-BI to indicate human prostate cancer formation, suggesting that increased levels of SR-BI may be involved in the generation of a castration-resistant phenotype.
p9466
sg4
(lp9467
(dp9468
g9
I14
sg39
g40
sg12
I5
sg13
VSR-BI
p9469
sg15
I1
sa(dp9470
g9
I14
sg39
g40
sg12
I5
sg13
VSR-BI
p9471
sg15
I1
sasg6
(lp9472
(dp9473
g9
I38
sg10
VC0600139
p9474
sg12
I15
sg13
Vprostate cancer
p9475
sg15
I2
sasa(dp9476
g2
VSilencing of SR-BI may impact the ability of prostate cancer cells, particularly those of castration-resistant state, to maintain the intracellular supply of androgens by removing a supply of cholesterol.
p9477
sg4
(lp9478
(dp9479
g9
I13
sg39
g40
sg12
I5
sg13
VSR-BI
p9480
sg15
I1
sasg6
(lp9481
(dp9482
g9
I45
sg10
VC0600139
p9483
sg12
I15
sg13
Vprostate cancer
p9484
sg15
I2
sasa(dp9485
g2
VThe down-regulation of SR-BI significantly impacts PSA production of prostate cancer cells, as well as the viability of C4-2 cells in the presence and absence of HDL.
p9486
sg4
(lp9487
(dp9488
g9
I51
sg39
VP55786
p9489
sg12
I3
sg13
VPSA
p9490
sg15
I1
sa(dp9491
g9
I23
sg39
g40
sg12
I5
sg13
VSR-BI
p9492
sg15
I1
sa(dp9493
g9
I162
sg39
VP28845
p9494
sg12
I3
sg13
VHDL
p9495
sg15
I1
sasg6
(lp9496
(dp9497
g9
I69
sg10
VC0600139
p9498
sg12
I15
sg13
Vprostate cancer
p9499
sg15
I2
sa(dp9500
g9
I51
sg10
VC1519176
p9501
sg12
I3
sg13
VPSA
p9502
sg15
I1
sasa(dp9503
g2
VThis may indicate a deficiency in cholesterol availability to the androgen synthesis pathway or may implicate a role for SR-BI in prostate cancer signal transduction pathways.
p9504
sg4
(lp9505
(dp9506
g9
I121
sg39
g40
sg12
I5
sg13
VSR-BI
p9507
sg15
I1
sasg6
(lp9508
(dp9509
g9
I130
sg10
VC0600139
p9510
sg12
I15
sg13
Vprostate cancer
p9511
sg15
I2
sasa(dp9512
g2
Vplay roles in preterm labor and preterm premature rupture of membranes (pPROM); 3) integrated aspects of maternal and fetal host responses (inflammation, altered immune adaptations, endocrine and paracrine mechanisms) play increasingly understood roles in premature activation of parturition; and 4) identification and systemic treatment of common genitourinary infections, most importantly bacterial vaginosis (BV), reduce the risks of preterm delivery and PROM.
p9513
sg4
(lp9514
(dp9515
g9
I72
sg39
VP50454
p9516
sg12
I5
sg13
VpPROM
p9517
sg15
I1
sasg6
(lp9518
(dp9519
g9
I391
sg10
VC0085166
p9520
sg12
I19
sg13
Vbacterial vaginosis
p9521
sg15
I2
sa(dp9522
g9
I437
sg10
VC0151526
p9523
sg12
I16
sg13
Vpreterm delivery
p9524
sg15
I2
sa(dp9525
g9
I14
sg10
VC0022876
p9526
sg12
I13
sg13
Vpreterm labor
p9527
sg15
I2
sa(dp9528
g9
I362
sg10
VC0021311
p9529
sg12
I10
sg13
Vinfections
p9530
sg15
I1
sa(dp9531
g9
I0
sg10
VC0699820
p9532
sg12
I10
sg13
Vplay roles
p9533
sg15
I2
sa(dp9534
g9
I72
sg10
VC0729264
p9535
sg12
I5
sg13
VpPROM
p9536
sg15
I1
sa(dp9537
g9
I140
sg10
VC0021368
p9538
sg12
I12
sg13
Vinflammation
p9539
sg15
I1
sa(dp9540
g9
I32
sg10
VC0729264
p9541
sg12
I38
sg13
Vpreterm premature rupture of membranes
p9542
sg15
I5
sasa(dp9543
g2
VUnivariate analysis showed the following to be significant predictors of PPROM at &lt; 35 weeks: a past history of PTD between 25 and 30 weeks (P &lt; 0.008), cerclage in the current pregnancy (P &lt; 0.0001), bacterial vaginosis (P &lt; 0.011), CL &lt; 25 mm (P &lt; 0.0001) and CF &gt; 25% (P &lt; 0.0001).
p9544
sg4
(lp9545
sg6
(lp9546
(dp9547
g9
I73
sg10
VC0729264
p9548
sg12
I5
sg13
VPPROM
p9549
sg15
I1
sa(dp9550
g9
I210
sg10
VC0085166
p9551
sg12
I19
sg13
Vbacterial vaginosis
p9552
sg15
I2
sa(dp9553
g9
I115
sg10
VC0266006
p9554
sg12
I3
sg13
VPTD
p9555
sg15
I1
sasa(dp9556
g2
VIn this study, localization of gelatinase activities in six cases of glioblastoma, two cases of anaplastic astrocytoma, and six cases of low-grade astrocytomas was investigated by film in situ zymography (FIZ).
p9557
sg4
(lp9558
sg6
(lp9559
(dp9560
g9
I147
sg10
VC0004114
p9561
sg12
I12
sg13
Vastrocytomas
p9562
sg15
I1
sa(dp9563
g9
I96
sg10
VC0334579
p9564
sg12
I22
sg13
Vanaplastic astrocytoma
p9565
sg15
I2
sa(dp9566
g9
I69
sg10
VC0017636
p9567
sg12
I12
sg13
Vglioblastoma
p9568
sg15
I1
sasa(dp9569
g2
VIn situ hybridization of the null cell line HLN-STL-C established from an adult T-cell leukemia patient showed that 100% of the cells contained both EBERs and LMP1 mRNA and about 0.1% of the cells contained gp350/220 mRNA, indicating that a few of the null cells which carried the EBV genome spontaneously entered the late EBV replication cycle.
p9570
sg4
(lp9571
(dp9572
g9
I159
sg39
g40
sg12
I9
sg13
VLMP1 mRNA
p9573
sg15
I2
sasg6
(lp9574
(dp9575
g9
I74
sg10
VC0023492
p9576
sg12
I21
sg13
Vadult T-cell leukemia
p9577
sg15
I3
sasa(dp9578
g2
VIQ and CELF-3 performance were highly interrelated regardless of whether subjects had autism or were controls.
p9579
sg4
(lp9580
sg6
(lp9581
(dp9582
g9
I86
sg10
VC0004352
p9583
sg12
I6
sg13
Vautism
p9584
sg15
I1
sasa(dp9585
g2
VBoth IQ and CELF-3 ability were positively correlated with STG in controls, but a different pattern was observed in subjects with autism.
p9586
sg4
(lp9587
sg6
(lp9588
(dp9589
g9
I130
sg10
VC0004352
p9590
sg12
I6
sg13
Vautism
p9591
sg15
I1
sasa(dp9592
g2
VIn controls, left STG gray matter was significantly (r = .42, p &lt; or = .05) related to receptive language on the CELF-3; in contrast, a zero order correlation was found with autism.
p9593
sg4
(lp9594
(dp9595
g9
I116
sg39
g40
sg12
I6
sg13
VCELF-3
p9596
sg15
I1
sasg6
(lp9597
(dp9598
g9
I177
sg10
VC0004352
p9599
sg12
I6
sg13
Vautism
p9600
sg15
I1
sasa(dp9601
g2
VHere, we showed that DUSP10 knockout (KO) mice had increased intestinal epithelial cell (IEC) proliferation and migration and developed less severe colitis than wild-type (WT) mice in response to dextran sodium sulphate (DSS) treatment, which is associated with increased ERK1/2 activation and Kruppel-like factor 5 (KLF5) expression in IEC.
p9602
sg4
(lp9603
(dp9604
g9
I272
sg39
VP27361
p9605
sg12
I6
sg13
VERK1/2
p9606
sg15
I1
sa(dp9607
g9
I294
sg39
g40
sg12
I21
sg13
VKruppel-like factor 5
p9608
sg15
I3
sa(dp9609
g9
I317
sg39
g40
sg12
I4
sg13
VKLF5
p9610
sg15
I1
sa(dp9611
g9
I21
sg39
g40
sg12
I6
sg13
VDUSP10
p9612
sg15
I1
sasg6
(lp9613
(dp9614
g9
I221
sg10
VC0011195
p9615
sg12
I3
sg13
VDSS
p9616
sg15
I1
sa(dp9617
g9
I148
sg10
VC0009319
p9618
sg12
I7
sg13
Vcolitis
p9619
sg15
I1
sa(dp9620
g9
I196
sg10
VC0011195
p9621
sg12
I23
sg13
Vdextran sodium sulphate
p9622
sg15
I3
sa(dp9623
g9
I94
sg10
VC0334094
p9624
sg12
I13
sg13
Vproliferation
p9625
sg15
I1
sasa(dp9626
g2
VModels of painful small-fiber sensory neuropathy were developed and several laboratories have progressed in the conception of TRPV1 agonists and antagonists.
p9627
sg4
(lp9628
(dp9629
g9
I126
sg39
g40
sg12
I5
sg13
VTRPV1
p9630
sg15
I1
sasg6
(lp9631
(dp9632
g9
I30
sg10
VC0151313
p9633
sg12
I18
sg13
Vsensory neuropathy
p9634
sg15
I2
sa(dp9635
g9
I10
sg10
VC0030193
p9636
sg12
I7
sg13
Vpainful
p9637
sg15
I1
sasa(dp9638
g2
VTRPV1 is involved in oxidant stress-induced pain and in neuronal injury, contributing to diabetic sensory neuropathy.
p9639
sg4
(lp9640
(dp9641
g9
I0
sg39
g40
sg12
I5
sg13
VTRPV1
p9642
sg15
I1
sasg6
(lp9643
(dp9644
g9
I98
sg10
VC0151313
p9645
sg12
I18
sg13
Vsensory neuropathy
p9646
sg15
I2
sasa(dp9647
g2
VDespite the impediments posed by phenotypic and genetic heterogeneity among women with PCOS, investigation into one locus, the DENND1A gene, is providing insight into the ovarian steroidogenesis.
p9648
sg4
(lp9649
(dp9650
g9
I127
sg39
g40
sg12
I12
sg13
VDENND1A gene
p9651
sg15
I2
sasg6
(lp9652
(dp9653
g9
I87
sg10
VC0032460
p9654
sg12
I4
sg13
VPCOS
p9655
sg15
I1
sasa(dp9656
g2
VWe conducted a meta-analysis to evaluate the rs10818854, rs2479106, and rs10986105 polymorphism in DENND1A gene with PCOS susceptibility.
p9657
sg4
(lp9658
(dp9659
g9
I99
sg39
g40
sg12
I12
sg13
VDENND1A gene
p9660
sg15
I2
sasg6
(lp9661
(dp9662
g9
I117
sg10
VC0032460
p9663
sg12
I4
sg13
VPCOS
p9664
sg15
I1
sasa(dp9665
g2
VIn conclusion, the DENND1A gene variant is likely to have influence on PCOS risk.
p9666
sg4
(lp9667
(dp9668
g9
I19
sg39
g40
sg12
I12
sg13
VDENND1A gene
p9669
sg15
I2
sasg6
(lp9670
(dp9671
g9
I71
sg10
VC0032460
p9672
sg12
I4
sg13
VPCOS
p9673
sg15
I1
sasa(dp9674
g2
VPCOS has a strong genetic component, and genome-wide association studies have identified several candidate genes, notably DENND1A, which encodes connecdenn 1, involved in trafficking of endosomes.
p9675
sg4
(lp9676
(dp9677
g9
I145
sg39
g40
sg12
I12
sg13
Vconnecdenn 1
p9678
sg15
I2
sa(dp9679
g9
I122
sg39
g40
sg12
I7
sg13
VDENND1A
p9680
sg15
I1
sasg6
(lp9681
(dp9682
g9
I0
sg10
VC0032460
p9683
sg12
I4
sg13
VPCOS
p9684
sg15
I1
sasa(dp9685
g2
VFurthermore, overexpression of DENND1A variant 2 in normal theca cells resulted in a PCOS phenotype with increased androgen production.
p9686
sg4
(lp9687
(dp9688
g9
I31
sg39
g40
sg12
I17
sg13
VDENND1A variant 2
p9689
sg15
I3
sasg6
(lp9690
(dp9691
g9
I85
sg10
VC0032460
p9692
sg12
I4
sg13
VPCOS
p9693
sg15
I1
sasa(dp9694
g2
VIn addition, GWAS have suggested that DENND1A, epidermal growth factor signaling, and DNA repair pathways play a role in PCOS pathogenesis.
p9695
sg4
(lp9696
(dp9697
g9
I47
sg39
VP01133
p9698
sg12
I23
sg13
Vepidermal growth factor
p9699
sg15
I3
sa(dp9700
g9
I38
sg39
g40
sg12
I7
sg13
VDENND1A
p9701
sg15
I1
sasg6
(lp9702
(dp9703
g9
I126
sg10
VC0699748
p9704
sg12
I12
sg13
Vpathogenesis
p9705
sg15
I1
sa(dp9706
g9
I121
sg10
VC0032460
p9707
sg12
I4
sg13
VPCOS
p9708
sg15
I1
sasa(dp9709
g2
VThe rs2479106 and rs10818854 polymorphisms in the DENND1A gene have been reported to be extensively associated with risk of polycystic ovary syndrome (PCOS).
p9710
sg4
(lp9711
(dp9712
g9
I50
sg39
g40
sg12
I12
sg13
VDENND1A gene
p9713
sg15
I2
sasg6
(lp9714
(dp9715
g9
I151
sg10
VC0032460
p9716
sg12
I4
sg13
VPCOS
p9717
sg15
I1
sa(dp9718
g9
I124
sg10
VC0032460
p9719
sg12
I25
sg13
Vpolycystic ovary syndrome
p9720
sg15
I3
sasa(dp9721
g2
VOverall, significant increase of PCOS risk was found between DENND1A-rs10818854 and PCOS susceptibility.
p9722
sg4
(lp9723
(dp9724
g9
I61
sg39
g40
sg12
I7
sg13
VDENND1A
p9725
sg15
I1
sasg6
(lp9726
(dp9727
g9
I33
sg10
VC0032460
p9728
sg12
I4
sg13
VPCOS
p9729
sg15
I1
sa(dp9730
g9
I33
sg10
VC0032460
p9731
sg12
I4
sg13
VPCOS
p9732
sg15
I1
sasa(dp9733
g2
VThis meta-analysis suggested that rs2479106 and rs10818854 polymorphisms in the DENND1A gene were associated with increased risk of PCOS.
p9734
sg4
(lp9735
(dp9736
g9
I80
sg39
g40
sg12
I12
sg13
VDENND1A gene
p9737
sg15
I2
sasg6
(lp9738
(dp9739
g9
I132
sg10
VC0032460
p9740
sg12
I4
sg13
VPCOS
p9741
sg15
I1
sasa(dp9742
g2
VVariant 2 of the DENND1A gene was found overexpressed in PCOS theca cells and confirmed to enhance androgen production.
p9743
sg4
(lp9744
(dp9745
g9
I17
sg39
g40
sg12
I12
sg13
VDENND1A gene
p9746
sg15
I2
sasg6
(lp9747
(dp9748
g9
I57
sg10
VC0032460
p9749
sg12
I4
sg13
VPCOS
p9750
sg15
I1
sasa(dp9751
g2
VOur previous research had identified three susceptibility loci (rs2479106, DENND1A; rs13405728, LHCGR; rs13429458, THADA) for PCOS in Han Chinese women.
p9752
sg4
(lp9753
(dp9754
g9
I75
sg39
g40
sg12
I7
sg13
VDENND1A
p9755
sg15
I1
sa(dp9756
g9
I96
sg39
VP22888
p9757
sg12
I5
sg13
VLHCGR
p9758
sg15
I1
sasg6
(lp9759
(dp9760
g9
I126
sg10
VC0032460
p9761
sg12
I4
sg13
VPCOS
p9762
sg15
I1
sasa(dp9763
g2
VThree of the eleven variants associated with PCOS in the Han Chinese genome-wide association studies were also associated with PCOS in at least one European population when corrected for multiple testing (DENND1A, THADA and YAP1).
p9764
sg4
(lp9765
(dp9766
g9
I224
sg39
VP46937
p9767
sg12
I4
sg13
VYAP1
p9768
sg15
I1
sa(dp9769
g9
I205
sg39
g40
sg12
I7
sg13
VDENND1A
p9770
sg15
I1
sasg6
(lp9771
(dp9772
g9
I45
sg10
VC0032460
p9773
sg12
I4
sg13
VPCOS
p9774
sg15
I1
sa(dp9775
g9
I45
sg10
VC0032460
p9776
sg12
I4
sg13
VPCOS
p9777
sg15
I1
sasa(dp9778
g2
VMicroRNA-106a-5p (MiR-106a-5p), a small non-coding RNA, has been reported to be downregulated in astrocytoma, osteosarcoma and colorectal cancer.
p9779
sg4
(lp9780
(dp9781
g9
I0
sg39
g40
sg12
I16
sg13
VMicroRNA-106a-5p
p9782
sg15
I1
sa(dp9783
g9
I18
sg39
g40
sg12
I11
sg13
VMiR-106a-5p
p9784
sg15
I1
sasg6
(lp9785
(dp9786
g9
I127
sg10
VC1527249
p9787
sg12
I17
sg13
Vcolorectal cancer
p9788
sg15
I2
sa(dp9789
g9
I97
sg10
VC0004114
p9790
sg12
I11
sg13
Vastrocytoma
p9791
sg15
I1
sa(dp9792
g9
I110
sg10
VC0029463
p9793
sg12
I12
sg13
Vosteosarcoma
p9794
sg15
I1
sasa(dp9795
g2
VThe study aimed to evaluate the effects of miR-106a on prostate cancer cells and the underlying molecular mechanism.
p9796
sg4
(lp9797
(dp9798
g9
I43
sg39
g40
sg12
I8
sg13
VmiR-106a
p9799
sg15
I1
sasg6
(lp9800
(dp9801
g9
I55
sg10
VC0600139
p9802
sg12
I15
sg13
Vprostate cancer
p9803
sg15
I2
sasa(dp9804
g2
VMiR-106a as an oncogene could promote proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro.
p9805
sg4
(lp9806
(dp9807
g9
I114
sg39
VP60484
p9808
sg12
I4
sg13
VPTEN
p9809
sg15
I1
sa(dp9810
g9
I0
sg39
g40
sg12
I8
sg13
VMiR-106a
p9811
sg15
I1
sasg6
(lp9812
(dp9813
g9
I38
sg10
VC0334094
p9814
sg12
I13
sg13
Vproliferation
p9815
sg15
I1
sa(dp9816
g9
I56
sg10
VC0027627
p9817
sg12
I10
sg13
Vmetastasis
p9818
sg15
I1
sa(dp9819
g9
I70
sg10
VC0600139
p9820
sg12
I15
sg13
Vprostate cancer
p9821
sg15
I2
sasa(dp9822
g2
VCXCL1 secreted by hAdSCs downregulated miR-106a expression in triple negative breast cancer, and resulted in ABCG2 upregulation and doxorubicin resistance.
p9823
sg4
(lp9824
(dp9825
g9
I39
sg39
g40
sg12
I8
sg13
VmiR-106a
p9826
sg15
I1
sa(dp9827
g9
I0
sg39
VP09341
p9828
sg12
I5
sg13
VCXCL1
p9829
sg15
I1
sasg6
(lp9830
(dp9831
g9
I78
sg10
VC0678222
p9832
sg12
I13
sg13
Vbreast cancer
p9833
sg15
I2
sasa(dp9834
g2
VOur findings suggest that CXCL1 secreted by hAdSCs elicits doxorubicin resistance through miR-106a-mediated ABCG2 upregulation in triple negative breast cancer.
p9835
sg4
(lp9836
(dp9837
g9
I90
sg39
g40
sg12
I8
sg13
VmiR-106a
p9838
sg15
I1
sa(dp9839
g9
I26
sg39
VP09341
p9840
sg12
I5
sg13
VCXCL1
p9841
sg15
I1
sasg6
(lp9842
(dp9843
g9
I146
sg10
VC0678222
p9844
sg12
I13
sg13
Vbreast cancer
p9845
sg15
I2
sasa(dp9846
g2
VPrevious studies have revealed that miR-106a is abnormally expressed in various cancers.
p9847
sg4
(lp9848
(dp9849
g9
I36
sg39
g40
sg12
I8
sg13
VmiR-106a
p9850
sg15
I1
sasg6
(lp9851
(dp9852
g9
I80
sg10
VC0006826
p9853
sg12
I7
sg13
Vcancers
p9854
sg15
I1
sasa(dp9855
g2
VCopy number gains in SOX2 in the region of 3q26-28 occur in 94% of SQCCs, and appear to act both early and late in disease progression by stabilizing the initial squamous injury response in stem cells and promoting growth of invasive carcinoma.
p9856
sg4
(lp9857
(dp9858
g9
I21
sg39
VP48431
p9859
sg12
I4
sg13
VSOX2
p9860
sg15
I1
sasg6
(lp9861
(dp9862
g9
I225
sg10
VC1334274
p9863
sg12
I18
sg13
Vinvasive carcinoma
p9864
sg15
I2
sa(dp9865
g9
I115
sg10
VC0242656
p9866
sg12
I19
sg13
Vdisease progression
p9867
sg15
I2
sasa(dp9868
g2
VA key feature of high-grade serous ovarian carcinoma (HGSOC) is frequent amplification of the 3q26 locus harboring PRKC-l (PRKCI).
p9869
sg4
(lp9870
(dp9871
g9
I115
sg39
g40
sg12
I6
sg13
VPRKC-l
p9872
sg15
I1
sa(dp9873
g9
I123
sg39
VP41743
p9874
sg12
I5
sg13
VPRKCI
p9875
sg15
I1
sasg6
(lp9876
(dp9877
g9
I73
sg10
VC1705759
p9878
sg12
I13
sg13
Vamplification
p9879
sg15
I1
sa(dp9880
g9
I35
sg10
VC0029925
p9881
sg12
I17
sg13
Vovarian carcinoma
p9882
sg15
I2
sasa(dp9883
g2
VFour loci, 5p15.33 (TERT), 6p21.3 (BTNL2), 3q28 (TP63) and 17q24.2 (BPTF), previously shown to be strongly associated with overall lung adenocarcinoma risk in East Asians, were re-discovered as loci associated with a higher susceptibility to EGFR mutation-positive lung adenocarcinoma.
p9884
sg4
(lp9885
sg6
(lp9886
(dp9887
g9
I131
sg10
VC0152013
p9888
sg12
I19
sg13
Vlung adenocarcinoma
p9889
sg15
I2
sa(dp9890
g9
I131
sg10
VC0152013
p9891
sg12
I19
sg13
Vlung adenocarcinoma
p9892
sg15
I2
sasa(dp9893
g2
VChromosome 3q26-28 is a critical region of genomic amplification in non-small cell lung cancer (NSCLC), particularly lung squamous cell carcinomas (SCCs).
p9894
sg4
(lp9895
sg6
(lp9896
(dp9897
g9
I96
sg10
VC0007131
p9898
sg12
I5
sg13
VNSCLC
p9899
sg15
I1
sa(dp9900
g9
I68
sg10
VC0007131
p9901
sg12
I26
sg13
Vnon-small cell lung cancer
p9902
sg15
I4
sa(dp9903
g9
I51
sg10
VC1705759
p9904
sg12
I13
sg13
Vamplification
p9905
sg15
I1
sa(dp9906
g9
I148
sg10
VC0007137
p9907
sg12
I4
sg13
VSCCs
p9908
sg15
I1
sa(dp9909
g9
I122
sg10
VC0007137
p9910
sg12
I24
sg13
Vsquamous cell carcinomas
p9911
sg15
I3
sasa(dp9912
g2
VThe PIK3CA gene at chromosome 3q26.32 was found to be amplified in up to 45% of patients with squamous cell carcinoma of the lung.
p9913
sg4
(lp9914
(dp9915
g9
I4
sg39
VP42336
p9916
sg12
I11
sg13
VPIK3CA gene
p9917
sg15
I2
sasg6
(lp9918
(dp9919
g9
I94
sg10
VC0149782
p9920
sg12
I35
sg13
Vsquamous cell carcinoma of the lung
p9921
sg15
I6
sasa(dp9922
g2
VAspirin/NSAID interacted with MAP3K7 (colon cancer) and with MAPK14, NFAT5, and TRAF2 (rectal cancer); smoking cigarettes interacted with NFAM1 and NFAT2 (colon cancer) and MAPK8, NFAT5, and TNFRSF1A (rectal cancer); BMI interacted with NFAM1 and NFAT5 (colon cancer) and with MAPK8 and TNFRSF1A (rectal cancer).
p9923
sg4
(lp9924
(dp9925
g9
I148
sg39
g40
sg12
I20
sg13
VNFAT2 (colon cancer)
p9926
sg15
I3
sa(dp9927
g9
I191
sg39
VP19438
p9928
sg12
I8
sg13
VTNFRSF1A
p9929
sg15
I1
sa(dp9930
g9
I69
sg39
g40
sg12
I5
sg13
VNFAT5
p9931
sg15
I1
sa(dp9932
g9
I138
sg39
g40
sg12
I5
sg13
VNFAM1
p9933
sg15
I1
sa(dp9934
g9
I69
sg39
g40
sg12
I5
sg13
VNFAT5
p9935
sg15
I1
sa(dp9936
g9
I30
sg39
g40
sg12
I21
sg13
VMAP3K7 (colon cancer)
p9937
sg15
I3
sa(dp9938
g9
I80
sg39
g40
sg12
I5
sg13
VTRAF2
p9939
sg15
I1
sa(dp9940
g9
I173
sg39
VP45983
p9941
sg12
I5
sg13
VMAPK8
p9942
sg15
I1
sa(dp9943
g9
I138
sg39
g40
sg12
I5
sg13
VNFAM1
p9944
sg15
I1
sa(dp9945
g9
I247
sg39
g40
sg12
I20
sg13
VNFAT5 (colon cancer)
p9946
sg15
I3
sa(dp9947
g9
I173
sg39
VP45983
p9948
sg12
I5
sg13
VMAPK8
p9949
sg15
I1
sa(dp9950
g9
I61
sg39
g40
sg12
I6
sg13
VMAPK14
p9951
sg15
I1
sa(dp9952
g9
I191
sg39
VP19438
p9953
sg12
I8
sg13
VTNFRSF1A
p9954
sg15
I1
sasg6
(lp9955
(dp9956
g9
I87
sg10
VC0007113
p9957
sg12
I13
sg13
Vrectal cancer
p9958
sg15
I2
sa(dp9959
g9
I87
sg10
VC0007113
p9960
sg12
I13
sg13
Vrectal cancer
p9961
sg15
I2
sa(dp9962
g9
I38
sg10
VC0699790
p9963
sg12
I12
sg13
Vcolon cancer
p9964
sg15
I2
sa(dp9965
g9
I38
sg10
VC0699790
p9966
sg12
I12
sg13
Vcolon cancer
p9967
sg15
I2
sa(dp9968
g9
I87
sg10
VC0007113
p9969
sg12
I13
sg13
Vrectal cancer
p9970
sg15
I2
sa(dp9971
g9
I38
sg10
VC0699790
p9972
sg12
I12
sg13
Vcolon cancer
p9973
sg15
I2
sasa(dp9974
g2
VPreviously, we have cloned the cDNAs for the meningioma expressed antigen 6 (MGEA6) and its splice variant MGEA11.
p9975
sg4
(lp9976
sg6
(lp9977
(dp9978
g9
I45
sg10
VC0025286
p9979
sg12
I10
sg13
Vmeningioma
p9980
sg15
I1
sasa(dp9981
g2
VHere, we show that antibodies against recombinantly expressed MGEA6/11 are found in 41.7% (10/24) of the sera from meningioma patients and in 2/8 sera of glioblastoma patients, whereas no response was seen in 12 sera from healthy persons.
p9982
sg4
(lp9983
(dp9984
g9
I62
sg39
g40
sg12
I8
sg13
VMGEA6/11
p9985
sg15
I1
sasg6
(lp9986
(dp9987
g9
I154
sg10
VC0017636
p9988
sg12
I12
sg13
Vglioblastoma
p9989
sg15
I1
sa(dp9990
g9
I115
sg10
VC0025286
p9991
sg12
I10
sg13
Vmeningioma
p9992
sg15
I1
sasa(dp9993
g2
VThe immune response to MGEA6/11 is frequent in both meningioma and glioma patients and may likely be attributed to overexpression of the MGEA6/11 protein in the tumor cells.
p9994
sg4
(lp9995
(dp9996
g9
I137
sg39
g40
sg12
I16
sg13
VMGEA6/11 protein
p9997
sg15
I2
sa(dp9998
g9
I23
sg39
g40
sg12
I8
sg13
VMGEA6/11
p9999
sg15
I1
sasg6
(lp10000
(dp10001
g9
I161
sg10
VC0027651
p10002
sg12
I5
sg13
Vtumor
p10003
sg15
I1
sa(dp10004
g9
I67
sg10
VC0017638
p10005
sg12
I6
sg13
Vglioma
p10006
sg15
I1
sa(dp10007
g9
I52
sg10
VC0025286
p10008
sg12
I10
sg13
Vmeningioma
p10009
sg15
I1
sasa(dp10010
g2
VThe meningioma expressed antigen-6 (MGEA6) was originally identified as an immunogenic antigen in meningioma patients.
p10011
sg4
(lp10012
(dp10013
g9
I4
sg39
g40
sg12
I30
sg13
Vmeningioma expressed antigen-6
p10014
sg15
I3
sa(dp10015
g9
I36
sg39
g40
sg12
I5
sg13
VMGEA6
p10016
sg15
I1
sasg6
(lp10017
(dp10018
g9
I4
sg10
VC0025286
p10019
sg12
I10
sg13
Vmeningioma
p10020
sg15
I1
sa(dp10021
g9
I4
sg10
VC0025286
p10022
sg12
I10
sg13
Vmeningioma
p10023
sg15
I1
sasa(dp10024
g2
VThe clones were sequenced, and sequence comparison revealed that the seven clones represent five different genes, providing evidence that meningiomas express a spectrum of immunoreactive antigens, which were termed meningioma expressed antigens (MGEAs).
p10025
sg4
(lp10026
sg6
(lp10027
(dp10028
g9
I138
sg10
VC0025286
p10029
sg12
I10
sg13
Vmeningioma
p10030
sg15
I1
sa(dp10031
g9
I138
sg10
VC0025286
p10032
sg12
I11
sg13
Vmeningiomas
p10033
sg15
I1
sasa(dp10034
g2
VThese data suggest that the newly identified MGEA genes may be useful for diagnosis and possibly therapy of meningioma.
p10035
sg4
(lp10036
(dp10037
g9
I45
sg39
g40
sg12
I10
sg13
VMGEA genes
p10038
sg15
I2
sasg6
(lp10039
(dp10040
g9
I108
sg10
VC0025286
p10041
sg12
I10
sg13
Vmeningioma
p10042
sg15
I1
sasa(dp10043
g2
VThe longest open reading frame was found to be 2412 bp encoding an immunoreactive antigen termed meningioma expressed antigen 6 (MEA6).
p10044
sg4
(lp10045
sg6
(lp10046
(dp10047
g9
I97
sg10
VC0025286
p10048
sg12
I10
sg13
Vmeningioma
p10049
sg15
I1
sasa(dp10050
g2
VUsing the keywords [St John's Wort OR Hypericum perforatum OR hypericin OR hyperforin OR johanniskraut OR] AND [depression OR antidepressant OR SSRI], a preliminary search (without language restriction) on the PubMed, Ovid, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group, Cochrane Field for Complementary Medicine, China National Knowledge Infrastructure and WanFang database yielded 5428 papers between 1-Jan-1960 and 1-May-2016.
p10051
sg4
(lp10052
sg6
(lp10053
(dp10054
g9
I303
sg10
VC0027932
p10055
sg12
I8
sg13
VNeurosis
p10056
sg15
I1
sa(dp10057
g9
I112
sg10
VC0011581
p10058
sg12
I10
sg13
Vdepression
p10059
sg15
I1
sa(dp10060
g9
I279
sg10
VC0011581
p10061
sg12
I10
sg13
VDepression
p10062
sg15
I1
sasa(dp10063
g2
VThere is evidence to suggest that caregivers of patients with head and neck cancer (HNC) are susceptible to post-traumatic stress disorder (PTSD) symptoms.
p10064
sg4
(lp10065
sg6
(lp10066
(dp10067
g9
I108
sg10
VC0038436
p10068
sg12
I30
sg13
Vpost-traumatic stress disorder
p10069
sg15
I3
sa(dp10070
g9
I140
sg10
VC0038436
p10071
sg12
I4
sg13
VPTSD
p10072
sg15
I1
sa(dp10073
g9
I62
sg10
VC0278996
p10074
sg12
I20
sg13
Vhead and neck cancer
p10075
sg15
I4
sa(dp10076
g9
I84
sg10
VC0278996
p10077
sg12
I3
sg13
VHNC
p10078
sg15
I1
sasa(dp10079
g2
VEvidence suggests that patients with head and neck cancer (HNC) are susceptible to post-traumatic stress disorder (PTSD).
p10080
sg4
(lp10081
sg6
(lp10082
(dp10083
g9
I83
sg10
VC0038436
p10084
sg12
I30
sg13
Vpost-traumatic stress disorder
p10085
sg15
I3
sa(dp10086
g9
I115
sg10
VC0038436
p10087
sg12
I4
sg13
VPTSD
p10088
sg15
I1
sa(dp10089
g9
I59
sg10
VC0278996
p10090
sg12
I3
sg13
VHNC
p10091
sg15
I1
sa(dp10092
g9
I37
sg10
VC0278996
p10093
sg12
I20
sg13
Vhead and neck cancer
p10094
sg15
I4
sasa(dp10095
g2
VAmong distressed HNC survivors, higher PTG was associated with lower tumor stage, absence of an anxiety disorder, absence of an alcohol use disorder, and better social functioning.
p10096
sg4
(lp10097
sg6
(lp10098
(dp10099
g9
I69
sg10
VC0027651
p10100
sg12
I5
sg13
Vtumor
p10101
sg15
I1
sa(dp10102
g9
I96
sg10
VC0003469
p10103
sg12
I16
sg13
Vanxiety disorder
p10104
sg15
I2
sa(dp10105
g9
I6
sg10
VC0700361
p10106
sg12
I10
sg13
Vdistressed
p10107
sg15
I1
sa(dp10108
g9
I128
sg10
VC0001956
p10109
sg12
I20
sg13
Valcohol use disorder
p10110
sg15
I3
sasa(dp10111
g2
VAlthough lysyl oxidase-like 1 (LOXL1) is known as the principal genetic risk factor for pseudoexfoliation (PEX) syndrome, a major cause of glaucoma and cardiovascular complications, no functional variants have been identified to date.
p10112
sg4
(lp10113
(dp10114
g9
I31
sg39
g40
sg12
I5
sg13
VLOXL1
p10115
sg15
I1
sa(dp10116
g9
I9
sg39
g40
sg12
I20
sg13
Vlysyl oxidase-like 1
p10117
sg15
I3
sasg6
(lp10118
(dp10119
g9
I112
sg10
VC0039082
p10120
sg12
I8
sg13
Vsyndrome
p10121
sg15
I1
sa(dp10122
g9
I139
sg10
VC0017601
p10123
sg12
I8
sg13
Vglaucoma
p10124
sg15
I1
sasa(dp10125
g2
VRecent studies have shed new light on the genetic factors underlying pseudoexfoliation syndrome, growing our understanding of the role of the lysyl oxidase-like 1 (LOXL1) gene and its various polymorphisms as well as identifying new genetic associations.
p10126
sg4
(lp10127
(dp10128
g9
I142
sg39
g40
sg12
I20
sg13
Vlysyl oxidase-like 1
p10129
sg15
I3
sa(dp10130
g9
I164
sg39
g40
sg12
I5
sg13
VLOXL1
p10131
sg15
I1
sasg6
(lp10132
(dp10133
g9
I69
sg10
VC0206368
p10134
sg12
I26
sg13
Vpseudoexfoliation syndrome
p10135
sg15
I2
sasa(dp10136
g2
VWe found that TAPP2, syntrophin, and utrophin are coexpressed in normal human B cells and B-chronic lymphocytic leukemia (B-CLL) cells.
p10137
sg4
(lp10138
(dp10139
g9
I37
sg39
VP46939
p10140
sg12
I8
sg13
Vutrophin
p10141
sg15
I1
sa(dp10142
g9
I14
sg39
g40
sg12
I5
sg13
VTAPP2
p10143
sg15
I1
sasg6
(lp10144
(dp10145
g9
I124
sg10
VC0023434
p10146
sg12
I3
sg13
VCLL
p10147
sg15
I1
sa(dp10148
g9
I92
sg10
VC0023434
p10149
sg12
I28
sg13
Vchronic lymphocytic leukemia
p10150
sg15
I3
sasa(dp10151
g2
VCREB1 expression, which was activated by E2F, was coupled with RFC3 expression during the G1/S progression in the KG-1 acute myeloid leukemia (AML) cell line.
p10152
sg4
(lp10153
(dp10154
g9
I0
sg39
VP16220
p10155
sg12
I5
sg13
VCREB1
p10156
sg15
I1
sa(dp10157
g9
I63
sg39
VP40938
p10158
sg12
I4
sg13
VRFC3
p10159
sg15
I1
sasg6
(lp10160
(dp10161
g9
I143
sg10
VC0023467
p10162
sg12
I3
sg13
VAML
p10163
sg15
I1
sa(dp10164
g9
I119
sg10
VC0023467
p10165
sg12
I22
sg13
Vacute myeloid leukemia
p10166
sg15
I3
sasa(dp10167
g2
VThe National Reference Center for equine infectious anemia (EIA) validated a commercial ELISA (Eradikit(R) EIAV Indirect ELISA, In3diagnostic(R), Turin, Italy) employing a chimeric recombinant gag and env peptide for the detection of EIA virus antibodies, following the guidelines of the World Organization for Animal Health.
p10168
sg4
(lp10169
(dp10170
g9
I172
sg39
VP87889
p10171
sg12
I24
sg13
Vchimeric recombinant gag
p10172
sg15
I3
sa(dp10173
g9
I201
sg39
g40
sg12
I3
sg13
Venv
p10174
sg15
I1
sasg6
(lp10175
(dp10176
g9
I60
sg10
VC0014661
p10177
sg12
I3
sg13
VEIA
p10178
sg15
I1
sa(dp10179
g9
I60
sg10
VC0014661
p10180
sg12
I3
sg13
VEIA
p10181
sg15
I1
sa(dp10182
g9
I34
sg10
VC0014661
p10183
sg12
I24
sg13
Vequine infectious anemia
p10184
sg15
I3
sasa(dp10185
g2
VThe development of anaemia in feline leukaemia virus (FeLV)-infected cats is associated with the emergence of a novel viral subgroup, FeLV-C. FeLV-C arises from the subgroup that is transmitted, FeLV-A, through alterations in the amino acid sequence of the receptor binding domain (RBD) of the envelope glycoprotein that result in a shift in the receptor usage and the cell tropism of the virus.
p10186
sg4
(lp10187
(dp10188
g9
I294
sg39
g40
sg12
I21
sg13
Venvelope glycoprotein
p10189
sg15
I2
sasg6
(lp10190
(dp10191
g9
I37
sg10
VC0023418
p10192
sg12
I9
sg13
Vleukaemia
p10193
sg15
I1
sa(dp10194
g9
I19
sg10
VC0002871
p10195
sg12
I7
sg13
Vanaemia
p10196
sg15
I1
sa(dp10197
g9
I182
sg10
VC0242781
p10198
sg12
I11
sg13
Vtransmitted
p10199
sg15
I1
sasa(dp10200
g2
VThese results suggest that the interaction between sf-Stk and the envelope proteins of the polycythemia- and anemia-inducing variants of SFFV is architecturally different.
p10201
sg4
(lp10202
(dp10203
g9
I66
sg39
g40
sg12
I8
sg13
Venvelope
p10204
sg15
I1
sa(dp10205
g9
I51
sg39
VP52823
p10206
sg12
I6
sg13
Vsf-Stk
p10207
sg15
I1
sasg6
(lp10208
(dp10209
g9
I109
sg10
VC0002871
p10210
sg12
I6
sg13
Vanemia
p10211
sg15
I1
sa(dp10212
g9
I91
sg10
VC0032461
p10213
sg12
I12
sg13
Vpolycythemia
p10214
sg15
I1
sasa(dp10215
g2
VWe conclude that the common clinical features of patients with an isolated mutation of ZRSR2 are a macrocytic anemia without leukopenia, thrombocytopenia or an increase in marrow blast percentage.
p10216
sg4
(lp10217
(dp10218
g9
I87
sg39
g40
sg12
I5
sg13
VZRSR2
p10219
sg15
I1
sasg6
(lp10220
(dp10221
g9
I99
sg10
VC0002886
p10222
sg12
I17
sg13
Vmacrocytic anemia
p10223
sg15
I2
sa(dp10224
g9
I125
sg10
VC0023530
p10225
sg12
I10
sg13
Vleukopenia
p10226
sg15
I1
sasa(dp10227
g2
VRecent studies have shown that recombinant human thrombomodulin (rhTM) improves exacerbation and clinical outcome of idiopathic pulmonary fibrosis, but the mechanism remains unknown.
p10228
sg4
(lp10229
(dp10230
g9
I31
sg39
VP07204
p10231
sg12
I32
sg13
Vrecombinant human thrombomodulin
p10232
sg15
I3
sa(dp10233
g9
I65
sg39
VP07204
p10234
sg12
I4
sg13
VrhTM
p10235
sg15
I1
sasg6
(lp10236
(dp10237
g9
I117
sg10
VC3161101
p10238
sg12
I29
sg13
Vidiopathic pulmonary fibrosis
p10239
sg15
I3
sasa(dp10240
g2
VThis furthers our understanding of the regulatory mechanism of cardiac sarcomere assembly in both physiologic and pathologic contexts, and uncovers a potential novel pathway to cardiomyopathy through modulating the Stk38/Rbm24 protein activity.
p10241
sg4
(lp10242
(dp10243
g9
I215
sg39
g40
sg12
I5
sg13
VStk38
p10244
sg15
I1
sa(dp10245
g9
I221
sg39
g40
sg12
I13
sg13
VRbm24 protein
p10246
sg15
I2
sasg6
(lp10247
(dp10248
g9
I177
sg10
VC0878544
p10249
sg12
I14
sg13
Vcardiomyopathy
p10250
sg15
I1
sasa(dp10251
g2
VThis study uncovers a potential novel pathway to cardiomyopathy through down-regulation of the RBP Rbm24.
p10252
sg4
(lp10253
(dp10254
g9
I95
sg39
g40
sg12
I9
sg13
VRBP Rbm24
p10255
sg15
I2
sasg6
(lp10256
(dp10257
g9
I49
sg10
VC0878544
p10258
sg12
I14
sg13
Vcardiomyopathy
p10259
sg15
I1
sasa(dp10260
g2
VNsp3 proteins of Semliki Forest (SFV), Sindbis (SINV), and Chikungunya viruses all showed avid and SH3-dependent binding to amphiphysins.
p10261
sg4
(lp10262
(dp10263
g9
I0
sg39
g40
sg12
I13
sg13
VNsp3 proteins
p10264
sg15
I2
sasg6
(lp10265
(dp10266
g9
I59
sg10
VC0008055
p10267
sg12
I11
sg13
VChikungunya
p10268
sg15
I1
sasa(dp10269
g2
VColitis severity was assessed by body weight, colonoscopy, colon length, histological score, cytokine mRNA expression, and myeloperoxidase (MPO) activity.
p10270
sg4
(lp10271
(dp10272
g9
I123
sg39
VP05164
p10273
sg12
I15
sg13
Vmyeloperoxidase
p10274
sg15
I1
sa(dp10275
g9
I140
sg39
VP05164
p10276
sg12
I3
sg13
VMPO
p10277
sg15
I1
sasg6
(lp10278
(dp10279
g9
I0
sg10
VC0009319
p10280
sg12
I7
sg13
VColitis
p10281
sg15
I1
sasa(dp10282
g2
VPigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) is associated with recessive mutations in SLC29A3, encoding the equilibrative nucleoside transporter hENT3 expressed in mitochondria, causing PHID and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy-plus syndrome.
p10283
sg4
(lp10284
(dp10285
g9
I45
sg39
VP01308
p10286
sg12
I7
sg13
Vinsulin
p10287
sg15
I1
sa(dp10288
g9
I166
sg39
g40
sg12
I28
sg13
Vnucleoside transporter hENT3
p10289
sg15
I3
sasg6
(lp10290
(dp10291
g9
I82
sg10
VC1864445
p10292
sg12
I4
sg13
VPHID
p10293
sg15
I1
sa(dp10294
g9
I241
sg10
VC0039082
p10295
sg12
I8
sg13
Vsyndrome
p10296
sg15
I1
sa(dp10297
g9
I11
sg10
VC0020555
p10298
sg12
I14
sg13
Vhypertrichosis
p10299
sg15
I1
sa(dp10300
g9
I288
sg10
VC0019618
p10301
sg12
I13
sg13
Vhistiocytosis
p10302
sg15
I1
sa(dp10303
g9
I34
sg10
VC0443146
p10304
sg12
I10
sg13
Vautoimmune
p10305
sg15
I1
sa(dp10306
g9
I241
sg10
VC0039082
p10307
sg12
I9
sg13
Vsyndromes
p10308
sg15
I1
sa(dp10309
g9
I82
sg10
VC1864445
p10310
sg12
I4
sg13
VPHID
p10311
sg15
I1
sa(dp10312
g9
I261
sg10
VC0019625
p10313
sg12
I21
sg13
VRosai-Dorfman disease
p10314
sg15
I2
sa(dp10315
g9
I45
sg10
VC0011854
p10316
sg12
I35
sg13
Vinsulin-dependent diabetes mellitus
p10317
sg15
I3
sasa(dp10318
g2
VThe patients share many of the characteristics previously reported with H syndrome, including hyperpigmentation, hypertrichosis, short stature, insulin-dependent diabetes, arthritis and systemic inflammation, as well as some novel features, including selective IgG subclass deficiency and autoimmune hepatitis.
p10319
sg4
(lp10320
(dp10321
g9
I144
sg39
VP01308
p10322
sg12
I7
sg13
Vinsulin
p10323
sg15
I1
sasg6
(lp10324
(dp10325
g9
I172
sg10
VC0003864
p10326
sg12
I9
sg13
Varthritis
p10327
sg15
I1
sa(dp10328
g9
I251
sg10
VC0162539
p10329
sg12
I33
sg13
Vselective IgG subclass deficiency
p10330
sg15
I4
sa(dp10331
g9
I129
sg10
VC0013336
p10332
sg12
I13
sg13
Vshort stature
p10333
sg15
I2
sa(dp10334
g9
I195
sg10
VC0021368
p10335
sg12
I12
sg13
Vinflammation
p10336
sg15
I1
sa(dp10337
g9
I94
sg10
VC0162834
p10338
sg12
I17
sg13
Vhyperpigmentation
p10339
sg15
I1
sa(dp10340
g9
I72
sg10
VC1864445
p10341
sg12
I10
sg13
VH syndrome
p10342
sg15
I2
sa(dp10343
g9
I289
sg10
VC0241910
p10344
sg12
I20
sg13
Vautoimmune hepatitis
p10345
sg15
I2
sa(dp10346
g9
I144
sg10
VC0011854
p10347
sg12
I26
sg13
Vinsulin-dependent diabetes
p10348
sg15
I2
sa(dp10349
g9
I113
sg10
VC0020555
p10350
sg12
I14
sg13
Vhypertrichosis
p10351
sg15
I1
sasa(dp10352
g2
VLoss of function recessive mutations in the SLC29A3 gene that encodes human equilibrative nucleoside transporter 3 (ENT3) have been identified in patients with pigmented hypertrichotic dermatosis with insulin-dependent diabetes (PHID).
p10353
sg4
(lp10354
(dp10355
g9
I70
sg39
g40
sg12
I44
sg13
Vhuman equilibrative nucleoside transporter 3
p10356
sg15
I5
sa(dp10357
g9
I201
sg39
VP01308
p10358
sg12
I7
sg13
Vinsulin
p10359
sg15
I1
sasg6
(lp10360
(dp10361
g9
I160
sg10
VC1864445
p10362
sg12
I67
sg13
Vpigmented hypertrichotic dermatosis with insulin-dependent diabetes
p10363
sg15
I6
sa(dp10364
g9
I229
sg10
VC1864445
p10365
sg12
I4
sg13
VPHID
p10366
sg15
I1
sasa(dp10367
g2
VThus, apoptotic loss of islet Beta-cells may contribute to the occurrence of autoantibody-negative insulin-dependent diabetes in individuals with non-functional ENT3 mutations.
p10368
sg4
(lp10369
(dp10370
g9
I99
sg39
VP01308
p10371
sg12
I7
sg13
Vinsulin
p10372
sg15
I1
sasg6
(lp10373
(dp10374
g9
I99
sg10
VC0011854
p10375
sg12
I26
sg13
Vinsulin-dependent diabetes
p10376
sg15
I2
sasa(dp10377
g2
VH syndrome and pigmented hypertrichosis with insulin-dependent diabetes mellitus (PHID) had been described as two autosomal recessive disorders.
p10378
sg4
(lp10379
(dp10380
g9
I45
sg39
VP01308
p10381
sg12
I7
sg13
Vinsulin
p10382
sg15
I1
sasg6
(lp10383
(dp10384
g9
I82
sg10
VC1864445
p10385
sg12
I4
sg13
VPHID
p10386
sg15
I1
sa(dp10387
g9
I0
sg10
VC1864445
p10388
sg12
I10
sg13
VH syndrome
p10389
sg15
I2
sa(dp10390
g9
I15
sg10
VC1864445
p10391
sg12
I65
sg13
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p10392
sg15
I6
sasa(dp10393
g2
VThe term H syndrome was coined to denote the major clinical findings which include hyperpigmentation, hypertrichosis, hearing loss, hepatosplenomegaly, hypogonadism, hyperglycemia/diabetes mellitus and hallux valgus/flexion contractures.
p10394
sg4
(lp10395
sg6
(lp10396
(dp10397
g9
I202
sg10
VC0018536
p10398
sg12
I13
sg13
Vhallux valgus
p10399
sg15
I2
sa(dp10400
g9
I152
sg10
VC0020619
p10401
sg12
I12
sg13
Vhypogonadism
p10402
sg15
I1
sa(dp10403
g9
I180
sg10
VC0011849
p10404
sg12
I17
sg13
Vdiabetes mellitus
p10405
sg15
I2
sa(dp10406
g9
I118
sg10
VC0011053
p10407
sg12
I12
sg13
Vhearing loss
p10408
sg15
I2
sa(dp10409
g9
I9
sg10
VC1864445
p10410
sg12
I10
sg13
VH syndrome
p10411
sg15
I2
sa(dp10412
g9
I132
sg10
VC0019214
p10413
sg12
I18
sg13
Vhepatosplenomegaly
p10414
sg15
I1
sa(dp10415
g9
I166
sg10
VC0020456
p10416
sg12
I13
sg13
Vhyperglycemia
p10417
sg15
I1
sa(dp10418
g9
I51
sg10
VC0037088
p10419
sg12
I17
sg13
Vclinical findings
p10420
sg15
I2
sa(dp10421
g9
I83
sg10
VC0162834
p10422
sg12
I17
sg13
Vhyperpigmentation
p10423
sg15
I1
sa(dp10424
g9
I216
sg10
VC0333068
p10425
sg12
I20
sg13
Vflexion contractures
p10426
sg15
I2
sa(dp10427
g9
I102
sg10
VC0020555
p10428
sg12
I14
sg13
Vhypertrichosis
p10429
sg15
I1
sasa(dp10430
g2
VMutations in SLC29A3 lead to pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy plus syndrome.
p10431
sg4
(lp10432
(dp10433
g9
I74
sg39
VP01308
p10434
sg12
I7
sg13
Vinsulin
p10435
sg15
I1
sasg6
(lp10436
(dp10437
g9
I63
sg10
VC0443146
p10438
sg12
I10
sg13
Vautoimmune
p10439
sg15
I1
sa(dp10440
g9
I74
sg10
VC0011854
p10441
sg12
I35
sg13
Vinsulin-dependent diabetes mellitus
p10442
sg15
I3
sa(dp10443
g9
I170
sg10
VC1864445
p10444
sg12
I43
sg13
Vhistiocytosis-lymphadenopathy plus syndrome
p10445
sg15
I3
sa(dp10446
g9
I123
sg10
VC0039082
p10447
sg12
I9
sg13
Vsyndromes
p10448
sg15
I1
sa(dp10449
g9
I111
sg10
VC1864445
p10450
sg12
I4
sg13
VPHID
p10451
sg15
I1
sa(dp10452
g9
I40
sg10
VC0020555
p10453
sg12
I14
sg13
Vhypertrichosis
p10454
sg15
I1
sa(dp10455
g9
I143
sg10
VC0019625
p10456
sg12
I21
sg13
VRosai-Dorfman disease
p10457
sg15
I2
sasa(dp10458
g2
VThis report describes an insulin-dependent diabetes patient with a syndromic presentation in whom a homozygous SLC29A3 mutation was identified.
p10459
sg4
(lp10460
(dp10461
g9
I25
sg39
VP01308
p10462
sg12
I7
sg13
Vinsulin
p10463
sg15
I1
sasg6
(lp10464
(dp10465
g9
I25
sg10
VC0011854
p10466
sg12
I26
sg13
Vinsulin-dependent diabetes
p10467
sg15
I2
sasa(dp10468
g2
VThese clinical features overlapped with pigmented hypertrichosis with insulin-dependent diabetes (PHID), H syndrome, Faisalabad histiocytosis and sinus histiocytosis with massive lymphadenopathy (SHML), all of which are also caused by SLC29A3 mutations.
p10469
sg4
(lp10470
(dp10471
g9
I70
sg39
VP01308
p10472
sg12
I7
sg13
Vinsulin
p10473
sg15
I1
sasg6
(lp10474
(dp10475
g9
I146
sg10
VC0019625
p10476
sg12
I48
sg13
Vsinus histiocytosis with massive lymphadenopathy
p10477
sg15
I5
sa(dp10478
g9
I105
sg10
VC1864445
p10479
sg12
I10
sg13
VH syndrome
p10480
sg15
I2
sa(dp10481
g9
I40
sg10
VC1864445
p10482
sg12
I56
sg13
Vpigmented hypertrichosis with insulin-dependent diabetes
p10483
sg15
I5
sa(dp10484
g9
I117
sg10
VC1864445
p10485
sg12
I24
sg13
VFaisalabad histiocytosis
p10486
sg15
I2
sa(dp10487
g9
I196
sg10
VC1864445
p10488
sg12
I4
sg13
VSHML
p10489
sg15
I1
sa(dp10490
g9
I98
sg10
VC1864445
p10491
sg12
I4
sg13
VPHID
p10492
sg15
I1
sasa(dp10493
g2
VGermline mutations in the SLC29A3 gene result in a range of recessive, clinically related syndromes: H syndrome, pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome, Faisalabad histiocytosis, and sinus histiocytosis with massive lymphadenopathy.
p10494
sg4
(lp10495
(dp10496
g9
I143
sg39
VP01308
p10497
sg12
I7
sg13
Vinsulin
p10498
sg15
I1
sasg6
(lp10499
(dp10500
g9
I101
sg10
VC1864445
p10501
sg12
I10
sg13
VH syndrome
p10502
sg15
I2
sa(dp10503
g9
I219
sg10
VC0019625
p10504
sg12
I48
sg13
Vsinus histiocytosis with massive lymphadenopathy
p10505
sg15
I5
sa(dp10506
g9
I189
sg10
VC1864445
p10507
sg12
I24
sg13
VFaisalabad histiocytosis
p10508
sg15
I2
sa(dp10509
g9
I90
sg10
VC0039082
p10510
sg12
I8
sg13
Vsyndrome
p10511
sg15
I1
sa(dp10512
g9
I113
sg10
VC1864445
p10513
sg12
I65
sg13
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p10514
sg15
I6
sa(dp10515
g9
I90
sg10
VC0039082
p10516
sg12
I9
sg13
Vsyndromes
p10517
sg15
I1
sasa(dp10518
g2
VCharacteristic ADC map features were identified for protrusion, extrusion and sequester types of lumbar disk herniations, spondylolisthesis, reactive Modic endplate changes, Pfirrmann grades of IVD degeneration, and compromised spinal nerves.
p10519
sg4
(lp10520
sg6
(lp10521
(dp10522
g9
I122
sg10
VC0038017
p10523
sg12
I17
sg13
Vspondylolisthesis
p10524
sg15
I1
sa(dp10525
g9
I52
sg10
VC0333056
p10526
sg12
I10
sg13
Vprotrusion
p10527
sg15
I1
sa(dp10528
g9
I198
sg10
VC0011164
p10529
sg12
I12
sg13
Vdegeneration
p10530
sg15
I1
sa(dp10531
g9
I109
sg10
VC0019270
p10532
sg12
I11
sg13
Vherniations
p10533
sg15
I1
sasa(dp10534
g2
VWe measured T2 relaxation time of the intervertebral discs (IVD) and facet joints (FJ) in patients with degenerative spondylolisthesis (DS) and no spondylolisthesis (NS) and investigated the characteristics of these parts in DS.
p10535
sg4
(lp10536
sg6
(lp10537
(dp10538
g9
I136
sg10
VC0264184
p10539
sg12
I2
sg13
VDS
p10540
sg15
I1
sa(dp10541
g9
I117
sg10
VC0038017
p10542
sg12
I17
sg13
Vspondylolisthesis
p10543
sg15
I1
sa(dp10544
g9
I104
sg10
VC0264184
p10545
sg12
I30
sg13
Vdegenerative spondylolisthesis
p10546
sg15
I2
sa(dp10547
g9
I136
sg10
VC0264184
p10548
sg12
I2
sg13
VDS
p10549
sg15
I1
sasa(dp10550
g2
VEarly stages of scoliosis and spondylolisthesis entail changes in the intervertebral disc (IVD) structure and biochemistry.
p10551
sg4
(lp10552
sg6
(lp10553
(dp10554
g9
I30
sg10
VC0038017
p10555
sg12
I17
sg13
Vspondylolisthesis
p10556
sg15
I1
sa(dp10557
g9
I16
sg10
VC0700208
p10558
sg12
I9
sg13
Vscoliosis
p10559
sg15
I1
sasa(dp10560
g2
VTherefore, this study aims to develop the AMRSID (analysis of MR signal intensity distribution) method to analyze the 3D distribution of the MR signal intensity within the IVD and to evaluate their sensitivity to scoliosis and spondylolisthesis and their severities.
p10561
sg4
(lp10562
sg6
(lp10563
(dp10564
g9
I227
sg10
VC0038017
p10565
sg12
I17
sg13
Vspondylolisthesis
p10566
sg15
I1
sa(dp10567
g9
I213
sg10
VC0700208
p10568
sg12
I9
sg13
Vscoliosis
p10569
sg15
I1
sasa(dp10570
g2
VIVDs were collected from patients with lumbar fracture, vertebral tumor, disc herniation or spondylolisthesis.
p10571
sg4
(lp10572
sg6
(lp10573
(dp10574
g9
I92
sg10
VC0038017
p10575
sg12
I17
sg13
Vspondylolisthesis
p10576
sg15
I1
sa(dp10577
g9
I66
sg10
VC0027651
p10578
sg12
I5
sg13
Vtumor
p10579
sg15
I1
sa(dp10580
g9
I78
sg10
VC0019270
p10581
sg12
I10
sg13
Vherniation
p10582
sg15
I1
sasa(dp10583
g2
V"Pedra hume caa" is the common name of five species of Myrcia genus used as traditional medicine for the treatment of diabetes mellitus.
p10584
sg4
(lp10585
sg6
(lp10586
(dp10587
g9
I12
sg10
VC1842937
p10588
sg12
I3
sg13
Vcaa
p10589
sg15
I1
sa(dp10590
g9
I118
sg10
VC0011849
p10591
sg12
I17
sg13
Vdiabetes mellitus
p10592
sg15
I2
sasa(dp10593
g2
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p10594
sg4
(lp10595
(dp10596
g9
I112
sg39
VP01308
p10597
sg12
I7
sg13
Vinsulin
p10598
sg15
I1
sasg6
(lp10599
(dp10600
g9
I84
sg10
VC1842937
p10601
sg12
I3
sg13
Vcaa
p10602
sg15
I1
sa(dp10603
g9
I84
sg10
VC1842937
p10604
sg12
I3
sg13
Vcaa
p10605
sg15
I1
sa(dp10606
g9
I183
sg10
VC0011849
p10607
sg12
I8
sg13
Vdiabetes
p10608
sg15
I1
sasa(dp10609
g2
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p10610
sg4
(lp10611
(dp10612
g9
I112
sg39
VP01308
p10613
sg12
I7
sg13
Vinsulin
p10614
sg15
I1
sasg6
(lp10615
(dp10616
g9
I84
sg10
VC1842937
p10617
sg12
I3
sg13
Vcaa
p10618
sg15
I1
sa(dp10619
g9
I84
sg10
VC1842937
p10620
sg12
I3
sg13
Vcaa
p10621
sg15
I1
sa(dp10622
g9
I183
sg10
VC0011849
p10623
sg12
I8
sg13
Vdiabetes
p10624
sg15
I1
sasa(dp10625
g2
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p10626
sg4
(lp10627
(dp10628
g9
I112
sg39
VP01308
p10629
sg12
I7
sg13
Vinsulin
p10630
sg15
I1
sasg6
(lp10631
(dp10632
g9
I84
sg10
VC1842937
p10633
sg12
I3
sg13
Vcaa
p10634
sg15
I1
sa(dp10635
g9
I84
sg10
VC1842937
p10636
sg12
I3
sg13
Vcaa
p10637
sg15
I1
sa(dp10638
g9
I183
sg10
VC0011849
p10639
sg12
I8
sg13
Vdiabetes
p10640
sg15
I1
sasa(dp10641
g2
VAdult Tshz1(+/-) mice display glucose intolerance due to defects in glucose-stimulated insulin secretion associated with reduced Pdx1 and Clec16a expression in Tshz1(+/-) islets.
p10642
sg4
(lp10643
(dp10644
g9
I138
sg39
g40
sg12
I7
sg13
VClec16a
p10645
sg15
I1
sa(dp10646
g9
I129
sg39
VP52945
p10647
sg12
I4
sg13
VPdx1
p10648
sg15
I1
sa(dp10649
g9
I6
sg39
g40
sg12
I5
sg13
VTshz1
p10650
sg15
I1
sa(dp10651
g9
I87
sg39
VP01308
p10652
sg12
I7
sg13
Vinsulin
p10653
sg15
I1
sasg6
(lp10654
(dp10655
g9
I30
sg10
VC0271650
p10656
sg12
I19
sg13
Vglucose intolerance
p10657
sg15
I2
sasa(dp10658
g2
VLastly, we demonstrate that TSHZ1 levels are reduced in human islets of donors with type 2 diabetes.
p10659
sg4
(lp10660
(dp10661
g9
I28
sg39
g40
sg12
I5
sg13
VTSHZ1
p10662
sg15
I1
sasg6
(lp10663
(dp10664
g9
I84
sg10
VC0011860
p10665
sg12
I15
sg13
Vtype 2 diabetes
p10666
sg15
I3
sasa(dp10667
g2
VThus, we position Tshz1 in the transcriptional network of maturing Beta-cells and suggest that its dysregulation could contribute to the islet phenotype of human type 2 diabetes.
p10668
sg4
(lp10669
(dp10670
g9
I18
sg39
g40
sg12
I5
sg13
VTshz1
p10671
sg15
I1
sasg6
(lp10672
(dp10673
g9
I162
sg10
VC0011860
p10674
sg12
I15
sg13
Vtype 2 diabetes
p10675
sg15
I3
sasa(dp10676
g2
VMaterial e Metodos: Revisao bibliografica, atraves da Medline e PubMed, utilizando como palavras-chave: 'borderline personality disorder', 'cognitive-behavioral therapy', 'efficacy'.
p10677
sg4
(lp10678
sg6
(lp10679
(dp10680
g9
I104
sg10
VC0006012
p10681
sg12
I32
sg13
V'borderline personality disorder
p10682
sg15
I3
sasa(dp10683
g2
V#\u76ee#\u7684#\uff1a #\u7814#\u7a76#\u963b#\u585e#\u6027#\u7761#\u7720#\u547c#\u5438#\u6682#\u505c#\u4f4e#\u901a#\u6c14#\u7efc#\u5408#\u5f81(obstructive sleep apnea hypopnea syndrome, OSAHS)#\u5408#\u5e76#\u96be#\u6cbb#\u6027#\u9ad8#\u8840#\u538b(resistant hypertension, RH)#\u60a3#\u8005#\u4e2d, OSAHS#\u7684#\u6cbb#\u7597#\u5bf9#\u8840#\u538b#\u63a7#\u5236#\u7684#\u610f#\u4e49#\u3002 #\u65b9#\u6cd5#\uff1a 80#\u4f8bOSAHS#\u5408#\u5e76RH#\u60a3#\u8005[#\u81f3#\u5c113#\u79cd#\u6297#\u9ad8#\u8840#\u538b#\u836f(#\u5305#\u62ec#\u5229#\u5c3f#\u5242)#\u6cbb#\u7597, #\u4ecd#\u4e0d#\u80fd#\u5c06#\u6536#\u7f29#\u538b#\u548c#\u8212#\u5f20#\u538b#\u63a7#\u5236#\u5728#\u76ee#\u6807#\u6c34#\u5e73(140/90 mmHg, 1 mmHg=0.133 kPa)]#\u884c#\u624b#\u672f#\u6216#\u6301#\u7eed#\u6b63#\u538b#\u901a#\u6c14#\u6cbb#\u7597, #\u6cbb#\u7597#\u524d#\u53ca#\u6cbb#\u75976#\u4e2a#\u6708#\u540e#\u884c#\u591a#\u9053#\u7761#\u7720#\u76d1#\u6d4b#\u548c#\u52a8#\u6001#\u8840#\u538b#\u76d1#\u6d4b, #\u8bb0#\u5f55#\u547c#\u5438#\u6682#\u505c#\u4f4e#\u901a#\u6c14#\u6307#\u6570(apnea hypopnea index, AHI)#\u3001#\u6700#\u4f4e#\u8840#\u6c27#\u9971#\u548c#\u5ea6(SaO(2))#\u3001#\u8840#\u538b#\u3001#\u591c#\u95f4#\u8840#\u538b#\u4e0b#\u964d#\u7387, #\u6bd4#\u8f83#\u6cbb#\u7597#\u524d#\u540e#\u964d#\u538b#\u836f#\u7269#\u79cd#\u7c7b#\u7684#\u53d8#\u5316#\u3002 #\u7ed3#\u679c#\uff1a #\u6cbb#\u7597#\u540e, AHI#\u7531(32.9+/-10.8)#\u6b21/h(x+/-s, #\u4e0b#\u540c)#\u964d#\u81f3(9.4+/-6.5)#\u6b21/h, #\u6700#\u4f4eSaO(2)#\u7531(0.682+/-0.062)#\u589e#\u81f3(0.884+/-0.056), #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a18.863#\u300126.614, P#\u503c#\u5747&lt;0.001)#\u3002#\u5168#\u5929#\u6536#\u7f29#\u538b#\u7531(150.5+/-9.8) mmHg#\u964d#\u81f3(140.7+/-6.8) mmHg, #\u8212#\u5f20#\u538b#\u7531(97.8+/-7.3) mmHg#\u964d#\u81f3(88.6+/-6.3) mmHg#\uff1b#\u65e5#\u95f4#\u6536#\u7f29#\u538b#\u7531(154.3+/-8.9) mmHg#\u964d#\u81f3(144.8+/-5.8) mmHg, #\u8212#\u5f20#\u538b#\u7531(100.6+/-7.4) mmHg#\u964d#\u81f3(91.3+/-5.5) mmHg#\uff1b#\u591c#\u95f4#\u6536#\u7f29#\u538b#\u7531(145.5+/-8.8) mmHg#\u964d#\u81f3(135.8+/-5.7) mmHg, #\u8212#\u5f20#\u538b#\u7531(93.8+/-6.4) mmHg#\u964d#\u81f3(84.6+/-5.9) mmHg, #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a7.832#\u30016.903#\u30017.005#\u30016.848#\u30018.025#\u30017.554, P#\u503c#\u5747&lt;0.001)#\u3002#\u591c#\u95f4#\u6536#\u7f29#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(11.5+/-2.2)mmHg#\u3001#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(10.2+/-3.1)mmHg, #\u65e5#\u95f4#\u6536#\u7f29#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(9.0+/-2.8)mmHg#\u3001#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(7.9+/-3.5)mmHg, #\u591c#\u95f4#\u6536#\u7f29#\u538b#\u53ca#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u8f83#\u65e5#\u95f4#\u66f4#\u660e#\u663e, #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a9.732#\u30016.936, P#\u503c#\u5747&lt;0.001)#\u3002#\u591c#\u95f4#\u8840#\u538b#\u4e0b#\u964d#\u7387&lt;10%#\u7684#\u60a3#\u8005#\u6bd4#\u4f8b#\u7531#\u6cbb#\u7597#\u524d#\u768475.0%#\u964d#\u4e3a#\u6cbb#\u7597#\u540e#\u768437.5%, #\u5dee#\u5f02#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(X(2)=22.857, P&lt;0.01), #\u63d0#\u793a#\u8840#\u538b#\u663c#\u591c#\u8282#\u5f8b#\u53d8#\u5316#\u60c5#\u51b5#\u597d#\u8f6c#\u300245#\u4f8b#\u60a3#\u8005#\u670d#\u7528#\u7684#\u964d#\u538b#\u836f#\u7269#\u79cd#\u7c7b#\u51cf#\u5c11, #\u7531#\u6cbb#\u7597#\u524d#\u7684(3.2+/-0.4)#\u79cd#\u51cf#\u4e3a#\u6cbb#\u7597#\u540e#\u7684(2.6+/-0.5)#\u79cd, #\u5dee#\u5f02#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t=9.276, P&lt;0.01)#\u3002 #\u7ed3#\u8bba#\uff1a OSAHS#\u5408#\u5e76RH#\u60a3#\u8005#\u4e2d, #\u6cbb#\u7597OSAHS#\u80fd#\u6709#\u6548#\u6539#\u5584#\u8840#\u538b#\u63a7#\u5236#\u6c34#\u5e73, #\u6539#\u5584#\u8840#\u538b#\u663c#\u591c#\u8282#\u5f8b, #\u51cf#\u5c11#\u964d#\u538b#\u836f#\u7269#\u7684#\u4f7f#\u7528#\u3002.
p10684
sg4
(lp10685
sg6
(lp10686
(dp10687
g9
I85
sg10
VC0520679
p10688
sg12
I5
sg13
VOSAHS
p10689
sg15
I1
sa(dp10690
g9
I118
sg10
VC0020538
p10691
sg12
I12
sg13
Vhypertension
p10692
sg15
I1
sa(dp10693
g9
I85
sg10
VC0520679
p10694
sg12
I5
sg13
VOSAHS
p10695
sg15
I1
sa(dp10696
g9
I42
sg10
VC0520679
p10697
sg12
I23
sg13
Vobstructive sleep apnea
p10698
sg15
I3
sa(dp10699
g9
I66
sg10
VC2748060
p10700
sg12
I17
sg13
Vhypopnea syndrome
p10701
sg15
I2
sa(dp10702
g9
I60
sg10
VC0003578
p10703
sg12
I5
sg13
Vapnea
p10704
sg15
I1
sa(dp10705
g9
I85
sg10
VC0520679
p10706
sg12
I5
sg13
VOSAHS
p10707
sg15
I1
sasa(dp10708
g2
VIn case of coronary atherosclerosis the organism reaction to expressed CMC is manifested basically by intensified synthesis of cathodic complement-C3-similar autoprecipitin, but in case of endocarditis--by consumption of one with formation of anodic autoprecipitin and by intensified synthesis of autoprecipitating immunoglobulin G. These membranotropic autoimmune reactions are identical with the organism reactions to alien (heterologous) agents and differentially participate in development both of basic disease and perioperational complications after cardiac operations using trans- and implants, hence, they should be taken into account during membrane-stabilising and immunocorrecting therapy of recipients.
p10709
sg4
(lp10710
(dp10711
g9
I315
sg39
g40
sg12
I16
sg13
Vimmunoglobulin G
p10712
sg15
I2
sa(dp10713
g9
I127
sg39
g40
sg12
I22
sg13
Vcathodic complement-C3
p10714
sg15
I2
sasg6
(lp10715
(dp10716
g9
I354
sg10
VC0443146
p10717
sg12
I20
sg13
Vautoimmune reactions
p10718
sg15
I2
sa(dp10719
g9
I11
sg10
VC2733225
p10720
sg12
I24
sg13
Vcoronary atherosclerosis
p10721
sg15
I2
sa(dp10722
g9
I189
sg10
VC0014118
p10723
sg12
I12
sg13
Vendocarditis
p10724
sg15
I1
sasa(dp10725
g2
VIn cultured rat hepatoma (H4IIE) cells, TNF-Alfa significantly increased hemopexin mRNA accumulation.
p10726
sg4
(lp10727
(dp10728
g9
I73
sg39
VP02790
p10729
sg12
I14
sg13
Vhemopexin mRNA
p10730
sg15
I2
sa(dp10731
g9
I40
sg39
VP01375
p10732
sg12
I8
sg13
VTNF-Alfa
p10733
sg15
I1
sasg6
(lp10734
(dp10735
g9
I16
sg10
VC0023903
p10736
sg12
I8
sg13
Vhepatoma
p10737
sg15
I1
sasa(dp10738
g2
VThis analytical method was applied to an in vitro diagnostic multivariate index assay where a panel of hepatocellular carcinoma (HCC) biomarkers comprising alpha-fetoprotein, hemopexin, and alpha-2-macroglobulin (A2M) was examined in terms of the serum level and their fuco-fractions.
p10739
sg4
(lp10740
(dp10741
g9
I175
sg39
VP02790
p10742
sg12
I9
sg13
Vhemopexin
p10743
sg15
I1
sa(dp10744
g9
I156
sg39
VP02771
p10745
sg12
I17
sg13
Valpha-fetoprotein
p10746
sg15
I1
sa(dp10747
g9
I190
sg39
VP01023
p10748
sg12
I21
sg13
Valpha-2-macroglobulin
p10749
sg15
I1
sa(dp10750
g9
I213
sg39
VP01023
p10751
sg12
I3
sg13
VA2M
p10752
sg15
I1
sasg6
(lp10753
(dp10754
g9
I129
sg10
VC2239176
p10755
sg12
I3
sg13
VHCC
p10756
sg15
I1
sa(dp10757
g9
I103
sg10
VC2239176
p10758
sg12
I24
sg13
Vhepatocellular carcinoma
p10759
sg15
I2
sasa(dp10760
g2
VThe aim of this study was to identify new target genes for microRNA polymorphisms (miR-146aC&gt;G and miR-196a2T&gt;C) in primary ovarian insufficiency (POI).
p10761
sg4
(lp10762
(dp10763
g9
I-1
sg39
g40
sg12
I12
sg13
VmiR-196a2T>C
p10764
sg15
I1
sa(dp10765
g9
I83
sg39
g40
sg12
I9
sg13
VmiR-146aC
p10766
sg15
I1
sasg6
(lp10767
(dp10768
g9
I153
sg10
VC0041408
p10769
sg12
I3
sg13
VPOI
p10770
sg15
I1
sa(dp10771
g9
I122
sg10
VC0041408
p10772
sg12
I29
sg13
Vprimary ovarian insufficiency
p10773
sg15
I3
sasa(dp10774
g2
VIn addition, several specific miRNAs (miR-23a, miR-27a, miR-22-3p, miR-146a, miR-196a, miR-290-295, miR-423, and miR-608) related to POI are also examined in order to highlight the issues that deserve further investigation.
p10775
sg4
(lp10776
(dp10777
g9
I67
sg39
g40
sg12
I8
sg13
VmiR-146a
p10778
sg15
I1
sa(dp10779
g9
I47
sg39
g40
sg12
I7
sg13
VmiR-27a
p10780
sg15
I1
sa(dp10781
g9
I56
sg39
g40
sg12
I9
sg13
VmiR-22-3p
p10782
sg15
I1
sa(dp10783
g9
I113
sg39
g40
sg12
I7
sg13
VmiR-608
p10784
sg15
I1
sa(dp10785
g9
I77
sg39
g40
sg12
I8
sg13
VmiR-196a
p10786
sg15
I1
sa(dp10787
g9
I38
sg39
g40
sg12
I7
sg13
VmiR-23a
p10788
sg15
I1
sasg6
(lp10789
sa(dp10790
g2
V(2) Expand sample size to 14 cases for endometriosis group and 16 cases for control group.Reverse transcription (RT)-PCR technique was utilized to detect the expression of miR- 142- 5p, miR- 146a- 5p and miR- 543 in endometrial tissues, and verify miRNA microarray results.
p10791
sg4
(lp10792
(dp10793
g9
I186
sg39
g40
sg12
I13
sg13
VmiR- 146a- 5p
p10794
sg15
I3
sa(dp10795
g9
I172
sg39
g40
sg12
I12
sg13
VmiR- 142- 5p
p10796
sg15
I3
sa(dp10797
g9
I204
sg39
g40
sg12
I8
sg13
VmiR- 543
p10798
sg15
I2
sasg6
(lp10799
(dp10800
g9
I39
sg10
VC0014175
p10801
sg12
I13
sg13
Vendometriosis
p10802
sg15
I1
sasa(dp10803
g2
V(1) miRNA and mRNA microarray screening results showed that, among the endometrial tissues of patients with endometriosis infertility and with implantation window phase, 6 differentially expressed miRNA were indentified, among which miR-142-5p, miR-146a-5p, miR-1281, miR-940, miR-4634 showed significantly enhanced expression and miR- 543 showed significantly inhibited expression.
p10804
sg4
(lp10805
(dp10806
g9
I233
sg39
g40
sg12
I10
sg13
VmiR-142-5p
p10807
sg15
I1
sa(dp10808
g9
I268
sg39
g40
sg12
I7
sg13
VmiR-940
p10809
sg15
I1
sa(dp10810
g9
I277
sg39
g40
sg12
I8
sg13
VmiR-4634
p10811
sg15
I1
sa(dp10812
g9
I245
sg39
g40
sg12
I11
sg13
VmiR-146a-5p
p10813
sg15
I1
sa(dp10814
g9
I258
sg39
g40
sg12
I8
sg13
VmiR-1281
p10815
sg15
I1
sa(dp10816
g9
I331
sg39
g40
sg12
I8
sg13
VmiR- 543
p10817
sg15
I2
sasg6
(lp10818
(dp10819
g9
I122
sg10
VC0021359
p10820
sg12
I11
sg13
Vinfertility
p10821
sg15
I1
sa(dp10822
g9
I108
sg10
VC0014175
p10823
sg12
I13
sg13
Vendometriosis
p10824
sg15
I1
sasa(dp10825
g2
V(2) RT- PCR test showed that the average levels of expression of miR-142-5p and miR-146a-5p in implantation window phase endometrium in endometriosis group were 8.3+/-10.6 and 1.9+/-0.8 respectively; the average levels of that in control group were 1.1+/-0.6 and 0.9+/-0.4, respectively.
p10826
sg4
(lp10827
(dp10828
g9
I80
sg39
g40
sg12
I11
sg13
VmiR-146a-5p
p10829
sg15
I1
sa(dp10830
g9
I65
sg39
g40
sg12
I10
sg13
VmiR-142-5p
p10831
sg15
I1
sasg6
(lp10832
(dp10833
g9
I136
sg10
VC0014175
p10834
sg12
I13
sg13
Vendometriosis
p10835
sg15
I1
sasa(dp10836
g2
VThere are multiple differential expressions of miRNA in the implantation window phase endometrium tissues of endometriosis infertility patients, among which miR-142-5p and miR-146a-5p show significantly enhanced expression and may affect embryo implantation by acting on a variety of endometrial receptivity marker molecules.
p10837
sg4
(lp10838
(dp10839
g9
I172
sg39
g40
sg12
I11
sg13
VmiR-146a-5p
p10840
sg15
I1
sa(dp10841
g9
I157
sg39
g40
sg12
I10
sg13
VmiR-142-5p
p10842
sg15
I1
sasg6
(lp10843
(dp10844
g9
I123
sg10
VC0021359
p10845
sg12
I11
sg13
Vinfertility
p10846
sg15
I1
sa(dp10847
g9
I109
sg10
VC0014175
p10848
sg12
I13
sg13
Vendometriosis
p10849
sg15
I1
sasa(dp10850
g2
VWe also analyze the ezrin-meditated regulation of critical pathways associated with asthma, such as the RhoA, Rho-associated protein kinase (ROCK), and protein kinase A (cAMP/PKA) pathways.
p10851
sg4
(lp10852
(dp10853
g9
I141
sg39
g40
sg12
I4
sg13
VROCK
p10854
sg15
I1
sa(dp10855
g9
I170
sg39
VP49913
p10856
sg12
I8
sg13
VcAMP/PKA
p10857
sg15
I1
sa(dp10858
g9
I110
sg39
VP08100
p10859
sg12
I29
sg13
VRho-associated protein kinase
p10860
sg15
I3
sa(dp10861
g9
I152
sg39
VP17612
p10862
sg12
I16
sg13
Vprotein kinase A
p10863
sg15
I3
sa(dp10864
g9
I104
sg39
VP61586
p10865
sg12
I4
sg13
VRhoA
p10866
sg15
I1
sasg6
(lp10867
(dp10868
g9
I84
sg10
VC0004096
p10869
sg12
I6
sg13
Vasthma
p10870
sg15
I1
sasa(dp10871
g2
VPneumothorax is a well-recognized complication of central venous line insertion (CVL).
p10872
sg4
(lp10873
sg6
(lp10874
(dp10875
g9
I34
sg10
VC0009566
p10876
sg12
I12
sg13
Vcomplication
p10877
sg15
I1
sa(dp10878
g9
I0
sg10
VC0032326
p10879
sg12
I12
sg13
VPneumothorax
p10880
sg15
I1
sasa(dp10881
g2
VWe identify and replicate an association between the constituents of the apical plasma membrane and CF lung disease (p = 0.0099 and p = 0.0180, respectively) and highlight a role for the SLC9A3-SLC9A3R1/2-EZR complex in contributing to CF lung disease.
p10882
sg4
(lp10883
(dp10884
g9
I187
sg39
VP48764
p10885
sg12
I29
sg13
VSLC9A3-SLC9A3R1/2-EZR complex
p10886
sg15
I2
sasg6
(lp10887
(dp10888
g9
I103
sg10
VC0024115
p10889
sg12
I12
sg13
Vlung disease
p10890
sg15
I2
sa(dp10891
g9
I103
sg10
VC0024115
p10892
sg12
I12
sg13
Vlung disease
p10893
sg15
I2
sasa(dp10894
g2
VThe BrGR-expressing yeast strain induced the activation of metabolic enzymes (Hxt, G6PDH, GAPDH and Ald), antioxidant systems (Gpx, Trx2, Trx3, Trr1, Tsa1 and porin) and molecular chaperones (Hsp104, Hsp90, Hsp70, Hsp42, Hsp26, Grp, Sti1 and Zpr1), which led to lower oxidative protein damage after a reduction in the level of cellular ROS in the BrGR-expressing yeast strain exposed to H(2)O(2) than in the wild-type yeast strain.
p10895
sg4
(lp10896
(dp10897
g9
I100
sg39
VP33897
p10898
sg12
I3
sg13
VAld
p10899
sg15
I1
sa(dp10900
g9
I127
sg39
g40
sg12
I3
sg13
VGpx
p10901
sg15
I1
sa(dp10902
g9
I228
sg39
VP07492
p10903
sg12
I3
sg13
VGrp
p10904
sg15
I1
sa(dp10905
g9
I90
sg39
VP04406
p10906
sg12
I5
sg13
VGAPDH
p10907
sg15
I1
sa(dp10908
g9
I159
sg39
VP21796
p10909
sg12
I5
sg13
Vporin
p10910
sg15
I1
sa(dp10911
g9
I132
sg39
g40
sg12
I4
sg13
VTrx2
p10912
sg15
I1
sa(dp10913
g9
I150
sg39
g40
sg12
I4
sg13
VTsa1
p10914
sg15
I1
sa(dp10915
g9
I207
sg39
VP34932
p10916
sg12
I5
sg13
VHsp70
p10917
sg15
I1
sa(dp10918
g9
I242
sg39
g40
sg12
I4
sg13
VZpr1
p10919
sg15
I1
sa(dp10920
g9
I83
sg39
VP11413
p10921
sg12
I5
sg13
VG6PDH
p10922
sg15
I1
sa(dp10923
g9
I200
sg39
VP07900
p10924
sg12
I5
sg13
VHsp90
p10925
sg15
I1
sa(dp10926
g9
I78
sg39
g40
sg12
I3
sg13
VHxt
p10927
sg15
I1
sa(dp10928
g9
I233
sg39
VP31948
p10929
sg12
I4
sg13
VSti1
p10930
sg15
I1
sasg6
(lp10931
(dp10932
g9
I100
sg10
VC0162309
p10933
sg12
I3
sg13
VAld
p10934
sg15
I1
sasa(dp10935
g2
VIn this review, we focus on the use of these agents in children to treat inflammatory skin diseases other than psoriasis, including atopic dermatitis, hidradenitis suppurativa, pemphigus vulgaris, bullous pemphigoid, and toxic epidermal necrolysis, with an emphasis on the use of etanercept, infliximab, rituximab, omalizumab, and ustekinumab.
p10936
sg4
(lp10937
sg6
(lp10938
(dp10939
g9
I177
sg10
VC0030809
p10940
sg12
I18
sg13
Vpemphigus vulgaris
p10941
sg15
I2
sa(dp10942
g9
I111
sg10
VC0033860
p10943
sg12
I9
sg13
Vpsoriasis
p10944
sg15
I1
sa(dp10945
g9
I151
sg10
VC0162836
p10946
sg12
I24
sg13
Vhidradenitis suppurativa
p10947
sg15
I2
sa(dp10948
g9
I221
sg10
VC0014518
p10949
sg12
I26
sg13
Vtoxic epidermal necrolysis
p10950
sg15
I3
sa(dp10951
g9
I197
sg10
VC0030805
p10952
sg12
I18
sg13
Vbullous pemphigoid
p10953
sg15
I2
sa(dp10954
g9
I132
sg10
VC0011615
p10955
sg12
I17
sg13
Vatopic dermatitis
p10956
sg15
I2
sa(dp10957
g9
I86
sg10
VC0037274
p10958
sg12
I13
sg13
Vskin diseases
p10959
sg15
I2
sasa(dp10960
g2
VThe addition of distamycin A enhanced the double-strand DNA cleavage at the 5'-CCT-3'/3'-GGA-5' and 5'-CCA-3'/3'-GGT-5' sequences, with a two-nucleotide 3'-stagger of the cleaved residues.
p10961
sg4
(lp10962
sg6
(lp10963
(dp10964
g9
I79
sg10
VC2752078
p10965
sg12
I3
sg13
VCCT
p10966
sg15
I1
sa(dp10967
g9
I103
sg10
VC0220668
p10968
sg12
I3
sg13
VCCA
p10969
sg15
I1
sasa(dp10970
g2
VBesides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).
p10971
sg4
(lp10972
(dp10973
g9
I133
sg39
VP02545
p10974
sg12
I6
sg13
VCMT2B1
p10975
sg15
I1
sa(dp10976
g9
I112
sg39
g40
sg12
I6
sg13
VCMT2A2
p10977
sg15
I1
sa(dp10978
g9
I140
sg39
VP02545
p10979
sg12
I4
sg13
VLMNA
p10980
sg15
I1
sa(dp10981
g9
I127
sg39
g40
sg12
I4
sg13
VMFN2
p10982
sg15
I1
sa(dp10983
g9
I214
sg39
g40
sg12
I6
sg13
VLRSAM1
p10984
sg15
I1
sa(dp10985
g9
I195
sg39
g40
sg12
I5
sg13
VCMT2K
p10986
sg15
I1
sa(dp10987
g9
I235
sg39
g40
sg12
I5
sg13
VCMT2S
p10988
sg15
I1
sa(dp10989
g9
I294
sg39
g40
sg12
I3
sg13
VGAN
p10990
sg15
I1
sa(dp10991
g9
I449
sg39
g40
sg12
I5
sg13
VSPG15
p10992
sg15
I1
sa(dp10993
g9
I439
sg39
g40
sg12
I4
sg13
VSPG7
p10994
sg15
I1
sa(dp10995
g9
I294
sg39
g40
sg12
I3
sg13
VGAN
p10996
sg15
I1
sa(dp10997
g9
I483
sg39
g40
sg12
I4
sg13
VFA2H
p10998
sg15
I1
sa(dp10999
g9
I455
sg39
g40
sg12
I7
sg13
VZFYVE26
p11000
sg15
I1
sa(dp11001
g9
I241
sg39
VP38935
p11002
sg12
I7
sg13
VIGHMBP2
p11003
sg15
I1
sa(dp11004
g9
I256
sg39
VP25686
p11005
sg12
I4
sg13
VHSJ1
p11006
sg15
I1
sa(dp11007
g9
I444
sg39
VP00747
p11008
sg12
I3
sg13
VPGN
p11009
sg15
I1
sa(dp11010
g9
I228
sg39
g40
sg12
I5
sg13
VTRIM2
p11011
sg15
I1
sa(dp11012
g9
I153
sg39
g40
sg12
I5
sg13
VMED25
p11013
sg15
I1
sa(dp11014
g9
I495
sg39
g40
sg12
I4
sg13
VGBA2
p11015
sg15
I1
sa(dp11016
g9
I167
sg39
VP07196
p11017
sg12
I4
sg13
VNEFL
p11018
sg15
I1
sa(dp11019
g9
I285
sg39
VP49773
p11020
sg12
I4
sg13
VHINT
p11021
sg15
I1
sa(dp11022
g9
I507
sg39
g40
sg12
I8
sg13
VC12orf65
p11023
sg15
I1
sa(dp11024
g9
I470
sg39
g40
sg12
I5
sg13
VACP33
p11025
sg15
I1
sa(dp11026
g9
I520
sg39
g40
sg12
I12
sg13
VSPG56/CYP2U1
p11027
sg15
I1
sa(dp11028
g9
I201
sg39
g40
sg12
I5
sg13
VGDAP1
p11029
sg15
I1
sa(dp11030
g9
I119
sg39
g40
sg12
I7
sg13
VHMSN2A2
p11031
sg15
I1
sa(dp11032
g9
I464
sg39
g40
sg12
I5
sg13
VSPG21
p11033
sg15
I1
sa(dp11034
g9
I269
sg39
VP12074
p11035
sg12
I6
sg13
VCOX6A1
p11036
sg15
I1
sasg6
(lp11037
(dp11038
g9
I208
sg10
VC3280797
p11039
sg12
I5
sg13
VCMT2P
p11040
sg15
I1
sa(dp11041
g9
I146
sg10
VC1854150
p11042
sg12
I6
sg13
VCMT2B2
p11043
sg15
I1
sa(dp11044
g9
I294
sg10
VC1850386
p11045
sg12
I3
sg13
VGAN
p11046
sg15
I1
sa(dp11047
g9
I449
sg10
VC1849128
p11048
sg12
I5
sg13
VSPG15
p11049
sg15
I1
sa(dp11050
g9
I439
sg10
VC1846564
p11051
sg12
I4
sg13
VSPG7
p11052
sg15
I1
sa(dp11053
g9
I133
sg10
VC1854154
p11054
sg12
I6
sg13
VCMT2B1
p11055
sg15
I1
sa(dp11056
g9
I294
sg10
VC1850386
p11057
sg12
I3
sg13
VGAN
p11058
sg15
I1
sa(dp11059
g9
I83
sg10
VC0007959
p11060
sg12
I27
sg13
VCharcot-Marie-Tooth disease
p11061
sg15
I2
sa(dp11062
g9
I112
sg10
VC1836485
p11063
sg12
I6
sg13
VCMT2A2
p11064
sg15
I1
sa(dp11065
g9
I119
sg10
VC1836485
p11066
sg12
I7
sg13
VHMSN2A2
p11067
sg15
I1
sa(dp11068
g9
I409
sg10
VC1263857
p11069
sg12
I28
sg13
Vaxonal peripheral neuropathy
p11070
sg15
I3
sa(dp11071
g9
I181
sg10
VC2608087
p11072
sg12
I6
sg13
VdHMN2B
p11073
sg15
I1
sa(dp11074
g9
I610
sg10
VC0175754
p11075
sg12
I31
sg13
Vagenesis of the corpus callosum
p11076
sg15
I5
sa(dp11077
g9
I464
sg10
VC1855346
p11078
sg12
I5
sg13
VSPG21
p11079
sg15
I1
sa(dp11080
g9
I329
sg10
VC0751603
p11081
sg12
I49
sg13
Vautosomal recessive hereditary spastic paraplegia
p11082
sg15
I5
sa(dp11083
g9
I416
sg10
VC0031117
p11084
sg12
I21
sg13
Vperipheral neuropathy
p11085
sg15
I2
sa(dp11086
g9
I195
sg10
VC1842983
p11087
sg12
I5
sg13
VCMT2K
p11088
sg15
I1
sasa(dp11089
g2
VPlasmacytomas often present as a collection of findings known as POEMS-syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein spike, and Skin changes).
p11090
sg4
(lp11091
sg6
(lp11092
(dp11093
g9
I71
sg10
VC0039082
p11094
sg12
I8
sg13
Vsyndrome
p11095
sg15
I1
sa(dp11096
g9
I111
sg10
VC0014130
p11097
sg12
I14
sg13
VEndocrinopathy
p11098
sg15
I1
sa(dp11099
g9
I0
sg10
VC0032131
p11100
sg12
I13
sg13
VPlasmacytomas
p11101
sg15
I1
sa(dp11102
g9
I81
sg10
VC0152025
p11103
sg12
I14
sg13
VPolyneuropathy
p11104
sg15
I1
sasa(dp11105
g2
VPOEMS (acronym for polyneuropathy, organomegaly, endocrinopathy, M protein myeloma and skin changes), is a rare disease which occurs in the setting of plasma cell dyscrasias.
p11106
sg4
(lp11107
(dp11108
g9
I65
sg39
VP54296
p11109
sg12
I9
sg13
VM protein
p11110
sg15
I2
sasg6
(lp11111
(dp11112
g9
I107
sg10
VC0678236
p11113
sg12
I12
sg13
Vrare disease
p11114
sg15
I2
sa(dp11115
g9
I49
sg10
VC0014130
p11116
sg12
I14
sg13
Vendocrinopathy
p11117
sg15
I1
sa(dp11118
g9
I19
sg10
VC0152025
p11119
sg12
I14
sg13
Vpolyneuropathy
p11120
sg15
I1
sa(dp11121
g9
I151
sg10
VC1136084
p11122
sg12
I22
sg13
Vplasma cell dyscrasias
p11123
sg15
I3
sa(dp11124
g9
I75
sg10
VC0026764
p11125
sg12
I7
sg13
Vmyeloma
p11126
sg15
I1
sasa(dp11127
g2
VPrevious case reports and studies have shown that anti-myelin-associated glycoprotein (MAG) antibody can be detected in patients with polyneuropathy without any detectable M-protein.
p11128
sg4
(lp11129
(dp11130
g9
I50
sg39
VP20916
p11131
sg12
I50
sg13
Vanti-myelin-associated glycoprotein (MAG) antibody
p11132
sg15
I4
sasg6
(lp11133
(dp11134
g9
I134
sg10
VC0152025
p11135
sg12
I14
sg13
Vpolyneuropathy
p11136
sg15
I1
sasa(dp11137
g2
VPolyneuropathy, Organomegaly, Endocrinopathy, M protein and Skin changes (POEMS) syndrome is rare plasma cell dyscrasia with multisystem involvement.
p11138
sg4
(lp11139
sg6
(lp11140
(dp11141
g9
I81
sg10
VC0039082
p11142
sg12
I8
sg13
Vsyndrome
p11143
sg15
I1
sa(dp11144
g9
I98
sg10
VC1136084
p11145
sg12
I21
sg13
Vplasma cell dyscrasia
p11146
sg15
I3
sa(dp11147
g9
I30
sg10
VC0014130
p11148
sg12
I14
sg13
VEndocrinopathy
p11149
sg15
I1
sa(dp11150
g9
I0
sg10
VC0152025
p11151
sg12
I14
sg13
VPolyneuropathy
p11152
sg15
I1
sasa(dp11153
g2
VThe name comes from the five characteristic features: Polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes.
p11154
sg4
(lp11155
sg6
(lp11156
(dp11157
g9
I84
sg10
VC0014130
p11158
sg12
I14
sg13
Vendocrinopathy
p11159
sg15
I1
sa(dp11160
g9
I54
sg10
VC0152025
p11161
sg12
I14
sg13
VPolyneuropathy
p11162
sg15
I1
sasa(dp11163
g2
VPolyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome and monoclonal gammopathy of undetermined significance (MGUS) are paraproteinemic disorders that can cause demyelinating polyneuropathy.
p11164
sg4
(lp11165
sg6
(lp11166
(dp11167
g9
I82
sg10
VC0039082
p11168
sg12
I8
sg13
Vsyndrome
p11169
sg15
I1
sa(dp11170
g9
I95
sg10
VC0026470
p11171
sg12
I50
sg13
Vmonoclonal gammopathy of undetermined significance
p11172
sg15
I5
sa(dp11173
g9
I147
sg10
VC0026470
p11174
sg12
I4
sg13
VMGUS
p11175
sg15
I1
sa(dp11176
g9
I198
sg10
VC0270922
p11177
sg12
I28
sg13
Vdemyelinating polyneuropathy
p11178
sg15
I2
sa(dp11179
g9
I30
sg10
VC0014130
p11180
sg12
I14
sg13
Vendocrinopathy
p11181
sg15
I1
sa(dp11182
g9
I0
sg10
VC0152025
p11183
sg12
I14
sg13
VPolyneuropathy
p11184
sg15
I1
sasa(dp11185
g2
VPolyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome, a form of osteosclerotic myeloma, is a multisystem disease related to a monoclonal plasma cell proliferative disorder.
p11186
sg4
(lp11187
sg6
(lp11188
(dp11189
g9
I82
sg10
VC0039082
p11190
sg12
I8
sg13
Vsyndrome
p11191
sg15
I1
sa(dp11192
g9
I102
sg10
VC1510415
p11193
sg12
I22
sg13
Vosteosclerotic myeloma
p11194
sg15
I2
sa(dp11195
g9
I187
sg10
VC0334094
p11196
sg12
I13
sg13
Vproliferative
p11197
sg15
I1
sa(dp11198
g9
I30
sg10
VC0014130
p11199
sg12
I14
sg13
Vendocrinopathy
p11200
sg15
I1
sa(dp11201
g9
I0
sg10
VC0152025
p11202
sg12
I14
sg13
VPolyneuropathy
p11203
sg15
I1
sasa(dp11204
g2
VShe had been treated with cyclophosphamide, melphalan, lenalidomide and corticosteroids for POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy or edema, M protein, skin changes).
p11205
sg4
(lp11206
sg6
(lp11207
(dp11208
g9
I138
sg10
VC0014130
p11209
sg12
I14
sg13
Vendocrinopathy
p11210
sg15
I1
sa(dp11211
g9
I156
sg10
VC0013604
p11212
sg12
I5
sg13
Vedema
p11213
sg15
I1
sa(dp11214
g9
I108
sg10
VC0152025
p11215
sg12
I14
sg13
Vpolyneuropathy
p11216
sg15
I1
sa(dp11217
g9
I92
sg10
VC0085404
p11218
sg12
I14
sg13
VPOEMS syndrome
p11219
sg15
I2
sasa(dp11220
g2
VPolyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome is a rare cause of demyelinating neuropathy, with multi-organ involvement characterised by plasma cell dyscrasia and VEGF overproduction.
p11221
sg4
(lp11222
sg6
(lp11223
(dp11224
g9
I110
sg10
VC0270922
p11225
sg12
I24
sg13
Vdemyelinating neuropathy
p11226
sg15
I2
sa(dp11227
g9
I82
sg10
VC0039082
p11228
sg12
I8
sg13
Vsyndrome
p11229
sg15
I1
sa(dp11230
g9
I30
sg10
VC0014130
p11231
sg12
I14
sg13
Vendocrinopathy
p11232
sg15
I1
sa(dp11233
g9
I182
sg10
VC1136084
p11234
sg12
I21
sg13
Vplasma cell dyscrasia
p11235
sg15
I3
sa(dp11236
g9
I0
sg10
VC0152025
p11237
sg12
I14
sg13
VPolyneuropathy
p11238
sg15
I1
sasa(dp11239
g2
VAs a consequence, leukemia induction and leukemia maintenance were severely impaired in Inca1-/- bone marrow cells.
p11240
sg4
(lp11241
sg6
(lp11242
(dp11243
g9
I18
sg10
VC0023418
p11244
sg12
I8
sg13
Vleukemia
p11245
sg15
I1
sa(dp11246
g9
I18
sg10
VC0023418
p11247
sg12
I8
sg13
Vleukemia
p11248
sg15
I1
sa(dp11249
g9
I76
sg10
VC0684336
p11250
sg12
I8
sg13
Vimpaired
p11251
sg15
I1
sasa(dp11252
g2
VThe re-initiation of leukemia was also significantly inhibited in absence of Inca1-/- in MLL-AF9- and c-myc/BCL2-positive leukemia mouse models.
p11253
sg4
(lp11254
(dp11255
g9
I102
sg39
VP12524
p11256
sg12
I5
sg13
Vc-myc
p11257
sg15
I1
sa(dp11258
g9
I93
sg39
VP42568
p11259
sg12
I3
sg13
VAF9
p11260
sg15
I1
sa(dp11261
g9
I108
sg39
VP10415
p11262
sg12
I4
sg13
VBCL2
p11263
sg15
I1
sa(dp11264
g9
I77
sg39
g40
sg12
I15
sg13
VInca1-/- in MLL
p11265
sg15
I3
sasg6
(lp11266
(dp11267
g9
I21
sg10
VC0023418
p11268
sg12
I8
sg13
Vleukemia
p11269
sg15
I1
sa(dp11270
g9
I21
sg10
VC0023418
p11271
sg12
I8
sg13
Vleukemia
p11272
sg15
I1
sasa(dp11273
g2
VThese findings indicate distinct functional properties of Inca1 in normal hematopoietic cells compared to leukemia initiating cells.
p11274
sg4
(lp11275
(dp11276
g9
I58
sg39
g40
sg12
I5
sg13
VInca1
p11277
sg15
I1
sasg6
(lp11278
(dp11279
g9
I106
sg10
VC0023418
p11280
sg12
I8
sg13
Vleukemia
p11281
sg15
I1
sasa(dp11282
g2
VThis preliminary study indicated the tumor suppressing roles of miR-372 in cell cycle progression of TW01 cells, possibly via the down-regulation of CDK2 and CCNA1 as well as the up-regulation of CDKN1A and INCA1.Key Words: apoptosis, microRNA, nasopharyngeal carcinoma, miR-372, CDK2, CCNA1.
p11283
sg4
(lp11284
(dp11285
g9
I158
sg39
VP78396
p11286
sg12
I5
sg13
VCCNA1
p11287
sg15
I1
sa(dp11288
g9
I196
sg39
VP38936
p11289
sg12
I6
sg13
VCDKN1A
p11290
sg15
I1
sa(dp11291
g9
I149
sg39
VP24941
p11292
sg12
I4
sg13
VCDK2
p11293
sg15
I1
sa(dp11294
g9
I149
sg39
VP24941
p11295
sg12
I4
sg13
VCDK2
p11296
sg15
I1
sa(dp11297
g9
I158
sg39
VP78396
p11298
sg12
I5
sg13
VCCNA1
p11299
sg15
I1
sa(dp11300
g9
I207
sg39
g40
sg12
I5
sg13
VINCA1
p11301
sg15
I1
sasg6
(lp11302
(dp11303
g9
I245
sg10
VC2931822
p11304
sg12
I24
sg13
Vnasopharyngeal carcinoma
p11305
sg15
I2
sa(dp11306
g9
I37
sg10
VC0027651
p11307
sg12
I5
sg13
Vtumor
p11308
sg15
I1
sasa(dp11309
g2
VFurthermore, blasts from acute lymphoid leukemia and acute myeloid leukemia patients expressed significantly reduced INCA1 levels highlighting its relevance for growth control in vivo.
p11310
sg4
(lp11311
(dp11312
g9
I117
sg39
g40
sg12
I5
sg13
VINCA1
p11313
sg15
I1
sasg6
(lp11314
(dp11315
g9
I25
sg10
VC1961102
p11316
sg12
I23
sg13
Vacute lymphoid leukemia
p11317
sg15
I3
sa(dp11318
g9
I53
sg10
VC0023467
p11319
sg12
I22
sg13
Vacute myeloid leukemia
p11320
sg15
I3
sasa(dp11321
g2
VOur objectives were (i) to assess the current prevalence of childhood overweight (including obesity) (OWOB) in France and its relationship with comprehensive socioeconomic status (SES) indicators and (ii) to examine trends in OWOB prevalence and changes in energy intake (EI) and sedentary behavior (SED) based on the previous INCA 1 (Individuelle Nationale des Consommations Alimentaires) data (1998-1999).
p11322
sg4
(lp11323
(dp11324
g9
I327
sg39
g40
sg12
I6
sg13
VINCA 1
p11325
sg15
I2
sasg6
(lp11326
(dp11327
g9
I92
sg10
VC0028754
p11328
sg12
I7
sg13
Vobesity
p11329
sg15
I1
sa(dp11330
g9
I70
sg10
VC0497406
p11331
sg12
I10
sg13
Voverweight
p11332
sg15
I1
sa(dp11333
g9
I358
sg10
VC0394006
p11334
sg12
I3
sg13
Vdes
p11335
sg15
I1
sasa(dp11336
g2
VBoth estradiol and global ischemia markedly increased ERalpha, but not ERbeta, protein in CA1.
p11337
sg4
(lp11338
(dp11339
g9
I54
sg39
VP03372
p11340
sg12
I7
sg13
VERalpha
p11341
sg15
I1
sasg6
(lp11342
(dp11343
g9
I26
sg10
VC0022116
p11344
sg12
I8
sg13
Vischemia
p11345
sg15
I1
sasa(dp11346
g2
VIt has been reported that BMPR2 is associated with chondrosarcoma.
p11347
sg4
(lp11348
(dp11349
g9
I26
sg39
g40
sg12
I5
sg13
VBMPR2
p11350
sg15
I1
sasg6
(lp11351
(dp11352
g9
I51
sg10
VC0008479
p11353
sg12
I14
sg13
Vchondrosarcoma
p11354
sg15
I1
sasa(dp11355
g2
VMoreover, the detection of BMPR2 is more frequent in dedifferentiated chondrosarcomas (DDCS) than in conventional chondrosarcomas (CCS).
p11356
sg4
(lp11357
(dp11358
g9
I27
sg39
g40
sg12
I5
sg13
VBMPR2
p11359
sg15
I1
sasg6
(lp11360
(dp11361
g9
I131
sg10
VC0008479
p11362
sg12
I3
sg13
VCCS
p11363
sg15
I1
sa(dp11364
g9
I70
sg10
VC0008479
p11365
sg12
I15
sg13
Vchondrosarcomas
p11366
sg15
I1
sa(dp11367
g9
I70
sg10
VC0008479
p11368
sg12
I15
sg13
Vchondrosarcomas
p11369
sg15
I1
sasa(dp11370
g2
VBMPR2, phospho-SMAD1/5 (pSMAD1/5), and runt-related transcription factor 2 (RUNX2) expressions were found to be associated with the pathological grades of chondrosarcoma and could be a promising target of treatment outcome.
p11371
sg4
(lp11372
(dp11373
g9
I76
sg39
g40
sg12
I5
sg13
VRUNX2
p11374
sg15
I1
sa(dp11375
g9
I0
sg39
g40
sg12
I5
sg13
VBMPR2
p11376
sg15
I1
sa(dp11377
g9
I7
sg39
VP41250
p11378
sg12
I15
sg13
Vphospho-SMAD1/5
p11379
sg15
I1
sa(dp11380
g9
I24
sg39
VP41250
p11381
sg12
I8
sg13
VpSMAD1/5
p11382
sg15
I1
sasg6
(lp11383
(dp11384
g9
I39
sg10
VC0013336
p11385
sg12
I4
sg13
Vrunt
p11386
sg15
I1
sa(dp11387
g9
I155
sg10
VC0008479
p11388
sg12
I14
sg13
Vchondrosarcoma
p11389
sg15
I1
sasa(dp11390
g2
VIt has been demonstrated that more prevalent expression of bone morphogenetic protein receptor 2 (BMPR2) has been detected in dedifferentiated chondrosarcomas than conventional chondrosarcomas.
p11391
sg4
(lp11392
(dp11393
g9
I98
sg39
g40
sg12
I5
sg13
VBMPR2
p11394
sg15
I1
sa(dp11395
g9
I59
sg39
g40
sg12
I37
sg13
Vbone morphogenetic protein receptor 2
p11396
sg15
I5
sasg6
(lp11397
(dp11398
g9
I143
sg10
VC0008479
p11399
sg12
I15
sg13
Vchondrosarcomas
p11400
sg15
I1
sa(dp11401
g9
I143
sg10
VC0008479
p11402
sg12
I15
sg13
Vchondrosarcomas
p11403
sg15
I1
sasa(dp11404
g2
VHere, we find that BMPR2 inhibition induces apoptosis and autophagy of chondrosarcoma.
p11405
sg4
(lp11406
(dp11407
g9
I19
sg39
g40
sg12
I5
sg13
VBMPR2
p11408
sg15
I1
sasg6
(lp11409
(dp11410
g9
I71
sg10
VC0008479
p11411
sg12
I14
sg13
Vchondrosarcoma
p11412
sg15
I1
sasa(dp11413
g2
VWe found that BMPR2 expression was correlated with the clinicopathological features of chondrosarcomas, and could predict the treatment outcome.
p11414
sg4
(lp11415
(dp11416
g9
I14
sg39
g40
sg12
I5
sg13
VBMPR2
p11417
sg15
I1
sasg6
(lp11418
(dp11419
g9
I87
sg10
VC0008479
p11420
sg12
I15
sg13
Vchondrosarcomas
p11421
sg15
I1
sasa(dp11422
g2
VKnockdown of BMPR2 by small interfering RNA results in growth inhibition in chondrosarcoma cells.
p11423
sg4
(lp11424
(dp11425
g9
I13
sg39
g40
sg12
I5
sg13
VBMPR2
p11426
sg15
I1
sasg6
(lp11427
(dp11428
g9
I76
sg10
VC0008479
p11429
sg12
I14
sg13
Vchondrosarcoma
p11430
sg15
I1
sasa(dp11431
g2
VSilencing BMPR2 promoted G2/M cell cycle arrest, induced chondrosarcoma cell apoptosis through caspase-3-dependent pathway via repression of X-linked inhibitor of apoptosis protein (XIAP) and induced autophagy of chondrosarcoma cells via XIAP-Mdm2-p53 pathway.
p11432
sg4
(lp11433
(dp11434
g9
I248
sg39
VP42771
p11435
sg12
I3
sg13
Vp53
p11436
sg15
I1
sa(dp11437
g9
I95
sg39
VP42574
p11438
sg12
I9
sg13
Vcaspase-3
p11439
sg15
I1
sa(dp11440
g9
I182
sg39
VP98170
p11441
sg12
I4
sg13
VXIAP
p11442
sg15
I1
sa(dp11443
g9
I10
sg39
g40
sg12
I5
sg13
VBMPR2
p11444
sg15
I1
sa(dp11445
g9
I182
sg39
VP98170
p11446
sg12
I4
sg13
VXIAP
p11447
sg15
I1
sa(dp11448
g9
I141
sg39
VP98170
p11449
sg12
I39
sg13
VX-linked inhibitor of apoptosis protein
p11450
sg15
I5
sasg6
(lp11451
(dp11452
g9
I57
sg10
VC0008479
p11453
sg12
I14
sg13
Vchondrosarcoma
p11454
sg15
I1
sa(dp11455
g9
I57
sg10
VC0008479
p11456
sg12
I14
sg13
Vchondrosarcoma
p11457
sg15
I1
sasa(dp11458
g2
VInhibition of autophagy induced by BMPR2 small interfering RNA (siBMPR2) sensitized chondrosarcoma cells to siBMPR2-induced apoptotic cell death, suggesting that autophagy has a protective role for chondrosarcoma cells in context of siBMPR2-induced apoptotic cell death.
p11459
sg4
(lp11460
(dp11461
g9
I35
sg39
g40
sg12
I27
sg13
VBMPR2 small interfering RNA
p11462
sg15
I4
sasg6
(lp11463
(dp11464
g9
I84
sg10
VC0008479
p11465
sg12
I14
sg13
Vchondrosarcoma
p11466
sg15
I1
sa(dp11467
g9
I84
sg10
VC0008479
p11468
sg12
I14
sg13
Vchondrosarcoma
p11469
sg15
I1
sasa(dp11470
g2
VTaken together, our results suggest that BMPR2 has a significant role in the tumorigenesis of chondrosarcoma, and could be an important prognostic marker for chondrosarcoma.
p11471
sg4
(lp11472
(dp11473
g9
I41
sg39
g40
sg12
I5
sg13
VBMPR2
p11474
sg15
I1
sasg6
(lp11475
(dp11476
g9
I94
sg10
VC0008479
p11477
sg12
I14
sg13
Vchondrosarcoma
p11478
sg15
I1
sa(dp11479
g9
I77
sg10
VC0007621
p11480
sg12
I13
sg13
Vtumorigenesis
p11481
sg15
I1
sa(dp11482
g9
I94
sg10
VC0008479
p11483
sg12
I14
sg13
Vchondrosarcoma
p11484
sg15
I1
sasa(dp11485
g2
VBMPR2 inhibition could eventually provide a promising therapy for chondrosarcoma treatment.
p11486
sg4
(lp11487
(dp11488
g9
I0
sg39
g40
sg12
I5
sg13
VBMPR2
p11489
sg15
I1
sasg6
(lp11490
(dp11491
g9
I66
sg10
VC0008479
p11492
sg12
I14
sg13
Vchondrosarcoma
p11493
sg15
I1
sasa(dp11494
g2
VThe role of Beta-defensin-1 in asthma and chronic obstructive pulmonary disease (COPD) remains unclear.
p11495
sg4
(lp11496
(dp11497
g9
I12
sg39
VP60022
p11498
sg12
I15
sg13
VBeta-defensin-1
p11499
sg15
I1
sasg6
(lp11500
(dp11501
g9
I81
sg10
VC0024117
p11502
sg12
I4
sg13
VCOPD
p11503
sg15
I1
sa(dp11504
g9
I42
sg10
VC0024117
p11505
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p11506
sg15
I4
sa(dp11507
g9
I31
sg10
VC0004096
p11508
sg12
I6
sg13
Vasthma
p11509
sg15
I1
sasa(dp11510
g2
VIn Japanese and Chinese populations, two different beta-defensin-1 polymorphisms have been associated with chronic obstructive pulmonary disease phenotypes.
p11511
sg4
(lp11512
(dp11513
g9
I51
sg39
VP60022
p11514
sg12
I15
sg13
Vbeta-defensin-1
p11515
sg15
I1
sasg6
(lp11516
(dp11517
g9
I107
sg10
VC0024117
p11518
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p11519
sg15
I4
sasa(dp11520
g2
VThe autosomal recessive ataxias are separated into Friedreich ataxia, ataxia due to vitamin E deficiency, ataxia due to Abeta-lipoproteinemia, Refsum disease, late-onset Tay-Sachs disease, cerebrotendineous xanthomatosis, spinocerebellar ataxia with axonal neuropathy, ataxia telangiectasia, ataxia telangiectasia-like disorder, ataxia with oculomotor apraxia 1 and 2, spastic ataxia of Charlevoix-Saguenay, Cayman ataxia, Marinesco-Sjoegren syndrome, and autosomal recessive mitochondrial ataxias (AR-CPEO, SANDO, SCAE, AHS, IOSCA, MEMSA, LBSL CoQ-deficiency, PDC-deficiency).
p11521
sg4
(lp11522
(dp11523
g9
I120
sg39
g40
sg12
I5
sg13
VAbeta
p11524
sg15
I1
sa(dp11525
g9
I526
sg39
g40
sg12
I5
sg13
VIOSCA
p11526
sg15
I1
sa(dp11527
g9
I508
sg39
VP54098
p11528
sg12
I5
sg13
VSANDO
p11529
sg15
I1
sa(dp11530
g9
I561
sg39
VP20941
p11531
sg12
I3
sg13
VPDC
p11532
sg15
I1
sa(dp11533
g9
I521
sg39
VP02765
p11534
sg12
I3
sg13
VAHS
p11535
sg15
I1
sa(dp11536
g9
I540
sg39
g40
sg12
I8
sg13
VLBSL CoQ
p11537
sg15
I2
sa(dp11538
g9
I515
sg39
VP54098
p11539
sg12
I4
sg13
VSCAE
p11540
sg15
I1
sasg6
(lp11541
(dp11542
g9
I269
sg10
VC0004135
p11543
sg12
I21
sg13
Vataxia telangiectasia
p11544
sg15
I2
sa(dp11545
g9
I508
sg10
VC1843851
p11546
sg12
I5
sg13
VSANDO
p11547
sg15
I1
sa(dp11548
g9
I369
sg10
VC1849140
p11549
sg12
I37
sg13
Vspastic ataxia of Charlevoix-Saguenay
p11550
sg15
I4
sa(dp11551
g9
I24
sg10
VC0004134
p11552
sg12
I7
sg13
Vataxias
p11553
sg15
I1
sa(dp11554
g9
I515
sg10
VC1843852
p11555
sg12
I4
sg13
VSCAE
p11556
sg15
I1
sa(dp11557
g9
I51
sg10
VC0016719
p11558
sg12
I17
sg13
VFriedreich ataxia
p11559
sg15
I2
sa(dp11560
g9
I222
sg10
VC0087012
p11561
sg12
I22
sg13
Vspinocerebellar ataxia
p11562
sg15
I2
sa(dp11563
g9
I207
sg10
VC0043325
p11564
sg12
I13
sg13
Vxanthomatosis
p11565
sg15
I1
sa(dp11566
g9
I143
sg10
VC0034960
p11567
sg12
I14
sg13
VRefsum disease
p11568
sg15
I2
sa(dp11569
g9
I526
sg10
VC1849096
p11570
sg12
I5
sg13
VIOSCA
p11571
sg15
I1
sa(dp11572
g9
I250
sg10
VC0270921
p11573
sg12
I17
sg13
Vaxonal neuropathy
p11574
sg15
I2
sa(dp11575
g9
I24
sg10
VC0004134
p11576
sg12
I6
sg13
Vataxia
p11577
sg15
I1
sa(dp11578
g9
I341
sg10
VC0271270
p11579
sg12
I18
sg13
Voculomotor apraxia
p11580
sg15
I2
sa(dp11581
g9
I84
sg10
VC0042875
p11582
sg12
I20
sg13
Vvitamin E deficiency
p11583
sg15
I3
sa(dp11584
g9
I502
sg10
VC0162674
p11585
sg12
I4
sg13
VCPEO
p11586
sg15
I1
sa(dp11587
g9
I170
sg10
VC0039373
p11588
sg12
I17
sg13
VTay-Sachs disease
p11589
sg15
I2
sa(dp11590
g9
I442
sg10
VC0039082
p11591
sg12
I8
sg13
Vsyndrome
p11592
sg15
I1
sa(dp11593
g9
I24
sg10
VC0004134
p11594
sg12
I6
sg13
Vataxia
p11595
sg15
I1
sa(dp11596
g9
I24
sg10
VC0004134
p11597
sg12
I6
sg13
Vataxia
p11598
sg15
I1
sa(dp11599
g9
I269
sg10
VC0004135
p11600
sg12
I21
sg13
Vataxia telangiectasia
p11601
sg15
I2
sa(dp11602
g9
I24
sg10
VC0004134
p11603
sg12
I6
sg13
Vataxia
p11604
sg15
I1
sa(dp11605
g9
I540
sg10
VC1970180
p11606
sg12
I4
sg13
VLBSL
p11607
sg15
I1
sa(dp11608
g9
I24
sg10
VC0004134
p11609
sg12
I7
sg13
Vataxias
p11610
sg15
I1
sa(dp11611
g9
I561
sg10
VC1869117
p11612
sg12
I3
sg13
VPDC
p11613
sg15
I1
sasa(dp11614
g2
VOnly patients presenting PEO as part of their clinical phenotype had POLG mutations, in seven of them together with myopathic signs and in one with a sensori-motor peripheral neuropathy.
p11615
sg4
(lp11616
(dp11617
g9
I69
sg39
VP54098
p11618
sg12
I4
sg13
VPOLG
p11619
sg15
I1
sasg6
(lp11620
(dp11621
g9
I158
sg10
VC0235025
p11622
sg12
I27
sg13
Vmotor peripheral neuropathy
p11623
sg15
I3
sasa(dp11624
g2
VMoreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate.
p11625
sg4
(lp11626
(dp11627
g9
I197
sg39
g40
sg12
I15
sg13
V5-HT3 receptors
p11628
sg15
I2
sa(dp11629
g9
I44
sg39
g40
sg12
I25
sg13
V5-HT3 and 5-HT4 receptors
p11630
sg15
I4
sa(dp11631
g9
I54
sg39
g40
sg12
I15
sg13
V5-HT4 receptors
p11632
sg15
I2
sa(dp11633
g9
I54
sg39
g40
sg12
I15
sg13
V5-HT4 receptors
p11634
sg15
I2
sasg6
(lp11635
(dp11636
g9
I105
sg10
VC0026603
p11637
sg12
I15
sg13
Vmotion sickness
p11638
sg15
I2
sa(dp11639
g9
I284
sg10
VC0042963
p11640
sg12
I6
sg13
Vemesis
p11641
sg15
I1
sa(dp11642
g9
I157
sg10
VC0233660
p11643
sg12
I8
sg13
Vblocking
p11644
sg15
I1
sa(dp11645
g9
I284
sg10
VC0042963
p11646
sg12
I6
sg13
Vemesis
p11647
sg15
I1
sasa(dp11648
g2
VTherefore, we used Biolog GN2 microplates to analyze the ability of 103 clinical, predominantly diarrheal, isolates of Aeromonas to use various carbon sources, and we verified whether, among the substrates metabolized by these strains, there were some endogenous to the human intestine.
p11649
sg4
(lp11650
sg6
(lp11651
sa(dp11652
g2
VRP30 was one of these strains that was randomly selected and analysed by using a morphological, physiological and biochemical plate, Biolog GN2 Microplate System and API 20E system.
p11653
sg4
(lp11654
(dp11655
g9
I0
sg39
g40
sg12
I4
sg13
VRP30
p11656
sg15
I1
sasg6
(lp11657
(dp11658
g9
I0
sg10
VC1842816
p11659
sg12
I4
sg13
VRP30
p11660
sg15
I1
sasa(dp11661
g2
VHistological and clinical diagnoses of the 14 patients were as follows: IgA nephropathy 3, non-IgA GN 2, and asymptomatic significant microscopic hematuria [more than 100 red blood cells per high-power field (x400)] with or without proteinuria 9.
p11662
sg4
(lp11663
(dp11664
g9
I91
sg39
g40
sg12
I12
sg13
Vnon-IgA GN 2
p11665
sg15
I3
sa(dp11666
g9
I72
sg39
VP11912
p11667
sg12
I17
sg13
VIgA nephropathy 3
p11668
sg15
I3
sasg6
(lp11669
(dp11670
g9
I134
sg10
VC0239937
p11671
sg12
I21
sg13
Vmicroscopic hematuria
p11672
sg15
I2
sa(dp11673
g9
I72
sg10
VC0017661
p11674
sg12
I15
sg13
VIgA nephropathy
p11675
sg15
I2
sasa(dp11676
g2
VThe incidence of membranous form of glomerulonephritis was high (34 out of 44 kidney biopsy cases, 77%), the rest of patients showing mesangiocapillary GN-8 (18%) and mesangial proliferative GN-2 (5%).
p11677
sg4
(lp11678
sg6
(lp11679
(dp11680
g9
I36
sg10
VC0017658
p11681
sg12
I18
sg13
Vglomerulonephritis
p11682
sg15
I1
sa(dp11683
g9
I177
sg10
VC0334094
p11684
sg12
I13
sg13
Vproliferative
p11685
sg15
I1
sasa(dp11686
g2
VIn organ cultures, nephrosis-producing IBV strains (GN-2 and M-41) were slightly more ciliostatic and respiratory strains (Beaudette and Kita-1/Tokushima) less ciliostatic at 40.5 degrees C than at 37 degrees C. Mortality of chicken embryos infected with the GN-2, M-41 and Kita-1/Tokushima strains was greater at 40.5 degrees C than at 37 degrees C, while the reverse was true of the Beaudette strain which caused no embryo mortality at 40.5 degrees C. The Beaudette strain of IBV was the only one which could not be recovered from the kidneys of young chickens four days after infection.
p11687
sg4
(lp11688
(dp11689
g9
I52
sg39
g40
sg12
I4
sg13
VGN-2
p11690
sg15
I1
sasg6
(lp11691
(dp11692
g9
I19
sg10
VC0027720
p11693
sg12
I9
sg13
Vnephrosis
p11694
sg15
I1
sa(dp11695
g9
I579
sg10
VC0009450
p11696
sg12
I9
sg13
Vinfection
p11697
sg15
I1
sasa(dp11698
g2
VIn addition, in Alzheimer's disease we found simple gangliosides (GN2, GM3) to be elevated in the frontal and parietal cortex, which might correlate accelerated lysosomal degradation of gangliosides and/or astrogliosis occurring during neuronal death.
p11699
sg4
(lp11700
sg6
(lp11701
(dp11702
g9
I16
sg10
VC1521724
p11703
sg12
I19
sg13
VAlzheimer's disease
p11704
sg15
I2
sa(dp11705
g9
I206
sg10
VC0017639
p11706
sg12
I12
sg13
Vastrogliosis
p11707
sg15
I1
sasa(dp11708
g2
VThe aim of this study was to investigate the immunoreactivity to tryptase and to cathepsin-G of MC from human cutaneous mastocytosis and to compare their number in normal skin and cutaneous mastocytosis.
p11709
sg4
(lp11710
(dp11711
g9
I81
sg39
VP25774
p11712
sg12
I11
sg13
Vcathepsin-G
p11713
sg15
I1
sasg6
(lp11714
(dp11715
g9
I110
sg10
VC1136033
p11716
sg12
I22
sg13
Vcutaneous mastocytosis
p11717
sg15
I2
sa(dp11718
g9
I110
sg10
VC1136033
p11719
sg12
I22
sg13
Vcutaneous mastocytosis
p11720
sg15
I2
sasa(dp11721
g2
VMorphometric evaluation of MC number demostrated that the number of both tryptase- and cathepsin-G-positive MC was significantly higher in cutaneous mastocytosis as compared to normal skin and that in both conditions the number of tryptase-positive MC was significantly higher as compared to the number of cathepsin-G-positive MC.
p11722
sg4
(lp11723
(dp11724
g9
I87
sg39
VP25774
p11725
sg12
I11
sg13
Vcathepsin-G
p11726
sg15
I1
sa(dp11727
g9
I87
sg39
VP25774
p11728
sg12
I11
sg13
Vcathepsin-G
p11729
sg15
I1
sasg6
(lp11730
(dp11731
g9
I139
sg10
VC1136033
p11732
sg12
I22
sg13
Vcutaneous mastocytosis
p11733
sg15
I2
sasa(dp11734
g2
VIn conclusion, in this study, for the first time we have demonstrated the presence of MC with immunoreactivity to cathepsin-G in human cutaneous mastocytosis, as well as the co-localization of tryptase and cathepsin-G in MC secretory granules.
p11735
sg4
(lp11736
(dp11737
g9
I114
sg39
VP25774
p11738
sg12
I11
sg13
Vcathepsin-G
p11739
sg15
I1
sa(dp11740
g9
I114
sg39
VP25774
p11741
sg12
I11
sg13
Vcathepsin-G
p11742
sg15
I1
sasg6
(lp11743
(dp11744
g9
I135
sg10
VC1136033
p11745
sg12
I22
sg13
Vcutaneous mastocytosis
p11746
sg15
I2
sasa(dp11747
g2
VThe aim of our retrospective study was to evaluate the association of miR-126-3p, miR-126-5p and miR-664-3p tumour expression levels with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.
p11748
sg4
(lp11749
(dp11750
g9
I97
sg39
g40
sg12
I10
sg13
VmiR-664-3p
p11751
sg15
I1
sa(dp11752
g9
I82
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11753
sg15
I1
sa(dp11754
g9
I70
sg39
g40
sg12
I10
sg13
VmiR-126-3p
p11755
sg15
I1
sasg6
(lp11756
(dp11757
g9
I164
sg10
VC0948380
p11758
sg12
I28
sg13
Vmetastatic colorectal cancer
p11759
sg15
I3
sa(dp11760
g9
I108
sg10
VC0027651
p11761
sg12
I6
sg13
Vtumour
p11762
sg15
I1
sasa(dp11763
g2
VIn the present study, we investigated the role of miR-126-5p and Bcl2l2 in cervical cancer cells.
p11764
sg4
(lp11765
(dp11766
g9
I65
sg39
g40
sg12
I6
sg13
VBcl2l2
p11767
sg15
I1
sa(dp11768
g9
I50
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11769
sg15
I1
sasg6
(lp11770
(dp11771
g9
I75
sg10
VC0302592
p11772
sg12
I15
sg13
Vcervical cancer
p11773
sg15
I2
sasa(dp11774
g2
VFirst, miR-126-5p expression was aberrantly downregulated in human cervical cancer tumor tissues in comparison with normal tissues, as evaluated by RT-PCR.
p11775
sg4
(lp11776
(dp11777
g9
I7
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11778
sg15
I1
sasg6
(lp11779
(dp11780
g9
I83
sg10
VC0027651
p11781
sg12
I5
sg13
Vtumor
p11782
sg15
I1
sa(dp11783
g9
I67
sg10
VC0302592
p11784
sg12
I15
sg13
Vcervical cancer
p11785
sg15
I2
sasa(dp11786
g2
VConsistently, the levels of miR-126-5p were also significantly reduced in cervical cancer cell lines when compared to normal cervical epithelial cells.
p11787
sg4
(lp11788
(dp11789
g9
I28
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11790
sg15
I1
sasg6
(lp11791
(dp11792
g9
I74
sg10
VC0302592
p11793
sg12
I15
sg13
Vcervical cancer
p11794
sg15
I2
sasa(dp11795
g2
VFlow cytometric analysis showed that the rate of apoptosis of cervical cancer cells was significantly increased by miR-126-5p overexpression but inhibited by miR-126-5p inhibitor.
p11796
sg4
(lp11797
(dp11798
g9
I115
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11799
sg15
I1
sa(dp11800
g9
I115
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11801
sg15
I1
sasg6
(lp11802
(dp11803
g9
I62
sg10
VC0302592
p11804
sg12
I15
sg13
Vcervical cancer
p11805
sg15
I2
sasa(dp11806
g2
VA similar change pattern was observed in the expression of apoptosis-regulated protein caspase 3 in cervical cancer cells transfected with miR-126-5p mimic or inhibitor.
p11807
sg4
(lp11808
(dp11809
g9
I139
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11810
sg15
I1
sa(dp11811
g9
I79
sg39
VP42574
p11812
sg12
I17
sg13
Vprotein caspase 3
p11813
sg15
I3
sasg6
(lp11814
(dp11815
g9
I100
sg10
VC0302592
p11816
sg12
I15
sg13
Vcervical cancer
p11817
sg15
I2
sasa(dp11818
g2
VBy bioinformatic prediction with online databases and verification using luciferase reporter assay, we then identified that Bcl2l2 is a direct target of miR-126-5p in cervical cancer cells.
p11819
sg4
(lp11820
(dp11821
g9
I124
sg39
g40
sg12
I6
sg13
VBcl2l2
p11822
sg15
I1
sa(dp11823
g9
I153
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11824
sg15
I1
sasg6
(lp11825
(dp11826
g9
I167
sg10
VC0302592
p11827
sg12
I15
sg13
Vcervical cancer
p11828
sg15
I2
sasa(dp11829
g2
VThe expression of Bcl2l2 was strongly downregulated by the miR-126-5p mimic but upregulated by the miR-126-5p inhibitor in cervical cancer cells, and Bcl2l2 expression was significantly increased in human cervical cancer tumor tissues, which was negatively correlated with miR-126-5p levels.
p11830
sg4
(lp11831
(dp11832
g9
I18
sg39
g40
sg12
I6
sg13
VBcl2l2
p11833
sg15
I1
sa(dp11834
g9
I59
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11835
sg15
I1
sa(dp11836
g9
I59
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11837
sg15
I1
sa(dp11838
g9
I18
sg39
g40
sg12
I6
sg13
VBcl2l2
p11839
sg15
I1
sasg6
(lp11840
(dp11841
g9
I123
sg10
VC0302592
p11842
sg12
I15
sg13
Vcervical cancer
p11843
sg15
I2
sa(dp11844
g9
I123
sg10
VC0302592
p11845
sg12
I15
sg13
Vcervical cancer
p11846
sg15
I2
sa(dp11847
g9
I221
sg10
VC0027651
p11848
sg12
I5
sg13
Vtumor
p11849
sg15
I1
sasa(dp11850
g2
VFurthermore, we confirmed that the rate of apoptosis was significantly increased by Bcl2l2 silencing in cervical cancer cells, which was not affected by the miR-126-5p inhibitor.
p11851
sg4
(lp11852
(dp11853
g9
I84
sg39
g40
sg12
I6
sg13
VBcl2l2
p11854
sg15
I1
sa(dp11855
g9
I157
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11856
sg15
I1
sasg6
(lp11857
(dp11858
g9
I104
sg10
VC0302592
p11859
sg12
I15
sg13
Vcervical cancer
p11860
sg15
I2
sasa(dp11861
g2
VIn summary, miR-126-5p plays an inhibitory role in human cervical cancer progression, regulating the apoptosis of cancer cells via directly targeting Bcl2l2.
p11862
sg4
(lp11863
(dp11864
g9
I12
sg39
g40
sg12
I10
sg13
VmiR-126-5p
p11865
sg15
I1
sa(dp11866
g9
I150
sg39
g40
sg12
I6
sg13
VBcl2l2
p11867
sg15
I1
sasg6
(lp11868
(dp11869
g9
I66
sg10
VC0006826
p11870
sg12
I6
sg13
Vcancer
p11871
sg15
I1
sa(dp11872
g9
I66
sg10
VC0178874
p11873
sg12
I18
sg13
Vcancer progression
p11874
sg15
I2
sasa(dp11875
g2
VPatients with miR-126*low myelodysplastic syndrome had significantly lower response rates (P = 0.04) and higher relapse rates (P = 0.03), as well as shorter progression-free (PFS; P = 0.004) and overall survival (OS; P = 0.004).
p11876
sg4
(lp11877
sg6
(lp11878
(dp11879
g9
I26
sg10
VC0033027
p11880
sg12
I24
sg13
Vmyelodysplastic syndrome
p11881
sg15
I2
sa(dp11882
g9
I112
sg10
VC0277556
p11883
sg12
I7
sg13
Vrelapse
p11884
sg15
I1
sasa(dp11885
g2
VIn the present study, the relationship between miR-126-5p/3p expression levels and overall survival in 109 patients with acute myeloid leukemia (AML) who received intensive therapy were evaluated.
p11886
sg4
(lp11887
(dp11888
g9
I47
sg39
g40
sg12
I13
sg13
VmiR-126-5p/3p
p11889
sg15
I1
sasg6
(lp11890
(dp11891
g9
I121
sg10
VC0023467
p11892
sg12
I22
sg13
Vacute myeloid leukemia
p11893
sg15
I3
sa(dp11894
g9
I145
sg10
VC0023467
p11895
sg12
I3
sg13
VAML
p11896
sg15
I1
sasa(dp11897
g2
VThe presence of XBP-1s, the active form of XBP-1, after administration of anti-Ig to Akata Burkitt's lymphoma cells is consistent with a role for this factor in reactivation of the EBV lytic cycle, although signalling through MEF2D was quantitatively much more significant in activation of Zp.
p11898
sg4
(lp11899
(dp11900
g9
I16
sg39
g40
sg12
I6
sg13
VXBP-1s
p11901
sg15
I1
sa(dp11902
g9
I226
sg39
g40
sg12
I5
sg13
VMEF2D
p11903
sg15
I1
sa(dp11904
g9
I16
sg39
VP17861
p11905
sg12
I5
sg13
VXBP-1
p11906
sg15
I1
sasg6
(lp11907
(dp11908
g9
I185
sg10
VC0024348
p11909
sg12
I5
sg13
Vlytic
p11910
sg15
I1
sa(dp11911
g9
I91
sg10
VC0006413
p11912
sg12
I18
sg13
VBurkitt's lymphoma
p11913
sg15
I2
sasa(dp11914
g2
VAs expected, markers of neuronal differentiation such as anti-apoptotic protein B-cell lymphoma 2 (BCL2), myocyte enhancer factor-2D (MEF2D) and zipper protein kinase (MAP3K12; aka ZPK/MUK/DLK) were each up-regulated in response to differentiation.
p11915
sg4
(lp11916
(dp11917
g9
I189
sg39
VP80370
p11918
sg12
I3
sg13
VDLK
p11919
sg15
I1
sa(dp11920
g9
I99
sg39
VP10415
p11921
sg12
I4
sg13
VBCL2
p11922
sg15
I1
sa(dp11923
g9
I134
sg39
g40
sg12
I5
sg13
VMEF2D
p11924
sg15
I1
sa(dp11925
g9
I168
sg39
g40
sg12
I7
sg13
VMAP3K12
p11926
sg15
I1
sa(dp11927
g9
I185
sg39
g40
sg12
I3
sg13
VMUK
p11928
sg15
I1
sa(dp11929
g9
I145
sg39
g40
sg12
I21
sg13
Vzipper protein kinase
p11930
sg15
I3
sa(dp11931
g9
I106
sg39
g40
sg12
I26
sg13
Vmyocyte enhancer factor-2D
p11932
sg15
I3
sa(dp11933
g9
I177
sg39
g40
sg12
I7
sg13
Vaka ZPK
p11934
sg15
I2
sa(dp11935
g9
I57
sg39
g40
sg12
I40
sg13
Vanti-apoptotic protein B-cell lymphoma 2
p11936
sg15
I5
sasg6
(lp11937
(dp11938
g9
I80
sg10
VC0079731
p11939
sg12
I15
sg13
VB-cell lymphoma
p11940
sg15
I2
sasa(dp11941
g2
VThe decrease in T-Shc and T1 were less obvious in mucinous adenocarcinoma and not observed in serous or endometrioid adenocarcinoma.
p11942
sg4
(lp11943
sg6
(lp11944
(dp11945
g9
I104
sg10
VC1569637
p11946
sg12
I27
sg13
Vendometrioid adenocarcinoma
p11947
sg15
I2
sa(dp11948
g9
I50
sg10
VC0007130
p11949
sg12
I23
sg13
Vmucinous adenocarcinoma
p11950
sg15
I2
sasa(dp11951
g2
VOverexpression of the signalling adaptor protein ShcD in melanoma was found to be a prerequisite for melanoma migration and invasion.
p11952
sg4
(lp11953
(dp11954
g9
I49
sg39
g40
sg12
I4
sg13
VShcD
p11955
sg15
I1
sasg6
(lp11956
(dp11957
g9
I124
sg10
VC2699153
p11958
sg12
I8
sg13
Vinvasion
p11959
sg15
I1
sa(dp11960
g9
I57
sg10
VC0025202
p11961
sg12
I8
sg13
Vmelanoma
p11962
sg15
I1
sa(dp11963
g9
I57
sg10
VC0025202
p11964
sg12
I8
sg13
Vmelanoma
p11965
sg15
I1
sasa(dp11966
g2
VWe have further demonstrated that ShcD accumulates in the nucleus upon hydrogen peroxide treatment in FLAG-ShcD expressing HEK293 cells, as well as 518.A2 melanoma cells.
p11967
sg4
(lp11968
(dp11969
g9
I34
sg39
g40
sg12
I4
sg13
VShcD
p11970
sg15
I1
sa(dp11971
g9
I34
sg39
g40
sg12
I4
sg13
VShcD
p11972
sg15
I1
sasg6
(lp11973
(dp11974
g9
I155
sg10
VC0025202
p11975
sg12
I8
sg13
Vmelanoma
p11976
sg15
I1
sasa(dp11977
g2
VWe suggest that ShcD nuclear translocation might provide melanoma cells with a mechanism that enables them to resist DNA damage due to oxidative stress.
p11978
sg4
(lp11979
(dp11980
g9
I16
sg39
g40
sg12
I4
sg13
VShcD
p11981
sg15
I1
sasg6
(lp11982
(dp11983
g9
I135
sg10
VC0242606
p11984
sg12
I16
sg13
Voxidative stress
p11985
sg15
I2
sa(dp11986
g9
I57
sg10
VC0025202
p11987
sg12
I8
sg13
Vmelanoma
p11988
sg15
I1
sa(dp11989
g9
I117
sg10
VC0012860
p11990
sg12
I10
sg13
VDNA damage
p11991
sg15
I2
sa(dp11992
g9
I29
sg10
VC0040715
p11993
sg12
I13
sg13
Vtranslocation
p11994
sg15
I1
sasa(dp11995
g2
VRai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target.
p11996
sg4
(lp11997
(dp11998
g9
I46
sg39
VP12931
p11999
sg12
I52
sg13
VSrc homology 2 domain containing (Shc) family member
p12000
sg15
I8
sa(dp12001
g9
I18
sg39
g40
sg12
I4
sg13
VRaLP
p12002
sg15
I1
sa(dp12003
g9
I0
sg39
VP13489
p12004
sg12
I16
sg13
VRai like protein
p12005
sg15
I3
sasg6
(lp12006
(dp12007
g9
I132
sg10
VC0599156
p12008
sg12
I10
sg13
Vtransition
p12009
sg15
I1
sa(dp12010
g9
I157
sg10
VC0025202
p12011
sg12
I8
sg13
Vmelanoma
p12012
sg15
I1
sa(dp12013
g9
I146
sg10
VC0278883
p12014
sg12
I19
sg13
Vmetastatic melanoma
p12015
sg15
I2
sasa(dp12016
g2
VMutations in ABHD5 gene are associated with the onset of Chanarin-Dorfman syndrome (CDS), a rare autosomal recessive lipid storage disorder, characterized by non-bullous congenital ichthyosiform erythroderma (NCIE), hepatomegaly and liver steatosis.
p12017
sg4
(lp12018
(dp12019
g9
I13
sg39
g40
sg12
I10
sg13
VABHD5 gene
p12020
sg15
I2
sasg6
(lp12021
(dp12022
g9
I216
sg10
VC0019209
p12023
sg12
I12
sg13
Vhepatomegaly
p12024
sg15
I1
sa(dp12025
g9
I209
sg10
VC1855792
p12026
sg12
I4
sg13
VNCIE
p12027
sg15
I1
sa(dp12028
g9
I57
sg10
VC0268238
p12029
sg12
I25
sg13
VChanarin-Dorfman syndrome
p12030
sg15
I2
sa(dp12031
g9
I158
sg10
VC1855792
p12032
sg12
I49
sg13
Vnon-bullous congenital ichthyosiform erythroderma
p12033
sg15
I4
sa(dp12034
g9
I233
sg10
VC0015695
p12035
sg12
I15
sg13
Vliver steatosis
p12036
sg15
I2
sa(dp12037
g9
I84
sg10
VC0268238
p12038
sg12
I3
sg13
VCDS
p12039
sg15
I1
sasa(dp12040
g2
VIt is an autosomal recessive disease caused by mutations in the ABHD5 gene.
p12041
sg4
(lp12042
(dp12043
g9
I64
sg39
g40
sg12
I10
sg13
VABHD5 gene
p12044
sg15
I2
sasg6
(lp12045
sa(dp12046
g2
VMutations of comparative gene identification 58 (CGI-58) in humans cause Chanarin-Dorfman syndrome, a rare autosomal recessive disease in which excess triacylglycerol (TAG) accumulates in multiple tissues.
p12047
sg4
(lp12048
sg6
(lp12049
(dp12050
g9
I151
sg10
VC0037293
p12051
sg12
I15
sg13
Vtriacylglycerol
p12052
sg15
I1
sa(dp12053
g9
I168
sg10
VC0037293
p12054
sg12
I3
sg13
VTAG
p12055
sg15
I1
sa(dp12056
g9
I73
sg10
VC0268238
p12057
sg12
I25
sg13
VChanarin-Dorfman syndrome
p12058
sg15
I2
sasa(dp12059
g2
VThe case histories of two children (aged two months) affected by myocarditis showing an atypical band of serum creatine kinase (EC 2.7.3.2; CK) in the CK isoenzyme electrophoretic pattern are reported.
p12060
sg4
(lp12061
(dp12062
g9
I105
sg39
VP12532
p12063
sg12
I21
sg13
Vserum creatine kinase
p12064
sg15
I3
sasg6
(lp12065
(dp12066
g9
I65
sg10
VC0027059
p12067
sg12
I11
sg13
Vmyocarditis
p12068
sg15
I1
sasa(dp12069
g2
VThe objective of this study was to evaluate the nephroprotective potential of resveratrol and piperine at same dose on cationic bovine serum albumin (cBSA) induced immune complex glomerulonephritis (ICGN) in BALB/c mice.
p12070
sg4
(lp12071
(dp12072
g9
I128
sg39
VP49639
p12073
sg12
I20
sg13
Vbovine serum albumin
p12074
sg15
I3
sasg6
(lp12075
(dp12076
g9
I199
sg10
VC0744421
p12077
sg12
I4
sg13
VICGN
p12078
sg15
I1
sa(dp12079
g9
I164
sg10
VC0744421
p12080
sg12
I33
sg13
Vimmune complex glomerulonephritis
p12081
sg15
I3
sasa(dp12082
g2
VThe object of the present study was to investigate the effects of VA, alone and in combination with methylprednisolone (MP), on cationic bovine serum albumin (cBSA induced immune-complex glomerulonephritis in female BALB/c mice.
p12083
sg4
(lp12084
(dp12085
g9
I128
sg39
VP49639
p12086
sg12
I29
sg13
Vcationic bovine serum albumin
p12087
sg15
I4
sasg6
(lp12088
(dp12089
g9
I172
sg10
VC0744421
p12090
sg12
I33
sg13
Vimmune-complex glomerulonephritis
p12091
sg15
I2
sasa(dp12092
g2
VBovine serum albumin (BSA) glomerulonephritis is a type of immune complex glomerulonephritis that is characterized by a large number of leukocytes infiltrating the kidney.
p12093
sg4
(lp12094
(dp12095
g9
I22
sg39
VP49639
p12096
sg12
I3
sg13
VBSA
p12097
sg15
I1
sa(dp12098
g9
I0
sg39
VP49639
p12099
sg12
I20
sg13
VBovine serum albumin
p12100
sg15
I3
sasg6
(lp12101
(dp12102
g9
I27
sg10
VC0017658
p12103
sg12
I18
sg13
Vglomerulonephritis
p12104
sg15
I1
sa(dp12105
g9
I147
sg10
VC0332448
p12106
sg12
I12
sg13
Vinfiltrating
p12107
sg15
I1
sa(dp12108
g9
I59
sg10
VC0744421
p12109
sg12
I33
sg13
Vimmune complex glomerulonephritis
p12110
sg15
I3
sasa(dp12111
g2
VThe aim of this study is to show the results of the retrospective analysis (2010-2012) on hospital discharge records (HDRs) related to diseases potentially due to S. pneumoniae, using a selection of ICD9-CM codes.
p12112
sg4
(lp12113
sg6
(lp12114
(dp12115
g9
I90
sg10
VC1840333
p12116
sg12
I26
sg13
Vhospital discharge records
p12117
sg15
I3
sa(dp12118
g9
I118
sg10
VC1840333
p12119
sg12
I4
sg13
VHDRs
p12120
sg15
I1
sasa(dp12121
g2
VThe aim of this study is to show the results of the retrospective analysis (2010-2012) on hospital discharge records (HDRs) related to diseases potentially due to S. pneumoniae, using a selection of ICD9-CM codes.
p12122
sg4
(lp12123
sg6
(lp12124
(dp12125
g9
I90
sg10
VC1840333
p12126
sg12
I26
sg13
Vhospital discharge records
p12127
sg15
I3
sa(dp12128
g9
I118
sg10
VC1840333
p12129
sg12
I4
sg13
VHDRs
p12130
sg15
I1
sasa(dp12131
g2
VGATA binding protein 3 (GATA3) and suppressors of cytokine signalling3 mRNA were differentially regulated in HDM and influenza-stimulated cultures+/-IFN-Beta.
p12132
sg4
(lp12133
(dp12134
g9
I149
sg39
VP01574
p12135
sg12
I8
sg13
VIFN-Beta
p12136
sg15
I1
sa(dp12137
g9
I0
sg39
VP23771
p12138
sg12
I22
sg13
VGATA binding protein 3
p12139
sg15
I4
sa(dp12140
g9
I24
sg39
VP23771
p12141
sg12
I5
sg13
VGATA3
p12142
sg15
I1
sasg6
(lp12143
(dp12144
g9
I117
sg10
VC0021400
p12145
sg12
I9
sg13
Vinfluenza
p12146
sg15
I1
sasa(dp12147
g2
VIn this article we review the current available evidence describing the effects of allopurinol in hypertension, kidney disease, and coronary heart disease, highlighting unresolved issues surrounding allopurinol use for uric acid lowering in individuals without gout.
p12148
sg4
(lp12149
sg6
(lp12150
(dp12151
g9
I98
sg10
VC0020538
p12152
sg12
I12
sg13
Vhypertension
p12153
sg15
I1
sa(dp12154
g9
I261
sg10
VC0018099
p12155
sg12
I4
sg13
Vgout
p12156
sg15
I1
sa(dp12157
g9
I112
sg10
VC0022658
p12158
sg12
I14
sg13
Vkidney disease
p12159
sg15
I2
sa(dp12160
g9
I132
sg10
VC0010054
p12161
sg12
I22
sg13
Vcoronary heart disease
p12162
sg15
I3
sasa(dp12163
g2
VMany epidemiological studies have evaluated associations of platelet glycoprotein receptor alpha2beta1 integrin (ITGA2) and glycoprotein IIIa (ITGB3) gene polymorphisms with diabetic retinopathy (DR), but the published data are inconclusive.
p12164
sg4
(lp12165
(dp12166
g9
I124
sg39
VP05106
p12167
sg12
I17
sg13
Vglycoprotein IIIa
p12168
sg15
I2
sa(dp12169
g9
I60
sg39
VP14770
p12170
sg12
I51
sg13
Vplatelet glycoprotein receptor alpha2beta1 integrin
p12171
sg15
I5
sa(dp12172
g9
I143
sg39
VP05106
p12173
sg12
I5
sg13
VITGB3
p12174
sg15
I1
sa(dp12175
g9
I113
sg39
VP17301
p12176
sg12
I5
sg13
VITGA2
p12177
sg15
I1
sasg6
(lp12178
(dp12179
g9
I174
sg10
VC0011884
p12180
sg12
I20
sg13
Vdiabetic retinopathy
p12181
sg15
I2
sa(dp12182
g9
I196
sg10
VC0011884
p12183
sg12
I2
sg13
VDR
p12184
sg15
I1
sasa(dp12185
g2
VGenetic polymorphisms of the alpha2beta1 integrin and glycoprotein IIIa (GPIIIa) have been associated with myocardial infarction, stroke, and diabetic retinopathy.
p12186
sg4
(lp12187
(dp12188
g9
I29
sg39
VP05106
p12189
sg12
I42
sg13
Valpha2beta1 integrin and glycoprotein IIIa
p12190
sg15
I5
sa(dp12191
g9
I73
sg39
VP05106
p12192
sg12
I6
sg13
VGPIIIa
p12193
sg15
I1
sasg6
(lp12194
(dp12195
g9
I130
sg10
VC0038454
p12196
sg12
I6
sg13
Vstroke
p12197
sg15
I1
sa(dp12198
g9
I142
sg10
VC0011884
p12199
sg12
I20
sg13
Vdiabetic retinopathy
p12200
sg15
I2
sa(dp12201
g9
I107
sg10
VC0027051
p12202
sg12
I21
sg13
Vmyocardial infarction
p12203
sg15
I2
sasa(dp12204
g2
VImmunostaining procedures were used to seek for the expression of the following 30 membrane antigens related to the immune system, using dendriform cells obtained in conjunctival specimens from 80 normal subjects and 105 with chronic conjunctivitis: class II antigens HLADR and DQ, CD1a (T6) and CD5, which usually mark Langerhans cells, macrophage markers CD14, CD36 and CD63, various lymphocyte antigens (CD2, CD4 and CD8), receptor to interleukin 2 (CD25), adhesion molecules and integrins (CD11a, CD11b, CD11c, CD18, CD29, CD41, CD61), the selectin CD62, ICAM-1 (CD54), ICAM-3 (CD50) and ELAM-1, CD45RO, related to activation of immune cells, and its ligand CD22, receptors to immunoglobulins (CD23 and CD32) and complement (CD21), transferrin receptor CD71, tryptase and vimentin, were thus investigated.
p12205
sg4
(lp12206
(dp12207
g9
I592
sg39
VP16581
p12208
sg12
I6
sg13
VELAM-1
p12209
sg15
I1
sa(dp12210
g9
I296
sg39
VP06127
p12211
sg12
I3
sg13
VCD5
p12212
sg15
I1
sa(dp12213
g9
I420
sg39
VP01732
p12214
sg12
I3
sg13
VCD8
p12215
sg15
I1
sa(dp12216
g9
I527
sg39
VP08514
p12217
sg12
I4
sg13
VCD41
p12218
sg15
I1
sa(dp12219
g9
I508
sg39
VP20702
p12220
sg12
I5
sg13
VCD11c
p12221
sg15
I1
sa(dp12222
g9
I372
sg39
VP08962
p12223
sg12
I4
sg13
VCD63
p12224
sg15
I1
sa(dp12225
g9
I494
sg39
VP20701
p12226
sg12
I5
sg13
VCD11a
p12227
sg15
I1
sa(dp12228
g9
I438
sg39
VP60568
p12229
sg12
I13
sg13
Vinterleukin 2
p12230
sg15
I2
sa(dp12231
g9
I501
sg39
VP11215
p12232
sg12
I5
sg13
VCD11b
p12233
sg15
I1
sa(dp12234
g9
I707
sg39
VP12318
p12235
sg12
I4
sg13
VCD32
p12236
sg15
I1
sa(dp12237
g9
I453
sg39
VP01589
p12238
sg12
I4
sg13
VCD25
p12239
sg15
I1
sa(dp12240
g9
I412
sg39
VP01730
p12241
sg12
I3
sg13
VCD4
p12242
sg15
I1
sa(dp12243
g9
I574
sg39
VP32942
p12244
sg12
I6
sg13
VICAM-3
p12245
sg15
I1
sa(dp12246
g9
I698
sg39
VP06734
p12247
sg12
I4
sg13
VCD23
p12248
sg15
I1
sa(dp12249
g9
I736
sg39
VP02787
p12250
sg12
I25
sg13
Vtransferrin receptor CD71
p12251
sg15
I3
sa(dp12252
g9
I567
sg39
VP05362
p12253
sg12
I4
sg13
VCD54
p12254
sg15
I1
sa(dp12255
g9
I515
sg39
VP05107
p12256
sg12
I4
sg13
VCD18
p12257
sg15
I1
sa(dp12258
g9
I533
sg39
VP05106
p12259
sg12
I4
sg13
VCD61
p12260
sg15
I1
sa(dp12261
g9
I559
sg39
VP05362
p12262
sg12
I6
sg13
VICAM-1
p12263
sg15
I1
sa(dp12264
g9
I407
sg39
VP06729
p12265
sg12
I3
sg13
VCD2
p12266
sg15
I1
sa(dp12267
g9
I282
sg39
VP15813
p12268
sg12
I4
sg13
VCD1a
p12269
sg15
I1
sa(dp12270
g9
I681
sg39
g40
sg12
I15
sg13
Vimmunoglobulins
p12271
sg15
I1
sa(dp12272
g9
I386
sg39
VP30486
p12273
sg12
I19
sg13
Vlymphocyte antigens
p12274
sg15
I2
sa(dp12275
g9
I582
sg39
VP32942
p12276
sg12
I4
sg13
VCD50
p12277
sg15
I1
sa(dp12278
g9
I729
sg39
VP20023
p12279
sg12
I4
sg13
VCD21
p12280
sg15
I1
sa(dp12281
g9
I250
sg39
g40
sg12
I8
sg13
Vclass II
p12282
sg15
I2
sa(dp12283
g9
I553
sg39
VP16109
p12284
sg12
I4
sg13
VCD62
p12285
sg15
I1
sa(dp12286
g9
I357
sg39
VP08571
p12287
sg12
I4
sg13
VCD14
p12288
sg15
I1
sasg6
(lp12289
(dp12290
g9
I226
sg10
VC0155145
p12291
sg12
I22
sg13
Vchronic conjunctivitis
p12292
sg15
I2
sa(dp12293
g9
I460
sg10
VC0001511
p12294
sg12
I8
sg13
Vadhesion
p12295
sg15
I1
sasa(dp12296
g2
VIn order to elucidate the involvement of adhesion mechanisms in the process of megakaryocyte-dependent fibroblast growth, we applied BSA-coupled polymers of glucose, galactose, fucose, mannose, and several lectins (AAA, LCA, LTA, UEA-I) to cocultures of CD61 -positive (CD61+)/MACS-enriched megakaryocytes and human bone marrow fibroblasts.
p12297
sg4
(lp12298
(dp12299
g9
I254
sg39
VP05106
p12300
sg12
I14
sg13
VCD61 -positive
p12301
sg15
I2
sa(dp12302
g9
I270
sg39
VP05106
p12303
sg12
I5
sg13
VCD61+
p12304
sg15
I1
sa(dp12305
g9
I215
sg39
g40
sg12
I3
sg13
VAAA
p12306
sg15
I1
sa(dp12307
g9
I133
sg39
VP49639
p12308
sg12
I3
sg13
VBSA
p12309
sg15
I1
sa(dp12310
g9
I220
sg39
VP09496
p12311
sg12
I3
sg13
VLCA
p12312
sg15
I1
sa(dp12313
g9
I225
sg39
VP10515
p12314
sg12
I3
sg13
VLTA
p12315
sg15
I1
sasg6
(lp12316
(dp12317
g9
I41
sg10
VC0001511
p12318
sg12
I8
sg13
Vadhesion
p12319
sg15
I1
sa(dp12320
g9
I220
sg10
VC0339527
p12321
sg12
I3
sg13
VLCA
p12322
sg15
I1
sa(dp12323
g9
I215
sg10
VC0162871
p12324
sg12
I3
sg13
VAAA
p12325
sg15
I1
sasa(dp12326
g2
VComplications included pyogenic granuloma (10 patients, 24.4%), exposure keratopathy (7 patients, 17.1%) lagophthalmos (5 patients, 12.2%), ectropion (6 patients, 14.6%), lateral canthal dystopia (2 cases, 4.9%), eyelid notch (2 cases, 4.9%) and trichiasis (4 cases, 9.8%).
p12327
sg4
(lp12328
sg6
(lp12329
(dp12330
g9
I23
sg10
VC0085653
p12331
sg12
I18
sg13
Vpyogenic granuloma
p12332
sg15
I2
sa(dp12333
g9
I246
sg10
VC0221259
p12334
sg12
I10
sg13
Vtrichiasis
p12335
sg15
I1
sa(dp12336
g9
I105
sg10
VC0152226
p12337
sg12
I13
sg13
Vlagophthalmos
p12338
sg15
I1
sa(dp12339
g9
I64
sg10
VC0339295
p12340
sg12
I20
sg13
Vexposure keratopathy
p12341
sg15
I2
sa(dp12342
g9
I140
sg10
VC0013592
p12343
sg12
I9
sg13
Vectropion
p12344
sg15
I1
sasa(dp12345
g2
VComplications included eyelid margin notch (3 cases), persistent canthal dystopia (3 cases), trichiasis (2 cases), pyogenic granuloma (2 cases), eyelid margin nodule (1 case), lower eyelid elevation of 1 mm (1 case), and mild resolving medial lagophthalmos (1 case).
p12346
sg4
(lp12347
sg6
(lp12348
(dp12349
g9
I159
sg10
VC0028259
p12350
sg12
I6
sg13
Vnodule
p12351
sg15
I1
sa(dp12352
g9
I93
sg10
VC0221259
p12353
sg12
I10
sg13
Vtrichiasis
p12354
sg15
I1
sa(dp12355
g9
I115
sg10
VC0085653
p12356
sg12
I18
sg13
Vpyogenic granuloma
p12357
sg15
I2
sa(dp12358
g9
I243
sg10
VC0152226
p12359
sg12
I13
sg13
Vlagophthalmos
p12360
sg15
I1
sasa(dp12361
g2
VAfter operation slight entropion occurred in 8 cases, slight ectropion in 3 cases, lagophthalmos for 2 -- 3 mm in 7 cases, notch of the palpebral margin in 5 cases and thinness of the donor tarsal plates in 4 cases, but the functional and aesthetic results were normal.
p12362
sg4
(lp12363
sg6
(lp12364
(dp12365
g9
I23
sg10
VC0014390
p12366
sg12
I9
sg13
Ventropion
p12367
sg15
I1
sa(dp12368
g9
I83
sg10
VC0152226
p12369
sg12
I13
sg13
Vlagophthalmos
p12370
sg15
I1
sa(dp12371
g9
I61
sg10
VC0013592
p12372
sg12
I9
sg13
Vectropion
p12373
sg15
I1
sasa(dp12374
g2
VWe screened the exons of RAY1/ST7 and ST7OT1-3 for sequence variants in 90 unrelated autism probands and identified several rare variants, including a Ile361Val substitution.
p12375
sg4
(lp12376
(dp12377
g9
I30
sg39
g40
sg12
I3
sg13
VST7
p12378
sg15
I1
sa(dp12379
g9
I25
sg39
g40
sg12
I4
sg13
VRAY1
p12380
sg15
I1
sasg6
(lp12381
(dp12382
g9
I85
sg10
VC0004352
p12383
sg12
I6
sg13
Vautism
p12384
sg15
I1
sasa(dp12385
g2
VSeveral signaling systems downstream of G-CSFR have been identified that are defective or hyperactivated in myeloid cells of patients with congenital neutropenia: severely reduced expression of myeloid-specific transcription factors LEF-1 and C/EBPAlfa, severely reduced expression and functions of HCLS1 protein, severely reduced expression of neutrophil elastase protein, dramatic compensatory up-regulation of the NAMPT/NAD(+)/SIRT pathway leading to continuous activation of emergency granulopoiesis via the transcription factor C/EBPBeta, and hyperactivation of STAT5 protein by tyrosine phosphorylation.
p12386
sg4
(lp12387
(dp12388
g9
I40
sg39
VP07333
p12389
sg12
I6
sg13
VG-CSFR
p12390
sg15
I1
sa(dp12391
g9
I345
sg39
VP08246
p12392
sg12
I19
sg13
Vneutrophil elastase
p12393
sg15
I2
sa(dp12394
g9
I299
sg39
VP14317
p12395
sg12
I13
sg13
VHCLS1 protein
p12396
sg15
I2
sa(dp12397
g9
I512
sg39
VP35398
p12398
sg12
I30
sg13
Vtranscription factor C/EBPBeta
p12399
sg15
I3
sa(dp12400
g9
I194
sg39
g40
sg12
I44
sg13
Vmyeloid-specific transcription factors LEF-1
p12401
sg15
I4
sa(dp12402
g9
I567
sg39
VP42229
p12403
sg12
I13
sg13
VSTAT5 protein
p12404
sg15
I2
sasg6
(lp12405
(dp12406
g9
I139
sg10
VC0340970
p12407
sg12
I22
sg13
Vcongenital neutropenia
p12408
sg15
I2
sa(dp12409
g9
I479
sg10
VC2745965
p12410
sg12
I9
sg13
Vemergency
p12411
sg15
I1
sa(dp12412
g9
I423
sg10
VC1850380
p12413
sg12
I3
sg13
VNAD
p12414
sg15
I1
sasa(dp12415
g2
VWe observed spontaneous osteoclastogenesis with a significant increase in OC formation and bone resorbing activity in late-stage CKD and HD patients when compared with early-stage CKD patients and healthy donors, likely due to an increased expression of RANKL and LIGHT (homologous to Lymphotoxins exhibiting Inducible expression and competing with herpes simplex virus Glycoprotein D for herpes virus entry mediator [HVEM], a receptor expressed by T lymphocytes) in PBMCs.
p12416
sg4
(lp12417
(dp12418
g9
I264
sg39
g40
sg12
I5
sg13
VLIGHT
p12419
sg15
I1
sa(dp12420
g9
I254
sg39
g40
sg12
I5
sg13
VRANKL
p12421
sg15
I1
sasg6
(lp12422
(dp12423
g9
I349
sg10
VC0019348
p12424
sg12
I14
sg13
Vherpes simplex
p12425
sg15
I2
sa(dp12426
g9
I349
sg10
VC0019340
p12427
sg12
I6
sg13
Vherpes
p12428
sg15
I1
sasa(dp12429
g2
VHealthy individuals of African ancestry have neutropenia that has been linked with the variant rs2814778(G) of the gene encoding atypical chemokine receptor 1 (ACKR1).
p12430
sg4
(lp12431
(dp12432
g9
I115
sg39
VP61073
p12433
sg12
I43
sg13
Vgene encoding atypical chemokine receptor 1
p12434
sg15
I6
sasg6
(lp12435
sa(dp12436
g2
VHere we describe an unexpected fundamental role for ACKR1 in hematopoiesis and provide the mechanism that links its absence with neutropenia.
p12437
sg4
(lp12438
sg6
(lp12439
sa(dp12440
g2
VThe absence of erythroid ACKR1 altered mouse hematopoiesis including stem and progenitor cells, which ultimately gave rise to phenotypically distinct neutrophils that readily left the circulation, causing neutropenia.
p12441
sg4
(lp12442
(dp12443
g9
I15
sg39
VP22557
p12444
sg12
I15
sg13
Verythroid ACKR1
p12445
sg15
I2
sasg6
(lp12446
sa(dp12447
g2
VIn vivo studies in Adult Dark Agouti (DA) rats with unilateral surgically-induced ocular hypertension (OHT) treated with either CoQ10/TPGS micelles or TPGS vehicle twice daily for three weeks were performed, following which retinal cell health was assessed in vivo using DARC (Detection of Apoptotic Retinal Cells) and post-mortem with Brn3a histological assessment on whole retinal mounts.
p12448
sg4
(lp12449
(dp12450
g9
I271
sg39
VP55283
p12451
sg12
I4
sg13
VDARC
p12452
sg15
I1
sa(dp12453
g9
I277
sg39
VP55283
p12454
sg12
I36
sg13
VDetection of Apoptotic Retinal Cells
p12455
sg15
I5
sa(dp12456
g9
I336
sg39
g40
sg12
I5
sg13
VBrn3a
p12457
sg15
I1
sasg6
(lp12458
(dp12459
g9
I103
sg10
VC0028840
p12460
sg12
I3
sg13
VOHT
p12461
sg15
I1
sa(dp12462
g9
I82
sg10
VC0028840
p12463
sg12
I19
sg13
Vocular hypertension
p12464
sg15
I2
sasa(dp12465
g2
VAfter correction for multiple testing, DARC polymorphism rs3027012 in 5'-UTR was associated with higher risk of low absolute phagocyte count (APC&lt;500 and &lt;1000 cells per microliter, P=0.001 and P&lt;0.0005, respectively) and hospitalization due to febrile neutropenia (P=0.002).
p12466
sg4
(lp12467
sg6
(lp12468
(dp12469
g9
I254
sg10
VC0746883
p12470
sg12
I19
sg13
Vfebrile neutropenia
p12471
sg15
I2
sa(dp12472
g9
I142
sg10
VC0033036
p12473
sg12
I3
sg13
VAPC
p12474
sg15
I1
sasa(dp12475
g2
VWe examined the effects of PR and EZ on NPC1L1, ABCG5, and ABCG8 expression in human hepatoma HepG2 cells and the murine small intestine.
p12476
sg4
(lp12477
(dp12478
g9
I40
sg39
g40
sg12
I6
sg13
VNPC1L1
p12479
sg15
I1
sa(dp12480
g9
I48
sg39
g40
sg12
I5
sg13
VABCG5
p12481
sg15
I1
sa(dp12482
g9
I59
sg39
g40
sg12
I5
sg13
VABCG8
p12483
sg15
I1
sasg6
(lp12484
(dp12485
g9
I85
sg10
VC0023903
p12486
sg12
I8
sg13
Vhepatoma
p12487
sg15
I1
sasa(dp12488
g2
VIn addition, knockdown of epigenetic regulator UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) in RIP3-null cancer cells reduces the methylation level of the Rip3 promoter.
p12489
sg4
(lp12490
(dp12491
g9
I115
sg39
g40
sg12
I4
sg13
VRIP3
p12492
sg15
I1
sa(dp12493
g9
I175
sg39
g40
sg12
I13
sg13
VRip3 promoter
p12494
sg15
I2
sa(dp12495
g9
I81
sg39
VP20941
p12496
sg12
I3
sg13
VPHD
p12497
sg15
I1
sa(dp12498
g9
I54
sg39
VP62979
p12499
sg12
I9
sg13
Vubiquitin
p12500
sg15
I1
sa(dp12501
g9
I47
sg39
g40
sg12
I5
sg13
VUHRF1
p12502
sg15
I1
sasg6
(lp12503
(dp12504
g9
I125
sg10
VC0006826
p12505
sg12
I6
sg13
Vcancer
p12506
sg15
I1
sasa(dp12507
g2
VA previous study revealed that ubiquitin-like with PHD and RING finger domains 1 (UHRF1) promoted cell proliferation and was a potential biomarker in medulloblastoma (MB).
p12508
sg4
(lp12509
(dp12510
g9
I82
sg39
g40
sg12
I5
sg13
VUHRF1
p12511
sg15
I1
sa(dp12512
g9
I31
sg39
g40
sg12
I49
sg13
Vubiquitin-like with PHD and RING finger domains 1
p12513
sg15
I8
sasg6
(lp12514
(dp12515
g9
I150
sg10
VC0025149
p12516
sg12
I15
sg13
Vmedulloblastoma
p12517
sg15
I1
sa(dp12518
g9
I103
sg10
VC0334094
p12519
sg12
I13
sg13
Vproliferation
p12520
sg15
I1
sa(dp12521
g9
I167
sg10
VC0025149
p12522
sg12
I2
sg13
VMB
p12523
sg15
I1
sasa(dp12524
g2
VThree lncRNAs, sex determining region Y-box 2 overlapping transcript (SOX2-OT), NCBP2 antisense RNA 2 (NCBP2-AS2) and ubiquitin like with PHD and ring finger domains 1 (UHRF1), were predicted to be associated with lung cancer; RT-qPCR confirmed that SOX2-OT and NCBP2-AS2 were associated with lung cancer.
p12525
sg4
(lp12526
(dp12527
g9
I118
sg39
g40
sg12
I49
sg13
Vubiquitin like with PHD and ring finger domains 1
p12528
sg15
I9
sa(dp12529
g9
I169
sg39
g40
sg12
I5
sg13
VUHRF1
p12530
sg15
I1
sa(dp12531
g9
I103
sg39
VP52298
p12532
sg12
I9
sg13
VNCBP2-AS2
p12533
sg15
I1
sa(dp12534
g9
I70
sg39
VP48431
p12535
sg12
I7
sg13
VSOX2-OT
p12536
sg15
I1
sa(dp12537
g9
I103
sg39
VP52298
p12538
sg12
I9
sg13
VNCBP2-AS2
p12539
sg15
I1
sa(dp12540
g9
I80
sg39
VP52298
p12541
sg12
I21
sg13
VNCBP2 antisense RNA 2
p12542
sg15
I4
sa(dp12543
g9
I15
sg39
VP48431
p12544
sg12
I53
sg13
Vsex determining region Y-box 2 overlapping transcript
p12545
sg15
I7
sa(dp12546
g9
I70
sg39
VP48431
p12547
sg12
I7
sg13
VSOX2-OT
p12548
sg15
I1
sasg6
(lp12549
(dp12550
g9
I214
sg10
VC0684249
p12551
sg12
I11
sg13
Vlung cancer
p12552
sg15
I2
sa(dp12553
g9
I214
sg10
VC0684249
p12554
sg12
I11
sg13
Vlung cancer
p12555
sg15
I2
sasa(dp12556
g2
VUHRF1 (ubiquitin-like, with PHD and RING finger domains 1) plays a crucial role in DNA methylation, chromatin remodeling and gene expression and is aberrantly upregulated in various types of human cancers.
p12557
sg4
(lp12558
(dp12559
g9
I28
sg39
VP20941
p12560
sg12
I3
sg13
VPHD
p12561
sg15
I1
sa(dp12562
g9
I7
sg39
VP62979
p12563
sg12
I14
sg13
Vubiquitin-like
p12564
sg15
I1
sa(dp12565
g9
I0
sg39
g40
sg12
I5
sg13
VUHRF1
p12566
sg15
I1
sasg6
(lp12567
(dp12568
g9
I197
sg10
VC0006826
p12569
sg12
I7
sg13
Vcancers
p12570
sg15
I1
sasa(dp12571
g2
VUHRF1 (ubiquitin-like with PHD and RING finger domains 1) is a critical regulator for DNA methylation, and its frequent overexpression in human cancers has been associated with tumor-promoting effects.
p12572
sg4
(lp12573
(dp12574
g9
I0
sg39
g40
sg12
I5
sg13
VUHRF1
p12575
sg15
I1
sa(dp12576
g9
I7
sg39
VP20941
p12577
sg12
I49
sg13
Vubiquitin-like with PHD and RING finger domains 1
p12578
sg15
I8
sasg6
(lp12579
(dp12580
g9
I177
sg10
VC0027651
p12581
sg12
I5
sg13
Vtumor
p12582
sg15
I1
sa(dp12583
g9
I144
sg10
VC0006826
p12584
sg12
I7
sg13
Vcancers
p12585
sg15
I1
sasa(dp12586
g2
VThe lower level of PHRF1 mRNA was observed in human lung cancer tissues than that in paracancerous tissues.
p12587
sg4
(lp12588
(dp12589
g9
I19
sg39
g40
sg12
I10
sg13
VPHRF1 mRNA
p12590
sg15
I2
sasg6
(lp12591
(dp12592
g9
I52
sg10
VC0684249
p12593
sg12
I11
sg13
Vlung cancer
p12594
sg15
I2
sasa(dp12595
g2
VIn conclusion, our findings suggest that overexpression of PHRF1 attenuated the proliferation and tumorigenicity of non-small cell lung cancer cell line of H1299.
p12596
sg4
(lp12597
(dp12598
g9
I59
sg39
g40
sg12
I5
sg13
VPHRF1
p12599
sg15
I1
sasg6
(lp12600
(dp12601
g9
I98
sg10
VC1519697
p12602
sg12
I14
sg13
Vtumorigenicity
p12603
sg15
I1
sa(dp12604
g9
I80
sg10
VC0334094
p12605
sg12
I13
sg13
Vproliferation
p12606
sg15
I1
sa(dp12607
g9
I116
sg10
VC0007131
p12608
sg12
I26
sg13
Vnon-small cell lung cancer
p12609
sg15
I4
sasa(dp12610
g2
VRecessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
p12611
sg4
(lp12612
(dp12613
g9
I35
sg39
g40
sg12
I4
sg13
VORC6
p12614
sg15
I1
sa(dp12615
g9
I49
sg39
g40
sg12
I4
sg13
VCDC6
p12616
sg15
I1
sa(dp12617
g9
I23
sg39
g40
sg12
I4
sg13
VORC1
p12618
sg15
I1
sa(dp12619
g9
I41
sg39
g40
sg12
I4
sg13
VCDT1
p12620
sg15
I1
sa(dp12621
g9
I29
sg39
g40
sg12
I4
sg13
VORC4
p12622
sg15
I1
sasg6
(lp12623
(dp12624
g9
I181
sg10
VC0025958
p12625
sg12
I12
sg13
Vmicrocephaly
p12626
sg15
I1
sa(dp12627
g9
I135
sg10
VC0684336
p12628
sg12
I8
sg13
Vimpaired
p12629
sg15
I1
sa(dp12630
g9
I82
sg10
VC1868684
p12631
sg12
I21
sg13
VMeier-Gorlin syndrome
p12632
sg15
I2
sa(dp12633
g9
I105
sg10
VC1969653
p12634
sg12
I3
sg13
VMGS
p12635
sg15
I1
sa(dp12636
g9
I163
sg10
VC0013336
p12637
sg12
I13
sg13
Vshort stature
p12638
sg15
I2
sasa(dp12639
g2
VMutations in ORC1, ORC4, ORC6, CDT1, and CDC6, which encode proteins required for DNA replication origin licensing, cause Meier-Gorlin syndrome (MGS), a disorder conferring microcephaly, primordial dwarfism, underdeveloped ears, and skeletal abnormalities.
p12640
sg4
(lp12641
(dp12642
g9
I41
sg39
g40
sg12
I4
sg13
VCDC6
p12643
sg15
I1
sa(dp12644
g9
I31
sg39
g40
sg12
I4
sg13
VCDT1
p12645
sg15
I1
sa(dp12646
g9
I25
sg39
g40
sg12
I4
sg13
VORC6
p12647
sg15
I1
sa(dp12648
g9
I13
sg39
g40
sg12
I4
sg13
VORC1
p12649
sg15
I1
sa(dp12650
g9
I19
sg39
g40
sg12
I4
sg13
VORC4
p12651
sg15
I1
sasg6
(lp12652
(dp12653
g9
I145
sg10
VC1969653
p12654
sg12
I3
sg13
VMGS
p12655
sg15
I1
sa(dp12656
g9
I187
sg10
VC0013336
p12657
sg12
I19
sg13
Vprimordial dwarfism
p12658
sg15
I2
sa(dp12659
g9
I173
sg10
VC0025958
p12660
sg12
I12
sg13
Vmicrocephaly
p12661
sg15
I1
sa(dp12662
g9
I122
sg10
VC1868684
p12663
sg12
I21
sg13
VMeier-Gorlin syndrome
p12664
sg15
I2
sasa(dp12665
g2
VSignificantly higher concentrations of HMGB1 were found in nasal secretions from patients with chronic rhinosinusitis with nasal polyp or allergic rhinitis compared with the control subjects.
p12666
sg4
(lp12667
(dp12668
g9
I39
sg39
VP09429
p12669
sg12
I5
sg13
VHMGB1
p12670
sg15
I1
sasg6
(lp12671
(dp12672
g9
I123
sg10
VC0027430
p12673
sg12
I11
sg13
Vnasal polyp
p12674
sg15
I2
sa(dp12675
g9
I95
sg10
VC0149516
p12676
sg12
I22
sg13
Vchronic rhinosinusitis
p12677
sg15
I2
sa(dp12678
g9
I138
sg10
VC2607914
p12679
sg12
I17
sg13
Vallergic rhinitis
p12680
sg15
I2
sasa(dp12681
g2
VPrevious studies have shown that HMGB1 is elevated in the nasal lavage fluids (NLF) of children suffering from allergic rhinitis (AR) and is associated with the severity of this disease.
p12682
sg4
(lp12683
(dp12684
g9
I33
sg39
VP09429
p12685
sg12
I5
sg13
VHMGB1
p12686
sg15
I1
sasg6
(lp12687
(dp12688
g9
I96
sg10
VC0683278
p12689
sg12
I9
sg13
Vsuffering
p12690
sg15
I1
sa(dp12691
g9
I130
sg10
VC2607914
p12692
sg12
I2
sg13
VAR
p12693
sg15
I1
sa(dp12694
g9
I111
sg10
VC2607914
p12695
sg12
I17
sg13
Vallergic rhinitis
p12696
sg15
I2
sasa(dp12697
g2
VThe major cystinosis mutation is a 57 kb deletion on human chromosome 17p13 that removes the majority of CTNS and the entire adjacent gene, CARKL/SHPK.
p12698
sg4
(lp12699
(dp12700
g9
I140
sg39
g40
sg12
I5
sg13
VCARKL
p12701
sg15
I1
sa(dp12702
g9
I146
sg39
g40
sg12
I4
sg13
VSHPK
p12703
sg15
I1
sasg6
(lp12704
(dp12705
g9
I105
sg10
VC0015624
p12706
sg12
I4
sg13
VCTNS
p12707
sg15
I1
sa(dp12708
g9
I10
sg10
VC0010690
p12709
sg12
I10
sg13
Vcystinosis
p12710
sg15
I1
sasa(dp12711
g2
VThe most common mutation in the nephropathic cystinosis (CTNS) gene is a homozygous 57-kb deletion that also includes an adjacent gene carbohydrate kinase-like (CARKL).
p12712
sg4
(lp12713
(dp12714
g9
I161
sg39
g40
sg12
I5
sg13
VCARKL
p12715
sg15
I1
sa(dp12716
g9
I135
sg39
g40
sg12
I24
sg13
Vcarbohydrate kinase-like
p12717
sg15
I2
sasg6
(lp12718
(dp12719
g9
I57
sg10
VC0015624
p12720
sg12
I4
sg13
VCTNS
p12721
sg15
I1
sa(dp12722
g9
I32
sg10
VC0015624
p12723
sg12
I23
sg13
Vnephropathic cystinosis
p12724
sg15
I2
sasa(dp12725
g2
VAnalysis of the resulting data revealed a number of interesting features about this genomic region, including the long-range organization of CTNS, insight about the breakpoints and intervening DNA associated with the common cystinosis-causing deletion, and structural information about five genes neighboring CTNS (human ortholog of rat vanilloid receptor subtype 1 gene, CARKL, TIP-1, P2X5, and HUMINAE).
p12726
sg4
(lp12727
(dp12728
g9
I141
sg39
g40
sg12
I4
sg13
VCTNS
p12729
sg15
I1
sa(dp12730
g9
I372
sg39
g40
sg12
I5
sg13
VCARKL
p12731
sg15
I1
sa(dp12732
g9
I379
sg39
g40
sg12
I5
sg13
VTIP-1
p12733
sg15
I1
sa(dp12734
g9
I386
sg39
g40
sg12
I4
sg13
VP2X5
p12735
sg15
I1
sa(dp12736
g9
I333
sg39
g40
sg12
I37
sg13
Vrat vanilloid receptor subtype 1 gene
p12737
sg15
I6
sasg6
(lp12738
(dp12739
g9
I141
sg10
VC0015624
p12740
sg12
I4
sg13
VCTNS
p12741
sg15
I1
sa(dp12742
g9
I224
sg10
VC0010690
p12743
sg12
I10
sg13
Vcystinosis
p12744
sg15
I1
sa(dp12745
g9
I141
sg10
VC0015624
p12746
sg12
I4
sg13
VCTNS
p12747
sg15
I1
sasa(dp12748
g2
VIn particular, sequence analysis detected the presence of a novel gene (CARKL) residing within the most common cystinosis-causing deletion.
p12749
sg4
(lp12750
(dp12751
g9
I72
sg39
g40
sg12
I5
sg13
VCARKL
p12752
sg15
I1
sasg6
(lp12753
(dp12754
g9
I111
sg10
VC0010690
p12755
sg12
I10
sg13
Vcystinosis
p12756
sg15
I1
sasa(dp12757
g2
VInterestingly, both CTNS and CARKL are absent in nearly half of all cystinosis patients (i.e., those homozygous for the common deletion).
p12758
sg4
(lp12759
(dp12760
g9
I20
sg39
g40
sg12
I4
sg13
VCTNS
p12761
sg15
I1
sa(dp12762
g9
I29
sg39
g40
sg12
I5
sg13
VCARKL
p12763
sg15
I1
sasg6
(lp12764
(dp12765
g9
I68
sg10
VC0010690
p12766
sg12
I10
sg13
Vcystinosis
p12767
sg15
I1
sa(dp12768
g9
I20
sg10
VC0015624
p12769
sg12
I4
sg13
VCTNS
p12770
sg15
I1
sasa(dp12771
g2
VThere is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).
p12772
sg4
(lp12773
sg6
(lp12774
(dp12775
g9
I187
sg10
VC0024117
p12776
sg12
I4
sg13
VCOPD
p12777
sg15
I1
sa(dp12778
g9
I68
sg10
VC0013364
p12779
sg12
I3
sg13
Vdys
p12780
sg15
I1
sa(dp12781
g9
I148
sg10
VC0024117
p12782
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p12783
sg15
I4
sasa(dp12784
g2
VBackground There is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).
p12785
sg4
(lp12786
sg6
(lp12787
(dp12788
g9
I79
sg10
VC0013364
p12789
sg12
I3
sg13
Vdys
p12790
sg15
I1
sa(dp12791
g9
I198
sg10
VC0024117
p12792
sg12
I4
sg13
VCOPD
p12793
sg15
I1
sa(dp12794
g9
I159
sg10
VC0024117
p12795
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p12796
sg15
I4
sasa(dp12797
g2
VRecent progress in our understanding of the developmental regulation of this tissue, the differentiation pathways, recognition of pathogens and antimicrobial responses is now exploited to help understand how epithelial cell function and dysfunction contributes to the pathogenesis of a variety of inflammatory lung diseases.
p12798
sg4
(lp12799
sg6
(lp12800
(dp12801
g9
I310
sg10
VC0024115
p12802
sg12
I13
sg13
Vlung diseases
p12803
sg15
I2
sa(dp12804
g9
I268
sg10
VC0699748
p12805
sg12
I12
sg13
Vpathogenesis
p12806
sg15
I1
sasa(dp12807
g2
VHerein, advances in our knowledge of the biology of airway epithelium, as well as its role and (dys)function in asthma, chronic obstructive pulmonary fibrosis and cystic fibrosis will be discussed.
p12808
sg4
(lp12809
sg6
(lp12810
(dp12811
g9
I163
sg10
VC0010674
p12812
sg12
I15
sg13
Vcystic fibrosis
p12813
sg15
I2
sa(dp12814
g9
I96
sg10
VC0013364
p12815
sg12
I3
sg13
Vdys
p12816
sg15
I1
sa(dp12817
g9
I112
sg10
VC0004096
p12818
sg12
I6
sg13
Vasthma
p12819
sg15
I1
sa(dp12820
g9
I140
sg10
VC0034069
p12821
sg12
I18
sg13
Vpulmonary fibrosis
p12822
sg15
I2
sasa(dp12823
g2
VManaging neurogenic dysphagia with effective protection of the airway passages and prompt treatment of aspiration pneumonias is necessary to prevent respiratory failure.
p12824
sg4
(lp12825
sg6
(lp12826
(dp12827
g9
I103
sg10
VC0032290
p12828
sg12
I21
sg13
Vaspiration pneumonias
p12829
sg15
I2
sa(dp12830
g9
I9
sg10
VC1955520
p12831
sg12
I20
sg13
Vneurogenic dysphagia
p12832
sg15
I2
sa(dp12833
g9
I149
sg10
VC1145670
p12834
sg12
I19
sg13
Vrespiratory failure
p12835
sg15
I2
sasa(dp12836
g2
VMultivariate analysis identified four independent risk factors for mortality in patients with severe sepsis and septic shock: three or more organ dysfunctions (OR, 3.212; 95% CI, 1.585-6.506; p&lt;0.001), acute respiratory failure (OR, 2.649 95% CI, 1.327-5.287; p=0.006), positive blood culture (OR, 2.708; 95% CI, 1.289-5.689; p=0.009) and chronic heart failure (OR, 2.112; 95% CI, 1.036-4.308; p=0.040).
p12837
sg4
(lp12838
sg6
(lp12839
(dp12840
g9
I112
sg10
VC0036983
p12841
sg12
I12
sg13
Vseptic shock
p12842
sg15
I2
sa(dp12843
g9
I205
sg10
VC0264490
p12844
sg12
I25
sg13
Vacute respiratory failure
p12845
sg15
I3
sa(dp12846
g9
I342
sg10
VC0264716
p12847
sg12
I21
sg13
Vchronic heart failure
p12848
sg15
I3
sa(dp12849
g9
I94
sg10
VC1719672
p12850
sg12
I13
sg13
Vsevere sepsis
p12851
sg15
I2
sasa(dp12852
g2
VOur results highlight the importance of three or more organ dys-functions, acute respiratory failure, positive blood culture and chronic heart failure as independent risk factors for mortality in the first 24 hours after admission in patients with severe sepsis and septic shock.
p12853
sg4
(lp12854
sg6
(lp12855
(dp12856
g9
I248
sg10
VC1719672
p12857
sg12
I13
sg13
Vsevere sepsis
p12858
sg15
I2
sa(dp12859
g9
I266
sg10
VC0036983
p12860
sg12
I12
sg13
Vseptic shock
p12861
sg15
I2
sa(dp12862
g9
I75
sg10
VC0264490
p12863
sg12
I25
sg13
Vacute respiratory failure
p12864
sg15
I3
sa(dp12865
g9
I129
sg10
VC0264716
p12866
sg12
I21
sg13
Vchronic heart failure
p12867
sg15
I3
sa(dp12868
g9
I60
sg10
VC0013364
p12869
sg12
I3
sg13
Vdys
p12870
sg15
I1
sasa(dp12871
g2
VThis review briefly touches on CF genetics as it applies to lung disease and will focus on the current hypotheses of CFTR (dys)function and its impact on pulmonary fluid homeostasis.
p12872
sg4
(lp12873
(dp12874
g9
I117
sg39
VP13569
p12875
sg12
I4
sg13
VCFTR
p12876
sg15
I1
sa(dp12877
g9
I123
sg39
VP11532
p12878
sg12
I3
sg13
Vdys
p12879
sg15
I1
sasg6
(lp12880
(dp12881
g9
I123
sg10
VC0013364
p12882
sg12
I3
sg13
Vdys
p12883
sg15
I1
sa(dp12884
g9
I60
sg10
VC0024115
p12885
sg12
I12
sg13
Vlung disease
p12886
sg15
I2
sasa(dp12887
g2
VTo investigate the expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia(CML) patients at different stages and explore their relationship.
p12888
sg4
(lp12889
(dp12890
g9
I52
sg39
VP11274
p12891
sg12
I3
sg13
VBCR
p12892
sg15
I1
sa(dp12893
g9
I37
sg39
VP55290
p12894
sg12
I10
sg13
VCDH13 gene
p12895
sg15
I2
sa(dp12896
g9
I56
sg39
VP55157
p12897
sg12
I3
sg13
VABL
p12898
sg15
I1
sasg6
(lp12899
(dp12900
g9
I100
sg10
VC0023473
p12901
sg12
I3
sg13
VCML
p12902
sg15
I1
sa(dp12903
g9
I56
sg10
VC0000744
p12904
sg12
I3
sg13
VABL
p12905
sg15
I1
sa(dp12906
g9
I75
sg10
VC0023473
p12907
sg12
I24
sg13
Vchronic myeloid leukemia
p12908
sg15
I3
sasa(dp12909
g2
VWe performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4.
p12910
sg4
(lp12911
(dp12912
g9
I198
sg39
g40
sg12
I4
sg13
VNPM2
p12913
sg15
I1
sa(dp12914
g9
I204
sg39
g40
sg12
I5
sg13
VOLIG2
p12915
sg15
I1
sa(dp12916
g9
I180
sg39
g40
sg12
I4
sg13
VNOR1
p12917
sg15
I1
sa(dp12918
g9
I186
sg39
VP55290
p12919
sg12
I5
sg13
VCDH13
p12920
sg15
I1
sa(dp12921
g9
I226
sg39
g40
sg12
I7
sg13
VSLC26A4
p12922
sg15
I1
sa(dp12923
g9
I216
sg39
g40
sg12
I4
sg13
VHIN1
p12924
sg15
I1
sa(dp12925
g9
I211
sg39
VP06401
p12926
sg12
I3
sg13
VPGR
p12927
sg15
I1
sa(dp12928
g9
I193
sg39
VP53999
p12929
sg12
I3
sg13
Vp15
p12930
sg15
I1
sasg6
(lp12931
(dp12932
g9
I150
sg10
VC0023467
p12933
sg12
I22
sg13
Vacute myeloid leukemia
p12934
sg15
I3
sa(dp12935
g9
I174
sg10
VC0023467
p12936
sg12
I3
sg13
VAML
p12937
sg15
I1
sa(dp12938
g9
I109
sg10
VC0023418
p12939
sg12
I8
sg13
Vleukemia
p12940
sg15
I1
sasa(dp12941
g2
VAlthough defective progenitor-stromal adhesion is a well-recognized feature of chronic myeloid leukemia (CML), the role of CDH13 abnormalities has not been evaluated in this disease.
p12942
sg4
(lp12943
(dp12944
g9
I123
sg39
VP55290
p12945
sg12
I5
sg13
VCDH13
p12946
sg15
I1
sasg6
(lp12947
(dp12948
g9
I38
sg10
VC0001511
p12949
sg12
I8
sg13
Vadhesion
p12950
sg15
I1
sa(dp12951
g9
I105
sg10
VC0023473
p12952
sg12
I3
sg13
VCML
p12953
sg15
I1
sa(dp12954
g9
I79
sg10
VC0023473
p12955
sg12
I24
sg13
Vchronic myeloid leukemia
p12956
sg15
I3
sasa(dp12957
g2
VRecent work from our laboratory suggested pIgR may be upregulated in pancreatic ductal adenocarcinoma (PDAC).
p12958
sg4
(lp12959
(dp12960
g9
I42
sg39
VP01833
p12961
sg12
I4
sg13
VpIgR
p12962
sg15
I1
sasg6
(lp12963
(dp12964
g9
I103
sg10
VC1335302
p12965
sg12
I4
sg13
VPDAC
p12966
sg15
I1
sa(dp12967
g9
I69
sg10
VC1335302
p12968
sg12
I32
sg13
Vpancreatic ductal adenocarcinoma
p12969
sg15
I3
sasa(dp12970
g2
VIn this work we investigated the expression of the SERCA3-type calcium pump in choroid plexus epithelial cells grown in vitro, and in normal and hyperplastic choroid plexus tissue, in choroid plexus papillomas displaying various degrees of atypia, and in choroid plexus carcinoma by immunohistochemistry in situ.
p12971
sg4
(lp12972
sg6
(lp12973
(dp12974
g9
I255
sg10
VC0431109
p12975
sg12
I24
sg13
Vchoroid plexus carcinoma
p12976
sg15
I3
sa(dp12977
g9
I145
sg10
VC0020507
p12978
sg12
I12
sg13
Vhyperplastic
p12979
sg15
I1
sa(dp12980
g9
I184
sg10
VC0205770
p12981
sg12
I25
sg13
Vchoroid plexus papillomas
p12982
sg15
I3
sasa(dp12983
g2
VWhereas normal choroid plexus epithelial cells express SERCA3 abundantly, SERCA3 expression is strongly decreased in papillomas, and is absent in choroid plexus carcinoma, while expression in hyperplastic epithelium is high, similarly to normal epithelium.
p12984
sg4
(lp12985
sg6
(lp12986
(dp12987
g9
I117
sg10
VC0030354
p12988
sg12
I10
sg13
Vpapillomas
p12989
sg15
I1
sa(dp12990
g9
I192
sg10
VC0020507
p12991
sg12
I12
sg13
Vhyperplastic
p12992
sg15
I1
sa(dp12993
g9
I146
sg10
VC0431109
p12994
sg12
I24
sg13
Vchoroid plexus carcinoma
p12995
sg15
I3
sasa(dp12996
g2
VDue to the inverse interaction of Rac1 and Ras homolog family member A (RhoA) signaling in the transition between mesenchymal and amoeboid morphology, simultaneous treatment of NSC23766 and Y27632 (selective Rho associated coiled-coil containing protein kinase 1 inhibitor), abolished U87 GBM cell migration through inhibiting MAT and amoeboid-mesenchymal transition.
p12997
sg4
(lp12998
(dp12999
g9
I285
sg39
g40
sg12
I7
sg13
VU87 GBM
p13000
sg15
I2
sa(dp13001
g9
I327
sg39
VP24752
p13002
sg12
I3
sg13
VMAT
p13003
sg15
I1
sa(dp13004
g9
I43
sg39
VP01116
p13005
sg12
I27
sg13
VRas homolog family member A
p13006
sg15
I5
sa(dp13007
g9
I34
sg39
VP63000
p13008
sg12
I4
sg13
VRac1
p13009
sg15
I1
sa(dp13010
g9
I72
sg39
VP61586
p13011
sg12
I4
sg13
VRhoA
p13012
sg15
I1
sa(dp13013
g9
I223
sg39
VP38432
p13014
sg12
I39
sg13
Vcoiled-coil containing protein kinase 1
p13015
sg15
I5
sa(dp13016
g9
I72
sg39
VP08100
p13017
sg12
I3
sg13
VRho
p13018
sg15
I1
sasg6
(lp13019
(dp13020
g9
I289
sg10
VC0017636
p13021
sg12
I3
sg13
VGBM
p13022
sg15
I1
sa(dp13023
g9
I95
sg10
VC0599156
p13024
sg12
I10
sg13
Vtransition
p13025
sg15
I1
sa(dp13026
g9
I95
sg10
VC0599156
p13027
sg12
I10
sg13
Vtransition
p13028
sg15
I1
sasa(dp13029
g2
VThe combined inhibition of Rac1 and RhoA signaling would be a promising strategy to suppress GBM invasion.
p13030
sg4
(lp13031
(dp13032
g9
I36
sg39
VP61586
p13033
sg12
I4
sg13
VRhoA
p13034
sg15
I1
sa(dp13035
g9
I27
sg39
VP63000
p13036
sg12
I4
sg13
VRac1
p13037
sg15
I1
sasg6
(lp13038
(dp13039
g9
I97
sg10
VC2699153
p13040
sg12
I8
sg13
Vinvasion
p13041
sg15
I1
sa(dp13042
g9
I93
sg10
VC0017636
p13043
sg12
I3
sg13
VGBM
p13044
sg15
I1
sasa(dp13045
g2
VSpecifically, combination therapy inhibited TLR7 expression in the kidneys of mice with lupus nephritis; combination of tacrolimus and mycophenolate mofetil led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities.
p13046
sg4
(lp13047
(dp13048
g9
I44
sg39
g40
sg12
I4
sg13
VTLR7
p13049
sg15
I1
sa(dp13050
g9
I257
sg39
VP61586
p13051
sg12
I4
sg13
VRhoA
p13052
sg15
I1
sa(dp13053
g9
I266
sg39
VP63000
p13054
sg12
I4
sg13
VRac1
p13055
sg15
I1
sasg6
(lp13056
(dp13057
g9
I88
sg10
VC0024143
p13058
sg12
I15
sg13
Vlupus nephritis
p13059
sg15
I2
sasa(dp13060
g2
VWe hypothesized that mutations in AP2S1 and GNA11 are causative in Danish patients with suspected FHH and that these mutations are not found in patients with primary hyperparathyroidism (PHPT), which is the main differential diagnostic disorder.
p13061
sg4
(lp13062
(dp13063
g9
I44
sg39
VP29992
p13064
sg12
I5
sg13
VGNA11
p13065
sg15
I1
sa(dp13066
g9
I34
sg39
VP53680
p13067
sg12
I5
sg13
VAP2S1
p13068
sg15
I1
sasg6
(lp13069
(dp13070
g9
I187
sg10
VC0221002
p13071
sg12
I4
sg13
VPHPT
p13072
sg15
I1
sa(dp13073
g9
I158
sg10
VC0221002
p13074
sg12
I27
sg13
Vprimary hyperparathyroidism
p13075
sg15
I2
sasa(dp13076
g2
VFamilial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous condition resembling primary hyperparathyroidism (PHPT) but not curable by surgery; FHH types 1, 2, and 3 are due to loss-of-function mutations of the CASR, GNA11, or AP2S1 genes, respectively.
p13077
sg4
(lp13078
(dp13079
g9
I225
sg39
VP41180
p13080
sg12
I4
sg13
VCASR
p13081
sg15
I1
sa(dp13082
g9
I231
sg39
VP29992
p13083
sg12
I5
sg13
VGNA11
p13084
sg15
I1
sa(dp13085
g9
I241
sg39
VP53680
p13086
sg12
I11
sg13
VAP2S1 genes
p13087
sg15
I2
sasg6
(lp13088
(dp13089
g9
I124
sg10
VC0221002
p13090
sg12
I4
sg13
VPHPT
p13091
sg15
I1
sa(dp13092
g9
I74
sg10
VC0012634
p13093
sg12
I9
sg13
Vcondition
p13094
sg15
I1
sa(dp13095
g9
I38
sg10
VC0342637
p13096
sg12
I3
sg13
VFHH
p13097
sg15
I1
sa(dp13098
g9
I38
sg10
VC0342637
p13099
sg12
I3
sg13
VFHH
p13100
sg15
I1
sa(dp13101
g9
I95
sg10
VC0221002
p13102
sg12
I27
sg13
Vprimary hyperparathyroidism
p13103
sg15
I2
sa(dp13104
g9
I0
sg10
VC0342637
p13105
sg12
I36
sg13
VFamilial hypocalciuric hypercalcemia
p13106
sg15
I3
sasa(dp13107
g2
VThe aim of this study was to analyse prevalence and pathogenicity of CaSR, GNA11 and AP2S1 mutations in patients with an FHH phenotype and to compare them with a sample of patients with primary hyperparathyroidism (PHPT) in order to identify the most useful laboratory parameter for a differential diagnosis.
p13108
sg4
(lp13109
(dp13110
g9
I85
sg39
VP53680
p13111
sg12
I5
sg13
VAP2S1
p13112
sg15
I1
sa(dp13113
g9
I69
sg39
VP41180
p13114
sg12
I4
sg13
VCaSR
p13115
sg15
I1
sa(dp13116
g9
I75
sg39
VP29992
p13117
sg12
I5
sg13
VGNA11
p13118
sg15
I1
sa(dp13119
g9
I121
sg39
VP41180
p13120
sg12
I3
sg13
VFHH
p13121
sg15
I1
sasg6
(lp13122
(dp13123
g9
I215
sg10
VC0221002
p13124
sg12
I4
sg13
VPHPT
p13125
sg15
I1
sa(dp13126
g9
I186
sg10
VC0221002
p13127
sg12
I27
sg13
Vprimary hyperparathyroidism
p13128
sg15
I2
sasa(dp13129
g2
VTripartite motif-containing protein 37 (TRIM37), a new member of the RING-B-box-coiled-coil (RBCC) subfamily of zinc finger proteins, was found to be involved in the development and progression of several cancers.
p13130
sg4
(lp13131
(dp13132
g9
I112
sg39
g40
sg12
I20
sg13
Vzinc finger proteins
p13133
sg15
I3
sa(dp13134
g9
I40
sg39
g40
sg12
I6
sg13
VTRIM37
p13135
sg15
I1
sa(dp13136
g9
I69
sg39
VP38432
p13137
sg12
I22
sg13
VRING-B-box-coiled-coil
p13138
sg15
I1
sa(dp13139
g9
I93
sg39
g40
sg12
I4
sg13
VRBCC
p13140
sg15
I1
sa(dp13141
g9
I0
sg39
g40
sg12
I38
sg13
VTripartite motif-containing protein 37
p13142
sg15
I4
sasg6
(lp13143
(dp13144
g9
I205
sg10
VC0006826
p13145
sg12
I7
sg13
Vcancers
p13146
sg15
I1
sasa(dp13147
g2
VIn the present work, we clearly demonstrate that HMGB1 secreted by cancer cells is N-glycosylated at Asn37, which facilitates monocytic (M)-MDSC differentiation from bone marrow via the p38/NFKB/Erk1/2 pathway and also contributes to conversion of monocytes into MDSC-like cells; HMGB1 blockade by a monoclonal antibody against the HMGB1 B box obviously reduced the accumulation of M-MDSC in tumor-bearing mice, delaying tumor growth and development; additionally, MDSC expansion and HMGB1 up-regulation were also found in breast cancer patients.
p13148
sg4
(lp13149
(dp13150
g9
I195
sg39
VP27361
p13151
sg12
I6
sg13
VErk1/2
p13152
sg15
I1
sa(dp13153
g9
I49
sg39
VP09429
p13154
sg12
I5
sg13
VHMGB1
p13155
sg15
I1
sa(dp13156
g9
I190
sg39
g40
sg12
I4
sg13
VNFKB
p13157
sg15
I1
sa(dp13158
g9
I49
sg39
VP09429
p13159
sg12
I5
sg13
VHMGB1
p13160
sg15
I1
sa(dp13161
g9
I186
sg39
VP46108
p13162
sg12
I3
sg13
Vp38
p13163
sg15
I1
sa(dp13164
g9
I49
sg39
VP09429
p13165
sg12
I5
sg13
VHMGB1
p13166
sg15
I1
sa(dp13167
g9
I332
sg39
VP09429
p13168
sg12
I7
sg13
VHMGB1 B
p13169
sg15
I2
sasg6
(lp13170
(dp13171
g9
I67
sg10
VC0006826
p13172
sg12
I6
sg13
Vcancer
p13173
sg15
I1
sa(dp13174
g9
I523
sg10
VC0678222
p13175
sg12
I13
sg13
Vbreast cancer
p13176
sg15
I2
sa(dp13177
g9
I421
sg10
VC0598934
p13178
sg12
I12
sg13
Vtumor growth
p13179
sg15
I2
sa(dp13180
g9
I392
sg10
VC0027651
p13181
sg12
I5
sg13
Vtumor
p13182
sg15
I1
sasa(dp13183
g2
VWe examined a possible association between the COMT Val158Met polymorphism and conversion disorder in a study of 48 patients with conversion disorder and 48 control patients.
p13184
sg4
(lp13185
(dp13186
g9
I47
sg39
VP21964
p13187
sg12
I14
sg13
VCOMT Val158Met
p13188
sg15
I2
sasg6
(lp13189
(dp13190
g9
I79
sg10
VC0009946
p13191
sg12
I19
sg13
Vconversion disorder
p13192
sg15
I2
sa(dp13193
g9
I79
sg10
VC0009946
p13194
sg12
I19
sg13
Vconversion disorder
p13195
sg15
I2
sasa(dp13196
g2
VWe conclude that the COMT Val158Met genotype is quite common in Turkey and that it is not a risk factor for conversion disorder in the Turkish population.
p13197
sg4
(lp13198
(dp13199
g9
I21
sg39
VP21964
p13200
sg12
I23
sg13
VCOMT Val158Met genotype
p13201
sg15
I3
sasg6
(lp13202
(dp13203
g9
I108
sg10
VC0009946
p13204
sg12
I19
sg13
Vconversion disorder
p13205
sg15
I2
sasa(dp13206
g2
VFactor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.
p13207
sg4
(lp13208
(dp13209
g9
I0
sg39
VP08709
p13210
sg12
I37
sg13
VFactor VII (FVII) activating protease
p13211
sg15
I5
sa(dp13212
g9
I39
sg39
g40
sg12
I4
sg13
VFSAP
p13213
sg15
I1
sa(dp13214
g9
I62
sg39
VP57727
p13215
sg12
I15
sg13
Vserine protease
p13216
sg15
I2
sasg6
(lp13217
(dp13218
g9
I150
sg10
VC0038454
p13219
sg12
I6
sg13
Vstroke
p13220
sg15
I1
sa(dp13221
g9
I158
sg10
VC0004153
p13222
sg12
I15
sg13
Vatherosclerosis
p13223
sg15
I1
sa(dp13224
g9
I175
sg10
VC0239946
p13225
sg12
I14
sg13
Vliver fibrosis
p13226
sg15
I2
sa(dp13227
g9
I206
sg10
VC0006826
p13228
sg12
I6
sg13
Vcancer
p13229
sg15
I1
sa(dp13230
g9
I191
sg10
VC0040053
p13231
sg12
I10
sg13
Vthrombosis
p13232
sg15
I1
sasa(dp13233
g2
VWith purpose to study content of alpha-defensins (1-3) and synthesis and liberation of other proteins and peptides by neutrophils the concentrations of alpha-defensins, lipoprotein (alpha), C-reactive protein, precursor of cerebral natriuretic peptide, coagulation factor VII and von Willebrand factor were determined in supernatants of leukocytal cultures in patients with exertional angina pectoris and atherosclerosis of lower extremities.
p13234
sg4
(lp13235
(dp13236
g9
I280
sg39
VP04275
p13237
sg12
I21
sg13
Vvon Willebrand factor
p13238
sg15
I3
sa(dp13239
g9
I190
sg39
VP02741
p13240
sg12
I18
sg13
VC-reactive protein
p13241
sg15
I2
sa(dp13242
g9
I223
sg39
VP16860
p13243
sg12
I28
sg13
Vcerebral natriuretic peptide
p13244
sg15
I3
sa(dp13245
g9
I33
sg39
VP59665
p13246
sg12
I15
sg13
Valpha-defensins
p13247
sg15
I1
sa(dp13248
g9
I253
sg39
VP08709
p13249
sg12
I22
sg13
Vcoagulation factor VII
p13250
sg15
I3
sa(dp13251
g9
I169
sg39
VP02652
p13252
sg12
I19
sg13
Vlipoprotein (alpha)
p13253
sg15
I2
sasg6
(lp13254
(dp13255
g9
I374
sg10
VC0577698
p13256
sg12
I17
sg13
Vexertional angina
p13257
sg15
I2
sa(dp13258
g9
I405
sg10
VC0004153
p13259
sg12
I15
sg13
Vatherosclerosis
p13260
sg15
I1
sasa(dp13261
g2
VThe frequency of HLA-DR4 was increased in patients with optic neuritis alone compared to controls and to patients with multiple sclerosis, but further studies are required to confirm this finding.
p13262
sg4
(lp13263
(dp13264
g9
I17
sg39
VP30486
p13265
sg12
I7
sg13
VHLA-DR4
p13266
sg15
I1
sasg6
(lp13267
(dp13268
g9
I56
sg10
VC0029134
p13269
sg12
I14
sg13
Voptic neuritis
p13270
sg15
I2
sa(dp13271
g9
I119
sg10
VC0026769
p13272
sg12
I18
sg13
Vmultiple sclerosis
p13273
sg15
I2
sasa(dp13274
g2
VThe MS profiling by PGC-LC also revealed several glycan structural isomers that corresponded to LacdiNAc-type (GalNAcBeta1-4GlcNAc) motifs that were unique to the serous ovarian cancers and that correlated with elevated gene expression of B4GALNT3 and B4GALNT4 in patients with serous cancer.
p13275
sg4
(lp13276
(dp13277
g9
I252
sg39
g40
sg12
I8
sg13
VB4GALNT4
p13278
sg15
I1
sa(dp13279
g9
I239
sg39
g40
sg12
I8
sg13
VB4GALNT3
p13280
sg15
I1
sasg6
(lp13281
(dp13282
g9
I178
sg10
VC0006826
p13283
sg12
I6
sg13
Vcancer
p13284
sg15
I1
sa(dp13285
g9
I170
sg10
VC1140680
p13286
sg12
I15
sg13
Vovarian cancers
p13287
sg15
I2
sasa(dp13288
g2
VWe previously showed that B4GALNT3 overexpression enhances colon cancer cell malignant phenotypes in vitro and in vivo.
p13289
sg4
(lp13290
(dp13291
g9
I26
sg39
g40
sg12
I8
sg13
VB4GALNT3
p13292
sg15
I1
sasg6
(lp13293
(dp13294
g9
I59
sg10
VC0699790
p13295
sg12
I12
sg13
Vcolon cancer
p13296
sg15
I2
sasa(dp13297
g2
VHowever, the role of B4GALNT3 in cancer stemness remains unclear.
p13298
sg4
(lp13299
(dp13300
g9
I21
sg39
g40
sg12
I8
sg13
VB4GALNT3
p13301
sg15
I1
sasg6
(lp13302
(dp13303
g9
I33
sg10
VC0006826
p13304
sg12
I6
sg13
Vcancer
p13305
sg15
I1
sasa(dp13306
g2
VWe found that B4GALNT3 expression was positively correlated with advanced stages and poor survival in colorectal cancer patients.
p13307
sg4
(lp13308
(dp13309
g9
I14
sg39
g40
sg12
I8
sg13
VB4GALNT3
p13310
sg15
I1
sasg6
(lp13311
(dp13312
g9
I102
sg10
VC1527249
p13313
sg12
I17
sg13
Vcolorectal cancer
p13314
sg15
I2
sasa(dp13315
g2
VKnockdown of B4GALNT3 using small interfering (si) RNAs in colon cancer cell lines (HCT116, SW480, HCT15, and HT29 cells) decreased sphere formation and the expression of stem cell markers, OCT4 and NANOG.
p13316
sg4
(lp13317
(dp13318
g9
I199
sg39
g40
sg12
I5
sg13
VNANOG
p13319
sg15
I1
sasg6
(lp13320
(dp13321
g9
I59
sg10
VC0699790
p13322
sg12
I12
sg13
Vcolon cancer
p13323
sg15
I2
sasa(dp13324
g2
VTaken together, these data suggest B4GALNT3 regulates cancer stemness and the invasive properties of colon cancer cells through modifying EGFR glycosylation and signaling.
p13325
sg4
(lp13326
(dp13327
g9
I35
sg39
g40
sg12
I8
sg13
VB4GALNT3
p13328
sg15
I1
sasg6
(lp13329
(dp13330
g9
I54
sg10
VC0006826
p13331
sg12
I6
sg13
Vcancer
p13332
sg15
I1
sa(dp13333
g9
I101
sg10
VC0699790
p13334
sg12
I12
sg13
Vcolon cancer
p13335
sg15
I2
sasa(dp13336
g2
VIn this study, we investigated the expression and role of B4GALNT3 in human neuroblastoma (NB).
p13337
sg4
(lp13338
(dp13339
g9
I58
sg39
g40
sg12
I8
sg13
VB4GALNT3
p13340
sg15
I1
sasg6
(lp13341
(dp13342
g9
I91
sg10
VC0027819
p13343
sg12
I2
sg13
VNB
p13344
sg15
I1
sa(dp13345
g9
I76
sg10
VC0027819
p13346
sg12
I13
sg13
Vneuroblastoma
p13347
sg15
I1
sasa(dp13348
g2
VDetection rates were as follows: IL-7: NVG higher than POAG; IL-10: POAG lower than cataract or NVG; and GM-CSF: cataract higher than POAG or NVG.
p13349
sg4
(lp13350
(dp13351
g9
I105
sg39
VP04141
p13352
sg12
I6
sg13
VGM-CSF
p13353
sg15
I1
sa(dp13354
g9
I33
sg39
VP13232
p13355
sg12
I4
sg13
VIL-7
p13356
sg15
I1
sasg6
(lp13357
(dp13358
g9
I55
sg10
VC0339573
p13359
sg12
I4
sg13
VPOAG
p13360
sg15
I1
sa(dp13361
g9
I84
sg10
VC0086543
p13362
sg12
I8
sg13
Vcataract
p13363
sg15
I1
sa(dp13364
g9
I55
sg10
VC0339573
p13365
sg12
I4
sg13
VPOAG
p13366
sg15
I1
sa(dp13367
g9
I84
sg10
VC0086543
p13368
sg12
I8
sg13
Vcataract
p13369
sg15
I1
sa(dp13370
g9
I55
sg10
VC0339573
p13371
sg12
I4
sg13
VPOAG
p13372
sg15
I1
sasa(dp13373
g2
VSixty-four vitreous samples (40 RVO, 24 controls with idiopathic floaters) were analyzed in this retrospective case series using LC/MS for LPAs 16:0, 18:0, 18:1, 20:4, and ELISA kits or Luminex technology for ATX, angiopoetin-1 (ANG-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), pigment epithelium-derived factor (PEDF), and vascular endothelial growth factor (VEGF).
p13374
sg4
(lp13375
(dp13376
g9
I274
sg39
VP13232
p13377
sg12
I4
sg13
VIL-7
p13378
sg15
I1
sa(dp13379
g9
I393
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p13380
sg15
I4
sa(dp13381
g9
I237
sg39
VP05231
p13382
sg12
I13
sg13
Vinterleukin-6
p13383
sg15
I1
sa(dp13384
g9
I259
sg39
VP13232
p13385
sg12
I13
sg13
Vinterleukin-7
p13386
sg15
I1
sa(dp13387
g9
I339
sg39
VP41597
p13388
sg12
I5
sg13
VMCP-1
p13389
sg15
I1
sa(dp13390
g9
I209
sg39
g40
sg12
I3
sg13
VATX
p13391
sg15
I1
sa(dp13392
g9
I229
sg39
VP03950
p13393
sg12
I5
sg13
VANG-1
p13394
sg15
I1
sa(dp13395
g9
I214
sg39
VP03950
p13396
sg12
I13
sg13
Vangiopoetin-1
p13397
sg15
I1
sa(dp13398
g9
I252
sg39
VP05231
p13399
sg12
I4
sg13
VIL-6
p13400
sg15
I1
sa(dp13401
g9
I429
sg39
g40
sg12
I4
sg13
VVEGF
p13402
sg15
I1
sa(dp13403
g9
I281
sg39
VP60568
p13404
sg12
I13
sg13
Vinterleukin-8
p13405
sg15
I1
sa(dp13406
g9
I303
sg39
VP41597
p13407
sg12
I34
sg13
Vmonocyte chemoattractant protein-1
p13408
sg15
I3
sa(dp13409
g9
I296
sg39
VP60568
p13410
sg12
I4
sg13
VIL-8
p13411
sg15
I1
sasg6
(lp13412
sa(dp13413
g2
VPoly I:C induces IL-7 production, early inflammatory responses, and characteristic pathologies of SS-like dacryoadenitis in non-autoimmune-prone C57BL/6 mice.
p13414
sg4
(lp13415
(dp13416
g9
I17
sg39
VP13232
p13417
sg12
I4
sg13
VIL-7
p13418
sg15
I1
sasg6
(lp13419
(dp13420
g9
I40
sg10
VC1155266
p13421
sg12
I22
sg13
Vinflammatory responses
p13422
sg15
I2
sa(dp13423
g9
I106
sg10
VC0155223
p13424
sg12
I14
sg13
Vdacryoadenitis
p13425
sg15
I1
sa(dp13426
g9
I128
sg10
VC0443146
p13427
sg12
I10
sg13
Vautoimmune
p13428
sg15
I1
sasa(dp13429
g2
VDiagnosis of AIDS-NHL was preceded by a significantly elevated frequency of activated/germinal center-like CD19CD10CD71CD86AID B cells (P = 0.0072), elevated serum prevalence of the TLR2 ligand, and significantly elevated B-cell TLR2 expression (P = 0.0015), positively correlating with the frequency of activated/germinal center-like B cells (rho = 0.7273, P = 0.0144).
p13430
sg4
(lp13431
(dp13432
g9
I222
sg39
g40
sg12
I11
sg13
VB-cell TLR2
p13433
sg15
I2
sa(dp13434
g9
I182
sg39
g40
sg12
I11
sg13
VTLR2 ligand
p13435
sg15
I2
sasg6
(lp13436
(dp13437
g9
I18
sg10
VC0024305
p13438
sg12
I3
sg13
VNHL
p13439
sg15
I1
sasa(dp13440
g2
VTLR2-stimulated purified B cells exhibited the activated B-cell phenotype observed in HIV+ subjects before AIDS-NHL diagnosis.
p13441
sg4
(lp13442
(dp13443
g9
I0
sg39
g40
sg12
I4
sg13
VTLR2
p13444
sg15
I1
sasg6
(lp13445
(dp13446
g9
I112
sg10
VC0024305
p13447
sg12
I3
sg13
VNHL
p13448
sg15
I1
sasa(dp13449
g2
VThese results indicate that an elevated fraction of B cells display an activated/germinal center phenotype in those HIV+ subjects who go on to develop AIDS-NHL and suggest that TLR2-mediated activation may play a role in HIV infection-associated B-cell activation, potentially contributing to the genesis of AIDS-NHL.
p13450
sg4
(lp13451
(dp13452
g9
I177
sg39
g40
sg12
I4
sg13
VTLR2
p13453
sg15
I1
sasg6
(lp13454
(dp13455
g9
I156
sg10
VC0024305
p13456
sg12
I3
sg13
VNHL
p13457
sg15
I1
sa(dp13458
g9
I221
sg10
VC0019693
p13459
sg12
I13
sg13
VHIV infection
p13460
sg15
I2
sa(dp13461
g9
I156
sg10
VC0024305
p13462
sg12
I3
sg13
VNHL
p13463
sg15
I1
sasa(dp13464
g2
VThe regulatory role of AVP on the hypothalamic-pituitary-adrenal (HPA) axis suggests potential uses for AVP receptor modulators in various CNS indications, including depression, anxiety and post-traumatic stress disorder.
p13465
sg4
(lp13466
(dp13467
g9
I104
sg39
VP01185
p13468
sg12
I12
sg13
VAVP receptor
p13469
sg15
I2
sa(dp13470
g9
I23
sg39
VP01185
p13471
sg12
I3
sg13
VAVP
p13472
sg15
I1
sasg6
(lp13473
(dp13474
g9
I190
sg10
VC0038436
p13475
sg12
I30
sg13
Vpost-traumatic stress disorder
p13476
sg15
I3
sa(dp13477
g9
I166
sg10
VC0011581
p13478
sg12
I10
sg13
Vdepression
p13479
sg15
I1
sasa(dp13480
g2
VWhen POLN was ectopically overexpressed in human cells, it specifically coimmunoprecipitated with the homologous recombination factors BRCA1 and FANCJ, but not with previously suggested interaction partners (HELQ and members of the Fanconi anemia core complex).
p13481
sg4
(lp13482
(dp13483
g9
I208
sg39
g40
sg12
I4
sg13
VHELQ
p13484
sg15
I1
sa(dp13485
g9
I232
sg39
VP51587
p13486
sg12
I27
sg13
VFanconi anemia core complex
p13487
sg15
I4
sa(dp13488
g9
I145
sg39
g40
sg12
I5
sg13
VFANCJ
p13489
sg15
I1
sa(dp13490
g9
I102
sg39
VP19883
p13491
sg12
I38
sg13
Vhomologous recombination factors BRCA1
p13492
sg15
I4
sasg6
(lp13493
(dp13494
g9
I232
sg10
VC3469521
p13495
sg12
I14
sg13
VFanconi anemia
p13496
sg15
I2
sa(dp13497
g9
I145
sg10
VC1836860
p13498
sg12
I5
sg13
VFANCJ
p13499
sg15
I1
sasa(dp13500
g2
VMoreover, we obtained evidence for physical and functional interaction of POLN with factors belonging to the Fanconi anemia pathway, a master regulator of cross-link repair.
p13501
sg4
(lp13502
(dp13503
g9
I74
sg39
g40
sg12
I4
sg13
VPOLN
p13504
sg15
I1
sasg6
(lp13505
(dp13506
g9
I109
sg10
VC3469521
p13507
sg12
I14
sg13
VFanconi anemia
p13508
sg15
I2
sasa(dp13509
g2
VThe results indicate that the Pol n I component MV is an allergen for human beings as well as for mice, and useful as a diagnostic tool for chironomid allergy.
p13510
sg4
(lp13511
(dp13512
g9
I30
sg39
VP10266
p13513
sg12
I20
sg13
VPol n I component MV
p13514
sg15
I5
sasg6
(lp13515
(dp13516
g9
I151
sg10
VC0020517
p13517
sg12
I7
sg13
Vallergy
p13518
sg15
I1
sasa(dp13519
g2
VPrevalence of service receipt was highest among women in the highest family income category (&gt;400% of federal poverty level [FPL]) and among women with insurance coverage for each of the following: contraceptive services among women at risk for unintended pregnancy; medical services beyond advice to help achieve pregnancy; vaccinations (hepatitis B and human papillomavirus [HPV], ever; tetanus, past 10 years; influenza, past year); discussions with a health care professional about improving health before pregnancy and taking vitamins with folic acid; blood pressure and diabetes screening; discussions with a health care professional in the past year about diet, among those with obesity; discussions with a health care professional in the past year about smoking, among current smokers; Pap tests within the past 3 years; and mammograms within the past 2 years.
p13520
sg4
(lp13521
sg6
(lp13522
(dp13523
g9
I689
sg10
VC0028754
p13524
sg12
I7
sg13
Vobesity
p13525
sg15
I1
sa(dp13526
g9
I416
sg10
VC0021400
p13527
sg12
I9
sg13
Vinfluenza
p13528
sg15
I1
sa(dp13529
g9
I797
sg10
VC1863340
p13530
sg12
I3
sg13
VPap
p13531
sg15
I1
sa(dp13532
g9
I342
sg10
VC0019163
p13533
sg12
I11
sg13
Vhepatitis B
p13534
sg15
I2
sa(dp13535
g9
I579
sg10
VC0011849
p13536
sg12
I8
sg13
Vdiabetes
p13537
sg15
I1
sa(dp13538
g9
I392
sg10
VC0039614
p13539
sg12
I7
sg13
Vtetanus
p13540
sg15
I1
sasa(dp13541
g2
VHerein we describe a new phenotype associated with a mutation in exon 11 of the LMNA gene: hypertrophic cardiomyopathy, atrioventricular block, severe dyslipidemia and diabetes.
p13542
sg4
(lp13543
(dp13544
g9
I80
sg39
VP02545
p13545
sg12
I9
sg13
VLMNA gene
p13546
sg15
I2
sasg6
(lp13547
(dp13548
g9
I168
sg10
VC0011849
p13549
sg12
I8
sg13
Vdiabetes
p13550
sg15
I1
sa(dp13551
g9
I91
sg10
VC0007194
p13552
sg12
I27
sg13
Vhypertrophic cardiomyopathy
p13553
sg15
I2
sa(dp13554
g9
I120
sg10
VC0004245
p13555
sg12
I22
sg13
Vatrioventricular block
p13556
sg15
I2
sa(dp13557
g9
I151
sg10
VC0242339
p13558
sg12
I12
sg13
Vdyslipidemia
p13559
sg15
I1
sasa(dp13560
g2
VIndependent analysis of LMNA variants via the type 2 diabetes (T2D) Knowledge Portal showed that variant p.G602S associated significantly with type 2 diabetes (p = 0.02; odds ratio = 4.58), and was more frequent in African Americans (allele frequency 0.297%).
p13561
sg4
(lp13562
(dp13563
g9
I24
sg39
VP02545
p13564
sg12
I13
sg13
VLMNA variants
p13565
sg15
I2
sasg6
(lp13566
(dp13567
g9
I63
sg10
VC0011860
p13568
sg12
I3
sg13
VT2D
p13569
sg15
I1
sa(dp13570
g9
I46
sg10
VC0011860
p13571
sg12
I15
sg13
Vtype 2 diabetes
p13572
sg15
I3
sa(dp13573
g9
I46
sg10
VC0011860
p13574
sg12
I15
sg13
Vtype 2 diabetes
p13575
sg15
I3
sasa(dp13576
g2
VLipodystrophy is a rare disorder characterized by the complete or partial loss of subcutaneous adipose tissue, insulin resistance, diabetes mellitus and hyperlipidemia.Proteinuric renal disease is a prevalent feature of generalized lipodystrophy but rare in familial partial lipodystrophy.Patients carrying the c.1045C &gt; T missense LMNA mutation (p.R349W) may present with familial partial lipodystrophy, proteinuric nephropathy, cardiomyopathy and atypical myopathy.
p13577
sg4
(lp13578
(dp13579
g9
I111
sg39
VP01308
p13580
sg12
I7
sg13
Vinsulin
p13581
sg15
I1
sasg6
(lp13582
(dp13583
g9
I220
sg10
VC0221032
p13584
sg12
I25
sg13
Vgeneralized lipodystrophy
p13585
sg15
I2
sa(dp13586
g9
I131
sg10
VC0011849
p13587
sg12
I17
sg13
Vdiabetes mellitus
p13588
sg15
I2
sa(dp13589
g9
I258
sg10
VC0271694
p13590
sg12
I30
sg13
Vfamilial partial lipodystrophy
p13591
sg15
I3
sa(dp13592
g9
I439
sg10
VC0026848
p13593
sg12
I8
sg13
Vmyopathy
p13594
sg15
I1
sa(dp13595
g9
I420
sg10
VC0022658
p13596
sg12
I11
sg13
Vnephropathy
p13597
sg15
I1
sa(dp13598
g9
I433
sg10
VC0878544
p13599
sg12
I14
sg13
Vcardiomyopathy
p13600
sg15
I1
sa(dp13601
g9
I153
sg10
VC0020473
p13602
sg12
I14
sg13
Vhyperlipidemia
p13603
sg15
I1
sa(dp13604
g9
I180
sg10
VC0022658
p13605
sg12
I13
sg13
Vrenal disease
p13606
sg15
I2
sa(dp13607
g9
I111
sg10
VC0021655
p13608
sg12
I18
sg13
Vinsulin resistance
p13609
sg15
I2
sa(dp13610
g9
I19
sg10
VC0678236
p13611
sg12
I13
sg13
Vrare disorder
p13612
sg15
I2
sa(dp13613
g9
I258
sg10
VC0271694
p13614
sg12
I30
sg13
Vfamilial partial lipodystrophy
p13615
sg15
I3
sa(dp13616
g9
I0
sg10
VC0023787
p13617
sg12
I13
sg13
VLipodystrophy
p13618
sg15
I1
sasa(dp13619
g2
VBAT 5'-deiodinase activity was unaffected by propylthiouracil (PTU) and was elevated in hypothyroid rats, whereas EPI 5'-deiodinase was totally inhibited by PTU and was depressed in hypothyroidism.
p13620
sg4
(lp13621
(dp13622
g9
I114
sg39
VP10646
p13623
sg12
I17
sg13
VEPI 5'-deiodinase
p13624
sg15
I2
sa(dp13625
g9
I0
sg39
g40
sg12
I17
sg13
VBAT 5'-deiodinase
p13626
sg15
I2
sasg6
(lp13627
(dp13628
g9
I88
sg10
VC0020676
p13629
sg12
I11
sg13
Vhypothyroid
p13630
sg15
I1
sa(dp13631
g9
I114
sg10
VC0267963
p13632
sg12
I3
sg13
VEPI
p13633
sg15
I1
sa(dp13634
g9
I182
sg10
VC0020676
p13635
sg12
I14
sg13
Vhypothyroidism
p13636
sg15
I1
sasa(dp13637
g2
VHere, we report a novel mutation in ERCC8 gene in a 16-year-old boy who suffers from poor weight gain, short stature, microcephaly, intellectual disability, and photosensitivity.
p13638
sg4
(lp13639
(dp13640
g9
I36
sg39
VP01243
p13641
sg12
I10
sg13
VERCC8 gene
p13642
sg15
I2
sasg6
(lp13643
(dp13644
g9
I85
sg10
VC0231246
p13645
sg12
I16
sg13
Vpoor weight gain
p13646
sg15
I3
sa(dp13647
g9
I161
sg10
VC0393720
p13648
sg12
I16
sg13
Vphotosensitivity
p13649
sg15
I1
sa(dp13650
g9
I72
sg10
VC0683278
p13651
sg12
I7
sg13
Vsuffers
p13652
sg15
I1
sa(dp13653
g9
I118
sg10
VC0025958
p13654
sg12
I12
sg13
Vmicrocephaly
p13655
sg15
I1
sa(dp13656
g9
I132
sg10
VC0025362
p13657
sg12
I23
sg13
Vintellectual disability
p13658
sg15
I2
sa(dp13659
g9
I18
sg10
VC2985438
p13660
sg12
I14
sg13
Vnovel mutation
p13661
sg15
I2
sa(dp13662
g9
I103
sg10
VC0013336
p13663
sg12
I13
sg13
Vshort stature
p13664
sg15
I2
sasa(dp13665
g2
VCockayne syndrome is caused by biallelic ERCC8 (CSA) or ERCC6 (CSB) mutations and is characterized by growth restriction, microcephaly, developmental delay, and premature pathological aging.
p13666
sg4
(lp13667
(dp13668
g9
I41
sg39
VP01243
p13669
sg12
I11
sg13
VERCC8 (CSA)
p13670
sg15
I2
sa(dp13671
g9
I56
sg39
g40
sg12
I5
sg13
VERCC6
p13672
sg15
I1
sa(dp13673
g9
I63
sg39
VP35548
p13674
sg12
I3
sg13
VCSB
p13675
sg15
I1
sasg6
(lp13676
(dp13677
g9
I122
sg10
VC0025958
p13678
sg12
I12
sg13
Vmicrocephaly
p13679
sg15
I1
sa(dp13680
g9
I0
sg10
VC0009207
p13681
sg12
I17
sg13
VCockayne syndrome
p13682
sg15
I2
sa(dp13683
g9
I48
sg10
VC0751039
p13684
sg12
I3
sg13
VCSA
p13685
sg15
I1
sa(dp13686
g9
I63
sg10
VC1858160
p13687
sg12
I3
sg13
VCSB
p13688
sg15
I1
sa(dp13689
g9
I21
sg10
VC0751039
p13690
sg12
I25
sg13
Vcaused by biallelic ERCC8
p13691
sg15
I4
sa(dp13692
g9
I136
sg10
VC0424605
p13693
sg12
I19
sg13
Vdevelopmental delay
p13694
sg15
I2
sasa(dp13695
g2
VThis study included 54 beta-thalassemia major patients divided into 2 groups; group A consisted of 28 patients who have thrombocytosis secondary to a previous splenectomy and group B comprised of 26 patients who did not have a splenectomy with normal platelet count, as well as a control group of 30 healthy individuals.
p13696
sg4
(lp13697
sg6
(lp13698
(dp13699
g9
I28
sg10
VC0002875
p13700
sg12
I17
sg13
Vthalassemia major
p13701
sg15
I2
sa(dp13702
g9
I120
sg10
VC0836924
p13703
sg12
I14
sg13
Vthrombocytosis
p13704
sg15
I1
sa(dp13705
g9
I175
sg10
VC0348801
p13706
sg12
I7
sg13
Vgroup B
p13707
sg15
I2
sasa(dp13708
g2
VA microarray analysis of the B-1 lymphocytes revealed that IL-10 deficiency is associated with down-regulation of the genes that code for claudin-10, a protein that is involved in cell-to-cell contact and that has been linked to lung adenocarcinoma.
p13709
sg4
(lp13710
(dp13711
g9
I138
sg39
VP78369
p13712
sg12
I10
sg13
Vclaudin-10
p13713
sg15
I1
sasg6
(lp13714
(dp13715
g9
I229
sg10
VC0152013
p13716
sg12
I19
sg13
Vlung adenocarcinoma
p13717
sg15
I2
sasa(dp13718
g2
VThus, our findings suggest that the axis IL-10/claudin-10 is a promising target for the development of therapeutic agents against aggressive melanoma.
p13719
sg4
(lp13720
(dp13721
g9
I47
sg39
VP78369
p13722
sg12
I10
sg13
Vclaudin-10
p13723
sg15
I1
sasg6
(lp13724
(dp13725
g9
I141
sg10
VC0025202
p13726
sg12
I8
sg13
Vmelanoma
p13727
sg15
I1
sa(dp13728
g9
I130
sg10
VC0001807
p13729
sg12
I10
sg13
Vaggressive
p13730
sg15
I1
sasa(dp13731
g2
VTo explore the expression distinction of the cell adhesion proteins claudin-10,-14,-17 and E-cadherin in the adjacent non-neoplastic tissues and gastric cancer tissues, 50 gastric cancer tissues and 50 samples of adjacent non-neoplastic tissues adjacent to the tumors were examined for expression of claudin-10,-14,-17 and E-cadherin by streptavidin-perosidase immunohistochemical staining method.
p13732
sg4
(lp13733
(dp13734
g9
I68
sg39
VP78369
p13735
sg12
I18
sg13
Vclaudin-10,-14,-17
p13736
sg15
I1
sa(dp13737
g9
I337
sg39
g40
sg12
I23
sg13
Vstreptavidin-perosidase
p13738
sg15
I1
sa(dp13739
g9
I68
sg39
VP78369
p13740
sg12
I18
sg13
Vclaudin-10,-14,-17
p13741
sg15
I1
sa(dp13742
g9
I91
sg39
VP12830
p13743
sg12
I10
sg13
VE-cadherin
p13744
sg15
I1
sa(dp13745
g9
I91
sg39
VP12830
p13746
sg12
I10
sg13
VE-cadherin
p13747
sg15
I1
sasg6
(lp13748
(dp13749
g9
I145
sg10
VC0024623
p13750
sg12
I14
sg13
Vgastric cancer
p13751
sg15
I2
sa(dp13752
g9
I261
sg10
VC0027651
p13753
sg12
I6
sg13
Vtumors
p13754
sg15
I1
sa(dp13755
g9
I50
sg10
VC0001511
p13756
sg12
I8
sg13
Vadhesion
p13757
sg15
I1
sa(dp13758
g9
I145
sg10
VC0024623
p13759
sg12
I14
sg13
Vgastric cancer
p13760
sg15
I2
sasa(dp13761
g2
VThe positive expression rates of claudin-10 in gastric cancer tissues and adjacent non-neoplastic tissues were 24% and 72% respectively (P &lt; 0.01).
p13762
sg4
(lp13763
(dp13764
g9
I33
sg39
VP78369
p13765
sg12
I10
sg13
Vclaudin-10
p13766
sg15
I1
sasg6
(lp13767
(dp13768
g9
I47
sg10
VC0024623
p13769
sg12
I14
sg13
Vgastric cancer
p13770
sg15
I2
sasa(dp13771
g2
VIn contrast, the positive expression rates of claudin-14 in gastric cancer tissues and adjacent non-neoplastic tissues were 58% and 24% respectively (P = 0.015 &lt; 0.05) Thus in our study, the expression of E-cadherin, claudin-10, and claudin-17 was down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated.
p13772
sg4
(lp13773
(dp13774
g9
I46
sg39
g40
sg12
I10
sg13
Vclaudin-14
p13775
sg15
I1
sa(dp13776
g9
I208
sg39
VP12830
p13777
sg12
I10
sg13
VE-cadherin
p13778
sg15
I1
sa(dp13779
g9
I236
sg39
VP56750
p13780
sg12
I10
sg13
Vclaudin-17
p13781
sg15
I1
sa(dp13782
g9
I220
sg39
VP78369
p13783
sg12
I10
sg13
Vclaudin-10
p13784
sg15
I1
sasg6
(lp13785
(dp13786
g9
I60
sg10
VC0024623
p13787
sg12
I14
sg13
Vgastric cancer
p13788
sg15
I2
sa(dp13789
g9
I60
sg10
VC0024623
p13790
sg12
I14
sg13
Vgastric cancer
p13791
sg15
I2
sasa(dp13792
g2
VOur study reveals that the expression of E-cadherin, claudin-10, and claudin-17 were down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated and correlation between claudins and E-cadherin expression with lymphatic metastasis were observed.
p13793
sg4
(lp13794
(dp13795
g9
I69
sg39
VP56750
p13796
sg12
I10
sg13
Vclaudin-17
p13797
sg15
I1
sa(dp13798
g9
I41
sg39
VP12830
p13799
sg12
I10
sg13
VE-cadherin
p13800
sg15
I1
sa(dp13801
g9
I41
sg39
VP12830
p13802
sg12
I10
sg13
VE-cadherin
p13803
sg15
I1
sa(dp13804
g9
I53
sg39
VP78369
p13805
sg12
I10
sg13
Vclaudin-10
p13806
sg15
I1
sasg6
(lp13807
(dp13808
g9
I103
sg10
VC0024623
p13809
sg12
I14
sg13
Vgastric cancer
p13810
sg15
I2
sa(dp13811
g9
I241
sg10
VC0024232
p13812
sg12
I20
sg13
Vlymphatic metastasis
p13813
sg15
I2
sasa(dp13814
g2
VFour genes (MMP-2, c-fos, claudin 1 (CLDN1) and claudin 10(CLDN10)) were correlated with the results of microarray and real time RT-PCR analyses for the gene-expression data in samples from 41 patients with lung adenocarcinoma.
p13815
sg4
(lp13816
(dp13817
g9
I12
sg39
VP08253
p13818
sg12
I5
sg13
VMMP-2
p13819
sg15
I1
sa(dp13820
g9
I48
sg39
VP78369
p13821
sg12
I10
sg13
Vclaudin 10
p13822
sg15
I2
sa(dp13823
g9
I19
sg39
VP01100
p13824
sg12
I5
sg13
Vc-fos
p13825
sg15
I1
sa(dp13826
g9
I26
sg39
g40
sg12
I9
sg13
Vclaudin 1
p13827
sg15
I2
sa(dp13828
g9
I37
sg39
g40
sg12
I5
sg13
VCLDN1
p13829
sg15
I1
sa(dp13830
g9
I59
sg39
VP78369
p13831
sg12
I6
sg13
VCLDN10
p13832
sg15
I1
sasg6
(lp13833
(dp13834
g9
I207
sg10
VC0152013
p13835
sg12
I19
sg13
Vlung adenocarcinoma
p13836
sg15
I2
sasa(dp13837
g2
VImmunohistochemical staining for these genes in samples from 81 cases of lung adenocarcinoma demonstrated the expressions of CLDN1 and CLDN10 were correlated with overall survival of patients with lung adenocarcinoma.
p13838
sg4
(lp13839
(dp13840
g9
I135
sg39
VP78369
p13841
sg12
I6
sg13
VCLDN10
p13842
sg15
I1
sa(dp13843
g9
I125
sg39
g40
sg12
I5
sg13
VCLDN1
p13844
sg15
I1
sasg6
(lp13845
(dp13846
g9
I73
sg10
VC0152013
p13847
sg12
I19
sg13
Vlung adenocarcinoma
p13848
sg15
I2
sa(dp13849
g9
I73
sg10
VC0152013
p13850
sg12
I19
sg13
Vlung adenocarcinoma
p13851
sg15
I2
sasa(dp13852
g2
VOverexpression of CLDN1 and CLDN10 indicates a favorable prognosis for overall survival in some patients with lung adenocarcinoma.
p13853
sg4
(lp13854
(dp13855
g9
I18
sg39
g40
sg12
I5
sg13
VCLDN1
p13856
sg15
I1
sa(dp13857
g9
I28
sg39
VP78369
p13858
sg12
I6
sg13
VCLDN10
p13859
sg15
I1
sasg6
(lp13860
(dp13861
g9
I110
sg10
VC0152013
p13862
sg12
I19
sg13
Vlung adenocarcinoma
p13863
sg15
I2
sasa(dp13864
g2
VFurthermore, circadian regulation of Gnaz was disturbed in the db/db mouse, a model of diabetic retinopathy.
p13865
sg4
(lp13866
sg6
(lp13867
(dp13868
g9
I87
sg10
VC0011884
p13869
sg12
I20
sg13
Vdiabetic retinopathy
p13870
sg15
I2
sasa(dp13871
g2
VThe highest rates of somatic, non-synonymous mutations were found in GNG10 and GNAZ, neither of which has been previously reported to be mutated in melanoma.
p13872
sg4
(lp13873
(dp13874
g9
I69
sg39
VP50151
p13875
sg12
I5
sg13
VGNG10
p13876
sg15
I1
sa(dp13877
g9
I79
sg39
VP19086
p13878
sg12
I4
sg13
VGNAZ
p13879
sg15
I1
sasg6
(lp13880
(dp13881
g9
I148
sg10
VC0025202
p13882
sg12
I8
sg13
Vmelanoma
p13883
sg15
I1
sasa(dp13884
g2
VVarious other protein products of genes associated with bipolar disorder either bind to or are affected by phosphatidyl-inositol phosphate products of this pathway (ADBRK2, HIP1R, KCNQ2, RGS4, WFS1), are associated with its constituent elements (BCR, DUSP6, FAT, GNAZ) or are downstream targets of this signalling cascade (DPYSL2, DRD3, GAD1, G6PD, GCH1, KCNQ2, NOS3, SLC6A3, SLC6A4, SST, TH, TIMELESS).
p13885
sg4
(lp13886
(dp13887
g9
I343
sg39
VP11441
p13888
sg12
I4
sg13
VG6PD
p13889
sg15
I1
sa(dp13890
g9
I193
sg39
g40
sg12
I4
sg13
VWFS1
p13891
sg15
I1
sa(dp13892
g9
I384
sg39
VP61278
p13893
sg12
I3
sg13
VSST
p13894
sg15
I1
sa(dp13895
g9
I251
sg39
g40
sg12
I5
sg13
VDUSP6
p13896
sg15
I1
sa(dp13897
g9
I263
sg39
VP19086
p13898
sg12
I4
sg13
VGNAZ
p13899
sg15
I1
sa(dp13900
g9
I337
sg39
g40
sg12
I4
sg13
VGAD1
p13901
sg15
I1
sa(dp13902
g9
I258
sg39
g40
sg12
I3
sg13
VFAT
p13903
sg15
I1
sa(dp13904
g9
I323
sg39
g40
sg12
I6
sg13
VDPYSL2
p13905
sg15
I1
sa(dp13906
g9
I349
sg39
VP30793
p13907
sg12
I4
sg13
VGCH1
p13908
sg15
I1
sa(dp13909
g9
I393
sg39
VP60174
p13910
sg12
I8
sg13
VTIMELESS
p13911
sg15
I1
sa(dp13912
g9
I362
sg39
VP60323
p13913
sg12
I4
sg13
VNOS3
p13914
sg15
I1
sa(dp13915
g9
I376
sg39
VP31645
p13916
sg12
I6
sg13
VSLC6A4
p13917
sg15
I1
sa(dp13918
g9
I368
sg39
g40
sg12
I6
sg13
VSLC6A3
p13919
sg15
I1
sa(dp13920
g9
I246
sg39
VP11274
p13921
sg12
I3
sg13
VBCR
p13922
sg15
I1
sa(dp13923
g9
I180
sg39
g40
sg12
I5
sg13
VKCNQ2
p13924
sg15
I1
sa(dp13925
g9
I331
sg39
VP35462
p13926
sg12
I4
sg13
VDRD3
p13927
sg15
I1
sa(dp13928
g9
I173
sg39
g40
sg12
I5
sg13
VHIP1R
p13929
sg15
I1
sa(dp13930
g9
I187
sg39
VP49798
p13931
sg12
I4
sg13
VRGS4
p13932
sg15
I1
sa(dp13933
g9
I180
sg39
g40
sg12
I5
sg13
VKCNQ2
p13934
sg15
I1
sasg6
(lp13935
(dp13936
g9
I56
sg10
VC0005586
p13937
sg12
I16
sg13
Vbipolar disorder
p13938
sg15
I2
sa(dp13939
g9
I193
sg10
VC0043207
p13940
sg12
I4
sg13
VWFS1
p13941
sg15
I1
sasa(dp13942
g2
VIn a recent study we found that the risk for unilateral retinoblastoma in offspring is 4 fold higher in women that are homozygotes for the 19 bp deletion in the DHFR gene and took folic acid supplement during pregnancy.
p13943
sg4
(lp13944
(dp13945
g9
I161
sg39
VP00374
p13946
sg12
I9
sg13
VDHFR gene
p13947
sg15
I2
sasg6
(lp13948
(dp13949
g9
I45
sg10
VC0854915
p13950
sg12
I25
sg13
Vunilateral retinoblastoma
p13951
sg15
I2
sasa(dp13952
g2
VRetinoblastoma protein (pRb) was highly phosphorylated but p107 was upregulated, and the expression of E2f target genes was dysregulated as shown by upregulation of Cdc6 but downregulation of cyclin E, dihydrofolate reductase (dhfr), Cdc25a and B-Myb in chondrocytes of K6(H)/D1(H) mice.
p13953
sg4
(lp13954
(dp13955
g9
I103
sg39
VP01893
p13956
sg12
I16
sg13
VE2f target genes
p13957
sg15
I3
sa(dp13958
g9
I192
sg39
VP24864
p13959
sg12
I8
sg13
Vcyclin E
p13960
sg15
I2
sa(dp13961
g9
I234
sg39
VP30304
p13962
sg12
I6
sg13
VCdc25a
p13963
sg15
I1
sa(dp13964
g9
I227
sg39
VP00374
p13965
sg12
I4
sg13
Vdhfr
p13966
sg15
I1
sa(dp13967
g9
I0
sg39
g40
sg12
I22
sg13
VRetinoblastoma protein
p13968
sg15
I2
sa(dp13969
g9
I245
sg39
VP10244
p13970
sg12
I5
sg13
VB-Myb
p13971
sg15
I1
sa(dp13972
g9
I24
sg39
g40
sg12
I3
sg13
VpRb
p13973
sg15
I1
sa(dp13974
g9
I165
sg39
g40
sg12
I4
sg13
VCdc6
p13975
sg15
I1
sa(dp13976
g9
I59
sg39
VP28749
p13977
sg12
I4
sg13
Vp107
p13978
sg15
I1
sa(dp13979
g9
I202
sg39
VP00374
p13980
sg12
I23
sg13
Vdihydrofolate reductase
p13981
sg15
I2
sasg6
(lp13982
(dp13983
g9
I0
sg10
VC0035335
p13984
sg12
I14
sg13
VRetinoblastoma
p13985
sg15
I1
sasa(dp13986
g2
VThe authors used a case-control study design to examine the association between retinoblastoma risk and maternal variations in the folate-metabolizing genes methylenetetrahydrofolate reductase (MTHFR) (a cytosine-to-thymine substitution at nucleotide 677 [MTHFR677C-&gt;T]; reference single nucleotide polymorphism rs1801133) and dihydrofolate reductase (DHFR) (a 19-base-pair deletion of intron 1a [DHFR19bpdel]; rs70991108).
p13987
sg4
(lp13988
(dp13989
g9
I330
sg39
VP00374
p13990
sg12
I23
sg13
Vdihydrofolate reductase
p13991
sg15
I2
sa(dp13992
g9
I355
sg39
VP00374
p13993
sg12
I4
sg13
VDHFR
p13994
sg15
I1
sa(dp13995
g9
I194
sg39
VP42898
p13996
sg12
I5
sg13
VMTHFR
p13997
sg15
I1
sa(dp13998
g9
I131
sg39
VP42898
p13999
sg12
I61
sg13
Vfolate-metabolizing genes methylenetetrahydrofolate reductase
p14000
sg15
I4
sasg6
(lp14001
(dp14002
g9
I80
sg10
VC0035335
p14003
sg12
I14
sg13
Vretinoblastoma
p14004
sg15
I1
sasa(dp14005
g2
VThe risk of having a child with unilateral retinoblastoma was associated with maternal homozygosity for DHFR19bpdel (odds ratio, 3.78; 95% confidence interval, 1.89-7.55; P = .0002), even after controlling for the child's DHFR19bpdel genotype (odds ratio, 2.81; 95% confidence interval, 1.32-5.99; P = .0073).
p14006
sg4
(lp14007
sg6
(lp14008
(dp14009
g9
I32
sg10
VC0854915
p14010
sg12
I25
sg13
Vunilateral retinoblastoma
p14011
sg15
I2
sasa(dp14012
g2
VMaternal homozygosity for a polymorphism in the DHFR gene necessary for converting synthetic folic acid into biologic folate was associated with an increased risk for retinoblastoma.
p14013
sg4
(lp14014
(dp14015
g9
I48
sg39
VP00374
p14016
sg12
I9
sg13
VDHFR gene
p14017
sg15
I2
sasg6
(lp14018
(dp14019
g9
I167
sg10
VC0035335
p14020
sg12
I14
sg13
Vretinoblastoma
p14021
sg15
I1
sasa(dp14022
g2
VTo explore the role of Major Vault Protein (MVP) in oral cavity squamous cell carcinoma patients.
p14023
sg4
(lp14024
(dp14025
g9
I23
sg39
g40
sg12
I19
sg13
VMajor Vault Protein
p14026
sg15
I3
sa(dp14027
g9
I44
sg39
g40
sg12
I3
sg13
VMVP
p14028
sg15
I1
sasg6
(lp14029
(dp14030
g9
I23
sg10
VC0026267
p14031
sg12
I19
sg13
VMajor Vault Protein
p14032
sg15
I3
sa(dp14033
g9
I44
sg10
VC0026267
p14034
sg12
I3
sg13
VMVP
p14035
sg15
I1
sa(dp14036
g9
I52
sg10
VC0585362
p14037
sg12
I35
sg13
Voral cavity squamous cell carcinoma
p14038
sg15
I5
sasa(dp14039
g2
VMolecular analysis of the GYS2 gene was not feasible, but this particular gene was included in the panel of hypoglycemia of whole exome sequencing (WES) which was at our disposal.
p14040
sg4
(lp14041
(dp14042
g9
I26
sg39
VP54840
p14043
sg12
I9
sg13
VGYS2 gene
p14044
sg15
I2
sasg6
(lp14045
(dp14046
g9
I108
sg10
VC0020615
p14047
sg12
I12
sg13
Vhypoglycemia
p14048
sg15
I1
sasa(dp14049
g2
VTo understand the frequency of GSD0 in patients presenting with ketotic hypoglycaemia and to report a novel mutation in the GYS2 gene.
p14050
sg4
(lp14051
(dp14052
g9
I124
sg39
VP54840
p14053
sg12
I9
sg13
VGYS2 gene
p14054
sg15
I2
sasg6
(lp14055
(dp14056
g9
I64
sg10
VC0271713
p14057
sg12
I21
sg13
Vketotic hypoglycaemia
p14058
sg15
I2
sa(dp14059
g9
I102
sg10
VC2985438
p14060
sg12
I14
sg13
Vnovel mutation
p14061
sg15
I2
sasa(dp14062
g2
VThe GYS2 gene was sequenced in 50 patients diagnosed with ketotic hypoglycaemia.
p14063
sg4
(lp14064
(dp14065
g9
I4
sg39
VP54840
p14066
sg12
I9
sg13
VGYS2 gene
p14067
sg15
I2
sasg6
(lp14068
(dp14069
g9
I58
sg10
VC0271713
p14070
sg12
I21
sg13
Vketotic hypoglycaemia
p14071
sg15
I2
sasa(dp14072
g2
VSequencing of the GYS2 gene is more likely to be positive in patients with fasting ketotic hypoglycaemia and concomitant postprandial hyperglycaemia with hyperlactataemia.
p14073
sg4
(lp14074
(dp14075
g9
I18
sg39
VP54840
p14076
sg12
I9
sg13
VGYS2 gene
p14077
sg15
I2
sasg6
(lp14078
(dp14079
g9
I83
sg10
VC0271713
p14080
sg12
I21
sg13
Vketotic hypoglycaemia
p14081
sg15
I2
sa(dp14082
g9
I134
sg10
VC0020456
p14083
sg12
I14
sg13
Vhyperglycaemia
p14084
sg15
I1
sasa(dp14085
g2
VBiochemical evaluation as well as direct sequencing of exons and exon-intron boundary regions of the GYS2 gene were performed in a patient presenting fasting hypoglycemia and postprandial hyperglycemia and her parents.
p14086
sg4
(lp14087
(dp14088
g9
I101
sg39
VP54840
p14089
sg12
I9
sg13
VGYS2 gene
p14090
sg15
I2
sasg6
(lp14091
(dp14092
g9
I188
sg10
VC0020456
p14093
sg12
I13
sg13
Vhyperglycemia
p14094
sg15
I1
sa(dp14095
g9
I150
sg10
VC0271708
p14096
sg12
I20
sg13
Vfasting hypoglycemia
p14097
sg15
I2
sasa(dp14098
g2
VA 7 year-old boy presenting with growth retardation, fasting hypoglycemia and ketoacidosis was diagnosed as having both idiopathic growth hormone (GH) deficiency and hepatic glycogen synthase (GS) deficiency caused by a homozygous mutation in exon 5 of the liver glycogen synthase gene (GYS-2).
p14099
sg4
(lp14100
(dp14101
g9
I120
sg39
VP01242
p14102
sg12
I25
sg13
Vidiopathic growth hormone
p14103
sg15
I3
sa(dp14104
g9
I287
sg39
VP13807
p14105
sg12
I5
sg13
VGYS-2
p14106
sg15
I1
sa(dp14107
g9
I263
sg39
VP13807
p14108
sg12
I22
sg13
Vglycogen synthase gene
p14109
sg15
I3
sa(dp14110
g9
I193
sg39
VP15104
p14111
sg12
I2
sg13
VGS
p14112
sg15
I1
sa(dp14113
g9
I166
sg39
g40
sg12
I25
sg13
Vhepatic glycogen synthase
p14114
sg15
I3
sasg6
(lp14115
(dp14116
g9
I53
sg10
VC0271708
p14117
sg12
I20
sg13
Vfasting hypoglycemia
p14118
sg15
I2
sa(dp14119
g9
I78
sg10
VC0220982
p14120
sg12
I12
sg13
Vketoacidosis
p14121
sg15
I1
sa(dp14122
g9
I33
sg10
VC0151686
p14123
sg12
I18
sg13
Vgrowth retardation
p14124
sg15
I2
sasa(dp14125
g2
VGPB dosed at 6 mL BID lowered fasting ammonia levels in cirrhotic patients with HE as compared with baseline, was better tolerated than 9 mL BID, and is appropriate for further evaluation in patients with cirrhosis and episodic HE.
p14126
sg4
(lp14127
sg6
(lp14128
(dp14129
g9
I205
sg10
VC0023890
p14130
sg12
I9
sg13
Vcirrhosis
p14131
sg15
I1
sasa(dp14132
g2
VGPB reduced HE events as well as ammonia in patients with cirrhosis and HE and its safety profile was similar to placebo.
p14133
sg4
(lp14134
sg6
(lp14135
(dp14136
g9
I58
sg10
VC0023890
p14137
sg12
I9
sg13
Vcirrhosis
p14138
sg15
I1
sasa(dp14139
g2
VIn vitro and clinical studies have been performed to assess GPB digestion, safety, and pharmacology in healthy adults and individuals with cirrhosis.
p14140
sg4
(lp14141
sg6
(lp14142
(dp14143
g9
I139
sg10
VC0023890
p14144
sg12
I9
sg13
Vcirrhosis
p14145
sg15
I1
sasa(dp14146
g2
VGPB exhibits delayed release characteristics, presumably reflecting gradual PBA release by pancreatic lipases, and is well tolerated in adults with cirrhosis, suggesting that further clinical testing for HE is warranted.
p14147
sg4
(lp14148
(dp14149
g9
I0
sg39
VP06028
p14150
sg12
I3
sg13
VGPB
p14151
sg15
I1
sa(dp14152
g9
I102
sg39
VP04118
p14153
sg12
I7
sg13
Vlipases
p14154
sg15
I1
sasg6
(lp14155
(dp14156
g9
I148
sg10
VC0023890
p14157
sg12
I9
sg13
Vcirrhosis
p14158
sg15
I1
sasa(dp14159
g2
VHowever, the role of S1PR1 in the progression of human acute myeloid leukemia (AML) remains to be fully elucidated.
p14160
sg4
(lp14161
(dp14162
g9
I21
sg39
VP21453
p14163
sg12
I5
sg13
VS1PR1
p14164
sg15
I1
sasg6
(lp14165
(dp14166
g9
I79
sg10
VC0023467
p14167
sg12
I3
sg13
VAML
p14168
sg15
I1
sa(dp14169
g9
I55
sg10
VC0023467
p14170
sg12
I22
sg13
Vacute myeloid leukemia
p14171
sg15
I3
sasa(dp14172
g2
VUsing overexpression and RNA interference knockdown assays, it was shown that the expression of S1PR1 in several human myeloid leukemia cell lines contributed to the suppression of cell apoptosis and promotion of cell proliferation.
p14173
sg4
(lp14174
(dp14175
g9
I96
sg39
VP21453
p14176
sg12
I5
sg13
VS1PR1
p14177
sg15
I1
sasg6
(lp14178
(dp14179
g9
I218
sg10
VC0334094
p14180
sg12
I13
sg13
Vproliferation
p14181
sg15
I1
sa(dp14182
g9
I166
sg10
VC0221103
p14183
sg12
I11
sg13
Vsuppression
p14184
sg15
I1
sa(dp14185
g9
I119
sg10
VC0023470
p14186
sg12
I16
sg13
Vmyeloid leukemia
p14187
sg15
I2
sasa(dp14188
g2
VCirculating chronic lymphocytic leukemia (CLL) cells display an abnormal increase in the surface levels of the homing receptors CCR7 and CXCR4 concomitant with low S1P receptor 1 (S1P1) expression.
p14189
sg4
(lp14190
(dp14191
g9
I128
sg39
VP32248
p14192
sg12
I4
sg13
VCCR7
p14193
sg15
I1
sa(dp14194
g9
I164
sg39
g40
sg12
I14
sg13
VS1P receptor 1
p14195
sg15
I3
sa(dp14196
g9
I137
sg39
VP61073
p14197
sg12
I5
sg13
VCXCR4
p14198
sg15
I1
sa(dp14199
g9
I180
sg39
g40
sg12
I4
sg13
VS1P1
p14200
sg15
I1
sasg6
(lp14201
(dp14202
g9
I12
sg10
VC0023434
p14203
sg12
I28
sg13
Vchronic lymphocytic leukemia
p14204
sg15
I3
sa(dp14205
g9
I42
sg10
VC0023434
p14206
sg12
I3
sg13
VCLL
p14207
sg15
I1
sasa(dp14208
g2
VPrevious work in our laboratory identified keratin 17 (K17) as a specific and sensitive biomarker for high-grade squamous intraepithelial lesions and cervical squamous cell carcinoma (SCC).
p14209
sg4
(lp14210
(dp14211
g9
I55
sg39
VP02533
p14212
sg12
I3
sg13
VK17
p14213
sg15
I1
sa(dp14214
g9
I43
sg39
VP02533
p14215
sg12
I10
sg13
Vkeratin 17
p14216
sg15
I2
sasg6
(lp14217
(dp14218
g9
I150
sg10
VC0279671
p14219
sg12
I32
sg13
Vcervical squamous cell carcinoma
p14220
sg15
I4
sasa(dp14221
g2
VIn this study, we show that high expression of keratin-17 (K17) predicts poor outcome in patients with cervical cancer, at early or late stages of disease, surpassing in accuracy either tumor staging or loss of p27(KIP1) as a negative prognostic marker in this setting.
p14222
sg4
(lp14223
(dp14224
g9
I47
sg39
VP02533
p14225
sg12
I10
sg13
Vkeratin-17
p14226
sg15
I1
sa(dp14227
g9
I211
sg39
VP40305
p14228
sg12
I3
sg13
Vp27
p14229
sg15
I1
sa(dp14230
g9
I59
sg39
VP02533
p14231
sg12
I3
sg13
VK17
p14232
sg15
I1
sa(dp14233
g9
I215
sg39
VP46527
p14234
sg12
I4
sg13
VKIP1
p14235
sg15
I1
sasg6
(lp14236
(dp14237
g9
I103
sg10
VC0302592
p14238
sg12
I15
sg13
Vcervical cancer
p14239
sg15
I2
sa(dp14240
g9
I186
sg10
VC0027651
p14241
sg12
I5
sg13
Vtumor
p14242
sg15
I1
sasa(dp14243
g2
VIn summary, both KRT4 and KRT17 expressions are related to the histopathology of the cervical squamous mucosa; KRT17 is highly overexpressed in immature squamous metaplasia, in HSIL, and in squamous cell carcinoma and the level of KRT17 in squamous cell carcinoma may help to identify patients who are at greatest risk for cervical cancer mortality.
p14244
sg4
(lp14245
(dp14246
g9
I17
sg39
VP19013
p14247
sg12
I4
sg13
VKRT4
p14248
sg15
I1
sasg6
(lp14249
(dp14250
g9
I323
sg10
VC0302592
p14251
sg12
I15
sg13
Vcervical cancer
p14252
sg15
I2
sa(dp14253
g9
I153
sg10
VC0025570
p14254
sg12
I19
sg13
Vsquamous metaplasia
p14255
sg15
I2
sa(dp14256
g9
I177
sg10
VC0333875
p14257
sg12
I4
sg13
VHSIL
p14258
sg15
I1
sa(dp14259
g9
I190
sg10
VC0007137
p14260
sg12
I23
sg13
Vsquamous cell carcinoma
p14261
sg15
I3
sa(dp14262
g9
I190
sg10
VC0007137
p14263
sg12
I23
sg13
Vsquamous cell carcinoma
p14264
sg15
I3
sasa(dp14265
g2
VP2X4 receptors in microglia are up-regulated in epilepsy and in neuropathic pain; that is to say, their total and/or PM expression levels increase.
p14266
sg4
(lp14267
(dp14268
g9
I0
sg39
g40
sg12
I14
sg13
VP2X4 receptors
p14269
sg15
I2
sasg6
(lp14270
(dp14271
g9
I48
sg10
VC0014544
p14272
sg12
I8
sg13
Vepilepsy
p14273
sg15
I1
sa(dp14274
g9
I64
sg10
VC0027796
p14275
sg12
I16
sg13
Vneuropathic pain
p14276
sg15
I2
sasa(dp14277
g2
VExpression of several members of the family including P2X2, P2X4, and P2X7 receptors has been reported to be altered in the hippocampus following status epilepticus.
p14278
sg4
(lp14279
(dp14280
g9
I70
sg39
g40
sg12
I14
sg13
VP2X7 receptors
p14281
sg15
I2
sasg6
(lp14282
(dp14283
g9
I146
sg10
VC0038220
p14284
sg12
I18
sg13
Vstatus epilepticus
p14285
sg15
I2
sasa(dp14286
g2
VRecent work also found altered neuronal injury and inflammation after status epilepticus in mice lacking the P2X4 receptor.
p14287
sg4
(lp14288
(dp14289
g9
I109
sg39
g40
sg12
I13
sg13
VP2X4 receptor
p14290
sg15
I2
sasg6
(lp14291
(dp14292
g9
I70
sg10
VC0038220
p14293
sg12
I18
sg13
Vstatus epilepticus
p14294
sg15
I2
sa(dp14295
g9
I51
sg10
VC0021368
p14296
sg12
I12
sg13
Vinflammation
p14297
sg15
I1
sasa(dp14298
g2
VIn this study, we investigated the potential involvement of P2X4R in microglial functions in a model of kainate (KA)-induced status epilepticus (SE).
p14299
sg4
(lp14300
(dp14301
g9
I60
sg39
g40
sg12
I5
sg13
VP2X4R
p14302
sg15
I1
sasg6
(lp14303
(dp14304
g9
I125
sg10
VC0038220
p14305
sg12
I18
sg13
Vstatus epilepticus
p14306
sg15
I2
sa(dp14307
g9
I145
sg10
VC0038220
p14308
sg12
I2
sg13
VSE
p14309
sg15
I1
sasa(dp14310
g2
VHere we show that, in the seizure-sensitive (SS) gerbil hippocampus, a recognized genetic epilepsy model, the expressions of both P2X2 and P2X4 receptors are markedly decreased as compared with that in the seizure-resistant (SR) gerbil.
p14311
sg4
(lp14312
(dp14313
g9
I139
sg39
g40
sg12
I14
sg13
VP2X4 receptors
p14314
sg15
I2
sasg6
(lp14315
(dp14316
g9
I26
sg10
VC0036572
p14317
sg12
I7
sg13
Vseizure
p14318
sg15
I1
sa(dp14319
g9
I26
sg10
VC0036572
p14320
sg12
I7
sg13
Vseizure
p14321
sg15
I1
sa(dp14322
g9
I90
sg10
VC0014544
p14323
sg12
I8
sg13
Vepilepsy
p14324
sg15
I1
sasa(dp14325
g2
VIn addition to pathogen recognition, DCIR has been shown to be pivotal in preventing autoimmune disease by controlling dendritic cell proliferation.
p14326
sg4
(lp14327
(dp14328
g9
I37
sg39
g40
sg12
I4
sg13
VDCIR
p14329
sg15
I1
sasg6
(lp14330
(dp14331
g9
I134
sg10
VC0334094
p14332
sg12
I13
sg13
Vproliferation
p14333
sg15
I1
sa(dp14334
g9
I85
sg10
VC0004364
p14335
sg12
I18
sg13
Vautoimmune disease
p14336
sg15
I2
sasa(dp14337
g2
VThis study was aimed to further investigate whether DCIR polymorphisms are novel susceptibility factors for other autoimmune diseases, i.e.
p14338
sg4
(lp14339
sg6
(lp14340
(dp14341
g9
I114
sg10
VC0004364
p14342
sg12
I19
sg13
Vautoimmune diseases
p14343
sg15
I2
sasa(dp14344
g2
VTubulointerstitial nephritis and uveitis syndrome, HLA-B27-associated uveitis, inflammatory bowel disease, and Kawasaki disease each made up fewer than 5% of diagnoses.
p14345
sg4
(lp14346
(dp14347
g9
I51
sg39
VP30486
p14348
sg12
I7
sg13
VHLA-B27
p14349
sg15
I1
sasg6
(lp14350
(dp14351
g9
I0
sg10
VC1639520
p14352
sg12
I49
sg13
VTubulointerstitial nephritis and uveitis syndrome
p14353
sg15
I5
sa(dp14354
g9
I79
sg10
VC0021390
p14355
sg12
I26
sg13
Vinflammatory bowel disease
p14356
sg15
I3
sa(dp14357
g9
I33
sg10
VC0042164
p14358
sg12
I7
sg13
Vuveitis
p14359
sg15
I1
sa(dp14360
g9
I111
sg10
VC0026691
p14361
sg12
I16
sg13
VKawasaki disease
p14362
sg15
I2
sasa(dp14363
g2
VStromal tissue was isolated from epithelial cells with laser capture microdissection (LCMD) and analyzed by cDNA array for the expression of TGFalpha, TGF-beta1, HGF, PDGF-alpha, IGFII, bFGF, aFGF, VEGFC, and VEGF.
p14364
sg4
(lp14365
(dp14366
g9
I151
sg39
VP01137
p14367
sg12
I9
sg13
VTGF-beta1
p14368
sg15
I1
sa(dp14369
g9
I192
sg39
VP05230
p14370
sg12
I4
sg13
VaFGF
p14371
sg15
I1
sa(dp14372
g9
I198
sg39
VP49767
p14373
sg12
I5
sg13
VVEGFC
p14374
sg15
I1
sa(dp14375
g9
I141
sg39
VP01135
p14376
sg12
I8
sg13
VTGFalpha
p14377
sg15
I1
sa(dp14378
g9
I167
sg39
VP04085
p14379
sg12
I10
sg13
VPDGF-alpha
p14380
sg15
I1
sa(dp14381
g9
I162
sg39
VP05231
p14382
sg12
I3
sg13
VHGF
p14383
sg15
I1
sa(dp14384
g9
I186
sg39
VP53370
p14385
sg12
I4
sg13
VbFGF
p14386
sg15
I1
sa(dp14387
g9
I179
sg39
VP01344
p14388
sg12
I5
sg13
VIGFII
p14389
sg15
I1
sasg6
(lp14390
(dp14391
g9
I162
sg10
VC0399440
p14392
sg12
I3
sg13
VHGF
p14393
sg15
I1
sasa(dp14394
g2
VHere, we demonstrate that Inositol Polyphosphate-5-Phosphatase F (INPP5F), one of the polyphosphoinositide phosphatases, is differentially expressed in GSCs from glioma patients, and is identified as an inhibitor of STAT3 signaling via interaction with STAT3 and inhibition of its phosphorylation.
p14395
sg4
(lp14396
(dp14397
g9
I66
sg39
g40
sg12
I6
sg13
VINPP5F
p14398
sg15
I1
sa(dp14399
g9
I216
sg39
VP40763
p14400
sg12
I5
sg13
VSTAT3
p14401
sg15
I1
sa(dp14402
g9
I216
sg39
VP40763
p14403
sg12
I5
sg13
VSTAT3
p14404
sg15
I1
sa(dp14405
g9
I26
sg39
g40
sg12
I38
sg13
VInositol Polyphosphate-5-Phosphatase F
p14406
sg15
I3
sasg6
(lp14407
(dp14408
g9
I162
sg10
VC0017638
p14409
sg12
I6
sg13
Vglioma
p14410
sg15
I1
sasa(dp14411
g2
VIn addition, loss of INPP5F gene in gliomas is significantly correlated with lower overall patient survivals.
p14412
sg4
(lp14413
(dp14414
g9
I21
sg39
g40
sg12
I11
sg13
VINPP5F gene
p14415
sg15
I2
sasg6
(lp14416
(dp14417
g9
I36
sg10
VC0017638
p14418
sg12
I7
sg13
Vgliomas
p14419
sg15
I1
sasa(dp14420
g2
VThese findings suggest that INPP5F is a potential tumor suppressor in gliomas via inhibition of STAT3 pathway, and that deregulation of INPP5F may lead to contribution to gliomagenesis.
p14421
sg4
(lp14422
(dp14423
g9
I28
sg39
g40
sg12
I6
sg13
VINPP5F
p14424
sg15
I1
sa(dp14425
g9
I96
sg39
VP40763
p14426
sg12
I5
sg13
VSTAT3
p14427
sg15
I1
sa(dp14428
g9
I28
sg39
g40
sg12
I6
sg13
VINPP5F
p14429
sg15
I1
sasg6
(lp14430
(dp14431
g9
I70
sg10
VC0017638
p14432
sg12
I7
sg13
Vgliomas
p14433
sg15
I1
sa(dp14434
g9
I50
sg10
VC0027651
p14435
sg12
I5
sg13
Vtumor
p14436
sg15
I1
sasa(dp14437
g2
VThe patient and his identical twin show a retinal dystrophy that, based on clinical appearance, visual fields, amd electrophysiology, is most likely autosomal recessive retinitis pigmentosa.
p14438
sg4
(lp14439
sg6
(lp14440
(dp14441
g9
I42
sg10
VC0854723
p14442
sg12
I17
sg13
Vretinal dystrophy
p14443
sg15
I2
sa(dp14444
g9
I149
sg10
VC0339526
p14445
sg12
I40
sg13
Vautosomal recessive retinitis pigmentosa
p14446
sg15
I4
sa(dp14447
g9
I111
sg10
VC0242383
p14448
sg12
I3
sg13
Vamd
p14449
sg15
I1
sasa(dp14450
g2
VAlthough Gln supplementation had no effect on the loss of the tight junction protein occludin, the increased portal endotoxin and fasting glucose concentrations found in WSD-fed mice, markers of liver damage (e.g., nonalcoholic fatty liver disease activity score and number of neutrophils in the liver) were significantly lower in the WSD+Gln group than in the WSD group (~47% and ~60% less, respectively; P &lt; 0.05).
p14451
sg4
(lp14452
(dp14453
g9
I109
sg39
g40
sg12
I16
sg13
Vportal endotoxin
p14454
sg15
I2
sasg6
(lp14455
(dp14456
g9
I215
sg10
VC0400966
p14457
sg12
I32
sg13
Vnonalcoholic fatty liver disease
p14458
sg15
I4
sa(dp14459
g9
I195
sg10
VC0151763
p14460
sg12
I12
sg13
Vliver damage
p14461
sg15
I2
sasa(dp14462
g2
VThe purpose of this Evidence-Based Practice (EBP) paper is to answer PICOT questions by a review the effectiveness of chronotherapeutics interventions on depressive symptoms with depression and the depressive episode in the course of bipolar disorder.
p14463
sg4
(lp14464
sg6
(lp14465
(dp14466
g9
I179
sg10
VC0011581
p14467
sg12
I10
sg13
Vdepression
p14468
sg15
I1
sa(dp14469
g9
I234
sg10
VC0005586
p14470
sg12
I16
sg13
Vbipolar disorder
p14471
sg15
I2
sa(dp14472
g9
I154
sg10
VC0086132
p14473
sg12
I19
sg13
Vdepressive symptoms
p14474
sg15
I2
sa(dp14475
g9
I198
sg10
VC0349217
p14476
sg12
I18
sg13
Vdepressive episode
p14477
sg15
I2
sasa(dp14478
g2
VWe evaluated whether post-bronchiolitis asthma was associated with polymorphisms in the TLR3 rs3775291, TLR4 rs4986790, TLR7 rs179008, TLR8 rs2407992, TLR9 rs187084, and TLR10 rs4129009 genes.
p14479
sg4
(lp14480
(dp14481
g9
I151
sg39
g40
sg12
I13
sg13
VTLR9 rs187084
p14482
sg15
I2
sa(dp14483
g9
I170
sg39
g40
sg12
I21
sg13
VTLR10 rs4129009 genes
p14484
sg15
I3
sa(dp14485
g9
I135
sg39
g40
sg12
I14
sg13
VTLR8 rs2407992
p14486
sg15
I2
sa(dp14487
g9
I88
sg39
g40
sg12
I14
sg13
VTLR3 rs3775291
p14488
sg15
I2
sa(dp14489
g9
I120
sg39
g40
sg12
I13
sg13
VTLR7 rs179008
p14490
sg15
I2
sasg6
(lp14491
(dp14492
g9
I40
sg10
VC0004096
p14493
sg12
I6
sg13
Vasthma
p14494
sg15
I1
sa(dp14495
g9
I26
sg10
VC0006271
p14496
sg12
I13
sg13
Vbronchiolitis
p14497
sg15
I1
sasa(dp14498
g2
VThere were no significant associations between TLR3, TLR4, TLR8, or TLR9 polymorphisms and post-bronchiolitis asthma.
p14499
sg4
(lp14500
(dp14501
g9
I68
sg39
g40
sg12
I4
sg13
VTLR9
p14502
sg15
I1
sa(dp14503
g9
I59
sg39
g40
sg12
I4
sg13
VTLR8
p14504
sg15
I1
sa(dp14505
g9
I47
sg39
g40
sg12
I4
sg13
VTLR3
p14506
sg15
I1
sasg6
(lp14507
(dp14508
g9
I110
sg10
VC0004096
p14509
sg12
I6
sg13
Vasthma
p14510
sg15
I1
sa(dp14511
g9
I96
sg10
VC0006271
p14512
sg12
I13
sg13
Vbronchiolitis
p14513
sg15
I1
sasa(dp14514
g2
VSignificant associations with SAFS compared with atopic asthma included Toll-like receptor 3 (TLR3) (p = .009), TLR9 (p = .025), C-type lectin domain family seven member A (dectin-1) (p = .043), interleukin-10 (IL-10) (p = .0010), mannose-binding lectin (MBL2) (p = .007), CC-chemokine ligand 2 (CCL2) (2 SNPs, p = .025 and .041), CCL17 (p = .002), plasminogen (p = .049) and adenosine A2a receptor (p = .024).
p14515
sg4
(lp14516
(dp14517
g9
I211
sg39
VP22301
p14518
sg12
I5
sg13
VIL-10
p14519
sg15
I1
sa(dp14520
g9
I94
sg39
g40
sg12
I4
sg13
VTLR3
p14521
sg15
I1
sa(dp14522
g9
I129
sg39
g40
sg12
I42
sg13
VC-type lectin domain family seven member A
p14523
sg15
I7
sa(dp14524
g9
I195
sg39
VP22301
p14525
sg12
I14
sg13
Vinterleukin-10
p14526
sg15
I1
sa(dp14527
g9
I376
sg39
VP29274
p14528
sg12
I22
sg13
Vadenosine A2a receptor
p14529
sg15
I3
sa(dp14530
g9
I349
sg39
VP00747
p14531
sg12
I11
sg13
Vplasminogen
p14532
sg15
I1
sa(dp14533
g9
I112
sg39
g40
sg12
I4
sg13
VTLR9
p14534
sg15
I1
sa(dp14535
g9
I72
sg39
g40
sg12
I20
sg13
VToll-like receptor 3
p14536
sg15
I3
sa(dp14537
g9
I255
sg39
VP11226
p14538
sg12
I4
sg13
VMBL2
p14539
sg15
I1
sa(dp14540
g9
I331
sg39
g40
sg12
I5
sg13
VCCL17
p14541
sg15
I1
sa(dp14542
g9
I296
sg39
VP13500
p14543
sg12
I4
sg13
VCCL2
p14544
sg15
I1
sa(dp14545
g9
I231
sg39
VP11226
p14546
sg12
I22
sg13
Vmannose-binding lectin
p14547
sg15
I2
sa(dp14548
g9
I273
sg39
VP51671
p14549
sg12
I21
sg13
VCC-chemokine ligand 2
p14550
sg15
I3
sasg6
(lp14551
(dp14552
g9
I49
sg10
VC0155877
p14553
sg12
I13
sg13
Vatopic asthma
p14554
sg15
I2
sasa(dp14555
g2
VAsthmatics had significantly lower circulating HPC expressing TLR-2 and TLR-9 with a similar trend for TLR-4.
p14556
sg4
(lp14557
(dp14558
g9
I47
sg39
g40
sg12
I3
sg13
VHPC
p14559
sg15
I1
sa(dp14560
g9
I62
sg39
g40
sg12
I5
sg13
VTLR-2
p14561
sg15
I1
sa(dp14562
g9
I72
sg39
g40
sg12
I5
sg13
VTLR-9
p14563
sg15
I1
sasg6
(lp14564
(dp14565
g9
I47
sg10
VC0238339
p14566
sg12
I3
sg13
VHPC
p14567
sg15
I1
sa(dp14568
g9
I0
sg10
VC0004096
p14569
sg12
I10
sg13
VAsthmatics
p14570
sg15
I1
sasa(dp14571
g2
VThe endosomal TLRs have been shown to be associated with the induction of asthmatic inflammation (TLR3), and with disease exacerbations (TLR7, TLR8 and TLR9).
p14572
sg4
(lp14573
(dp14574
g9
I137
sg39
g40
sg12
I4
sg13
VTLR7
p14575
sg15
I1
sa(dp14576
g9
I152
sg39
g40
sg12
I4
sg13
VTLR9
p14577
sg15
I1
sa(dp14578
g9
I143
sg39
g40
sg12
I4
sg13
VTLR8
p14579
sg15
I1
sa(dp14580
g9
I98
sg39
g40
sg12
I4
sg13
VTLR3
p14581
sg15
I1
sasg6
(lp14582
(dp14583
g9
I84
sg10
VC0021368
p14584
sg12
I12
sg13
Vinflammation
p14585
sg15
I1
sa(dp14586
g9
I74
sg10
VC0004096
p14587
sg12
I9
sg13
Vasthmatic
p14588
sg15
I1
sasa(dp14589
g2
VA defect in the P-protein component of the glycine cleavage system has been the most frequent abnormality found in patients with glycine encephalopathy (NKH).
p14590
sg4
(lp14591
sg6
(lp14592
(dp14593
g9
I153
sg10
VC0751748
p14594
sg12
I3
sg13
VNKH
p14595
sg15
I1
sa(dp14596
g9
I129
sg10
VC0751748
p14597
sg12
I22
sg13
Vglycine encephalopathy
p14598
sg15
I2
sasa(dp14599
g2
VSoluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin-1 receptor antagonist (IL-1Ra), von Willebrand factor (VWF), and osteoprotegerin (OPG) were measured in schizophrenia (n = 69) and affective (n = 55) spectrum patients at baseline and at one-year follow-up, and compared to healthy controls (HC) (n = 92) with analysis of covariance.
p14600
sg4
(lp14601
(dp14602
g9
I96
sg39
VP04275
p14603
sg12
I21
sg13
Vvon Willebrand factor
p14604
sg15
I3
sa(dp14605
g9
I129
sg39
g40
sg12
I15
sg13
Vosteoprotegerin
p14606
sg15
I1
sa(dp14607
g9
I52
sg39
VP18510
p14608
sg12
I33
sg13
Vinterleukin-1 receptor antagonist
p14609
sg15
I3
sa(dp14610
g9
I0
sg39
g40
sg12
I40
sg13
VSoluble tumor necrosis factor receptor 1
p14611
sg15
I6
sa(dp14612
g9
I146
sg39
g40
sg12
I3
sg13
VOPG
p14613
sg15
I1
sa(dp14614
g9
I87
sg39
VP18510
p14615
sg12
I6
sg13
VIL-1Ra
p14616
sg15
I1
sa(dp14617
g9
I119
sg39
VP04275
p14618
sg12
I3
sg13
VVWF
p14619
sg15
I1
sa(dp14620
g9
I42
sg39
g40
sg12
I7
sg13
VsTNF-R1
p14621
sg15
I1
sasg6
(lp14622
(dp14623
g9
I168
sg10
VC0036341
p14624
sg12
I13
sg13
Vschizophrenia
p14625
sg15
I1
sa(dp14626
g9
I8
sg10
VC0333516
p14627
sg12
I14
sg13
Vtumor necrosis
p14628
sg15
I2
sasa(dp14629
g2
VSerum sTNFR1 was significantly higher in patients with acute-stage schizophrenia compared to matched controls while no significant group differences were observed for the other markers.
p14630
sg4
(lp14631
sg6
(lp14632
(dp14633
g9
I67
sg10
VC0036341
p14634
sg12
I13
sg13
Vschizophrenia
p14635
sg15
I1
sasa(dp14636
g2
VPlasma levels of soluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin 1 receptor antagonist (IL-1Ra), osteoprotegerin (OPG), and von Willebrand factor (vWf) were measured in patients (n=992) with schizophrenia spectrum (SCZ, n=584), schizoaffective disorder (SA, n=93), affective spectrum disorders (AFF, n=315), and healthy controls (HC, n=638).
p14637
sg4
(lp14638
(dp14639
g9
I163
sg39
VP04275
p14640
sg12
I3
sg13
VvWf
p14641
sg15
I1
sa(dp14642
g9
I17
sg39
g40
sg12
I40
sg13
Vsoluble tumor necrosis factor receptor 1
p14643
sg15
I6
sa(dp14644
g9
I104
sg39
VP18510
p14645
sg12
I6
sg13
VIL-1Ra
p14646
sg15
I1
sa(dp14647
g9
I130
sg39
g40
sg12
I3
sg13
VOPG
p14648
sg15
I1
sa(dp14649
g9
I59
sg39
g40
sg12
I7
sg13
VsTNF-R1
p14650
sg15
I1
sa(dp14651
g9
I69
sg39
VP18510
p14652
sg12
I33
sg13
Vinterleukin 1 receptor antagonist
p14653
sg15
I4
sa(dp14654
g9
I140
sg39
VP04275
p14655
sg12
I21
sg13
Vvon Willebrand factor
p14656
sg15
I3
sa(dp14657
g9
I113
sg39
g40
sg12
I15
sg13
Vosteoprotegerin
p14658
sg15
I1
sasg6
(lp14659
(dp14660
g9
I244
sg10
VC0036337
p14661
sg12
I24
sg13
Vschizoaffective disorder
p14662
sg15
I2
sa(dp14663
g9
I25
sg10
VC0333516
p14664
sg12
I14
sg13
Vtumor necrosis
p14665
sg15
I2
sa(dp14666
g9
I270
sg10
VC0036337
p14667
sg12
I2
sg13
VSA
p14668
sg15
I1
sa(dp14669
g9
I207
sg10
VC0036341
p14670
sg12
I13
sg13
Vschizophrenia
p14671
sg15
I1
sasa(dp14672
g2
VMIS includes 10 components: dry weight changes, dietary intake, functional capacity, comorbidity, muscle wasting and loss of subcutaneous fat as well as body mass index (BMI), serum albumin level and total iron binding capacity (TIBC).
p14673
sg4
(lp14674
(dp14675
g9
I176
sg39
g40
sg12
I13
sg13
Vserum albumin
p14676
sg15
I2
sasg6
(lp14677
(dp14678
g9
I98
sg10
VC0026846
p14679
sg12
I14
sg13
Vmuscle wasting
p14680
sg15
I2
sasa(dp14681
g2
VThis study suggests that consecutive PNC contributed to the improvement of the protein intake, serum levels of albumin, cholesterol and to the delay of muscle wasting, which could also have a positive impact on the nutritional status, particularly in malnourished patients receiving HD treatment.
p14682
sg4
(lp14683
(dp14684
g9
I111
sg39
VP00441
p14685
sg12
I7
sg13
Valbumin
p14686
sg15
I1
sasg6
(lp14687
(dp14688
g9
I152
sg10
VC0026846
p14689
sg12
I14
sg13
Vmuscle wasting
p14690
sg15
I2
sa(dp14691
g9
I251
sg10
VC0162429
p14692
sg12
I12
sg13
Vmalnourished
p14693
sg15
I1
sasa(dp14694
g2
VGCs = glucocorticoids; HDG = high-dose glucocorticoids; A1C = Hemoglobin A1C; GA = Glycated Albumin; FBG = fasting blood glucose; IG = interstitial glucose; BG = blood glucose; GIH = Glucocorticoids-induced hyperglycemia; HOMA-IR = Homeostasis Model Assessment-Insulin Resistance; CGMS = continuous glucose monitoring system; AUC = the area under the curve; MODD = absolute means of daily differences; LAGE = the largest amplitude of glycemic excursions; BMI = body mass index; DM = diabetes mellitus; SLE = systemic lupus erythematosus; IQR = interquartile range; HR = hazard ratio; PUMCH = Peking Union Medical College Hospital.
p14695
sg4
(lp14696
(dp14697
g9
I261
sg39
VP01308
p14698
sg12
I7
sg13
VInsulin
p14699
sg15
I1
sa(dp14700
g9
I62
sg39
g40
sg12
I10
sg13
VHemoglobin
p14701
sg15
I1
sasg6
(lp14702
(dp14703
g9
I502
sg10
VC0024141
p14704
sg12
I3
sg13
VSLE
p14705
sg15
I1
sa(dp14706
g9
I508
sg10
VC0024141
p14707
sg12
I28
sg13
Vsystemic lupus erythematosus
p14708
sg15
I3
sa(dp14709
g9
I483
sg10
VC0011849
p14710
sg12
I17
sg13
Vdiabetes mellitus
p14711
sg15
I2
sa(dp14712
g9
I261
sg10
VC0021655
p14713
sg12
I18
sg13
VInsulin Resistance
p14714
sg15
I2
sa(dp14715
g9
I207
sg10
VC0020456
p14716
sg12
I13
sg13
Vhyperglycemia
p14717
sg15
I1
sasa(dp14718
g2
VObjective To evaluate the presence and localization of folate receptor expressing macrophages in the rat groove model of osteoarthritis and determine the suitability of a new folate conjugate with albumin-binding entity (cm09) for in vivo SPECT (single-photon emission computed tomography) analysis.
p14719
sg4
(lp14720
(dp14721
g9
I55
sg39
VP15328
p14722
sg12
I15
sg13
Vfolate receptor
p14723
sg15
I2
sa(dp14724
g9
I197
sg39
VP00441
p14725
sg12
I7
sg13
Valbumin
p14726
sg15
I1
sasg6
(lp14727
(dp14728
g9
I121
sg10
VC0029408
p14729
sg12
I14
sg13
Vosteoarthritis
p14730
sg15
I1
sasa(dp14731
g2
VResults In vivo SPECT/CT imaging of the new folate conjugate (cm09) was as useful as a folate conjugate without albumin-binding entity in the groove model of osteoarthritis with less renal accumulation.
p14732
sg4
(lp14733
(dp14734
g9
I112
sg39
VP00441
p14735
sg12
I7
sg13
Valbumin
p14736
sg15
I1
sasg6
(lp14737
(dp14738
g9
I158
sg10
VC0029408
p14739
sg12
I14
sg13
Vosteoarthritis
p14740
sg15
I1
sasa(dp14741
g2
VHowever, the effects of agonistic anti-4-1BB Abs have not been examined in an experimental mouse model of psoriasis.
p14742
sg4
(lp14743
sg6
(lp14744
(dp14745
g9
I106
sg10
VC0033860
p14746
sg12
I9
sg13
Vpsoriasis
p14747
sg15
I1
sasa(dp14748
g2
VTherefore, we investigated the protective effects of agonistic anti-4-1BB Abs, using imiquimod (IMQ)-induced psoriasis-like dermatitis in mice, a condition histologically and clinically similar to human psoriasis.
p14749
sg4
(lp14750
sg6
(lp14751
(dp14752
g9
I109
sg10
VC0033860
p14753
sg12
I9
sg13
Vpsoriasis
p14754
sg15
I1
sa(dp14755
g9
I109
sg10
VC0033860
p14756
sg12
I9
sg13
Vpsoriasis
p14757
sg15
I1
sa(dp14758
g9
I146
sg10
VC0012634
p14759
sg12
I9
sg13
Vcondition
p14760
sg15
I1
sa(dp14761
g9
I124
sg10
VC0011603
p14762
sg12
I10
sg13
Vdermatitis
p14763
sg15
I1
sasa(dp14764
g2
VWe found that administration of agonistic anti-4-1BB Abs (10mg/kg) significantly alleviated the severity of IMQ-induced psoriasis-like skin inflammation in mice, with reduced histologic symptoms, including inflammatory infiltration, parakeratosis, and hyperkeratosis.
p14765
sg4
(lp14766
sg6
(lp14767
(dp14768
g9
I252
sg10
VC0870082
p14769
sg12
I14
sg13
Vhyperkeratosis
p14770
sg15
I1
sa(dp14771
g9
I233
sg10
VC0030436
p14772
sg12
I13
sg13
Vparakeratosis
p14773
sg15
I1
sa(dp14774
g9
I206
sg10
VC0302158
p14775
sg12
I25
sg13
Vinflammatory infiltration
p14776
sg15
I2
sa(dp14777
g9
I135
sg10
VC0011603
p14778
sg12
I17
sg13
Vskin inflammation
p14779
sg15
I2
sa(dp14780
g9
I120
sg10
VC0033860
p14781
sg12
I9
sg13
Vpsoriasis
p14782
sg15
I1
sasa(dp14783
g2
VTaken together, our data provide evidence that agonistic anti-4-1BB Abs possesses immunosuppressive properties in IMQ-induced psoriasis-like skin inflammation, providing insight into the immunomodulatory effect of agonistic anti-4-1BB Abs for psoriasis immunotherapy.
p14784
sg4
(lp14785
sg6
(lp14786
(dp14787
g9
I126
sg10
VC0033860
p14788
sg12
I9
sg13
Vpsoriasis
p14789
sg15
I1
sa(dp14790
g9
I72
sg10
VC0850310
p14791
sg12
I9
sg13
Vpossesses
p14792
sg15
I1
sa(dp14793
g9
I141
sg10
VC0011603
p14794
sg12
I17
sg13
Vskin inflammation
p14795
sg15
I2
sa(dp14796
g9
I126
sg10
VC0033860
p14797
sg12
I9
sg13
Vpsoriasis
p14798
sg15
I1
sasa(dp14799
g2
VAmong identified psoriasis risk variants, three were more strongly associated with PsC than PsA (rs12189871 near HLA-C, p = 5.0 x 10(-19); rs4908742 near TNFRSF9, p = 0.00020; rs10888503 near LCE3A, p = 0.0014), and two were more strongly associated with PsA than PsC (rs12044149 near IL23R, p = 0.00018; rs9321623 near TNFAIP3, p = 0.00022).
p14800
sg4
(lp14801
(dp14802
g9
I192
sg39
g40
sg12
I5
sg13
VLCE3A
p14803
sg15
I1
sa(dp14804
g9
I154
sg39
g40
sg12
I7
sg13
VTNFRSF9
p14805
sg15
I1
sa(dp14806
g9
I320
sg39
VP21580
p14807
sg12
I7
sg13
VTNFAIP3
p14808
sg15
I1
sa(dp14809
g9
I113
sg39
VP30486
p14810
sg12
I3
sg13
VHLA
p14811
sg15
I1
sasg6
(lp14812
(dp14813
g9
I83
sg10
VC0566602
p14814
sg12
I3
sg13
VPsC
p14815
sg15
I1
sa(dp14816
g9
I92
sg10
VC1519176
p14817
sg12
I3
sg13
VPsA
p14818
sg15
I1
sa(dp14819
g9
I83
sg10
VC0566602
p14820
sg12
I3
sg13
VPsC
p14821
sg15
I1
sa(dp14822
g9
I92
sg10
VC1519176
p14823
sg12
I3
sg13
VPsA
p14824
sg15
I1
sa(dp14825
g9
I17
sg10
VC0033860
p14826
sg12
I9
sg13
Vpsoriasis
p14827
sg15
I1
sasa(dp14828
g2
VInteratrial electromechanical delay (IA-EMD) and intra-left atrial electromechanical delay (ILA-EMD) were significantly longer in the psoriasis group compared with controls.
p14829
sg4
(lp14830
(dp14831
g9
I49
sg39
g40
sg12
I41
sg13
Vintra-left atrial electromechanical delay
p14832
sg15
I4
sa(dp14833
g9
I92
sg39
g40
sg12
I7
sg13
VILA-EMD
p14834
sg15
I1
sasg6
(lp14835
(dp14836
g9
I40
sg10
VC0340861
p14837
sg12
I3
sg13
VEMD
p14838
sg15
I1
sa(dp14839
g9
I134
sg10
VC0033860
p14840
sg12
I9
sg13
Vpsoriasis
p14841
sg15
I1
sa(dp14842
g9
I40
sg10
VC0340861
p14843
sg12
I3
sg13
VEMD
p14844
sg15
I1
sasa(dp14845
g2
VTo investigate the expression of the peripheral blood retinoid-related orphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA in oral lichen planus (OLP) patients.
p14846
sg4
(lp14847
(dp14848
g9
I71
sg39
VP25106
p14849
sg12
I58
sg13
Vorphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA
p14850
sg15
I9
sasg6
(lp14851
(dp14852
g9
I153
sg10
VC0206139
p14853
sg12
I3
sg13
VOLP
p14854
sg15
I1
sa(dp14855
g9
I133
sg10
VC0206139
p14856
sg12
I18
sg13
Voral lichen planus
p14857
sg15
I3
sasa(dp14858
g2
VBlood and tissue eosinophils from patients with IgE-mediated allergic responses (atopic dermatitis, extrinsic asthma) express CD137.
p14859
sg4
(lp14860
(dp14861
g9
I126
sg39
g40
sg12
I5
sg13
VCD137
p14862
sg15
I1
sa(dp14863
g9
I48
sg39
VP01854
p14864
sg12
I3
sg13
VIgE
p14865
sg15
I1
sasg6
(lp14866
(dp14867
g9
I81
sg10
VC0011615
p14868
sg12
I17
sg13
Vatopic dermatitis
p14869
sg15
I2
sa(dp14870
g9
I100
sg10
VC0155877
p14871
sg12
I16
sg13
Vextrinsic asthma
p14872
sg15
I2
sa(dp14873
g9
I48
sg10
VC0270850
p14874
sg12
I3
sg13
VIgE
p14875
sg15
I1
sasa(dp14876
g2
VProteomic analysis revealed 14 statistically significant differentially expressed proteins, with nine showing increased expression (PDIA3, VIM/HEXA, SELENBP1, ENO1, CAPZA1, ERP29, TPI1, PARK7, and FABP3) and five showing decreased expression (EIF2S, PSMA3, RPSA, TUBB, and TUBA1B) in uveal melanomas that subsequently metastasized compared with those that did not.
p14877
sg4
(lp14878
(dp14879
g9
I165
sg39
VP52907
p14880
sg12
I6
sg13
VCAPZA1
p14881
sg15
I1
sa(dp14882
g9
I149
sg39
g40
sg12
I8
sg13
VSELENBP1
p14883
sg15
I1
sa(dp14884
g9
I132
sg39
VP30101
p14885
sg12
I5
sg13
VPDIA3
p14886
sg15
I1
sa(dp14887
g9
I143
sg39
VP06865
p14888
sg12
I4
sg13
VHEXA
p14889
sg15
I1
sa(dp14890
g9
I273
sg39
VP68363
p14891
sg12
I6
sg13
VTUBA1B
p14892
sg15
I1
sa(dp14893
g9
I197
sg39
VP05413
p14894
sg12
I5
sg13
VFABP3
p14895
sg15
I1
sa(dp14896
g9
I173
sg39
VP30040
p14897
sg12
I5
sg13
VERP29
p14898
sg15
I1
sa(dp14899
g9
I250
sg39
VP25788
p14900
sg12
I5
sg13
VPSMA3
p14901
sg15
I1
sa(dp14902
g9
I263
sg39
VP04350
p14903
sg12
I4
sg13
VTUBB
p14904
sg15
I1
sa(dp14905
g9
I180
sg39
VP60174
p14906
sg12
I4
sg13
VTPI1
p14907
sg15
I1
sa(dp14908
g9
I186
sg39
g40
sg12
I5
sg13
VPARK7
p14909
sg15
I1
sasg6
(lp14910
(dp14911
g9
I318
sg10
VC0027627
p14912
sg12
I12
sg13
Vmetastasized
p14913
sg15
I1
sa(dp14914
g9
I290
sg10
VC0025202
p14915
sg12
I9
sg13
Vmelanomas
p14916
sg15
I1
sa(dp14917
g9
I186
sg10
VC1853445
p14918
sg12
I5
sg13
VPARK7
p14919
sg15
I1
sasa(dp14920
g2
VAmong these, 14 genes (FTL, K-ALPHA1, LDHA, RPL4, ENO1, ANXA2, RPL9, RPL10, RPL13A, GNB2L1, AMBP, GC, A1BG, and SERPINC1), in addition to previously well-known liver cancer related genes, were confirmed to be differentially expressed in seven liver cancer cell lines and 17 HCC tissues by semi-quantitative RT-PCR.
p14921
sg4
(lp14922
(dp14923
g9
I69
sg39
VP61313
p14924
sg12
I5
sg13
VRPL10
p14925
sg15
I1
sa(dp14926
g9
I56
sg39
VP07355
p14927
sg12
I5
sg13
VANXA2
p14928
sg15
I1
sa(dp14929
g9
I28
sg39
VP25100
p14930
sg12
I8
sg13
VK-ALPHA1
p14931
sg15
I1
sa(dp14932
g9
I92
sg39
VP02760
p14933
sg12
I4
sg13
VAMBP
p14934
sg15
I1
sa(dp14935
g9
I76
sg39
VP40429
p14936
sg12
I6
sg13
VRPL13A
p14937
sg15
I1
sa(dp14938
g9
I102
sg39
VP04217
p14939
sg12
I4
sg13
VA1BG
p14940
sg15
I1
sa(dp14941
g9
I63
sg39
VP32969
p14942
sg12
I4
sg13
VRPL9
p14943
sg15
I1
sa(dp14944
g9
I44
sg39
VP36578
p14945
sg12
I4
sg13
VRPL4
p14946
sg15
I1
sa(dp14947
g9
I23
sg39
VP02792
p14948
sg12
I3
sg13
VFTL
p14949
sg15
I1
sa(dp14950
g9
I84
sg39
VP63244
p14951
sg12
I6
sg13
VGNB2L1
p14952
sg15
I1
sa(dp14953
g9
I38
sg39
VP00338
p14954
sg12
I4
sg13
VLDHA
p14955
sg15
I1
sasg6
(lp14956
(dp14957
g9
I160
sg10
VC0345904
p14958
sg12
I12
sg13
Vliver cancer
p14959
sg15
I2
sa(dp14960
g9
I274
sg10
VC2239176
p14961
sg12
I3
sg13
VHCC
p14962
sg15
I1
sa(dp14963
g9
I160
sg10
VC0345904
p14964
sg12
I12
sg13
Vliver cancer
p14965
sg15
I2
sasa(dp14966
g2
VExpression profiles of the 9 genes ACTB, ALAS1, G6PD, GAPD, HMBS, HPRT1, K-ALPHA-1, SDHA and TBP were established in matched malignant and nonmalignant tissue specimens from 14 patients with bladder cancer.
p14967
sg4
(lp14968
(dp14969
g9
I73
sg39
VP68363
p14970
sg12
I9
sg13
VK-ALPHA-1
p14971
sg15
I1
sa(dp14972
g9
I41
sg39
VP13196
p14973
sg12
I5
sg13
VALAS1
p14974
sg15
I1
sa(dp14975
g9
I66
sg39
VP55884
p14976
sg12
I5
sg13
VHPRT1
p14977
sg15
I1
sa(dp14978
g9
I93
sg39
VP20226
p14979
sg12
I3
sg13
VTBP
p14980
sg15
I1
sa(dp14981
g9
I48
sg39
VP11441
p14982
sg12
I4
sg13
VG6PD
p14983
sg15
I1
sa(dp14984
g9
I54
sg39
VP04406
p14985
sg12
I4
sg13
VGAPD
p14986
sg15
I1
sa(dp14987
g9
I35
sg39
VP63261
p14988
sg12
I4
sg13
VACTB
p14989
sg15
I1
sa(dp14990
g9
I84
sg39
VP31040
p14991
sg12
I4
sg13
VSDHA
p14992
sg15
I1
sa(dp14993
g9
I60
sg39
VP08397
p14994
sg12
I4
sg13
VHMBS
p14995
sg15
I1
sasg6
(lp14996
(dp14997
g9
I191
sg10
VC0699885
p14998
sg12
I14
sg13
Vbladder cancer
p14999
sg15
I2
sasa(dp15000
g2
VThe use of HPRT1 alone as a reference gene shown in our study was sufficient, but the normalization factors generated from two (HRPT1, ALAS1) or all three genes (HRPT1, ALAS1, K-ALPHA-1) should be considered for an improved reliability of normalization in gene profiling studies of prostate cancer.
p15001
sg4
(lp15002
(dp15003
g9
I128
sg39
g40
sg12
I5
sg13
VHRPT1
p15004
sg15
I1
sa(dp15005
g9
I176
sg39
VP68363
p15006
sg12
I9
sg13
VK-ALPHA-1
p15007
sg15
I1
sa(dp15008
g9
I128
sg39
g40
sg12
I5
sg13
VHRPT1
p15009
sg15
I1
sa(dp15010
g9
I11
sg39
VP55884
p15011
sg12
I5
sg13
VHPRT1
p15012
sg15
I1
sa(dp15013
g9
I135
sg39
VP13196
p15014
sg12
I5
sg13
VALAS1
p15015
sg15
I1
sa(dp15016
g9
I135
sg39
VP13196
p15017
sg12
I5
sg13
VALAS1
p15018
sg15
I1
sasg6
(lp15019
(dp15020
g9
I128
sg10
VC1840402
p15021
sg12
I5
sg13
VHRPT1
p15022
sg15
I1
sa(dp15023
g9
I282
sg10
VC0600139
p15024
sg12
I15
sg13
Vprostate cancer
p15025
sg15
I2
sa(dp15026
g9
I128
sg10
VC1840402
p15027
sg12
I5
sg13
VHRPT1
p15028
sg15
I1
sasa(dp15029
g2
VWe show that glucose clearance rates are affected in both children with marasmus as well as kwashiorkor, which correlate with plasma albumin concentrations.
p15030
sg4
(lp15031
(dp15032
g9
I126
sg39
VP00441
p15033
sg12
I14
sg13
Vplasma albumin
p15034
sg15
I2
sasg6
(lp15035
(dp15036
g9
I92
sg10
VC0022806
p15037
sg12
I11
sg13
Vkwashiorkor
p15038
sg15
I1
sa(dp15039
g9
I72
sg10
VC0086588
p15040
sg12
I8
sg13
Vmarasmus
p15041
sg15
I1
sasa(dp15042
g2
VAlthough marasmus is characterized by clinical wasting, kwashiorkor is associated with peripheral edema, oxidative stress, hypoalbuminemia, and hypoglycemia.
p15043
sg4
(lp15044
sg6
(lp15045
(dp15046
g9
I47
sg10
VC0235394
p15047
sg12
I7
sg13
Vwasting
p15048
sg15
I1
sa(dp15049
g9
I56
sg10
VC0022806
p15050
sg12
I11
sg13
Vkwashiorkor
p15051
sg15
I1
sa(dp15052
g9
I105
sg10
VC0242606
p15053
sg12
I16
sg13
Voxidative stress
p15054
sg15
I2
sa(dp15055
g9
I98
sg10
VC0013604
p15056
sg12
I5
sg13
Vedema
p15057
sg15
I1
sa(dp15058
g9
I9
sg10
VC0086588
p15059
sg12
I8
sg13
Vmarasmus
p15060
sg15
I1
sa(dp15061
g9
I144
sg10
VC0020615
p15062
sg12
I12
sg13
Vhypoglycemia
p15063
sg15
I1
sasa(dp15064
g2
VTotal proteins, albumin and transferrin were all significantly lower in children with edema than in those with marasmus.
p15065
sg4
(lp15066
(dp15067
g9
I28
sg39
VP02787
p15068
sg12
I11
sg13
Vtransferrin
p15069
sg15
I1
sa(dp15070
g9
I16
sg39
VP00441
p15071
sg12
I7
sg13
Valbumin
p15072
sg15
I1
sasg6
(lp15073
(dp15074
g9
I86
sg10
VC0013604
p15075
sg12
I5
sg13
Vedema
p15076
sg15
I1
sa(dp15077
g9
I111
sg10
VC0086588
p15078
sg12
I8
sg13
Vmarasmus
p15079
sg15
I1
sasa(dp15080
g2
VIn this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.
p15081
sg4
(lp15082
(dp15083
g9
I216
sg39
VP01375
p15084
sg12
I8
sg13
VTNF-Alfa
p15085
sg15
I1
sa(dp15086
g9
I177
sg39
VP01584
p15087
sg12
I8
sg13
VIL-1Beta
p15088
sg15
I1
sa(dp15089
g9
I158
sg39
VP01584
p15090
sg12
I17
sg13
Vinterleukin-1Beta
p15091
sg15
I1
sa(dp15092
g9
I188
sg39
VP01375
p15093
sg12
I26
sg13
Vtumor necrosis factor Alfa
p15094
sg15
I4
sa(dp15095
g9
I70
sg39
VP14555
p15096
sg12
I5
sg13
VsPLA2
p15097
sg15
I1
sasg6
(lp15098
(dp15099
g9
I8
sg10
VC0012634
p15100
sg12
I9
sg13
Vcondition
p15101
sg15
I1
sa(dp15102
g9
I43
sg10
VC0235957
p15103
sg12
I11
sg13
Vmyonecrosis
p15104
sg15
I1
sa(dp15105
g9
I33
sg10
VC0013604
p15106
sg12
I5
sg13
Vedema
p15107
sg15
I1
sa(dp15108
g9
I188
sg10
VC0333516
p15109
sg12
I14
sg13
Vtumor necrosis
p15110
sg15
I2
sasa(dp15111
g2
VIn addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.
p15112
sg4
(lp15113
(dp15114
g9
I60
sg39
VP14555
p15115
sg12
I5
sg13
VsPLA2
p15116
sg15
I1
sasg6
(lp15117
(dp15118
g9
I115
sg10
VC0235957
p15119
sg12
I11
sg13
Vmyonecrosis
p15120
sg15
I1
sa(dp15121
g9
I105
sg10
VC0013604
p15122
sg12
I5
sg13
Vedema
p15123
sg15
I1
sa(dp15124
g9
I81
sg10
VC0242606
p15125
sg12
I16
sg13
Voxidative stress
p15126
sg15
I2
sasa(dp15127
g2
VMoreover, 5CQA significantly decreased the enzymatic activity and the oedema and myonecrosis induced by native sPLA2.
p15128
sg4
(lp15129
sg6
(lp15130
(dp15131
g9
I70
sg10
VC0013604
p15132
sg12
I6
sg13
Voedema
p15133
sg15
I1
sa(dp15134
g9
I81
sg10
VC0235957
p15135
sg12
I11
sg13
Vmyonecrosis
p15136
sg15
I1
sasa(dp15137
g2
VThis flavonoid was able to decrease enzymatic activity and some pharmacological effects, such as myonecrosis, platelet aggregation, and neurotoxic activity caused by sPLA2, however, the inflammatory effect was not affected by naringin.
p15138
sg4
(lp15139
sg6
(lp15140
(dp15141
g9
I97
sg10
VC0235957
p15142
sg12
I11
sg13
Vmyonecrosis
p15143
sg15
I1
sasa(dp15144
g2
VUnder the conditions tested, we observed that both Boc-5 and Boc-10 strongly decreased edema, myonecrosis, and neurotoxicity induced by native sPLA2.
p15145
sg4
(lp15146
(dp15147
g9
I51
sg39
g40
sg12
I5
sg13
VBoc-5
p15148
sg15
I1
sa(dp15149
g9
I61
sg39
g40
sg12
I6
sg13
VBoc-10
p15150
sg15
I1
sasg6
(lp15151
(dp15152
g9
I94
sg10
VC0235957
p15153
sg12
I11
sg13
Vmyonecrosis
p15154
sg15
I1
sa(dp15155
g9
I87
sg10
VC0013604
p15156
sg12
I5
sg13
Vedema
p15157
sg15
I1
sasa(dp15158
g2
VIncubation with pertussis toxin prior to the addition of either sPLA2 or LPA only showed abrogation of the response to LPA, thus suggesting the involvement of pertussis-sensitive Gi-proteins in the case of LPA.
p15159
sg4
(lp15160
(dp15161
g9
I64
sg39
VP14555
p15162
sg12
I5
sg13
VsPLA2
p15163
sg15
I1
sa(dp15164
g9
I16
sg39
g40
sg12
I15
sg13
Vpertussis toxin
p15165
sg15
I2
sa(dp15166
g9
I179
sg39
VP63096
p15167
sg12
I11
sg13
VGi-proteins
p15168
sg15
I1
sasg6
(lp15169
(dp15170
g9
I16
sg10
VC0043167
p15171
sg12
I9
sg13
Vpertussis
p15172
sg15
I1
sa(dp15173
g9
I16
sg10
VC0043167
p15174
sg12
I9
sg13
Vpertussis
p15175
sg15
I1
sasa(dp15176
g2
VIn contrast, all of the four classical CMNs tested were negative, as were cases of Wilms' tumor and clear cell sarcoma of the kidney.
p15177
sg4
(lp15178
sg6
(lp15179
(dp15180
g9
I100
sg10
VC0334488
p15181
sg12
I32
sg13
Vclear cell sarcoma of the kidney
p15182
sg15
I6
sa(dp15183
g9
I83
sg10
VC0027708
p15184
sg12
I12
sg13
VWilms' tumor
p15185
sg15
I2
sasa(dp15186
g2
VThe aspirates were from 16 cases of classical Wilms' tumor (WT), one anaplastic WT, 2 clear cell sarcomas of the kidney (CCSK), 2 malignant rhabdoid tumors of the kidney (MRTK) and 6 congenital mesoblastic nephromas (CMNs).
p15187
sg4
(lp15188
sg6
(lp15189
(dp15190
g9
I60
sg10
VC0027708
p15191
sg12
I2
sg13
VWT
p15192
sg15
I1
sa(dp15193
g9
I46
sg10
VC0027708
p15194
sg12
I12
sg13
VWilms' tumor
p15195
sg15
I2
sa(dp15196
g9
I183
sg10
VC1332965
p15197
sg12
I32
sg13
Vcongenital mesoblastic nephromas
p15198
sg15
I3
sa(dp15199
g9
I60
sg10
VC0027708
p15200
sg12
I2
sg13
VWT
p15201
sg15
I1
sa(dp15202
g9
I86
sg10
VC0206651
p15203
sg12
I19
sg13
Vclear cell sarcomas
p15204
sg15
I3
sa(dp15205
g9
I140
sg10
VC0206743
p15206
sg12
I15
sg13
Vrhabdoid tumors
p15207
sg15
I2
sa(dp15208
g9
I217
sg10
VC1332965
p15209
sg12
I4
sg13
VCMNs
p15210
sg15
I1
sasa(dp15211
g2
VArchival tissue from 38 patients with superficial smooth muscle cell and so-called fibrohistiocytic tumors (8 benign fibrous histiocytomas (BFHs), 6 dermatofibrosarcoma protuberans (DFPT), 9 malignant fibrous histiocytomas (MFHs), 9 leiomyomas (LMs) and 6 leiomyosarcomas (LMSs)) were immunostained with antibodies against SMA, HCD, CALP, PLAP and HPL.
p15212
sg4
(lp15213
(dp15214
g9
I323
sg39
g40
sg12
I3
sg13
VSMA
p15215
sg15
I1
sa(dp15216
g9
I339
sg39
VP51003
p15217
sg12
I4
sg13
VPLAP
p15218
sg15
I1
sa(dp15219
g9
I348
sg39
VP09382
p15220
sg12
I3
sg13
VHPL
p15221
sg15
I1
sa(dp15222
g9
I328
sg39
VP0C7U2
p15223
sg12
I3
sg13
VHCD
p15224
sg15
I1
sa(dp15225
g9
I333
sg39
g40
sg12
I4
sg13
VCALP
p15226
sg15
I1
sasg6
(lp15227
(dp15228
g9
I110
sg10
VC0206644
p15229
sg12
I28
sg13
Vbenign fibrous histiocytomas
p15230
sg15
I3
sa(dp15231
g9
I233
sg10
VC0023267
p15232
sg12
I10
sg13
Vleiomyomas
p15233
sg15
I1
sa(dp15234
g9
I100
sg10
VC0027651
p15235
sg12
I6
sg13
Vtumors
p15236
sg15
I1
sa(dp15237
g9
I191
sg10
VC0334463
p15238
sg12
I31
sg13
Vmalignant fibrous histiocytomas
p15239
sg15
I3
sa(dp15240
g9
I256
sg10
VC0023269
p15241
sg12
I15
sg13
Vleiomyosarcomas
p15242
sg15
I1
sa(dp15243
g9
I323
sg10
VC0026847
p15244
sg12
I3
sg13
VSMA
p15245
sg15
I1
sa(dp15246
g9
I328
sg10
VC0235833
p15247
sg12
I3
sg13
VHCD
p15248
sg15
I1
sa(dp15249
g9
I245
sg10
VC1851710
p15250
sg12
I3
sg13
VLMs
p15251
sg15
I1
sa(dp15252
g9
I149
sg10
VC0392784
p15253
sg12
I31
sg13
Vdermatofibrosarcoma protuberans
p15254
sg15
I2
sa(dp15255
g9
I273
sg10
VC0023269
p15256
sg12
I4
sg13
VLMSs
p15257
sg15
I1
sa(dp15258
g9
I224
sg10
VC0334463
p15259
sg12
I4
sg13
VMFHs
p15260
sg15
I1
sasa(dp15261
g2
VIn cell culture, d12.CALP at low multiplicity of infection (0.001 plaque-forming unit/cell) selectively killed calponin-positive human synovial sarcoma, leiomyosarcoma, and osteosarcoma cells.
p15262
sg4
(lp15263
(dp15264
g9
I111
sg39
VP51911
p15265
sg12
I8
sg13
Vcalponin
p15266
sg15
I1
sasg6
(lp15267
(dp15268
g9
I49
sg10
VC0009450
p15269
sg12
I9
sg13
Vinfection
p15270
sg15
I1
sa(dp15271
g9
I66
sg10
VC0011389
p15272
sg12
I6
sg13
Vplaque
p15273
sg15
I1
sa(dp15274
g9
I173
sg10
VC0029463
p15275
sg12
I12
sg13
Vosteosarcoma
p15276
sg15
I1
sa(dp15277
g9
I135
sg10
VC0039101
p15278
sg12
I16
sg13
Vsynovial sarcoma
p15279
sg15
I2
sa(dp15280
g9
I153
sg10
VC0023269
p15281
sg12
I14
sg13
Vleiomyosarcoma
p15282
sg15
I1
sasa(dp15283
g2
VTo investigate the possible role of beta-defensins in gingival health and periodontal disease, we examined the effect of several stimuli on the expression of interleukin-8 (IL-8), human beta-defensin-1, -2, -3, and -4 (hBD) in primary human diseased gingival epithelial (HGE) cell cultures from periodontitis patients by quantitative TaqMan reverse transcription polymerase chain reaction (RT-PCR).
p15284
sg4
(lp15285
(dp15286
g9
I219
sg39
VP02042
p15287
sg12
I3
sg13
VhBD
p15288
sg15
I1
sa(dp15289
g9
I36
sg39
g40
sg12
I14
sg13
Vbeta-defensins
p15290
sg15
I1
sa(dp15291
g9
I173
sg39
VP60568
p15292
sg12
I4
sg13
VIL-8
p15293
sg15
I1
sa(dp15294
g9
I158
sg39
VP60568
p15295
sg12
I13
sg13
Vinterleukin-8
p15296
sg15
I1
sasg6
(lp15297
(dp15298
g9
I219
sg10
VC1840321
p15299
sg12
I3
sg13
VhBD
p15300
sg15
I1
sa(dp15301
g9
I295
sg10
VC0031099
p15302
sg12
I13
sg13
Vperiodontitis
p15303
sg15
I1
sa(dp15304
g9
I74
sg10
VC0031090
p15305
sg12
I19
sg13
Vperiodontal disease
p15306
sg15
I2
sasa(dp15307
g2
VHuman gingival epithelial cells (HGE) express two antimicrobial peptides of the beta-defensin family, human beta-defensin 1 (hBD-1) and hBD-2, as well as cytokines and chemokines that contribute to innate immunity.
p15308
sg4
(lp15309
(dp15310
g9
I125
sg39
VP60022
p15311
sg12
I5
sg13
VhBD-1
p15312
sg15
I1
sa(dp15313
g9
I136
sg39
g40
sg12
I5
sg13
VhBD-2
p15314
sg15
I1
sa(dp15315
g9
I102
sg39
VP60022
p15316
sg12
I21
sg13
Vhuman beta-defensin 1
p15317
sg15
I3
sa(dp15318
g9
I80
sg39
VP59861
p15319
sg12
I20
sg13
Vbeta-defensin family
p15320
sg15
I2
sasg6
(lp15321
(dp15322
g9
I125
sg10
VC1840321
p15323
sg12
I3
sg13
VhBD
p15324
sg15
I1
sa(dp15325
g9
I125
sg10
VC1840321
p15326
sg12
I3
sg13
VhBD
p15327
sg15
I1
sasa(dp15328
g2
VSSKcnj16-/- rats exhibited hypokalemia and reduced blood pressure, and when fed a high-salt diet (4% NaCl), experienced 100% mortality within a few days triggered by salt wasting and severe hypokalemia.
p15329
sg4
(lp15330
sg6
(lp15331
(dp15332
g9
I171
sg10
VC0235394
p15333
sg12
I7
sg13
Vwasting
p15334
sg15
I1
sasa(dp15335
g2
VHence, patients with HNF1Beta mutations may have reduced Kir5.1 activity in the kidney, resulting in hypokalemia and hypomagnesemia.
p15336
sg4
(lp15337
(dp15338
g9
I57
sg39
g40
sg12
I6
sg13
VKir5.1
p15339
sg15
I1
sa(dp15340
g9
I21
sg39
VP35680
p15341
sg12
I18
sg13
VHNF1Beta mutations
p15342
sg15
I2
sasg6
(lp15343
sa(dp15344
g2
VThe Kir5.1(-/-) mice displayed hypokalemic, hyperchloremic metabolic acidosis with hypercalciuria.
p15345
sg4
(lp15346
(dp15347
g9
I4
sg39
g40
sg12
I6
sg13
VKir5.1
p15348
sg15
I1
sasg6
(lp15349
(dp15350
g9
I83
sg10
VC0020438
p15351
sg12
I14
sg13
Vhypercalciuria
p15352
sg15
I1
sa(dp15353
g9
I59
sg10
VC0220981
p15354
sg12
I18
sg13
Vmetabolic acidosis
p15355
sg15
I2
sasa(dp15356
g2
VIn conclusion, disruption of Kcnj16 induces a severe renal phenotype that, apart from hypokalemia, is the opposite of the phenotype seen in SeSAME/EAST syndrome.
p15357
sg4
(lp15358
(dp15359
g9
I29
sg39
g40
sg12
I6
sg13
VKcnj16
p15360
sg15
I1
sasg6
(lp15361
(dp15362
g9
I147
sg10
VC2748572
p15363
sg12
I13
sg13
VEAST syndrome
p15364
sg15
I2
sasa(dp15365
g2
VWe found that Kir5.1(-/-) mice presented with persistent metabolic acidosis and a clear respiratory phenotype.
p15366
sg4
(lp15367
(dp15368
g9
I14
sg39
g40
sg12
I6
sg13
VKir5.1
p15369
sg15
I1
sasg6
(lp15370
(dp15371
g9
I57
sg10
VC0220981
p15372
sg12
I18
sg13
Vmetabolic acidosis
p15373
sg15
I2
sasa(dp15374
g2
VDespite metabolic acidosis, ventilation at rest and in hyperoxic hypercapnia were similar in wild-type and Kir5.1(-/-) mice.
p15375
sg4
(lp15376
sg6
(lp15377
(dp15378
g9
I8
sg10
VC0220981
p15379
sg12
I18
sg13
Vmetabolic acidosis
p15380
sg15
I2
sa(dp15381
g9
I65
sg10
VC0020440
p15382
sg12
I11
sg13
Vhypercapnia
p15383
sg15
I1
sasa(dp15384
g2
VWe suggest that this compensatory modulation of the peripheral chemosensory inputs develops in Kir5.1(-/-) mice in order to counteract the effect of continuing metabolic acidosis on the activity of the peripheral chemoreceptors.
p15385
sg4
(lp15386
(dp15387
g9
I95
sg39
g40
sg12
I6
sg13
VKir5.1
p15388
sg15
I1
sasg6
(lp15389
(dp15390
g9
I160
sg10
VC0220981
p15391
sg12
I18
sg13
Vmetabolic acidosis
p15392
sg15
I2
sasa(dp15393
g2
VIn this study, CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in 137 advanced stage NSCLC patients were investigated.
p15394
sg4
(lp15395
(dp15396
g9
I36
sg39
VP05181
p15397
sg12
I9
sg13
VCYP2E1*7B
p15398
sg15
I1
sa(dp15399
g9
I15
sg39
VP05181
p15400
sg12
I9
sg13
VCYP2E1*5B
p15401
sg15
I1
sa(dp15402
g9
I47
sg39
VP78417
p15403
sg12
I23
sg13
VGSTO1 (A140D), and TP53
p15404
sg15
I4
sa(dp15405
g9
I26
sg39
VP05181
p15406
sg12
I8
sg13
VCYP2E1*6
p15407
sg15
I1
sasg6
(lp15408
(dp15409
g9
I175
sg10
VC0007131
p15410
sg12
I5
sg13
VNSCLC
p15411
sg15
I1
sasa(dp15412
g2
VGSTO1-1 expression pattern has not been studied in transitional cell carcinoma (TCC), as yet.
p15413
sg4
(lp15414
(dp15415
g9
I0
sg39
VP78417
p15416
sg12
I7
sg13
VGSTO1-1
p15417
sg15
I1
sasg6
(lp15418
(dp15419
g9
I80
sg10
VC1861305
p15420
sg12
I3
sg13
VTCC
p15421
sg15
I1
sa(dp15422
g9
I51
sg10
VC0007138
p15423
sg12
I27
sg13
Vtransitional cell carcinoma
p15424
sg15
I3
sasa(dp15425
g2
VIncreased GSTO1-1 expression might contribute to TCC development and/or progression supporting the notion that GSTO1-1 may be a promising novel cancer target.
p15426
sg4
(lp15427
(dp15428
g9
I10
sg39
VP78417
p15429
sg12
I7
sg13
VGSTO1-1
p15430
sg15
I1
sa(dp15431
g9
I10
sg39
VP78417
p15432
sg12
I7
sg13
VGSTO1-1
p15433
sg15
I1
sasg6
(lp15434
(dp15435
g9
I49
sg10
VC1861305
p15436
sg12
I3
sg13
VTCC
p15437
sg15
I1
sa(dp15438
g9
I144
sg10
VC0006826
p15439
sg12
I6
sg13
Vcancer
p15440
sg15
I1
sasa(dp15441
g2
VGlutathione S-transferase omega 1 (GSTO1) is an atypical GST isoform that is overexpressed in several cancers and has been implicated in drug resistance.
p15442
sg4
(lp15443
(dp15444
g9
I0
sg39
VP78417
p15445
sg12
I33
sg13
VGlutathione S-transferase omega 1
p15446
sg15
I4
sa(dp15447
g9
I35
sg39
g40
sg12
I3
sg13
VGST
p15448
sg15
I1
sa(dp15449
g9
I35
sg39
VP78417
p15450
sg12
I5
sg13
VGSTO1
p15451
sg15
I1
sasg6
(lp15452
(dp15453
g9
I102
sg10
VC0006826
p15454
sg12
I7
sg13
Vcancers
p15455
sg15
I1
sasa(dp15456
g2
VHere we show that silencing of GSTO1 with siRNA significantly impairs cancer cell viability, validating GSTO1 as a potential new target in oncology.
p15457
sg4
(lp15458
(dp15459
g9
I31
sg39
VP78417
p15460
sg12
I5
sg13
VGSTO1
p15461
sg15
I1
sa(dp15462
g9
I31
sg39
VP78417
p15463
sg12
I5
sg13
VGSTO1
p15464
sg15
I1
sasg6
(lp15465
(dp15466
g9
I70
sg10
VC0006826
p15467
sg12
I6
sg13
Vcancer
p15468
sg15
I1
sasa(dp15469
g2
VThese potent GSTO1 inhibitors suppress cancer cell growth, enhance the cytotoxic effects of cisplatin and inhibit tumour growth in colon cancer models as single agent.
p15470
sg4
(lp15471
(dp15472
g9
I13
sg39
VP78417
p15473
sg12
I5
sg13
VGSTO1
p15474
sg15
I1
sasg6
(lp15475
(dp15476
g9
I114
sg10
VC0027651
p15477
sg12
I6
sg13
Vtumour
p15478
sg15
I1
sa(dp15479
g9
I131
sg10
VC0699790
p15480
sg12
I12
sg13
Vcolon cancer
p15481
sg15
I2
sa(dp15482
g9
I39
sg10
VC1516170
p15483
sg12
I18
sg13
Vcancer cell growth
p15484
sg15
I3
sasa(dp15485
g2
VOur findings demonstrate the therapeutic utility of GSTO1 inhibitors as anticancer agents and identify the novel cellular pathways under GSTO1 regulation in colorectal cancer.
p15486
sg4
(lp15487
(dp15488
g9
I52
sg39
VP78417
p15489
sg12
I5
sg13
VGSTO1
p15490
sg15
I1
sasg6
(lp15491
(dp15492
g9
I157
sg10
VC1527249
p15493
sg12
I17
sg13
Vcolorectal cancer
p15494
sg15
I2
sasa(dp15495
g2
VTo explore the relationship between angiogenin-1/2 (Ang-1/2) and clinical parameters of idiopathic pulmonary fibrosis (IPF), and to assess the value of Ang-1/2 in predicting the prognosis of patients with IPF.
p15496
sg4
(lp15497
(dp15498
g9
I36
sg39
VP03950
p15499
sg12
I14
sg13
Vangiogenin-1/2
p15500
sg15
I1
sa(dp15501
g9
I52
sg39
VP03950
p15502
sg12
I7
sg13
VAng-1/2
p15503
sg15
I1
sa(dp15504
g9
I52
sg39
VP03950
p15505
sg12
I7
sg13
VAng-1/2
p15506
sg15
I1
sasg6
(lp15507
(dp15508
g9
I119
sg10
VC3161101
p15509
sg12
I3
sg13
VIPF
p15510
sg15
I1
sa(dp15511
g9
I88
sg10
VC3161101
p15512
sg12
I29
sg13
Vidiopathic pulmonary fibrosis
p15513
sg15
I3
sa(dp15514
g9
I119
sg10
VC3161101
p15515
sg12
I3
sg13
VIPF
p15516
sg15
I1
sasa(dp15517
g2
VPreterm infants exposed to oxygen and mechanical ventilation are at risk for bronchopulmonary dysplasia (BPD), a multifactorial chronic lung disorder characterized by arrested alveolar development and nonsprouting, dysmorphic microvascular angiogenesis.
p15518
sg4
(lp15519
sg6
(lp15520
(dp15521
g9
I77
sg10
VC0006287
p15522
sg12
I26
sg13
Vbronchopulmonary dysplasia
p15523
sg15
I2
sa(dp15524
g9
I128
sg10
VC0746102
p15525
sg12
I21
sg13
Vchronic lung disorder
p15526
sg15
I3
sa(dp15527
g9
I167
sg10
VC0018790
p15528
sg12
I8
sg13
Varrested
p15529
sg15
I1
sa(dp15530
g9
I105
sg10
VC0006012
p15531
sg12
I3
sg13
VBPD
p15532
sg15
I1
sasa(dp15533
g2
VMany genes previously known to be affected by BPA and involved in obesity, hypertension, or heart disease were altered following these treatments, and AP-1, EGR1, and EGFR were key hubs affected by BPA and/or overfeeding.
p15534
sg4
(lp15535
(dp15536
g9
I157
sg39
VP18146
p15537
sg12
I4
sg13
VEGR1
p15538
sg15
I1
sa(dp15539
g9
I151
sg39
VP01100
p15540
sg12
I4
sg13
VAP-1
p15541
sg15
I1
sasg6
(lp15542
(dp15543
g9
I66
sg10
VC0028754
p15544
sg12
I7
sg13
Vobesity
p15545
sg15
I1
sa(dp15546
g9
I75
sg10
VC0020538
p15547
sg12
I12
sg13
Vhypertension
p15548
sg15
I1
sa(dp15549
g9
I92
sg10
VC0018799
p15550
sg12
I13
sg13
Vheart disease
p15551
sg15
I2
sasa(dp15552
g2
VUsing immunohistochemistry, we studied Egr-1 expression specifically in a wide morphologic spectrum of pulmonary arteries in the lung tissue of 72 patients with different forms and stages of PAH, specifically idiopathic PAH (n = 18), advanced-stage congenital heart disease-associated PAH (PAH-CHD) (n = 21), early-stage PAH-CHD (n = 19) and non-neointimal hypoxic pulmonary hypertension (PH) (n = 4), and controls (n = 10).
p15553
sg4
(lp15554
(dp15555
g9
I290
sg39
g40
sg12
I7
sg13
VPAH-CHD
p15556
sg15
I1
sa(dp15557
g9
I191
sg39
VP00439
p15558
sg12
I3
sg13
VPAH
p15559
sg15
I1
sa(dp15560
g9
I39
sg39
VP18146
p15561
sg12
I5
sg13
VEgr-1
p15562
sg15
I1
sa(dp15563
g9
I191
sg39
VP00439
p15564
sg12
I3
sg13
VPAH
p15565
sg15
I1
sasg6
(lp15566
(dp15567
g9
I389
sg10
VC0020542
p15568
sg12
I2
sg13
VPH
p15569
sg15
I1
sa(dp15570
g9
I365
sg10
VC0020542
p15571
sg12
I22
sg13
Vpulmonary hypertension
p15572
sg15
I2
sa(dp15573
g9
I191
sg10
VC0152171
p15574
sg12
I3
sg13
VPAH
p15575
sg15
I1
sa(dp15576
g9
I191
sg10
VC0152171
p15577
sg12
I3
sg13
VPAH
p15578
sg15
I1
sa(dp15579
g9
I191
sg10
VC0152171
p15580
sg12
I3
sg13
VPAH
p15581
sg15
I1
sa(dp15582
g9
I191
sg10
VC0152171
p15583
sg12
I3
sg13
VPAH
p15584
sg15
I1
sa(dp15585
g9
I357
sg10
VC0242184
p15586
sg12
I7
sg13
Vhypoxic
p15587
sg15
I1
sa(dp15588
g9
I249
sg10
VC0152021
p15589
sg12
I24
sg13
Vcongenital heart disease
p15590
sg15
I3
sa(dp15591
g9
I191
sg10
VC0152171
p15592
sg12
I3
sg13
VPAH
p15593
sg15
I1
sasa(dp15594
g2
VParkin substrates include two septins; SEPT4/CDCrel-2 which coaggregates with Alfa-synuclein as Lewy bodies in Parkinson's disease, and its closest homolog SEPT5/CDCrel-1/PNUTL1 whose overload with viral vector can rapidly eliminate dopamine neurons in rats.
p15595
sg4
(lp15596
(dp15597
g9
I156
sg39
g40
sg12
I5
sg13
VSEPT5
p15598
sg15
I1
sa(dp15599
g9
I30
sg39
g40
sg12
I7
sg13
Vseptins
p15600
sg15
I1
sa(dp15601
g9
I171
sg39
g40
sg12
I6
sg13
VPNUTL1
p15602
sg15
I1
sa(dp15603
g9
I78
sg39
VP37840
p15604
sg12
I14
sg13
VAlfa-synuclein
p15605
sg15
I1
sa(dp15606
g9
I39
sg39
g40
sg12
I5
sg13
VSEPT4
p15607
sg15
I1
sa(dp15608
g9
I162
sg39
g40
sg12
I8
sg13
VCDCrel-1
p15609
sg15
I1
sa(dp15610
g9
I45
sg39
g40
sg12
I8
sg13
VCDCrel-2
p15611
sg15
I1
sasg6
(lp15612
(dp15613
g9
I111
sg10
VC0030567
p15614
sg12
I19
sg13
VParkinson's disease
p15615
sg15
I2
sasa(dp15616
g2
VAfter validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to neurodegenerative disease, septin 5, Alfa-internexin, and Alfa-synuclein, were identified to be altered by MCLR exposure.
p15617
sg4
(lp15618
(dp15619
g9
I168
sg39
VP37840
p15620
sg12
I14
sg13
VAlfa-synuclein
p15621
sg15
I1
sa(dp15622
g9
I137
sg39
g40
sg12
I8
sg13
Vseptin 5
p15623
sg15
I2
sasg6
(lp15624
(dp15625
g9
I110
sg10
VC0524851
p15626
sg12
I25
sg13
Vneurodegenerative disease
p15627
sg15
I2
sasa(dp15628
g2
VInterestingly, Septin 5, one of the genes isolated from HPAI H5N1-infected brain tissues has been reported to participate in the pathogenic process of Parkinson's disease.
p15629
sg4
(lp15630
(dp15631
g9
I15
sg39
g40
sg12
I8
sg13
VSeptin 5
p15632
sg15
I2
sasg6
(lp15633
(dp15634
g9
I61
sg10
VC0016627
p15635
sg12
I4
sg13
VH5N1
p15636
sg15
I1
sa(dp15637
g9
I151
sg10
VC0030567
p15638
sg12
I19
sg13
VParkinson's disease
p15639
sg15
I2
sasa(dp15640
g2
VA previous study successfully developed and validated a self-report BPD measure, the Minnesota Borderline Personality Disorder Scale (MBPD).
p15641
sg4
(lp15642
sg6
(lp15643
(dp15644
g9
I68
sg10
VC0006012
p15645
sg12
I3
sg13
VBPD
p15646
sg15
I1
sa(dp15647
g9
I95
sg10
VC0006012
p15648
sg12
I31
sg13
VBorderline Personality Disorder
p15649
sg15
I3
sasa(dp15650
g2
VA previous study successfully developed and validated a BPD measure embedded within a normal trait measure, the Minnesota Borderline Personality Disorder Scale (MBPD).
p15651
sg4
(lp15652
sg6
(lp15653
(dp15654
g9
I122
sg10
VC0006012
p15655
sg12
I31
sg13
VBorderline Personality Disorder
p15656
sg15
I3
sa(dp15657
g9
I56
sg10
VC0006012
p15658
sg12
I3
sg13
VBPD
p15659
sg15
I1
sasa(dp15660
g2
VThis study was to investigate HSP70 expression in the peripheral lung tissues of chronic obstructive pulmonary disease (COPD) patients and in human bronchial epithelial cells (16-HBE) exposed to cigarette smoke extract (CSE).
p15661
sg4
(lp15662
(dp15663
g9
I30
sg39
VP34932
p15664
sg12
I5
sg13
VHSP70
p15665
sg15
I1
sasg6
(lp15666
(dp15667
g9
I220
sg10
VC1832855
p15668
sg12
I3
sg13
VCSE
p15669
sg15
I1
sa(dp15670
g9
I81
sg10
VC0024117
p15671
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p15672
sg15
I4
sa(dp15673
g9
I195
sg10
VC1832855
p15674
sg12
I23
sg13
Vcigarette smoke extract
p15675
sg15
I3
sa(dp15676
g9
I120
sg10
VC0024117
p15677
sg12
I4
sg13
VCOPD
p15678
sg15
I1
sasa(dp15679
g2
VSequencing analysis of the endogenous E2F4 gene in a series of colorectal cancer cell lines showed that the microsatellite-unstable cell line SW48 exhibited a serine deletion in this gene.
p15680
sg4
(lp15681
(dp15682
g9
I38
sg39
g40
sg12
I9
sg13
VE2F4 gene
p15683
sg15
I2
sasg6
(lp15684
(dp15685
g9
I63
sg10
VC1527249
p15686
sg12
I17
sg13
Vcolorectal cancer
p15687
sg15
I2
sasa(dp15688
g2
VIn conclusion, our data demonstrate that cancer-associated E2F4 mutations enhance the capacity of colorectal cancer cells to grow without anchorage, thereby contributing to tumor progression.
p15689
sg4
(lp15690
(dp15691
g9
I59
sg39
g40
sg12
I4
sg13
VE2F4
p15692
sg15
I1
sasg6
(lp15693
(dp15694
g9
I41
sg10
VC0006826
p15695
sg12
I6
sg13
Vcancer
p15696
sg15
I1
sa(dp15697
g9
I173
sg10
VC0178874
p15698
sg12
I17
sg13
Vtumor progression
p15699
sg15
I2
sa(dp15700
g9
I98
sg10
VC1527249
p15701
sg12
I17
sg13
Vcolorectal cancer
p15702
sg15
I2
sasa(dp15703
g2
VThe inverse immunohistochemical relationship between E2F1 and E2F4 indicates a possible mechanistic interlink in colorectal cancer.
p15704
sg4
(lp15705
(dp15706
g9
I62
sg39
g40
sg12
I4
sg13
VE2F4
p15707
sg15
I1
sa(dp15708
g9
I53
sg39
g40
sg12
I4
sg13
VE2F1
p15709
sg15
I1
sasg6
(lp15710
(dp15711
g9
I113
sg10
VC1527249
p15712
sg12
I17
sg13
Vcolorectal cancer
p15713
sg15
I2
sasa(dp15714
g2
VIn an attempt to identify the role of E2F-4 as a potential mediator of cell proliferation, differentiation, tumorigenesis, and apoptosis in colorectal mucosa comparing with that of E2F-1, the authors examine 20 patients with human colon cancer and their corresponding histologically healthy mucosa by using immunohistochemical methods, computerized quantitative image analysis, and immunoblot analysis.
p15715
sg4
(lp15716
(dp15717
g9
I38
sg39
g40
sg12
I5
sg13
VE2F-4
p15718
sg15
I1
sa(dp15719
g9
I181
sg39
g40
sg12
I5
sg13
VE2F-1
p15720
sg15
I1
sasg6
(lp15721
(dp15722
g9
I108
sg10
VC0007621
p15723
sg12
I13
sg13
Vtumorigenesis
p15724
sg15
I1
sa(dp15725
g9
I76
sg10
VC0334094
p15726
sg12
I13
sg13
Vproliferation
p15727
sg15
I1
sa(dp15728
g9
I231
sg10
VC0699790
p15729
sg12
I12
sg13
Vcolon cancer
p15730
sg15
I2
sasa(dp15731
g2
VEighteen colorectal cancer (CRC) patients from 13 kindreds meeting the Amsterdam criteria for HNPCC were analyzed and compared to sporadic CRC patients with MSI-H. We detected mutations of E2F-4 at the same repeat sequence in HNPCC.
p15732
sg4
(lp15733
(dp15734
g9
I189
sg39
g40
sg12
I5
sg13
VE2F-4
p15735
sg15
I1
sasg6
(lp15736
(dp15737
g9
I28
sg10
VC1527249
p15738
sg12
I3
sg13
VCRC
p15739
sg15
I1
sa(dp15740
g9
I157
sg10
VC0920269
p15741
sg12
I3
sg13
VMSI
p15742
sg15
I1
sa(dp15743
g9
I9
sg10
VC1527249
p15744
sg12
I17
sg13
Vcolorectal cancer
p15745
sg15
I2
sa(dp15746
g9
I28
sg10
VC1527249
p15747
sg12
I3
sg13
VCRC
p15748
sg15
I1
sa(dp15749
g9
I94
sg10
VC1333990
p15750
sg12
I5
sg13
VHNPCC
p15751
sg15
I1
sa(dp15752
g9
I94
sg10
VC1333990
p15753
sg12
I5
sg13
VHNPCC
p15754
sg15
I1
sasa(dp15755
g2
VAlthough the implication of vascular endothelial growth factor, angiopoietin-2, and C-X-C motif chemokine 10 has been suggested, the pathogenesis of systemic capillary leak syndrome remains unclear.
p15756
sg4
(lp15757
(dp15758
g9
I64
sg39
g40
sg12
I14
sg13
Vangiopoietin-2
p15759
sg15
I1
sa(dp15760
g9
I28
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p15761
sg15
I4
sasg6
(lp15762
(dp15763
g9
I149
sg10
VC0343084
p15764
sg12
I32
sg13
Vsystemic capillary leak syndrome
p15765
sg15
I4
sa(dp15766
g9
I133
sg10
VC0699748
p15767
sg12
I12
sg13
Vpathogenesis
p15768
sg15
I1
sasa(dp15769
g2
VMicrovascular dysfunction under septic shock is related to: increased capillary permeability that manifests as a breakdown of the microvascular endothelial barrier (factors which may contribute to capillary leak syndrome include endogenous proinflammatory cytokines, angiopoietin 2, vascular endothelial growth factor); arteriolar hyporesponsiveness to vasoconstrictors and vasodilators, the loss of adrenergic sensitivity and tone of smooth muscle cells lining the arterioles; loss of the anti-adhesive function of endothelial surfaces; decreased density of perfused capillaries (due to several contributing factors: decreased deformability of erythrocytes and neutrophils; activation of the clotting cascade with fibrin deposition and the formation of microthrombi; dysfunction of vascular autoregulatory mechanisms by nitric oxide; enhanced functional arteriovenous shunting of the microcirculation).
p15770
sg4
(lp15771
(dp15772
g9
I283
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p15773
sg15
I4
sa(dp15774
g9
I267
sg39
g40
sg12
I14
sg13
Vangiopoietin 2
p15775
sg15
I2
sa(dp15776
g9
I715
sg39
VP22087
p15777
sg12
I6
sg13
Vfibrin
p15778
sg15
I1
sasg6
(lp15779
(dp15780
g9
I113
sg10
VC1265875
p15781
sg12
I9
sg13
Vbreakdown
p15782
sg15
I1
sa(dp15783
g9
I715
sg10
VC0333565
p15784
sg12
I17
sg13
Vfibrin deposition
p15785
sg15
I2
sa(dp15786
g9
I197
sg10
VC0343084
p15787
sg12
I23
sg13
Vcapillary leak syndrome
p15788
sg15
I3
sa(dp15789
g9
I32
sg10
VC0036983
p15790
sg12
I12
sg13
Vseptic shock
p15791
sg15
I2
sasa(dp15792
g2
VFurther investigations of AL-1 as a promising new agent for treatment and/or prevention of diabetes are warranted.
p15793
sg4
(lp15794
sg6
(lp15795
(dp15796
g9
I91
sg10
VC0011849
p15797
sg12
I8
sg13
Vdiabetes
p15798
sg15
I1
sasa(dp15799
g2
VIn established cardiac ATTR amyloidosis, T1 elevation was not as high as in AL amyloidosis (AL 1,130 +/- 68 ms; p = 0.01).
p15800
sg4
(lp15801
sg6
(lp15802
(dp15803
g9
I28
sg10
VC0002726
p15804
sg12
I11
sg13
Vamyloidosis
p15805
sg15
I1
sa(dp15806
g9
I76
sg10
VC0268381
p15807
sg12
I14
sg13
VAL amyloidosis
p15808
sg15
I2
sasa(dp15809
g2
VWe previously reported that EphA5 receptor-ephrinA5 interactions within the ventromedial hypothalamus (VMH) influence counterregulatory hormone responses during acute hypoglycemia in nondiabetic rats.
p15810
sg4
(lp15811
(dp15812
g9
I28
sg39
VP54756
p15813
sg12
I14
sg13
VEphA5 receptor
p15814
sg15
I2
sasg6
(lp15815
(dp15816
g9
I161
sg10
VC0745150
p15817
sg12
I18
sg13
Vacute hypoglycemia
p15818
sg15
I2
sasa(dp15819
g2
VIn this study, we examined whether recurrent hypoglycemia alters the capacity of the ephrinA5 ligand to activate VMH EphA5 receptors, and if so, whether these changes could contribute to pathogenesis of defective glucose counterregulation in response to a standard hypoglycemic stimulus.
p15820
sg4
(lp15821
(dp15822
g9
I85
sg39
g40
sg12
I15
sg13
VephrinA5 ligand
p15823
sg15
I2
sa(dp15824
g9
I113
sg39
VP54756
p15825
sg12
I19
sg13
VVMH EphA5 receptors
p15826
sg15
I3
sasg6
(lp15827
(dp15828
g9
I187
sg10
VC0699748
p15829
sg12
I12
sg13
Vpathogenesis
p15830
sg15
I1
sa(dp15831
g9
I45
sg10
VC0020615
p15832
sg12
I12
sg13
Vhypoglycemia
p15833
sg15
I1
sasa(dp15834
g2
VThe expression of ephrinA5, but not EphA5 receptors within the VMH, was reduced by antecedent recurrent hypoglycemia.
p15835
sg4
(lp15836
(dp15837
g9
I36
sg39
VP54756
p15838
sg12
I15
sg13
VEphA5 receptors
p15839
sg15
I2
sasg6
(lp15840
(dp15841
g9
I104
sg10
VC0020615
p15842
sg12
I12
sg13
Vhypoglycemia
p15843
sg15
I1
sasa(dp15844
g2
VActivation of VMH EphA5 receptors via targeted microinjection of ephrinA5-Fc before a hyperinsulinemic hypoglycemic clamp study caused a reduction in the glucose infusion rate in nondiabetic rats exposed to recurrent hypoglycemia.
p15845
sg4
(lp15846
(dp15847
g9
I14
sg39
VP54756
p15848
sg12
I19
sg13
VVMH EphA5 receptors
p15849
sg15
I3
sasg6
(lp15850
(dp15851
g9
I217
sg10
VC0020615
p15852
sg12
I12
sg13
Vhypoglycemia
p15853
sg15
I1
sasa(dp15854
g2
VThese data suggest that changes in ephrinA5/EphA5 interactions and synaptic plasticity within the VMH, a key glucose-sensing region in the brain, may contribute to the impairment in glucagon secretion and counterregulatory responses caused by recurrent hypoglycemia.
p15855
sg4
(lp15856
(dp15857
g9
I44
sg39
VP54756
p15858
sg12
I5
sg13
VEphA5
p15859
sg15
I1
sa(dp15860
g9
I182
sg39
VP01275
p15861
sg12
I8
sg13
Vglucagon
p15862
sg15
I1
sasg6
(lp15863
(dp15864
g9
I253
sg10
VC0020615
p15865
sg12
I12
sg13
Vhypoglycemia
p15866
sg15
I1
sa(dp15867
g9
I168
sg10
VC0684336
p15868
sg12
I10
sg13
Vimpairment
p15869
sg15
I1
sasa(dp15870
g2
VActivation of Beta-cell EphA5 receptors by its ligand ephrinA5 from adjacent Beta-cells has been reported to decrease insulin secretion during hypoglycemia.
p15871
sg4
(lp15872
(dp15873
g9
I14
sg39
VP54756
p15874
sg12
I25
sg13
VBeta-cell EphA5 receptors
p15875
sg15
I3
sa(dp15876
g9
I118
sg39
VP01308
p15877
sg12
I7
sg13
Vinsulin
p15878
sg15
I1
sasg6
(lp15879
(dp15880
g9
I143
sg10
VC0020615
p15881
sg12
I12
sg13
Vhypoglycemia
p15882
sg15
I1
sasa(dp15883
g2
VGiven the similarities between islet and ventromedial hypothalamus (VMH) glucose sensing, we tested the hypothesis that the EphA5/ephrinA5 system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.
p15884
sg4
(lp15885
(dp15886
g9
I124
sg39
VP54756
p15887
sg12
I5
sg13
VEphA5
p15888
sg15
I1
sasg6
(lp15889
(dp15890
g9
I183
sg10
VC0020615
p15891
sg12
I12
sg13
Vhypoglycemia
p15892
sg15
I1
sasa(dp15893
g2
VLocal stimulation of VMH EphA5 receptors by ephrinA5-Fc or ephrinA5 overexpression increased, whereas knockdown of VMH ephrinA5 reduced counterregulatory responses during hypoglycemia.
p15894
sg4
(lp15895
(dp15896
g9
I21
sg39
VP54756
p15897
sg12
I19
sg13
VVMH EphA5 receptors
p15898
sg15
I3
sasg6
(lp15899
(dp15900
g9
I171
sg10
VC0020615
p15901
sg12
I12
sg13
Vhypoglycemia
p15902
sg15
I1
sasa(dp15903
g2
VOverexpression of VMH ephrinA5 transiently increased local glutamate concentrations, whereas ephrinA5 knockdown produced profound suppression of VMH interstitial fluid glutamine concentrations in the basal state and during hypoglycemia.
p15904
sg4
(lp15905
(dp15906
g9
I93
sg39
g40
sg12
I18
sg13
VephrinA5 knockdown
p15907
sg15
I2
sasg6
(lp15908
(dp15909
g9
I223
sg10
VC0020615
p15910
sg12
I12
sg13
Vhypoglycemia
p15911
sg15
I1
sa(dp15912
g9
I130
sg10
VC0221103
p15913
sg12
I11
sg13
Vsuppression
p15914
sg15
I1
sasa(dp15915
g2
VChanges in ephrinA5/EphA5 interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.
p15916
sg4
(lp15917
(dp15918
g9
I20
sg39
VP54756
p15919
sg12
I5
sg13
VEphA5
p15920
sg15
I1
sasg6
(lp15921
(dp15922
g9
I156
sg10
VC0745150
p15923
sg12
I18
sg13
Vacute hypoglycemia
p15924
sg15
I2
sasa(dp15925
g2
VFractionation of dichloromethane (DCM) molecules with different chlorine isotopes by aerobic methylobacteria Methylobacterium dichloromethanicum DM4 and Albibacter nethylovorans DM10; cell-free extract of strain DM4; and transconjugant Methylobacterium evtorquens Al1/pME 8220, expressing the dcmA gene for DCM dehalogenase but unable to grow on DCM, was studied.
p15926
sg4
(lp15927
(dp15928
g9
I268
sg39
VP04080
p15929
sg12
I3
sg13
VpME
p15930
sg15
I1
sa(dp15931
g9
I293
sg39
g40
sg12
I9
sg13
VdcmA gene
p15932
sg15
I2
sasg6
(lp15933
(dp15934
g9
I268
sg10
VC0751785
p15935
sg12
I3
sg13
VpME
p15936
sg15
I1
sa(dp15937
g9
I293
sg10
VC1857776
p15938
sg12
I4
sg13
VdcmA
p15939
sg15
I1
sasa(dp15940
g2
VWe also describe the first RCC with a DVL2-TFE3 gene fusion, in addition to an extrarenal pigmented PEComa with a NONO-TFE3 gene fusion.
p15941
sg4
(lp15942
(dp15943
g9
I43
sg39
VP19532
p15944
sg12
I4
sg13
VTFE3
p15945
sg15
I1
sa(dp15946
g9
I114
sg39
g40
sg12
I4
sg13
VNONO
p15947
sg15
I1
sa(dp15948
g9
I38
sg39
g40
sg12
I4
sg13
VDVL2
p15949
sg15
I1
sa(dp15950
g9
I43
sg39
VP19532
p15951
sg12
I4
sg13
VTFE3
p15952
sg15
I1
sasg6
(lp15953
(dp15954
g9
I48
sg10
VC1705736
p15955
sg12
I11
sg13
Vgene fusion
p15956
sg15
I2
sa(dp15957
g9
I100
sg10
VC1300127
p15958
sg12
I6
sg13
VPEComa
p15959
sg15
I1
sa(dp15960
g9
I48
sg10
VC1705736
p15961
sg12
I11
sg13
Vgene fusion
p15962
sg15
I2
sa(dp15963
g9
I27
sg10
VC0007134
p15964
sg12
I3
sg13
VRCC
p15965
sg15
I1
sasa(dp15966
g2
VFurthermore, among neoplasms with the SFPQ-TFE3, NONO-TFE3, DVL2-TFE3, and ASPL-TFE3 gene fusions, the RCCs are almost always PAX8 positive, cathepsin K negative by immunohistochemistry, whereas the mesenchymal counterparts (Xp11 translocation PEComas, melanotic Xp11 translocation renal cancers, and alveolar soft part sarcoma) are PAX8 negative, cathepsin K positive.
p15967
sg4
(lp15968
(dp15969
g9
I225
sg39
g40
sg12
I26
sg13
VXp11 translocation PEComas
p15970
sg15
I3
sa(dp15971
g9
I49
sg39
g40
sg12
I4
sg13
VNONO
p15972
sg15
I1
sa(dp15973
g9
I38
sg39
VP23246
p15974
sg12
I4
sg13
VSFPQ
p15975
sg15
I1
sa(dp15976
g9
I43
sg39
VP19532
p15977
sg12
I4
sg13
VTFE3
p15978
sg15
I1
sa(dp15979
g9
I126
sg39
g40
sg12
I4
sg13
VPAX8
p15980
sg15
I1
sa(dp15981
g9
I43
sg39
VP19532
p15982
sg12
I4
sg13
VTFE3
p15983
sg15
I1
sa(dp15984
g9
I141
sg39
VP43235
p15985
sg12
I11
sg13
Vcathepsin K
p15986
sg15
I2
sa(dp15987
g9
I75
sg39
g40
sg12
I4
sg13
VASPL
p15988
sg15
I1
sa(dp15989
g9
I253
sg39
g40
sg12
I42
sg13
Vmelanotic Xp11 translocation renal cancers
p15990
sg15
I5
sa(dp15991
g9
I43
sg39
VP19532
p15992
sg12
I4
sg13
VTFE3
p15993
sg15
I1
sa(dp15994
g9
I126
sg39
g40
sg12
I4
sg13
VPAX8
p15995
sg15
I1
sa(dp15996
g9
I60
sg39
g40
sg12
I4
sg13
VDVL2
p15997
sg15
I1
sa(dp15998
g9
I141
sg39
VP43235
p15999
sg12
I11
sg13
Vcathepsin K
p16000
sg15
I2
sa(dp16001
g9
I43
sg39
VP19532
p16002
sg12
I4
sg13
VTFE3
p16003
sg15
I1
sasg6
(lp16004
(dp16005
g9
I244
sg10
VC1300127
p16006
sg12
I7
sg13
VPEComas
p16007
sg15
I1
sa(dp16008
g9
I19
sg10
VC0027651
p16009
sg12
I9
sg13
Vneoplasms
p16010
sg15
I1
sa(dp16011
g9
I230
sg10
VC0040715
p16012
sg12
I13
sg13
Vtranslocation
p16013
sg15
I1
sa(dp16014
g9
I230
sg10
VC0040715
p16015
sg12
I13
sg13
Vtranslocation
p16016
sg15
I1
sa(dp16017
g9
I282
sg10
VC0740457
p16018
sg12
I13
sg13
Vrenal cancers
p16019
sg15
I2
sa(dp16020
g9
I301
sg10
VC0206657
p16021
sg12
I26
sg13
Valveolar soft part sarcoma
p16022
sg15
I4
sa(dp16023
g9
I103
sg10
VC0007134
p16024
sg12
I4
sg13
VRCCs
p16025
sg15
I1
sasa(dp16026
g2
VThe compound was further tested in vitro for acetylation of histone H4 and other non-histone proteins, and in vivo in a colon carcinoma model, showing significant proapoptotic and antitumor activities.
p16027
sg4
(lp16028
(dp16029
g9
I81
sg39
VP62805
p16030
sg12
I20
sg13
Vnon-histone proteins
p16031
sg15
I2
sa(dp16032
g9
I60
sg39
VP62805
p16033
sg12
I10
sg13
Vhistone H4
p16034
sg15
I2
sasg6
(lp16035
(dp16036
g9
I120
sg10
VC0699790
p16037
sg12
I15
sg13
Vcolon carcinoma
p16038
sg15
I2
sasa(dp16039
g2
VAs a proof-of-principle, we have identified cytochrome C and Histone H4 as two of the predominant protein species in the 3D colon carcinoma cultures.
p16040
sg4
(lp16041
(dp16042
g9
I44
sg39
VP99999
p16043
sg12
I12
sg13
Vcytochrome C
p16044
sg15
I2
sa(dp16045
g9
I61
sg39
VP62805
p16046
sg12
I10
sg13
VHistone H4
p16047
sg15
I2
sasg6
(lp16048
(dp16049
g9
I124
sg10
VC0699790
p16050
sg12
I15
sg13
Vcolon carcinoma
p16051
sg15
I2
sasa(dp16052
g2
VDouble 2-mm core tissue microarrays were made from 261 paraffin-embedded gastric adenocarcinoma samples and examined by immunohistochemistry for histone H3 lysine 9 (H3K9) acetylation and trimethylation, histone H4 lysine 16 acetylation, and histone H4 lysine 20 trimethylation.
p16053
sg4
(lp16054
(dp16055
g9
I145
sg39
g40
sg12
I19
sg13
Vhistone H3 lysine 9
p16056
sg15
I4
sa(dp16057
g9
I204
sg39
VP62805
p16058
sg12
I10
sg13
Vhistone H4
p16059
sg15
I2
sa(dp16060
g9
I204
sg39
VP62805
p16061
sg12
I20
sg13
Vhistone H4 lysine 16
p16062
sg15
I4
sasg6
(lp16063
(dp16064
g9
I73
sg10
VC0278701
p16065
sg12
I22
sg13
Vgastric adenocarcinoma
p16066
sg15
I2
sasa(dp16067
g2
VThis study aimed to investigate the expression of NOR1 in hepatocellular carcinoma (HCC) tissue and its relationship with prognosis.
p16068
sg4
(lp16069
(dp16070
g9
I50
sg39
g40
sg12
I4
sg13
VNOR1
p16071
sg15
I1
sasg6
(lp16072
(dp16073
g9
I84
sg10
VC2239176
p16074
sg12
I3
sg13
VHCC
p16075
sg15
I1
sa(dp16076
g9
I58
sg10
VC2239176
p16077
sg12
I24
sg13
Vhepatocellular carcinoma
p16078
sg15
I2
sasa(dp16079
g2
VOxidored-nitro domain-containing protein 1 (NOR1) expression levels are greater in hepatitis, cirrhosis and hepatocellular carcinoma samples compared with from normal liver samples.
p16080
sg4
(lp16081
(dp16082
g9
I44
sg39
g40
sg12
I4
sg13
VNOR1
p16083
sg15
I1
sa(dp16084
g9
I0
sg39
g40
sg12
I42
sg13
VOxidored-nitro domain-containing protein 1
p16085
sg15
I4
sasg6
(lp16086
(dp16087
g9
I94
sg10
VC0023890
p16088
sg12
I9
sg13
Vcirrhosis
p16089
sg15
I1
sa(dp16090
g9
I108
sg10
VC1512411
p16091
sg12
I24
sg13
Vhepatocellular carcinoma
p16092
sg15
I2
sa(dp16093
g9
I83
sg10
VC0019159
p16094
sg12
I9
sg13
Vhepatitis
p16095
sg15
I1
sasa(dp16096
g2
VIn conclusion, these results indicate that NOR1 may be involved in the progression of HCC and thus may be a potential target for the treatment of liver cancer.
p16097
sg4
(lp16098
(dp16099
g9
I43
sg39
g40
sg12
I4
sg13
VNOR1
p16100
sg15
I1
sasg6
(lp16101
(dp16102
g9
I86
sg10
VC2239176
p16103
sg12
I3
sg13
VHCC
p16104
sg15
I1
sa(dp16105
g9
I146
sg10
VC0345904
p16106
sg12
I12
sg13
Vliver cancer
p16107
sg15
I2
sasa(dp16108
g2
VTo date, several studies have revealed that gene mutations of the transporters are likely to be associated with some diseases; however, there are no data concerning the genetic polymorphism of the hOSCP1 gene in Japanese patients with non-viral liver carcinoma (LC).
p16109
sg4
(lp16110
(dp16111
g9
I197
sg39
g40
sg12
I11
sg13
VhOSCP1 gene
p16112
sg15
I2
sasg6
(lp16113
(dp16114
g9
I245
sg10
VC2239176
p16115
sg12
I15
sg13
Vliver carcinoma
p16116
sg15
I2
sa(dp16117
g9
I262
sg10
VC2239176
p16118
sg12
I2
sg13
VLC
p16119
sg15
I1
sasa(dp16120
g2
VThe nitroreductase oxidored-nitro domain containing protein 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and nasopharyngeal carcinoma (NPC).
p16121
sg4
(lp16122
(dp16123
g9
I63
sg39
g40
sg12
I4
sg13
VNOR1
p16124
sg15
I1
sa(dp16125
g9
I4
sg39
VP14222
p16126
sg12
I57
sg13
Vnitroreductase oxidored-nitro domain containing protein 1
p16127
sg15
I6
sasg6
(lp16128
(dp16129
g9
I124
sg10
VC0345904
p16130
sg12
I14
sg13
Vhepatic cancer
p16131
sg15
I2
sa(dp16132
g9
I97
sg10
VC0596321
p16133
sg12
I23
sg13
Vchemical carcinogenesis
p16134
sg15
I2
sa(dp16135
g9
I169
sg10
VC2931822
p16136
sg12
I3
sg13
VNPC
p16137
sg15
I1
sa(dp16138
g9
I143
sg10
VC2931822
p16139
sg12
I24
sg13
Vnasopharyngeal carcinoma
p16140
sg15
I2
sasa(dp16141
g2
VUsing cDNA microarrays and quantitative real-time PCR, we previously discovered that NOR1 increases the expression of growth factor receptor-bound protein 2 (Grb2) mRNA by 4.8-fold in the human hepatocellular carcinoma cell line HepG2.
p16142
sg4
(lp16143
(dp16144
g9
I158
sg39
VP62993
p16145
sg12
I4
sg13
VGrb2
p16146
sg15
I1
sa(dp16147
g9
I85
sg39
g40
sg12
I4
sg13
VNOR1
p16148
sg15
I1
sa(dp16149
g9
I118
sg39
VP62993
p16150
sg12
I38
sg13
Vgrowth factor receptor-bound protein 2
p16151
sg15
I5
sasg6
(lp16152
(dp16153
g9
I194
sg10
VC1512411
p16154
sg12
I24
sg13
Vhepatocellular carcinoma
p16155
sg15
I2
sasa(dp16156
g2
VIn addition, expression of human NOR1 protein in different normal and cancerous human tissues was analyzed via search of the human RNA and protein databases; the data showed that although most malignant cells weakly stained or were negative for NOR1 expression, the liver cancer cells displayed moderate to strong expression of NOR1.
p16157
sg4
(lp16158
(dp16159
g9
I33
sg39
g40
sg12
I4
sg13
VNOR1
p16160
sg15
I1
sa(dp16161
g9
I27
sg39
g40
sg12
I18
sg13
Vhuman NOR1 protein
p16162
sg15
I3
sa(dp16163
g9
I33
sg39
g40
sg12
I4
sg13
VNOR1
p16164
sg15
I1
sasg6
(lp16165
(dp16166
g9
I266
sg10
VC0345904
p16167
sg12
I12
sg13
Vliver cancer
p16168
sg15
I2
sasa(dp16169
g2
VThese data suggested that NOR1 might serve as a cancer/testis/brain antigen in cells, and that altered NOR1 expression in liver cancer may help us to elucidate the functions of NOR1 protein in liver carcinogenesis.
p16170
sg4
(lp16171
(dp16172
g9
I26
sg39
g40
sg12
I4
sg13
VNOR1
p16173
sg15
I1
sa(dp16174
g9
I26
sg39
g40
sg12
I4
sg13
VNOR1
p16175
sg15
I1
sa(dp16176
g9
I177
sg39
g40
sg12
I12
sg13
VNOR1 protein
p16177
sg15
I2
sasg6
(lp16178
(dp16179
g9
I48
sg10
VC0006826
p16180
sg12
I6
sg13
Vcancer
p16181
sg15
I1
sa(dp16182
g9
I122
sg10
VC0345904
p16183
sg12
I12
sg13
Vliver cancer
p16184
sg15
I2
sa(dp16185
g9
I193
sg10
VC1512409
p16186
sg12
I20
sg13
Vliver carcinogenesis
p16187
sg15
I2
sasa(dp16188
g2
VSignificant allelic associations with SLE were detected in European Americans (EA) and African Americans (AA), which could be attributed to an intronic CFH SNP (rs6677604, in intron 11, P(meta) = 6.6x10(-8), OR = 1.18) and an intergenic SNP between CFHR1 and CFHR4 (rs16840639, P(meta) = 2.9x10(-7), OR = 1.17) rather than to previously identified disease-associated CFH exonic SNPs, including I62V, Y402H, A474A, and D936E.
p16189
sg4
(lp16190
(dp16191
g9
I152
sg39
g40
sg12
I7
sg13
VCFH SNP
p16192
sg15
I2
sa(dp16193
g9
I249
sg39
g40
sg12
I5
sg13
VCFHR1
p16194
sg15
I1
sa(dp16195
g9
I259
sg39
g40
sg12
I5
sg13
VCFHR4
p16196
sg15
I1
sasg6
(lp16197
(dp16198
g9
I38
sg10
VC0014060
p16199
sg12
I3
sg13
VSLE
p16200
sg15
I1
sasa(dp16201
g2
VGastroschisis and omphalocele are the most common fetal abdominal wall defects (AWDs).
p16202
sg4
(lp16203
sg6
(lp16204
(dp16205
g9
I0
sg10
VC0265706
p16206
sg12
I13
sg13
VGastroschisis
p16207
sg15
I1
sa(dp16208
g9
I18
sg10
VC0795690
p16209
sg12
I11
sg13
Vomphalocele
p16210
sg15
I1
sasa(dp16211
g2
VAWDs were identified through gastroschisis and omphalocele checkboxes from publicly available US Natality data (2006 to 2010).
p16212
sg4
(lp16213
sg6
(lp16214
(dp16215
g9
I47
sg10
VC0795690
p16216
sg12
I11
sg13
Vomphalocele
p16217
sg15
I1
sa(dp16218
g9
I29
sg10
VC0265706
p16219
sg12
I13
sg13
Vgastroschisis
p16220
sg15
I1
sasa(dp16221
g2
VThe angiogenic proteins vascular endothelial growth factor (VEGF) and prokineticin1 (PROK1) proteins are considered important in colorectal cancer, the relationship between their simultaneous expression and prognosis was investigated in the present study.
p16222
sg4
(lp16223
(dp16224
g9
I60
sg39
g40
sg12
I4
sg13
VVEGF
p16225
sg15
I1
sa(dp16226
g9
I24
sg39
g40
sg12
I34
sg13
Vvascular endothelial growth factor
p16227
sg15
I4
sa(dp16228
g9
I70
sg39
VP58294
p16229
sg12
I30
sg13
Vprokineticin1 (PROK1) proteins
p16230
sg15
I3
sasg6
(lp16231
(dp16232
g9
I129
sg10
VC1527249
p16233
sg12
I17
sg13
Vcolorectal cancer
p16234
sg15
I2
sasa(dp16235
g2
VVEGF and PROK1 expression in 620 primary human colorectal cancer lesions was confirmed via immunohistochemical staining with anti-VEGF and anti-PROK1 antibodies, and the correlation between the expression of these 2 proteins and recurrence/prognosis were investigated.
p16236
sg4
(lp16237
(dp16238
g9
I139
sg39
VP58294
p16239
sg12
I21
sg13
Vanti-PROK1 antibodies
p16240
sg15
I2
sa(dp16241
g9
I9
sg39
VP58294
p16242
sg12
I5
sg13
VPROK1
p16243
sg15
I1
sasg6
(lp16244
(dp16245
g9
I229
sg10
VC1458156
p16246
sg12
I10
sg13
Vrecurrence
p16247
sg15
I1
sa(dp16248
g9
I47
sg10
VC1527249
p16249
sg12
I17
sg13
Vcolorectal cancer
p16250
sg15
I2
sasa(dp16251
g2
VThe prognosis was poorer in colorectal cancers that expressed both PROK1 and VEGF relative to the cases that expressed only 1 protein, and the expression of both proteins was found to be an independent prognostic factor.
p16252
sg4
(lp16253
(dp16254
g9
I67
sg39
VP58294
p16255
sg12
I5
sg13
VPROK1
p16256
sg15
I1
sasg6
(lp16257
(dp16258
g9
I28
sg10
VC1527249
p16259
sg12
I18
sg13
Vcolorectal cancers
p16260
sg15
I2
sasa(dp16261
g2
VTwo angiogenic growth factors, in particular, Vascular endothelial growth factor (VEGF) and Prokineticin1(PROK1), are considered to have an important role in hematogenous metastasis of colorectal cancer.
p16262
sg4
(lp16263
(dp16264
g9
I4
sg39
VP19883
p16265
sg12
I25
sg13
Vangiogenic growth factors
p16266
sg15
I3
sa(dp16267
g9
I82
sg39
g40
sg12
I4
sg13
VVEGF
p16268
sg15
I1
sa(dp16269
g9
I46
sg39
g40
sg12
I34
sg13
VVascular endothelial growth factor
p16270
sg15
I4
sa(dp16271
g9
I106
sg39
VP58294
p16272
sg12
I5
sg13
VPROK1
p16273
sg15
I1
sasg6
(lp16274
(dp16275
g9
I185
sg10
VC1527249
p16276
sg12
I17
sg13
Vcolorectal cancer
p16277
sg15
I2
sa(dp16278
g9
I171
sg10
VC0027627
p16279
sg12
I10
sg13
Vmetastasis
p16280
sg15
I1
sasa(dp16281
g2
VAccordingly, we report our findings on the importance of the anti-tumor efffect by inhibiting these two factors in human colorectal cancer.When the culture fluid of Colorectal cancer cell lines(DLD-1, HCT116, and LoVo) with high levels of VEGF/PROK1 expression was injected subcutaneously into mice, the culture fluid increased subcutaneous angiogenesis.
p16282
sg4
(lp16283
(dp16284
g9
I194
sg39
VP98173
p16285
sg12
I5
sg13
VDLD-1
p16286
sg15
I1
sa(dp16287
g9
I244
sg39
VP58294
p16288
sg12
I5
sg13
VPROK1
p16289
sg15
I1
sasg6
(lp16290
(dp16291
g9
I66
sg10
VC0027651
p16292
sg12
I5
sg13
Vtumor
p16293
sg15
I1
sa(dp16294
g9
I165
sg10
VC1527249
p16295
sg12
I17
sg13
VColorectal cancer
p16296
sg15
I2
sa(dp16297
g9
I121
sg10
VC1527249
p16298
sg12
I17
sg13
Vcolorectal cancer
p16299
sg15
I2
sasa(dp16300
g2
VAlso, tumor masses were produced in mice by subcutaneously embedding colorectal cancer cells with high levels VEGF/PROK1 expression.
p16301
sg4
(lp16302
(dp16303
g9
I115
sg39
VP58294
p16304
sg12
I5
sg13
VPROK1
p16305
sg15
I1
sasg6
(lp16306
(dp16307
g9
I6
sg10
VC0027651
p16308
sg12
I5
sg13
Vtumor
p16309
sg15
I1
sa(dp16310
g9
I69
sg10
VC1527249
p16311
sg12
I17
sg13
Vcolorectal cancer
p16312
sg15
I2
sasa(dp16313
g2
VWhen both anti-PROK1 and anti-VEGF antibodies were simultaneously applied, tumor formation and peritumoral angiogenesis were strongly suppressed, compared with when either anti-PROK1 antibody or anti-VEGF antibody was applied alone.Simultaneous targeting of both angiogenic growth factors (VEGF/PROK1) may prove more useful in colorectal cancer.
p16314
sg4
(lp16315
(dp16316
g9
I15
sg39
VP58294
p16317
sg12
I5
sg13
VPROK1
p16318
sg15
I1
sa(dp16319
g9
I172
sg39
VP58294
p16320
sg12
I19
sg13
Vanti-PROK1 antibody
p16321
sg15
I2
sa(dp16322
g9
I10
sg39
VP58294
p16323
sg12
I10
sg13
Vanti-PROK1
p16324
sg15
I1
sa(dp16325
g9
I263
sg39
VP19883
p16326
sg12
I25
sg13
Vangiogenic growth factors
p16327
sg15
I3
sasg6
(lp16328
(dp16329
g9
I327
sg10
VC1527249
p16330
sg12
I17
sg13
Vcolorectal cancer
p16331
sg15
I2
sa(dp16332
g9
I75
sg10
VC0027651
p16333
sg12
I5
sg13
Vtumor
p16334
sg15
I1
sasa(dp16335
g2
VThe current study established the anti-PROK1 monoclonal antibody (mAb) and examined the relationship between the expression of PROK1 protein and human colorectal cancer.
p16336
sg4
(lp16337
(dp16338
g9
I34
sg39
VP58294
p16339
sg12
I30
sg13
Vanti-PROK1 monoclonal antibody
p16340
sg15
I3
sa(dp16341
g9
I127
sg39
VP58294
p16342
sg12
I13
sg13
VPROK1 protein
p16343
sg15
I2
sasg6
(lp16344
(dp16345
g9
I151
sg10
VC1527249
p16346
sg12
I17
sg13
Vcolorectal cancer
p16347
sg15
I2
sasa(dp16348
g2
VThe expression of PROK1 protein was assessed in 620 resected sporadic colorectal cancer tissue samples by immunohistochemical staining with in-house-developed human PROK1 mAb to investigate the relationship of PROK1 expression to clinicopathologic factors, recurrence, and survival rate and to evaluate its prognostic significance.
p16349
sg4
(lp16350
(dp16351
g9
I18
sg39
VP58294
p16352
sg12
I13
sg13
VPROK1 protein
p16353
sg15
I2
sa(dp16354
g9
I18
sg39
VP58294
p16355
sg12
I5
sg13
VPROK1
p16356
sg15
I1
sa(dp16357
g9
I159
sg39
VP58294
p16358
sg12
I15
sg13
Vhuman PROK1 mAb
p16359
sg15
I3
sasg6
(lp16360
(dp16361
g9
I70
sg10
VC1527249
p16362
sg12
I17
sg13
Vcolorectal cancer
p16363
sg15
I2
sa(dp16364
g9
I257
sg10
VC1458156
p16365
sg12
I10
sg13
Vrecurrence
p16366
sg15
I1
sasa(dp16367
g2
VThe expression of PROK1 protein was detected in 36 % (223/620) of human primary colorectal cancer lesions but no in the healthy mucosa adjacent to the colorectal cancer lesions.
p16368
sg4
(lp16369
(dp16370
g9
I18
sg39
VP58294
p16371
sg12
I13
sg13
VPROK1 protein
p16372
sg15
I2
sasg6
(lp16373
(dp16374
g9
I80
sg10
VC1527249
p16375
sg12
I17
sg13
Vcolorectal cancer
p16376
sg15
I2
sa(dp16377
g9
I80
sg10
VC1527249
p16378
sg12
I17
sg13
Vcolorectal cancer
p16379
sg15
I2
sasa(dp16380
g2
VThe expression of PROK1 protein was identified for the first time as a new prognostic factor in colorectal cancer.
p16381
sg4
(lp16382
(dp16383
g9
I18
sg39
VP58294
p16384
sg12
I13
sg13
VPROK1 protein
p16385
sg15
I2
sasg6
(lp16386
(dp16387
g9
I96
sg10
VC1527249
p16388
sg12
I17
sg13
Vcolorectal cancer
p16389
sg15
I2
sasa(dp16390
g2
VHere we investigated how the anti-PROK1 monoclonal antibody (mAb; established by our department) would affect the high-PROK1-expressing colorectal cancer (CRC) cells in vitro and vivo.
p16391
sg4
(lp16392
(dp16393
g9
I29
sg39
VP58294
p16394
sg12
I30
sg13
Vanti-PROK1 monoclonal antibody
p16395
sg15
I3
sa(dp16396
g9
I34
sg39
VP58294
p16397
sg12
I5
sg13
VPROK1
p16398
sg15
I1
sasg6
(lp16399
(dp16400
g9
I155
sg10
VC1527249
p16401
sg12
I3
sg13
VCRC
p16402
sg15
I1
sa(dp16403
g9
I136
sg10
VC1527249
p16404
sg12
I17
sg13
Vcolorectal cancer
p16405
sg15
I2
sasa(dp16406
g2
VPROK1 expression was not observed in healthy gastrointestinal mucosa, but was observed in the primary lesions in 23 out of 98 (31.6%) patients with colorectal cancer, 19 out of 55 (34.5%) patients with gastric cancer, and 5 of 10 (50%) patients with cancer of the small intestine.
p16407
sg4
(lp16408
(dp16409
g9
I0
sg39
VP58294
p16410
sg12
I5
sg13
VPROK1
p16411
sg15
I1
sasg6
(lp16412
(dp16413
g9
I148
sg10
VC1527249
p16414
sg12
I17
sg13
Vcolorectal cancer
p16415
sg15
I2
sa(dp16416
g9
I202
sg10
VC0024623
p16417
sg12
I14
sg13
Vgastric cancer
p16418
sg15
I2
sa(dp16419
g9
I159
sg10
VC0006826
p16420
sg12
I6
sg13
Vcancer
p16421
sg15
I1
sasa(dp16422
g2
VEndocrine gland-derived vascular endothelial growth factor (EG-VEGF) has             recently been identified as one of the vascular endothelial growth factors, and             it is considered that the overexpression of EG-VEGF in colon cancer is related             to hepatic metastasis.
p16423
sg4
(lp16424
(dp16425
g9
I60
sg39
VP58294
p16426
sg12
I7
sg13
VEG-VEGF
p16427
sg15
I1
sa(dp16428
g9
I124
sg39
VP19883
p16429
sg12
I35
sg13
Vvascular endothelial growth factors
p16430
sg15
I4
sa(dp16431
g9
I0
sg39
VP58294
p16432
sg12
I58
sg13
VEndocrine gland-derived vascular endothelial growth factor
p16433
sg15
I6
sa(dp16434
g9
I60
sg39
VP58294
p16435
sg12
I7
sg13
VEG-VEGF
p16436
sg15
I1
sasg6
(lp16437
(dp16438
g9
I271
sg10
VC0494165
p16439
sg12
I18
sg13
Vhepatic metastasis
p16440
sg15
I2
sa(dp16441
g9
I232
sg10
VC0699790
p16442
sg12
I12
sg13
Vcolon cancer
p16443
sg15
I2
sasa(dp16444
g2
VIn this study, we report our recent novel findings of the             involvement of EG-VEGF in cell invasion of colon cancer cells.
p16445
sg4
(lp16446
(dp16447
g9
I85
sg39
VP58294
p16448
sg12
I7
sg13
VEG-VEGF
p16449
sg15
I1
sasg6
(lp16450
(dp16451
g9
I113
sg10
VC0699790
p16452
sg12
I12
sg13
Vcolon cancer
p16453
sg15
I2
sa(dp16454
g9
I96
sg10
VC2699153
p16455
sg12
I13
sg13
Vcell invasion
p16456
sg15
I2
sasa(dp16457
g2
VFinally, the EG-VEGF receptor on the colon cancer cell membrane             was blocked by anti-PK-R1 and -PK-R2 antibodies to study whether cell invasion             ability would be altered.
p16458
sg4
(lp16459
(dp16460
g9
I13
sg39
VP58294
p16461
sg12
I16
sg13
VEG-VEGF receptor
p16462
sg15
I2
sa(dp16463
g9
I91
sg39
g40
sg12
I32
sg13
Vanti-PK-R1 and -PK-R2 antibodies
p16464
sg15
I4
sasg6
(lp16465
(dp16466
g9
I141
sg10
VC2699153
p16467
sg12
I13
sg13
Vcell invasion
p16468
sg15
I2
sa(dp16469
g9
I37
sg10
VC0699790
p16470
sg12
I12
sg13
Vcolon cancer
p16471
sg15
I2
sasa(dp16472
g2
VIn colon cancer cell lines where the expression of PK-R1             and 2 was confirmed, stimulation with EG-VEGF increased cell invasion a maximum             of ~3-5 times.
p16473
sg4
(lp16474
(dp16475
g9
I107
sg39
VP58294
p16476
sg12
I7
sg13
VEG-VEGF
p16477
sg15
I1
sasg6
(lp16478
(dp16479
g9
I3
sg10
VC0699790
p16480
sg12
I12
sg13
Vcolon cancer
p16481
sg15
I2
sa(dp16482
g9
I125
sg10
VC2699153
p16483
sg12
I13
sg13
Vcell invasion
p16484
sg15
I2
sasa(dp16485
g2
VThe study showed that the EG-VEGF             protein may act on MMP-2, -7 and -9 via PK-R2 to strengthen cell invasion ability             in colon cancer cell lines.
p16486
sg4
(lp16487
(dp16488
g9
I26
sg39
VP58294
p16489
sg12
I7
sg13
VEG-VEGF
p16490
sg15
I1
sa(dp16491
g9
I65
sg39
VP08253
p16492
sg12
I9
sg13
VMMP-2, -7
p16493
sg15
I2
sasg6
(lp16494
(dp16495
g9
I143
sg10
VC0699790
p16496
sg12
I12
sg13
Vcolon cancer
p16497
sg15
I2
sa(dp16498
g9
I106
sg10
VC2699153
p16499
sg12
I13
sg13
Vcell invasion
p16500
sg15
I2
sasa(dp16501
g2
VTo study the implication of prokineticin 1 (PK1/EG-VEGF) and prokineticin 2 (PK2/Bv8) in hepatocellular carcinoma angiogenesis.
p16502
sg4
(lp16503
(dp16504
g9
I28
sg39
VP58294
p16505
sg12
I14
sg13
Vprokineticin 1
p16506
sg15
I2
sa(dp16507
g9
I77
sg39
g40
sg12
I3
sg13
VPK2
p16508
sg15
I1
sa(dp16509
g9
I81
sg39
g40
sg12
I3
sg13
VBv8
p16510
sg15
I1
sa(dp16511
g9
I61
sg39
g40
sg12
I14
sg13
Vprokineticin 2
p16512
sg15
I2
sa(dp16513
g9
I44
sg39
VP58294
p16514
sg12
I3
sg13
VPK1
p16515
sg15
I1
sa(dp16516
g9
I48
sg39
VP58294
p16517
sg12
I7
sg13
VEG-VEGF
p16518
sg15
I1
sasg6
(lp16519
(dp16520
g9
I89
sg10
VC1512411
p16521
sg12
I24
sg13
Vhepatocellular carcinoma
p16522
sg15
I2
sasa.